FN Thomson Reuters Web of Science™ VR 1.0 PT J AU Chew, KW Daar, ES Lake, JE Li, Z Shufelt, C Tseng, CH Liao, D Murkey, JA Guerrero, M Jordan, W Chung, RT Merz, CNB Currier, JS Bhattacharya, D AF Chew, K. W. Daar, E. S. Lake, J. E. Li, Z. Shufelt, C. Tseng, C-H Liao, D. Murkey, J. A. Guerrero, M. Jordan, W. Chung, R. T. Merz, C. N. Bairey Currier, J. S. Bhattacharya, D. TI Impact of hepatitis C virus (HCV) treatment on endothelial function in HIV-coinfected persons SO ANTIVIRAL THERAPY LA English DT Meeting Abstract CT 18th International Workshop on Co-Morbidities and Adverse Drug Reactions in HIV CY SEP 12-13, 2016 CL New York, NY C1 [Chew, K. W.; Daar, E. S.; Lake, J. E.; Li, Z.; Tseng, C-H; Liao, D.; Murkey, J. A.; Jordan, W.; Merz, C. N. Bairey; Currier, J. S.; Bhattacharya, D.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Daar, E. S.; Guerrero, M.] Harbor UCLA Med Ctr, Los Angeles Biomed Res Inst, Torrance, CA 90509 USA. [Shufelt, C.; Merz, C. N. Bairey] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. [Jordan, W.] Charles R Drew Univ Med & Sci, 1621 E 120th St, Los Angeles, CA 90059 USA. [Chung, R. T.] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU INT MEDICAL PRESS LTD PI LONDON PA 2-4 IDOL LANE, LONDON EC3R 5DD, ENGLAND SN 1359-6535 J9 ANTIVIR THER JI Antivir. Ther. PY 2016 VL 21 SU 1 MA O21 BP A24 EP A24 PG 1 WC Infectious Diseases; Pharmacology & Pharmacy; Virology SC Infectious Diseases; Pharmacology & Pharmacy; Virology GA EE6UF UT WOS:000389747500022 ER PT J AU Sharma, A Ma, Y Tien, PC Scherzer, R Anastos, K Cohen, M Hans, D Yin, MT AF Sharma, A. Ma, Y. Tien, P. C. Scherzer, R. Anastos, K. Cohen, M. Hans, D. Yin, M. T. TI Measurement of bone microarchitecture among HIV-infected and uninfected women using trabecular bone score SO ANTIVIRAL THERAPY LA English DT Meeting Abstract CT 18th International Workshop on Co-Morbidities and Adverse Drug Reactions in HIV CY SEP 12-13, 2016 CL New York, NY C1 [Sharma, A.; Anastos, K.] Albert Einstein Coll Med, Bronx, NY 10467 USA. [Ma, Y.; Tien, P. C.; Scherzer, R.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Tien, P. C.] San Francisco VA Med Ctr, San Francisco, CA USA. [Cohen, M.] John H Stroger Jr Hosp Cook Cty, Chicago, IL USA. [Hans, D.] Univ Lausanne Hosp, Ctr Bone Dis, Lausanne, Switzerland. [Yin, M. T.] Columbia Univ, Coll Phys & Surg, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU INT MEDICAL PRESS LTD PI LONDON PA 2-4 IDOL LANE, LONDON EC3R 5DD, ENGLAND SN 1359-6535 J9 ANTIVIR THER JI Antivir. Ther. PY 2016 VL 21 SU 1 MA O04 BP A6 EP A6 PG 1 WC Infectious Diseases; Pharmacology & Pharmacy; Virology SC Infectious Diseases; Pharmacology & Pharmacy; Virology GA EE6UF UT WOS:000389747500005 ER PT J AU Stanley, TL Mamputu, JC Morin, J Marsolais, C Grinspoon, SK AF Stanley, T. L. Mamputu, J-C Morin, J. Marsolais, C. Grinspoon, S. K. TI Reduction in visceral fat with tesamorelin is associated with improved transaminases in patients with baseline transaminase elevation SO ANTIVIRAL THERAPY LA English DT Meeting Abstract CT 18th International Workshop on Co-Morbidities and Adverse Drug Reactions in HIV CY SEP 12-13, 2016 CL New York, NY C1 [Stanley, T. L.; Grinspoon, S. K.] Massachusetts Gen Hosp, Program Nutr Metab, Boston, MA 02114 USA. [Stanley, T. L.; Grinspoon, S. K.] Harvard Med Sch, Boston, MA USA. [Mamputu, J-C; Marsolais, C.] Theratechnologies Inc, Montreal, PQ, Canada. [Morin, J.] Excelsus Stat Inc, Montreal, PQ, Canada. NR 0 TC 0 Z9 0 U1 0 U2 0 PU INT MEDICAL PRESS LTD PI LONDON PA 2-4 IDOL LANE, LONDON EC3R 5DD, ENGLAND SN 1359-6535 J9 ANTIVIR THER JI Antivir. Ther. PY 2016 VL 21 SU 1 MA A53 BP A53 EP A53 PG 1 WC Infectious Diseases; Pharmacology & Pharmacy; Virology SC Infectious Diseases; Pharmacology & Pharmacy; Virology GA EE6UF UT WOS:000389747500047 ER PT J AU Bond, A Manian, FA AF Bond, Allison Manian, Farrin A. TI Spinal Epidural Abscess: A Review with Special Emphasis on Earlier Diagnosis SO BIOMED RESEARCH INTERNATIONAL LA English DT Review ID STAPHYLOCOCCUS-AUREUS INFECTIONS; OPERATIVE MANAGEMENT; SURGICAL-MANAGEMENT; CLINICAL ARTICLE; RISK-FACTORS; EPIDEMIOLOGY; METAANALYSIS; ALGORITHM; ORIGIN AB Spinal epidural abscess (SEA) is an uncommon but serious condition with significant morbidity andmortality. The prognosis of SEA is highly dependent on the timeliness of its diagnosis before neurological deficits develop. Unfortunately, often due to its nonspecific presentation, such as back pain, the diagnosis of SEA may be delayed in up to 75% of cases. Although many risk factors for SEA can be found in the published literature, their utility is limited by their frequent lack of objective evidence, numerousness, and absence in a significant proportion of cases. In this review, we call for a more discriminate evidence-based use of the term "risk factor" when discussing SEA and explore several approaches to its earlier diagnosis, including a simple algorithm based on its pathophysiology and serum C-reactive protein or erythrocyte sedimentation rate. C1 [Bond, Allison; Manian, Farrin A.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Med, Boston, MA 02115 USA. RP Manian, FA (reprint author), Harvard Med Sch, Massachusetts Gen Hosp, Dept Med, Boston, MA 02115 USA. EM fmanian@mgh.harvard.edu NR 55 TC 0 Z9 0 U1 1 U2 1 PU HINDAWI PUBLISHING CORP PI NEW YORK PA 315 MADISON AVE 3RD FLR, STE 3070, NEW YORK, NY 10017 USA SN 2314-6133 EI 2314-6141 J9 BIOMED RES INT JI Biomed Res. Int. PY 2016 AR 1614328 DI 10.1155/2016/1614328 PG 6 WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental SC Biotechnology & Applied Microbiology; Research & Experimental Medicine GA EE9EQ UT WOS:000389929100001 ER PT J AU Gonzalez, C Droguett, K Rios, M Cohen, NA Villalon, M AF Gonzalez, Claudia Droguett, Karla Rios, Mariana Cohen, Noam A. Villalon, Manuel TI TNF alpha Affects Ciliary Beat Response to Increased Viscosity in Human Pediatric Airway Epithelium SO BIOMED RESEARCH INTERNATIONAL LA English DT Article ID TUMOR-NECROSIS-FACTOR; CELLS IN-VITRO; SMOOTH-MUSCLE; EXPRESSION; RECEPTORS; CYTOKINES; MUCUS; CA2+; FREQUENCY; IL-1-BETA AB In airway epithelium, mucociliary clearance (MCC) velocity depends on the ciliary beat frequency (CBF), and it is affected by mucus viscoelastic properties. Local inflammation induces secretion of cytokines (TNF alpha) that can alter mucus viscosity; however airway ciliated cells have an autoregulatory mechanism to prevent the collapse of CBF in response to increase in mucus viscosity, mechanism that is associated with an increment in intracellular Ca+2 level ([Ca (2+)] i). We studied the effect of TNF alpha on the autoregulatory mechanism that regulates CBF in response to increased viscosity using dextran solutions, in ciliated cells cultured from human pediatric epithelial adenoid tissue. Cultures were treated with TNF alpha, before and after the viscous load was changed. TNF alpha treatment produced a significantly larger decrease in CBF in cultures exposed to dextran. Furthermore, an increment in [Ca2+] i was observed, which was significantly larger after TNF alpha treatment. In conclusion, although TNF alpha has deleterious effects on ciliated cells in response to maintaining CBF after increasing viscous loading, it has a positive effect, since increasing [Ca2+] i may prevent the MCC collapse. These findings suggest that augmented levels of TNF alpha associated with an inflammatory response of the nasopharyngeal epitheliummay have dual effects that contribute to maintaining the effectiveness of MCC in the upper airways. C1 [Gonzalez, Claudia] Pontificia Univ Catolica Chile, Fac Med, Dept Otorhinolaryngol, Santiago, Chile. [Droguett, Karla; Rios, Mariana; Villalon, Manuel] Pontificia Univ Catolica Chile, Fac Biol Sci, Dept Physiol, Santiago, Chile. [Cohen, Noam A.] Univ Penn, Dept Otorhinolaryngol Head & Neck Surg, Philadelphia, PA 19104 USA. [Cohen, Noam A.] Philadelphia Vet Affairs Med Ctr, Surg Serv, Philadelphia, PA USA. RP Villalon, M (reprint author), Pontificia Univ Catolica Chile, Fac Biol Sci, Dept Physiol, Santiago, Chile. EM mvilla@uc.cl FU Puente [21/2014]; Flight Attendants Medical Research Institute [082478]; Fondecyt [3150652] FX This work was supported by Puente [21/2014]; the Flight Attendants Medical Research Institute [082478], and Fondecyt [3150652 (Karla Droguett)]. NR 43 TC 0 Z9 0 U1 3 U2 3 PU HINDAWI PUBLISHING CORP PI NEW YORK PA 315 MADISON AVE 3RD FLR, STE 3070, NEW YORK, NY 10017 USA SN 2314-6133 EI 2314-6141 J9 BIOMED RES INT JI Biomed Res. Int. PY 2016 AR 3628501 DI 10.1155/2016/3628501 PG 9 WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental SC Biotechnology & Applied Microbiology; Research & Experimental Medicine GA EE9II UT WOS:000389939200001 ER PT J AU Holland, JP AF Holland, Jason P. TI The Role of Molecular Imaging in Personalised Healthcare SO CHIMIA LA English DT Article DE Cancer; Molecular imaging; Oncogenic signalling; Personalised medicine; PET ID POSITRON-EMISSION-TOMOGRAPHY; MESOPOROUS SILICA NANOPARTICLES; CU-CATALYZED FLUORINATION; IRON-OXIDE NANOPARTICLES; ELECTRON-RICH ARENES; IN-VIVO; PROSTATE-CANCER; MEMBRANE ANTIGEN; INORGANIC NANOPARTICLES; DIARYLIODONIUM SALTS AB Functional molecular imaging provides a unique perspective on a disease. Methods including positron emission tomography and magnetic resonance imaging allow us to interrogate spatial and temporal changes in biomarkers as well as probe the underlying biochemistry. When imaging is combined with molecular diagnostic tools, opportunities arise for measuring aberrant cellular signalling pathways with unprecedented detail. This brief commentary illustrates how radiotracers and nuclear imaging methods are being developed to monitor drug efficacy and simultaneously support the goal of personalised healthcare. C1 [Holland, Jason P.] Mem Sloan Kettering Canc Ctr, Radiochem & Translat Mol Imaging, 1275 York Ave, New York, NY 10021 USA. [Holland, Jason P.] Swiss Fed Inst Technol, Zurich, Switzerland. [Holland, Jason P.] Paul Scherrer Inst, Villigen, Switzerland. [Holland, Jason P.] Massachusetts Gen Hosp, Div Nucl Med & Mol Imaging, Chem, Boston, MA 02114 USA. [Holland, Jason P.] Harvard Med Sch, Radiol, Boston, MA USA. RP Holland, JP (reprint author), Univ Zurich, Dept Chem, Winterthurerstr 190, CH-8057 Zurich, Switzerland. EM jason.holland@chem.uzh.ch FU Swiss National Science Foundation (SNSF Professorship) [PP00P2_163683]; European Research Council (ERC-StG, NanoSCAN) [676904] FX I am grateful for the support of my mentors and continued collaboration with many co-workers. In particular, I thank professors Jonathan Dilworth, Jennifer Green and Jason Lewis for providing me with opportunities to join the fields of radiochemistry and molecular imaging. I thank Michael Evans for productive conversations and Jennifer Lamb for her critique of this article. I am grateful to the Swiss National Science Foundation (SNSF Professorship PP00P2_163683) and the European Research Council (ERC-StG-2015, NanoSCAN 676904) for generous financial support. NR 81 TC 0 Z9 0 U1 2 U2 2 PU SWISS CHEMICAL SOC PI BERN PA SCHWARZTORSTRASSE 9, CH-3007 BERN, SWITZERLAND SN 0009-4293 J9 CHIMIA JI Chimia PY 2016 VL 70 IS 11 BP 787 EP 795 DI 10.2533/chimia.2016.787 PG 9 WC Chemistry, Multidisciplinary SC Chemistry GA EE8IX UT WOS:000389870000006 ER PT J AU Singh, JA Hossain, A Ghogomu, ET Mudano, AS Tugwella, P Wellsb, GA AF Singh, Jasvinder A. Hossain, Alomgir Ghogomu, Elizabeth Tanjong Mudano, Amy S. Tugwella, Peter Wellsb, George A. TI Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA) SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS LA English DT Review ID PLACEBO-CONTROLLED TRIAL; ANTITUMOR NECROSIS FACTOR; RANDOMIZED-CONTROLLED-TRIAL; INTERLEUKIN-1 RECEPTOR ANTAGONIST; ADALIMUMAB PLUS METHOTREXATE; ALPHA MONOCLONAL-ANTIBODY; QUALITY-OF-LIFE; RECEIVING CONCOMITANT METHOTREXATE; PATIENT-REPORTED OUTCOMES; TREAT-TO-TARGET AB Background We performed a systematic review, a standard meta-analysis and network meta-analysis (NMA), which updates the 2009 Cochrane Overview, 'Biologics for rheumatoid arthritis (RA)'. This review is focused on biologic monotherapy in people with RA in whom treatment with traditional disease-modifying anti-rheumatic drugs (DMARDs) including methotrexate (MTX) had failed (MTX/other DMARD-experienced). Objectives To assess the benefits and harms of biologic monotherapy (includes anti-tumor necrosis factor (TNF) (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab) or non-TNF (abatacept, anakinra, rituximab, tocilizumab)) or tofacitinib monotherapy (oral small molecule) versus comparator (placebo or MTX/other DMARDs) in adults with RA who were MTX/other DMARD-experienced. Methods We searched for randomized controlled trials (RCTs) in the Cochrane Central Register of Controlled Trials (CENTRAL; The Cochrane Library 2015, Issue 6, June), MEDLINE (viaOVID 1946 to June 2015), and Embase (via OVID1947 to June 2015). Article selection, data extraction and risk of bias and GRADE assessments were done in duplicate. We calculated direct estimates with 95% confidence intervals (CI) using standard meta-analysis. We used a Bayesian mixed treatment comparisons (MTC) approach for NMA estimates with 95% credible intervals (CrI). We converted odds ratios (OR) to risk ratios (RR) for ease of understanding. We calculated absolute measures as risk difference (RD) and number needed to treat for an additional beneficial outcome (NNTB). Main results This update includes 40 new RCTs for a total of 46 RCTs, of which 41 studies with 14,049 participants provided data. The comparator was placebo in 16 RCTs (4,532 patients), MTX or other DMARD in 13 RCTs (5,602 patients), and another biologic in 12 RCTs (3,915 patients). Monotherapy versus placebo Based on moderate-quality direct evidence, biologic monotherapy (without concurrent MTX/other DMARDs) was associated with a clinically meaningful and statistically significant improvement in American College of Rheumatology score (ACR50) and physical function, as measured by the Health Assessment Questionnaire (HAQ) versus placebo. RR was 4.68 for ACR50 (95% CI, 2.93 to 7.48); absolute benefit RD 23% (95% CI, 18% to 29%); and NNTB = 5 (95% CI, 3 to 8). The mean difference (MD) was -0.32 for HAQ (95% CI, -0.42 to -0.23; a negative sign represents greater HAQ improvement); absolute benefit of -10.7% (95% CI, -14% to 7.7%); and NNTB = 4 (95% CI, 3 to 5). Direct and NMA estimates for TNF biologic, non-TNF biologic or tofacitinib monotherapy showed similar results for ACR50, downgraded to moderate-quality evidence. Direct and NMA estimates for TNF biologic, anakinra or tofacitinib monotherapy showed a similar results for HAQ versus placebo with mostly moderate quality evidence. Based onmoderate-quality direct evidence, biologic monotherapy was associated with a clinically meaningful and statistically significant greater proportion of disease remission versus placebo with RR 1.12 (95% CI 1.03 to 1.22); absolute benefit 10% (95% CI, 3% to 17%; NNTB = 10 (95% CI, 8 to 21)). Based on low-quality direct evidence, results for biologic monotherapy for withdrawals due to adverse events and serious adverse events were inconclusive, with wide confidence intervals encompassing the null effect and evidence of an important increase. The direct estimate for TNF monotherapy for withdrawals due to adverse events showed a clinically meaningful and statistically significant result with RR 2.02 (95% CI, 1.08 to 3.78), absolute benefit RD 3% (95% CI, 1% to 4%), based on moderate-quality evidence. The NMA estimates for TNF biologic, non-TNF biologic, anakinra, or tofacitinib monotherapy for withdrawals due to adverse events and for serious adverse events were all inconclusive and downgraded to low-quality evidence. Monotherapy versus active comparator (MTX/other DMARDs) Based on direct evidence of moderate quality, biologic monotherapy (without concurrent MTX/other DMARDs) was associated with a clinically meaningful and statistically significant improvement in ACR50 and HAQ scores versus MTX/other DMARDs with a RR of 1.54 (95% CI, 1.14 to 2.08); absolute benefit 13% (95% CI, 2% to 23%), NNTB = 7 (95% CI, 4 to 26) and a mean difference in HAQ of -0.27 (95% CI, -0.40 to -0.14); absolute benefit of -9% (95% CI, -13.3% to -4.7%), NNTB = 2 (95% CI, 2 to 4). Direct and NMA estimates for TNF monotherapy and NMA estimate for non-TNF biologic monotherapy for ACR50 showed similar results, based on moderate-quality evidence. Direct and NMA estimates for non-TNF biologic monotherapy, but not TNF monotherapy, showed similar HAQ improvements, based on mostly moderate-quality evidence. There were no statistically significant or clinically meaningful differences for direct estimates of biologic monotherapy versus active comparator for RA disease remission. NMA estimates showed a statistically significant and clinically meaningful difference versus active comparator for TNF monotherapy (absolute improvement 7% (95% CI, 2% to 14%)) and non-TNF monotherapy (absolute improvement 19% (95% CrI, 7% to 36%)), both downgraded to moderate quality. Based on moderate-quality direct evidence from a single study, radiographic progression (scale 0 to 448) was statistically significantly reduced in those on biologic monotherapy versus active comparator, MD-4.34 (95% CI, -7.56 to -1.12), though the absolute reduction was small, -0.97% (95% CI, -1.69% to -0.25%). We are not sure of the clinical relevance of this reduction. Direct and NMA evidence (downgraded to low quality), showed inconclusive results for withdrawals due to adverse events, serious adverse events and cancer, with wide confidence intervals encompassing the null effect and evidence of an important increase. Authors' conclusions Based mostly on RCTs of six to 12-month duration in people with RA who had previously experienced and failed treatment with MTX/other DMARDs, biologic monotherapy improved ACR50, function and RA remission rates compared to placebo or MTX/other DMARDs. Radiographic progression was reduced versus active comparator, although the clinical significance was unclear. Results were inconclusive for whether biologic monotherapy was associated with an increased risk of withdrawals due to adverse events, serious adverse events or cancer, versus placebo (no data on cancer) or MTX/other DMARDs. C1 [Singh, Jasvinder A.] Birmingham VA Med Ctr, Dept Med, Fac Off Tower 805B,510 20th St South, Birmingham, AL 35294 USA. [Hossain, Alomgir] Univ Ottawa, Inst Heart, Cardiovasc Res Methods Ctr, Ottawa, ON, Canada. [Ghogomu, Elizabeth Tanjong] Univ Ottawa, Bruyere Res Inst, Ottawa, ON, Canada. [Mudano, Amy S.] Univ Alabama Birmingham, Dept Med Rheumatol, Birmingham, AL USA. [Tugwella, Peter] Univ Ottawa, Fac Med, Dept Med, Ottawa, ON, Canada. [Wellsb, George A.] Univ Ottawa, Dept Epidemiol & Community Med, Ottawa, ON, Canada. RP Singh, JA (reprint author), Birmingham VA Med Ctr, Dept Med, Fac Off Tower 805B,510 20th St South, Birmingham, AL 35294 USA. EM jasvinder.md@gmail.com OI Tugwell, Peter/0000-0001-5062-0556 NR 283 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1469-493X EI 1361-6137 J9 COCHRANE DB SYST REV JI Cochrane Database Syst Rev. PY 2016 IS 11 AR CD012437 DI 10.1002/14651858.CD012437 PG 124 WC Medicine, General & Internal SC General & Internal Medicine GA EE4UH UT WOS:000389600300041 ER PT J AU Thanos, A Yonekawa, Y Todorich, B Moshfeghi, DM Trese, MT AF Thanos, Aristomenis Yonekawa, Yoshihiro Todorich, Bozho Moshfeghi, Darius M. Trese, Michael T. TI Screening and treatments using telemedicine in retinopathy of prematurity SO EYE AND BRAIN LA English DT Review DE retinopathy of prematurity; screening; telemedicine ID ACUTE-PHASE RETINOPATHY; INTEREXPERT AGREEMENT; PLUS DISEASE; DIAGNOSIS; IMAGE; MANAGEMENT; ACCURACY; RELIABILITY; INFANTS; DESIGN AB Several studies have validated the role of telemedicine as a new powerful screening and diagnostic tool for retinal disorders, such as diabetic retinopathy and retinopathy of prematurity. With regard to retinopathy of prematurity, bedside examination with binocular indirect ophthalmoscopy has been the gold standard technique for screening, yet with several limitations. Herein, we review the current evidence that supports the role of telemedicine for the screening of infants with retinopathy of prematurity. C1 [Thanos, Aristomenis; Yonekawa, Yoshihiro; Todorich, Bozho; Trese, Michael T.] William Beaumont Hosp, Associated Retinal Consultants, Royal Oak, MI 48072 USA. [Yonekawa, Yoshihiro] Harvard Med Sch, Retina Serv, Massachusetts Eye & Ear Infirm, Boston, MA USA. [Moshfeghi, Darius M.] Stanford Univ, Sch Med, Dept Ophthalmol, Horngren Family Vitreoretinal Ctr,Byers Eye Inst, Palo Alto, CA 94304 USA. RP Trese, MT (reprint author), Associated Retinal Consultants PC, 3535 W 13 Mile Rd,Suite 344, Royal Oak, MI 48074 USA. EM mgjt46@aol.com NR 35 TC 0 Z9 0 U1 0 U2 0 PU DOVE MEDICAL PRESS LTD PI ALBANY PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND SN 1179-2744 J9 EYE BRAIN JI EYE BRAIN PY 2016 VL 8 BP 147 EP 151 DI 10.2147/EB.S94440 PG 5 WC Ophthalmology SC Ophthalmology GA EF1AX UT WOS:000390058500001 ER PT J AU Hanna, P Mantovani, G Grybek, V Juppner, H Brehin, AC Kottler, ML Rothenbuhler, A Linglart, A AF Hanna, Patrick Mantovani, Giovanna Grybek, Virginie Juppner, Harald Brehin, Anne-Claire Kottler, Marie-Laure Rothenbuhler, Anya Linglart, Agnes TI Final Heights and BMI in Patients Affected with Different Types of Pseudohypoparathyroidism SO HORMONE RESEARCH IN PAEDIATRICS LA English DT Meeting Abstract C1 [Hanna, Patrick; Grybek, Virginie] INSERM Bicetre Paris Sud, Bicetre Paris Sud, France. [Mantovani, Giovanna] Univ Milan, Milan, Italy. [Juppner, Harald] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Juppner, Harald] Harvard Med Sch, Boston, MA USA. [Brehin, Anne-Claire] Normandy Univ, Univ Hosp, Caen, France. [Brehin, Anne-Claire] Normandy Univ, CMR Calcium Phosphore, Caen, France. [Kottler, Marie-Laure; Linglart, Agnes] APHP, CMR Calcium Phosphore, Bicetre Paris Sud, France. [Rothenbuhler, Anya] OSI Araba Univ, Vitoria, Spain. [Linglart, Agnes] INSERM, Bicetre Paris Sud, France. NR 0 TC 0 Z9 0 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1663-2818 EI 1663-2826 J9 HORM RES PAEDIAT JI Horm. Res. Paediatr. PY 2016 VL 86 SU 1 MA RFC2.8 BP 75 EP 76 PG 2 WC Endocrinology & Metabolism; Pediatrics SC Endocrinology & Metabolism; Pediatrics GA DX1ZQ UT WOS:000384166800175 ER PT J AU Fernandez, M Riquelme, J Castiglioni, C Jueppner, HW Mericq, V AF Fernandez, Monica Riquelme, Joel Castiglioni, Claudia Jueppner, Harald W. Mericq, Veronica TI Pseudohypoparathyroidism Type IB Associated to Assisted Reproductive Technologies: Case Report SO HORMONE RESEARCH IN PAEDIATRICS LA English DT Meeting Abstract C1 [Fernandez, Monica; Riquelme, Joel; Mericq, Veronica] Univ Chile, Inst Maternal & Child Res, Santiago, Chile. [Castiglioni, Claudia] Clin Las Condes, Santiago, Chile. [Jueppner, Harald W.] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1663-2818 EI 1663-2826 J9 HORM RES PAEDIAT JI Horm. Res. Paediatr. PY 2016 VL 86 SU 1 MA P2-P181 BP 195 EP 195 PG 1 WC Endocrinology & Metabolism; Pediatrics SC Endocrinology & Metabolism; Pediatrics GA DX1ZQ UT WOS:000384166800454 ER PT J AU Houang, M Kottler, ML Bensman, A Haymann, JP Richard, N Dunand, O Bastepe, M Silve, C Coudray, N Netchine, I Linglart, A AF Houang, Muriel Kottler, Marie-Laure Bensman, Albert Haymann, Jean-Philippe Richard, Nicolas Dunand, Olivier Bastepe, Murate Silve, Caroline Coudray, Nathalie Netchine, Irene Linglart, Agnes TI Thyrotoxicosis, Nephrogenic Syndrome of Inappropriate Antidiuresis, Tall Stature and Mental Retardation Caused by a Novel GNAS Gain of Function Mutation SO HORMONE RESEARCH IN PAEDIATRICS LA English DT Meeting Abstract C1 [Houang, Muriel; Netchine, Irene] Hop Trousseau, APHP, Explorat Fonct Endocriniennes, Paris, France. [Houang, Muriel] INSERM, U938, Paris, France. [Kottler, Marie-Laure; Richard, Nicolas] Normandy Univ, Univ Hosp, Caen, France. [Houang, Muriel] Normandy Univ, CMR Calcium Phosphore, Caen, France. [Bensman, Albert; Dunand, Olivier] Hop Trousseau, APHP, Serv Nephrol Pediat, Paris, France. [Bensman, Albert; Haymann, Jean-Philippe; Netchine, Irene] Univ UMPC Paris VI, Paris, France. [Haymann, Jean-Philippe] Hop Tenon, APHP, Explorat Fonct, Paris, France. [Bastepe, Murate] Massachussetts Gen Hosp, Endocrine Unit, Boston, MA USA. [Silve, Caroline] Hop Cochin, APHP, Serv Biol Mol Hormonale, Paris, France. [Coudray, Nathalie; Linglart, Agnes] Bicetre Paris Sud, INSERM, Paris, France. [Coudray, Nathalie; Linglart, Agnes] Bicetre Paris Sud, APHP, CMR Calcium Phosphore, Paris, France. NR 0 TC 0 Z9 0 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1663-2818 EI 1663-2826 J9 HORM RES PAEDIAT JI Horm. Res. Paediatr. PY 2016 VL 86 SU 1 MA P1-P688 BP 399 EP 400 PG 2 WC Endocrinology & Metabolism; Pediatrics SC Endocrinology & Metabolism; Pediatrics GA DX1ZQ UT WOS:000384166801337 ER PT J AU Jindal, RD AF Jindal, Ripu D. TI Sleep and Weight among Our Veterans SO JOURNAL OF CLINICAL SLEEP MEDICINE LA English DT Editorial Material ID RANDOMIZED CONTROLLED-TRIAL; TRAUMATIC BRAIN-INJURY; CLINICAL-TRIAL; DISORDERS; METABOLISM; MANAGEMENT; INSOMNIA; IMPACT; PAIN; NEED C1 [Jindal, Ripu D.] Birmingham VA Med Ctr, Birmingham, AL 35233 USA. [Jindal, Ripu D.] Univ Alabama Birmingham, Birmingham, AL USA. RP Jindal, RD (reprint author), Birmingham VA Med Ctr, Birmingham, AL 35233 USA.; Jindal, RD (reprint author), Univ Alabama Birmingham, Psychiat & Neurol, Birmingham, AL 35294 USA. EM ripu.jindal@va.gov NR 29 TC 0 Z9 0 U1 0 U2 0 PU AMER ACAD SLEEP MEDICINE PI DARIEN PA 2510 N FRONTAGE RD, DARIEN, IL 60561 USA SN 1550-9389 EI 1550-9397 J9 J CLIN SLEEP MED JI J. Clin. Sleep Med. PY 2016 VL 12 IS 7 BP 943 EP 945 DI 10.5664/jcsm.5918 PG 3 WC Clinical Neurology SC Neurosciences & Neurology GA EF0AQ UT WOS:000389988200002 PM 27306395 ER PT J AU Bianchi, MT Kim, S Galvan, T White, DP Joffe, H AF Bianchi, Matt T. Kim, Semmie Galvan, Thania White, David P. Joffe, Hadine TI Nocturnal Hot Flashes: Relationship to Objective Awakenings and Sleep Stage Transitions SO JOURNAL OF CLINICAL SLEEP MEDICINE LA English DT Article DE menopause; hot flashes; vasomotor symptom; polysomnography; sleep; sleep disruption; sleep stages; sleep-wake stages; sleep architecture ID CORE BODY-TEMPERATURE; WOMEN; AGONIST; DISTURBANCE; SEVERITY; PERIMENOPAUSAL; PREMENOPAUSAL; SUPPRESSION; INSOMNIA; QUALITY AB Study Objectives: While women report sleep interruption secondary to nighttime hot flashes, the sleep disrupting impact of nocturnal hot flashes (HF) is not well characterized. We utilized a model of induced HF to investigate the relationship of nighttime HF to sleep architecture and sleep-stage transitions. Methods: Twenty-eight healthy, premenopausal volunteers received the depot gonadotropin-releasing hormone agonist (GnRHa) leuprolide to rapidly induce menopause, manifesting with HF. Sleep disruption was measured on 2 polysomnograms conducted before and after 4-5 weeks on leuprolide, when HF had developed. Results: 165 HF episodes were recorded objectively during 48 sleep studies (mean 3.4 HF/ night). After standardizing to sleep-stage time distribution, the majority of HF were recorded during wake (51.0%) and stage N1 (18.8%). Sixty-six percent of HF occurred within 5 minutes of an awakening, with 80% occurring just before or during the awakening. Objective HF were not associated with sleep disruption as measured by increased transitions to wake or N1, but self-reported nocturnal HF correlated with an increase from pre-to post-leuprolide in the rate of transitions to wake (p = 0.01), and to N1 (p = 0.008). Conclusions: By isolating the effect of HF on sleep in women without the confound of age-related sleep changes associated with natural menopause, this experimental model shows that HF arise most commonly during N1 and wake, typically preceding or occurring simultaneously with wake episodes. Perception of HF, but not objective HF, is linked to increased sleep-stage transitions, suggesting that sleep disruption increases awareness of and memory for nighttime HF events. C1 [Bianchi, Matt T.] Harvard Med Sch, Massachusetts Gen Hosp, Sleep Div, Dept Neurol, Boston, MA USA. [Kim, Semmie; Galvan, Thania; Joffe, Hadine] Harvard Med Sch, Brigham & Womens Hosp, Dept Psychiat, Womens Hormones & Aging Res Program, Boston, MA USA. [White, David P.] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA USA. [Joffe, Hadine] Harvard Med Sch, Dana Farber Canc Inst, Dept Psychosocial Oncol & Palliat Care Med, Boston, MA USA. [Joffe, Hadine] Harvard Med Sch, Massachusetts Gen Hosp, Dept Psychiat, Ctr Womens Mental Hlth, Boston, MA USA. RP Joffe, H (reprint author), Brigham & Womens Hosp, 75 Francis St,BB232C, Boston, MA 02115 USA. EM hjoffe@partners.org FU National Institutes of Health; Center for Integration of Medicine and Innovative Technology; Department of Defense; Milton Family Foundation; Servier; Merck; [5R01MH082922] FX This was not an industry-supported study. Funding source was 5R01MH082922 (HJ). ClinicalTrials.gov Identifier: NCT01116401. Dr. Joffe receives grant support from the National Institutes of Health, Merck, and serves as a consultant/advisor for Noven, Merck, and Mitsubishi Tanabe. Dr. Bianchi receives funding from the Center for Integration of Medicine and Innovative Technology, the Department of Defense, and the Milton Family Foundation; has a patent pending on a home sleep monitoring device; has received travel funding from Servier; serves on the advisory board of Foramis; is a consultant for GrandRounds; has provided expert testimony in sleep medicine. Dr. White is the Chief Medical Officer for Apnicure Inc and is a consultant for Philips Respironics. The other authors have indicated no financial conflicts of interest. NR 31 TC 2 Z9 2 U1 1 U2 1 PU AMER ACAD SLEEP MEDICINE PI DARIEN PA 2510 N FRONTAGE RD, DARIEN, IL 60561 USA SN 1550-9389 EI 1550-9397 J9 J CLIN SLEEP MED JI J. Clin. Sleep Med. PY 2016 VL 12 IS 7 BP 1003 EP 1009 DI 10.5664/jcsm.5936 PG 7 WC Clinical Neurology SC Neurosciences & Neurology GA EF0AQ UT WOS:000389988200011 PM 26951410 ER PT J AU Gaughan, T Buckley, A Hommer, R Grant, P Williams, K Leckman, JF Swedo, SE AF Gaughan, Thomas Buckley, Ashura Hommer, Rebecca Grant, Paul Williams, Kyle Leckman, James F. Swedo, Susan E. TI Rapid Eye Movement Sleep Abnormalities in Children with Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS) SO JOURNAL OF CLINICAL SLEEP MEDICINE LA English DT Article DE obsessive compulsive disorder; PANS; polysomnography; REM sleep behavior disorder ID ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; BEHAVIOR DISORDER; REM-SLEEP; METAANALYSIS; CHILDHOOD AB Study Objectives: Polysomnographic investigation of sleep architecture in children presenting with pediatric acute-onset neuropsychiatric syndrome (PANS). Methods: Fifteen consecutive subjects meeting criteria for PANS (mean age = 7.2 y; range 3-10 y) underwent single-night full polysomnography (PSG) read by a pediatric neurologist. Results: Thirteen of 15 subjects (87%) had abnormalities detected with PSG. Twelve of 15 had evidence of rapid eye movement (REM) sleep motor disinhibition, as characterized by excessive movement, laughing, hand stereotypies, moaning, or the continuation of periodic limb movements during sleep (PLMS) into REM sleep. Conclusions: This study shows various forms of REM sleep motor disinhibition present in a population of children with PANS. C1 [Gaughan, Thomas; Buckley, Ashura; Hommer, Rebecca; Grant, Paul; Swedo, Susan E.] NIMH, Dept Pediat & Dev Neurosci, Bethesda, MD 20892 USA. [Williams, Kyle] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Pediat Neuropsychiat & Immunol Program, Boston, MA USA. [Leckman, James F.] Yale Univ, Sch Med, Ctr Child Study, New Haven, CT 06510 USA. RP Buckley, A (reprint author), NIMH, Dept Pediat & Dev Neurosci, Bethesda, MD 20892 USA. EM shu.buckley@nih.gov FU Intramural Research Program of the National Institute of Mental Health [MH002666, NCT01281969, 11-M-0058, NCT01778504, 13-M-0028]; NIH; Tourette Syndrome Association; Grifols LLC; Klingenstein Third Generation Foundation FX This was not an industry supported study. Support for this project was provided by the Intramural Research Program of the National Institute of Mental Health MH002666 (NCT01281969, protocol 11-M-0058 and NCT01778504, protocol 13-M-0028). Dr. Leckman has received support from the NIH (salary and research funding), Tourette Syndrome Association (research funding), Grifols LLC (research funding) and Klingenstein Third Generation Foundation (medical student fellowship program); he receives book royalties from John Wiley and Sons, McGraw-Hill, and Oxford University Press. The other authors have indicated no financial conflicts of interest. The remaining authors indicate no financial conflicts of interest. NR 33 TC 1 Z9 1 U1 4 U2 4 PU AMER ACAD SLEEP MEDICINE PI DARIEN PA 2510 N FRONTAGE RD, DARIEN, IL 60561 USA SN 1550-9389 EI 1550-9397 J9 J CLIN SLEEP MED JI J. Clin. Sleep Med. PY 2016 VL 12 IS 7 BP 1027 EP 1032 DI 10.5664/jcsm.5942 PG 6 WC Clinical Neurology SC Neurosciences & Neurology GA EF0AQ UT WOS:000389988200014 PM 27166296 ER PT J AU Dietch, JR Taylor, DJ Sethi, K Kelly, K Bramoweth, AD Roane, BM AF Dietch, Jessica R. Taylor, Daniel J. Sethi, Kevin Kelly, Kimberly Bramoweth, Adam D. Roane, Brandy M. TI Psychometric Evaluation of the PSQI in US College Students SO JOURNAL OF CLINICAL SLEEP MEDICINE LA English DT Article DE PSQI; sleep quality; students; college; psychometrics; validation; undergraduate; insomnia ID SLEEP QUALITY INDEX; TEST-RETEST RELIABILITY; CANCER-PATIENTS; MENTAL-HEALTH; INSOMNIA; VALIDITY; VALIDATION; EPIDEMIOLOGY; DEPRESSION; INVENTORY AB Study Objectives: Examine the psychometric properties of the PSQI in two U.S. college samples. Methods: Study I assessed convergent and divergent validity in 866 undergraduates who completed a sleep diary, PSQI, and other sleep and psychosocial measures. Study II assessed PSQI insomnia diagnostic accuracy in a separate sample of 147 healthy undergraduates with and without insomnia. Results: The PSQI global score had only moderate convergent validity with sleep diary sleep efficiency (prospective global measure of sleep continuity; r = 0.53), the Insomnia Severity Index (r = 0.63), and fatigue (r = 0.44). The PSQI global score demonstrated good divergent validity with measures of excessive daytime sleepiness (r = 0.18), circadian preference (r = -0.08), alcohol (r = 0.08) and marijuana (r = 0.05) abuse scales, and poor divergent validity with depression (r = 0.48), anxiety (r = 0.40), and perceived stress (r = 0.33). Examination of other analogous PSQI and sleep diary components showed low to moderate convergent validity: sleep latency (r = 0.70), wake after sleep onset (r = 0.37), sleep duration (r = 0.51), and sleep efficiency (r = -0.32). Diagnostic accuracy of the PSQI to detect insomnia was very high (area under the curve = 0.999). Sensitivity and specificity were maximized at a cutoff of 6. Conclusions: The PSQI demonstrated moderate convergent validity compared to measures of insomnia and fatigue and good divergent validity with measures of daytime sleepiness, circadian phase preference, and alcohol and marijuana use. The PSQI demonstrated considerable overlap with depression, anxiety, and perceived stress. Therefore, caution should be used with interpretation. C1 [Dietch, Jessica R.; Taylor, Daniel J.; Sethi, Kevin; Kelly, Kimberly] Univ North Texas, Dept Psychol, 1155 Union Circle 311280, Denton, TX 76203 USA. [Bramoweth, Adam D.] VA Pittsburgh Healthcare Syst, VISN Mental Illness Res Educ & Clin Ctr 4, Pittsburgh, PA USA. [Roane, Brandy M.] Univ North Texas Hlth Sci Ctr, Dept Internal Med, Ft Worth, TX USA. RP Taylor, DJ (reprint author), Univ North Texas, Dept Psychol, 1155 Union Circle 311280, Denton, TX 76203 USA. EM Daniel.Taylor@unt.edu FU University of North Texas [G69250]; National Institute of Allergy and Infectious Diseases [1R15AI085558-01A2] FX This was not an industry supported study. This study was supported by a grant from the University of North Texas (G69250) and from the National Institute of Allergy and Infectious Diseases (1R15AI085558-01A2). Dr. Roane has consulted for Johnson & Johnson. The other authors have indicated no financial conflicts of interest. The study was performed at the University of North Texas, Denton, TX. NR 49 TC 0 Z9 0 U1 3 U2 3 PU AMER ACAD SLEEP MEDICINE PI DARIEN PA 2510 N FRONTAGE RD, DARIEN, IL 60561 USA SN 1550-9389 EI 1550-9397 J9 J CLIN SLEEP MED JI J. Clin. Sleep Med. PY 2016 VL 12 IS 8 BP 1121 EP 1129 DI 10.5664/jcsm.6050 PG 9 WC Clinical Neurology SC Neurosciences & Neurology GA EF0BE UT WOS:000389989600009 PM 27166299 ER PT J AU Saline, A Goparaju, B Bianchi, MT AF Saline, Austin Goparaju, Balaji Bianchi, Matt T. TI Sleep Fragmentation Does Not Explain Misperception of Latency or Total Sleep Time SO JOURNAL OF CLINICAL SLEEP MEDICINE LA English DT Article DE misperception; insomnia; sleep latency; paradoxical; phenotype ID CHRONIC INSOMNIA; STATE MISPERCEPTION; APNEA PATIENTS; WAKE TIME; DURATION; PERCEPTION; DISORDER; IMPAIRMENT; DEPRESSION; COMPLAINTS AB Study Objectives: Perception of sleep-wake times may differ from objective measures, although the mechanisms remain elusive. Quantifying the misperception phenotype involves two operational challenges: defining objective sleep latency and treating sleep latency and total sleep time as independent factors. We evaluated a novel approach to address these challenges and test the hypothesis that sleep fragmentation underlies misperception. Methods: We performed a retrospective analysis on patients with or without obstructive sleep apnea during overnight diagnostic polysomnography in our laboratory (n = 391; n = 252). We compared subjective and objective sleep-wake durations to characterize misperception. We introduce a new metric, sleep during subjective latency (SDSL), which captures latency misperception without defining objective sleep latency and allows correction for latency misperception when assessing total sleep time (TST) misperception. Results: The stage content of SDSL is related to latency misperception, but in the opposite manner as our hypothesis: those with > 20 minutes of SDSL had less N1%, more N3%, and lower transition frequency. After adjusting for misperceived sleep during subjective sleep latency, TST misperception was greater in those with longer bouts of REM and N2 stages (OSA patients) as well as N3 (non-OSA patients), which also did not support our hypothesis. Conclusions: Despite the advantages of SDSL as a phenotyping tool to overcome operational issues with quantifying misperception, our results argue against the hypothesis that light or fragmented sleep underlies misperception. Further investigation of sleep physiology utilizing alternative methods than that captured by conventional stages may yield additional mechanistic insights into misperception. C1 [Saline, Austin; Goparaju, Balaji; Bianchi, Matt T.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. [Bianchi, Matt T.] Harvard Med Sch, Div Sleep Med, Boston, MA USA. RP Bianchi, MT (reprint author), Massachusetts Gen Hosp, Wang Neurol 7, 55 Fruit St, Boston, MA 02114 USA. EM mtbianchi@partners.org FU Department of Neurology, Massachusetts General Hospital; Center for Integration of Medicine and Innovative Technology; Milton Family Foundation; Servier FX This was not an industry supported study. Dr. Bianchi receives funding from the Department of Neurology, Massachusetts General Hospital, the Center for Integration of Medicine and Innovative Technology, and the Milton Family Foundation. Dr. Bianchi has a patent pending on a home sleep monitoring device. Dr. Bianchi received travel funding from Servier, has consulting agreements with Foramis, MC10, Insomnisolv, International Flavors and Fragrances, and GrandRounds, and has provided expert testimony in sleep medicine. The authors have indicated no financial conflicts of interest. NR 45 TC 2 Z9 2 U1 1 U2 1 PU AMER ACAD SLEEP MEDICINE PI DARIEN PA 2510 N FRONTAGE RD, DARIEN, IL 60561 USA SN 1550-9389 EI 1550-9397 J9 J CLIN SLEEP MED JI J. Clin. Sleep Med. PY 2016 VL 12 IS 9 BP 1245 EP 1255 DI 10.5664/jcsm.6124 PG 11 WC Clinical Neurology SC Neurosciences & Neurology GA EF0CF UT WOS:000389992400008 PM 27250816 ER PT J AU Aurora, RN Bista, SR Casey, KR Chowdhuri, S Kristo, DA Mallea, JM Ramar, K Rowley, JA Zak, RS Heald, JL AF Aurora, R. Nisha Bista, Sabin R. Casey, Kenneth R. Chowdhuri, Susmita Kristo, David A. Mallea, Jorge M. Ramar, Kannan Rowley, James A. Zak, Rochelle S. Heald, Jonathan L. TI Keep Calm and Debate On SO JOURNAL OF CLINICAL SLEEP MEDICINE LA English DT Letter ID ADAPTIVE SERVO-VENTILATION; CENTRAL SLEEP-APNEA; HEART-FAILURE PATIENTS; PROGNOSIS C1 [Aurora, R. Nisha] Johns Hopkins Univ, Sch Med, Baltimore, MD USA. [Bista, Sabin R.] Univ Nebraska Med Ctr, Omaha, NE USA. [Casey, Kenneth R.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. [Chowdhuri, Susmita] John D Dingell VA Med Ctr, Detroit, MI USA. [Chowdhuri, Susmita] Wayne State Univ, Detroit, MI USA. [Kristo, David A.] Univ Pittsburgh, Pittsburgh, PA USA. [Mallea, Jorge M.] Mayo Clin Florida, Transplant Ctr, Jacksonville, FL USA. [Ramar, Kannan] Mayo Clin, Rochester, MN USA. [Rowley, James A.] Wayne State Univ, Sch Med, Dept Med, Detroit, MI 48201 USA. [Zak, Rochelle S.] Univ Calif San Francisco, Sleep Disorders Ctr, San Francisco, CA 94143 USA. [Heald, Jonathan L.] Amer Acad Sleep Med, Darien, IL USA. RP Aurora, RN (reprint author), Johns Hopkins Sleep Disorders Ctr, Johns Hopkins Sch Med, Baltimore, MD 21224 USA. EM research@aasmnet.org NR 9 TC 0 Z9 0 U1 0 U2 0 PU AMER ACAD SLEEP MEDICINE PI DARIEN PA 2510 N FRONTAGE RD, DARIEN, IL 60561 USA SN 1550-9389 EI 1550-9397 J9 J CLIN SLEEP MED JI J. Clin. Sleep Med. PY 2016 VL 12 IS 9 BP 1315 EP 1316 DI 10.5664/jcsm.6148 PG 2 WC Clinical Neurology SC Neurosciences & Neurology GA EF0CF UT WOS:000389992400020 PM 27568903 ER PT J AU Palen, BN Donovan, LM Parsons, EC AF Palen, Brian N. Donovan, Lucas M. Parsons, Elizabeth C. TI An Unexpected Polysomnogram Finding SO JOURNAL OF CLINICAL SLEEP MEDICINE LA English DT Editorial Material ID POSITIVE AIRWAY PRESSURE; OBSTRUCTIVE SLEEP-APNEA; REM-SLEEP; BUPROPION C1 [Palen, Brian N.; Parsons, Elizabeth C.] VA Puget Sound Hlth Care Syst, Div Pulm & Crit Care Med, Seattle, WA USA. [Palen, Brian N.; Donovan, Lucas M.; Parsons, Elizabeth C.] Univ Washington, Div Pulm & Crit Care Med, Seattle, WA 98195 USA. RP Parsons, EC (reprint author), 1660 S Columbian Way,S-111 Pulm, Seattle, WA 98118 USA. EM elizabeth.parsons@va.gov FU NHLBI NIH HHS [T32 HL007287] NR 5 TC 0 Z9 0 U1 0 U2 0 PU AMER ACAD SLEEP MEDICINE PI DARIEN PA 2510 N FRONTAGE RD, DARIEN, IL 60561 USA SN 1550-9389 EI 1550-9397 J9 J CLIN SLEEP MED JI J. Clin. Sleep Med. PY 2016 VL 12 IS 11 BP 1567 EP 1569 DI 10.5664/jcsm.6294 PG 3 WC Clinical Neurology SC Neurosciences & Neurology GA EF0DU UT WOS:000389996700019 PM 27707444 ER PT J AU Haverhals, LM Manheim, CE Gilman, CV Jones, J Levy, C AF Haverhals, Leah M. Manheim, Chelsea E. Gilman, Carrie V. Jones, Jacqueline Levy, Cari TI Caregivers Create a Veteran-Centric Community in VHA Medical Foster Homes SO JOURNAL OF GERONTOLOGICAL SOCIAL WORK LA English DT Article DE caregiving/informal care; community-based service providers/systems; Veterans ID LONG-TERM-CARE; NURSING-HOME; FAMILY; VIEWS; INTERVIEW; BURDEN; LABOR; WANT; RACE AB The Veteran's Health Administration's Medical Foster Home program offers a unique long-term care option for veterans who require nursing-home-or assisted-living-level care. Veterans in a medical foster home reside with community-based caregivers who provide 24-hr-a-day care and monitoring. The veterans often remain in the medical foster home until end of life. Support and oversight is provided to the caregiver from the Veteran's Health Administration's community-based medical team. This qualitative descriptive study is based on secondary analysis of interviews with 20 medical foster home caregivers from 7 programs across the United States. The study's research aims are to describe and explain (a) the type of care backgrounds and skills these caregivers possess, (b) caregivers' primary motivations to open their homes to veterans who often have complex medical and social needs, and (c) how caregivers function in their role as primary caregiver for veterans. Findings indicated that caregivers interviewed had worked in long-term care settings and/or cared for family members. A strong desire to serve veterans was a primary motivation for caregivers, rather than financial gain. The caregivers' long-term care skills aided them in building and sustaining the unique medical foster home family-like community. C1 [Haverhals, Leah M.; Manheim, Chelsea E.; Gilman, Carrie V.; Jones, Jacqueline; Levy, Cari] Denver Vet Affairs Med Ctr, Denver Seattle Ctr Innovat, 1055 Clermont St Res A151, Denver, CO 80220 USA. [Jones, Jacqueline] Univ Colorado, Sch Nursing, Anschutz Med Campus, Aurora, CO USA. [Levy, Cari] Univ Colorado, Sch Med, Dept Med, Div Hlth Care Policy & Res, Anschutz Med Campus, Aurora, CO USA. RP Manheim, CE (reprint author), Denver Vet Affairs Med Ctr, Denver Seattle Ctr Innovat, 1055 Clermont St Res A151, Denver, CO 80220 USA. EM chelsea.manheim@va.gov NR 35 TC 0 Z9 0 U1 0 U2 0 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 1540-4048 EI 0163-4372 J9 J GERONTOL SOC WORK JI J. Gerontol. Soc. Work PY 2016 VL 59 IS 6 BP 441 EP 457 DI 10.1080/01634372.2016.1231730 PG 17 WC Geriatrics & Gerontology; Social Work SC Geriatrics & Gerontology; Social Work GA EE7JL UT WOS:000389791800002 PM 27598768 ER PT J AU Belstrom, D Paster, BJ Fiehn, NE Bardow, A Holmstrup, P AF Belstrom, Daniel Paster, Bruce J. Fiehn, Nils-Erik Bardow, Allan Holmstrup, Palle TI Salivary bacterial fingerprints of established oral disease revealed by the Human Oral Microbe Identification using Next Generation Sequencing (HOMINGS) technique SO JOURNAL OF ORAL MICROBIOLOGY LA English DT Article DE saliva; HOMINGS; periodontitis; dental caries ID EARLY-CHILDHOOD CARIES; HEALTH; PROFILES; PERIODONTITIS; MICROARRAY; LESIONS; MUTANS; COHORT; ADULTS AB Background and objective: The composition of the salivary microbiota, as determined using various molecular methods, has been reported to differentiate oral health from diseases. Thus, the purpose of this study was to utilize the newly developed molecular technique HOMINGS (Human Oral Microbe Identification using Next Generation Sequencing) for comparison of the salivary microbiota in patients with periodontitis, patients with dental caries, and orally healthy individuals. The hypothesis was that this method could add on to the existing knowledge on salivary bacterial profiles in oral health and disease. Design: Stimulated saliva samples (n = 30) were collected from 10 patients with untreated periodontitis, 10 patients with untreated dental caries, and 10 orally healthy individuals. Salivary microbiota was analyzed using HOMINGS and statistical analysis was performed using Kruskal-Wallis test with Benjamini-Hochberg's correction. Results: From a total of 30 saliva samples, a mean number of probe targets of 205 (range 120-353) were identified, and a statistically significant higher mean number of targets was registered in samples from patients with periodontitis (mean 220, range 143-306) and dental caries (mean 221, range 165-353) as compared to orally healthy individuals (mean 174, range 120-260) (p = 0.04 and p = 0.04). Nine probe targets were identified with a different relative abundance between groups (p=0.05). Conclusions: Cross-sectional comparison of salivary bacterial profiles by means of HOMINGS analysis showed that different salivary bacterial profiles were associated with oral health and disease. Future large-scale prospective studies are needed to evaluate if saliva-based screening for disease-associated oral bacterial profiles may be used for identification of patients at risk of acquiring periodontitis and dental caries. C1 [Belstrom, Daniel; Holmstrup, Palle] Univ Copenhagen, Sch Dent, Sect Periodontol & Microbiol, Fac Hlth Sci, Norre Alle 20, Copenhagen, Denmark. [Paster, Bruce J.] Forsyth Inst, Dept Microbiol, Cambridge, MA USA. [Paster, Bruce J.] Harvard Sch Dent Med, Dept Oral Med Infect & Immun, Boston, MA USA. [Fiehn, Nils-Erik] Univ Copenhagen, Dept Immunol & Microbiol, Copenhagen, Denmark. [Bardow, Allan] Univ Copenhagen, Sch Dent, Dept Oral Med, Copenhagen, Denmark. RP Belstrom, D (reprint author), Univ Copenhagen, Sch Dent, Sect Periodontol & Microbiol, Fac Hlth Sci, Norre Alle 20, Copenhagen, Denmark. EM dbel@sund.ku.dk FU Danish Dental Association; Danish Foundation of Mutual Efforts in Dental Care; Trygfonden; Simon Spies Foundation; NIH [DE021565] FX This study was supported by external financial support by: the Danish Dental Association, the Danish Foundation of Mutual Efforts in Dental Care, Trygfonden, and the Simon Spies Foundation. Partly funded by NIH (DE021565). NR 36 TC 7 Z9 8 U1 0 U2 3 PU CO-ACTION PUBLISHING PI JARFALLA PA RIPVAGEN 7, JARFALLA, SE-175 64, SWEDEN SN 2000-2297 J9 J ORAL MICROBIOL JI J. Oral Microbiology PY 2016 VL 8 AR 30170 DI 10.3402/jom.v8.30170 PG 7 WC Microbiology SC Microbiology GA EE9VR UT WOS:000389974900001 PM 26782357 ER PT J AU Olsen, I Taubman, MA Singhrao, SK AF Olsen, Ingar Taubman, Martin A. Singhrao, Sim K. TI Porphyromonas gingivalis suppresses adaptive immunity in periodontitis, atherosclerosis, and Alzheimer's disease SO JOURNAL OF ORAL MICROBIOLOGY LA English DT Review DE P. gingivalis; adaptive immunity; suppression; periodontitis; atherosclerosis; Alzheimer's disease ID REGULATORY T-CELLS; ALVEOLAR BONE LOSS; OSTEOPROTEGERIN LIGAND; TH17/TREG IMBALANCE; ORAL INFECTION; ANTIMICROBIAL ACTIVITY; MURINE MODEL; RESORPTION; MICE; RECEPTOR AB Porphyromonas gingivalis, a keystone pathogen in chronic periodontitis, has been found to associate with remote body organ inflammatory pathologies, including atherosclerosis and Alzheimer's disease (AD). Although P. gingivalis has a plethora of virulence factors, much of its pathogenicity is surprisingly related to the overall immunosuppression of the host. This review focuses on P. gingivalis aiding suppression of the host's adaptive immune system involving manipulation of cellular immunological responses, specifically Tcells and B cells in periodontitis and related conditions. In periodontitis, this bacterium inhibits the synthesis of IL-2 and increases humoral responses. This reduces the inflammatory responses related to T-and B-cell activation, and subsequent IFN-gamma secretion by a subset of Tcells. The Tcells further suppress upregulation of programmed cell death-1 (PD-1)-receptor on CD+ cells and its ligand PD-L1 on CD11b(+) -subset of T cells. IL-2 downregulates genes regulated by immune response and induces a cytokine pattern in which the Th17 lineage is favored, thereby modulating the Th17/T-regulatory cell (Treg) imbalance. The suppression of IFN-gamma-stimulated release of interferon-inducible protein-10 (IP-10) chemokine ligands [ITAC (CXCL11) and Mig (CXCL9)] by P. gingivalis capsular serotypes triggers distinct T cell responses and contributes to local immune evasion by release of its outer membrane vesicles. In atherosclerosis, P. gingivalis reduces Tregs, transforms growth factor beta-1 (TGF beta-1), and causes imbalance in the Th17 lineage of the Treg population. In AD, P. gingivalis may affect the blood-brain barrier permeability and inhibit local IFN-gamma response by preventing entry of immune cells into the brain. The scarcity of adaptive immune cells in AD neuropathology implies P. gingivalis infection of the brain likely causing impaired clearance of insoluble amyloid and inducing immunosuppression. By the effective manipulation of the armory of adaptive immune suppression through a plethora of virulence factors, P. gingivalis may act as a keystone organism in periodontitis and in related systemic diseases and other remote body inflammatory pathologies. C1 [Olsen, Ingar] Univ Oslo, Dept Oral Biol, Fac Dent, POB 1052 Blindern, NO-0316 Oslo, Norway. [Taubman, Martin A.] Forsyth Inst, Dept Immunol & Infect Dis, Cambridge, MA USA. [Taubman, Martin A.] Harvard Med Sch, Harvard Sch Dent Med, Dept Dev Biol, Boston, MA USA. [Singhrao, Sim K.] Univ Cent Lancashire, Sch Dent, Coll Clin & Biomed Sci, Dementia & Neurodegenerat Res Grp, Preston, Lancs, England. RP Olsen, I (reprint author), Univ Oslo, Dept Oral Biol, Fac Dent, POB 1052 Blindern, NO-0316 Oslo, Norway. EM ingar.olsen@odont.uio.no FU European Commission [FP7-HEALTH-306029]; University of Central Lancashire FX Ingar Olsen acknowledges funding through the European Commission (FP7-HEALTH-306029 'TRIGGER'). Daniel J Smith is acknowledged for his help with the manuscript. Sim K. Singhrao acknowledges the continued financial support for her research by the University of Central Lancashire. NR 90 TC 0 Z9 0 U1 4 U2 4 PU CO-ACTION PUBLISHING PI JARFALLA PA RIPVAGEN 7, JARFALLA, SE-175 64, SWEDEN SN 2000-2297 J9 J ORAL MICROBIOL JI J. Oral Microbiology PY 2016 VL 8 AR 33029 DI 10.3402/jom.v8.33029 PG 13 WC Microbiology SC Microbiology GA EE9VA UT WOS:000389973100001 PM 27882863 ER PT J AU Finkelman, MD Kulich, RJ Butler, SF Jackson, WC Friedman, FD Smits, N Weiner, SG AF Finkelman, Matthew D. Kulich, Ronald J. Butler, Stephen F. Jackson, William C. Friedman, Franklin D. Smits, Niels Weiner, Scott G. TI An investigation of completion times on the Screener and Opioid Assessment for Patients with Pain - revised (SOAPP-R) SO JOURNAL OF PAIN RESEARCH LA English DT Article DE chronic pain; substance abuse; risk stratification; aberrant drug-related behavior; response times; response latency ID RESPONSE LATENCIES; EMERGENCY-DEPARTMENT; PERSONALITY TEST; TABLET COMPUTER; ATTITUDE ACCESSIBILITY; SOCIAL DESIRABILITY; ONLINE QUESTIONNAIRE; INCREMENTAL VALIDITY; MONITORING PROGRAM; DETECTING FAKERS AB Background: Respondents' scores to the Screener and Opioid Assessment for Patients with Pain -revised (SOAPP-R) have been shown to be predictive of aberrant drug-related behavior (ADB). However, research is lacking on whether an individual's completion time (the amount of time that he/she takes to finish the screener) has utility in predicting ADB, despite the fact that response speed has been useful in predicting behavior in other fields. The purpose of this study was to evaluate the degree to which SOAPP-R completion time is predictive of ADB. Materials and methods: This retrospective study analyzed completion-time data from 82 adult emergency department patients who completed the SOAPP-R on a tablet computer. The utility of SOAPP-R completion times in predicting ADB was assessed via logistic regression and the area under the curve (AUC) statistic. An external measure of ADB using Prescription Drug Monitoring Program data defined ADB to have occurred in individuals with at least four opioid prescriptions and at least four prescribers in 12 months. Results: Although there was a slight trend for individuals with greater completion times to have greater odds of ADB (odds ratio 1.004 in simple logistic regression), the association between SOAPP-R completion time and ADB was not statistically significant in either simple logistic regression (P=0.307) or multiple logistic regression adjusting for SOAPP-R score (P=0.419). AUC values for the prediction of ADB using completion time alone, SOAPP-R score alone, and both completion time and SOAPP-R score were 0.63, 0.64, and 0.65, respectively. Conclusion: There was no significant evidence that SOAPP-R completion times were predictive of ADB among emergency department patients. However, the AUC value for completion times was only slightly less than that for SOAPP-R total scores. C1 [Finkelman, Matthew D.] Tufts Univ, Sch Dent Med, Dept Publ Hlth & Community Serv, 1 Kneeland St, Boston, MA 02111 USA. [Kulich, Ronald J.] Tufts Univ, Sch Dent Med, Craniofacial Pain & Headache Ctr, Boston, MA 02111 USA. [Kulich, Ronald J.; Jackson, William C.] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA. [Butler, Stephen F.] Inflexxion Inc, Newton, MA USA. [Friedman, Franklin D.] Tufts Med Ctr, Dept Emergency Med, Boston, MA USA. [Smits, Niels] Univ Amsterdam, Res Inst Child Dev & Educ, Dept Methods & Stat, Amsterdam, Netherlands. [Weiner, Scott G.] Brigham & Womens Hosp, Dept Emergency Med, 75 Francis St, Boston, MA 02115 USA. RP Finkelman, MD (reprint author), Tufts Univ, Sch Dent Med, Dept Publ Hlth & Community Serv, 1 Kneeland St, Boston, MA 02111 USA. EM matthew.finkelman@tufts.edu NR 67 TC 0 Z9 0 U1 0 U2 0 PU DOVE MEDICAL PRESS LTD PI ALBANY PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND SN 1178-7090 J9 J PAIN RES JI J. Pain Res. PY 2016 VL 9 BP 1163 EP 1171 DI 10.2147/JPR.S123454 PG 9 WC Clinical Neurology SC Neurosciences & Neurology GA EE7YJ UT WOS:000389841100003 PM 27980436 ER PT J AU Kasar, S Brown, JR AF Kasar, S. Brown, J. R. TI Mutational landscape and underlying mutational processes in chronic lymphocytic leukemia SO MOLECULAR & CELLULAR ONCOLOGY LA English DT Editorial Material DE CLL; mutation signature; somatic hypermutation; Whole genome sequencing ID EVOLUTION; SIGNATURES AB Sequencing studies have been instrumental in understanding the genetic basis of chronic lymphocytic leukemia (CLL). Our recent whole-genome sequencing study focusing on lower cytogenetic risk CLL demonstrated that CLL mutations can be attributed to 3 key mutational processes-2 types of activation induced-cytidine deaminase (AID) signatures and an aging signature-that operate at different times throughout CLL evolution. C1 [Kasar, S.; Brown, J. R.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Kasar, S.; Brown, J. R.] Harvard Med Sch, Brigham & Womens Hosp, Dept Med, Boston, MA USA. RP Brown, JR (reprint author), Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.; Brown, JR (reprint author), Harvard Med Sch, Brigham & Womens Hosp, Dept Med, Boston, MA USA. EM Jennifer_Brown@dfci.harvard.edu NR 10 TC 0 Z9 0 U1 0 U2 0 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 2372-3556 EI 2372-3548 J9 MOL CELL ONCOL JI MOL. CELL ONCOL. PY 2016 VL 3 IS 4 DI 10.1080/23723556.2016.1157667 PG 3 WC Oncology SC Oncology GA ED9GX UT WOS:000389179300004 ER PT J AU Montero, J Letai, A AF Montero, Joan Letai, Anthony TI Dynamic BH3 profiling-poking cancer cells with a stick SO MOLECULAR & CELLULAR ONCOLOGY LA English DT Article ID CLINICAL-RESPONSE; CHEMOTHERAPY AB The vast majority of efforts in precision medicine for cancer try to link static genetic information to tumor biology and from there predict clinical response. Dynamic BH3 profiling offers an alternative functional approach by measuring death signaling induced by specific drugs in tumors from patients ex vivo to predict clinical response. C1 [Montero, Joan; Letai, Anthony] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA 02115 USA. RP Letai, A (reprint author), Harvard Med Sch, Dana Farber Canc Inst, Boston, MA 02115 USA. EM anthony_letai@dfci.harvard.edu NR 10 TC 1 Z9 1 U1 0 U2 2 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 2372-3556 EI 2372-3548 J9 MOL CELL ONCOL JI MOL. CELL ONCOL. PY 2016 VL 3 IS 3 AR UNSP e1040144 DI 10.1080/23723556.2015.1040144 PG 3 WC Oncology SC Oncology GA ED9GJ UT WOS:000389177900011 PM 27314085 ER PT S AU Paulson, B Shin, I Kong, B Sauer, G Dugasani, SR Khazaeinezhad, R Jung, W Joo, B Oh, K AF Paulson, Bjorn Shin, Inchul Kong, Byungjoo Sauer, Gregor Dugasani, Sreekantha Reddy Khazaeinezhad, Reza Jung, Woohyun Joo, Boram Oh, Kyunghwan BE Kobayashi, N Ouchen, F Rau, I TI Preparation and optical characterization of DNA-riboflavin thin films SO NANOBIOSYSTEMS: PROCESSING, CHARACTERIZATION, AND APPLICATIONS IX SE Proceedings of SPIE LA English DT Proceedings Paper CT Conference on Nanobiosystems - Processing, Characterization, and Applications IX CY AUG 28-31, 2016 CL San Diego, CA SP SPIE DE DNA; riboflavin; ellipsometry; biocompatible; waveguide; spectrometry; host matrix ID RING AB Thin films of DNA biopolymer thin film are fabricated by a drop casting process on glass and silicon substrates, as well as freestanding. The refractive index is measured by elliposmetry and in bulk DNA film the refractive index is shown to be increased in the 600 to 900 nm DNA transparency window by doping with riboflavin. Further analysis with FT-IR, Raman, and XRD are used to determine whether binding between riboflavin and DNA occurs. C1 [Paulson, Bjorn; Kong, Byungjoo; Jung, Woohyun; Oh, Kyunghwan] Yonsei Univ, Dept Phys, 50 Yonsei Ro, Seoul 03722, South Korea. [Shin, Inchul] Samsung Elect Co Ltd, Suwon, South Korea. [Sauer, Gregor] Fredrich Schiller Univ, Fac Phys & Astron, Max Wein Pl 1, D-07743 Jena, Germany. [Dugasani, Sreekantha Reddy] Sungkyunkwan Univ, Dept Phys, Suwon 440746, South Korea. [Khazaeinezhad, Reza] Massachusetts Gen Hosp, Wellman Ctr Photomed, 55 Fruit St, Boston, MA 02114 USA. [Joo, Boram] LG Display Inc, Paju, South Korea. RP Paulson, B (reprint author), Yonsei Univ, Dept Phys, 50 Yonsei Ro, Seoul 03722, South Korea. EM paulson@yonsei.ac.kr NR 17 TC 0 Z9 0 U1 0 U2 0 PU SPIE-INT SOC OPTICAL ENGINEERING PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA SN 0277-786X BN 978-1-5106-0247-2; 978-1-5106-0248-9 J9 PROC SPIE PY 2016 VL 9928 AR 99280F DI 10.1117/12.2237516 PG 6 WC Biophysics; Nanoscience & Nanotechnology; Optics SC Biophysics; Science & Technology - Other Topics; Optics GA BG6DF UT WOS:000390026900008 ER PT J AU McLaughlin, S Ahumada, M Franco, W Mah, TF Seymour, R Suuronen, EJ Alarcon, EI AF McLaughlin, Sarah Ahumada, Manuel Franco, Walfre Mah, Thien-Fah Seymour, Richard Suuronen, Erik J. Alarcon, Emilio I. TI Sprayable peptide-modified silver nanoparticles as a barrier against bacterial colonization SO NANOSCALE LA English DT Article ID TOXICITY; STABILITY; DISSOLUTION; MEDICINE; EFFICACY; LIGANDS; PH AB Sprayable formulations of AgNPs were prepared by exchanging citrate capping agents with LL37-SH peptides. The AgNP@LL37 material was then combined with type I collagen to form a stable film once sprayed. The AgNP@LL37 spray prevented Pseudomonas aeruginosa (P. aeruginosa) proliferation and eradicated a P. aeruginosa biofilm, while being non-toxic for human skin fibroblasts embedded within 3D artificial skin constructs. Finally, no silver infiltration was observed after spraying on a full-thickness skin wound in a mouse model. C1 [McLaughlin, Sarah; Ahumada, Manuel; Seymour, Richard; Suuronen, Erik J.; Alarcon, Emilio I.] Univ Ottawa, Div Cardiac Surg Res, Inst Heart, 40 Ruskin St, Ottawa, ON K1Y 4W7, Canada. [Franco, Walfre] Harvard Med Sch, Massachusetts Gen Hosp, Dept Dermatol, Wellman Ctr Photomed, Boston, MA USA. [Mah, Thien-Fah; Alarcon, Emilio I.] Univ Ottawa, Dept Biochem Microbiol & Immunol, Fac Med, Ottawa, ON, Canada. RP Suuronen, EJ; Alarcon, EI (reprint author), Univ Ottawa, Div Cardiac Surg Res, Inst Heart, 40 Ruskin St, Ottawa, ON K1Y 4W7, Canada.; Alarcon, EI (reprint author), Univ Ottawa, Dept Biochem Microbiol & Immunol, Fac Med, Ottawa, ON, Canada. EM esuuronen@ottawaheart.ca; ealarcon@ottawaheart.ca FU NSERC Canada [342107, RGPIN-2015-06325]; Burroughs Wellcome Fund; Cystic Fibrosis Canada; UOHI [1255] FX This work was made possible by funding from NSERC Canada to EIA and EJS (Discovery Grants #342107 to EJS and RGPIN-2015-06325 to EA), the Burroughs Wellcome Fund to EIA (Travel Grant), and Cystic Fibrosis Canada to TFM. EIA also thanks UOHI start-up grant 1255. The authors would like to thank Professor May Griffith for providing the LL37-SH peptide used in this work. NR 21 TC 0 Z9 0 U1 1 U2 1 PU ROYAL SOC CHEMISTRY PI CAMBRIDGE PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND SN 2040-3364 EI 2040-3372 J9 NANOSCALE JI Nanoscale PY 2016 VL 8 IS 46 BP 19200 EP 19203 DI 10.1039/c6nr07976h PG 4 WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied SC Chemistry; Science & Technology - Other Topics; Materials Science; Physics GA EE3AE UT WOS:000389457400003 PM 27834428 ER PT J AU Pankov, A Binney, RJ Staffaroni, AM Kornak, J Attygalle, S Schuff, N Weiner, MW Kramer, JH Dickerson, BC Miller, BL Rosen, HJ AF Pankov, Aleksandr Binney, Richard J. Staffaroni, Adam M. Kornak, John Attygalle, Suneth Schuff, Norbert Weiner, Michael W. Kramer, Joel H. Dickerson, Bradford C. Miller, Bruce L. Rosen, Howard J. TI Data-driven regions of interest for longitudinal change in frontotemporal lobar degeneration SO NEUROIMAGE-CLINICAL LA English DT Article DE Frontotemporal dementia; Magnetic resonance imaging ID MILD COGNITIVE IMPAIRMENT; TENSOR-BASED MORPHOMETRY; ALZHEIMERS-DISEASE; SEMANTIC DEMENTIA; BEHAVIORAL VARIANT; ATROPHY; BRAIN; MRI; PROGRESSION; PREVALENCE AB Current research is investigating the potential utility of longitudinal measurement of brain structure as a marker of drug effect in clinical trials for neurodegenerative disease. Recent studies in Alzheimer3s disease (AD) have shown that measurement of change in empirically derived regions of interest (ROIs) allows more reliable measurement of change over time compared with regions chosen a-priori based on known effects of AD on brain anatomy. Frontotemporal lobar degeneration (FTLD) is a devastating neurodegenerative disorder for which there are no approved treatments. The goal of this study was to identify an empirical ROI that maximizes the effect size for the annual rate of brain atrophy in FTLD compared with healthy age matched controls, and to estimate the effect size and associated power estimates for a theoretical study that would use change within this ROI as an outcome measure. Eighty six patients with FTLD were studied, including 43 who were imaged twice at 1.5 T and 43 at 3 T, along with 105 controls (37 imaged at 1.5 T and 67 at 3 T). Empirically-derived maps of change were generated separately for each field strength and included the bilateral insula, dorsolateral, medial and orbital frontal, basal ganglia and lateral and inferior temporal regions. The extent of regions included in the 3 T map was larger than that in the 1.5 T map. At both field strengths, the effect sizes for imaging were larger than for any clinical measures. At 3 T, the effect size for longitudinal change measured within the empirically derived ROI was larger than the effect sizes derived from frontal lobe, temporal lobe or whole brain ROIs. The effect size derived from the data-driven 1.5 T map was smaller than at 3 T, and was not larger than the effect size derived from a-priori ROIs. It was estimated that measurement of longitudinal change using 1.5 T MR systems requires approximately a 3-fold increase in sample size to obtain effect sizes equivalent to those seen at 3 T. While the results should be confirmed in additional datasets, these results indicate that empirically derived ROIs can reduce the number of subjects needed for a longitudinal study of drug effects in FTLD compared with a-priori ROIs. Field strength may have a significant impact on the utility of imaging for measuring longitudinal change. c 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license. C1 [Pankov, Aleksandr] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Binney, Richard J.; Staffaroni, Adam M.; Attygalle, Suneth; Kramer, Joel H.; Miller, Bruce L.; Rosen, Howard J.] Univ Calif San Francisco, Dept Neurol, Memory & Aging Ctr, San Francisco, CA USA. [Schuff, Norbert; Weiner, Michael W.] Univ Calif San Francisco, Dept Radiol, San Francisco, CA USA. [Pankov, Aleksandr] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA USA. [Dickerson, Bradford C.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. RP Pankov, A; Rosen, HJ (reprint author), Univ Calif San Francisco, Memory & Aging Ctr, Suite 190,Box 1207,675 Nelson Rising Lane, San Francisco, CA 94158 USA. FU National Science Foundation [1144247]; National Institute of General Medical Sciences [T32GM067547]; National Institutes of Health [AG045333, AG032306, AG019724, AG023501] FX This project was supported by the National Science Foundation 1144247 (A.P.); The National Institute of General Medical Sciences T32GM067547 (A.P.); The National Institutes of Health grant numbers AG045333 and AG032306 (H.J.R.), and AG019724 and AG023501 (B.L.M.). The authors declare no competing financial interests. NR 45 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 2213-1582 J9 NEUROIMAGE-CLIN JI NeuroImage-Clin. PY 2016 VL 12 BP 332 EP 340 DI 10.1016/j.nicl.2015.08.002 PG 9 WC Neuroimaging SC Neurosciences & Neurology GA EF3AI UT WOS:000390196400039 PM 27547726 ER PT J AU Oestreich, LKL Pasternak, O Shenton, ME Kubicki, M Gong, X McCarthy-Jones, S Whitford, TJ AF Oestreich, Lena K. L. Pasternak, Ofer Shenton, Martha E. Kubicki, Marek Gong, Xue McCarthy-Jones, Simon Whitford, Thomas J. CA Australian Schizophrenia Res Bank TI Abnormal white matter microstructure and increased extracellular free-water in the cingulum bundle associated with delusions in chronic schizophrenia SO NEUROIMAGE-CLINICAL LA English DT Article DE Free-water imaging; Schizophrenia; Delusions; Limbic system; Diffusion Tensor Imaging ID POSITRON-EMISSION-TOMOGRAPHY; RECENT-ONSET SCHIZOPHRENIA; UNCINATE FASCICULUS; DIFFUSION MRI; MEMORY PERFORMANCE; RADIAL DIFFUSIVITY; LIMBIC SYSTEM; 1ST EPISODE; HUMAN BRAIN; TRACTOGRAPHY AB Background: There is growing evidence to suggest that delusions associated with schizophrenia arise from altered structural brain connectivity. The present study investigated whether structural changes in three major fasciculi that interconnect the limbic system-the cingulum bundle, uncinate fasciculus and fornix-are associated with delusions in chronic schizophrenia patients. Methods: Free-water corrected Diffusion Tensor Imaging was used to investigate the association between delusions and both microstructural changes within these three fasciculi and extracellular changes in the surrounding free-water. Clinical data and diffusion MRI scans were obtained from 28 healthy controls and 86 schizophrenia patients, of whom 34 had present state delusions, 35 had a lifetime history but currently remitted delusions, and 17 had never experienced delusions. Results: While present state and remitted delusions were found to be associated with reduced free-water corrected fractional anisotropy (FAT) and increased free-water corrected radial diffusivity (RDT) in the cingulum bundle bilaterally, extracellular free-water (FW) in the left cingulum bundle was found to be specifically associated with present state delusions in chronic schizophrenia. No changes were observed in the remaining tracts. Conclusions: These findings suggest that state and trait delusions in chronic schizophrenia are associated with microstructural processes, such as myelin abnormalities (as indicated by decreased FAT and increased RDT) in the cingulum bundle and that state delusions are additionally associated with extracellular processes such as neuroinflammation or atrophy (as indicated by increased FW) in the left cingulum bundle. (C) 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license. C1 [Oestreich, Lena K. L.; Whitford, Thomas J.] UNSW Australia, Sch Psychol, Sydney, NSW, Australia. [Oestreich, Lena K. L.] Univ Queensland, Queensland Brain Inst, QBI Bldg 79, St Lucia, Qld 4072, Australia. [Pasternak, Ofer; Shenton, Martha E.; Kubicki, Marek; Gong, Xue] Harvard Med Sch, Brigham & Womens Hosp, Dept Psychiat, Psychiat Neuroimaging Lab, Boston, MA USA. [Pasternak, Ofer; Shenton, Martha E.; Kubicki, Marek] Harvard Med Sch, Brigham & Womens Hosp, Dept Radiol, Boston, MA USA. [Shenton, Martha E.] VA Boston Healthcare Syst, Boston, MA USA. [Australian Schizophrenia Res Bank] Schizophrenia Res Inst, Randwick, NSW, Australia. [McCarthy-Jones, Simon] Macquarie Univ, Dept Cognit Sci, Sydney, NSW, Australia. [McCarthy-Jones, Simon] Trinity Coll Dublin, Dept Psychiat, Dublin, Ireland. RP Oestreich, LKL (reprint author), Univ Queensland, Queensland Brain Inst, QBI Bldg 79, St Lucia, Qld 4072, Australia. EM l.oestreich@uq.edu.au OI Oestreich, Lena/0000-0002-4978-7794 FU NHMRC [386500]; Pratt Foundation; Ramsay Health Care; Sylvia and Charles Viertel Charitable Foundation; Schizophrenia Research Institute, from the NSW Ministry of Health; Australian Research Council [DP140104394, DE140101077]; National Health and Medical Research Council of Australia [APP1090507]; National Institutes of Health [R01MH108574, R01MH085953, R01MH074794, 2P41EB015902, 1R01AG042512, R01MH102377, R01 MH102377]; NARSAD young investigator award; VA merit award FX This study was supported by the Schizophrenia Research Institute using data from the Australian Schizophrenia Research Bank, funded by NHMRC Enabling Grant (No. 386500) held by V Carr, U Schall, R Scott, A Jablensky, B Mowry, P Michie, S Catts, F Henskens and C Pantelis (Chief Investigators), and the Pratt Foundation, Ramsay Health Care, the Sylvia and Charles Viertel Charitable Foundation, as well the Schizophrenia Research Institute, using an infrastructure grant from the NSW Ministry of Health. Thomas Whitford is supported by a Discovery Project from the Australian Research Council (DP140104394) and a Career Development Fellowship from the National Health and Medical Research Council of Australia (APP1090507). Simon McCarthy-Jones is supported by an Australian Research Council Discovery Early Career Research Award (DE140101077). Ofer Pasternak is supported by the National Institutes of Health grants R01MH108574, R01MH085953, R01MH074794, 2P41EB015902, 1R01AG042512, R01MH102377, and a NARSAD young investigator award. Martha Shenton is supported by a VA merit award. Marek Kubicki is supported by a National Institutes of Health grant R01 MH102377. This work is part of Lena Oestreich's doctorate thesis (PhD). NR 57 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 2213-1582 J9 NEUROIMAGE-CLIN JI NeuroImage-Clin. PY 2016 VL 12 BP 405 EP 414 DI 10.1016/j.nicl.2016.08.004 PG 10 WC Neuroimaging SC Neurosciences & Neurology GA EF3AI UT WOS:000390196400047 PM 27622137 ER PT J AU Ford, JM Roach, BJ Palzes, VA Mathalon, DH AF Ford, Judith M. Roach, Brian J. Palzes, Vanessa A. Mathalon, Daniel H. TI Using concurrent EEG and fMRI to probe the state of the brain in schizophrenia SO NEUROIMAGE-CLINICAL LA English DT Article DE Concurrent EEG plus fMRI; Perception; N100; P200; Schizophrenia; Avolition/apathy ID EVENT-RELATED POTENTIALS; HUMAN AUDITORY-CORTEX; SELECTIVE-ATTENTION; DEFAULT MODE; NEUROMAGNETIC RESPONSES; FUNCTIONAL MRI; RESTING-STATE; COMPONENT; HALLUCINATIONS; PERCEPTION AB Perceptional abnormalities in schizophrenia are associated with hallucinations and delusions, but alsowith negative symptoms and poor functional outcome. Perception can be studied using EEG-derived event related potentials (ERPs). Because of their excellent temporal resolution, ERPs have been used to ask when perception is affected by schizophrenia. Because of its excellent spatial resolution, functional magnetic resonance imaging (fMRI) has been used to ask where in the brain these effects are seen. We acquired EEG and fMRI data simultaneously to explore when and where auditory perception is affected by schizophrenia. Thirty schizophrenia (SZ) patients and 23 healthy comparison subjects (HC) listened to 1000 Hz tones occurring about every second. We used joint independent components analysis (jICA) to combine EEG-based event-related potential (ERP) and fMRI responses to tones. Five ERP-fMRI joint independent components (JIC) were extracted. The "N100" JIC had temporal weights during N100 (peaking at 100 ms post-tone onset) and fMRI spatial weights in superior and middle temporal gyri (STG/MTG); however, it did not differ between groups. The "P200" JIC had temporal weights during P200 and positive fMRI spatial weights in STG/MTG and frontal areas, and negative spatial weights in the nodes of the default mode network (DMN) and visual cortex. Groups differed on the "P200" JIC: SZ had smaller "P200" JIC, especially those with more severe avolition/apathy. This is consistent with negative symptoms being related to perceptual deficits, and suggests patients with avolition/apathy may allocate too few resources to processing external auditory events and too many to processing internal events. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license. C1 [Ford, Judith M.; Roach, Brian J.; Palzes, Vanessa A.; Mathalon, Daniel H.] San Francisco VA Med Ctr, 4150 Clement St, San Francisco, CA 94121 USA. [Ford, Judith M.; Mathalon, Daniel H.] Univ Calif San Francisco, 505 Parnassus Ave, San Francisco, CA 94143 USA. RP Ford, JM (reprint author), San Francisco VA Med Ctr, Mental Hlth Serv, 116D,4150 Clement St, San Francisco, CA 94121 USA. EM Judith.Ford@ucsf.edu; Brian.Roach@ncire.org; Vanessa.Palzes@ncire.org; Daniel.Mathalon@ucsf.edu FU National Institute of Mental Health [MH58262]; VA [I01 CX000497] FX This work was supported by grants from National Institute of Mental Health (MH58262 to JMF) and the VA (I01 CX000497 to JMF). DHM consults for Boehringer Ingelheim. The authors have declared that there are no conflicts of interest in relation to the subject of this study. NR 71 TC 0 Z9 0 U1 3 U2 3 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 2213-1582 J9 NEUROIMAGE-CLIN JI NeuroImage-Clin. PY 2016 VL 12 BP 429 EP 441 DI 10.1016/j.nicl.2016.08.009 PG 13 WC Neuroimaging SC Neurosciences & Neurology GA EF3AI UT WOS:000390196400050 PM 27622140 ER PT J AU Helpman, L Marin, MF Papini, S Zhu, X Sullivan, GM Schneier, F Neria, M Shvil, E Aragon, MJM Markowitz, JC Lindquist, MA Wager, TD Milad, MR Neria, Y AF Helpman, Liat Marin, Marie-France Papini, Santiago Zhu, Xi Sullivan, Gregory M. Schneier, Franklin Neria, Mariana Shvil, Erel Aragon, Maria Josefa Malaga Markowitz, John C. Lindquist, Martin A. Wager, Tor D. Milad, Mohammed R. Neria, Yuval TI Neural changes in extinction recall following prolonged exposure treatment for PTSD: A longitudinal fMRI study SO NEUROIMAGE-CLINICAL LA English DT Article ID POSTTRAUMATIC-STRESS-DISORDER; MEDIAL PREFRONTAL CORTEX; IMPAIRED FEAR INHIBITION; CONDITIONED FEAR; EMOTIONAL PERSEVERATION; HORMONAL CONTRACEPTIVES; SEX-DIFFERENCES; AMYGDALA; RESPONSES; TRAUMA AB Background: Neurobiological models of posttraumatic stress disorder (PTSD) implicate fear processing impairments in the maintenance of the disorder. Specific deficits in extinction recall, the retention of learned extinction, have been demonstrated. While deficient extinction recall, and the associated activation pattern of prefrontal and hippocampal regions, distinguishes individuals with PTSD from controls, research has not yet examined changes following treatment. We examined the behavioral and neural correlates of extinction recall before and after cognitive behavioral treatment of PTSD. Methods: Fifty-eight participants (30 with PTSD, 28 trauma-exposed matched controls) underwent a 2-day behavioral fear conditioning, extinction, and recall paradigm during functional magnetic resonance imaging (fMRI). The same procedures were repeated 10 weeks later, after PTSD patients had completed prolonged exposure treatment. We analyzed fMRI data from 32 subjects (16 PTSD; 16 controls) and skin conductance response (SCR) data from 33 subjects (16 PTSD; 17 controls). Neural activity during extinction recall, SCR, and PTSD symptoms were compared across groups and over time. Results: PTSD patients exhibited pre-to post-treatment reduction in rostral anterior cingulate cortex (rACC) activation during extinction recall, and increase in functional coherence between the rACC and the ventromedial prefrontal cortex (vmPFC) and subgenual anterior cingulate cortex (sgACC). Reduced PTSD symptom severity from pre-to post-treatment was significantly associated with reduced subgenual ACC and parahippocampal activation during this task. SCR during the extinction recall phase did not significantly change with treatment in the PTSD group, but change in SCR was associated with reduction in PTSD symptom severity. Conclusions: Prolonged exposure treatment appears to alter neural activation in PTSD patients during recall of fear extinction, and change in extinction recall (measured by SCR) is associated with symptom reduction. We discuss results in the context of neural systems involved in response to affective stimuli. (C) 2016 The Authors. Published by Elsevier Inc. C1 [Helpman, Liat; Zhu, Xi; Sullivan, Gregory M.; Schneier, Franklin; Neria, Mariana; Shvil, Erel; Aragon, Maria Josefa Malaga; Markowitz, John C.; Neria, Yuval] Columbia Univ, Dept Psychiat, 1051 Riverside Dr, New York, NY 10032 USA. [Helpman, Liat; Zhu, Xi; Sullivan, Gregory M.; Schneier, Franklin; Neria, Mariana; Shvil, Erel; Aragon, Maria Josefa Malaga; Markowitz, John C.; Neria, Yuval] New York State Psychiat Inst & Hosp, 1051 Riverside Dr, New York, NY 10032 USA. [Marin, Marie-France] Massachusetts Gen Hosp, Dept Psychiat, 149 13th St, Charlestown, MA 02129 USA. [Marin, Marie-France] Harvard Med Sch, 149 13th St, Charlestown, MA 02129 USA. [Papini, Santiago] Univ Texas Austin, Mental Hlth Res Inst, 305 E 23rd St,Stop E9000, Austin, TX 78712 USA. [Lindquist, Martin A.; Milad, Mohammed R.] Johns Hopkins Univ, Dept Biostat, 615 N Wolfe St,E3634, Baltimore, MD 21205 USA. [Wager, Tor D.] Univ Colorado, Dept Psychol & Neurosci, 345 UCB, Boulder, CO 80309 USA. RP Neria, Y (reprint author), New York State Psychiat Inst & Hosp, 1051 Riverside Dr, New York, NY 10032 USA.; Neria, Y (reprint author), Columbia Univ, Dept Psychiat, Coll Phys & Surg, Unit 69, 1051 Riverside Dr, New York, NY 10032 USA. EM ny126@cumc.columbia.edu OI Helpman, Liat/0000-0002-0141-3785 FU NIMH grant [R01 MH072833]; National Institutes of Health (NIH) [5T32MH096724-03] FX This study was supported by NIMH grant R01 MH072833 (Dr. Neria, principal investigator). Dr. Helpman is supported by National Institutes of Health (NIH) grant 5T32MH096724-03. NR 51 TC 0 Z9 0 U1 3 U2 3 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 2213-1582 J9 NEUROIMAGE-CLIN JI NeuroImage-Clin. PY 2016 VL 12 BP 715 EP 723 DI 10.1016/j.nicl.2016.10.007 PG 9 WC Neuroimaging SC Neurosciences & Neurology GA EF3AI UT WOS:000390196400082 PM 27761402 ER PT J AU Wang, XY Wang, ZJ Liu, J Chen, J Liu, X Nie, GN Byun, JS Liang, YL Park, J Huang, RW Liu, M Liu, B Kong, J AF Wang, Xiaoyun Wang, Zengjian Liu, Jian Chen, Jun Liu, Xian Nie, Guangning Byun, Joon-Seok Liang, Yilin Park, Joel Huang, Ruiwang Liu, Ming Liu, Bo Kong, Jian TI Repeated acupuncture treatments modulate amygdala resting state functional connectivity of depressive patients SO NEUROIMAGE-CLINICAL LA English DT Article DE Depression; Acupuncture; Resting-state functional connectivity; Amygdala; Limbic system; Fluoxetine; Combination effect ID DEFAULT MODE NETWORK; RAPID ANTIDEPRESSANT RESPONSE; KNEE OSTEOARTHRITIS PATIENTS; MAJOR DEPRESSION; ANTERIOR CINGULATE; FACIAL EXPRESSIONS; PLACEBO ANALGESIA; SEX-DIFFERENCES; SUBTHRESHOLD DEPRESSION; PARAHIPPOCAMPAL CORTEX AB As a widely-applied alternative therapy, acupuncture is gaining popularity in Western society. One challenge that remains, however, is incorporating it into mainstream medicine. One solution is to combine acupuncture with other conventional, mainstream treatments. In this study, we investigated the combination effect of acupuncture and the antidepressant fluoxetine, as well as its underlying mechanism using resting state functional connectivity (rsFC) in patients with major depressive disorders. Forty-six female depressed patients were randomized into a verum acupuncture plus fluoxetine or a sham acupuncture plus fluoxetine group for eight weeks. Resting-state fMRI data was collected before the first and last treatments. Results showed that compared with those in the sham acupuncture treatment, verum acupuncture treatment patients showed 1) greater clinical improvement as indicated by Montgomery-Asberg Depression Rating Scale (MADRS) and Self-Rating Depression Scale (SDS) scores; 2) increased rsFC between the left amygdala and subgenual anterior cingulate cortex (sgACC)/preguenual anterior cingulate cortex (pgACC); 3) increased rsFC between the right amygdala and left parahippocampus (Para)/putamen (Pu). The strength of the amygdala-sgACC/pgACC rsFC was positively associated with corresponding clinical improvement (as indicated by a negative correlation with MADRS and SDS scores). Our findings demonstrate the additive effect of acupuncture to antidepressant treatment and suggest that this effect may be achieved through the limbic system, especially the amygdala and the ACC. (C) 2016 The Authors. Published by Elsevier Inc. C1 [Wang, Xiaoyun; Liu, Jian; Chen, Jun; Liu, Xian; Nie, Guangning; Liu, Bo] Tradit Chinese Med Hosp Guangdong Prov, Guangzhou 510120, Guangdong, Peoples R China. [Wang, Zengjian; Huang, Ruiwang; Liu, Ming] South China Normal Univ, Ctr Study Appl Psychol, Key Lab Mental Hlth & Cognit Sci Guangdong Prov, Sch Psychol, Guangzhou 510631, Guangdong, Peoples R China. [Wang, Zengjian; Liang, Yilin; Park, Joel; Kong, Jian] Harvard Med Sch, Massachusetts Gen Hosp, Dept Psychiat, Charlestown, MA USA. [Byun, Joon-Seok] Daegu Haany Univ, Coll Korean Med, Dept Internal Med, 165 Sang Dong, Daegu 706828, South Korea. [Liang, Yilin] Wellesley Coll, Wellesley, MA 02181 USA. RP Liu, B (reprint author), Traditional Chinese Med Guangdong Prov, Dept Radiol, Guangzhou, Guangdong, Peoples R China.; Kong, J (reprint author), Massachusetts Gen Hosp, Dept Psychiat, Charlestown, MA USA. EM lbgdhtcm@163.com; kongj@nmr.mgh.harvard.edu FU South Korean Health Ministry [CIMI-13-01-32]; NIH/NCCIH [R01AT006364, R01AT008563, R21AT008707, P01 AT006663] FX The study was funded by a 2013 project of the South Korean Health Ministry (CIMI-13-01-32). Jian Kong is supported by R01AT006364, R01AT008563, R21AT008707, and P01 AT006663 from NIH/NCCIH. NR 110 TC 1 Z9 1 U1 5 U2 5 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 2213-1582 J9 NEUROIMAGE-CLIN JI NeuroImage-Clin. PY 2016 VL 12 BP 746 EP 752 DI 10.1016/j.nicl.2016.07.011 PG 7 WC Neuroimaging SC Neurosciences & Neurology GA EF3AI UT WOS:000390196400085 PM 27812501 ER PT J AU Stoodley, CJ MacMore, JP Makris, N Sherman, JC Schmahmann, JD AF Stoodley, Catherine J. MacMore, Jason P. Makris, Nikos Sherman, Janet C. Schmahmann, Jeremy D. TI Location of lesion determines motor vs. cognitive consequences in patients with cerebellar stroke SO NEUROIMAGE-CLINICAL LA English DT Article DE Cerebellum; Stroke; MRI; Cognition; Ataxia; Cerebellar cognitive affective syndrome ID INTRINSIC FUNCTIONAL CONNECTIVITY; ATAXIA RATING-SCALE; NORMATIVE DATA; TUMOR RESECTION; CHILDREN; TOPOGRAPHY; FMRI; VISUALIZATION; ORGANIZATION; INFARCTION AB Cerebellar lesions can cause motor deficits and/or the cerebellar cognitive affective syndrome (CCAS; Schmahmann's syndrome). We used voxel-based lesion-symptom mapping to test the hypothesis that the cerebellar motor syndrome results from anterior lobe damage whereas lesions in the posterolateral cerebellum produce the CCAS. Eighteen patients with isolated cerebellar stroke (13 males, 5 females; 20-66 years old) were evaluated using measures of ataxia and neurocognitive ability. Patients showed a wide range of motor and cognitive performance, from normal to severely impaired; individual deficits varied according to lesion location within the cerebellum. Patients with damage to cerebellar lobules III-VI had worse ataxia scores: as predicted, the cerebellar motor syndrome resulted from lesions involving the anterior cerebellum. Poorer performance on fine motor tasks was associated primarily with strokes affecting the anterior lobe extending into lobule VI, with right-handed finger tapping and peg-placement associated with damage to the right cerebellum, and left-handed finger tapping associated with left cerebellar damage. Patients with the CCAS in the absence of cerebellar motor syndrome had damage to posterior lobe regions, with lesions leading to significantly poorer scores on language (e.g. right Crus I and II extending through IX), spatial (bilateral Crus I, Crus II, and right lobule VIII), and executive function measures (lobules VII-VIII). These data reveal clinically significant functional regions underpinning movement and cognition in the cerebellum, with a broad anterior-posterior distinction. Motor and cognitive outcomes following cerebellar damage appear to reflect the disruption of different cerebro-cerebellar motor and cognitive loops. (C) 2016 The Authors. Published by Elsevier Inc. C1 [Stoodley, Catherine J.] Amer Univ, Dept Psychol, Asbury Bldg 321B,4400 Massachusetts Ave NW, Washington, DC 20016 USA. [Stoodley, Catherine J.] Amer Univ, Ctr Behav Neurosci, Washington, DC 20016 USA. [MacMore, Jason P.; Schmahmann, Jeremy D.] Massachusetts Gen Hosp, Dept Neurol, Lab Neuroanat & Cerebellar Neurobiol, Ataxia Unit,Cognit Behav Neurol Unit, Boston, MA 02114 USA. [Makris, Nikos] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Ctr Morphometr Anal, Dept Psychiat, Charlestown, MA USA. [Makris, Nikos] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Ctr Morphometr Anal, Dept Neurol, Charlestown, MA USA. [Sherman, Janet C.] Massachusetts Gen Hosp, Dept Psychiat, Psychol Assessment Ctr, Boston, MA 02114 USA. RP Stoodley, CJ (reprint author), Amer Univ, Dept Psychol, Asbury Bldg 321B,4400 Massachusetts Ave NW, Washington, DC 20016 USA.; Schmahmann, JD (reprint author), Massachusetts Gen Hosp, Dept Neurol, 100 Cambridge St,Suite 2000, Boston, MA 02114 USA. EM stoodley@american.edu; jschmahmann@partners.org FU National Institutes of Health [NIMH RO1MH67980, NCRR P41RR14075]; MINDlink Foundation; Birmingham Foundation FX This work was supported in part by the National Institutes of Health [NIMH RO1MH67980, NCRR P41RR14075], and the MINDlink and Birmingham Foundations. NR 65 TC 0 Z9 0 U1 4 U2 4 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 2213-1582 J9 NEUROIMAGE-CLIN JI NeuroImage-Clin. PY 2016 VL 12 BP 765 EP 775 DI 10.1016/j.nicl.2016.10.013 PG 11 WC Neuroimaging SC Neurosciences & Neurology GA EF3AI UT WOS:000390196400087 PM 27812503 ER PT J AU Louapre, C Govindarajan, ST Gianni, C Madigan, N Nielsen, AS Sloane, JA Kinkel, RP Mainero, C AF Louapre, Celine Govindarajan, Sindhuja T. Gianni, Costanza Madigan, Nancy Nielsen, A. Scott Sloane, Jacob A. Kinkel, Revere P. Mainero, Caterina TI The association between intra- and juxta-cortical pathology and cognitive impairment in multiple sclerosis by quantitative T-2* mapping at 7 T MRI SO NEUROIMAGE-CLINICAL LA English DT Article DE Multiple sclerosis; Cognitive impairment; Laminar cortical pathology; 7 Tesla MRI; T-2* ID RELAPSING-REMITTING MS; NEOCORTICAL VOLUME DECREASE; HUMAN CEREBRAL-CORTEX; IN-VIVO; FUNCTIONAL CONNECTIVITY; LESIONS; DYSFUNCTION; ATROPHY; DISABILITY; SURFACE AB Using quantitative T-2* at 7 Tesla (T) magnetic resonance imaging, we investigated whether impairment in selective cognitive functions in multiple sclerosis (MS) can be explained by pathology in specific areas and/or layers of the cortex. Thirty-one MS patients underwent neuropsychological evaluation, acquisition of 7 T multi-echo T-2* gradient-echo sequences, and 3 T anatomical images for cortical surfaces reconstruction. Seventeen age-matched healthy subjects served as controls. Cortical T-2* maps were sampled at various depths throughout the cortex and juxtacortex. Relation between T-2*, neuropsychological scores and a cognitive index (CI), calculated from a principal component analysis on the whole battery, was tested by a general linear model. Cognitive impairment correlated with T-2* increase, independently from white matter lesions and cortical thickness, in cortical areas highly relevant for cognition belonging to the default-mode network (p < 0.05 corrected). Dysfunction in different cognitive functions correlated with longer T-2* in selective cortical regions, most of which showed longer T-2* relative to controls. For most tests, this association was strongest in deeper cortical layers. Executive dysfunction, however, was mainly related with pathology in juxtameningeal cortex. T-2* explained up to 20% of the variance of the CI, independently of conventional imaging metrics (adjusted-R-2: 52-67%, p < 5.10(-4)). Location of pathology across the cortical width and mantle showed selective correlation with impairment in differing cognitive domains. These findings may guide studies at lower field strength designed to develop surrogate markers of cognitive impairment in MS. (C) 2016 The Authors. Published by Elsevier Inc. C1 [Louapre, Celine; Govindarajan, Sindhuja T.; Gianni, Costanza; Mainero, Caterina] Massachusetts Gen Hosp, AA Martinos Ctr Biomed Imaging, Bldg 149,Thirteenth St, Charlestown, MA 02129 USA. [Louapre, Celine; Gianni, Costanza; Sloane, Jacob A.; Mainero, Caterina] Harvard Med Sch, Boston, MA USA. [Madigan, Nancy; Sloane, Jacob A.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. [Nielsen, A. Scott] Virginia Mason Med Ctr, Seattle, WA 98101 USA. [Kinkel, Revere P.] Univ Calif San Diego, Dept Neurosci, San Diego, CA 92103 USA. RP Mainero, C (reprint author), Massachusetts Gen Hosp, AA Martinos Ctr Biomed Imaging, Bldg 149,Thirteenth St, Charlestown, MA 02129 USA. EM celine.louapre@gmail.com; sindhuja.tirumalaigovindaraj@stonybrook.edu; costanza.gia@gmail.com; nmadigan@bidmc.harvard.edu; a.scott.nielsen@gmail.com; jsloane@bidmc.harvard.edu; rkinkel@ucsd.edu; caterina@nmr.mgh.harvard.edu FU National MS Society [NMSS 4281-RG-A1, NMSS RG 4729A2/1]; Claflin Award; NIH [R01NS078322-01-A1]; US Army [W81XWH-13-1-0122]; Shared Instrumentation Grant [1S10RR023043]; National Center for Research Resources [NCRR P41-RR14075] FX This work was supported by a grant of the National MS Society (NMSS 4281-RG-A1 and NMSS RG 4729A2/1), the Claflin Award, and partly by NIH R01NS078322-01-A1, US Army W81XWH-13-1-0122, Shared Instrumentation Grant 1S10RR023043, National Center for Research Resources (NCRR P41-RR14075). NR 40 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 2213-1582 J9 NEUROIMAGE-CLIN JI NeuroImage-Clin. PY 2016 VL 12 BP 879 EP 886 DI 10.1016/j.nicl.2016.11.001 PG 8 WC Neuroimaging SC Neurosciences & Neurology GA EF3AI UT WOS:000390196400100 PM 27872810 ER PT J AU Baran, B Karahanoglu, FI Agam, Y Mantonakis, L Manoach, DS AF Baran, Bengi Karahanoglu, F. Isik Agam, Yigal Mantonakis, Leonidas Manoach, Dara S. TI Failure to mobilize cognitive control for challenging tasks correlates with symptom severity in schizophrenia SO NEUROIMAGE-CLINICAL LA English DT Article DE Schizophrenia; Anterior cingulate cortex; Prefrontal cortex; Antisaccade; Cognitive control; Functional MRI ID ANTERIOR CINGULATE CORTEX; EVENT-RELATED FMRI; FRONTAL EYE FIELD; SURFACE-BASED ANALYSIS; FUNCTIONAL CONNECTIVITY; PREFRONTAL CORTEX; 1ST-EPISODE SCHIZOPHRENIA; BRAIN ACTIVATION; REACTION-TIME; SACCADES AB Deficits in the adaptive, flexible control of behavior contribute to the clinical manifestations of schizophrenia. We used functional MRI and an antisaccade paradigm to examine the neural correlates of cognitive control deficits and their relations to symptom severity. Thirty-three chronic medicated outpatients with schizophrenia and 31 healthy controls performed an antisaccade paradigm. We examined differences in recruitment of the cognitive control network and task performance for Hard (high control) versus Easy (low control) antisaccade trials within and between groups. We focused on the key regions involved in 'top-down' control of ocular motor structures - dorsal anterior cingulate cortex, dorsolateral and ventrolateral prefrontal cortex. In patients, we examined whether difficulty implementing cognitive control correlated with symptom severity. Patients made more errors overall, and had shorter saccadic latencies than controls on correct Hard vs. Easy trials. Unlike controls, patients failed to increase activation in the cognitive control network for Hard vs. Easy trials. Reduced activation for Hard vs. Easy trials predicted higher error rates in both groups and increased symptom severity in schizophrenia. These findings suggest that patients with schizophrenia are impaired in mobilizing cognitive control when presented with challenges and that this contributes to deficits suppressing prepotent but contextually inappropriate responses, to behavior that is stimulus-bound and error-prone rather than flexibly guided by context, and to symptom expression. Therapies aimed at increasing cognitive control may improve both cognitive flexibility and reduce the impact of symptoms. (C) 2016 The Authors. Published by Elsevier Inc. C1 [Baran, Bengi; Karahanoglu, F. Isik; Agam, Yigal; Manoach, Dara S.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Psychiat, Boston, MA USA. [Baran, Bengi; Karahanoglu, F. Isik; Agam, Yigal; Manoach, Dara S.] Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA. [Mantonakis, Leonidas] Univ Athens, Sch Med, Eginit Hosp, Dept Psychiat, Athens, Greece. RP Manoach, DS (reprint author), Massachusetts Gen Hosp, Psychiat Neuroimaging, 149 13th St,Room 1-111, Charlestown, MA 02129 USA. EM Dara.Manoach@mgh.harvard.edu OI Manoach, Dara/0000-0001-9208-1167 FU National Institute of Mental Health [R01 MH67720, K24 MH099421]; National Alliance for Research on Schizophrenia and Depression; Mental Illness and Neuroscience Discovery (MIND) Institute; MGH Fund for Medical Discovery Clinical Fellowship Award [44EA - MGH]; National Heart, Lung, and Blood Institute [5T32HL007901-17]; Swiss National Science Foundation [P2ELP2_159891] FX This work was supported by the National Institute of Mental Health (R01 MH67720; K24 MH099421); National Alliance for Research on Schizophrenia and Depression; Mental Illness and Neuroscience Discovery (MIND) Institute to DSM; MGH Fund for Medical Discovery Clinical Fellowship Award 44EA - MGH and National Heart, Lung, and Blood Institute 5T32HL007901-17 to BB; Swiss National Science Foundation P2ELP2_159891 to FIK and utilized resources provided by Shared Instrumentation Grants 1S10RR023401, 1S10RR019307, and 1S10RR023043. The authors have no conflicts of interest to declare. NR 52 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 2213-1582 J9 NEUROIMAGE-CLIN JI NeuroImage-Clin. PY 2016 VL 12 BP 887 EP 893 DI 10.1016/j.nicl.2016.10.020 PG 7 WC Neuroimaging SC Neurosciences & Neurology GA EF3AI UT WOS:000390196400101 PM 27872811 ER PT J AU Kwong, KK Chan, ST AF Kwong, Kenneth K. Chan, Suk-tak TI Neuroprotection and acidosis induced by cortical spreading depression SO NEUROPSYCHIATRIC DISEASE AND TREATMENT LA English DT Letter ID CEREBROVASCULAR REACTIVITY; BRAIN; RATS; ISCHEMIA C1 [Kwong, Kenneth K.; Chan, Suk-tak] Massachusetts Gen Hosp, MGH MIT HMS Athinoula A Martinos Ctr Biomed Imagi, Dept Radiol, Boston, MA 02114 USA. RP Kwong, KK (reprint author), Athinoula A Martinos Ctr Biomed Imaging, Bldg 149,13th St,Mail Code 149 301, Charlestown, MA 02129 USA. EM kwong@nmr.mgh.harvard.edu NR 16 TC 0 Z9 0 U1 2 U2 2 PU DOVE MEDICAL PRESS LTD PI ALBANY PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND SN 1178-2021 J9 NEUROPSYCH DIS TREAT JI Neuropsychiatr. Dis. Treat. PY 2016 VL 12 BP 3191 EP 3192 DI 10.2147/NDT.S125677 PG 2 WC Clinical Neurology; Psychiatry SC Neurosciences & Neurology; Psychiatry GA EE7JI UT WOS:000389791500001 PM 28003755 ER PT J AU AlQattan, B Butt, H Sabouri, A Yetisen, AK Ahmed, R Mahmoodi, N AF AlQattan, Bader Butt, Haider Sabouri, Aydin Yetisen, Ali K. Ahmed, Rajib Mahmoodi, Nasim TI Holographic direct pulsed laser writing of two-dimensional nanostructures SO RSC ADVANCES LA English DT Article ID THIN-FILM ELECTRODES; ABLATION AB The development of accurate and rapid techniques to produce nanophotonic structures is essential in data storage, sensors, and spectroscopy. Existing bottom-up and top-down approaches to fabricate nanophotonic devices are high cost and time consuming, limiting their mass manufacturing and practical applications. Here, we demonstrate a strategy to rapidly create 25-40 nm thick 1/2D Au-Ti nanopatterns using holographic direct laser interference patterning (DLIP). Pulses of an Nd:YAG laser (1064 nm) in holographic Denisyuk reflection mode were used to create ablative interference fringes. The constructive interference antinode regions of the standing wave selectively ablated a Au-Ti layer in localized regions to controllably form nanogratings. Varying the laser exposure parameters allowed for rapid patterning of 2D square and rectangular arrays within seconds. Controlling the distances between the laser source, recording medium, and the object, allowed for achieving a 2D spatial grating periodicity of 640 nm x 640 nm. Diffracted and transmitted light spectra of 2D nanostructure arrays were analyzed using angle-resolved measurements and spectroscopy. C1 [AlQattan, Bader; Butt, Haider; Sabouri, Aydin; Ahmed, Rajib; Mahmoodi, Nasim] Univ Birmingham, Sch Engn, Nanotechnol Lab, Birmingham B15 2TT, W Midlands, England. [Yetisen, Ali K.] Harvard Med Sch, 65 Landsdowne St, Cambridge, MA 02139 USA. [Yetisen, Ali K.] Massachusetts Gen Hosp, Wellman Ctr Photomed, 65 Landsdowne St, Cambridge, MA 02139 USA. [Yetisen, Ali K.] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA. RP Butt, H (reprint author), Univ Birmingham, Sch Engn, Nanotechnol Lab, Birmingham B15 2TT, W Midlands, England. EM h.butt@bham.ac.uk OI Butt, Haider/0000-0003-2434-9525 FU Leverhulme Trust; Welcome Trust; Engineering and Physical Sciences Research Council (EPSRC); Centre for Innovative Manufacturing in Laser-based Production Processes (CfIM LbPP) [EP/K030884/1] FX H. B. thanks the Leverhulme Trust and Welcome Trust for the research funding. This project was partly funded by the Engineering and Physical Sciences Research Council (EPSRC), the Centre for Innovative Manufacturing in Laser-based Production Processes (CfIM LbPP, Grant no. EP/K030884/1). NR 21 TC 1 Z9 1 U1 2 U2 2 PU ROYAL SOC CHEMISTRY PI CAMBRIDGE PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND SN 2046-2069 J9 RSC ADV JI RSC Adv. PY 2016 VL 6 IS 112 BP 111269 EP 111275 DI 10.1039/c6ra22241b PG 7 WC Chemistry, Multidisciplinary SC Chemistry GA EE3CD UT WOS:000389463600088 PM 28066547 ER PT J AU Zaid, H Mahdi, AA Tamrakar, AK Saad, B Razzaque, MS Dasgupta, A AF Zaid, Hilal Mahdi, Abbas A. Tamrakar, Akhilesh K. Saad, Bashar Razzaque, Mohammed S. Dasgupta, Amitava TI Natural Active Ingredients for Diabetes and Metabolism Disorders Treatment SO EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE LA English DT Editorial Material C1 [Zaid, Hilal; Saad, Bashar] Al Qasemi Acad Coll, Qasemi Res Ctr, POB 124, Baqa Al Gharbiyye 30100, Israel. [Zaid, Hilal; Saad, Bashar] Arab Amer Univ Jenin, Fac Arts & Sci, POB 240, Jenin, State Of Palest, Israel. [Mahdi, Abbas A.] King Georges Med Univ, Dept Biochem, Lucknow, Uttar Pradesh, India. [Tamrakar, Akhilesh K.] CSIR Cent Drug Res Inst, Div Biochem, Lucknow, Uttar Pradesh, India. [Razzaque, Mohammed S.] Harvard Sch Dent Med Affiliate, Forsyth Inst, Dept Appl Oral Sci, Cambridge, MA USA. [Dasgupta, Amitava] Univ Texas Houston, Sch Med, Dept Pathol & Lab Med, Houston, TX 77030 USA. RP Zaid, H (reprint author), Al Qasemi Acad Coll, Qasemi Res Ctr, POB 124, Baqa Al Gharbiyye 30100, Israel.; Zaid, H (reprint author), Arab Amer Univ Jenin, Fac Arts & Sci, POB 240, Jenin, State Of Palest, Israel. EM hilal.zaid@aauj.edu NR 4 TC 0 Z9 0 U1 0 U2 0 PU HINDAWI PUBLISHING CORP PI NEW YORK PA 315 MADISON AVE 3RD FLR, STE 3070, NEW YORK, NY 10017 USA SN 1741-427X EI 1741-4288 J9 EVID-BASED COMPL ALT JI Evid.-based Complement Altern. Med. PY 2016 AR 2965214 DI 10.1155/2016/2965214 PG 2 WC Integrative & Complementary Medicine SC Integrative & Complementary Medicine GA EC8IB UT WOS:000388383800001 ER PT J AU Bazou, D Maimon, N Gruionu, G Munn, LL AF Bazou, Despina Maimon, Nir Gruionu, Gabriel Munn, Lance L. TI Self-assembly of vascularized tissue to support tumor explants in vitro SO Integrative Biology LA English DT Article ID DUCTAL PANCREATIC-CANCER; DRUG DISCOVERY; ENDOTHELIAL-CELLS; SPHEROID MODEL; SLICE CULTURES; MATRIX; ANGIOGENESIS; NETWORKS; FIBROBLASTS; ANASTOMOSIS AB Testing the efficacy of cancer drugs requires functional assays that recapitulate the cell populations, anatomy and biological responses of human tumors. Although current animal models and in vitro cell culture platforms are informative, they have significant shortcomings. Mouse models can reproduce tissue-level and systemic responses to tumor growth and treatments observed in humans, but xenografts from patients often do not grow, or require months to develop. On the other hand, current in vitro assays are useful for studying the molecular bases of tumorigenesis or drug activity, but often lack the appropriate in vivo cell heterogeneity and natural microenvironment. Therefore, there is a need for novel tools that allow rapid analysis of patient-derived tumors in a robust and representative microenvironment. We have developed methodology for maintaining harvested tumor tissue in vitro by placing them in a support bed with self-assembled stroma and vasculature. The harvested biopsy or tumor explant integrates with the stromal bed and vasculature, providing the correct extracellular matrix (collagen I, IV, fibronectin), associated stromal cells, and a lumenized vessel network. Our system provides a new tool that will allow ex vivo drug-screening and can be adapted for the guidance of patient-specific therapeutic strategies. C1 [Bazou, Despina; Maimon, Nir; Munn, Lance L.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Radiat Oncol, Edwin L Steele Lab, 100 Blossom St, Boston, MA 02114 USA. [Gruionu, Gabriel] Harvard Med Sch, Massachusetts Gen Hosp, Dept Surg, 55 Fruit St, Boston, MA 02114 USA. RP Munn, LL (reprint author), Harvard Med Sch, Massachusetts Gen Hosp, Dept Radiat Oncol, Edwin L Steele Lab, 100 Blossom St, Boston, MA 02114 USA. EM munn@steele.mgh.harvard.edu FU National Institutes of Health [R01HL106584] FX The authors would like to acknowledge funding from the National Institutes of Health (R01HL106584). We thank Vera Verbruggen for generating the vascular bed mosaic image and Julia Kahn for her help with tumor implantations. NR 42 TC 0 Z9 0 U1 0 U2 0 PU ROYAL SOC CHEMISTRY PI CAMBRIDGE PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND SN 1757-9694 EI 1757-9708 J9 INTEGR BIOL-UK JI Integr. Biol. PY 2016 VL 8 IS 12 BP 1301 EP 1311 DI 10.1039/c6ib00108d PG 11 WC Cell Biology SC Cell Biology GA EE2ML UT WOS:000389418300009 PM 27787529 ER PT J AU Yu, J Zhu, H Gattoni-Celli, S Taheri, S Kindy, MS AF Yu, Jin Zhu, Hong Gattoni-Celli, Sebastiano Taheri, Saeid Kindy, Mark Stephen TI Dietary supplementation of GrandFusion (R) mitigates cerebral ischemia-induced neuronal damage and attenuates inflammation SO NUTRITIONAL NEUROSCIENCE LA English DT Article DE Cerebral ischemia; Inflammation; Oxidative stress; Diet; Neuroprotection ID BRAIN-INJURY; REPERFUSION INJURY; OXIDATIVE STRESS; VEGETABLE CONSUMPTION; BEHAVIORAL DEFICITS; ANTIOXIDANT ENZYMES; EXPERIMENTAL STROKE; TRANSIENT ISCHEMIA; GLOBAL BURDEN; CATHEPSIN-B AB Objectives: Dietary supplementation of fruits and vegetables has been the main stay for nutritional benefit and overall well-being. GrandFusion (R) is a nutritional supplement that contains the natural nutrients from whole fruits and vegetables that include complex nutrients and phytonutrients that contain anti-oxidant, anti-inflammatory, and neuroprotective properties. Methods: In this study, C57BL/6 mice were fed a diet supplemented with GrandFusion (R) for 2 months prior to 1 hour of ischemia induced by occlusion of the middle cerebral artery (MCAo) followed by various times of reperfusion. Mice were subjected to MCAo for 1 hour and then at various times following reperfusion, animals were assessed for behavioral outcomes (open field testing, rotarod, and adhesive test removal), and infarct volumes (cresyl violet and triphenyltetrazolium chloride). In addition, to determine the potential mechanisms associated with treatment, the brain tissue was examined for changes in oxidative stress and inflammatory markers. Results: The GrandFusion (R) diet was able to show a significant protection from infarct damage in the brain and an improvement in neurological outcomes. The diet did not alter heart rate, blood pressure, pO(2), pCO(2), or pH. In addition, the diet mitigated inflammation by reducing microglial and astrocytic activation following ischemia and reperfusion and limiting oxidative stress. Discussion: The study demonstrates the neuroprotective effect of a diet rich in fruits and vegetables that contain anti-oxidant and anti-inflammatory against the impact of cerebral ischemia and reperfusion injury. C1 [Yu, Jin; Zhu, Hong; Taheri, Saeid; Kindy, Mark Stephen] Med Univ South Carolina, Dept Regenerat Med & Cell Biol, Charleston, SC 29425 USA. [Gattoni-Celli, Sebastiano] Med Univ South Carolina, Dept Radiat Oncol, Charleston, SC 29425 USA. [Gattoni-Celli, Sebastiano; Kindy, Mark Stephen] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Kindy, Mark Stephen] Univ S Florida, Coll Pharm, Dept Pharmaceut Sci, 12901 Bruce B Downs Blvd,MDC 30, Tampa, FL 33612 USA. [Kindy, Mark Stephen] James A Haley VA Med Ctr, Tampa, FL 33612 USA. RP Kindy, MS (reprint author), MUSC, Charleston, SC 29403 USA. EM kindym@health.usf.edu NR 68 TC 0 Z9 0 U1 1 U2 1 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND SN 1028-415X EI 1476-8305 J9 NUTR NEUROSCI JI Nutr. Neurosci. PY 2016 VL 19 IS 7 BP 290 EP 300 DI 10.1179/1476830515Y.0000000021 PG 11 WC Neurosciences; Nutrition & Dietetics SC Neurosciences & Neurology; Nutrition & Dietetics GA DW5SP UT WOS:000383707500003 PM 25879584 ER PT J AU Narayanan, AK Harding, JD Saba, SK Conley, J Gordon, AJ AF Narayanan, Arthi K. Harding, John D. Saba, Shaddy K. Conley, James Gordon, Adam J. TI Left, right, and meeting in the middle: Addressing addiction is something we can agree about SO Substance Abuse LA English DT Editorial Material DE Addiction crisis; addiction policy; Democratic; policy review; Republican; United States Election 2016 ID PRESCRIPTION-OPIOID USE; PARTY PLATFORMS AB The United States faces an addiction health crisis. Presidential election cycles in the United States are cause for creation of political party platforms. These platforms provide general stances and specific policies on a variety of issues. We undertook a review of the addiction policies of the 2016 Republican and Democratic platforms. Despite differences in focus, we found more similarities than differences between the two. We call upon those in political power to use every evidence-based policy at their disposal to promote addiction treatment and prevention. C1 [Narayanan, Arthi K.; Gordon, Adam J.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. [Harding, John D.; Conley, James; Gordon, Adam J.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot CHERP, Pittsburgh, PA USA. [Harding, John D.; Conley, James; Gordon, Adam J.] VA Pittsburgh Healthcare Syst, MIRECC, Pittsburgh, PA USA. [Saba, Shaddy K.; Gordon, Adam J.] VA Pittsburgh Healthcare Syst, VA Pittsburgh Healthcare Syst Interdisciplinary A, Pittsburgh, PA USA. RP Gordon, AJ (reprint author), Univ Pittsburgh, Univ Dr C,Mailcode 151-C, Pittsburgh, PA 15240 USA.; Gordon, AJ (reprint author), VA Pittsburgh Healthcare Syst, Univ Dr C,Mailcode 151-C, Pittsburgh, PA 15240 USA. EM gordona@medschool.pitt.edu NR 12 TC 0 Z9 0 U1 0 U2 0 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 0889-7077 EI 1547-0164 J9 SUBST ABUS JI Subst. Abus. PY 2016 VL 37 IS 4 BP 495 EP 497 DI 10.1080/08897077.2016.1238655 PG 3 WC Substance Abuse SC Substance Abuse GA ED5TQ UT WOS:000388915600001 PM 27648701 ER PT J AU Stringfellow, EJ Kim, TW Gordon, AJ Pollio, DE Grucza, RA Austin, EL Johnson, NK Kertesz, SG AF Stringfellow, Erin J. Kim, Theresa W. Gordon, Adam J. Pollio, David E. Grucza, Richard A. Austin, Erika L. Johnson, N. Kay Kertesz, Stefan G. TI Substance use among persons with homeless experience in primary care SO SUBSTANCE ABUSE LA English DT Article DE Homeless; primary care; substance use ID NATIONAL EPIDEMIOLOGIC SURVEY; EXTENDED-RELEASE NALTREXONE; RANDOMIZED CLINICAL-TRIAL; DRUG-USE; BRIEF INTERVENTION; UNITED-STATES; HEALTH-CARE; PSYCHIATRIC-DISORDERS; RELAPSE PREVENTION; MEDICAID EXPANSION AB Background: Community survey data suggest high prevalence of substance use disorders among currently homeless individuals. There are less data regarding illicit drug and alcohol use problems of homeless-experienced persons engaged in primary care. They may have less severe use and require different care responses from primary care teams. Methods: The authors surveyed currently and formerly homeless, i.e., homeless-experienced, persons engaged in primary care at five federally funded programs in the United States, administering the World Health Organization (WHO) Alcohol, Smoking and Substance Involvement Screening Test (ASSIST). The ASSIST definitions of lower, moderate, and high risk were used to assess a spectrum of lifetime and recent substance use, from any use to likely dependence, and to identify sociodemographic and health status characteristics associated with severity of use. Results: Almost one half of the sample (N = 601) had recently (within the past three months) used alcohol, and one third had recently used an illicit drug. The most commonly used illicit drugs in the past three months were cannabis (19%), cocaine (16%), and opioids (7.5%). Over one half (59%) of respondents had ASSIST-defined moderate- or high-risk substance use. A significant proportion (31%) of those identified as at moderate risk had no recent substance use, but did report past problematic use. Ten percent of the lower-risk group had past problematic use of alcohol. Severity of use was associated with worse health status, but not with housing status or type of homelessness experienced. Conclusions: Less severe (moderate-risk) use and past problematic use, potentially indicative of remitted substance use disorders, were more common than high-risk use in this primary care, homeless-experienced sample. These findings highlight the urgency of identifying effective ways to reduce risky substance use and prevent relapse in homeless-experienced persons. C1 [Stringfellow, Erin J.] Washington Univ, George Warren Brown Sch Social Work, One Brookings Dr,Campus Box 1196, St Louis, MO 63130 USA. [Kim, Theresa W.] Boston Med Ctr, Gen Internal Med Sect, Dept Med, Clin Addict Res & Educ CARE Unit, Boston, MA USA. [Gordon, Adam J.] Univ Pittsburgh, Sch Med, Div Gen Internal Med, Pittsburgh, PA USA. [Pollio, David E.] Univ Alabama Birmingham, Dept Social Work, Birmingham, AL USA. [Grucza, Richard A.] Washington Univ, Sch Med, Dept Psychiat, St Louis, MO 63110 USA. [Austin, Erika L.; Johnson, N. Kay; Kertesz, Stefan G.] Birmingham VA Med Ctr, Birmingham, AL USA. [Austin, Erika L.] Univ Alabama Birmingham, Dept Biostat, Birmingham Sch Publ Hlth, Birmingham, AL 35294 USA. [Kertesz, Stefan G.] Univ Alabama Birmingham, Sch Med, Div Prevent Med, Birmingham, AL USA. RP Stringfellow, EJ (reprint author), Washington Univ, George Warren Brown Sch Social Work, One Brookings Dr,Campus Box 1196, St Louis, MO 63130 USA. EM estringfellow@wustl.edu OI Kertesz, Stefan/0000-0001-6101-8421 FU Department of Veterans Affairs Health Services Research & Development Branch [IAA-07-069-2]; Social Work Training in Addictions Research Institutional Predoctoral Fellowship through the National Institute on Drug Abuse (NIDA) [T32 DA015035] FX The Department of Veterans Affairs Health Services Research & Development Branch (grant IAA-07-069-2) provided funding for the data collection on which this analysis is based. The Social Work Training in Addictions Research Institutional Predoctoral Fellowship (T32 DA015035) through the National Institute on Drug Abuse (NIDA) provided funding for the writing of the manuscript. NR 69 TC 1 Z9 1 U1 5 U2 5 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 0889-7077 EI 1547-0164 J9 SUBST ABUS JI Subst. Abus. PY 2016 VL 37 IS 4 BP 534 EP 541 DI 10.1080/08897077.2016.1145616 PG 8 WC Substance Abuse SC Substance Abuse GA ED5TQ UT WOS:000388915600009 PM 26914448 ER PT J AU Haibach, JP Homish, GG Collins, RL Ambrosone, CB Giovino, GA AF Haibach, Jeffrey P. Homish, Gregory G. Collins, R. Lorraine Ambrosone, Christine B. Giovino, Gary A. TI Fruit and vegetable intake as a moderator of the association between depressive symptoms and cigarette smoking SO SUBSTANCE ABUSE LA English DT Article DE Cigarette smoking; depression; depressive symptoms; fruit; moderation; vegetable; young adult ID NICOTINE DEPENDENCE; MONOAMINE-OXIDASE; MAJOR DEPRESSION; NUTRIENT INTAKE; SERUM COTININE; UNITED-STATES; DIETARY PATTERN; MENTAL-HEALTH; EX-SMOKERS; CESSATION AB Background: Studies have consistently reported associations among depression, cigarette smoking, and fruit and vegetable intake (FVI). This study evaluated FVI as a moderator of the association between depressive symptoms and smoking. Methods: The authors analyzed data from the National Longitudinal Survey of Youth 1979: Child and Young Adult. The study sample was adults aged 19-33years at baseline in the year 2004 from the Young Adult Survey portion. Moderation analyses were performed using the Johnson-Neyman technique to assess whether baseline FVI moderated the association between depressive symptoms and smoking status cross-sectionally and as a predictor of smoking cessation longitudinally at 4-year follow-up. Results: Cross-sectionally, at lower levels of FVI (<4.9 times/day), there was a significant association between smoking and depressive symptoms (P < .05), but not at higher levels of FVI (4.9 times/day; P > .05). Longitudinally, there was an inverse association between depressive symptoms and quitting smoking at FVI <1.2 times/day (P < .05), but there was not a significant association at FVI 1.2 times/day (P .05). Conclusions: FVI moderated the association between depressive symptoms and cigarette smoking cross-sectionally and longitudinally. The cross-sectional findings might be partially explained by the longitudinal findings paired with prior research; there might be fewer smokers with high FVI because depressive symptoms are removed as an impediment to cessation. Further experimental research is warranted to test the efficacy of increased FVI as an adjunct to smoking cessation, with a possible mechanism of action being reduced depressive symptoms during quit attempts. C1 [Haibach, Jeffrey P.; Homish, Gregory G.; Collins, R. Lorraine; Giovino, Gary A.] SUNY Buffalo, Sch Publ Hlth & Hlth Profess, Dept Community Hlth & Hlth Behav, Buffalo, NY USA. [Haibach, Jeffrey P.] US Dept Vet Affairs, Hlth Serv Res & Dev Serv, Washington, DE USA. [Ambrosone, Christine B.] Roswell Pk Canc Inst, Dept Canc Prevent & Control, Buffalo, NY 14263 USA. RP Haibach, JP (reprint author), US Dept Vet Affairs, 810 Vermont Ave NW,10P9H, Washington, DC 20420 USA. EM Jeffrey.Haibach@va.gov NR 73 TC 1 Z9 1 U1 9 U2 9 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 0889-7077 EI 1547-0164 J9 SUBST ABUS JI Subst. Abus. PY 2016 VL 37 IS 4 BP 571 EP 578 DI 10.1080/08897077.2016.1179703 PG 8 WC Substance Abuse SC Substance Abuse GA ED5TQ UT WOS:000388915600014 PM 27093192 ER PT J AU Rieckmann, T Muench, J McBurnie, MA Leo, MC Crawford, P Ford, D Stubbs, J O'Cleirigh, C Mayer, KH Fiscella, K Wright, N Doe-Simkins, M Cuddeback, M Salisbury-Afshar, E Nelson, C AF Rieckmann, Traci Muench, John McBurnie, Mary Ann Leo, Michael C. Crawford, Phillip Ford, Daren Stubbs, Jennifer O'Cleirigh, Conall Mayer, Kenneth H. Fiscella, Kevin Wright, Nicole Doe-Simkins, Maya Cuddeback, Matthew Salisbury-Afshar, Elizabeth Nelson, Christine TI Medication-assisted treatment for substance use disorders within a national community health center research network SO Substance Abuse LA English DT Article DE Community health centers; medication-assisted treatment; substance use disorders ID PRIMARY-CARE; HEPATITIS-C; ALCOHOL DEPENDENCE; ANXIETY DISORDERS; OPIOID ADDICTION; BUPRENORPHINE TREATMENT; REPRESENTATIVE SAMPLE; METHADONE-MAINTENANCE; CONTROLLED-TRIAL; SELF-MEDICATION AB Background: The Affordable Care Act increases access to treatment services for people who suffer from substance use disorders (SUDs), including alcohol use disorders (AUDs) and opioid use disorders (OUDs). This increased access to treatment has broad implications for delivering health services and creates a dramatic need for transformation in clinical care, service lines, and collaborative care models. Medication-assisted treatments (MAT) are effective for helping SUD patients reach better outcomes. This article uses electronic health record (EHR) data to examine the prevalence of EHR-documented SUDs, patient characteristics, and patterns of MAT prescribing and screening for patients within the Community Health Applied Research Network (CHARN), a national network of 17 community health centers that facilitates patient-centered outcomes research among underserved populations. Methods: Hierarchical generalized linear models examined patient characteristics, SUD occurrence rates, MAT prescription, and human immunodeficiency virus (HIV) and hepatitis virus C screening for patients with AUDs or OUDs.Results: Among 572,582 CHARN adult patients, 16,947 (3.0%)had a documented AUD diagnosis and 6,080 (1.1%) an OUD diagnosis. Alcohol MAT prescriptions were documented for 547 AUD patients (3.2%) and opioid MAT for 1,764 OUD patients (29.0%). Among OUD patients, opioid MAT was significantly associated with HIV screening (odds ratio [OR] = 1.31, P < .001) in OUD patients, as was alcohol MAT among AUD patients (OR = 1.30, P = .013). Conclusions: These findings suggest that effective opioid and alcohol MAT may be substantially underprescribed among safety-net patients identified as having OUDs or AUDs. C1 [Rieckmann, Traci] Oregon Hlth & Sci Univ, Sch Med, Portland, OR 97201 USA. [Rieckmann, Traci; Ford, Daren; Stubbs, Jennifer] Oregon Hlth & Sci Univ, Sch Publ Hlth, 3181 SW Sam Jackson Pk Rd,CB669, Portland, OR 97239 USA. [Muench, John] Oregon Hlth & Sci Univ, Dept Family Med, Richmond Clin, Portland, OR 97201 USA. [McBurnie, Mary Ann; Nelson, Christine] Oregon Community Hlth Informat Network, Portland, OR USA. [Leo, Michael C.; Crawford, Phillip] CHARN Data Coordinating Ctr, Portland, OR USA. [O'Cleirigh, Conall; Mayer, Kenneth H.] Harvard Med Sch, Fenway Hlth, Boston, MA USA. [O'Cleirigh, Conall; Mayer, Kenneth H.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Fiscella, Kevin] Univ Rochester, Med Ctr, Dept Family Med, Rochester, NY 14642 USA. [Fiscella, Kevin] Univ Rochester, Med Ctr, Dept Publ Hlth Sci, Rochester, NY 14642 USA. [Wright, Nicole] Assoc Asian Pacific Community Hlth Organizat, Oakland, CA USA. [Doe-Simkins, Maya; Cuddeback, Matthew; Salisbury-Afshar, Elizabeth] Alliance Chicago Community Hlth Serv, Chicago, IL USA. RP Rieckmann, T (reprint author), Oregon Hlth & Sci Univ, Sch Publ Hlth, 3181 SW Sam Jackson Pk Rd,CB669, Portland, OR 97239 USA. EM rieckman@ohsu.edu FU Health Resources and Services Administration [HHSH250201400001C]; [UB3HA20236] FX This work was supported by the Health Resources and Services Administration, contract HHSH250201400001C, and by grant UB3HA20236. HRSA had no role in any of the listed activities in the study. NR 90 TC 0 Z9 0 U1 2 U2 2 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 0889-7077 EI 1547-0164 J9 SUBST ABUS JI Subst. Abus. PY 2016 VL 37 IS 4 BP 625 EP 634 DI 10.1080/08897077.2016.1189477 PG 10 WC Substance Abuse SC Substance Abuse GA ED5TQ UT WOS:000388915600022 PM 27218678 ER PT J AU Wakeman, SE Pham-Kanter, G Donelan, K AF Wakeman, Sarah E. Pham-Kanter, Genevieve Donelan, Karen TI Attitudes, practices, and preparedness to care for patients with substance use disorder: Results from a survey of general internists SO Substance Abuse LA English DT Article DE Addiction; general internists; preparedness; stigma; substance use disorder ID DRUG-USERS; MEDICINE; STIGMA; PERSPECTIVES; PREVENTION; PHYSICIANS; RESIDENTS; DIAGNOSE; QUALITY; HEALTH AB Background: Previous research demonstrates that most primary care physicians feel unprepared to diagnose and treat substance use disorder (SUD). Confidence in SUD management has been associated with improved clinical practices. Methods: A cross-sectional survey of 290 inpatient and outpatient general internists in an academic medical center evaluating attitudes, preparedness, and clinical practice related to SUD. Results: 149 general internists responded, a response rate of 51%. Forty-six percent frequently cared for patients with SUD. Sixteen percent frequently referred patients to treatment and 6% frequently prescribed a medication to treat SUD. Twenty percent felt very prepared to screen for SUD, 9% to provide a brief intervention, 7% to discuss behavioral treatments, and 9% to discuss medication treatments. Thirty-one percent felt that SUD is different from other chronic diseases because they believe using substances is a choice. Fourteen percent felt treatment with opioid agonists was replacing one addiction with another. Twelve percent of hospitalists and 6% of PCPs believe that someone who uses drugs is committing a crime and deserves punishment. Preparedness was significantly associated with evidence-based clinical practice and favorable attitudes. Frequently caring for patients with SUD was significantly associated with preparedness, clinical practice, and favorable attitudes. Conclusions: SUD is a treatable and prevalent disease, yet a majority of general internists do not feel very prepared to screen, diagnose, provide a brief intervention, refer to treatment, or discuss treatment options with patients. Very few frequently prescribe medications to treat SUD. Some physicians view substance use as a crime and a choice. Physician preparedness and exposure to SUD is associated with improved clinical practice and favorable attitudes towards SUD. Physicians need education and support to provide better care for patients with SUD. C1 [Wakeman, Sarah E.; Donelan, Karen] Massachusetts Gen Hosp, Dept Med, 55 Fruit St,Founders 880, Boston, MA 02114 USA. [Wakeman, Sarah E.; Donelan, Karen] Harvard Med Sch, Boston, MA USA. [Pham-Kanter, Genevieve] Drexel Univ, Dornsife Sch Publ Hlth, Dept Hlth Management & Policy, Philadelphia, PA 19104 USA. [Donelan, Karen] Massachusetts Gen Hosp, Mongan Inst Hlth Policy, Boston, MA 02114 USA. RP Wakeman, SE (reprint author), Massachusetts Gen Hosp, Dept Med, 55 Fruit St,Founders 880, Boston, MA 02114 USA. EM swakeman@patners.org FU Massachusetts General Hospital Substance Use Disorder Initiative FX This work was supported by internal funding through the Massachusetts General Hospital Substance Use Disorder Initiative, who had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. This work had no external funding sources. This paper has not been presented. NR 22 TC 0 Z9 0 U1 1 U2 1 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 0889-7077 EI 1547-0164 J9 SUBST ABUS JI Subst. Abus. PY 2016 VL 37 IS 4 BP 635 EP 641 DI 10.1080/08897077.2016.1187240 PG 7 WC Substance Abuse SC Substance Abuse GA ED5TQ UT WOS:000388915600023 PM 27164025 ER PT J AU Guan, YC Fan, HF Styer, AK Xiao, ZY Li, Z Zhang, JR Sun, LJ Wang, XL Zhang, Z AF Guan, Yichun Fan, Hongfang Styer, Aaron K. Xiao, Zhiying Li, Zhen Zhang, Jianrui Sun, Lijun Wang, Xingling Zhang, Zhan TI A modified natural cycle results in higher live birth rate in vitrified-thawed embryo transfer for women with regular menstruation SO SYSTEMS BIOLOGY IN REPRODUCTIVE MEDICINE LA English DT Article DE Day three embryo transfer; endometrial preparation regimens; live birth rate; vitrification ID IN-VITRO FERTILIZATION; ENDOMETRIAL PREPARATION; NEONATAL OUTCOMES; FROZEN; IMPLANTATION; FRESH; CRYOPRESERVATION; RECEPTIVITY; WINDOW AB There is no consensus regimen for the optimal endometrial preparation for cryopreservation and vitrified-thawed embryo transfer cycles. This is largely caused by the lack of sufficient investigation and analyses on the respective pregnancy and perinatal outcomes by different regimens. This study aimed to compare both pregnancy and perinatal outcomes between the modified natural and artificial cycles in vitrified-thawed day three embryo transfer for women with regular menstruation. A total of 1,482 vitrified-thawed day three embryo transfer cycles were reviewed including 427 modified natural cycles (NC), 132 ovulation induction cycles (OC), 794 artificial cycles (AC), and 129 GnRH agonist artificial cycles (GAC). The primary outcome that was evaluated was live birth rate. The NC regimen demonstrated a higher rate of ongoing pregnancy (43.8% vs. 30.2%, P = 0.002) and a lower rate of late abortion (2.8% vs. 14.0%, P = 0.003) than the GAC regimen as well as a higher implantation rate (31.9% vs. 27.1%, P = 0.008) and live birth rate (43.1% vs. 34.1%, P = 0.002) than the AC regimen. A significantly higher peak endometrial thickness before transfer was observed in patients using the NC and GAC regimens (10.0 +/- 1.7, 9.9 +/- 2.4) compared to the AC regimens (9.2 +/- 1.5, P = 0.000). Multivariate logistic regression showed that the NC protocol was associated with a higher live birth rate. There were no significant differences in rates of pregnancy complications, neonatal mortality, birth defects, mean birth weight, and other perinatal outcomes among the regimens. Modified natural cycle endometrial preparation regimen for vitrified-thawed day three embryo transfer is associated with superior live birth pregnancy outcomes compared to artificial cycles. Future studies are warranted to investigate the underlying biologic mechanisms of these findings. C1 [Guan, Yichun; Fan, Hongfang; Xiao, Zhiying; Li, Zhen; Zhang, Jianrui; Sun, Lijun; Wang, Xingling] Zhengzhou Univ, Ctr Reprod Med, Affiliated Hosp 3, 7 KangFu Qian Rd, Zhengzhou 450052, Henan Province, Peoples R China. [Styer, Aaron K.] Harvard Med Sch, Massachusetts Gen Hosp, Vincent Dept Obstet & Gynecol, Boston, MA USA. [Zhang, Zhan] Zhengzhou Univ, Affiliated Hosp 3, Dept Clin Lab, 7 KangFu Qian Rd, Zhengzhou 450052, Henan Province, Peoples R China. RP Wang, XL (reprint author), Zhengzhou Univ, Ctr Reprod Med, Affiliated Hosp 3, 7 KangFu Qian Rd, Zhengzhou 450052, Henan Province, Peoples R China.; Zhang, Z (reprint author), Zhengzhou Univ, Affiliated Hosp 3, Dept Clin Lab, 7 KangFu Qian Rd, Zhengzhou 450052, Henan Province, Peoples R China. EM xinglingwanghn@163.com; zhanzhangcn@126.com FU Scientific and Technological Project of Henan Province [210203049]; Merck Serono China Research Fund for Fertility FX This work was supported in part by grants from the Scientific and Technological Project of Henan Province (NO. 210203049) and the Merck Serono China Research Fund for Fertility. The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the article. NR 31 TC 0 Z9 0 U1 5 U2 5 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 1939-6368 EI 1939-6376 J9 SYST BIOL REPROD MED JI Syst. Biol. Reprod. Med. PY 2016 VL 62 IS 5 BP 335 EP 342 DI 10.1080/19396368.2016.1199064 PG 8 WC Andrology; Reproductive Biology SC Endocrinology & Metabolism; Reproductive Biology GA DW3PA UT WOS:000383552800005 PM 27400398 ER PT J AU Partovi, S Ghoshhajra, BB AF Partovi, Sasan Ghoshhajra, Brian B. TI Multimodality versus single modality multiparametric imaging of carotid atherosclerotic disease - time to change the approach to patient evaluation? SO Vasa-European Journal of Vascular Medicine LA English DT Editorial Material ID CONTRAST-ENHANCED ULTRASOUND; PLAQUE; NEOVASCULARIZATION; ARTERY C1 [Partovi, Sasan] Case Western Reserve Univ, Uni Hosp Case Med Ctr, Dept Radiol, Sect Vasc & Intervent Radiol, Cleveland, OH USA. [Ghoshhajra, Brian B.] Massachusetts Gen Hosp, Harvard Med Sch, Dept Radiol, Div Cardiovasc Imaging, Boston, MA USA. RP Ghoshhajra, BB (reprint author), Massachusetts Gen Hosp, 165 Cambridge St,Suite 400, Boston, MA 02114 USA. EM bghoshhajra@mgh.harvard.edu NR 17 TC 0 Z9 0 U1 0 U2 0 PU VERLAG HANS HUBER HOGREFE AG PI BERN 9 PA LAENGGASS-STRASSE 76, CH-3000 BERN 9, SWITZERLAND SN 0301-1526 J9 VASA JI Vasa PY 2016 VL 45 IS 6 BP 433 EP 435 DI 10.1024/0301-1526/a000575 PG 3 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA ED8JQ UT WOS:000389118200001 PM 27855573 ER PT S AU Carr, CE Mojarro, A Tani, J Bhattaru, SA Zuber, MT Doebler, R Brown, M Herrington, K Talbot, R Fuller, CW Finney, M Church, G Ruvkun, G AF Carr, Christopher E. Mojarro, Angel Tani, Jacopo Bhattaru, Srinivasa Aditya Zuber, Maria T. Doebler, Robert Brown, Mark Herrington, Keith Talbot, Ryan Fuller, Carl W. Finney, Michael Church, George Ruvkun, Gary GP IEEE TI Advancing the Search for Extra-Terrestrial Genomes SO 2016 IEEE AEROSPACE CONFERENCE SE IEEE Aerospace Conference Proceedings LA English DT Proceedings Paper CT IEEE Aerospace Conference CY MAR 05-12, 2016 CL Big Sky, MT SP IEEE ID ROLLING-CIRCLE AMPLIFICATION; MURCHISON METEORITE; DNA-POLYMERASE; ULTRAVIOLET PHOTOIRRADIATION; CARBONACEOUS METEORITES; MARTIAN CONDITIONS; LIFE DETECTION; MARS; EARTH; NUCLEOBASES AB Widespread synthesis of complex organics, including nucleobases and ribose precursors, occurred early in the history of the solar system in the solar nebula. These organics, delivered to multiple potentially habitable zones, may have biased the evolution of life towards utilization of similar informational polymers. Meteoritic exchange might also have produced shared ancestry, most plausible for Earth and Mars. To test this hypothesis, we are developing the Search for Extra-Terrestrial Genomes (SETG), a life detection instrument for in-situ isolation and sequencing of nucleic acids. Our mission focus area is astrobiology and the search for life beyond Earth. Our science goal for Mars is to search for related or unrelated nucleic acid-based life, particularly life that has the potential to interact with life on Earth; this may also inform sample selection for Mars Sample Return (MSR) and reduce the risks of false positives through the first in-situ measurement of forward contamination. Our science goal for Enceladus is to search for a second genesis based on nucleic acids in the plumes emanating from the South Polar Region. Life detection may also be possible in Europa orbit but the availability of a suitable plume is tenuous and it is a challenge for biological reagents to survive intense radiation there. Here we describe advancements in SETG geared towards in-situ sequencing during a future Mars mission, including extraction of nucleic acids coupled with proof of principle for in-situ single-molecule nanopore-based sequencing. We briefly describe plans to advance SETG from Technology Readiness Level 3 to 6 in preparation for future flight definition and show that under realistic assumptions, a sensitivity of parts per billion or better is feasible. C1 [Carr, Christopher E.; Mojarro, Angel; Tani, Jacopo; Bhattaru, Srinivasa Aditya; Zuber, Maria T.] MIT, 77 Massachusetts Ave,Room 54-418, Cambridge, MA 02139 USA. [Doebler, Robert; Brown, Mark; Herrington, Keith; Talbot, Ryan] Claremont Biosolut LLC, 1182 Monte Vista Ave, Upland, CA 91786 USA. [Fuller, Carl W.] Genia Technol Inc, 2841 Scott Blvd, Santa Clara, CA 95050 USA. [Finney, Michael] 489 Douglass St, San Francisco, CA 94114 USA. [Church, George] Harvard Med Sch, 77 Ave Louis Pasteur,Room 238, Boston, MA 02115 USA. [Ruvkun, Gary] Massachusetts Gen Hosp, 185 Cambridge St, Boston, MA 02114 USA. RP Carr, CE (reprint author), MIT, 77 Massachusetts Ave,Room 54-418, Cambridge, MA 02139 USA. EM chrisc@mit.edu; mojarro@mit.edu; jtani@mit.edu; sbhattar@mit.edu; zuber@mit.edu; rdoebler@claremontbio.com; mbrown@claremontbio.com; kherrington@claremontbio.com; rtalbot@claremontbio.com; carl.fuller@roche.com; michael@finney.biz; gmc@harvard.edu; ruvkun@molbio.mgh.harvard.edu NR 74 TC 0 Z9 0 U1 1 U2 1 PU IEEE PI NEW YORK PA 345 E 47TH ST, NEW YORK, NY 10017 USA SN 1095-323X BN 978-1-4673-7676-1 J9 AEROSP CONF PROC PY 2016 PG 15 WC Engineering, Aerospace SC Engineering GA BG3XT UT WOS:000388374903081 ER PT S AU Karmali, F Artiles, AD Garza, RG Clark, TK Sherwood, DP Young, LR AF Karmali, Faisal Artiles, Ana Diaz Garza, Raquel Galvan Clark, Torin K. Sherwood, David P. Young, Laurence R. GP IEEE TI Development of a Countermeasure to Enhance Sensorimotor Adaptation to Altered Gravity Levels SO 2016 IEEE AEROSPACE CONFERENCE SE IEEE Aerospace Conference Proceedings LA English DT Proceedings Paper CT IEEE Aerospace Conference CY MAR 05-12, 2016 CL Big Sky, MT SP IEEE ID NEUROVESTIBULAR ADAPTATION; ROLL TILT; SPACEFLIGHT; INTEGRATION; THRESHOLDS; ROTATION AB Astronauts experience several gravitational transitions during their journey into space, and they must adapt their sensorimotor capabilities to perform their tasks safely and successfully. A decrement in orientation perception ability or motor skills during a critical mission phase such as landing or docking may lead to catastrophic consequences. The overall objective of this research effort is to investigate and quantify sensorimotor adaptation to altered gravity levels using a short-radius centrifuge. Individual differences, the effect of pre-training in a different gravity environment, and the effect of promethazine in reducing sensorimotor impairment and space motion sickness are of particular interest. The hypotheses are: (1) individual differences exist in the ability to adapt to altered gravity environments and these differences can be predicted for hypo-gravity by measuring adaptability in a hypo-gravity environment, (2) training in one altered gravity environment will improve sensorimotor adaptation in another altered gravity environment, and (3) promethazine will reduce motion sickness, but will have no influence on either basic vestibular perceptual function or sensorimotor adaptation. We are using two tasks to characterize performance decrements and subsequent adaptation that reduces errors: orientation perception and manual control. A series of experiments utilizing these tasks are being conducted on our short-radius centrifuge. For the perception task, subjects report their orientation during a series of roll tilts, while for manual control task, subjects attempt to null a pseudo-random roll tilt disturbance to keep themselves upright using a joystick. We describe preliminary results showing an initial disruption in ability to do both tasks in an altered gravity environment, followed by a learning process to reduce errors. We also tested whether promethazine impacts basic vestibular function by conducting a double-blind, within-subject study with 10 subjects, in which we compared vestibular perceptual thresholds measured with the administration of promethazine or a placebo. Results indicate that promethazine has little effect on perceptual thresholds. Since perceptual measurements can have some inherent measurement variability, we combined subject testing with Monte Carlo simulation tools we developed to evaluate how precisely adaptation rate can be measured. This approach allowed us to optimize experimental design to ensure that precise measures of adaptation rate will be determined. Experimental results show that subjects can, on average, report tilt with a precision of 2 degrees. Simulations show that this corresponds to a coefficient of variation on adaptation time constant of around 20%. C1 [Karmali, Faisal] Harvard Med Sch, Massachusetts Eye & Ear Infirm, 243 Charles St,JVPL 421, Boston, MA 02114 USA. [Artiles, Ana Diaz] Cornell Univ, 402 Rhodes,136 Hoy Rd, Ithaca, NY 14850 USA. [Garza, Raquel Galvan; Sherwood, David P.; Young, Laurence R.] MIT, 77 Massachusetts Ave 37-219, Cambridge, MA 02139 USA. [Clark, Torin K.] Univ Colorado, 429 UCB,ECAE 111, Boulder, CO 80309 USA. RP Karmali, F (reprint author), Harvard Med Sch, Massachusetts Eye & Ear Infirm, 243 Charles St,JVPL 421, Boston, MA 02114 USA. EM Faisal_karmali@meei.harvard.edu; ad877@cornell.edu; rgalvan@mit.edu; torin.clark@colorado.edu; dsherwoo@mit.edu; lry@mit.edu NR 17 TC 0 Z9 0 U1 1 U2 1 PU IEEE PI NEW YORK PA 345 E 47TH ST, NEW YORK, NY 10017 USA SN 1095-323X BN 978-1-4673-7676-1 J9 AEROSP CONF PROC PY 2016 PG 7 WC Engineering, Aerospace SC Engineering GA BG3XT UT WOS:000388374902044 ER PT S AU Kim, M Choi, W Choi, Y Yoon, C Choi, W AF Kim, Moonseok Choi, Wonjun Choi, Youngwoon Yoon, Changhyeong Choi, Wonshik BE Bifano, TG Kubby, J Gigan, S TI Biophotonic applications of eigenchannels in a scattering medium (Conference Presentation) SO ADAPTIVE OPTICS AND WAVEFRONT CONTROL FOR BIOLOGICAL SYSTEMS II SE Proceedings of SPIE LA English DT Proceedings Paper CT Conference on Adaptive Optics and Wavefront Control for Biological Systems II CY FEB 13-15, 2016 CL San Francisco, CA SP SPIE C1 [Kim, Moonseok] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. [Choi, Wonjun] Univ Exeter, Exeter EX4 4QJ, Devon, England. [Choi, Youngwoon; Yoon, Changhyeong; Choi, Wonshik] Korea Univ, Seoul, South Korea. RP Kim, M (reprint author), Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPIE-INT SOC OPTICAL ENGINEERING PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA SN 0277-786X BN 978-1-62841-951-1 J9 PROC SPIE PY 2016 VL 9717 AR UNSP 97170R DI 10.1117/12.2213169 PG 1 WC Microscopy; Optics; Imaging Science & Photographic Technology SC Microscopy; Optics; Imaging Science & Photographic Technology GA BG4TI UT WOS:000389085900022 ER PT J AU White, W Galanter, M Humphreys, K Kelly, J AF White, William Galanter, Marc Humphreys, Keith Kelly, John TI The Paucity of Attention to Narcotics Anonymous in Current Public, Professional, and Policy Responses to Rising Opioid Addiction SO ALCOHOLISM TREATMENT QUARTERLY LA English DT Article DE opioid addiction; Narcotics Anonymous ID SELF-HELP GROUPS; RANDOMIZED CLINICAL-TRIAL; 12-STEP GROUP PARTICIPATION; MULTIVARIATE PROCESS MODEL; SUBSTANCE USE DISORDERS; INJECTION-DRUG USERS; YOUNG-ADULTS; UNITED-STATES; RESIDENTIAL-TREATMENT; MUTUAL-HELP AB Increased opioid-related morbidity and mortality in the United States has triggered considerable professional, public, and political alarm and a wide array of community and clinical responses. The potential role of Narcotics Anonymous (NA) as a recovery support resource is rarely noted within recent media and professional reports addressing opioid addiction. In this brief review and commentary, the authors compare public and professional misconceptions about NA with the findings of available scientific studies of NA. The authors conclude that NA is an underutilized resource in contemporary responses to opioid addiction. C1 [White, William] Chestnut Hlth Syst, 329 Sunset Key Circle 203, Punta Gorda, FL 33955 USA. [Galanter, Marc] NYU, Sch Med, New York, NY USA. [Humphreys, Keith] Stanford Univ, Dept Psychiat & Behav Sci, Palo Alto, CA 94304 USA. [Kelly, John] Harvard Med Sch, Boston, MA USA. [Kelly, John] Massachusetts Gen Hosp, Recovery Res Inst, Boston, MA 02114 USA. RP White, W (reprint author), Chestnut Hlth Syst, 329 Sunset Key Circle 203, Punta Gorda, FL 33955 USA. EM bewhite@chestnut.org NR 171 TC 0 Z9 0 U1 6 U2 6 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 0734-7324 EI 1544-4538 J9 ALCOHOL TREAT Q JI Alcohol. Treat. Q. PY 2016 VL 34 IS 4 BP 437 EP 462 DI 10.1080/07347324.2016.1217712 PG 26 WC Substance Abuse SC Substance Abuse GA ED1LE UT WOS:000388606100007 ER PT J AU Mufson, EJ Perez, SE Nadeem, M Mahady, L Kanaan, NM Abrahamson, EE Ikonomovic, MD Crawford, F Alvarez, V Stein, T McKee, AC AF Mufson, Elliott J. Perez, Sylvia E. Nadeem, Muhammad Mahady, Laura Kanaan, Nicholas M. Abrahamson, Eric E. Ikonomovic, Milos D. Crawford, Fiona Alvarez, Victor Stein, Thor McKee, Ann C. TI Progression of tau pathology within cholinergic nucleus basalis neurons in chronic traumatic encephalopathy: A chronic effects of neurotrauma consortium study SO BRAIN INJURY LA English DT Article DE Cognition; head injury; memory; mild brain injury; traumatic brain injury ID MILD COGNITIVE IMPAIRMENT; NERVE GROWTH-FACTOR; BETA-AMYLOID DEPOSITION; ALZHEIMERS-DISEASE; BRAIN-INJURY; HEAD-INJURY; ACETYLTRANSFERASE ACTIVITY; FOREBRAIN NEURONS; CASPASE CLEAVAGE; UP-REGULATION AB Objective: To test the hypothesis that the nucleus basalis of Meynert (nbM), a cholinergic basal forebrain (CBF) cortical projection system, develops neurofibrillary tangles (NFTs) during the progressive pathological stages of chronic traumatic encephalopathy (CTE) in the brain of athletes.Method: To characterize NFT pathology, tau-antibodies marking early, intermediate and late stages of NFT development in CBF tissue obtained at autopsy from eighteen former athletes and veterans with a history of repetitive mild traumatic brain injury (TBI) were used.Results: Analysis revealed that cholinergic nbM neurons develop intracellular tau-immunoreactive changes progressively across the pathological stages of CTE. In particular, there was an increase in pre-tangle (phosphorylated pS422) and oligomeric (TOC1 and TNT1) forms of tau in stage IV compared to stage II CTE cases. The nbM neurons also displayed pathologic TDP-43 inclusions and diffuse extracellular and vascular amyloid- (A) deposits in CTE. A higher percentage of pS422/p75(NTR), pS422 and TNT1 labelled neurons were significantly correlated with age at symptom onset, interval between symptom onset and death and age at death.Conclusion: The development of NFTs within the cholinergic nbM neurons could contribute to an axonal disconnection in CTE. Further studies are needed to determine the mechanism driving NFT formation in the nbM neurons and its relation to chronic cognitive dysfunction in CTE. C1 [Mufson, Elliott J.; Perez, Sylvia E.; Nadeem, Muhammad; Mahady, Laura] Barrow Neurol Inst, Dept Neurobiol, Phoenix, AZ 85013 USA. [Kanaan, Nicholas M.] Michigan State Univ, Dept Translat Sci & Mol Med, Coll Human Med, Grand Rapids, MI USA. [Abrahamson, Eric E.; Ikonomovic, Milos D.] Univ Pittsburgh, Dept Neurol & Psychiat, Pittsburgh, PA USA. [Abrahamson, Eric E.; Ikonomovic, Milos D.] VA Pittsburgh Hlthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. [Crawford, Fiona] Roskamp Inst, Sarasota, FL USA. [Alvarez, Victor; Stein, Thor; McKee, Ann C.] Boston Univ, Sch Med, VA Boston HlthCare Syst, Alzheimer Dis Ctr, Boston, MA USA. [Alvarez, Victor; Stein, Thor; McKee, Ann C.] Boston Univ, Sch Med, CTE Program, Boston, MA USA. [Alvarez, Victor; Stein, Thor; McKee, Ann C.] Boston Univ, Sch Med, Dept Neurol, Boston, MA USA. [Alvarez, Victor; Stein, Thor; McKee, Ann C.] Boston Univ, Sch Med, Dept Pathol, Boston, MA USA. RP Mufson, EJ (reprint author), Barrow Neurol Inst, Alzheimers Dis Res Lab, 350 W Thomas St, Phoenix, AZ 85013 USA. EM elliott.mufson@dignityhealth.org FU US Army Medical Research and Material Command; US Department of Veterans Affairs [W81XWH-13-2-0095]; Department of Veterans Affairs [I01 RX001774]; National Institute of Neurological Disorders and Stroke; National Institute of Biomedical Imaging and Bioengineering [U01NS086659-01]; National Institute of Aging, Boston University AD Center [P30AG13846, 0572063345-5]; Veterans Affairs Biorepository [CSP 501]; National Operating Committee on Standards for Athletic Equipment; Concussion Legacy Foundation; Andlinger Foundation; World Wrestling Entertainment; National Football League FX The authors report no conflicts of interest. This material is based upon work supported by the US Army Medical Research and Material Command and from the US Department of Veterans Affairs [2] under Award No. W81XWH-13-2-0095. The US Army Medical Research Acquisition Activity, 820 Chandler Street, Fort Detrick, MD 21702-5014 is the awarding and administering acquisition office. Any opinions, findings, conclusions or recommendations expressed in this publication are those of the authors and do not necessarily reflect the views of the US Government, or the US Department of Veterans Affairs, and no official endorsement should be inferred. This work was also supported by an award from the Department of Veterans Affairs No. I01 RX001774, National Institute of Neurological Disorders and Stroke, National Institute of Biomedical Imaging and Bioengineering (U01NS086659-01) and National Institute of Aging, Boston University AD Center (P30AG13846; supplement 0572063345-5), the Veterans Affairs Biorepository (CSP 501), the National Operating Committee on Standards for Athletic Equipment, the Concussion Legacy Foundation, the Andlinger Foundation and the World Wrestling Entertainment and the National Football League. NR 83 TC 0 Z9 0 U1 4 U2 4 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 0269-9052 EI 1362-301X J9 BRAIN INJURY JI Brain Inj. PY 2016 VL 30 IS 12 BP 1399 EP 1413 DI 10.1080/02699052.2016.1219058 PG 15 WC Neurosciences; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA ED1IO UT WOS:000388599100002 PM 27834536 ER PT J AU Pugh, MJ Finley, EP Wang, CP Copeland, LA Jaramillo, CA Swan, AA Elnitsky, CA Leykum, LK Mortensen, EM Eapen, BA Noel, PH Pugh, JA AF Pugh, Mary Jo Finley, Erin P. Wang, Chen-Pin Copeland, Laurel A. Jaramillo, Carlos A. Swan, Alicia A. Elnitsky, Christine A. Leykum, Luci K. Mortensen, Eric M. Eapen, Blessen A. Noel, Polly H. Pugh, Jacqueline A. CA TRACC Res Team TI A retrospective cohort study of comorbidity trajectories associated with traumatic brain injury in veterans of the Iraq and Afghanistan wars SO BRAIN INJURY LA English DT Article DE Comorbidity; Trajectories; Iraq and Afghanistan wars; veteran; healthcare; brain injury ID POLYTRAUMA-CLINICAL-TRIAD; SUBSTANCE USE DISORDERS; COMBAT DEPLOYMENT; OEF/OIF VETERANS; MENTAL-HEALTH; GENDER-DIFFERENCES; MILITARY PERSONNEL; ALCOHOL-USE; CARE; PREVALENCE AB Objectives: To identify and validate trajectories of comorbidity associated with traumatic brain injury in male and female Iraq and Afghanistan war Veterans (IAV).Methods: Derivation and validation cohorts were compiled of IAV who entered the Department of Veterans Affairs (VA) care and received 3 years of VA care between 2002-2011. Chronic disease and comorbidities associated with deployment including TBI were identified using diagnosis codes. A latent class analysis (LCA) of longitudinal comorbidity data was used to identify trajectories of comorbidity.Results: LCA revealed five trajectories that were similar for women and men: (1) Healthy, (2) Chronic Disease, (3) Mental Health, (4) Pain and (5) Polytrauma Clinical Triad (PCT: pain, mental health and TBI). Two additional classes found in men were 6) Minor Chronic and 7) PCT with chronic disease. Among these gender-stratified trajectories, it was found that women were more likely to experience headache (Pain trajectory) and depression (Mental Health trajectory), while men were more likely to experience lower back pain (Pain trajectory) and substance use disorder (Mental Health trajectory). The probability of TBI was highest in the PCT-related trajectories, with significantly lower probabilities in other trajectories.Conclusions: It was found that TBI was most common in PCT-related trajectories, indicating that TBI is commonly comorbid with pain and mental health conditions for both men and women. The relatively young age of this cohort raises important questions regarding how disease burden, including the possibility of neurodegenerative sequelae, will accrue alongside normal age-related decline in individuals with TBI. Additional big data' methods and a longer observation period may allow the development of predictive models to identify individuals with TBI that are at-risk for adverse outcomes. C1 [Pugh, Mary Jo; Finley, Erin P.; Jaramillo, Carlos A.; Swan, Alicia A.; Leykum, Luci K.; Eapen, Blessen A.; Noel, Polly H.; Pugh, Jacqueline A.] South Texas Vet Hlth Care Syst, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA. [Pugh, Mary Jo; Wang, Chen-Pin] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA. [Finley, Erin P.; Swan, Alicia A.; Leykum, Luci K.; Pugh, Jacqueline A.] Univ Texas Hlth Sci Ctr San Antonio, Div Hosp Med, Dept Med, San Antonio, TX 78229 USA. [Copeland, Laurel A.] Cent Texas Vet Hlth Baylor Scott & White, Ctr Appl Hlth Res, Temple, TX USA. [Copeland, Laurel A.] Texas A&M Hlth Sci Ctr, Dept Med, Bryan, TX USA. [Elnitsky, Christine A.; TRACC Res Team] Univ N Carolina, Sch Nursing, Coll Hlth & Human Serv, Charlotte, NC USA. [Mortensen, Eric M.] VA North Texas Hlth Care Syst, Div Gen Internal Med, Dallas, TX USA. [Mortensen, Eric M.] Univ Texas Southwestern Med Ctr Dallas, Div Gen Internal Med, Dallas, TX USA. [Noel, Polly H.] Univ Texas Hlth Sci Ctr San Antonio, Dept Family & Community Med, San Antonio, TX 78229 USA. RP Pugh, MJ (reprint author), South Texas Vet Hlth Care Syst, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA. EM pughm@uthscsa.edu OI Copeland, Laurel/0000-0002-9478-0209; Mortensen, Eric/0000-0002-3880-5563; Finley, Erin/0000-0003-4497-7721 FU Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, VA Health Services Research and Development Service [DHI 09-237]; South Texas Veterans Healthcare System/Audie L. Murphy Division; Edith Nourse Rogers VA Memorial Hospital; VA Research and Development FX This material is based upon work supported by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, VA Health Services Research and Development Service (DHI 09-237). The funding agency had no role in data collection, analysis or manuscript development. The authors acknowledge and appreciate support from the South Texas Veterans Healthcare System/Audie L. Murphy Division and the Edith Nourse Rogers VA Memorial Hospital. We also acknowledge assistance with manuscript preparation by Natalie Rohde, Margaret Wells, Barbara Elizondo and Kathleen Franklin. The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs. Drs. Pugh, Finley, Copeland, Jaramillo, Leykum, Mortensen, Eapen and Pugh are VA employees; this study was funded by VA Research and Development. NR 53 TC 1 Z9 1 U1 1 U2 1 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 0269-9052 EI 1362-301X J9 BRAIN INJURY JI Brain Inj. PY 2016 VL 30 IS 12 BP 1481 EP 1490 DI 10.1080/02699052.2016.1219055 PG 10 WC Neurosciences; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA ED1IO UT WOS:000388599100010 PM 27834535 ER PT J AU Poulin, MF Deka, A Mohamedali, B Schaer, GL AF Poulin, Marie-France Deka, Anjan Mohamedali, Burhan Schaer, Gary L. TI Clinical Benefits of Stem Cells for Chronic Symptomatic Systolic Heart Failure: A Systematic Review of the Existing Data and Ongoing Trials SO CELL TRANSPLANTATION LA English DT Review DE Systolic heart failure; Stem cells; Bone marrow-derived stem cells; Cell therapy; Ischemic cardiomyopathy (ICM); Nonischemic cardiomyopathy (NICM) ID NONISCHEMIC DILATED CARDIOMYOPATHY; MARROW MONONUCLEAR-CELLS; AUTOLOGOUS SKELETAL MYOBLASTS; LEFT-VENTRICULAR FUNCTION; DOUBLE-BLIND TRIAL; FOLLOW-UP; ISCHEMIC CARDIOMYOPATHY; TRANSENDOCARDIAL INJECTION; MYOCARDIAL-INFARCTION; IXMYELOCEL-T AB The benefits of stem cell therapy for patients with chronic symptomatic systolic heart failure due to ischemic and nonischemic cardiomyopathy (ICM and NICM, respectively) are unclear. We performed a systematic review of major published and ongoing trials of stem cell therapy for systolic heart failure and compared measured clinical outcomes for both types of cardiomyopathy. The majority of the 29 published studies demonstrated clinical benefits of autologous bone marrow-derived mesenchymal stem cells (BM-MSCs). Left ventricular ejection fraction (LVEF) was improved in the majority of trials after therapy. Cell delivery combined with coronary artery bypass grafting was associated with the greatest improvement in LVEF. Left ventricular end-systolic volume (or diameter), New York Heart Association functional classification, quality of life, and exercise capacity were also improved in most studies after cell therapy. Most ICM trials demonstrated a significant improvement in perfusion defects, infarct size, and myocardial viability. Several larger clinical trials that are in progress employ alternative delivery modes, cell types, and longer follow-up periods. Stem cells are a promising therapeutic modality for patients with heart failure due to ICM or NICM. More data are required from larger blinded trials to determine which combination of cell type and delivery mode will yield the most benefit with avoidance of harm in these patient populations. C1 [Poulin, Marie-France] Beth Israel Deaconess Med Ctr, Dept Med, Div Cardiovasc Med, Boston, MA 02215 USA. [Deka, Anjan; Mohamedali, Burhan; Schaer, Gary L.] Rush Univ, Med Ctr, Dept Med, Div Cardiol, Chicago, IL 60612 USA. RP Schaer, GL (reprint author), Rush Univ, Med Ctr, 1717 West Congress Pkwy Suite 305 Kellogg Bldg, Chicago, IL 60612 USA. EM Gary_Schaer@Rush.edu OI Poulin, Marie-France/0000-0001-5217-6348 NR 35 TC 1 Z9 1 U1 1 U2 1 PU COGNIZANT COMMUNICATION CORP PI PUTNAM VALLEY PA 18 PEEKSKILL HOLLOW RD, PO BOX 37, PUTNAM VALLEY, NY 10579 USA SN 0963-6897 EI 1555-3892 J9 CELL TRANSPLANT JI Cell Transplant. PY 2016 VL 25 IS 11 BP 1911 EP 1923 DI 10.3727/096368916X692087 PG 13 WC Cell & Tissue Engineering; Medicine, Research & Experimental; Transplantation SC Cell Biology; Research & Experimental Medicine; Transplantation GA EC0FR UT WOS:000387774300001 PM 27931504 ER PT J AU Arias, SA Dumas, O Sullivan, AF Boudreaux, ED Miller, I Camargo, CA AF Arias, Sarah A. Dumas, Orianne Sullivan, Ashley F. Boudreaux, Edwin D. Miller, Ivan Camargo, Carlos A., Jr. TI Substance Use as a Mediator of the Association Between Demographics, Suicide Attempt History, and Future Suicide Attempts in Emergency Department Patients SO CRISIS-THE JOURNAL OF CRISIS INTERVENTION AND SUICIDE PREVENTION LA English DT Article DE suicide attempt; substance use; structural equation modeling; statistical mediation analysis; emergency departments ID USE DISORDERS; FOLLOW-UP; BEHAVIOR; HYPOTHESES; INJURY; VISITS; TRENDS; ABUSE; RISK AB Background: Identification of factors that predict and protect against attempted suicide are critical for the development of effective suicide prevention and intervention programs. Aims: To examine whether substance use mediates the association between demographic characteristics, suicide attempt history, and reports of a suicide attempt within 12 months after screening positive for active suicidal ideation or behavior during the index emergency department (ED) visit. Method: Data were collected during the first two phases of the Emergency Department Safety Assessment and Follow-up Evaluation (ED-SAFE) study. Data collection included baseline interview; 6- and 12-month chart reviews; and 6-, 12-, 24-, 36-, and 52-week telephone follow-up assessments. Structural equation modeling was used. All p values were two-tailed, with p < .05 considered statistically significant. Results: Among the 874 subjects, 195 (22%) reported a suicide attempt within 12 months after the index ED visit. Of participants reporting a suicide attempt, 59% were < 40 years old, 59% female, and 76% non-Hispanic White. Associations between race, sex, and suicide attempt 12 months after the index ED visit may be mediated by a combination of alcohol misuse and cocaine use. Conclusion: Findings from the mediation analyses provide insight into the impact of substance use on future suicide attempts in various sociodemographic groups. C1 [Arias, Sarah A.; Miller, Ivan] Brown Univ, Dept Psychiat & Human Behav, Butler Hosp, Providence, RI 02912 USA. [Dumas, Orianne; Sullivan, Ashley F.; Camargo, Carlos A., Jr.] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA. [Boudreaux, Edwin D.] Univ Massachusetts, Sch Med, Dept Emergency Med Psychiat & Quantitat Hlth Sci, Worcester, MA USA. [Camargo, Carlos A., Jr.] Harvard Med Sch, Boston, MA USA. RP Arias, SA (reprint author), Butler Hosp, Dept Psychiat & Human Behav, 345 Blackstone Blvd, Providence, RI 02906 USA. EM sarias@butler.org FU National Institute of Mental Health [U01MH 088278] FX This project was supported by Award Number U01MH 088278 from the National Institute of Mental Health. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Mental Health or the National Institutes of Health. NR 24 TC 0 Z9 0 U1 1 U2 1 PU HOGREFE & HUBER PUBLISHERS PI GOTTINGEN PA MERKELSTR 3, D-37085 GOTTINGEN, GERMANY SN 0227-5910 EI 2151-2396 J9 CRISIS JI Crisis PY 2016 VL 37 IS 5 BP 385 EP 391 DI 10.1027/0227-5910/a000380 PG 7 WC Psychiatry; Psychology, Multidisciplinary SC Psychiatry; Psychology GA ED5XQ UT WOS:000388927200009 PM 27040130 ER PT J AU Cardenas, A Allard, C Doyon, M Houseman, EA Bakulski, KM Perron, P Bouchard, L Hivert, MF AF Cardenas, Andres Allard, Catherine Doyon, Myriam Houseman, E. Andres Bakulski, Kelly M. Perron, Patrice Bouchard, Luigi Hivert, Marie-France TI Validation of a DNA methylation reference panel for the estimation of nucleated cells types in cord blood SO EPIGENETICS LA English DT Article DE Cord blood; DNA methylation; EWAS; birth cohort; Illumina 450K; nucleated red blood cells; white blood cell composition ID SYSMEX XE-5000 AB Cord blood is widely used as surrogate tissue in epigenome-wide association studies of prenatal conditions. Cell type composition variation across samples can be an important confounder of epigenome-wide association studies in blood that constitute a mixture of cells. We evaluated a newly developed cord blood reference panel to impute cell type composition from DNA methylation levels, including nucleated red blood cells (nRBCs). We estimated cell type composition from 154 unique cord blood samples with available DNA methylation data as well as direct measurements of nucleated cell types. We observed high correlations between the estimated and measured composition for nRBCs (r = 0.92, R-2 = 0.85), lymphocytes (r = 0.77, R-2 = 0.58), and granulocytes (r = 0.72, R-2 = 0.52), and a moderate correlation for monocytes (r = 0.51, R-2 = 0.25) as well as relatively low root mean square errors from the residuals ranging from 1.4 to 5.4%. These results validate the use of the cord blood reference panel and highlight its utility and limitations for epidemiological studies. C1 [Cardenas, Andres; Hivert, Marie-France] Harvard Med Sch, Harvard Pilgrim Hlth Care Inst, Dept Populat Med, Boston, MA USA. [Allard, Catherine; Doyon, Myriam; Perron, Patrice; Bouchard, Luigi; Hivert, Marie-France] CHU Sherbrooke, Ctr Rech, Sherbrooke, PQ, Canada. [Houseman, E. Andres] Oregon State Univ, Coll Publ Hlth & Human Sci, Corvallis, OR 97331 USA. [Bakulski, Kelly M.] Univ Michigan, Sch Publ Hlth, Dept Epidemiol, Ann Arbor, MI 48109 USA. [Perron, Patrice; Hivert, Marie-France] Univ Sherbrooke, Fac Med & Life Sci, Dept Med, Sherbrooke, PQ, Canada. [Bouchard, Luigi] Univ Sherbrooke, Fac Med & Life Sci, Dept Biochem, Sherbrooke, PQ, Canada. [Bouchard, Luigi] Chicoutimi Hosp, GECOGENE & Lipid Clin 21, Saguenay, PQ, Canada. [Hivert, Marie-France] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Hivert, MF (reprint author), Harvard Med Sch, Dept Populat Med, Landmark Ctr 401 Pk Dr,Suite 401, Boston, MA 02115 USA.; Hivert, MF (reprint author), Harvard Pilgrim Hlth Care Inst, Landmark Ctr 401 Pk Dr,Suite 401, Boston, MA 02115 USA. EM marie-france_hivert@harvardpilgrim.org OI Cardenas, Andres/0000-0003-2284-3298; Allard, Catherine/0000-0002-8829-4984 FU Fonds de recherche du Quebec en sante [20697]; Canadian Institute of Health Research [MOP 115071]; Diabete Quebec grant; ADA Accelerator Award [1-15-ACE-26] FX Fonds de recherche du Quebec en sante #20697 (M.-F.H.); Canadian Institute of Health Research #MOP 115071 (M.-F.H.); Diabete Quebec grant (P.P.); ADA Accelerator Award #1-15-ACE-26 (M.-F.H.). NR 18 TC 1 Z9 1 U1 1 U2 1 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 1559-2294 EI 1559-2308 J9 EPIGENETICS-US JI Epigenetics PY 2016 VL 11 IS 11 BP 773 EP 779 DI 10.1080/15592294.2016.1233091 PG 7 WC Biochemistry & Molecular Biology; Genetics & Heredity SC Biochemistry & Molecular Biology; Genetics & Heredity GA ED1RI UT WOS:000388622200001 PM 27668573 ER PT S AU Nitzsche, B Barthel, H Lobsien, D Boltze, J Zeisig, V Dreyer, AY AF Nitzsche, Bjoern Barthel, Henryk Lobsien, Donald Boltze, Johannes Zeisig, Vilia Dreyer, Antje Y. BE Janowski, M TI Focal Cerebral Ischemia by Permanent Middle Cerebral Artery Occlusion in Sheep: Surgical Technique, Clinical Imaging, and Histopathological Results SO EXPERIMENTAL NEUROSURGERY IN ANIMAL MODELS SE Neuromethods LA English DT Article; Book Chapter DE Large animal model; Sheep; Experimental neurosurgery; Craniotomy; Experimental stroke; Middle cerebral artery occlusion; MRI; PET ID EMISSION-TOMOGRAPHY; STROKE; MODEL; THROMBOLYSIS; CORTEX AB According to the recommendation of international expert committees, large animal stroke models are demanded for preclinical research. Based on a brief introduction to the ovine cranial anatomy, a sheep model of permanent middle cerebral artery occlusion (MCAO) will be described in this chapter. The model was particularly designed to verify several therapeutic strategies during both, acute and long-term studies, but is also feasible for development of diagnostic procedures. Further, exemplary application of imaging procedures and imaging data analyses using magnetic resonance imaging (MRI) and positron emission tomography (PET) are described. The chapter also includes recommendations for appropriate animal housing and medication. C1 [Nitzsche, Bjoern; Dreyer, Antje Y.] Fraunhofer Inst Cell Therapy & Immunol, Dept Cell Therapy, Leipzig, Germany. [Nitzsche, Bjoern; Barthel, Henryk; Zeisig, Vilia] Univ Leipzig, Dept Nucl Med, Leipzig, Germany. [Lobsien, Donald] Univ Leipzig, Dept Neuroradiol, Leipzig, Germany. [Boltze, Johannes] Fraunhofer Res Inst Marine Biotechnol, Dept Med Cell Technol, Lubeck, Germany. [Boltze, Johannes] Massachusetts Gen Hosp, Neurosci Ctr, Charlestown, MA USA. [Boltze, Johannes] Harvard Med Sch, Charlestown, MA USA. RP Nitzsche, B (reprint author), Fraunhofer Inst Cell Therapy & Immunol, Dept Cell Therapy, Leipzig, Germany.; Nitzsche, B (reprint author), Univ Leipzig, Dept Nucl Med, Leipzig, Germany. OI Nitzsche, Bjorn/0000-0002-4759-0760 NR 37 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES SN 0893-2336 BN 978-1-4939-3730-1; 978-1-4939-3728-8 J9 NEUROMETHODS JI Neuromethods PY 2016 VL 116 BP 195 EP 225 DI 10.1007/978-1-4939-3730-1_15 D2 10.1007/978-1-4939-3730-1 PG 31 WC Clinical Neurology; Surgery SC Neurosciences & Neurology; Surgery GA BG4LP UT WOS:000388975500017 ER PT S AU Bertaux-Skeirik, N Centeno, J Feng, R Schumacher, MA Shivdasani, RA Zavros, Y AF Bertaux-Skeirik, Nina Centeno, Jomaris Feng, Rui Schumacher, Michael A. Shivdasani, Ramesh A. Zavros, Yana BE Ivanov, AI TI Co-culture of Gastric Organoids and Immortalized Stomach Mesenchymal Cells SO GASTROINTESTINAL PHYSIOLOGY AND DISEASES: METHODS AND PROTOCOLS SE Methods in Molecular Biology LA English DT Article; Book Chapter DE Mouse fundic gastric organoids; Co-culture; Immortalized stomach mesenchymal cells ID IN-VITRO EXPANSION; STEM-CELLS; EPITHELIUM AB Three-dimensional primary epithelial-derived gastric organoids have recently been established as an important tool to study gastric development, physiology, and disease. Specifically, mouse-derived fundic gastric organoids (mFGOs) co-cultured with Immortalized Stomach Mesenchymal Cells (ISMCs) reflect expression patterns of mature fundic cell types seen in vivo, thus allowing for long-term in vitro studies of gastric epithelial cell physiology, regeneration, and bacterial-host interactions. Here, we describe the development and culture of mFGOs, co-cultured with ISMCs. C1 [Bertaux-Skeirik, Nina; Centeno, Jomaris; Zavros, Yana] Univ Cincinnati, Coll Med, Dept Mol & Cellular Physiol, Cincinnati, OH 45220 USA. [Feng, Rui] Sun Yatsen Univ, Affiliated Hosp 1, Dept Gastroenterol & Hepatol, Guangzhou, Guangdong, Peoples R China. [Schumacher, Michael A.] Childrens Hosp Los Angeles, Div Gastroenterol, Los Angeles, CA 90027 USA. [Shivdasani, Ramesh A.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Shivdasani, Ramesh A.] Harvard Med Sch, Dept Med, Boston, MA USA. RP Bertaux-Skeirik, N (reprint author), Univ Cincinnati, Coll Med, Dept Mol & Cellular Physiol, Cincinnati, OH 45220 USA. FU NCATS NIH HHS [UL1 TR001425] NR 15 TC 1 Z9 1 U1 1 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES SN 1064-3745 BN 978-1-4939-3603-8; 978-1-4939-3601-4 J9 METHODS MOL BIOL JI Methods Mol. Biol. PY 2016 VL 1422 BP 23 EP 31 DI 10.1007/978-1-4939-3603-8_3 D2 10.1007/978-1-4939-3603-8 PG 9 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA BG4KX UT WOS:000388940200004 PM 27246019 ER PT J AU Fernandez, M Zambrano, MJ Riquelme, J Jueppner, H Castiglioni, C Mericq, V AF Fernandez, M. Zambrano, M. J. Riquelme, J. Jueppner, H. Castiglioni, C. Mericq, V TI Pseudohypoparathyroidism Type IB Associated to Assisted Reproductive Technologies SO HORMONE RESEARCH IN PAEDIATRICS LA English DT Meeting Abstract C1 [Fernandez, M.; Riquelme, J.; Mericq, V] Univ Chile, Inst Invest Materno Infantil, Santiago, Chile. [Zambrano, M. J.] Pontificia Univ Catolica Chile, Fac Med, Santiago, Chile. [Jueppner, H.] MassGen Hosp Children, Div Pediat, Boston, MA USA. [Castiglioni, C.] Clin Las Condes, Dept Neurol Infantil, Santiago, Chile. NR 0 TC 0 Z9 0 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1663-2818 EI 1663-2826 J9 HORM RES PAEDIAT JI Horm. Res. Paediatr. PY 2016 VL 86 SU 2 MA O-40 BP 20 EP 21 PG 2 WC Endocrinology & Metabolism; Pediatrics SC Endocrinology & Metabolism; Pediatrics GA EC9ZZ UT WOS:000388504100041 ER PT S AU Van de Bittner, GC Hirayama, T AF Van de Bittner, Genevieve C. Hirayama, Tasuku BE Bai, M TI In Vivo Metal Ion Imaging Using Fluorescent Sensors SO IN VIVO FLUORESCENCE IMAGING: METHODS AND PROTOCOLS SE Methods in Molecular Biology LA English DT Article; Book Chapter DE Fluorescence; Near-infrared; Copper; In vivo imaging; IVIS spectrum; Wilson's disease; Metal; Ion ID PROBES AB In vivo imaging in living animals provides the ability to monitor alterations of signaling molecules, ions, and other biological components during various life stages and in disease. The data gained from in vivo imaging can be used for biological discovery or to determine elements of disease progression and can inform the development and translation of therapeutics. Herein, we present theories behind small-molecule, fluorescent, metal ion sensors as well as the methods for their successful application to in vivo metal ion imaging, including ex vivo validation. C1 [Van de Bittner, Genevieve C.] Harvard Med Sch, Dept Radiol, Athinoula A Martinos Ctr Biomed Imaging, Massachusetts Gen Hosp, Charlestown, MA 02115 USA. [Hirayama, Tasuku] Gifu Pharmaceut Univ, Lab Med & Pharmaceut Chem, Gifu, Japan. RP Van de Bittner, GC (reprint author), Harvard Med Sch, Dept Radiol, Athinoula A Martinos Ctr Biomed Imaging, Massachusetts Gen Hosp, Charlestown, MA 02115 USA. NR 18 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES SN 1064-3745 BN 978-1-4939-3721-9; 978-1-4939-3719-6 J9 METHODS MOL BIOL JI Methods Mol. Biol. PY 2016 VL 1444 BP 139 EP 152 DI 10.1007/978-1-4939-3721-9_13 D2 10.1007/978-1-4939-3721-9 PG 14 WC Biochemical Research Methods; Radiology, Nuclear Medicine & Medical Imaging SC Biochemistry & Molecular Biology; Radiology, Nuclear Medicine & Medical Imaging GA BG4LR UT WOS:000388977600014 PM 27283424 ER PT J AU Dang, C Guo, H Najita, J Yardley, D Marcom, K Albain, K Rugo, H Miller, K Ellis, M Shapira, I Wolff, AC Carey, LA Moy, B Groarke, J Moslehi, J Krop, I Burstein, HJ Hudis, C Winter, E Tolaney, SM AF Dang, Chau Guo, Hao Najita, Julie Yardley, Denise Marcom, Kelly Albain, Kathy Rugo, Hope Miller, Kathy Ellis, Matthew Shapira, Iuliana Wolff, Antonio C. Carey, Lisa A. Moy, Beverly Groarke, John Moslehi, Javid Krop, Ian Burstein, Harold J. Hudis, Clifford Winter, Eric Tolaney, Sara M. TI Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer SO JAMA ONCOLOGY LA English DT Article ID TRIAL COMPARING DOXORUBICIN; HEART-FAILURE; NSABP B-31; PLUS TRASTUZUMAB; FOLLOW-UP; CHEMOTHERAPY; THERAPY; N9831; WOMEN; CARDIOTOXICITY AB IMPORTANCE Trastuzumab is a life-saving therapy but is associated with symptomatic and asymptomatic left ventricular ejection fraction (LVEF) decline. We report the cardiac toxic effects of a nonanthracycline and trastuzumab-based treatment for patients with early-stage human epidermal growth factor receptor 2 (ERBB2, formerly HER2 or HER2/neu)-positive breast cancer. OBJECTIVE To determine the cardiac safety of paclitaxel with trastuzumab and the utility of LVEF monitoring in patients with node-negative, ERBB2-positive breast cancer. DESIGN, SETTING, AND PARTICIPANTS In this secondary analysis of an uncontrolled, single group study across 14 medical centers, enrollment of 406 patients with node-negative, ERBB2-positive breast cancer 3 cm, or smaller, and baseline LVEF of greater than or equal to 50% occurred from October 9, 2007, to September 3, 2010. Patients with a micrometastasis in a lymph node were later allowed with a study amendment. Median patient age was 55 years, 118 (29%) had hypertension, and 30 (7%) had diabetes. Patients received adjuvant paclitaxel for 12 weeks with trastuzumab, and trastuzumab was continued for 1 year. Median follow-up was 4 years. INTERVENTIONS Treatment consisted of weekly 80-mg/m(2) doses of paclitaxel administered concurrently with trastuzumab intravenously for 12 weeks, followed by trastuzumab monotherapy for 39 weeks. During the monotherapy phase, trastuzumab could be administered weekly 2-mg/kg or every 3 weeks as 6-mg/kg. Radiation and hormone therapy were administered per standard guidelines after completion of the 12 weeks of chemotherapy. Patient LVEF was assessed at baseline, 12 weeks, 6 months, and 1 year. MAIN OUTCOMES AND MEASURES Cardiac safety data, including grade 3 to 4 left ventricular systolic dysfunction (LVSD) and significant asymptomatic LVEF decline, as defined by our study, were reported. RESULTS Overall, 2 patients (0.5%) (95% CI, 0.1%-1.8%) developed grade 3 LVSD and came off study, and 13 (3.2%) (95% CI, 1.9%-5.4%) had significant asymptomatic LVEF decline, 11 of whom completed study treatment. Median LVEF at baseline was 65%; 12 weeks, 64%; 6 months, 64%; and 1 year, 64%. CONCLUSIONS AND RELEVANCE Cardiac toxic effects from paclitaxel with trastuzumab, manifesting as grade 3 or 4 LVSD or asymptomatic LVEF decline, were low. Patient LVEF was assessed at baseline, 12 weeks, 6 months, and 1 year, and our findings suggest that LVEF monitoring during trastuzumab therapy without anthracyclines could be simplified for many individuals. C1 [Dang, Chau; Hudis, Clifford] Mem Sloan Kettering Canc Ctr, Dept Med, West Harrison, NY USA. [Guo, Hao; Najita, Julie; Groarke, John; Krop, Ian; Burstein, Harold J.; Winter, Eric; Tolaney, Sara M.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [Yardley, Denise] Sarah Cannon Res Inst, Breast Canc Res, Nashville, TN USA. [Marcom, Kelly] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA. [Albain, Kathy] Loyola Univ Chicago, Cardinal Bernardin Canc Ctr, Dept Med, Chicago, IL USA. [Rugo, Hope] Univ Calif San Francisco, Dept Med, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA. [Miller, Kathy] Indiana Univ, Dept Med, Melvin & Bren Simon Canc Ctr, Indianapolis, IN USA. [Ellis, Matthew] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA. [Shapira, Iuliana] Hofstra North Shore Long Isl Jewish Sch Med, Dept Hematol Oncol, Hempstead, NY USA. [Wolff, Antonio C.] Johns Hopkins Univ, Sydney Kimmel Comprehens Canc Ctr, Dept Oncol, Baltimore, MD USA. [Carey, Lisa A.] Univ N Carolina, Dept Med, Chapel Hill, NC USA. [Moy, Beverly] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. [Moslehi, Javid] Vanderbilt Univ Sch Med, Dept Med, Cardiooncol Program, Nashville, TN USA. RP Dang, C (reprint author), Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10065 USA. EM dangc@mskcc.org FU Roche/Genentech FX This study was supported by Roche/Genentech. NR 38 TC 5 Z9 5 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2374-2445 J9 JAMA ONCOL JI JAMA Oncol. PD JAN PY 2016 VL 2 IS 1 BP 29 EP 36 DI 10.1001/jamaoncol.2015.3709 PG 8 WC Oncology SC Oncology GA DW5JE UT WOS:000383679300009 PM 26539793 ER PT J AU Shrime, MG Ferket, BS Scott, DJ Lee, J Barragan-Bradford, D Pollard, T Arabi, YM Al-Dorzi, HM Baron, RM Hunink, MGM Celi, LA Lai, PS AF Shrime, Mark G. Ferket, Bart S. Scott, Daniel J. Lee, Joon Barragan-Bradford, Diana Pollard, Tom Arabi, Yaseen M. Al-Dorzi, Hasan M. Baron, Rebecca M. Hunink, M. G. Myriam Celi, Leo A. Lai, Peggy S. TI Time-Limited Trials of Intensive Care for Critically Ill Patients With Cancer How Long Is Long Enough? SO JAMA ONCOLOGY LA English DT Article ID COST-EFFECTIVENESS; SOFA SCORE; UNIT; MORTALITY; LIFE; ICU; SURVIVAL; PREDICTIONS; PHYSICIANS; OUTCOMES AB IMPORTANCE Time-limited trials of intensive care are commonly used in patients perceived to have a poor prognosis. The optimal duration of such trials is unknown. Factors such as a cancer diagnosis are associated with clinician pessimism and may affect the decision to limit care independent of a patient's severity of illness. OBJECTIVE To identify the optimal duration of intensive care for short-term mortality in critically ill patients with cancer. DESIGN, SETTING, AND PARTICIPANTS Decision analysis using a state-transition microsimulation model was performed to simulate the hospital course of patients with poor-prognosis primary tumors, metastatic disease, or hematologic malignant neoplasms admitted to medical and surgical intensive care units. Transition probabilities were derived from 920 participants stratified by sequential organ failure assessment (SOFA) scores to identify severity of illness. The model was validated in 3 independent cohorts with 349, 158, and 117 participants from quaternary care academic hospitals. Monte Carlo microsimulation was performed, followed by probabilistic sensitivity analysis. Outcomes were assessed in the overall cohort and in solid tumors alone. INTERVENTIONS Time-unlimited vs time-limited trials of intensive care. MAIN OUTCOMES AND MEASURES 30-day all-cause mortality and mean survival duration. RESULTS The SOFA scores at ICU admission were significantly associated with mortality. A 3-,8-, or 15-day trial of intensive care resulted in decreased mean 30-day survival vs aggressive care in all but the sickest patients (SOFA score, 5-9: 48.4%[95% CI, 48.0%-48.8%], 60.6% [95% CI, 60.2%-61.1%], and 66.8%[95% CI, 66.4%-67.2%], respectively, vs 74.6%[95% CI, 74.3%-75.0%] with time-unlimited aggressive care; SOFA score, 10-14: 36.2%[95% CI, 35.8%-36.6%], 44.1%[95% CI, 43.6%-44.5%], and 46.1%[95% CI, 45.6%-46.5%], respectively, vs 48.4%[95% CI, 48.0%-48.8%] with aggressive care; SOFA score, >= 15: 5.8% [95% CI, 5.6%-6.0%], 8.1% [95% CI, 7.9%-8.3%], and 8.3%[95% CI, 8.1%-8.6%], respectively, vs 8.8% [95% CI, 8.5%-9.0%] with aggressive care). However, the clinical magnitude of these differences was variable. Trial durations of 8 days in the sickest patients offered mean survival duration that was no more than 1 day different from time-unlimited care, whereas trial durations of 10 to 12 days were required in healthier patients. For the subset of patients with solid tumors, trial durations of 1 to 4 days offered mean survival that was not statistically significantly different from time-unlimited care. CONCLUSIONS AND RELEVANCE Trials of ICU care lasting 1 to 4 days may be sufficient in patients with poor-prognosis solid tumors, whereas patients with hematologic malignant neoplasms or less severe illness seem to benefit from longer trials of intensive care. C1 [Shrime, Mark G.] Harvard Med Sch, Program Global Surg & Social Change, Boston, MA USA. [Shrime, Mark G.] Massachusetts Eye & Ear Infirm, Dept Otolaryngol, 243 Charles St, Boston, MA 02114 USA. [Ferket, Bart S.; Hunink, M. G. Myriam] Erasmus Univ, Med Ctr, Dept Epidemiol, Rotterdam, Netherlands. [Ferket, Bart S.] Icahn Sch Med Mt Sinai, Dept Populat Hlth Sci & Policy, Inst Healthcare Delivery Sci, New York, NY 10029 USA. [Scott, Daniel J.; Pollard, Tom] MIT, Harvard Div Hlth Sci & Technol, Boston, MA USA. [Lee, Joon] Univ Waterloo, Sch Publ Hlth & Hlth Syst, Waterloo, ON, Canada. [Barragan-Bradford, Diana; Baron, Rebecca M.] Brigham & Womens Hosp, Div Pulm & Crit Care Med, 75 Francis St, Boston, MA 02115 USA. [Barragan-Bradford, Diana; Baron, Rebecca M.; Celi, Leo A.; Lai, Peggy S.] Harvard Med Sch, Boston, MA USA. [Arabi, Yaseen M.; Al-Dorzi, Hasan M.] King Saud Bin Abdulaziz Univ Hlth Sci, Dept Intens Care, Riyadh, Saudi Arabia. [Arabi, Yaseen M.; Al-Dorzi, Hasan M.] King Abdullah Int Med Res Ctr, Riyadh, Saudi Arabia. [Hunink, M. G. Myriam] Harvard Sch Publ Hlth, Ctr Hlth Decis Sci, Boston, MA USA. [Lai, Peggy S.] Massachusetts Gen Hosp, Pulm & Crit Care Unit, Boston, MA 02114 USA. RP Shrime, MG (reprint author), Massachusetts Eye & Ear Infirm, Emergency Dept, 243 Charles St, Boston, MA 02114 USA. EM shrime@gmail.com FU National Institutes of Health [NIH R01 HL112747, NIH-NIEHS K23 ES023700, NIH-NIBIB R01 EB017205-01A1] FX This study received partial support from National Institutes of Health grants NIH R01 HL112747 to Dr Baron for collection of data, NIH-NIEHS K23 ES023700 to Dr Lai as part of a career development award, and NIH-NIBIB R01 EB017205-01A1 for support of the MIMIC database. NR 40 TC 2 Z9 2 U1 1 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2374-2445 J9 JAMA ONCOL JI JAMA Oncol. PD JAN PY 2016 VL 2 IS 1 BP 76 EP 83 DI 10.1001/jamaoncol.2015.3336 PG 8 WC Oncology SC Oncology GA DW5JE UT WOS:000383679300016 PM 26469222 ER PT J AU Schmid, M Meyer, CP Reznor, G Choueiri, TK Hanske, J Sammon, JD Abdollah, F Chun, FKH Kibel, AS Tucker-Seeley, RD Kantoff, PW Lipsitz, SR Menon, M Nguyen, PL Trinh, QD AF Schmid, Marianne Meyer, Christian P. Reznor, Gally Choueiri, Toni K. Hanske, Julian Sammon, Jesse D. Abdollah, Firas Chun, Felix K. H. Kibel, Adam S. Tucker-Seeley, Reginald D. Kantoff, Philip W. Lipsitz, Stuart R. Menon, Mani Nguyen, Paul L. Quoc-Dien Trinh TI Racial Differences in the Surgical Care of Medicare Beneficiaries With Localized Prostate Cancer SO JAMA ONCOLOGY LA English DT Article ID ANDROGEN-DEPRIVATION THERAPY; RADICAL PROSTATECTOMY; UNITED-STATES; CLAIMS DATA; OLDER MEN; SOCIOECONOMIC-STATUS; AFRICAN-AMERICAN; CAUCASIAN MEN; HEALTH-CARE; SURVIVAL AB IMPORTANCE There is extensive evidence suggesting that black men with localized prostate cancer (PCa) have worse cancer-specific mortality compared with their non-Hispanic white counterparts. OBJECTIVE To evaluate racial disparities in the use, quality of care, and outcomes of radical prostatectomy (RP) in elderly men (>= 65 years) with nonmetastatic PCa. DESIGN, SETTING, AND PARTICIPANTS This retrospective analysis of outcomes stratified according to race (black vs non-Hispanic white) included 2020 elderly black patients (7.6%) and 24 462 elderly non-Hispanic white patients (92.4%) with localized PCa who underwent RP within the first year of PCa diagnosis in the Surveillance, Epidemiology, and End Results (SEER)-Medicare database between 1992 and 2009. The study was performed in 2014. MAIN OUTCOMES AND MEASURES Process of care (ie, time to treatment, lymph node dissection), as well as outcome measures (ie, complications, emergency department visits, readmissions, PCa-specific and all-cause mortality, costs) were evaluated using Cox proportional hazards regression. Multivariable conditional logistic regression and quantile regression were used to study the association of racial disparities with process of care and outcome measures. RESULTS The proportion of black patients with localized prostate cancer who underwent RP within 90 days was 59.4% vs 69.5% of non-Hispanic white patients (P < .001). In quantile regression of the top 50% of patients, blacks had a 7-day treatment delay compared with non-Hispanic whites. (P < .001). Black patients were less likely to undergo lymph node dissection (odds ratio [OR], 0.76 [95% CI, 0.66-0.80]; P < .001) but had higher odds of postoperative visits to the emergency department (within 30 days: OR, 1.48 [95% CI, 1.18-1.86]); after 30 days or more (OR, 1.45 [95% CI, 1.19-1.76]) and readmissions (within 30 days: OR, 1.28 [95% CI, 1.02-1.61]); >= 30 days (OR, 1.27 [95% CI, 1.07-1.51]) compared with non-Hispanic whites. The surgical treatment of black patients was associated with a higher incremental annual cost (the top 50% of blacks spent $1185.50 (95% CI, $804.85-1 $1566.10; P < .001) more than the top 50% of non-Hispanic whites). There was no difference in PCa-specific mortality (P = .16) or all-cause mortality (P = .64) between black and non-Hispanic white men. CONCLUSIONS AND RELEVANCE Blacks treated with RP for localized PCa are more likely to experience adverse events and incur higher costs compared with non-Hispanic white men; however, this does not translate into a difference in PCa-specific or all-cause mortality. C1 [Schmid, Marianne; Meyer, Christian P.; Reznor, Gally; Hanske, Julian; Kibel, Adam S.; Lipsitz, Stuart R.; Quoc-Dien Trinh] Harvard Med Sch, Brigham & Womens Hosp, Ctr Surg & Publ Hlth, Div Urol Surg, 45 Francis St,ASB 2-3, Boston, MA 02115 USA. [Schmid, Marianne; Meyer, Christian P.; Chun, Felix K. H.] Univ Med Ctr Hamburg Eppendorf, Dept Urol, Hamburg, Germany. [Choueiri, Toni K.; Kantoff, Philip W.] Harvard Med Sch, Brigham & Womens Hosp, Dept Med Oncol, Dana Farber Canc Inst, Boston, MA USA. [Sammon, Jesse D.; Abdollah, Firas; Menon, Mani] Henry Ford Hlth Syst, Vattikuti Urol Inst, Detroit, MI USA. [Tucker-Seeley, Reginald D.] Harvard Med Sch, Brigham & Womens Hosp, Dana Farber Canc Inst, Ctr Community Based Res, Boston, MA USA. [Nguyen, Paul L.] Harvard Med Sch, Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA USA. RP Trinh, QD (reprint author), Harvard Med Sch, Brigham & Womens Hosp, Ctr Surg & Publ Hlth, Div Urol Surg, 45 Francis St,ASB 2-3, Boston, MA 02115 USA. EM qtrinh@partners.org FU Medical University Center Hamburg-Eppendorf; Vattikuti Urology Institute at Brigham and Women's Hospital; Professor Walter Morris-Hale Distinguished Chair in Urologic Oncology at Brigham and Women's Hospital FX Dr Schmid is supported by the Equal Opportunity Grant for Women of the Medical University Center Hamburg-Eppendorf. Dr Trinh is supported by an unrestricted educational grant from the Vattikuti Urology Institute and the Professor Walter Morris-Hale Distinguished Chair in Urologic Oncology at Brigham and Women's Hospital. NR 49 TC 9 Z9 9 U1 2 U2 3 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2374-2445 J9 JAMA ONCOL JI JAMA Oncol. PD JAN PY 2016 VL 2 IS 1 BP 85 EP 93 DI 10.1001/jamaoncol.2015.3384 PG 9 WC Oncology SC Oncology GA DW5JE UT WOS:000383679300018 PM 26502115 ER PT J AU Howitt, BE Shukla, SA Konstantinopoulos, PA AF Howitt, Brooke E. Shukla, Sachet A. Konstantinopoulos, Panagiotis A. TI Neoepitopes and CD3-Positive and CD8-Positive Cells in Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers Reply SO JAMA ONCOLOGY LA English DT Letter ID MUTATIONS C1 [Howitt, Brooke E.] Harvard Med Sch, Brigham & Womens Hosp, Dept Pathol, Boston, MA USA. [Shukla, Sachet A.] Broad Inst Harvard & MIT, Cambridge, MA USA. [Konstantinopoulos, Panagiotis A.] Harvard Med Sch, Dana Farber Canc Inst, Med Gynecol Oncol Program, Boston, MA USA. RP Konstantinopoulos, PA (reprint author), Dana Farber Canc Inst, YC-1424,450 Brookline Ave, Boston, MA 02215 USA. EM panagiotis_konstantinopoulos@dfci.harvard.edu NR 6 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2374-2445 J9 JAMA ONCOL JI JAMA Oncol. PD JAN PY 2016 VL 2 IS 1 BP 141 EP 142 PG 3 WC Oncology SC Oncology GA DW5JE UT WOS:000383679300034 PM 26767553 ER PT J AU Young, MR Craft, DL Colbert, CM Remillard, K Vanbenthuysen, L Wang, Y AF Young, Michael R. Craft, David L. Colbert, Caroline M. Remillard, Kyla Vanbenthuysen, Liam Wang, Yi TI Volumetric-modulated arc therapy using multicriteria optimization for body and extremity sarcoma SO JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS LA English DT Article DE VMAT; MCO; sarcoma; treatment planning; dosimetric comparison; deliverability; quality assurance ID RADIATION-THERAPY; PLAN QUALITY; CANCER AB This study evaluates the implementation of volumetric-modulated arc therapy (VMAT) using multicriteria optimization (MCO) in the RayStation treatment planning system (TPS) for complex sites, namely extremity and body sarcoma. The VMAT-MCO algorithm implemented in RayStation is newly developed and requires an integrated, comprehensive analysis of plan generation, delivery, and treatment efficiency. Ten patients previously treated by intensity-modulated radiation therapy (IMRT) with MCO were randomly selected and replanned using VMAT-MCO. The plan quality was compared using homogeneity index (HI) and conformity index (CI) of the planning target volume (PTV) and dose sparing of organs at risk (OARs). Given the diversity of the tumor location, the 10 plans did not have a common OAR except for skin. The skin D-50 and Dmean was directly compared between VMAT-MCO and IMRT-MCO. Additional OAR dose points were compared on a plan-by-plan basis. The treatment efficiency was compared using plan monitor units (MU) and net beam-on time. Plan quality assurance was performed using the Sun Nuclear ArcCHECK phantom and a gamma criteria of 3%/3 mm. No statistically significant differences were found between VMAT-and IMRT-MCO for HI and CI of the PTV or D50 and Dmean to the skin. The VMAT-MCO plans showed general improvements in sparing to OARs. The VMAT-MCO plan set showed statistically significant improvements over the IMRT-MCO set in treatment efficiency per plan MU (p < 0.05) and net beam-on time (p < 0.01). The VMAT-MCO plan deliverability was validated. Similar gamma passing rates were observed for the two modalities. This study verifies the suitability of VMAT-MCO for sarcoma cancer and highlighted the comparability in plan quality and improvement in treatment efficiency offered by VMAT-MCO as compared to IMRT-MCO. C1 [Young, Michael R.; Craft, David L.; Colbert, Caroline M.; Remillard, Kyla; Vanbenthuysen, Liam; Wang, Yi] Massachusetts Gen Hosp, Dept Radiat Oncol, 55 Fruit St, Boston, MA 02114 USA. [Young, Michael R.; Craft, David L.; Colbert, Caroline M.; Remillard, Kyla; Vanbenthuysen, Liam; Wang, Yi] Harvard Med Sch, Harvard Med Sch, Boston, MA 02114 USA. [Young, Michael R.] Univ Massachusetts, Intercampus, Dept Biomed Engn & Biotechnol, Amherst, MA 01003 USA. [Colbert, Caroline M.] MIT, Dept Nucl Sci & Engn, 77 Massachusetts Ave, Cambridge, MA 02139 USA. RP Young, MR (reprint author), Massachusetts Gen Hosp, Dept Radiat Oncol, 55 Fruit St, Boston, MA 02114 USA.; Young, MR (reprint author), Harvard Med Sch, Harvard Med Sch, Boston, MA 02114 USA. EM myoung22@mgh.harvard.edu NR 19 TC 0 Z9 0 U1 0 U2 0 PU MULTIMED INC PI TORONTO PA 66 MARTIN ST, TORONTO, ON L9T 2R2, CANADA SN 1526-9914 J9 J APPL CLIN MED PHYS JI J. Appl. Clin. Med. Phys PY 2016 VL 17 IS 6 BP 283 EP 291 PG 9 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA ED5XS UT WOS:000388927500025 PM 28297282 ER PT J AU Bu, YQ Zhou, XH AF Bu, Yunqi Zhou, Xiao-Hua TI Statistical evaluation of drug efficacy for bridging study in companion diagnostic test trials SO JOURNAL OF BIOPHARMACEUTICAL STATISTICS LA English DT Article DE Bridging study; causal inference; clinical trial assay; companion diagnostic assay; covariate imbalance; device-drug pivotal clinical trial; doubly robust estimator; drug efficacy; optimal matching; personalized medicine AB Personalized medicine is an area of growing attention in medical research and practice. A market-ready companion diagnostic test (CDx) is used in personalized medicine for identifying the best treatment for an individual patient. Unfortunately, development of CDx may lag behind the development of the drug, and consequently we use a clinical trial assay (CTA) to enroll patients into the drug pivotal clinical trial instead. Thus, when CDx becomes available, a bridging study will be required to assess the drug efficacy in the CDx intended use (CDx IU) population. Due to missingness of the CDx results that could be associated with randomization, one challenge we face in a bridging study is covariate imbalance between treatment arms for the subpopulation with both positive CDx and CTA. In this paper, we evaluate the performance of two methods in bridging studies under a causal inference framework. Particularly, we aim to use the propensity score method with doubly robust estimation and optimal matching to address the challenge. We extend under a current framework on drug efficacy estimation in the CDx IU population, using data from both the bridging study and the CTA drug pivotal clinical trial. Both approaches are discussed in the context of a randomized bridging study, and a targeted design clinical trial with simulations, followed by analyzing simulated data that mimic a real ongoing clinic trial. C1 [Bu, Yunqi; Zhou, Xiao-Hua] Univ Washington, Dept Biostat, Seattle, WA 98195 USA. [Zhou, Xiao-Hua] VA Puget Sound Hlth Care Syst, Seattle Denver HSR&D Ctr Innovat, Biostat Unit, Seattle, WA 98108 USA. RP Zhou, XH (reprint author), Univ Washington, Dept Biostat, Seattle, WA 98195 USA.; Zhou, XH (reprint author), VA Puget Sound Hlth Care Syst, Seattle Denver HSR&D Ctr Innovat, Biostat Unit, Seattle, WA 98108 USA.; Zhou, XH (reprint author), Univ Washington, HSB, Met Pk West 1400,Puget Care Syst Care & H 655E, Seattle, WA USA. EM azhou@uw.edu NR 9 TC 0 Z9 0 U1 0 U2 0 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 1054-3406 EI 1520-5711 J9 J BIOPHARM STAT JI J. Biopharm. Stat. PY 2016 VL 26 IS 6 SI SI BP 1118 EP 1124 DI 10.1080/10543406.2016.1226328 PG 7 WC Pharmacology & Pharmacy; Statistics & Probability SC Pharmacology & Pharmacy; Mathematics GA ED1HS UT WOS:000388596600011 PM 27649095 ER PT J AU Cook, NE Faust, D Meyer, JF Faust, KA AF Cook, Nathan E. Faust, David Meyer, Joseph F. Faust, Kyle A. TI The Impact of Careless and Random Responding on Juvenile Forensic Assessment: Susceptibility of Commonly Used Measures and Implications for Research and Practice SO JOURNAL OF FORENSIC PSYCHOLOGY PRACTICE LA English DT Article DE Careless responding; forensic assessment; juvenile justice; random responding; response bias ID INVENTORY; VALIDITY; SCALE AB Forensic assessment experts and practice guidelines strongly endorse appraisal of response styles that can distort psychological assessment results and lead to serious interpretive errors, including careless and random responding (C/RR). Little attention has been directed to the implications of C/RR for juvenile forensic mental health assessment. To address this gap in the literature, we reviewed frequently used measures in juvenile forensic assessment. We found that many such measures do not include built-in checks for detecting C/RR. We then conducted simulation studies examining two frequently used measures, one without a built-in check for C/RR and one with such a scale: the Youth Self-Report (YSR) and the Millon Adolescent Clinical Inventory (MACI), respectively. Results indicated that random responding substantially influenced scores on the YSR, raising most scales well above normative levels, yet often producing protocols that seemed genuine. On the MACI, random responding was undetected 25% of the time and another 50% of the time appears to yield computer-based reports that do not explicitly reject the test results as invalid. Taken together, these simulations suggest that randomly generated assessment protocols may often be mistaken for genuine results. Implications for both practitioners and applied researchers involved in juvenile forensic assessment are discussed. C1 [Cook, Nathan E.; Faust, David; Meyer, Joseph F.; Faust, Kyle A.] Univ Rhode Isl, Dept Psychol, Kingston, RI 02881 USA. [Faust, David] Brown Univ, Dept Psychiat & Human Behav, Providence, RI USA. [Cook, Nathan E.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Cook, Nathan E.] Harvard Med School, Boston, MA 02115 USA. [Meyer, Joseph F.] Brown Univ, Dept Psychiat & Human Behav, Alpert Med Sch, Providence, RI 02912 USA. [Faust, Kyle A.] Iowa City Vet Affairs Hlth Care Syst, Iowa City, IA USA. RP Cook, NE (reprint author), Univ Rhode Isl, Dept Psychol, Kingston, RI 02881 USA.; Cook, NE (reprint author), Massachusetts Gen Hosp, Learning & Emot Assessment Program, Dept Psychiat, 151 Merrimac St,5th Floor, Boston, MA 02114 USA.; Cook, NE (reprint author), Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.; Cook, NE (reprint author), Harvard Med School, Boston, MA 02115 USA. EM necook@mgh.harvard.edu NR 30 TC 0 Z9 0 U1 0 U2 0 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 1522-8932 EI 1522-9092 J9 J FORENSIC PSYCHOL P JI J. Forensic Psychol. Pract. PY 2016 VL 16 IS 5 BP 425 EP 447 DI 10.1080/15228932.2016.1234146 PG 23 WC Criminology & Penology; Psychology, Multidisciplinary SC Criminology & Penology; Psychology GA EC0LS UT WOS:000387793200007 ER PT J AU Obi, AT Andraska, E Kanthi, Y Luke, CE Elfline, M Madathilparambil, S Siahaan, TJ Jaffer, FA Wakefield, TW Raghavendran, K Henke, PK AF Obi, Andrea T. Andraska, Elizabeth Kanthi, Yogendra Luke, Catherine E. Elfline, Megan Madathilparambil, Suresh Siahaan, Teruna J. Jaffer, Farouc A. Wakefield, Thomas W. Raghavendran, Krishnan Henke, Peter K. TI Gram-Negative Pneumonia Alters Large-Vein Cell-Adhesion Molecule Profile and Potentiates Experimental Stasis Venous Thrombosis SO JOURNAL OF VASCULAR RESEARCH LA English DT Article DE Cell-adhesion molecules; Selectins; Venous thrombosis; Venous thromboembolism; Pneumonia; Thrombogenesis; P-selectin; E-selectin; ICAM-1 ID NEUTROPHIL EXTRACELLULAR TRAPS; IN-VIVO; LUNG CONTUSION; P-SELECTIN; HOST-DEFENSE; T-CELL; MODEL; MICE; SEPSIS; THROMBOEMBOLISM AB Background/Aims: Pneumonia is a significant risk factor for the development of venous thrombosis (VT). Cell-adhesion molecules (CAMs) are linked to the pathogenesis of both pneumonia and VT. We hypothesized that remote infection would confer a prothrombogenic milieu via systemic elevation of CAMs. Methods: Lung injury was induced in wild-type (C57BL/6) mice by lung contusion or intratracheal inoculation with Klebsiella pneumoniae or saline controls. K. pneumoniae-treated mice and controls additionally underwent inferior vena cava (IVC) ligation to generate VT. Results: Lung-contusion mice demonstrated no increase in E-selectin or P-selectin whereas mice infected with K. pneumoniae demonstrated increased circulating P-selectin, ICAM-1, VCAM-1 and thrombin-antithrombin (TAT) complexes. Mice with pneumonia formed VT 3 times larger than controls, demonstrated significantly more upregulation of vein-wall and systemic CAMs, and formed erythrocyte-rich thrombi. Conclusion: Elevated CAM expression was identified in mice with pneumonia, but not lung contusion, indicating that the type of inflammatory stimulus and the presence of infection drive the vein-wall response. Elevation of CAMs was associated with amplified VT and may represent an alternate mechanism by which to target the prevention of VT. (C) 2016 S. Karger AG, Basel C1 [Obi, Andrea T.; Andraska, Elizabeth; Luke, Catherine E.; Elfline, Megan; Wakefield, Thomas W.; Henke, Peter K.] Univ Michigan, Sch Med, Conrad Jobst Vasc Res Lab, Ann Arbor, MI USA. [Kanthi, Yogendra] Univ Michigan, Dept Surg, Div Cardiovasc Med, Ann Arbor, MI 48109 USA. [Madathilparambil, Suresh; Raghavendran, Krishnan] Univ Michigan, Dept Surg, Vasc Surg Sect, Ann Arbor, MI 48109 USA. [Siahaan, Teruna J.] Univ Kansas, Sch Pharm, Kansas City, KS USA. [Jaffer, Farouc A.] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02114 USA. RP Henke, PK (reprint author), Univ Michigan Hlth Syst, Cardiovasc Ctr 5463, 1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA. EM henke@umich.edu FU Elizabeth Anne Baiardi Research Fund; NIH [5 T32 HL076123-09, 2 T32HL007853]; [HL092129]; [HL089407] FX We appreciate the technical expertise and gift of P/E selectin inhibitor from Dr. Daniel Myers DVM. This study was supported by grants HL092129 (P.K.H.), NIH 5 T32 HL076123-09 (A.O.), NIH 2 T32HL007853 (Y.K.) and HL089407 (T.W.) and the Elizabeth Anne Baiardi Research Fund. NR 52 TC 0 Z9 0 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1018-1172 EI 1423-0135 J9 J VASC RES JI J. Vasc. Res. PY 2016 VL 53 IS 3-4 BP 186 EP 195 DI 10.1159/000447299 PG 10 WC Physiology; Peripheral Vascular Disease SC Physiology; Cardiovascular System & Cardiology GA ED1PC UT WOS:000388616400007 PM 27771726 ER PT S AU Dalca, AV Bobu, A Rost, NS Golland, P AF Dalca, Adrian V. Bobu, Andreea Rost, Natalia S. Golland, Polina BE Wu, G Coupe, P Zhan, Y Munsell, BC Rueckert, D TI Patch-Based Discrete Registration of Clinical Brain Images SO PATCH-BASED TECHNIQUES IN MEDICAL IMAGING, PATCH-MI 2016 SE Lecture Notes in Computer Science LA English DT Proceedings Paper CT 2nd International Workshop on Patch-Based Techniques in Medical Imaging (PatchMI) CY OCT 17, 2016 CL Athens, GREECE ID DEFORMABLE REGISTRATION AB We introduce a method for registration of brain images acquired in clinical settings. The algorithm relies on three-dimensional patches in a discrete registration framework to estimate correspondences. Clinical images present significant challenges for computational analysis. Fast acquisition often results in images with sparse slices, severe artifacts, and variable fields of view. Yet, large clinical datasets hold a wealth of clinically relevant information. Despite significant progress in image registration, most algorithms make strong assumptions about the continuity of image data, failing when presented with clinical images that violate these assumptions. In this paper, we demonstrate a non-rigid registration method for aligning such images. The method explicitly models the sparsely available image information to achieve robust registration. We demonstrate the algorithm on clinical images of stroke patients. The proposed method outperforms state of the art registration algorithms and avoids catastrophic failures often caused by these images. We provide a freely available open source implementation of the algorithm. C1 [Dalca, Adrian V.; Bobu, Andreea; Golland, Polina] MIT, Comp Sci & Artificial Intelligence Lab, EECS, Cambridge, MA 02139 USA. [Rost, Natalia S.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Neurol, Boston, MA USA. RP Dalca, AV (reprint author), MIT, Comp Sci & Artificial Intelligence Lab, EECS, Cambridge, MA 02139 USA. EM adalca@csail.mit.edu NR 15 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER INT PUBLISHING AG PI CHAM PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND SN 0302-9743 BN 978-3-319-47118-1; 978-3-319-47117-4 J9 LECT NOTES COMPUT SC PY 2016 VL 9993 BP 60 EP 67 DI 10.1007/978-3-319-47118-1_8 PG 8 WC Computer Science, Artificial Intelligence; Computer Science, Theory & Methods; Radiology, Nuclear Medicine & Medical Imaging SC Computer Science; Radiology, Nuclear Medicine & Medical Imaging GA BG4OL UT WOS:000389021100008 ER PT J AU Salzler, MJ Kirwan, HJ Scarborough, DM Walker, JT Guarino, AJ Berkson, EM AF Salzler, Matthew J. Kirwan, Hollie J. Scarborough, Donna M. Walker, James T. Guarino, Anthony J. Berkson, Eric M. TI Injuries observed in a prospective transition from traditional to minimalist footwear: correlation of high impact transient forces and lower injury severity SO PHYSICIAN AND SPORTSMEDICINE LA English DT Article DE Minimalist; shoes; running; injury; impact; biomechanics ID RUNNING SHOES; STRIKE PATTERNS; REDUCTION EFFECTIVENESS; REARFOOT STRIKERS; FEMALE RUNNERS; BAREFOOT; STRESS; BIOMECHANICS; RATES AB Objectives: Minimalist running is increasing in popularity based upon a concept that it can reduce impact forces and decrease injury rates. The purpose of this investigation is to identify the rate and severity of injuries in runners transitioning from traditional to minimalist footwear. The secondary aims were to identify factors correlated with injuries. Methods: Fourteen habitually shod (traditional running shoes) participants were enrolled for this prospective study investigating injury prevalence during transition from traditional running shoes to 5-toed minimalist shoes. Participants were uninjured, aged between 22-41years, and ran at least twenty kilometers per week in traditional running shoes. Participants were given industry recommended guidelines for transition to minimalist footwear and fit with a 5-toed minimalist running shoe. They completed weekly logs for identification of injury, pain using Visual Analogue Scale (VAS), injury location, and severity. Foot strike pattern and impact forces were collected using 3D motion analysis at baseline, 4weeks, and 12weeks. Injuries were scored according to a modified Running Injury Severity Score (RISS). Results: Fourteen runners completed weekly training and injury logs over an average of 30weeks. Twelve of 14 (86%) runners sustained injuries. Average injury onset was 6weeks (range 1-27weeks). Average weekly mileage of 23.9miles/week prior to transition declined to 18.3miles/week after the transition. The magnitude of the baseline impact transient peak in traditional shoes and in minimalist shoes negatively correlated with RISS scores (r=-0.45, p=0.055 and r=-0.53, p=0.026, respectively). Conclusion: High injury rates occurred during the transition from traditional to minimalist footwear. Non-compliance to transition guidelines and high injury rates suggest the need for improved education. High impact transient forces unexpectedly predicted lower modified RISS scores in this population. C1 [Salzler, Matthew J.] Tufts Med Ctr, Dept Orthopaed, 800 Washington St 306, Boston, MA 02118 USA. [Kirwan, Hollie J.; Scarborough, Donna M.; Walker, James T.; Berkson, Eric M.] Massachusetts Gen Hosp, Dept Orthopaed Surg, Boston, MA 02114 USA. [Guarino, Anthony J.] Massachusetts Gen Hosp, Ctr Interprofess Studies & Innovat, Boston, MA 02114 USA. RP Salzler, MJ (reprint author), Tufts Med Ctr, Dept Orthopaed, 800 Washington St 306, Boston, MA 02118 USA. EM Msalzler@tuftsmedicalcenter.org NR 48 TC 0 Z9 0 U1 6 U2 6 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND SN 0091-3847 EI 2326-3660 J9 PHYSICIAN SPORTSMED JI Physician Sportsmed. PY 2016 VL 44 IS 4 BP 373 EP 379 DI 10.1080/00913847.2016.1238282 PG 7 WC Primary Health Care; Orthopedics; Sport Sciences SC General & Internal Medicine; Orthopedics; Sport Sciences GA EC0HN UT WOS:000387780200009 PM 27653557 ER PT J AU DiPiro, ND Embry, AE Fritz, SL Middleton, A Krause, JS Gregory, CM AF DiPiro, N. D. Embry, A. E. Fritz, S. L. Middleton, A. Krause, J. S. Gregory, C. M. TI Effects of aerobic exercise training on fitness and walking-related outcomes in ambulatory individuals with chronic incomplete spinal cord injury SO SPINAL CORD LA English DT Article ID MULTIPLE-SCLEROSIS; OXYGEN-CONSUMPTION; PHYSICAL CAPACITY; CHRONIC STROKE; ADULTS; GAIT; RELIABILITY; PERFORMANCE; VALIDITY; DETERMINANTS AB Study design: Single group, pretest-post-test study. Objectives: To determine the effects of a non-task-specific, voluntary, progressive aerobic exercise training (AET) intervention on fitness and walking-related outcomes in ambulatory adults with chronic motor-incomplete SCI. Setting: Rehabilitation research center. Methods: Ten ambulatory individuals (50% female; 57.94 +/- 9.33 years old; 11.11 +/- 9.66 years postinjury) completed voluntary, progressive moderate-to-vigorous intensity AET on a recumbent stepper 3 days per week for 6 weeks. The primary outcome measures were aerobic capacity (VO2peak (volume of oxygen that the body can use during physical exertion)) and self-selected overground walking speed (OGWS). Secondary outcome measures included walking economy, 6-minute walk test (6MWT), daily step counts, Walking Index for Spinal Cord Injury (WISCI-II), Dynamic Gait Index (DGI) and Berg Balance Scale (BBS). Results: Nine participants completed all testing and training. Significant improvements in aerobic capacity (P= 0.011), OGWS (P= 0.023), the percentage of VO2peak used while walking at self-selected speed (P= 0.03) and daily step counts (P= 0.025) resulted following training. Conclusions: The results indicate that total-body, voluntary, progressive AET is safe, feasible, and effective for improving aerobic capacity, walking speed, and select walking- related outcomes in an exclusively ambulatory SCI sample. This study suggests the potential for non-task-specific aerobic exercise to improve walking following incomplete SCI and builds a foundation for further investigation aimed at the development of exercise based rehabilitation strategies to target functionally limiting impairments in ambulatory individuals with chronic SCI. C1 [DiPiro, N. D.; Embry, A. E.; Krause, J. S.; Gregory, C. M.] Med Univ South Carolina, Dept Hlth Sci & Res, 77 President St,MSC 700, Charleston, SC 29425 USA. [Embry, A. E.; Gregory, C. M.] Med Univ South Carolina, Div Phys Therapy, Charleston, SC 29425 USA. [Embry, A. E.; Gregory, C. M.] Ralph H Johnson VAMC, Charleston, SC USA. [Fritz, S. L.; Middleton, A.] Univ South Carolina, Dept Exercise Sci, Phys Therapy Program, Columbia, SC USA. RP DiPiro, ND (reprint author), Med Univ South Carolina, Dept Hlth Sci & Res, 77 President St,MSC 700, Charleston, SC 29425 USA. EM nicole.dipiro@gmail.com FU South Carolina Clinical and Translational Research (SCTR) Institute; NIH [UL1 TR000062, TL1 TR000061]; South Carolina Spinal Cord Injury Research Fund [13-003]; South Carolina Spinal Cord Injury Association FX This work was supported by the South Carolina Clinical and Translational Research (SCTR) Institute, with an academic home at the Medical University of South Carolina, through NIH Grant Number UL1 TR000062 and TL1 TR000061. Additional support was provided by the South Carolina Spinal Cord Injury Research Fund (Grant No. 13-003) and the South Carolina Spinal Cord Injury Association. We thank the staff Physical Therapist, Dr Lindsay Perry, and the project coordinators, Patrick Morgan and Katy Holthaus, for their assistance with study management and data collection. NR 55 TC 0 Z9 0 U1 5 U2 5 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1362-4393 EI 1476-5624 J9 SPINAL CORD JI Spinal Cord PY 2016 VL 54 IS 9 BP 675 EP 681 DI 10.1038/sc.2015.212 PG 7 WC Clinical Neurology; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA DW3ZK UT WOS:000383581400008 PM 26666508 ER PT S AU Kantarci, A Yen, S Will, LA AF Kantarci, Alpdogan Yen, Stephen Will, Leslie A. BE Kantarci, A Will, L Yen, S TI Tooth Movement Preface SO TOOTH MOVEMENT SE Frontiers of Oral Biology LA English DT Editorial Material; Book Chapter C1 [Kantarci, Alpdogan] Forsyth Inst, Dept Appl Oral Sci, 245 First St,6103, Cambridge, MA 02142 USA. [Yen, Stephen] Univ Southern Calif, Herman Ostrow Sch Dent, Dept Orthodont Oral Surg & Basic Sci, Los Angeles, CA USA. [Will, Leslie A.] Boston Univ, Henry M Goldman Sch Dent Med, Dept Orthodont & Dentofacial Orthoped, 100 East Newton St, Boston, MA 02118 USA. RP Kantarci, A (reprint author), Forsyth Inst, Dept Appl Oral Sci, 245 First St,6103, Cambridge, MA 02142 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU KARGER PI BASEL PA POSTFACH, CH-4009 BASEL, SWITZERLAND SN 1420-2433 BN 978-3-318-05480-4; 978-3-318-05479-8 J9 FRONT ORAL BIOL JI Front. Oral Biol. PY 2016 VL 18 BP VII EP VIII PG 2 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA BG2NB UT WOS:000387487700001 PM 26863692 ER PT S AU Baloul, SS AF Baloul, S. Susan BE Kantarci, A Will, L Yen, S TI Osteoclastogenesis and Osteogenesis during Tooth Movement SO TOOTH MOVEMENT SE Frontiers of Oral Biology LA English DT Article; Book Chapter ID PERIODONTAL-LIGAMENT CELLS; NITRIC-OXIDE; BONE-RESORPTION; ROOT RESORPTION; ALVEOLAR BONE; FLUID-FLOW; OSTEOCYTE APOPTOSIS; UP-REGULATION; IN-VIVO; RAT AB It is a well-known concept that bone remodeling occurs during orthodontic tooth movement. The orthodontic literature is vastly full of information about the changes occurring on the periodontal ligament level. However, changes occurring in the alveolar bone are being elucidated. The purpose of this chapter is to present some of the studies describing the bone changes associated with orthodontic tooth movement. Initiation of osteoclastogenesis requires inflammation in the adjacent area. Tissue biomarker RANKL responds to the compressive forces. Conversely, an increase in osteoprotegrin biomarker causes a decrease in RANKL and inhibits tooth movement. Osteocyte activity during tooth movement is not well understood. Emerging studies are showing the effect of osteocytes on orthodontic tooth movement. Nitric oxide (NO), produced by osteocytes, is an important regulator of bone response to loading and has been shown to mediate osteoclast activity. iNOS (which produces NO) has been shown to mediate inflammation-induced bone resorption on the compression side. Several molecules have been linked to osteogenesis in tooth movement: TGF-beta, BSP, BMPs and epidermal growth factor. Osteogenesis on the tension side is not well understood. Studies have shown increase in the expression of Runx2 on the tension side. Additionally, eNOS (produces NO) mediates bone formation on the tension side. The concept of osteoclastogenesis and osteogenesis is being unraveled. (C) 2016 S. Karger AG, Basel C1 [Baloul, S. Susan] Forsyth Inst, Cambridge, MA 02142 USA. RP Baloul, SS (reprint author), Forsyth Inst, Cambridge, MA 02142 USA. NR 47 TC 1 Z9 2 U1 3 U2 4 PU KARGER PI BASEL PA POSTFACH, CH-4009 BASEL, SWITZERLAND SN 1420-2433 BN 978-3-318-05480-4; 978-3-318-05479-8 J9 FRONT ORAL BIOL JI Front. Oral Biol. PY 2016 VL 18 BP 75 EP 79 DI 10.1159/000351901 PG 5 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA BG2NB UT WOS:000387487700010 PM 26599120 ER PT S AU Almpani, K Kantarci, A AF Almpani, Konstantinia Kantarci, Alpdogan BE Kantarci, A Will, L Yen, S TI Nonsurgical Methods for the Acceleration of the Orthodontic Tooth Movement SO TOOTH MOVEMENT SE Frontiers of Oral Biology LA English DT Article; Book Chapter ID EPIDERMAL-GROWTH-FACTOR; LOW-LEVEL LASER; LOW-POWER LASER; OSTEOBLAST-LIKE CELLS; PULSED ELECTROMAGNETIC-FIELDS; PERIODONTAL-LIGAMENT CELLS; OSTEOCLAST-LIKE CELLS; PARATHYROID-HORMONE; ROOT RESORPTION; BONE-RESORPTION AB While acceleration of the orthodontic tooth movement by surgical techniques has been shown to be effective for decades, noninvasive and nonsurgical methods have always been preferred by both the clinicians and the patients. These techniques have ranged from application of biological molecules to innovative technologies such as resonance vibration, cyclic forces, light electrical currents, magnetic field forces, low-intensity laser irradiation and low-level light therapy. Endogenously produced biologicals have been tested based on their roles in the turnover of alveolar bone in response to orthodontic tooth movement as well as during wound healing. The premise behind this approach is that these exogenously applied compounds will mimic their counterparts produced in vivo. Meanwhile, technologies tested so far target these pathways for the acceleration of the orthodontic tooth movement. All these approaches have shown favorable outcomes with varying success. This chapter presents the current knowledge and a discussion over their limitations with an emphasis on the mechanism of action for each technique. (C) 2016 S. Karger AG, Basel C1 [Almpani, Konstantinia; Kantarci, Alpdogan] Forsyth Inst, Cambridge, MA 02142 USA. RP Almpani, K (reprint author), Forsyth Inst, Cambridge, MA 02142 USA. NR 123 TC 0 Z9 0 U1 1 U2 2 PU KARGER PI BASEL PA POSTFACH, CH-4009 BASEL, SWITZERLAND SN 1420-2433 BN 978-3-318-05480-4; 978-3-318-05479-8 J9 FRONT ORAL BIOL JI Front. Oral Biol. PY 2016 VL 18 BP 80 EP 91 DI 10.1159/000382048 PG 12 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA BG2NB UT WOS:000387487700011 PM 26599121 ER PT S AU Almpani, K Kantarci, A AF Almpani, Konstantinia Kantarci, Alpdogan BE Kantarci, A Will, L Yen, S TI Surgical Methods for the Acceleration of the Orthodontic Tooth Movement SO TOOTH MOVEMENT SE Frontiers of Oral Biology LA English DT Article; Book Chapter ID CORTICOTOMY-FACILITATED ORTHODONTICS; DENTOALVEOLAR DISTRACTION OSTEOGENESIS; SELECTIVE ALVEOLAR DECORTICATION; MAXILLARY CANINE RETRACTION; MUCOPERIOSTEAL FLAP SURGERY; CLASS-II MALOCCLUSION; ANTERIOR OPEN BITE; OVERERUPTED MOLARS; ROOT RESORPTION; PERIODONTAL-LIGAMENT AB Surgical techniques for the acceleration of the orthodontic tooth movement have been tested for more than 100 years in clinical practice. Since original methods have been extremely invasive and have been associated with increased tooth morbidity and various other gaps, the research in this field has always followed an episodic trend. Modern approaches represent a well-refined strategy where the concept of the bony block has been abandoned and only a cortical plate around the orthodontic tooth movement has been desired. Selective alveolar decortication has been a reproducible gold standard to this end. Its proposed mechanism has been the induction of rapid orthodontic tooth movement through the involvement of the periodontal ligament. More recent techniques included further refinement of this procedure through less invasive techniques such as the use of piezoelectricity and corticision. This chapter focuses on the evolution of the surgical approaches and the mechanistic concepts underlying the biological process during the surgically accelerated orthodontic tooth movement. (C) 2016 S. Karger AG, Basel C1 [Almpani, Konstantinia; Kantarci, Alpdogan] Forsyth Inst, Cambridge, MA 02142 USA. RP Almpani, K (reprint author), Forsyth Inst, Cambridge, MA 02142 USA. NR 99 TC 0 Z9 0 U1 1 U2 2 PU KARGER PI BASEL PA POSTFACH, CH-4009 BASEL, SWITZERLAND SN 1420-2433 BN 978-3-318-05480-4; 978-3-318-05479-8 J9 FRONT ORAL BIOL JI Front. Oral Biol. PY 2016 VL 18 BP 92 EP 101 DI 10.1159/000382051 PG 10 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA BG2NB UT WOS:000387487700012 PM 26599122 ER PT S AU Kantarci, A Yen, S Will, LA AF Kantarci, Alpdogan Yen, Stephen Will, Leslie A. BE Kantarci, A Will, L Yen, S TI Conclusion and Future Directions SO TOOTH MOVEMENT SE Frontiers of Oral Biology LA English DT Editorial Material; Book Chapter C1 [Kantarci, Alpdogan] Forsyth Inst, Dept Appl Oral Sci, 245 First St,6103, Cambridge, MA 02142 USA. [Yen, Stephen] Univ Southern Calif, Herman Ostrow Sch Dent, Dept Orthodont Oral Surg & Basic Sci, Los Angeles, CA USA. [Will, Leslie A.] Boston Univ, Henry M Goldman Sch Dent Med, Dept Orthodont & Dentofacial Orthoped, 100 East Newton St, Boston, MA 02118 USA. RP Kantarci, A (reprint author), Forsyth Inst, Dept Appl Oral Sci, 245 First St,6103, Cambridge, MA 02142 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU KARGER PI BASEL PA POSTFACH, CH-4009 BASEL, SWITZERLAND SN 1420-2433 BN 978-3-318-05480-4; 978-3-318-05479-8 J9 FRONT ORAL BIOL JI Front. Oral Biol. PY 2016 VL 18 BP 130 EP 130 DI 10.1159/000351910 PG 1 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA BG2NB UT WOS:000387487700017 PM 26599127 ER PT J AU Gerding, DN File, TM McDonald, LC AF Gerding, Dale N. File, Thomas M., Jr. McDonald, L. Clifford TI Diagnosis and Treatment of Clostridium difficile Infection SO INFECTIOUS DISEASES IN CLINICAL PRACTICE LA English DT Article DE Clostridium difficile; CDI; diagnostic test; treatment AB Early and accurate diagnosis is essential for optimal treatment of individuals with Clostridium difficile infection (CDI) and for implementation of effective infection control procedures. The decision about which diagnostic test to use is an important one that should be based on test sensitivity, specificity, and predictive value. The challenges of CDI go beyond rapid identification and management of symptomatic patients. Asymptomatic carriage has long been suspected in C. difficile transmission, but it may play a larger role than previously thought. Emerging information also shows that patients treated for CDI remain colonized for many weeks after symptom resolution. In fact, stool culture positivity increases during the first weeks after treatment completion. Treatments that reduce the duration and degree of asymptomatic shedding could have added benefit for reduced transmission. C1 [Gerding, Dale N.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Hines, IL 60141 USA. [Gerding, Dale N.] Loyola Univ, Chicago Stritch Sch Med, Chicago, IL 60611 USA. [File, Thomas M., Jr.] Summa Hlth Syst, Div Infect Dis, Akron, OH 44304 USA. [File, Thomas M., Jr.] Northeast Ohio Med Univ, Infect Dis Sect, Rootstown, OH USA. [McDonald, L. Clifford] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA USA. RP File, TM (reprint author), Summa Hlth Syst, Div Infect Dis, 75Arch St,Suite 506, Akron, OH 44304 USA. EM FileT@summahealth.org NR 0 TC 2 Z9 2 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1056-9103 EI 1536-9943 J9 INFECT DIS CLIN PRAC JI Infect. Dis. Clin. Pract. PD JAN PY 2016 VL 24 IS 1 BP 3 EP 10 DI 10.1097/IPC.0000000000000350 PG 8 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA DA5CU UT WOS:000367820600002 ER PT J AU Daughters, SB Magidson, JF Lejuez, CW Chen, Y AF Daughters, Stacey B. Magidson, Jessica F. Lejuez, C. W. Chen, Yun TI LETS ACT: a behavioral activation treatment for substance use and depression SO ADVANCES IN DUAL DIAGNOSIS LA English DT Review DE Substance use disorders; Depression; Treatment; Behavioural activation ID RANDOMIZED CONTROLLED-TRIAL; COCAINE-DEPENDENT PATIENTS; ALCOHOL-USE DISORDERS; MAJOR DEPRESSION; ANTIDEPRESSANT MEDICATION; 12-STEP FACILITATION; RELAPSE PREVENTION; CLINICAL-OUTCOMES; COGNITIVE THERAPY; HEALTH-CARE AB Purpose - Substance use disorders (SUDs) often co-occur with major depressive disorder (MDD), yet treatments targeting this comorbidity are limited, especially in resource-limited settings where individuals with SUDs often receive treatment. The paper aims to discuss this issue. Design/methodology/approach - Based upon principles of reinforcement and behavioral economic models of substance use, as well as the Brief Behavioral Activation Treatment for Depression (Lejuez et al., 2011), the Life Enhancement Treatment for Substance Use (LETS ACT) (Daughters et al., 2008) was developed to meet the unique needs of patients with MDD-SUD comorbidity. Findings - This paper presents a summary of the theoretical foundations and key components of LETS ACT. Originality/value - A specific focus on increasing dissemination via the flexible delivery dependent on patient and treatment setting characteristics is provided throughout. C1 [Daughters, Stacey B.; Chen, Yun] Univ North Carolina Chapel Hill, Dept Psychol & Neurosci, Chapel Hill, NC 27514 USA. [Magidson, Jessica F.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Magidson, Jessica F.] Harvard Med Sch, Boston, MA USA. [Lejuez, C. W.] Univ Kansas, Lawrence, KS 66045 USA. RP Daughters, SB (reprint author), Univ North Carolina Chapel Hill, Dept Psychol & Neurosci, Chapel Hill, NC 27514 USA. EM daughter@unc.edu NR 52 TC 2 Z9 2 U1 3 U2 3 PU EMERALD GROUP PUBLISHING LTD PI BINGLEY PA HOWARD HOUSE, WAGON LANE, BINGLEY BD16 1WA, W YORKSHIRE, ENGLAND SN 1757-0972 EI 2042-8324 J9 ADV DUAL DIAGN JI Adv. Dual Diagn. PY 2016 VL 9 IS 2-3 BP 74 EP 84 DI 10.1108/ADD-02-2016-0006 PG 11 WC Psychology, Clinical SC Psychology GA DU9EZ UT WOS:000382520400004 ER PT B AU Ramalho, M Catalano, O AlObaidy, M Altun, E Semelka, RC AF Ramalho, Miguel Catalano, Onofrio AlObaidy, Mamdoh Altun, Ersan Semelka, Richard C. BE Semelka, RC TI Magnetic resonance-positron emission tomography SO ABDOMINAL-PELVIC MRI, 4TH EDITION LA English DT Article; Book Chapter ID WHOLE-BODY PET/MRI; PEDIATRIC DOSAGE CARD; SIMULTANEOUS PET-MRI; ATTENUATION CORRECTION; CLINICAL-EXPERIENCE; DIAGNOSTIC-VALUE; GADOXETIC ACID; LUNG-CANCER; COLORECTAL METASTASES; FUTURE-PERSPECTIVES C1 [Ramalho, Miguel; AlObaidy, Mamdoh] Univ North Carolina Chapel Hill, Dept Radiol, Chapel Hill, NC 27515 USA. [Ramalho, Miguel] EPE, Hosp Garcia Orta, Dept Radiol, Almada, Portugal. [Catalano, Onofrio] Harvard Med Sch, Massachusetts Gen Hosp, Radiol, Boston, MA USA. [Altun, Ersan] Univ North Carolina Chapel Hill, Radiol, Chapel Hill, NC USA. [Altun, Ersan] Univ North Carolina Chapel Hill, Dept Radiol, Abdominal Imaging Div, Chapel Hill, NC USA. [Semelka, Richard C.] Univ North Carolina Chapel Hill, Dept Radiol, Abdominal Imaging Div, Radiol, Chapel Hill, NC USA. [Semelka, Richard C.] Univ North Carolina Chapel Hill, MRI Serv, Chapel Hill, NC USA. [Semelka, Richard C.] Univ North Carolina Chapel Hill, Qual & Safety, Chapel Hill, NC USA. RP Ramalho, M (reprint author), Univ North Carolina Chapel Hill, Dept Radiol, Chapel Hill, NC 27515 USA.; Ramalho, M (reprint author), EPE, Hosp Garcia Orta, Dept Radiol, Almada, Portugal. NR 92 TC 0 Z9 0 U1 0 U2 0 PU JOHN WILEY & SONS LTD PI CHICHESTER PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, WEST SUSSEX, ENGLAND BN 978-1-119-01296-2; 978-1-119-01293-1 PY 2016 BP 1443 EP 1463 PG 21 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA BG1BO UT WOS:000386636500021 ER PT J AU Baljevic, M Dumitriu, B Lee, JW Paietta, EM Wiernik, PH Racevskis, J Chen, C Stein, EM Gallagher, RE Rowe, JM Appelbaum, FR Powell, BL Larson, RA Coutre, SE Lancet, J Litzow, MR Luger, SM Young, NS Tallman, MS AF Baljevic, Muhamed Dumitriu, Bogdan Lee, Ju-Whei Paietta, Elisabeth M. Wiernik, Peter H. Racevskis, Janis Chen, Christina Stein, Eytan M. Gallagher, Robert E. Rowe, Jacob M. Appelbaum, Frederick R. Powell, Bayard L. Larson, Richard A. Coutre, Steven E. Lancet, Jeffrey Litzow, Mark R. Luger, Selina M. Young, Neal S. Tallman, Martin S. TI Telomere Length Recovery: A Strong Predictor of Overall Survival in Acute Promyelocytic Leukemia SO ACTA HAEMATOLOGICA LA English DT Article DE Acute promyelocytic leukemia; Disease risk factors; Telomere length ID TRANS-RETINOIC ACID; BONE-MARROW FAILURE; ARSENIC TRIOXIDE; DYSKERATOSIS-CONGENITA; REVERSE-TRANSCRIPTASE; APLASTIC-ANEMIA; CELL-DEATH; MUTATIONS; CANCER; GENE AB Telomeres are the capping ends of chromosomes that protect the loss of genetic material and prevent chromosomal instability. In human tissue-specific stem/progenitor cells, telomere length (TL) is maintained by the telomerase complex, which consists of a reverse transcriptase catalytic subunit (TERT) and an RNA template (TERC). Very short telomeres and loss-of-function mutations in the TERT and TERC genes have been reported in acute myeloid leukemia, but the role of telomeres in acute promyelocytic leukemia (APL) has not been well established. We report the results for a large cohort of 187 PML/RAR alpha-positive APL patients. No germline mutations in the TERT or TERC genes were identified. Codon 279 and 1062 TERT polymorphisms were present at a frequency similar to that in the general population. TL measured in blood or marrow mononuclear cells at diagnosis was significantly shorter in the APL patients than in healthy volunteers, and shorter telomeres at diagnosis were significantly associated with high-risk disease. For patients who achieved complete remission, the median increase in TL from diagnosis to remission (delta TL) was 2.0 kilobase (kb), and we found delta TL to be the most powerful predictor of overall survival when compared with well-established risk factors for poor outcomes in APL. (C) 2016 S. Karger AG, Basel C1 [Baljevic, Muhamed] Univ Nebraska, Med Ctr, Div Hematol Oncol, Omaha, NE USA. [Dumitriu, Bogdan; Chen, Christina; Young, Neal S.] NHLBI, NIH, Bethesda, MD USA. [Lee, Ju-Whei] Dana Farber Canc Inst, ECOG ACRIN Biostat Ctr, Boston, MA 02115 USA. [Paietta, Elisabeth M.; Racevskis, Janis; Gallagher, Robert E.] Montefiore Med Ctr, 111 E 210th St, Bronx, NY 10467 USA. [Wiernik, Peter H.] Beth Israel Deaconess Med Ctr, New York, NY 10003 USA. [Stein, Eytan M.; Tallman, Martin S.] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA. [Rowe, Jacob M.] Northwestern Univ, Rambam Med Ctr, Chicago, IL 60611 USA. [Larson, Richard A.] Univ Chicago, Chicago, IL 60637 USA. [Appelbaum, Frederick R.] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA. [Powell, Bayard L.] Wake Forest Baptist Comprehens Canc Ctr, Winston Salem, NC USA. [Coutre, Steven E.] Stanford Univ, Stanford, CA 94305 USA. [Lancet, Jeffrey] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA. [Litzow, Mark R.] Mayo Clin, Rochester, MN USA. [Luger, Selina M.] Univ Penn, Philadelphia, PA 19104 USA. RP Tallman, MS (reprint author), Weill Cornell Med Coll, Mem Sloan Kettering Canc Ctr, Dept Med, Leukemia Serv, 1275 York Ave, New York, NY 10065 USA. EM TallmanM@mskcc.org OI Larson, Richard/0000-0001-9168-3203 FU Public Health Service Grants [CA180820, CA180794, CA189859, CA180791, CA180816, CA180819, CA180821, CA180790]; National Cancer Institute, National Institutes of Health and the Department of Health and Human Services FX This study was conducted by the ECOG-ACRIN Cancer Research Group (Robert L. Comis, MD, and Mitchell D. Schnall, MD, PhD, Group Co-Chairs) and supported in part by Public Health Service Grants CA180820, CA180794, CA189859, CA180791, CA180816, CA180819, CA180821 and CA180790 and the National Cancer Institute, National Institutes of Health and the Department of Health and Human Services. Its content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute. NR 25 TC 0 Z9 0 U1 1 U2 1 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0001-5792 EI 1421-9662 J9 ACTA HAEMATOL-BASEL JI Acta Haematol. PY 2016 VL 136 IS 4 BP 210 EP 218 DI 10.1159/000448160 PG 9 WC Hematology SC Hematology GA EC5FJ UT WOS:000388158200003 PM 27632567 ER PT J AU Daughters, SB Magidson, JF Lejuez, CW Chen, Y AF Daughters, Stacey B. Magidson, Jessica F. Lejuez, C. W. Chen, Yun TI LETS ACT: a behavioral activation treatment for substance use and depression SO ADVANCES IN DUAL DIAGNOSIS LA English DT Review DE Substance use disorders; Depression; Treatment; Behavioural activation ID RANDOMIZED CONTROLLED-TRIAL; COCAINE-DEPENDENT PATIENTS; ALCOHOL-USE DISORDERS; MAJOR DEPRESSION; ANTIDEPRESSANT MEDICATION; 12-STEP FACILITATION; RELAPSE PREVENTION; CLINICAL-OUTCOMES; COGNITIVE THERAPY; HEALTH-CARE AB Purpose - Substance use disorders (SUDs) often co-occur with major depressive disorder (MDD), yet treatments targeting this comorbidity are limited, especially in resource-limited settings where individuals with SUDs often receive treatment. The paper aims to discuss this issue. Design/methodology/approach - Based upon principles of reinforcement and behavioral economic models of substance use, as well as the Brief Behavioral Activation Treatment for Depression (Lejuez et al., 2011), the Life Enhancement Treatment for Substance Use (LETS ACT) (Daughters et al., 2008) was developed to meet the unique needs of patients with MDD-SUD comorbidity. Findings - This paper presents a summary of the theoretical foundations and key components of LETS ACT. Originality/value - A specific focus on increasing dissemination via the flexible delivery dependent on patient and treatment setting characteristics is provided throughout. C1 [Daughters, Stacey B.; Chen, Yun] Univ N Carolina, Dept Psychol & Neurosci, Chapel Hill, NC 27514 USA. [Magidson, Jessica F.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Magidson, Jessica F.] Harvard Med Sch, Boston, MA USA. [Lejuez, C. W.] Univ Kansas, Lawrence, KS 66045 USA. RP Daughters, SB (reprint author), Univ N Carolina, Dept Psychol & Neurosci, Chapel Hill, NC 27514 USA. EM daughter@unc.edu NR 53 TC 0 Z9 0 U1 1 U2 1 PU EMERALD GROUP PUBLISHING LTD PI BINGLEY PA HOWARD HOUSE, WAGON LANE, BINGLEY BD16 1WA, W YORKSHIRE, ENGLAND SN 1757-0972 EI 2042-8324 J9 ADV DUAL DIAGN JI Adv. Dual Diagn. PY 2016 VL 9 IS 2-3 BP 74 EP 84 DI 10.1108/ADD-02-2016-0006 PG 11 WC Psychology, Clinical SC Psychology GA EC9IF UT WOS:000388457400003 ER PT J AU Fischer, M AF Fischer, Martin TI p21 governs p53's repressive side SO CELL CYCLE LA English DT Editorial Material ID COMPLEX; GENES C1 [Fischer, Martin] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Fischer, Martin] Harvard Med Sch, Brigham & Womens Hosp, Dept Med, Boston, MA USA. RP Fischer, M (reprint author), Univ Leipzig, Sch Med, Mol Oncol, Semmelweisstr 14, D-04103 Leipzig, Germany. EM Martin.Fischer@medizin.uni-leipzig.de RI Fischer, Martin/I-4825-2014 OI Fischer, Martin/0000-0002-3429-1876 NR 7 TC 0 Z9 0 U1 0 U2 0 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 1538-4101 EI 1551-4005 J9 CELL CYCLE JI Cell Cycle PY 2016 VL 15 IS 21 BP 2852 EP + DI 10.1080/15384101.2016.1205393 PG 2 WC Cell Biology SC Cell Biology GA EC0BF UT WOS:000387761800005 PM 27355571 ER PT J AU Habib, SL Yadav, A Kidane, D Weiss, RH Liang, ST AF Habib, Samy L. Yadav, Anamika Kidane, Dawit Weiss, Robert H. Liang, Sitai TI Novel protective mechanism of reducing renal cell damage in diabetes: Activation AMPK by AICAR increased NRF2/OGG1 proteins and reduced oxidative DNA damage SO CELL CYCLE LA English DT Article DE AMPK; AICAR; diabetes; mTOR; Nrf2; OGG1 ID ENDOPLASMIC-RETICULUM STRESS; REPAIR ENZYME OGG1; DB/DB MICE; GLUCOSE; EXPRESSION; COMPLICATIONS; INJURY; OXYGEN; NRF2; NEPHROPATHY AB Exposure of renal cells to high glucose (HG) during diabetes has been recently proposed to be involved in renal injury. In the present study, we investigated a potential mechanism by which AICAR treatment regulates the DNA repair enzyme, 8-oxoG-DNA glycosylase (OGG1) in renal proximal tubular mouse cells exposed to HG and in kidney of db/db mice. Cells treated with HG for 2 days show inhibition in OGG1 promoter activity as well as OGG1 and Nrf2 protein expression. In addition, activation of AMPK by AICAR resulted in an increase raptor phosphorylation at Ser792 and leads to increase the promoter activity of OGG1 through upregulation of Nrf2. Downregulation of AMPK by DN-AMPK and raptor and Nrf2 by siRNA resulted in significant decease in promoter activity and protein expression of OGG1. On the other hand, downregulation of Akt by DN-Akt and rictor by siRNA resulted in significant increase in promoter activity and protein expression of Nrf2 and OGG1. Moreover, gel shift analysis shows reduction of Nrf2 binding to OGG1 promoter in cells treated with HG while cells treated with AICAR reversed the effect of HG. Furthermore, db/db mice treated with AICAR show significant increased in AMPK and raptor phosphroylation as well as OGG1 and Nrf2 protein expression that associated with significant decrease in oxidative DNA damage (8-oxodG) compared to non-treated mice. In summary, our data provide a novel protective mechanism by which AICAR prevents renal cell damage in diabetes and the consequence complications of hyperglycemia with a specific focus on nephropathy. C1 [Habib, Samy L.; Yadav, Anamika; Liang, Sitai] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA. [Habib, Samy L.] South Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Dept, San Antonio, TX USA. [Kidane, Dawit] Univ Texas Austin, Coll Pharm, Div Pharmacol & Toxicol, Dell Pediat Res Inst, Austin, TX 78712 USA. [Weiss, Robert H.] Univ Calif Davis, Div Nephrol, Davis, CA 95616 USA. [Weiss, Robert H.] Univ Calif Davis, Ctr Canc, Davis, CA 95616 USA. RP Habib, SL (reprint author), Univ Texas Hlth Sci Ctr San Antonio, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM habib@uthscsa.edu FU American Heart Association; South Texas Veterans Healthcare System FX This work was supported in part by grants from the American Heart Association and Merit Review Award from South Texas Veterans Healthcare System (to S.L.H.). NR 35 TC 0 Z9 0 U1 0 U2 0 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 1538-4101 EI 1551-4005 J9 CELL CYCLE JI Cell Cycle PY 2016 VL 15 IS 22 BP 3048 EP 3059 DI 10.1080/15384101.2016.1231259 PG 12 WC Cell Biology SC Cell Biology GA EC8EX UT WOS:000388374500020 PM 27611085 ER PT B AU Echague, AV AF Echague, Agustina Vila BE Bennun, RD Harfin, JF Sandor, GKB Genecov, D TI Laser treatment of cleft lip scars SO CLEFT LIP AND PALATE MANAGEMENT: A COMPREHENSIVE ATLAS LA English DT Article; Book Chapter ID HYPERTROPHIC SCARS; DYE-LASER; PHOTOTHERMOLYSIS C1 [Echague, Agustina Vila] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Echague, AV (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 12 TC 0 Z9 0 U1 0 U2 0 PU JOHN WILEY & SONS INC PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA BN 978-1-118-94724-1; 978-1-118-60754-1 PY 2016 BP 253 EP 255 PG 3 WC Dentistry, Oral Surgery & Medicine; Surgery SC Dentistry, Oral Surgery & Medicine; Surgery GA BG1BS UT WOS:000386637000018 ER PT J AU Jackson, CE Grande, LJ Doherty, K Archambault, E Kelly, B Driver, JA Milberg, WP McGlinchey, R Rudolph, JL AF Jackson, Colleen E. Grande, Laura J. Doherty, Kelly Archambault, Elizabeth Kelly, Brittany Driver, Jane A. Milberg, William P. McGlinchey, Regina Rudolph, James L. TI The Clock-in-the-Box, a brief cognitive screen, is associated with failure to return home in an elderly hospitalized sample SO CLINICAL INTERVENTIONS IN AGING LA English DT Article DE cognition; screening; aging; hospitalization; care transition ID INSTRUMENTAL ACTIVITIES; IMPAIRMENT; RECOGNITION; DEMENTIA; CARE AB Purpose: Cognitive screening upon hospital admission can provide important information about the patient's ability to process information during the inpatient stay. The Clock-in-the-Box (CIB) is a rapidly administered cognitive screening measure which has been previously validated with cognitive screening and neuropsychological assessments. The purpose of this study is to demonstrate the predictive validity of the CIB for discharge location among a sample of older medical inpatients. Patients and methods: Hospitalized Veterans (N= 218), aged 55 years and older, were recruited on the day after admission after they gave their consent. These participants completed the CIB, the Montreal Cognitive Assessment, and self-report measures of daily functioning. Using logistic regression models, the bivariable and multivariable impact of the cognitive screening and functional assessments were examined for their ability to predict whether the participants did not return home after hospitalization (eg, admission to subacute rehabilitation facilities or nursing facilities). Results: The participants were older (mean 71.5 +/- 9.5 years) and predominantly male (92.7%). The CIB score was independently associated with discharge to locations other than home (odds ratio = 0.72, 95% confidence interval = 0.60-0.87, P= 0.001) and remained associated after adjusting for demographics, prehospitalization functional abilities, and Montreal Cognitive Assessment score (adjusted odds ratio = 0.55, 95% confidence interval = 0.36-0.83, P= 0.004). Conclusion: The current evidence, combined with its brevity and ease of use, supports the use of the CIB as a cognitive screen for inpatient older adults, in order to help inform clinical treatment decisions and discharge planning. C1 [Jackson, Colleen E.; Grande, Laura J.; Doherty, Kelly; Archambault, Elizabeth; Kelly, Brittany; Driver, Jane A.; Milberg, William P.; McGlinchey, Regina] Boston Healthcare Syst, Dept Vet Affairs VA, Geriatr Res Educ & Clin Ctr, Boston, MA USA. [Jackson, Colleen E.; Grande, Laura J.; Milberg, William P.; McGlinchey, Regina] Boston Healthcare Syst, Dept Vet Affairs VA, Translat Res Ctr TBI & Stress Disorders, Boston, MA USA. [Jackson, Colleen E.; Grande, Laura J.] Boston Univ, Sch Med, Dept Psychiat, Boston, MA USA. [Driver, Jane A.] Harvard Med Sch, Dept Med, Boston, MA USA. [Milberg, William P.; McGlinchey, Regina] Harvard Med Sch, Dept Psychiat, Boston, MA USA. [Rudolph, James L.] Providence Med Ctr, Dept Vet Affairs VA, Ctr Innovat Long Term Serv & Supports, Providence, RI USA. [Rudolph, James L.] Brown Univ, Warren Alpert Sch Med, Dept Med, Providence, RI 02912 USA. RP Rudolph, JL (reprint author), Providence VA Med Ctr, Ctr Innovat Long Term Serv & Supports, 830 Chalkstone Ave, Providence, RI 02908 USA. EM james.rudolph@va.gov FU Delirium Patient Safety Center of Inquiry from the VA Office of Patient Safety; VA Fellowship in Advanced Geriatrics; VA Health Services Research and Development Center of Innovation in Long Term Services and Supports [CIN 13-419]; VA QUERI-Geriatrics and Extended Care Partnered Evaluation Center for Community Nursing Homes [PEC 15-465] FX Support for this study was provided by the Delirium Patient Safety Center of Inquiry from the VA Office of Patient Safety. The funders had no influence in the conduct, analysis, or interpretation of the study data.; Dr Jackson was funded by a VA Fellowship in Advanced Geriatrics. Dr Rudolph is supported by the VA Health Services Research and Development Center of Innovation in Long Term Services and Supports (CIN 13-419) and the VA QUERI-Geriatrics and Extended Care Partnered Evaluation Center for Community Nursing Homes (PEC 15-465). The views expressed here are the opinion of the authors and do not represent the official policy of the VA. NR 24 TC 0 Z9 0 U1 1 U2 1 PU DOVE MEDICAL PRESS LTD PI ALBANY PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND SN 1178-1998 J9 CLIN INTERV AGING JI Clin. Interv. Aging PY 2016 VL 11 BP 1715 EP 1721 DI 10.2147/CIA.S118235 PG 7 WC Geriatrics & Gerontology SC Geriatrics & Gerontology GA EC7NF UT WOS:000388325800002 PM 27920510 ER PT J AU Helke, KL McCrackin, MA Galloway, AM Poole, AZ Salgado, CD Marriott, BP AF Helke, Kristi L. McCrackin, M. A. Galloway, Ashley M. Poole, Ann Z. Salgado, Cassandra D. Marriott, Bernadette P. TI Effects of antimicrobial use in agricultural animals on drug-resistant foodborne salmonellosis in humans: A systematic literature review SO CRITICAL REVIEWS IN FOOD SCIENCE AND NUTRITION LA English DT Review DE Food safety; tetracycline; streptomycin; farm-to-fork; meat ID ENTERICA SEROVAR ENTERITIDIS; UNITED-STATES; ESCHERICHIA-COLI; DAIRY-CATTLE; RETAIL MEATS; NONTYPHOIDAL SALMONELLA; MOLECULAR CHARACTERIZATION; GENETIC-CHARACTERIZATION; MULTIDRUG-RESISTANCE; SEROTYPE TYPHIMURIUM AB Controversy continues concerning antimicrobial use in food animals and its relationship to drug-resistant infections in humans. We systematically reviewed published literature for evidence of a relationship between antimicrobial use in agricultural animals and drug-resistant meat or dairy-borne non-typhoidal salmonellosis in humans. Based on publications from the United States (U.S.), Canada, and Denmark from January 2010 to July 2014, 858 articles received title and abstract review, 104 met study criteria for full article review with 68 retained for which data are presented. Antibiotic exposure in both cattle and humans found an increased likelihood of Salmonella colonization, whereas in chickens, animals not exposed to antibiotics (organic) were more likely to be Salmonella positive and those that had antibiotic exposure were more likely to harbor antimicrobial resistant Salmonella organisms. In swine literature, only tylosin exposure was examined and no correlation was found among exposure, Salmonella colonization, or antimicrobial resistance. No studies that identified farm antimicrobial use also traced antimicrobial-resistant Salmonella from farm to fork. C1 [Helke, Kristi L.; McCrackin, M. A.] Med Univ South Carolina, Dept Comparat Med, Charleston, SC USA. [Helke, Kristi L.] Ralph H Johnson VA Med Ctr, Dept Res Serv, Charleston, SC USA. [McCrackin, M. A.; Galloway, Ashley M.; Marriott, Bernadette P.] Med Univ South Carolina, Div Gastroenterol, Nutr Sect, Dept Med, Charleston, SC USA. [Salgado, Cassandra D.] Med Univ South Carolina, Div Infect Dis, Dept Med, Charleston, SC USA. [Marriott, Bernadette P.] Med Univ South Carolina, Div Gastroenterol, Nutr Sect, Dept Psychiat, Charleston, SC USA. RP Marriott, BP (reprint author), Dept Med, Nutr Sect, Div Gastroenterol & Hepatol, 114 Doughty St STB 630D,MSC 770, Charleston, SC 29425 USA.; Marriott, BP (reprint author), Dept Psychiat & Behav Sci, Mil Div, 114 Doughty St STB 630D,MSC 770, Charleston, SC 29425 USA. EM marriobp@musc.edu OI Helke, Kris/0000-0001-9746-0764 FU Animal Health Institute FX Funding for this project was received from the Animal Health Institute. The funders had no role in study design, data collection and analysis, decision to publish or preparation of manuscript. NR 101 TC 0 Z9 0 U1 16 U2 16 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 1040-8398 EI 1549-7852 J9 CRIT REV FOOD SCI JI Crit. Rev. Food Sci. Nutr. PY 2016 VL 57 IS 3 BP 472 EP 488 DI 10.1080/10408398.2016.1230088 PG 17 WC Food Science & Technology; Nutrition & Dietetics SC Food Science & Technology; Nutrition & Dietetics GA EC0BY UT WOS:000387763800002 PM 27602884 ER PT J AU Shaw, LJ Xie, JX Phillips, LM Goyal, A Reynolds, HR Berman, DS Picard, MH Bhargava, B Devlin, G Chaitman, BR AF Shaw, Leslee J. Xie, Joe X. Phillips, Lawrence M. Goyal, Abhinav Reynolds, Harmony R. Berman, Daniel S. Picard, Michael H. Bhargava, Balram Devlin, Gerard Chaitman, Bernard R. TI Optimising diagnostic accuracy with the exercise ECG: opportunities for women and men with stable ischaemic heart disease SO HEART ASIA LA English DT Review ID CORONARY-ARTERY-DISEASE; EMISSION COMPUTED-TOMOGRAPHY; INDUCED VENTRICULAR-ARRHYTHMIA; ACUTE MYOCARDIAL-INFARCTION; LONG-TERM SURVIVAL; PROGNOSTIC VALUE; RATE RECOVERY; CONSENSUS STATEMENT; CLINICAL-EVALUATION; MEDICAL THERAPY AB The exercise ECG is an integral part within the evaluation algorithm for diagnosis and risk stratification of patients with stable ischaemic heart disease (SIHD). There is evidence, both older and new, that the exercise ECG can be an effective and cost-efficient option for patients capable of performing at maximal levels of exercise with suitable resting ECG findings. In this review, we will highlight the major dilemmas in interpreting suspected coronary artery disease symptoms in women and identify optimal strategies for employing exercise ECG as a first-line diagnostic test in the SIHD evaluation algorithm. We will highlight current evidence as well as recent guideline statements on this subject. C1 [Shaw, Leslee J.; Xie, Joe X.; Goyal, Abhinav] Emory Univ, Sch Med, Div Cardiol, Dept Med, Atlanta, GA 30322 USA. [Phillips, Lawrence M.; Reynolds, Harmony R.] NYU, Sch Med, Cardiovasc Clin Res Ctr, Leon H Charney Div Cardiol,Dept Med, New York, NY USA. [Berman, Daniel S.] Cedars Sinai Med Ctr, Cedars Sinai Heart Inst, Dept Imaging, Los Angeles, CA 90048 USA. [Picard, Michael H.] Massachusetts Gen Hosp, Div Cardiol, Dept Med, Boston, MA 02114 USA. [Bhargava, Balram] All India Inst Med Sci, SIB, Cardiol, Cardiothorac Sci Ctr, New Delhi, India. [Bhargava, Balram] All India Inst Med Sci, SIB, Stanford India Biodesign Ctr, New Delhi, India. [Devlin, Gerard] Waikato Hosp, New Zealand Heart Fdn, Dept Med, Div Cardiol, Hamilton, New Zealand. [Chaitman, Bernard R.] St Louis Univ, Sch Med, Dept Med, Div Cardiol, St Louis, MO 63104 USA. RP Shaw, LJ (reprint author), Emory Univ, Sch Med, Room 529,1462 Clifton Rd NE, Atlanta, GA 30322 USA. EM lshaw3@emory.edu OI Picard, Michael/0000-0002-9264-3243 NR 37 TC 1 Z9 1 U1 1 U2 1 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 2398-5968 EI 1759-1104 J9 HEART ASIA JI Heart Asia PY 2016 VL 8 IS 2 BP 1 EP 7 DI 10.1136/heartasia-2016-010736 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA EC0JS UT WOS:000387787500001 PM 27326241 ER PT J AU Krishnappa, V Gupta, M Manu, G Kwatra, S Owusu, OT Raina, R AF Krishnappa, Vinod Gupta, Mohit Manu, Gurusidda Kwatra, Shivani Owusu, Osei-Tutu Raina, Rupesh TI Acute Kidney Injury in Hematopoietic Stem Cell Transplantation: A Review SO INTERNATIONAL JOURNAL OF NEPHROLOGY LA English DT Review ID ACUTE-RENAL-FAILURE; BONE-MARROW-TRANSPLANTATION; HEPATIC VENOOCCLUSIVE DISEASE; TUMOR LYSIS SYNDROME; SINUSOIDAL OBSTRUCTION SYNDROME; SINGLE-CENTER EXPERIENCE; VERSUS-HOST-DISEASE; OF-THE-LITERATURE; RISK-FACTORS; THROMBOTIC MICROANGIOPATHY AB Hematopoietic stem cell transplantation (HSCT) is a highly effective treatment strategy for lymphoproliferative disorders and bone marrow failure states including aplastic anemia and thalassemia. However, its use has been limited by the increased treatment related complications, including acute kidney injury (AKI) with an incidence ranging from 20% to 73%. AKI after HSCT has been associated with an increased risk of mortality. The incidence of AKI reported in recipients of myeloablative allogeneic transplant is considerably higher in comparison to other subclasses mainly due to use of cyclosporine and development of graft-versus-host disease (GVHD) in allogeneic groups. Acute GVHD is by itself a major independent risk factor for the development of AKI in HSCT recipients. The other major risk factors are sepsis, nephrotoxic medications (amphotericin B, acyclovir, aminoglycosides, and cyclosporine), hepatic sinusoidal obstruction syndrome (SOS), thrombotic microangiopathy (TMA), marrow infusion toxicity, and tumor lysis syndrome. The mainstay of management of AKI in these patients is avoidance of risk factors contributing to AKI, including use of reduced intensity-conditioning regimen, close monitoring of nephrotoxic medications, and use of alternative antifungals for prophylaxis against infection. Also, early identification and effective management of sepsis, tumor lysis syndrome, marrow infusion toxicity, and hepatic SOS help in reducing the incidence of AKI in HSCT recipients. C1 [Krishnappa, Vinod; Kwatra, Shivani] Akron Nephrol Associates, Akron Gen Cleveland Clin, Akron, OH USA. [Gupta, Mohit] Akron Gen Cleveland Clin, Dept Internal Med, Akron, OH USA. [Manu, Gurusidda] Beth Israel Deaconness Med Ctr, Boston, MA USA. [Owusu, Osei-Tutu] Akron Gen Cleveland Clin, Dept Hematol Med Oncol, Akron, OH USA. [Raina, Rupesh] Akron Gen Cleveland Clin, Dept Nephrol Internal Med, Akron, OH 44307 USA. RP Raina, R (reprint author), Akron Gen Cleveland Clin, Dept Nephrol Internal Med, Akron, OH 44307 USA. EM rraina@chmca.org NR 86 TC 0 Z9 0 U1 2 U2 2 PU HINDAWI PUBLISHING CORP PI NEW YORK PA 315 MADISON AVE 3RD FLR, STE 3070, NEW YORK, NY 10017 USA SN 2090-214X EI 2090-2158 J9 INT J NEPHROL JI Int. J. Nephrol. PY 2016 AR 5163789 DI 10.1155/2016/5163789 PG 13 WC Urology & Nephrology SC Urology & Nephrology GA EC6GN UT WOS:000388234600001 ER PT J AU Teo, ZWW Schalock, PC AF Teo, Z. W. W. Schalock, P. C. TI Hypersensitivity Reactions to Implanted Metal Devices: Facts and Fictions SO JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY LA English DT Review DE Metal hypersensitivity; Metallic implants ID TOTAL HIP-ARTHROPLASTY; ALLERGIC-CONTACT-DERMATITIS; TOTAL KNEE ARTHROPLASTY; TOTAL JOINT ARTHROPLASTY; PATENT FORAMEN OVALE; AGGRESSIVE GRANULOMATOUS LESIONS; LYMPHOCYTE-TRANSFORMATION TEST; ORAL LICHEN-PLANUS; ORTHOPEDIC IMPLANTS; STAINLESS-STEEL AB The use of metals in the medical field has become increasingly prevalent over the past few decades. Patients find themselves being exposed to metals in a variety of ways, ranging from external exposure to instruments such as the stainless steel in surgical blades to internal exposure via medical devices being implanted in their bodies. There has been growing interest in the possibility of developing hypersensitivity reactions to constituent metals in medical implant devices, both in cutaneous and systemic forms. Hypersensitivity reactions to metals are uncommon, but they are reported and require appropriate evaluation and management, particularly if they are symptomatic. In view of the lack of consensus in the field on the appropriate steps to evaluate and manage patients with suspected metal hypersensitivity reactions, this review aims to analyze current evidence on hypersensitivity reactions to metallic implants in orthopedic surgery, endovascular surgery, obstetrics and gynecology, and dental surgery. C1 [Teo, Z. W. W.; Schalock, P. C.] Harvard Sch Med, Massachusetts Gen Hosp, Dept Dermatol, Boston, MA USA. RP Schalock, PC (reprint author), Massachusetts Gen Hosp, Dept Dermatol, BAR622 55 Fruit St, Boston, MA 02114 USA. EM schalock@dermatura.net NR 221 TC 0 Z9 0 U1 3 U2 3 PU ESMON PUBLICIDAD S A PI BARCELONA PA CALLE BALMES 209, 3 2, BARCELONA, 08006, SPAIN SN 1018-9068 J9 J INVEST ALLERG CLIN JI J. Invest. Allergol. Clin. Immunol. PY 2016 VL 26 IS 5 BP 279 EP 294 DI 10.18176/jiaci.0095 PG 16 WC Allergy; Immunology SC Allergy; Immunology GA EC3WE UT WOS:000388057000001 ER PT S AU Egawa, N Lok, J Arai, K AF Egawa, N. Lok, J. Arai, K. BE Masamoto, K Hirase, H Yamada, K TI Mechanisms of cellular plasticity in cerebral perivascular region SO NEW HORIZONS IN NEUROVASCULAR COUPLING: A BRIDGE BETWEEN BRAIN CIRCULATION AND NEURAL PLASTICITY SE Progress in Brain Research LA English DT Review; Book Chapter DE Perivascular region; Neurovascular coupling; Neurogenesis; Oligodendrogenesis; Neurovascular niche; Oligovascular niche; Neurovascular unit ID OLIGODENDROCYTE PRECURSOR CELLS; BLOOD-BRAIN-BARRIER; NEURAL STEM-CELLS; ADULT HUMAN BRAIN; A-BETA CLEARANCE; PROGENITOR-CELL; WHITE-MATTER; NG2 CELLS; NEURONAL DIFFERENTIATION; NEUROBLAST MIGRATION AB Brain vasculature acts in synergism with neurons to maintain brain function. This neurovascular coupling, or trophic coupling between cerebral endothelium and neuron, is now well accepted as a marker for mapping brain activity. Neurovascular coupling is most active in the perivascular region, in which there are ample opportunities for cell-cell interactions within the neurovascular unit. This trophic coupling between cells maintains neurovascular function and cellular plasticity. Recent studies have revealed that even adult brains contain multiple stem cells of various lineages, which may provide cellular plasticity through the process of differentiation among these stem cell populations. In this chapter, we provide an overview of the process by which neurovascular components contribute to cellular plasticity in the cerebral perivascular regions, focusing on mechanisms of cell-cell interaction in adult brain. C1 [Egawa, N.; Lok, J.; Arai, K.] Massachusetts Gen Hosp, Neuroprotect Res Lab, Charlestown, MA 02129 USA. [Egawa, N.; Lok, J.; Arai, K.] Harvard Med Sch, Charlestown, MA 02129 USA. [Lok, J.] Massachusetts Gen Hosp, Charlestown, MA USA. RP Arai, K (reprint author), Massachusetts Gen Hosp, Neuroprotect Res Lab, Charlestown, MA 02129 USA.; Arai, K (reprint author), Harvard Med Sch, Charlestown, MA 02129 USA. EM karai@partners.org FU NINDS NIH HHS [P01 NS055104, R01 NS065089] NR 109 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA SARA BURGERHARTSTRAAT 25, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0079-6123 BN 978-0-444-63706-2; 978-0-444-63704-8 J9 PROG BRAIN RES JI Prog. Brain Res. PY 2016 VL 225 BP 183 EP 200 DI 10.1016/bs.pbr.2016.03.005 PG 18 WC Neurosciences SC Neurosciences & Neurology GA BF9LH UT WOS:000385737200009 PM 27130416 ER PT S AU Iafe, NA Phasukkijwatana, N Sarraf, D AF Iafe, Nicholas A. Phasukkijwatana, Nopasak Sarraf, David BE Bandello, F Souied, EH Querques, G TI Optical Coherence Tomography Angiography of Type 1 Neovascularization in Age-Related Macular Degeneration SO OCT ANGIOGRAPHY IN RETINAL AND MACULAR DISEASES SE Developments in Ophthalmology LA English DT Article; Book Chapter ID CHOROIDAL NEOVASCULARIZATION; THERAPY; ANGIOGENESIS; EYES; CLASSIFICATION; FIBROSIS AB Age-related macular degeneration continues to be the leading cause of severe central vision loss in older adults of European descent. Optical coherence tomography angiography (OCT-A) enables more accurate identification of type 1 neovascularization in age-related macular degeneration than traditional fluorescein and indocyanine green angiographies. In addition, OCT-A facilitates the morphological classification of type 1 lesions, including features characteristic of early, mature, and fibrotic lesions. Vessel complex analysis, including lesion area and capillary density quantification, can also be readily measured and monitored over time. Performing this analysis following anti-vascular endothelial growth factor therapy may lead to a better understanding of the efficacies and responses to such treatments. Although some limitations currently exist, OCT-A is a promising imaging modality that could prove to have profound implications if incorporated into regular clinical practice. (C) 2016 S. Karger AG, Basel C1 [Iafe, Nicholas A.; Phasukkijwatana, Nopasak; Sarraf, David] Univ Calif Los Angeles, David Geffen Sch Med, Stein Eye Inst, 100 Stein Plaza, Los Angeles, CA 90095 USA. [Sarraf, David] Greater Los Angeles VA Healthcare Ctr, Los Angeles, CA USA. RP Sarraf, D (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Stein Eye Inst, Retinal Disorders & Ophthalm Genet Div, 100 Stein Plaza, Los Angeles, CA 90095 USA. EM Niafe@mednet.ucla.edu; nopasak.sioph@gmail.com; dsarraf@ucla.edu NR 20 TC 3 Z9 3 U1 0 U2 0 PU KARGER PI BASEL PA POSTFACH, CH-4009 BASEL, SWITZERLAND SN 0250-3751 BN 978-3-318-05830-7; 978-3-318-05829-1 J9 DEV OPHTHALMOL JI Dev. Ophthalmol. PY 2016 VL 56 BP 45 EP 51 DI 10.1159/000442776 D2 10.1159/isbn.978-3-318-05830-7 PG 7 WC Ophthalmology SC Ophthalmology GA BG2CY UT WOS:000387260100008 PM 27023719 ER PT S AU Nemiroff, J Phasukkijwatana, N Sarraf, D AF Nemiroff, Julia Phasukkijwatana, Nopasak Sarraf, David BE Bandello, F Souied, EH Querques, G TI Optical Coherence Tomography Angiography of Deep Capillary Ischemia SO OCT ANGIOGRAPHY IN RETINAL AND MACULAR DISEASES SE Developments in Ophthalmology LA English DT Article; Book Chapter ID ACUTE MIDDLE MACULOPATHY; ACUTE MACULAR NEURORETINOPATHY; NITRIC-OXIDE SYNTHASE; RETINAL ISCHEMIA; REPERFUSION INJURY; OCCLUSION; SPECTRUM AB Paracentral acute middle maculopathy (PAMM) is defined by the spectral-domain optical coherence tomography (OCT) finding of paracentral hyper-reflective band-like lesions of the inner nuclear layer (INL) of the macula that progress to corresponding areas of severe INL thinning. En face analysis has enabled more detailed analyses and quantifications of these lesions and has provided insights into the pathogenesis of this abnormality. While there is a wealth of demographic and anatomical data indicating that these PAMM lesions are the result of an INL infarct, OCT angiography is the first modality to provide direct evidence. Several studies have recently shown that old PAMM lesions are indeed associated with ischemia of the deep capillary retinal plexus, while acute lesions may or may not show initial perfusion of the deep capillary retinal plexus. (C) 2016 S. Karger AG, Basel C1 [Nemiroff, Julia; Phasukkijwatana, Nopasak; Sarraf, David] Univ Calif Los Angeles, David Geffen Sch Med, Stein Eye Inst, 100 Stein Plaza, Los Angeles, CA 90095 USA. [Sarraf, David] Greater Los Angeles VA Healthcare Ctr, Los Angeles, CA USA. RP Sarraf, D (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Stein Eye Inst, Retinal Disorders & Ophthalm Genet Div, 100 Stein Plaza, Los Angeles, CA 90095 USA. EM jnemiroff@gmail.com; nopasak.sioph@gmail.com; dsarraf@ucla.edu NR 18 TC 1 Z9 1 U1 0 U2 0 PU KARGER PI BASEL PA POSTFACH, CH-4009 BASEL, SWITZERLAND SN 0250-3751 BN 978-3-318-05830-7; 978-3-318-05829-1 J9 DEV OPHTHALMOL JI Dev. Ophthalmol. PY 2016 VL 56 BP 139 EP 145 DI 10.1159/000442806 D2 10.1159/isbn.978-3-318-05830-7 PG 7 WC Ophthalmology SC Ophthalmology GA BG2CY UT WOS:000387260100021 PM 27022753 ER PT J AU Sher, L AF Sher, Leo TI NARCISSISTIC PERSONALITY DISORDER AND SUICIDE SO PSYCHIATRIA DANUBINA LA English DT Letter ID BORDERLINE C1 [Sher, Leo] James J Peters Vet Adm Med Ctr, New York, NY USA. [Sher, Leo] Icahn Sch Med Mt Sinai, New York, NY 10029 USA. RP Sher, L (reprint author), James J Peters Vet Adm Med Ctr, 130 West Kingsbridge Rd, Bronx, NY 10468 USA. EM Leo.Sher@mssm.edu NR 7 TC 0 Z9 0 U1 0 U2 0 PU MEDICINSKA NAKLADA PI ZAGREB PA VLASKA 69, HR-10000 ZAGREB, CROATIA SN 0353-5053 J9 PSYCHIAT DANUB JI Psychiatr. Danub. PY 2016 VL 28 IS 3 BP 307 EP 307 PG 1 WC Psychiatry SC Psychiatry GA EC8OI UT WOS:000388400900015 ER PT J AU Allan, NP Gros, DF Hom, MA Joiner, TE Stecker, T AF Allan, Nicholas P. Gros, Daniel F. Hom, Melanie A. Joiner, Thomas E. Stecker, Tracy TI Suicidal Ideation and Interpersonal Needs: Factor Structure of a Short Version of the Interpersonal Needs Questionnaire in an At-Risk Military Sample SO PSYCHIATRY-INTERPERSONAL AND BIOLOGICAL PROCESSES LA English DT Article ID PERCEIVED BURDENSOMENESS; THWARTED BELONGINGNESS; PSYCHOLOGICAL THEORY; MODEL; PERSONNEL; VETERANS; VALIDITY; ARMY; FIT; RELIABILITY AB Objective: The interpersonal-psychological theory of suicide posits that perceived burdensomeness (PB; i.e., the belief that others would be better off if one were dead) and thwarted belongingness (TB; i.e., the belief that one lacks meaningful social connections) are both necessary risk factors for the development of suicidal ideation. To test these relations, measures are needed that are well validated, especially in samples of at-risk adults. Method: The current study was designed to examine the factor structure of an eight-item version of the Interpersonal Needs Questionnaire (INQ) in a sample of 405 U.S. past and current military personnel (M-age = 31.57 years, SD = 7.28; 90.4% male) who endorsed either current suicidal ideation and/or a past suicide attempt. Analyses were conducted using confirmatory factor analysis (CFA). Results: A bifactor model comprising a general factor, labeled interpersonal needs, and two specific factors, labeled PB and TB, fit the data best. The general factor captured a high proportion of overall variance (81.9%). In contrast, the TB factor captured only a modest amount of variance in items meant to capture this factor (59.1%) and the PB factor captured very little variance in items meant to capture this factor (13.5%). Further, only the interpersonal needs factor was associated with lifetime and past-week suicidal ideation as well as suicidal ideation frequency and duration. Conclusions: The current findings indicate that, for the INQ-8 in high-risk military personnel, a general interpersonal needs factor accounted for the relations PB and TB share with suicidal ideation. C1 [Allan, Nicholas P.; Gros, Daniel F.; Stecker, Tracy] Med Univ South Carolina, Ralph H Johnson Vet Affairs Med Ctr, Mental Hlth Serv, Charleston, SC USA. [Allan, Nicholas P.; Gros, Daniel F.; Stecker, Tracy] Med Univ South Carolina, Dept Psychiat & Behav Sci, Charleston, SC USA. [Hom, Melanie A.; Joiner, Thomas E.] Florida State Univ, Dept Psychol, Tallahassee, FL 32306 USA. RP Gros, DF (reprint author), Ralph H Johnson VAMC, Mental Hlth Serv 116, 109 Bee St, Charleston, SC 29401 USA. EM grosd@musc.edu FU Department of Defense Grant [W81XWH-13-2-0032]; Department of Veteran Affairs Clinical Sciences Research and Development Career Development Award [CX000845] FX This study is supported by a Department of Defense Grant (W81XWH-13-2-0032; PI: Stecker) and a Department of Veteran Affairs Clinical Sciences Research and Development Career Development Award (CX000845; PI:Gros). The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the U.S. government. There are no conflicts of interest. NR 40 TC 0 Z9 0 U1 1 U2 1 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 0033-2747 EI 1943-281X J9 PSYCHIATRY JI Psychiatry-Interpers. Biol. Process. PY 2016 VL 79 IS 3 BP 249 EP 261 DI 10.1080/00332747.2016.1185893 PG 13 WC Psychiatry SC Psychiatry GA EC8FC UT WOS:000388375200009 PM 27880629 ER PT B AU Catts, O Zurr, I AF Catts, Oron Zurr, Ionat BE Wilmer, SE Zukauskaite, A TI The Biopolitics of Life Removed from Context Neolifism SO RESISTING BIOPOLITICS: PHILOSOPHICAL, POLITICAL, AND PERFORMATIVE STRATEGIES SE Routledge Studies in Contemporary Philosophy LA English DT Article; Book Chapter C1 [Catts, Oron; Zurr, Ionat] Univ Western Australia, Sch Anat Human Biol, SymbioticA, Nedlands, WA, Australia. [Catts, Oron] Tissue Culture & Art Project, Nedlands, WA, Australia. [Zurr, Ionat] NCBS, InStem Inst, Bangalore, Karnataka, India. [Zurr, Ionat] Stanford Univ, Expt Art Ctr, Stanford, CA 94305 USA. [Zurr, Ionat] Harvard Med Sch, Massachusetts Gen Hosp, Tissue Engn & Organ Fabricat Lab, Cambridge, MA USA. RP Catts, O (reprint author), Univ Western Australia, Sch Anat Human Biol, SymbioticA, Nedlands, WA, Australia. NR 31 TC 0 Z9 0 U1 0 U2 0 PU ROUTLEDGE PI ABINGDON PA 2 PARK SQ, MILTON PARK, ABINGDON OX14 4RN, OXFORD, ENGLAND BN 978-1-315-76495-5; 978-1-138-78948-7 J9 ROUT STUD CONTEMP PH PY 2016 VL 71 BP 135 EP 155 PG 21 WC Philosophy; Political Science; Social Issues SC Philosophy; Government & Law; Social Issues GA BG2UC UT WOS:000387701700009 ER PT S AU Cheng, YS Bleier, BS AF Cheng, Y. Song Bleier, Benjamin S. BE Woodworth, BA Poetker, DM Reh, DD TI Influence of P-Glycoprotein Function on Chronic Rhinosinusitis/Nasal Polyps Pathophysiology SO RHINOSINUSITIS WITH NASAL POLYPOSIS SE Advances in Oto-Rhino-Laryngology LA English DT Article; Book Chapter ID INFLAMMATORY-BOWEL-DISEASE; CALCIUM-CHANNEL BLOCKERS; BLOOD MONONUCLEAR-CELLS; NASAL EPITHELIAL-CELLS; MULTIDRUG-RESISTANCE; DRUG-RESISTANCE; GLUCOCORTICOID RESISTANCE; CYTOKINE PRODUCTION; CHRONIC SINUSITIS; ABC TRANSPORTERS AB Permeability glycoprotein (P-gp) is an active efflux membrane transporter that has been researched extensively due to its ability to confer multidrug resistance in a wide range of cancers. P-gp has an impressively broad substrate specificity and is known to interact with hundreds of compounds, including drugs and toxins. This substrate promiscuity is the key to its physiological role, and P-gp is thought to be responsible for extruding xenobiotics and cellular metabolites, as well as maintaining tissue barriers at the blood-brain interface and gastrointestinal epithelium. In addition, P-gp is thought to be involved in regulating immune responses and is able to influence the secretion of cytokines and chemokines. This role as an immunomodulator links P-gp activity in the sinonasal epithelium with chronic rhinosinusitis (CRS), and a series of studies have provided evidence suggesting that P-gp may be a potential therapeutic target for treating CRS. Here, we highlight key knowledge about this intriguing protein, which may offer an important advancement in our understanding of CRS pathogenesis. (C) 2016 S. Karger AG, Basel C1 [Cheng, Y. Song; Bleier, Benjamin S.] Massachusetts Eye & Ear Infirm, Dept Otolaryngol Head & Neck Surg, Boston, MA 02114 USA. RP Bleier, BS (reprint author), Harvard Med Sch, Massachusetts Eye & Ear Infirm, Dept Otolaryngol Head & Neck Surg, 243 Charles St, Boston, MA 02114 USA. EM benjamin_bleier@meei.harvard.edu NR 98 TC 0 Z9 0 U1 0 U2 0 PU KARGER PI BASEL PA POSTFACH, CH-4009 BASEL, SWITZERLAND SN 0065-3071 BN 978-3-318-05854-3; 978-3-318-05853-6 J9 ADV OTO-RHINO-LARYNG JI Adv.Otorhinolaryngol. PY 2016 VL 79 BP 38 EP 47 DI 10.1159/000445094 D2 10.1159/isbn.978-3-318-05854-3 PG 10 WC Otorhinolaryngology SC Otorhinolaryngology GA BG2CX UT WOS:000387259200006 PM 27466845 ER PT S AU Deschler, DG Eisele, DW AF Deschler, Daniel G. Eisele, David W. BE Bradley, PJ Eisele, DW TI Surgery for Primary Malignant Parotid Neoplasms SO SALIVARY GLAND NEOPLASMS SE Advances in Oto-Rhino-Laryngology LA English DT Article; Book Chapter ID FINE-NEEDLE-ASPIRATION; MAJOR SALIVARY-GLANDS; LYMPH-NODE METASTASIS; ADENOID CYSTIC CARCINOMA; LOW-GRADE ADENOCARCINOMA; MUCOEPIDERMOID CARCINOMA; SUPERFICIAL PAROTIDECTOMY; EXTRACAPSULAR DISSECTION; COMPUTED-TOMOGRAPHY; PROGNOSTIC-FACTORS AB The successful treatment of salivary gland malignancies originating in the parotid gland begins with rigorous and thorough surgical management coupled with the directed and appropriate potential adjuvant use of radiation therapy and chemotherapy. The anatomic complexity of the region in relation to the facial nerve and adjoining neurovascular and musculoskeletal structures requires sound surgical planning and decision making based on preoperative and intraoperative findings. The clinical presentation of parotid malignancy is summarized, as well as the further evaluations that are performed, including imaging and tissue biopsy. A systematic approach to ensure resection with clear margins, management of the facial nerve, applicable extensions of the primary resection and management of the neck are presented. The key determinants of disease control, including the stage (early or advanced), histologic grade (low or high) and margin status (clear or positive), are highlighted as critical aspects of surgical management. (C) 2016 S. Karger AG, Basel C1 [Deschler, Daniel G.] Harvard Med Sch, Dept Otol & Laryngol, Massachusetts Eye & Ear Infirm, Boston, MA 02115 USA. [Eisele, David W.] Johns Hopkins Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Baltimore, MD 21205 USA. RP Deschler, DG (reprint author), Harvard Med Sch, Dept Otol & Laryngol, Massachusetts Eye & Ear Infirm, Boston, MA 02115 USA. NR 53 TC 1 Z9 1 U1 0 U2 0 PU KARGER PI BASEL PA POSTFACH, CH-4009 BASEL, SWITZERLAND SN 0065-3071 BN 978-3-318-05802-4; 978-3-318-05801-7 J9 ADV OTO-RHINO-LARYNG JI Adv.Otorhinolaryngol. PY 2016 VL 78 BP 83 EP 94 DI 10.1159/000442128 D2 10.1159/isbn.978-3-318-05802-4 PG 12 WC Otorhinolaryngology SC Otorhinolaryngology GA BG1RT UT WOS:000387054900011 PM 27093700 ER PT J AU Esfahani, SA Heidari, P Kim, SA Ogino, S Mahmood, U AF Esfahani, Shadi A. Heidari, Pedram Kim, Sun A. Ogino, Shuji Mahmood, Umar TI Optical Imaging of Mesenchymal Epithelial Transition Factor (MET) for Enhanced Detection and Characterization of Primary and Metastatic Hepatic Tumors SO THERANOSTICS LA English DT Article DE MET; Liver cancer; Tumor detection; Optical Imaging; Intra-operative interventions; molecularly-targeted therapy ID HEPATOCYTE GROWTH-FACTOR; C-MET; HEPATOCELLULAR-CARCINOMA; INDOCYANINE GREEN; EXPRESSION; CANCER; RECEPTOR; PATHWAY; FUTURE; PET AB Purpose: To assess optical imaging of Mesenchymal-Epithelial Transition factor (MET) for delineation and characterization of intrahepatic models of human hepatocellular carcinoma (HCC) and metastatic colorectal cancer (CRC), and thereby demonstrate its potential use in precision oncology. Materials and Methods: MET expression in human CRC and HCC was assessed in tissue microarrays. We used GE-137, a modified cyanine 5-tagged peptide for MET targeting. HepG2 and Huh-7 (HCC) and HT-29 (CRC) cells with MET overexpression, and LNCaP cells (negative control) with minimal MET expression were incubated with the probe. Correlation between the relative fluorescence signal intensity and cellular MET expression level was assessed. Flow cytometry was used to assess probe specific binding and dissociation constant (K-d). Orthotopic xenograft models of human HCC and metastatic CRC were generated in nu/nu mice by subcapsular implantation of cells. Epifluorescence imaging was performed to capture the changes in deferential probe accumulation at different time points after injection. Target-to-liver background ratio (TBR) was calculated and the probe biodistribution within different organs was assessed. Histopathologic analysis of extracted xenografts was performed to correlate the tumors MET expression with probe uptake by cancer cells. Results: Approximately 91.5% of HCC and 81% of CRC microarray cores showed MET expression. HCC and CRC cells incubated with the probe showed substantial fluorescence compared to control LNCaP, with strong correlation between fluorescence signal and MET expression (R-2 = 0.99, p < 0.001). Probe binding affinity to MET (K-d) was measured to be 2.9 +/- 0.36 nM. Epifluorescence imaging showed intense uptake in subcapsular tumors with peak TBR of 5.46 +/- 0.46 in Huh-7, 3.55 +/- 0.38 in HepG2, and 15.93 +/- 0.61 in HT-29 orthotopic xenografts at 4 hours post-injection (mean +/- standard deviation). We demonstrated that in vivo probe uptake in xenografts is specific and can be blocked when co-injected with unlabeled peptide; for instance the epifluorescence TBR is reduced from 13.5 +/- 1.2 to 1.7 +/- 0.3 (p < 0.05) in HT-29 and from 5.3 +/- 0.8 to 1.4 +/- 0.2 (p < 0.05) in Huh-7 xenografts after co-injection with unlabeled peptides. Biodistribution studies showed predominantly renal clearance of the probe. Conclusion: Optical imaging of MET resulted in high TBR in animal models of primary and metastatic hepatic tumors suggesting its utility for procedural guidance. C1 [Esfahani, Shadi A.; Heidari, Pedram; Mahmood, Umar] Harvard Med Sch, Massachusetts Gen Hosp, Dept Radiol, Athinoula A Martinos Ctr Biomed Imaging, Boston, MA 02115 USA. [Kim, Sun A.; Ogino, Shuji] Harvard Med Sch, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA. [Ogino, Shuji] Harvard Med Sch, Brigham & Womens Hosp, Dept Pathol, Boston, MA USA. [Ogino, Shuji] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA. RP Mahmood, U (reprint author), Massachusetts Gen Hosp, Dept Radiol, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA. EM umahmood@mgh.harvard.edu FU NIH [U01CA084301, P50CA127003, R35 CA197735] FX The authors would like to thank GE Healthcare for their generous gift of GE-137, and Mr. Igor Bagayev for his help with acquiring images using Zeiss Confocal Microscopy. This study was supported by NIH grants U01CA084301 and P50CA127003. S.O. was in part supported by NIH grant R35 CA197735. NR 39 TC 0 Z9 0 U1 4 U2 4 PU IVYSPRING INT PUBL PI LAKE HAVEN PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA SN 1838-7640 J9 THERANOSTICS JI Theranostics PY 2016 VL 6 IS 12 BP 2028 EP 2038 DI 10.7150/thno.15718 PG 11 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA ED0AR UT WOS:000388505900002 PM 27698938 ER PT J AU Tho, LC Bei, YH Chen, P Lei, ZY Fu, SY Zhang, HF Xu, JH Che, L Chen, XW Sluijter, JPG Das, S Cretoiu, D Xu, B Zhong, JC Xiao, JJ Li, XL AF Tho, Lichan Bei, Yihua Chen, Ping Lei, Zhiyong Fu, Siyi Zhang, Haifeng Xu, Jiahong Che, Lin Chen, Xiongwen Sluijter, Joost P. G. Das, Saumya Cretoiu, Dragos Xu, Bin Zhong, Jiuchang Xiao, Junjie Li, Xinli TI Crucial Role of miR-433 in Regulating Cardiac Fibrosis SO THERANOSTICS LA English DT Article DE cardiac fibrosis; miR-433; AZIN1; JNK1 ID NONCODING RNAS; HEART-FAILURE; CARDIOVASCULAR-DISEASE; MICRORNA THERAPEUTICS; MYOCARDIAL-INFARCTION; EXPRESSION; INHIBITION; IMPROVES; PROTEIN; CANCER AB Dysregulation of microRNAs has been implicated in many cardiovascular diseases including fibrosis. Here we report that miR-433 was consistently elevated in three models of heart disease with prominent cardiac fibrosis, and was enriched in fibroblasts compared to cardiomyocytes. Forced expression of miR-433 in neonatal rat cardiac fibroblasts increased proliferation and their differentiation into myofibroblasts as determined by EdU incorporation, alpha-SMA staining, and expression levels of fibrosis-associated genes. Conversely, inhibition of miR-433 exhibited opposite results. AZIN1 and JNK1 were identified as two target genes of miR-433. Decreased level of AZIN1 activated TGF-beta 1 while down-regulation of JNK1 resulted in activation of ERK and p38 kinase leading to Smad3 activation and ultimately cardiac fibrosis. Importantly, systemic neutralization of miR-433 or adeno-associated virus 9 (AAV9)-mediated cardiac transfer of a miR-433 sponge attenuated cardiac fibrosis and ventricular dysfunction following myocardial infarction. Thus, our work suggests that miR-433 is a potential target for amelioration of cardiac fibrosis. C1 [Tho, Lichan; Zhang, Haifeng; Li, Xinli] Nanjing Med Univ, Affiliated Hosp 1, Dept Cardiol, 300 Guangzhou Rd, Nanjing 210029, Jiangsu, Peoples R China. [Bei, Yihua; Chen, Ping; Fu, Siyi; Xiao, Junjie] Shanghai Univ, Sch Life Sci, Cardiac Regenerat & Ageing Lab, 333 Nan Chen Rd, Shanghai 200444, Peoples R China. [Lei, Zhiyong; Sluijter, Joost P. G.] Univ Med Ctr Utrecht, Lab Expt Cardiol, NL-3508 GA Utrecht, Netherlands. [Xu, Jiahong; Che, Lin] Tongji Univ, Sch Med, Tongji Hosp, Dept Cardiol, Shanghai 200065, Peoples R China. [Chen, Xiongwen] Temple Univ, Sch Med, Cardiovasc Res Ctr, Philadelphia, PA 19140 USA. [Chen, Xiongwen] Temple Univ, Sch Med, Dept Physiol, Philadelphia, PA 19140 USA. [Das, Saumya] Massachusetts Gen Hosp, Cardiovasc Div, Boston, MA 02215 USA. [Das, Saumya] Harvard Med Sch, Boston, MA 02215 USA. [Cretoiu, Dragos] Victor Babes Natl Inst Pathol, Bucharest 050096, Romania. [Cretoiu, Dragos] Carol Davila Univ Med & Pharm, Div Cellular & Mol Biol & Histol, Bucharest 050474, Romania. [Xu, Bin] Shanghai Univ, Innovat Drug Res Ctr, Shanghai 200444, Peoples R China. [Zhong, Jiuchang] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, State Key Lab Med Genom, Shanghai 200025, Peoples R China. [Zhong, Jiuchang] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Shanghai Inst Hypertens, Shanghai 200025, Peoples R China. RP Li, XL (reprint author), Nanjing Med Univ, Affiliated Hosp 1, Dept Cardiol, 300 Guangzhou Rd, Nanjing 210029, Jiangsu, Peoples R China.; Xiao, JJ (reprint author), Shanghai Univ, Sch Life Sci, Cardiac Regenerat & Ageing Lab, 333 Nan Chen Rd, Shanghai 200444, Peoples R China. EM junjiexiao@shu.edu.cn; xinli3267_nj@hotmail.com OI Sluijter, Joost/0000-0003-2088-9102 FU National Natural Science Foundation of China [81570362, 81200169, 81370332, 81170201, 81270314, 81470515, 81472158, 81400647, 81370362]; Priority Academic Program Development of Jiangsu Higher Education Institutions [PAPD20102013]; National Basic Research Program of China [2014CB542300]; National Major Research Plan Training Program [91339108]; Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant [20152509]; Shanghai Medical Guide Project from Shanghai Science and Technology Committee [134119a3000]; Natural Science Foundation of Shanghai [14ZR1437900]; Netherlands Cardiovascular Research Initiative (CVON): the Dutch Heart Foundation; Dutch Federation of University Medical Centers; Netherlands Organization for Health Research and Development; Royal Netherlands Academy of Science; National Institutes of Health (NCATS) [UH3 TR000901] FX This work was supported by the grants from National Natural Science Foundation of China (81570362 and 81200169 to JJ Xiao, 81370332 and 81170201 to XL Li, 81270314 and 81470515 to JH Xu, 81472158 to L Che, 81400647 to YH Bei, 81370362 to JC Zhong), the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD20102013 to XL Li), the National Basic Research Program of China (2014CB542300), the National Major Research Plan Training Program (91339108), Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant (20152509), Shanghai Medical Guide Project from Shanghai Science and Technology Committee (134119a3000 to JH Xu), Natural Science Foundation of Shanghai (14ZR1437900 to L. Che), the Netherlands Cardiovascular Research Initiative (CVON): the Dutch Heart Foundation, Dutch Federation of University Medical Centers, the Netherlands Organization for Health Research and Development, and the Royal Netherlands Academy of Science (to JPG Sluijter) and the National Institutes of Health (NCATS Grant UH3 TR000901 to S Das). Dr XL Li is an Associate Fellow at the Collaborative Innovation Center for Cardiovascular Disease Translational Medicine. NR 40 TC 0 Z9 0 U1 4 U2 4 PU IVYSPRING INT PUBL PI LAKE HAVEN PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA SN 1838-7640 J9 THERANOSTICS JI Theranostics PY 2016 VL 6 IS 12 BP 2068 EP 2083 DI 10.7150/thno.15007 PG 16 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA ED0AR UT WOS:000388505900005 ER PT J AU Jeong, HJ Kojima, T Dong, JH Ohashi, H Ueda, H AF Jeong, Hee-Jin Kojima, Tomoki Dong, Jinhua Ohashi, Hiroyuki Ueda, Hiroshi TI One-pot construction of Quenchbodies using antibody-binding proteins SO ANALYTICAL METHODS LA English DT Article ID ANTIGEN-DEPENDENT FLUORESCENCE; KNOWLEDGE-BASED DESIGN; Q-BODIES; FRAGMENT; PROBES; DOMAIN AB Fluorolabeled antibody-binding proteins were constructed based on Staphylococcus protein A and Streptococcus protein G domains, and used as an adaptor to convert the Fab fragment of interest to a Q-body, a fluorescent biosensor that exhibits antigen-dependent fluorescence enhancement. Without having to perform the tedious procedure of genetically introducing a fluorescent dye molecule into a cloned Fab fragment, we successfully converted both a cloned anti-osteocalcin Fab fragment and a commercially available anti-vimentin (Fab)(2) fragment to a Q-body using this method. This method is not only a simpler way for constructing Q-bodies but also a convenient alternative to finding a suitable antibody that has a greater potential to become an excellent biosensor. C1 [Jeong, Hee-Jin; Dong, Jinhua; Ueda, Hiroshi] Tokyo Inst Technol, Inst Innovat Res, Lab Chem & Life Sci, Tokyo, Japan. [Kojima, Tomoki; Ohashi, Hiroyuki] Univ Tokyo, Sch Engn, Dept Chem & Biotechnol, Tokyo 1138654, Japan. [Ohashi, Hiroyuki] Ushio Inc, Tokyo, Japan. [Jeong, Hee-Jin] Dana Farber Canc Inst, Dept Canc Immunol & Virol, Boston, MA 02115 USA. RP Ueda, H (reprint author), Tokyo Inst Technol, Inst Innovat Res, Lab Chem & Life Sci, Tokyo, Japan. EM ueda@res.titech.ac.jp OI Ueda, Hiroshi/0000-0001-8849-4217 FU Japan Society for the Promotion of Science [26889028, 15H04191, 26420793] FX This work was partly supported by a Grant-in-Aid for Scientific Research (No. 26889028 to HJJ, No. 15H04191 to HU, and No. 26420793 to JD) from the Japan Society for the Promotion of Science. NR 16 TC 0 Z9 0 U1 1 U2 1 PU ROYAL SOC CHEMISTRY PI CAMBRIDGE PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND SN 1759-9660 EI 1759-9679 J9 ANAL METHODS-UK JI Anal. Methods PY 2016 VL 8 IS 43 BP 7774 EP 7779 DI 10.1039/c6ay02108e PG 6 WC Chemistry, Analytical; Food Science & Technology; Spectroscopy SC Chemistry; Food Science & Technology; Spectroscopy GA EC2XZ UT WOS:000387989200008 ER PT S AU Jan, TA Jansson, L Atkinson, PJ Wang, T Cheng, AG AF Jan, Taha A. Jansson, Lina Atkinson, Patrick J. Wang, Tian Cheng, Alan G. BE Sokolowski, B TI Profiling Specific Inner Ear Cell Types Using Cell Sorting Techniques SO AUDITORY AND VESTIBULAR RESEARCH: METHODS AND PROTOCOLS, 2ND EDITION SE Methods in Molecular Biology LA English DT Article; Book Chapter DE Inner ear; Single cell analysis; Fluorescence; activated cell sorting; Profiling ID STEM-CELLS; HAIR-CELLS; PROGENITORS; EXPANSION; CULTURE AB Studies of specific tissue cell types are becoming increasingly important in advancing our understanding of cell biology and gene and protein expression. Prospective isolation of specific cell types is a powerful technique as it facilitates such investigations, allowing for analysis and characterization of individual cell populations. Such an approach to studying inner ear tissues presents a unique challenge because of the paucity of cells of interest and limited cell markers. In this chapter, we describe methods for selectively labeling and isolating different inner ear cell types from the neonatal mouse cochlea using fluorescence-activated cell sorting. C1 [Jan, Taha A.] Harvard Med Sch, Dept Otolaryngol, Massachusetts Eye & Ear Infirm, Boston, MA 02115 USA. [Jansson, Lina; Atkinson, Patrick J.; Cheng, Alan G.] Stanford Univ, Dept Otolaryngol Head & Neck Surg, Sch Med, Stanford, CA 94305 USA. [Wang, Tian] Oregon Hlth & Sci Univ, Oregon Hearing Res Ctr, Portland, OR 97201 USA. RP Jan, TA (reprint author), Harvard Med Sch, Dept Otolaryngol, Massachusetts Eye & Ear Infirm, Boston, MA 02115 USA. NR 18 TC 0 Z9 0 U1 2 U2 2 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES SN 1064-3745 BN 978-1-4939-3615-1; 978-1-4939-3613-7 J9 METHODS MOL BIOL JI Methods Mol. Biol. PY 2016 VL 1427 BP 431 EP 445 DI 10.1007/978-1-4939-3615-1_23 D2 10.1007/978-1-4939-3615-1 PG 15 WC Biochemical Research Methods; Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA BG1HW UT WOS:000386789500024 PM 27259940 ER PT J AU Tan, EK Srivastava, AK Arnold, WD Singh, MP Zhang, YY AF Tan, Eng King Srivastava, Amit K. Arnold, W. David Singh, Mahendra P. Zhang, Yiying TI Neurodegeneration: Etiologies and New Therapies 2016 SO BIOMED RESEARCH INTERNATIONAL LA English DT Editorial Material C1 [Tan, Eng King] Singapore Gen Hosp, Natl Neurosci Inst, Dept Neurol, Singapore 169857, Singapore. [Tan, Eng King] Duke NUS Grad Med Sch, Singapore 169857, Singapore. [Srivastava, Amit K.] Univ Texas Hlth Sci Ctr Houston, Dept Pediat Surg, Houston, TX 77030 USA. [Arnold, W. David] Ohio State Univ, Wexner Med Ctr, Dept Neurol, Div Neuromuscular Disorders, Columbus, OH 43210 USA. [Arnold, W. David] Ohio State Univ, Wexner Med Ctr, Dept PM&R, Columbus, OH 43210 USA. [Arnold, W. David] Ohio State Univ, Wexner Med Ctr, Dept Neurosci, Columbus, OH 43210 USA. [Singh, Mahendra P.] CSIR Indian Inst Toxicol Res, Toxicogen & Predict Toxicol Div, Lucknow 226001, Uttar Pradesh, India. [Zhang, Yiying] Harvard Med Sch, Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Charlestown, MA 02129 USA. RP Tan, EK (reprint author), Singapore Gen Hosp, Natl Neurosci Inst, Dept Neurol, Singapore 169857, Singapore.; Tan, EK (reprint author), Duke NUS Grad Med Sch, Singapore 169857, Singapore. EM tan.eng.king@sgh.com.sg NR 0 TC 0 Z9 0 U1 0 U2 0 PU HINDAWI PUBLISHING CORP PI NEW YORK PA 315 MADISON AVE 3RD FLR, STE 3070, NEW YORK, NY 10017 USA SN 2314-6133 EI 2314-6141 J9 BIOMED RES INT JI Biomed Res. Int. PY 2016 AR 8363179 DI 10.1155/2016/8363179 PG 1 WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental SC Biotechnology & Applied Microbiology; Research & Experimental Medicine GA EB9HQ UT WOS:000387704500001 ER PT J AU Panou, N Vavvas, DG AF Panou, Nikol Vavvas, Demetrios G. TI Optic Disk Pit with Sudden Central Visual Field Scotoma SO CASE REPORTS IN OPHTHALMOLOGICAL MEDICINE LA English DT Article ID GLAUCOMA; NERVE AB Purpose. To describe a case of optic disk pit (ODP) with sudden central visual field scotoma. Methods. A 49-year-old woman presented, reporting sudden painless central visual field loss 3 months prior to presentation. Neuroophthalmologic, systematic, and laboratory evaluation and full imaging processes were performed. Results. Fundoscopy and color photography demonstrated an optic disk pit inferotemporally. Perimetry identified central visual field horizontal scotoma. OCT revealed absence of serous retinal detachment, but disclosed inner retina thinning corresponding to the area of the visual field loss. Fluorescein angiography demonstrated delay in the cilioretinal arteries and also disclosed a relative delay in the perfusion of an arterial branch off the inferior retinal arcade. Clinical and laboratory evaluations were negative for any related pathology. Conclusion. Sudden central visual field scotoma in patients with ODP may be associated with delayed vascular filling of CRA and retinal arterioles within the optic disc anomaly region. C1 [Panou, Nikol] Gen Oncol Hosp Agioi Anargyroi, Ophthalm Clin, Athens 14564, Greece. [Vavvas, Demetrios G.] Monte J Wallace Ophthalmol Chair Retina, Boston, MA USA. [Vavvas, Demetrios G.] Harvard Med Sch, Boston, MA USA. [Vavvas, Demetrios G.] Massachusetts Eye & Ear Infirm, Ocular Regenerat Med Inst, 243 Charles St, Boston, MA 02114 USA. [Vavvas, Demetrios G.] Massachusetts Gen Hosp, 243 Charles St, Boston, MA 02114 USA. [Vavvas, Demetrios G.] Massachusetts Eye & Ear Infirm, Angiogenesis Lab, Boston, MA 02114 USA. RP Panou, N (reprint author), Gen Oncol Hosp Agioi Anargyroi, Ophthalm Clin, Athens 14564, Greece. EM nikolpanou@yahoo.gr NR 7 TC 0 Z9 0 U1 1 U2 1 PU HINDAWI PUBLISHING CORP PI NEW YORK PA 315 MADISON AVE 3RD FLR, STE 3070, NEW YORK, NY 10017 USA SN 2090-6722 EI 2090-6730 J9 CASE REP OPHTHALMOL JI Case Rep. Ophthalmol. Med. PY 2016 AR 1423481 DI 10.1155/2016/1423481 PG 4 WC Ophthalmology SC Ophthalmology GA EC0NF UT WOS:000387797200001 ER PT J AU Sohn, M Choi, M Jung, M AF Sohn, Minsung Choi, Mankyu Jung, Minsoo TI Working conditions, psychosocial environmental factors, and depressive symptoms among wage workers in South Korea SO INTERNATIONAL JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH LA English DT Article DE Depressive symptom; Working condition; Psychosocial environments; South Korea ID SICKNESS ABSENCE; MENTAL-HEALTH; HORDALAND HEALTH; SOCIAL SUPPORT; JOB STRAIN; FOLLOW-UP; RISK; POPULATION; PREVALENCE; EMPLOYMENT AB Background: In South Korea, the number of workers suffering from mental illnesses, such as depression, has rapidly increased. There is growing concern about depressive symptoms being associated with both working conditions and psychosocial environmental factors. Objectives: To investigate potential psychosocial environmental moderators in the relationship between working conditions and occupational depressive symptoms among wage workers. Methods: Data were obtained from the wage worker respondents (n = 4,095) of the Korean National Health and Nutrition Examination Survey of 2009. First, chi-square tests confirmed the differences in working conditions and psychosocial characteristics between depressive and non-depressive groups. Second, multivariate logistic regression analysis was performed to examine the moderating effects of the psychosocial environmental factors between working conditions and depressive symptoms. Results: After adjusting for potential covariates, the likelihood of depressive symptomatology was high among respondents who had dangerous jobs and flexible work hours compared to those who had standard jobs and fixed daytime work hours (OR = 1.66 and 1.59, respectively). Regarding psychosocial factors, respondents with high job demands, low job control, and low social support were more likely to have depressive symptoms (OR = 1.26, 1.58 and 1.61, respectively). Conclusions: There is a need to develop non-occupational intervention programs, which provide workers with training about workplace depression and improve social support, and the programs should provide time for employees to have active communication. Additionally, companies should provide employees with support to access mental healthcare thereby decreasing the occurrence of workplace depression. C1 [Sohn, Minsung; Choi, Mankyu] Korea Univ, Grad Sch, Dept Publ Hlth Sci, Seoul, South Korea. [Sohn, Minsung; Choi, Mankyu] Korea Univ, BK21PLUS Program Embodiment Hlth Soc Interact, Seoul, South Korea. [Choi, Mankyu] Korea Univ, Sch Hlth Policy & Management, Seoul, South Korea. [Jung, Minsoo] Dongduk Womens Univ, Dept Hlth Sci, 23-1 Wolgok Dong, Seoul 136714, South Korea. [Jung, Minsoo] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. RP Jung, M (reprint author), Dongduk Womens Univ, Dept Hlth Sci, 23-1 Wolgok Dong, Seoul 136714, South Korea. EM mj748@dongduk.ac.kr NR 48 TC 0 Z9 0 U1 1 U2 1 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND SN 1077-3525 EI 2049-3967 J9 INT J OCCUP ENV HEAL JI Int. J. Occup. Environ. Health PY 2016 VL 22 IS 3 BP 209 EP 217 DI 10.1080/10773525.2016.1200212 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA EB0TW UT WOS:000387059800005 ER PT J AU Romanoff, A Freed, J Heimann, T AF Romanoff, Anya Freed, Jeffrey Heimann, Tomas TI A case report of necrotizing fasciitis of the abdominal wall: A rare, life-threatening complication of a common disease process SO INTERNATIONAL JOURNAL OF SURGERY CASE REPORTS LA English DT Article DE Necrotizing fasciitis; Perforated appendicitis; Case report AB INTRODUCTION: Acute appendicitis is one of the most common surgical diseases, but perforated appendicitis resulting in necrotizing fasciitis of the abdominal wall is exceedingly rare. PRESENTATION OF CASE: A 71-year-old male presented to the emergency department with one week of severe right-sided abdominal pain. He was hypothermic, hypotensive, and tachycardic. His abdomen was distended, with a large, tender, erythematous region over the right abdominal wall. Laboratory evaluation revealed leukocytosis, acute kidney injury, and lactic acidosis. CT scan revealed large collections of fluid and gas in the right abdominal wall as well as inflammation surrounding the right colon. The patient was resuscitated with intra-venous fluid, started on broad-spectrum antibiotics, and emergently brought to the operating room. The patient underwent an exploratory laparotomy, and was found to have appendicitis, which perforated into his abdominal wall resulting in a necrotizing soft tissue infection. DISCUSSION: The diagnosis of perforated appendicitis resulting in necrotizing fasciitis is often delayed due to the unusual presentation of this common disease. Necrotizing fasciitis is associated with significant mortality and requires immediate intervention. CONCLUSION: It is imperative to maintain a high index of suspicion for intra-abdominal pathology in patients who present with necrotizing infections of the abdominal wall, flank, back, or groin. The importance of recognizing this complication early and proceeding immediately to the operating room cannot be overstated. (C) 2016 The Authors. Published by Elsevier Ltd C1 [Romanoff, Anya] Icahn Sch Med Mt Sinai, Dept Gen Surg, New York, NY 10029 USA. [Romanoff, Anya; Freed, Jeffrey; Heimann, Tomas] James J Peters VA Med Ctr, Dept Gen Surg, Bronx, NY USA. RP Romanoff, A (reprint author), Mt Sinai Med Ctr, Dept Gen Surg, Floor 15,5 East 98th St, New York, NY 10029 USA. EM anya.romanoff@mountsinai.org NR 3 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 2210-2612 J9 INT J SURG CASE REP JI Int. J. Surg. Case Rep. PY 2016 VL 28 BP 355 EP 356 DI 10.1016/j.ijscr.2016.09.005 PG 2 WC Surgery SC Surgery GA EC0MY UT WOS:000387796500090 PM 27794239 ER PT J AU Gupte, G Vimalananda, V Simon, SR DeVito, K Clark, J Orlander, JD AF Gupte, Gouri Vimalananda, Varsha Simon, Steven R. DeVito, Katerina Clark, Justice Orlander, Jay D. TI Disruptive Innovation: Implementation of Electronic Consultations in a Veterans Affairs Health Care System SO JMIR MEDICAL INFORMATICS LA English DT Article DE remote consultations; clinical communication; electronic consultation; telehealth; clinical information; decision making; telemonitoring; eHealth infrastructures ID SPECIALTY CARE; MODEL; COMMUNICATION AB Background: Electronic consultations (e-consults) offer rapid access to specialist input without the need for a patient visit. E-consult implementation began in 2011 at VA Boston Healthcare System (VABHS). By early 2013, e-consults were available for all clinical services. In this implementation, the requesting clinician selects the desired consultation within the electronic health record (EHR) ordering menu, which creates an electronic form that is pre-populated with patient demographic information and allows free-text entry of the reason for consult. This triggers a message to the requesting clinician and requested specialty, thereby enabling bidirectional clinician-clinician communication. Objective: The aim of this study is to examine the utilization of e-consults in a large Veterans Affairs (VA) health care system. Methods: Data from the electronic health record was used to measure frequency of e-consult use by provider type (physician or nurse practitioner (NP) and/or physician assistant), and by the requesting and responding specialty from January 2012 to December 2013. We conducted chart reviews for a purposive sample of e-consults and semi-structured interviews with a purposive sample of clinicians and hospital leaders to better characterize the process, challenges, and usability of e-consults. Results: A total of 7097 e-consults were identified, 1998 from 2012 and 5099 from 2013. More than one quarter (27.56%, 1956/7097) of the e-consult requests originated from VA facilities in New England other than VABHS and were excluded from subsequent analysis. Within the VABHS e-consults (72.44%, 5141/7097), variability in frequency and use of e-consults across provider types and specialties was found. A total of 64 NPs requested 2407 e-consults (median 12.5, range 1-415). In contrast, 448 physicians (including residents and fellows) requested 2349 e-consults (median 2, range 1-116). More than one third (37.35%, 1920/5141) of e-consults were sent from primary care to specialists. While most e-consults reflected a request for specialist input to a generalist's question in diagnosis or management in the ambulatory setting, we identified creative uses of e-consults, including requests for face-to-face appointments and documentation of pre-operative chart reviews; moreover, 7.00% (360/5141) of the e-consults originated from our sub-acute and chronic care inpatient units. In interviews, requesting providers reported high utility and usability. Specialists recognized the value of e-consults but expressed concerns about additional workload. Conclusions: The e-consult mechanism is frequently utilized for its initial intended purpose. It has also been adopted for unexpected clinical and administrative uses, developing into a "disruptive innovation" and highlighting existing gaps in mechanisms for provider communication. Further investigation is needed to characterize optimal utilization of e-consults within specialty and the medical center, and what features of the e-consult program, other than volume, represent valid measures of access and quality care. C1 [Gupte, Gouri] Boston Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Room 264 715 Albany St, Boston, MA 02118 USA. [Vimalananda, Varsha] Edith Nourse Rogers Mem Vet Affairs Med Ctr, CHOIR, Bedford, MA USA. [Vimalananda, Varsha] Boston Univ, Sch Med, Sect Endocrinol Diabet & Metab, Boston, MA 02118 USA. [Simon, Steven R.] VA Boston Healthcare Syst, CHOIR, Boston, MA USA. [Simon, Steven R.; Clark, Justice; Orlander, Jay D.] VA Boston Healthcare Syst, Gen Internal Med Sect, Boston, MA USA. [Simon, Steven R.] Brigham & Womens Hosp, Div Gen Internal Med & Primary Care, 75 Francis St, Boston, MA 02115 USA. [Simon, Steven R.] Harvard Med Sch, Boston, MA USA. [DeVito, Katerina] Harvard Sch Publ Hlth, Dept Nutr, Boston, MA USA. [Orlander, Jay D.] Boston Univ, Sch Med, Gen Internal Med Sect, Boston, MA 02118 USA. RP Gupte, G (reprint author), Boston Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Room 264 715 Albany St, Boston, MA 02118 USA. EM gourig@bu.edu OI Gupte, Gouri/0000-0001-7206-428X NR 28 TC 2 Z9 2 U1 2 U2 5 PU JMIR PUBLICATIONS, INC PI TORONTO PA 59 WINNERS CIRCLE, TORONTO, ON M4L 3Y7, CANADA SN 2291-9694 J9 JMIR MED INF JI JMIR Med. Inf. PD JAN-MAR PY 2016 VL 4 IS 1 AR e6 DI 10.2196/medinform.4801 PG 10 WC Medical Informatics SC Medical Informatics GA EC2XB UT WOS:000387986600007 PM 26872820 ER PT J AU Mehta, RL Andringa, KK Sanders, PW Agarwal, A AF Mehta, Ravindra L. Andringa, Kelly K. Sanders, Paul W. Agarwal, Anupam TI Changing Paradigms in Acute Kidney Injury: From Mechanisms to Management SO NEPHRON LA English DT Editorial Material C1 [Mehta, Ravindra L.] Univ Calif San Diego, Dept Med, Div Nephrol, San Diego, CA 92103 USA. [Andringa, Kelly K.; Sanders, Paul W.; Agarwal, Anupam] Univ Alabama Birmingham, Dept Med, Div Nephrol, Birmingham, AL 35294 USA. [Sanders, Paul W.; Agarwal, Anupam] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. RP Agarwal, A (reprint author), Univ Alabama Birmingham, Div Nephrol, THT 647, 1900 Univ Blvd, Birmingham, AL 35294 USA. EM agarwal@uab.edu NR 13 TC 0 Z9 0 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1660-8151 EI 2235-3186 J9 NEPHRON JI Nephron PY 2016 VL 134 IS 3 BP 131 EP 132 DI 10.1159/000447676 PG 2 WC Urology & Nephrology SC Urology & Nephrology GA EC2SM UT WOS:000387974200001 PM 27597998 ER PT J AU Ohnishi, T Nakamura, Y Tanaka, T Tanaka, T Hashimoto, N Haneishi, H Batchelor, TT Gerstner, ER Taylor, JW Snuderl, M Yagi, Y AF Ohnishi, Takashi Nakamura, Yuka Tanaka, Toru Tanaka, Takuya Hashimoto, Noriaki Haneishi, Hideaki Batchelor, Tracy T. Gerstner, Elizabeth R. Taylor, Jennie W. Snuderl, Matija Yagi, Yukako TI Deformable image registration between pathological images and MR image via an optical macro image SO PATHOLOGY RESEARCH AND PRACTICE LA English DT Article DE Image registration; Pathological image; Whole slide imaging; MR image; Optical image ID IN-VIVO MRI; HISTOLOGICAL SECTIONS; BRAIN IMAGES; MUTUAL INFORMATION; RECONSTRUCTION; PROSTATE; DEFORMATIONS; METHODOLOGY; SPECIMENS; ACCURATE AB Computed tomography (CT) and magnetic resonance (MR) imaging have been widely used for visualizing the inside of the human body. However, in many cases, pathological diagnosis is conducted through a biopsy or resection of an organ to evaluate the condition of tissues as definitive diagnosis. To provide more advanced information onto CT or MR image, it is necessary to reveal the relationship between tissue information and image signals. We propose a registration scheme for a set of PT images of divided specimens and a 3D-MR image by reference to an optical macro image (OM image) captured by an optical camera. We conducted a fundamental study using a resected human brain after the death of a brain cancer patient. We constructed two kinds of registration processes using the OM image as the base for both registrations to make conversion parameters between the PT and MR images. The aligned PT images had shapes similar to the OM image. On the other hand, the extracted cross-sectional MR image was similar to the OM image. From these resultant conversion parameters, the corresponding region on the PT image could be searched and displayed when an arbitrary pixel on the MR image was selected. The relationship between the PT and MR images of the whole brain can be analyzed using the proposed method. We confirmed that same regions between the PT and MR images could be searched and displayed using resultant information obtained by the proposed method. In terms of the accuracy of proposed method, the TREs were 0.56 +/- 0.39 mm and 0.87 +/- 0.42 mm. We can analyze the relationship between tissue information and MR signals using the proposed method. (C) 2016 The Authors. Published by Elsevier GmbH. C1 [Ohnishi, Takashi; Hashimoto, Noriaki; Haneishi, Hideaki] Chiba Univ, Ctr Frontier Med Engn, Inage Ku, 1-33 Yayoi Cho, Chiba 2638522, Japan. [Nakamura, Yuka; Tanaka, Toru; Tanaka, Takuya] Chiba Univ, Grad Sch Engn, Chiba, Japan. [Batchelor, Tracy T.; Gerstner, Elizabeth R.; Taylor, Jennie W.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02144 USA. [Batchelor, Tracy T.; Gerstner, Elizabeth R.; Taylor, Jennie W.; Yagi, Yukako] Harvard Med Sch, Boston, MA 02215 USA. [Snuderl, Matija] NYU, Langone Med Ctr, New York, NY 10016 USA. [Yagi, Yukako] Massachusetts Gen Hosp, Pathol Imaging & Commun Technol PICT Ctr, Boston, MA 02214 USA. [Taylor, Jennie W.] Univ Calif San Francisco, San Francisco, CA 94143 USA. RP Ohnishi, T (reprint author), Chiba Univ, Ctr Frontier Med Engn, Inage Ku, 1-33 Yayoi Cho, Chiba 2638522, Japan. EM t-ohnishi@chiba-u.jp RI Haneishi, Hideaki/E-4162-2017; OI Haneishi, Hideaki/0000-0001-7157-4309; Snuderl, Matija/0000-0003-0752-0917 FU JSPS [25560189, 15H01105]; National Institutes of Health [R01CA129371, K24CA125440A, K12CA090354] FX This study was partly supported by JSPS Grant-in-Aid for Challenging Exploratory Research, Grant No. 25560189, Grant-in-Aid for Scientific Research on Innovative Areas 15H01105 and National Institutes of Health Grants No. R01CA129371, K24CA125440A (T.T.B.), K12CA090354. NR 35 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER GMBH, URBAN & FISCHER VERLAG PI JENA PA OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY SN 0344-0338 J9 PATHOL RES PRACT JI Pathol. Res. Pract. PY 2016 VL 212 IS 10 BP 927 EP 936 DI 10.1016/j.prp.2016.07.018 PG 10 WC Pathology SC Pathology GA EC3WU UT WOS:000388058600012 PM 27613662 ER PT J AU Ross, SA Caballero, AE Del Prato, S Gallwitz, B Lewis-D'Agostino, D Bailes, Z Thiemann, S Patel, S Woerle, HJ von Eynatten, M AF Ross, Stuart A. Caballero, A. Enrique Del Prato, Stefano Gallwitz, Baptist Lewis-D'Agostino, Diane Bailes, Zelie Thiemann, Sandra Patel, Sanjay Woerle, Hans-Juergen von Eynatten, Maximilian TI Linagliptin plus metformin in patients with newly diagnosed type 2 diabetes and marked hyperglycemia SO POSTGRADUATE MEDICINE LA English DT Article DE Diabetes mellitus type 2; drug therapy combination; metformin; dipeptidyl peptidase 4 inhibitors; linagliptin; clinical trial ID FIXED-DOSE COMBINATION; CLINICAL-PRACTICE; CENTERED APPROACH; MANAGEMENT; MONOTHERAPY; THERAPY; HYPOGLYCEMIA; METAANALYSIS; ASSOCIATION; ADHERENCE AB Objectives: Few studies of oral glucose-lowering drugs exist in newly diagnosed type 2 diabetes (T2D) patients with marked hyperglycemia, and insulin is often proposed as initial treatment. We evaluated the oral initial combination of metformin and linagliptin, a dipeptidyl peptidase-4 inhibitor, in this population.Methods: We performed a pre-specified subgroup analysis of a randomized study in which newly diagnosed T2D patients with glycated hemoglobin A1c (HbA1c) 8.5%-12.0% received linagliptin/metformin or linagliptin monotherapy. Subgroups of baseline HbA1c, age, body-mass index (BMI), renal function, race, and ethnicity were evaluated, with efficacy measured by HbA1c change from baseline after 24weeks.Results: HbA1c reductions from baseline (mean 9.7%) at week 24 in the overall population were an adjusted mean -2.81% 0.12% with linagliptin/metformin (n=132) and -2.02% 0.13% with linagliptin (n=113); treatment difference -0.79% (95% CI -1.13 to -0.46, P<0.0001). In patients with baseline HbA1c 9.5%, HbA1c reduction was -3.37% with linagliptin/metformin (n=76) and -2.53% with linagliptin (n=61); difference -0.84% (95% CI -1.32 to -0.35). In those with baseline HbA1c <9.5%, HbA1c reduction was -2.08% with linagliptin/metformin (n=56) and -1.39% with linagliptin (n=52); difference -0.69% (95% CI -1.23 to -0.15). Changes in HbA1c and treatment differences between the linagliptin/metformin and linagliptin groups were of similar magnitudes to the overall population across patient subgroups based on age, BMI, renal function, and race. Drug-related adverse events occurred in 8.8% and 5.7% of linagliptin/metformin and linagliptin patients, respectively; no severe hypoglycemia occurred.Conclusion: Linagliptin/metformin combination in newly diagnosed T2D patients with marked hyperglycemia was well tolerated and elicited substantial improvements in glycemic control regardless of baseline HbA1c, age, BMI, renal function, or race. Thus, newly diagnosed, markedly hyperglycemic patients may be effectively treated by combinations of oral agents.Clinical trial registration: www.clinicaltrials.gov identifier is NCT01512979 C1 [Ross, Stuart A.] Univ Calgary, LMC Endocrinol Centres, 102-5940 MacLeod Trail SW, Calgary, AB T2H 2G4, Canada. [Caballero, A. Enrique] Harvard Med Sch, Joslin Diabet Ctr, Boston, MA USA. [Del Prato, Stefano] Univ Pisa, Sect Diabet, Dept Endocrinol & Metab, Pisa, Italy. [Gallwitz, Baptist] Univ Klinikum Tubingen, Dept Med 4, Tubingen, Germany. [Lewis-D'Agostino, Diane] Boehringer Ingelheim Pharmaceut Inc, 90 E Ridge POB 368, Ridgefield, CT 06877 USA. [Bailes, Zelie; Patel, Sanjay] Boehringer Ingelheim Ltd, Bracknell, Berks, England. [Thiemann, Sandra; Woerle, Hans-Juergen; von Eynatten, Maximilian] Boehringer Ingelheim Pharma GmbH Co KG, Ingelheim, Germany. [Patel, Sanjay] Daiichi Sankyo Developments Ltd, Gerrards Cross, Bucks, England. RP Ross, SA (reprint author), Univ Calgary, LMC Endocrinol Centres, 102-5940 MacLeod Trail SW, Calgary, AB T2H 2G4, Canada. EM drross@telus.net FU Boehringer Ingelheim; Eli Lilly and Company Diabetes Alliance FX This study was funded by the Boehringer Ingelheim & Eli Lilly and Company Diabetes Alliance. NR 26 TC 0 Z9 0 U1 3 U2 3 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND SN 0032-5481 EI 1941-9260 J9 POSTGRAD MED JI Postgrad. Med. PY 2016 VL 128 IS 8 BP 747 EP 754 DI 10.1080/00325481.2016.1238280 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA EC2GT UT WOS:000387928500004 PM 27684308 ER PT B AU Reeves, AZ Costa, SC Lesser, CF AF Reeves, Analise Z. Costa, Sonia C. Lesser, Cammie F. BE Picking, WD Picking, WL TI Molecular Approaches to Identifying Type 3 Secreted Effectors: a Shigella Case Study SO SHIGELLA: MOLECULAR AND CELLULAR BIOLOGY LA English DT Article; Book Chapter ID INVASION PLASMID ANTIGENS; GRAM-NEGATIVE BACTERIA; FLEXNERI IPA INVASINS; III SECRETION; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; EPITHELIAL-CELLS; SUBSTRATE-SPECIFICITY; VIRULENCE PROTEINS; HOST-CELLS AB Type 3 secretion systems are specialized machines common to plant and animal bacterial pathogens as well as insect endosymbionts that act to deliver tens of proteins directly from bacteria into eukaryotic cells. While protein components of these complex machines are highly conserved, each bacterium delivers its own unique repertoire of proteins, commonly referred to as effectors, into host cells. The function of effectors can be difficult to identify experimentally, as they often act in a functionally redundant manner to mediate specific steps in pathogenesis such that loss of expression of an individual protein does not result in a detectable phenotype. In addition, despite the growing availability of annotated bacterial genome sequences, effectors are challenging to identify via bioinformatic approaches as they have poorly defined secretion sequences and commonly do not share homology with other proteins. Extensive efforts over the past 30-40 years have been extended towards identifying these secreted virulence proteins, and discerning how they act to usurp host cell processes to promote bacterial survival and spread. Here, we provide a historical review of the means by which the currently known 30 Shigella effectors were discovered to illustrate the variety of experimental approaches including genetic, biochemical, functional and bioinformatic based assays that have been used to identify these important virulence factors. C1 [Lesser, Cammie F.] Massachusetts Gen Hosp, Div Infect Dis, Dept Med, Cambridge, MA USA. Harvard Med Sch, Dept Microbiol & Immunobiol, Boston, MA USA. RP Lesser, CF (reprint author), Massachusetts Gen Hosp, Div Infect Dis, Dept Med, Cambridge, MA USA. EM clesser@mgh.harvard.edu NR 64 TC 0 Z9 0 U1 0 U2 0 PU CAISTER ACADEMIC PRESS PI WYMONDHAM PA 32 HEWITTS LANE, WYMONDHAM NR 18 0JA, ENGLAND BN 978-1-910190-19-7 PY 2016 BP 259 EP 275 PG 17 WC Infectious Diseases; Microbiology SC Infectious Diseases; Microbiology GA BG3AY UT WOS:000387832800013 ER PT S AU Ngo, GH Eickhoff, SB Fox, PT Yeo, BTT AF Ngo, Gia H. Eickhoff, Simon B. Fox, Peter T. Yeo, B. T. Thomas GP IEEE TI Collapsed Variational Bayesian Inference of the Author-Topic Model: Application to Large-Scale Coordinate-Based Meta-Analysis SO 2016 6TH INTERNATIONAL WORKSHOP ON PATTERN RECOGNITION IN NEUROIMAGING (PRNI) SE International Workshop on Pattern Recognition in Neuroimaging LA English DT Proceedings Paper CT 6th International Workshop on Pattern Recognition in Neuroimaging (PRNI) CY JUN 22-24, 2016 CL Trento, ITALY SP Fondazione Bruno Kessler, Ctr Mind Brain Sci, Univ Degli Studi Trento, Max Planck Gesellschaft, Informat Math ID FUNCTIONAL ARCHITECTURE; CONNECTIVITY NETWORKS; HUMAN BRAIN; CORTEX AB The author-topic (AT) model has been recently used to discover the relationships between brain regions, cognitive components and behavioral tasks in the human brain. In this work, we propose a novel Collapsed Variational Bayesian (CVB) inference algorithm for the AT model. The proposed algorithm is compared with the Expectation-Maximization (EM) algorithm on the large-scale BrainMap database of brain activation coordinates and behavioral tasks. Experiments suggest that the proposed CVB algorithm produces parameter estimates with better generalization power than the EM algorithm. C1 [Ngo, Gia H.; Yeo, B. T. Thomas] Natl Univ Singapore, Singapore Inst Neurotechnol, Clin Imaging Res Ctr, Dept Elect & Comp Engn, Singapore, Singapore. [Ngo, Gia H.; Yeo, B. T. Thomas] Natl Univ Singapore, Memory Networks Programme, Singapore, Singapore. [Eickhoff, Simon B.] Heinrich Heine Univ Dusseldorf, Inst Clin Neurosci & Med Psychol, Dusseldorf, Germany. [Eickhoff, Simon B.] Res Ctr Julich, Inst Neurosci & Med INM 1, Julich, Germany. [Fox, Peter T.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, San Antonio, TX 78229 USA. [Fox, Peter T.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Ngo, GH (reprint author), Natl Univ Singapore, Singapore Inst Neurotechnol, Clin Imaging Res Ctr, Dept Elect & Comp Engn, Singapore, Singapore.; Ngo, GH (reprint author), Natl Univ Singapore, Memory Networks Programme, Singapore, Singapore. EM ngohgia@u.nus.edu; thomas.yeo@nus.edu.sg NR 20 TC 0 Z9 0 U1 0 U2 0 PU IEEE PI NEW YORK PA 345 E 47TH ST, NEW YORK, NY 10017 USA SN 2330-9989 BN 978-1-4673-6530-7 J9 INT WORKSHOP PATTERN PY 2016 BP 25 EP 28 PG 4 WC Computer Science, Interdisciplinary Applications; Neuroimaging SC Computer Science; Neurosciences & Neurology GA BG1SQ UT WOS:000387080100007 ER PT S AU Obertino, S Roffo, G Granziera, C Menegaz, G AF Obertino, S. Roffo, G. Granziera, C. Menegaz, G. GP IEEE TI INFINITE FEATURE SELECTION ON SHORE-BASED BIOMARKERS REVEALS CONNECTIVITY MODULATION AFTER STROKE SO 2016 6TH INTERNATIONAL WORKSHOP ON PATTERN RECOGNITION IN NEUROIMAGING (PRNI) SE International Workshop on Pattern Recognition in Neuroimaging LA English DT Proceedings Paper CT 6th International Workshop on Pattern Recognition in Neuroimaging (PRNI) CY JUN 22-24, 2016 CL Trento, ITALY SP Fondazione Bruno Kessler, Ctr Mind Brain Sci, Univ Degli Studi Trento, Max Planck Gesellschaft, Informat Math DE Feature Selection; Stroke; 3D-SHORE ID MRI AB Connectomics is gaining increasing interest in the scientific and clinical communities. It consists in deriving models of structural or functional brain connections based on some local measures. Here we focus on structural connectivity as detected by diffusion MRI. Connectivity matrices are derived from microstructural indices obtained by the 3D-SHORE. Typically, graphs are derived from connectivity matrices and used for inferring node properties that allow identifying those nodes that play a prominent role in the network. This information can then be used to detect network modulations induced by diseases. In this paper we take a complementary approach and focus on link as opposed to node properties. We hypothesize that network modulation can be better described by measuring the connectivity alteration directly in the form of modulation of the properties of white matter fiber bundles constituting the network communication backbone. The goal of this paper is to detect the paths that are most altered by the pathology by exploiting a feature selection paradigm. Temporal changes on connection weights are treated as features and those playing a leading role in a patient versus healthy controls classification task are detected by the Infinite Feature Selection (Inf-FS) method. Results show that connection paths with high discriminative power can be identified that are shared by the considered microstructural descriptors allowing a classification accuracy ranging between 8 3 % and 8 9 %. C1 [Obertino, S.; Roffo, G.; Menegaz, G.] Univ Verona, Dept Comp Sci, I-37100 Verona, Italy. [Granziera, C.] Massachusetts Gen Hosp, Martinos Ctr Biomed Imaging, Chalestown, MA USA. [Granziera, C.] Harvard Med Sch, Chalestown, MA USA. RP Obertino, S (reprint author), Univ Verona, Dept Comp Sci, I-37100 Verona, Italy. NR 7 TC 0 Z9 0 U1 0 U2 0 PU IEEE PI NEW YORK PA 345 E 47TH ST, NEW YORK, NY 10017 USA SN 2330-9989 BN 978-1-4673-6530-7 J9 INT WORKSHOP PATTERN PY 2016 BP 85 EP 88 PG 4 WC Computer Science, Interdisciplinary Applications; Neuroimaging SC Computer Science; Neurosciences & Neurology GA BG1SQ UT WOS:000387080100022 ER PT J AU Yaroslavsky, AN Joseph, C Patel, R Fan, B Musikansky, A Neel, VA Giles, R AF Yaroslavsky, Anna N. Joseph, Cecil Patel, Rakesh Fan, Bo Musikansky, Alona Neel, Victor A. Giles, Robert GP IEEE TI Combined Optical and Terahertz Imaging for Intraoperative Delineation of Nonmelanoma Skin Cancers SO 2016 INTERNATIONAL CONFERENCE LASER OPTICS (LO) LA English DT Proceedings Paper CT International Conference Laser Optics (LO) CY JUN 27-JUL 01, 2016 CL St Petersburg, RUSSIA DE Terahertz pulsed imaging; cross-polarized continuous wave terahertz imaging; polarization-enhanced optical imaging; nonmelnoma skin cancers; intraoperative tumor delineation AB Nonmelanoma skin cancers are the major cause of morbidity in fair-skinned population worldwide. We investigated the feasibility of combining terahertz and optical imaging for accurate intraoperative delineation of these cancers. Fresh thick skin excisions were used for the experiments. The tissue was imaged within four hours after surgery. Obtained images were compared to the corresponding histopathology, which was considered a gold standard. The results of the study indicate that combination of cross-polarized continuous wave terahertz imaging and polarized light optical imaging has potential as an intraoperative bedside tool for controlling the completeness of surgical excision. C1 [Yaroslavsky, Anna N.; Joseph, Cecil; Patel, Rakesh; Fan, Bo; Giles, Robert] Univ Massachusetts, Dept Phys & Appl Phys, One Univ Ave, Lowell, MA 01852 USA. [Yaroslavsky, Anna N.; Neel, Victor A.] Massachusetts Gen Hosp, Dept Dermatol, 50 Staniford St, Boston, MA 02114 USA. [Musikansky, Alona] Massachusetts Gen Hosp, Ctr Biostat, 50 Staniford St, Boston, MA 02114 USA. RP Yaroslavsky, AN (reprint author), Univ Massachusetts, Dept Phys & Appl Phys, One Univ Ave, Lowell, MA 01852 USA.; Yaroslavsky, AN (reprint author), Massachusetts Gen Hosp, Dept Dermatol, 50 Staniford St, Boston, MA 02114 USA. NR 1 TC 0 Z9 0 U1 1 U2 1 PU IEEE PI NEW YORK PA 345 E 47TH ST, NEW YORK, NY 10017 USA BN 978-1-4673-9735-3 PY 2016 PG 1 WC Engineering, Electrical & Electronic; Optics SC Engineering; Optics GA BG1QE UT WOS:000386975300356 ER PT S AU Brennan, CA Garrett, WS AF Brennan, Caitlin A. Garrett, Wendy S. BE Gottesman, S TI Gut Microbiota, Inflammation, and Colorectal Cancer SO ANNUAL REVIEW OF MICROBIOLOGY, VOL 70 SE Annual Review of Microbiology LA English DT Review; Book Chapter DE colorectal cancer; inflammation; colitis; mucosal immunology; microbiota/microbiome; Fusobacterium ID INTESTINAL EPITHELIAL-CELLS; REGULATORY T-CELLS; FUSOBACTERIUM-NUCLEATUM; COLON CARCINOGENESIS; MOLECULAR-FEATURES; AFRICAN-AMERICANS; GENE-EXPRESSION; RURAL AFRICANS; IMMUNE CELLS; DNA-DAMAGE AB Colorectal cancer is the second-leading cause of cancer-related deaths in the United States and fourth-leading cause of cancer-related deaths worldwide. While cancer is largely considered to be a disease of genetic and environmental factors, increasing evidence has demonstrated a role for the microbiota (the microorganisms associated with the human body) in shaping inflammatory environments and promoting tumor growth and spread. Herein, we discuss both human data from meta'omics analyses and data from mechanistic studies in cell culture and animal models that support specific bacterial agents as potentiators of tumorigenesis-including Fusobacterium nucleatum, enterotoxigenic Bacteroides fragilis, and colibactin-producing Escherichia coli. Further, we consider how microbes can be used in diagnosing colorectal cancer and manipulating the tumor environment to encourage better patient outcomes in response to immunotherapy treatments. C1 [Brennan, Caitlin A.; Garrett, Wendy S.] Harvard TH Chan Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA. [Brennan, Caitlin A.; Garrett, Wendy S.] Harvard TH Chan Sch Publ Hlth, Dept Genet & Complex Dis, Boston, MA 02115 USA. [Garrett, Wendy S.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Garrett, Wendy S.] Broad Inst Harvard & MIT, Canc Program, Cambridge, MA 02142 USA. [Garrett, Wendy S.] Harvard Med Sch, Dept Med, Boston, MA 02115 USA. RP Brennan, CA (reprint author), Harvard TH Chan Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA.; Brennan, CA (reprint author), Harvard TH Chan Sch Publ Hlth, Dept Genet & Complex Dis, Boston, MA 02115 USA. EM brennan@hsph.harvard.edu; wgarrett@hsph.harvard.edu NR 98 TC 3 Z9 3 U1 12 U2 13 PU ANNUAL REVIEWS PI PALO ALTO PA 4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0897 USA SN 0066-4227 BN 978-0-8243-1170-4 J9 ANNU REV MICROBIOL JI Annu. Rev. Microbiol. PY 2016 VL 70 BP 395 EP 411 DI 10.1146/annurev-micro-102215-095513 PG 17 WC Microbiology SC Microbiology GA BF6HF UT WOS:000383052200022 PM 27607555 ER PT J AU DiPasquale, DM Strangman, GE Harris, NS Muza, SR AF DiPasquale, Dana M. Strangman, Gary E. Harris, N. Stuart Muza, Stephen R. TI Acute Mountain Sickness Symptoms Depend on Normobaric versus Hypobaric Hypoxia SO BIOMED RESEARCH INTERNATIONAL LA English DT Article ID SIMULATED ALTITUDE; EXERCISE DURATION; VENTILATION; QUESTIONNAIRE; SEVERITY AB Acute mountain sickness (AMS), characterized by headache, nausea, fatigue, and dizziness when unacclimatized individuals rapidly ascend to high altitude, is exacerbated by exercise and can be disabling. Although AMS is observed in both normobaric (NH) and hypobaric hypoxia (IIII), recent evidence suggests that NH and HH produce different physiological responses. We evaluated whether AMS symptoms were different in NH and HH during the initial stages of exposure and if the assessment tool mattered. Seventy-two 8 h exposures to normobaric normoxia (NN), NH, or HH were experienced by 36 subjects. The Environmental Symptoms Questionnaire (ESQ) and Lake Louise Self-report (LLS) were administered, resulting in a total of 360 assessments, with each subject answering the questionnaire 5 times during each of their 2 exposure days. Classification tree analysis indicated that symptoms contributing most to AMS were different in NH (namely, feeling sick and shortness of breath) compared to HH (characterized most by feeling faint, appetite loss, light headedness, and dim vision). However, the differences were not detected using the LLS. These results suggest that during the initial hours of exposure (1) AMS in HH may be a qualitatively different experience than in NH and (2) NH and HH may not be interchangeable environments. C1 [DiPasquale, Dana M.; Strangman, Gary E.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Psychiat, Charlestown, MA 02129 USA. [Harris, N. Stuart] Harvard Med Sch, Massachusetts Gen Hosp, Div Wilderness Med, Dept Emergency Med, Boston, MA USA. [Muza, Stephen R.] US Army, Environm Med Res Inst, Thermal & Mt Med Div, Natick, MA 01760 USA. RP DiPasquale, DM (reprint author), Harvard Med Sch, Massachusetts Gen Hosp, Dept Psychiat, Charlestown, MA 02129 USA. EM dipasquale.dana@gmail.com FU DOD CDMRP program; [W81-XWH1020199] FX The authors gratefully acknowledge the support of the DOD CDMRP program and grant W81-XWH1020199. They also thank the following individuals for their assistance: Andrea Gunn, Janet Staab, Chuck Fulco, Beth Beidleman, Ingrid Sills, Vincent Forte, Marie Grunbeck, Sean Andrew, Katylin Guerriere, and Myra Jones. NR 25 TC 1 Z9 1 U1 1 U2 1 PU HINDAWI PUBLISHING CORP PI NEW YORK PA 315 MADISON AVE 3RD FLR, STE 3070, NEW YORK, NY 10017 USA SN 2314-6133 EI 2314-6141 J9 BIOMED RES INT JI Biomed Res. Int. PY 2016 AR 6245609 DI 10.1155/2016/6245609 PG 9 WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental SC Biotechnology & Applied Microbiology; Research & Experimental Medicine GA EB5DD UT WOS:000387392700001 ER PT S AU Miyabe, Y Kim, ND Miyabe, C Luster, AD AF Miyabe, Yoshishige Kim, Nancy D. Miyabe, Chie Luster, Andrew D. BE Jin, T Hereld, D TI Studying Neutrophil Migration In Vivo Using Adoptive Cell Transfer SO CHEMOTAXIS: METHODS AND PROTOCOLS SE Methods in Molecular Biology LA English DT Article; Book Chapter DE Neutrophil; Adoptive transfer; Arthritis ID ARTHRITIS; RECRUITMENT; MACROPHAGES; INHIBITION; CHEMOKINES AB Adoptive cell transfer experiments can be used to study the roles of cell trafficking molecules on the migratory behavior of specific immune cell populations in vivo. Chemoattractants and their G protein-coupled seven-transmembrane-spanning receptors regulate migration of cells in vivo, and dysregulated expression of chemoattractants and their receptors is implicated in autoimmune and inflammatory diseases. Inflammatory arthritides, such as rheumatoid arthritis ( RA), are characterized by the recruitment of inflammatory cells into joints. The K/BxN serum transfer mouse model of inflammatory arthritis shares many similar features with RA. In this autoantibody-induced model of arthritis, neutrophils are the critical immune cells necessary for the development of joint inflammation and damage. We have used adoptive neutrophil transfer to define the contributions of chemoattractant receptors, cytokines, and activation receptors expressed on neutrophils that critically regulate their entry into the inflamed joint. In this review, we describe the procedure of neutrophil adoptive transfer to study the influence of neutrophil-specific receptors or mediators upon the their recruitment into the joint using the K/BxN model of inflammatory arthritis as a model of how adoptive cell transfer studies can be used to study immune cell migration in vivo. C1 [Miyabe, Yoshishige; Kim, Nancy D.; Miyabe, Chie; Luster, Andrew D.] Harvard Med Sch, Massachusetts Gen Hosp, Ctr Immunol & Inflammatory Dis, Div Rheumatol Allergy & Immunol, Boston, MA 02115 USA. RP Miyabe, Y (reprint author), Harvard Med Sch, Massachusetts Gen Hosp, Ctr Immunol & Inflammatory Dis, Div Rheumatol Allergy & Immunol, Boston, MA 02115 USA. NR 19 TC 0 Z9 0 U1 1 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES SN 1064-3745 BN 978-1-4939-3480-5; 978-1-4939-3478-2 J9 METHODS MOL BIOL JI Methods Mol. Biol. PY 2016 VL 1407 BP 179 EP 194 DI 10.1007/978-1-4939-3480-5_14 D2 10.1007/978-1-4939-3480-5 PG 16 WC Biochemical Research Methods; Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA BG2YO UT WOS:000387780000015 PM 27271903 ER PT J AU Sharma, HS Muresanu, DF Lafuente, JV Nozari, A Patnaik, R Skaper, SD Sharma, A AF Sharma, Hari Shanker Muresanu, Dafin F. Lafuente, Jose V. Nozari, Ala Patnaik, Ranjana Skaper, Stephen D. Sharma, Aruna TI Pathophysiology of Blood-Brain Barrier in Brain Injury in Cold and Hot Environments: Novel Drug Targets for Neuroprotection SO CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS LA English DT Review DE Ambient temperature; blood-brain barrier; blunt head injury; brain edema; brain pathology; cognitive dysfunction; cold exposure; concussion; cortical injury; drug therapy; hot environment; penetrating brain injury; seasonal variations; traumatic brain injury ID NITRIC-OXIDE SYNTHASE; SPINAL-CORD-INJURY; CLOSED-HEAD INJURY; ANTIOXIDANT COMPOUND H-290/51; CENTRAL-NERVOUS-SYSTEM; MICROVASCULAR PERMEABILITY DISTURBANCES; FINE-STRUCTURAL LOCALIZATION; CORTICAL HISTAMINE LEVELS; NORMOTENSIVE YOUNG-RATS; INDUCED EDEMA FORMATION AB The blood-brain barrier (BBB) plays a pivotal role in the maintenance of central nervous system function in health and disease. Thus, in almost all neurodegenerative, traumatic or metabolic insults BBB breakdown occurs, allowing entry of serum proteins into the brain fluid microenvironment with subsequent edema formation and cellular injury. Accordingly, pharmacological restoration of BBB function will lead to neurorepair. However, brain injury which occurs following blast, bullet wounds, or knife injury appears to initiate different sets of pathophysiological responses. Moreover, other local factors at the time of injury such as cold or elevated ambient temperatures could also impact the final outcome. Obviously, drug therapy applied to different kinds of brain trauma occurring at either cold or hot environments may respond differently. This is largely due to the fact that internal defense mechanisms of the brain, gene expression, release of neurochemicals and binding of drugs to specific receptors are affected by external ambient temperature changes. These factors may also affect BBB function and development of edema formation after brain injury. In this review, the effects of seasonal exposure to heat and cold on traumatic brain injury using different models i.e., concussive brain injury and cerebral cortical lesion, on BBB dysfunction in relation to drug therapy are discussed. Our observations clearly suggest that closed head injury and open brain injury are two different entities and the external hot or cold environments affect both of them remarkably. Thus, effective pharmacological therapeutic strategies should be designed with these views in mind, as military personnel often experience blunt or penetrating head injuries in either cold or hot environments. C1 [Sharma, Hari Shanker; Sharma, Aruna] Uppsala Univ, Univ Uppsala Hosp, Dept Surg Sci Anesthesiol & Intens Care Med, SE-75185 Uppsala, Sweden. [Muresanu, Dafin F.] Univ Med Pharm, Dept Clin Neurosci, Cluj Napoca, Romania. [Muresanu, Dafin F.] RoNeuro Inst Neurol Res & Diagnost, 37 Mircea Eliade St, Cluj Napoca 400364, Romania. [Lafuente, Jose V.] Univ Basque Country, UPV EHU, Dept Neurosci, Lab Clin & Expt Neurosci LaNCE, Leioa, Bizkaia, Spain. [Lafuente, Jose V.] Univ Autonoma Chile, Fac Hlth Sci, Santiago, Chile. [Nozari, Ala] Harvard Univ, Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, 55 Fruit St, Boston, MA 02114 USA. [Patnaik, Ranjana] Banaras Hindu Univ, Indian Inst Technol, Sch Biomed Engn, Dept Biomat, Varanasi 221005, Uttar Pradesh, India. [Skaper, Stephen D.] Univ Padua, Dept Pharmaceut & Pharmacol Sci, Largo Egidio Meneghetti 2, I-35131 Padua, Italy. RP Sharma, HS (reprint author), Uppsala Univ, Univ Uppsala Hosp, Dept Surg Sci Anesthesiol & Intens Care Med, SE-75185 Uppsala, Sweden. EM Sharma@surgsci.uu.se FU Air Force Office of Scientific Research (EOARD, London, UK); Air Force Material Command, USAF [FA8655-05-1-3065]; Laerdal Foundation of Acute medicine, Stavanger, Norway; Swedish Medical Research Council [2710-HSS]; Goran Gustafsson Foundation, Stockholm, Sweden; Astra Zeneca, Molndal, Sweden; University Grants Commission, New Delhi, India; Ministry of Science & Technology, Govt. of India; Indian Medical Research Council, New Delhi, India; India-EU Co-operation Program [IT 794/13]; Government of Basque Country; University of Basque Country, Spain [UFI 11/32]; Society for Neuroprotection and Neuroplasticity (SSNN), Romania FX Supported by grants from the Air Force Office of Scientific Research (EOARD, London, UK), and Air Force Material Command, USAF, under grant number FA8655-05-1-3065; Laerdal Foundation of Acute medicine, Stavanger, Norway (HSS); Swedish Medical Research Council (Nr 2710-HSS), Goran Gustafsson Foundation, Stockholm, Sweden (HSS), Astra Zeneca, Molndal, Sweden (HSS/AS), The University Grants Commission, New Delhi, India (HSS/AS), Ministry of Science & Technology, Govt. of India (HSS/AS), Indian Medical Research Council, New Delhi, India (HSS/AS) and India-EU Co-operation Program (RP/AS/HSS) and IT 794/13 (JVL), Government of Basque Country and UFI 11/32 (JVL) University of Basque Country, Spain, & Society for Neuroprotection and Neuroplasticity (SSNN), Romania. The U. S. Government is authorized to reproduce and distribute reprints for Government purpose notwithstanding any copyright notation thereon. The views and conclusions contained herein are those of the authors and should not be interpreted as necessarily representing the official policies or endorsements, either expressed or implied, of the Air Force Office of Scientific Research or the U. S. Government. We thank Suraj Sharma (Uppsala) for graphic and artwork support. NR 267 TC 1 Z9 1 U1 5 U2 5 PU BENTHAM SCIENCE PUBL PI BUSUM PA PO BOX 294, BUSUM, 1400 AG, NETHERLANDS SN 1871-5273 EI 1996-3181 J9 CNS NEUROL DISORD-DR JI CNS Neurol. Disord.-Drug Targets PY 2016 VL 15 IS 9 BP 1045 EP 1071 DI 10.2174/1871527315666160902145145 PG 27 WC Neurosciences; Pharmacology & Pharmacy SC Neurosciences & Neurology; Pharmacology & Pharmacy GA EB1PJ UT WOS:000387125600005 PM 27592625 ER PT J AU Li, JY Shen, J Wang, KZ Hornicek, F Duan, ZF AF Li, Jingyuan Shen, Jacson Wang, Kunzheng Hornicek, Francis Duan, Zhenfeng TI The Roles of Sox Family Genes in Sarcoma SO CURRENT DRUG TARGETS LA English DT Review DE Sox family genes; sarcoma; pagthogenesis; targeted therapy ID CLEAR-CELL CHONDROSARCOMA; TRANSCRIPTION FACTOR SOX9; STEM-LIKE CHARACTERISTICS; AUTOSOMAL SEX REVERSAL; SRY-RELATED GENE; SYNOVIAL SARCOMA; SOFT-TISSUE; EWINGS-SARCOMA; DEDIFFERENTIATED CHONDROSARCOMA; OSTEOBLAST DIFFERENTIATION AB Sox (SRY-related HMG-box) family genes are important regulators of cell development, homeostasis, and regeneration. Deregulation of certain members of the Sox gene family has been implicated in a number of human malignancies, including in sarcoma. Accumulating evidence suggests that Sox genes play crucial roles in sarcoma cell pathogenesis, growth, and proliferation. Here, we review the biological relevance of Sox2 and Sox9 genes in osteosarcoma, chondrosarcoma and chordoma; Sox2, Sox6, and Sox17 genes in Ewing's sarcoma; Sox2, Sox9, and Sox10 genes in synovial sarcoma; Sox2 gene in fibrosarcoma; and Sox21 gene in liposarcoma. These findings potentiate the targeting of Sox genes for novel therapeutic interventions in sarcoma and may also hold valuable clinical potential to improve the care of patients with sarcoma. C1 [Li, Jingyuan; Shen, Jacson; Hornicek, Francis; Duan, Zhenfeng] Harvard Med Sch, Massachusetts Gen Hosp, Ctr Sarcoma & Connect Tissue Oncol, Sarcoma Biol Lab, Boston, MA USA. [Li, Jingyuan] Xi An Jiao Tong Univ, Xian Honghui Hosp, Hlth Sci Ctr, Dept Orthopaed, Xian, Shaanxi, Peoples R China. [Wang, Kunzheng] Xi An Jiao Tong Univ, Affiliated Hosp 2, Dept Orthopaed, Xian, Shaanxi, Peoples R China. RP Duan, ZF (reprint author), Massachusetts Gen Hosp, Ctr Sarcoma & Connect Tissue Oncol, Sarcoma Biol Lab, 100 Blossom St Jackson 1115, Boston, MA 02114 USA. EM zduan@mgh.harvard.edu FU Gattegno and Wechsler funds; Kenneth Stanton Fund; Jeff Guyer Fund; Sarcoma Foundation of America (SFA); National Cancer Institute (NCI)/National Institutes of Health (NIH) [UO1, CA 151452-01]; Sarcoma SPORE/NIH; Academic Enrichment Fund of MGH Orthopaedics; China Scholarship Council FX This work was supported, in part, by the Gattegno and Wechsler funds, the Kenneth Stanton Fund, a grant from the Jeff Guyer Fund. Dr. Duan is supported, in part, through a grant from Sarcoma Foundation of America (SFA), a grant from National Cancer Institute (NCI)/National Institutes of Health (NIH), UO1, CA 151452-01, a pilot grant from Sarcoma SPORE/NIH, and a grant from an Academic Enrichment Fund of MGH Orthopaedics. Dr. Li is supported by scholarship from China Scholarship Council. NR 132 TC 0 Z9 0 U1 0 U2 0 PU BENTHAM SCIENCE PUBL LTD PI SHARJAH PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES SN 1389-4501 EI 1873-5592 J9 CURR DRUG TARGETS JI Curr. Drug Targets PY 2016 VL 17 IS 15 BP 1761 EP 1772 DI 10.2174/1389450117666160502145311 PG 12 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA EB1DN UT WOS:000387087300008 PM 27138764 ER PT J AU Morrow, JD Cho, MH Hersh, CP Pinto-Plata, V Celli, B Marchetti, N Criner, G Bueno, R Washko, G Glass, K Choi, AMK Quackenbush, J Silverman, EK DeMeo, DL AF Morrow, Jarrett D. Cho, Michael H. Hersh, Craig P. Pinto-Plata, Victor Celli, Bartolome Marchetti, Nathaniel Criner, Gerard Bueno, Raphael Washko, George Glass, Kimberly Choi, Augustine M. K. Quackenbush, John Silverman, Edwin K. DeMeo, Dawn L. TI DNA methylation profiling in human lung tissue identifies genes associated with COPD SO EPIGENETICS LA English DT Article DE Chronic obstructive pulmonary disease; DNA methylation profiling; epigenetics ID GENOME-WIDE ASSOCIATION; OBSTRUCTIVE PULMONARY-DISEASE; MICROARRAY DATA; ILLUMINA MICROARRAY; NICOTINE DEPENDENCE; SUSCEPTIBILITY; EXPRESSION; ASTHMA; MODIFIER; REVEALS AB Chronic obstructive pulmonary disease (COPD) is a smoking-related disease characterized by genetic and phenotypic heterogeneity. Although association studies have identified multiple genomic regions with replicated associations to COPD, genetic variation only partially explains the susceptibility to lung disease, and suggests the relevance of epigenetic investigations. We performed genome-wide DNA methylation profiling in homogenized lung tissue samples from 46 control subjects with normal lung function and 114 subjects with COPD, all former smokers. The differentially methylated loci were integrated with previous genome-wide association study results. The top 535 differentially methylated sites, filtered for a minimum mean methylation difference of 5% between cases and controls, were enriched for CpG shelves and shores. Pathway analysis revealed enrichment for transcription factors. The top differentially methylated sites from the intersection with previous GWAS were in CHRM1, GLT1D1, and C10orf11; sorted by GWAS P-value, the top sites included FRMD4A, THSD4, and C10orf11. Epigenetic association studies complement genetic association studies to identify genes potentially involved in COPD pathogenesis. Enrichment for genes implicated in asthma and lung function and for transcription factors suggests the potential pathogenic relevance of genes identified through differential methylation and the intersection with a broader range of GWAS associations. C1 [Morrow, Jarrett D.; Cho, Michael H.; Hersh, Craig P.; Glass, Kimberly; Silverman, Edwin K.; DeMeo, Dawn L.] Brigham & Womens Hosp, Channing Div Network Med, 75 Francis St, Boston, MA 02115 USA. [Cho, Michael H.; Hersh, Craig P.; Celli, Bartolome; Washko, George; Silverman, Edwin K.; DeMeo, Dawn L.] Brigham & Womens Hosp, Div Pulm & Crit Care Med, Boston, MA 02115 USA. [Pinto-Plata, Victor] Baystate Hlth, Springfield, MA USA. [Marchetti, Nathaniel; Criner, Gerard] Temple Univ, Div Pulm & Crit Care Med, Philadelphia, PA 19122 USA. [Bueno, Raphael] Brigham & Womens Hosp, Div Thorac Surg, Boston, MA 02115 USA. [Choi, Augustine M. K.] New York Presbyterian Weill Cornell Med Ctr, Dept Med, New York, NY USA. [Quackenbush, John] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. RP Morrow, JD (reprint author), Brigham & Womens Hosp, Channing Div Network Med, 75 Francis St, Boston, MA 02115 USA. EM remdj@channing.harvard.edu FU NIH [P01 HL105339, R01 HL111759, P01 HL114501, NCT00608764]; COPD Foundation; NHLBI [N01HR76101, N01HR76102, N01HR76103, N01HR76104, N01HR76105, N01HR76106, N01HR76107, N01HR76108, 465 N01HR76109, N01HR76110, N01HR76111, N01HR76112, N01HR76113, N01HR76114, N01HR76115, N01HR76116, N01HR76118, N01HR76119]; Centers for Medicare and Medicaid Services; Agency for Healthcare Research and Quality; Cooperative Studies Program/ERIC of the US 470 Department of Veterans Affairs; Massachusetts Veterans Epidemiology Research and Information Center (MAVERIC) FX NIH grants P01 HL105339, R01 HL111759, P01 HL114501. The COPDGene study (R01HL089856 and R01 HL089897). (NCT00608764) was funded by the National Institutes of Health is also sup- 460 ported by the COPD Foundation through contributions made to an Industry Advisory Board comprised of AstraZeneca, Boehringer Ingelheim, Novartis, Pfizer, Siemens, GSK and Sunovion. The National Emphysema Treatment Trial was supported by the NHLBI N01HR76101, N01HR76102, N01HR76103, N01HR76104, N01HR76105, N01HR76106, N01HR76107, N01HR76108, 465 N01HR76109, N01HR76110, N01HR76111, N01HR76112, N01HR76113, N01HR76114, N01HR76115, N01HR76116, N01HR76118 and N01HR76119, the Centers for Medicare and Medicaid Services and the Agency for Healthcare Research and Quality. The Normative Aging Study is supported by the Cooperative Studies Program/ERIC of the US 470 Department of Veterans Affairs and is a component of the Massachusetts Veterans Epidemiology Research and Information Center (MAVERIC). The Norway GenKOLS study (Genetics of Chronic Obstructive Lung Disease, GSK code RES11080), the ECLIPSE study (NCT00292552; GSK code SCO104960), and the ICGN study were funded by GlaxoSmithKline. NR 52 TC 0 Z9 0 U1 0 U2 0 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 1559-2294 EI 1559-2308 J9 EPIGENETICS-US JI Epigenetics PY 2016 VL 11 IS 10 BP 730 EP 739 DI 10.1080/15592294.2016.1226451 PG 10 WC Biochemistry & Molecular Biology; Genetics & Heredity SC Biochemistry & Molecular Biology; Genetics & Heredity GA EB3UM UT WOS:000387293900003 ER PT J AU Khorasanizadeh, M Eskian, M Assa'ad, AH Camargo, CA Rezaei, N AF Khorasanizadeh, MirHojjat Eskian, Mahsa Assa'ad, Amal H. Camargo, Carlos A., Jr. Rezaei, Nima TI Efficacy and Safety of Benralizumab, a Monoclonal Antibody against IL-5R, in Uncontrolled Eosinophilic Asthma SO INTERNATIONAL REVIEWS OF IMMUNOLOGY LA English DT Review DE asthma; benralizumab; inflammation; interleukin-5; monoclonal antibody ID OBSTRUCTIVE PULMONARY-DISEASE; DEPENDENT CELLULAR CYTOTOXICITY; RANDOMIZED CONTROLLED-TRIAL; MESSENGER-RNA EXPRESSION; RECEPTOR-ALPHA CHAIN; SPUTUM EOSINOPHILIA; AIRWAY EOSINOPHILS; PERSISTENT ASTHMA; BLOOD EOSINOPHILS; ATOPIC ASTHMATICS AB Nonresponders to maximal guideline-based therapies of asthma account for most of the morbidity, mortality, and economic burden of the disease. Because eosinophils are key effector cells in asthmatic airway inflammation, blocking IL-5, the main cytokine responsible for its survival and activation, seems to be a rational strategy. While previous monoclonal antibodies against the IL-5 ligand resulted in inconsistent improvements in asthma outcomes, benralizumab has shown promise. Benralizumab is a monoclonal antibody against IL-5 receptor, and has an enhanced antibody dependent cell-mediated cytotoxicity function. In this article, we review the theoretical advantages of benralizumab compared to previous compounds, as well as current status of the clinical development of benralizumab in asthma. Lastly, we briefly discuss the potential role of benralizumab in chronic obstructive pulmonary disease. C1 [Khorasanizadeh, MirHojjat; Eskian, Mahsa; Rezaei, Nima] Univ Tehran Med Sci, Res Ctr Immunodeficiencies, Childrens Med Ctr, Tehran, Iran. [Assa'ad, Amal H.] Cincinnati Childrens Med Ctr, Div Allergy & Immunol, Cincinnati, OH USA. [Camargo, Carlos A., Jr.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA USA. [Camargo, Carlos A., Jr.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Med, Div Rheumatol Allergy & Immunol, Boston, MA USA. [Rezaei, Nima] Univ Tehran Med Sci, Sch Med, Mol Immunol Res Ctr, Tehran, Iran. [Rezaei, Nima] Univ Tehran Med Sci, Sch Med, Dept Immunol, Tehran, Iran. [Rezaei, Nima] USERN, NIIMA, Tehran, Iran. RP Rezaei, N (reprint author), Childrens Med Ctr Hosp, Res Ctr Immunodeficiencies, Dr Qarib St,Keshavarz Blvd, Tehran 14194, Iran. EM rezaei_nima@tums.ac.ir NR 70 TC 2 Z9 2 U1 0 U2 0 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 0883-0185 EI 1563-5244 J9 INT REV IMMUNOL JI Int. Rev. Immunol. PY 2016 VL 35 IS 4 BP 294 EP 311 DI 10.3109/08830185.2015.1128901 PG 18 WC Immunology SC Immunology GA EB6GE UT WOS:000387478900002 PM 27119985 ER PT J AU Huang, IC Cheing, G Rumrill, P Bengtson, K Chan, F Telzlaff, J Snitker, M AF Huang, I-Chun Cheing, Gladys Rumrill, Philip Bengtson, Kevin Chan, Fong Telzlaff, Jana Snitker, Mikael TI Characteristics of people with disabilities receiving assistive technology services in vocational rehabilitation: A logistic regression analysis SO JOURNAL OF VOCATIONAL REHABILITATION LA English DT Article DE Assistive technology; people with disabilities; vocational rehabilitation AB BACKGROUND: The provision of assistive technology (AT) services could help people with disabilities overcome social and environmental barriers in the workplace to facilitate employment outcomes. However, little is known about the types of consumers who receive assistive technology services and who can most benefit from the services in vocational rehabilitation (VR). OBJECTIVE: This study investigated the characteristics of consumers receiving AT services in state VR agencies and identified complementary VR services associated with the provision of AT services. METHODS: A 10% random sample of VR consumers (N=32,088) whose cases were closed in fiscal year 2009 (FY 2009) were extracted from the Rehabilitation Services Administration (RSA) database for a secondary data analysis multivariate logistic regression. RESULTS: Only 10.4% of VR consumers closed in FY 2009 received AT services. The majority of AT recipients reported sensory impairments (60.4%) and physical impairments (27.6%). Consumers older than 65 years of age (odds ratio [OR]=1.43; 95% confidence intervals [CI]: 1.18-1.74), with associate's degrees (OR=1.27; 95% CI: 1.15-1.41) and bachelor's degrees or higher (OR=1.77; 95% CI: 1.55-2.01), reporting sensory impairments (OR=3.78; 95% CI: 3.39-4.21), receiving cash benefits (OR=1.44; 95% CI: 1.29-1.60) and being employed at the time of application (OR=1.79; 95% CI: 1.62-1.98) were more likely to receive AT services. Compared to European Americans, African American (OR=0.77; 95% CI: 0.69-0.87) and Hispanic Americans (OR=0.84; 95% CI: 0.73-0.98) were less likely to receive AT services. Moreover, AT recipients were more likely to also obtain comprehensive assessment (OR=1.49; 95% CI: 1.38 to 1.66), college or university training (OR=1.56; 95% CI: 1.38 to 1.76), occupational or vocational training (OR=1.20; 95% CI: 1.05 to 1.37), augmentative skills training (OR=2.48; 95% CI: 2.09 to 2.94), and miscellaneous training (OR=1.47; 95% CI: 1.30 to 1.66); but less likely to obtain job readiness training (OR=0.75; 95% CI: 0.64 to 0.87) and job search assistance (OR=0.87; 95% CI: 0.76 to 0.99). CONCLUSION: The results provide insights into AT recipients in the state VR system. VR professionals and practitioners need to be aware of AT devices and job accommodation services as resources for people with disabilities to increase employability. Further consideration should be given to developing a systematic understanding of the provision of AT services in the VR system and evaluating its effectiveness. C1 [Huang, I-Chun] Natl Changhua Univ Educ, Changhua, Taiwan. [Cheing, Gladys] Hong Kong Polytech Univ, Hong Kong, Hong Kong, Peoples R China. [Rumrill, Philip] Kent State Univ, Kent, OH 44242 USA. [Bengtson, Kevin; Chan, Fong; Telzlaff, Jana] Univ Wisconsin, Madison, WI USA. [Snitker, Mikael] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. RP Huang, IC (reprint author), Natl Changhua Univ Educ, Grad Inst Rehabil Counseling, 1 Jin De Rd, Changhua 500, Taiwan. EM ichunhuang@cc.ncue.edu.tw NR 16 TC 1 Z9 1 U1 1 U2 1 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1052-2263 EI 1878-6316 J9 J VOCAT REHABIL JI J. Vocat. Rehabil. PY 2016 VL 45 IS 1 BP 63 EP 72 DI 10.3233/JVR-160811 PG 10 WC Rehabilitation SC Rehabilitation GA EB7NJ UT WOS:000387574300007 ER PT S AU Andreasen, D Edmund, JM Zografos, V Menze, BH Van Leemput, K AF Andreasen, Daniel Edmund, Jens M. Zografos, Vasileios Menze, Bjoern H. Van Leemput, Koen BE Styner, MA Angelini, ED TI Computed Tomography synthesis from Magnetic Resonance images in the pelvis using multiple Random Forests and Auto-Context features SO MEDICAL IMAGING 2016: IMAGE PROCESSING SE Proceedings of SPIE LA English DT Proceedings Paper CT Conference on Medical Imaging - Image Processing CY MAR 01-03, 2016 CL San Diego, CA SP SPIE, Modus Med Devices Inc, Bruker, Poco Graphite, imXPAD DE radiotherapy; magnetic resonance imaging; pseudo CT; CT synthesis; random forest; auto-context ID MRI-ONLY RADIOTHERAPY; ULTRASHORT ECHO TIME; ATTENUATION CORRECTION; BRAIN; SEQUENCES; PET/MRI; CT; REGISTRATION; SCALE AB In radiotherapy treatment planning that is only based on magnetic resonance imaging (MRI), the electron density information usually obtained from computed tomography (CT) must be derived from the MRI by synthesizing a so-called pseudo CT (pCT). This is a non-trivial task since MRI intensities are neither uniquely nor quantitatively related to electron density. Typical approaches involve either a classification or regression model requiring specialized MRI sequences to solve intensity ambiguities, or an atlas-based model necessitating multiple registrations between atlases and subject scans. In this work, we explore a machine learning approach for creating a pCT of the pelvic region from conventional MRI sequences without using atlases. We use a random forest provided with information about local texture, edges and spatial features derived from the MRI. This helps to solve intensity ambiguities. Furthermore, we use the concept of auto-context by sequentially training a number of classification forests to create and improve context features, which are finally used to train a regression forest for pCT prediction. We evaluate the pCT quality in terms of the voxel-wise error and the radiologic accuracy as measured by water-equivalent path lengths. We compare the performance of our method against two baseline pCT strategies, which either set all MRI voxels in the subject equal to the CT value of water, or in addition transfer the bone volume from the real CT. We show an improved performance compared to both baseline pCTs suggesting that our method may be useful for MRI-only radiotherapy. C1 [Andreasen, Daniel; Van Leemput, Koen] Tech Univ Denmark, Dept Appl Math & Comp Sci, Lyngby, Denmark. [Andreasen, Daniel; Edmund, Jens M.] Univ Copenhagen, Gentofte & Herlev Hosp, Dept Oncol, Radiotherapy Res Unit, Herlev, Denmark. [Zografos, Vasileios; Menze, Bjoern H.] Tech Univ Munich, Dept Comp Sci, Munich, Germany. [Van Leemput, Koen] Harvard Med Sch, Massachusetts Gen Hosp, AA Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA. RP Andreasen, D (reprint author), Tech Univ Denmark, Dept Appl Math & Comp Sci, Lyngby, Denmark.; Andreasen, D (reprint author), Univ Copenhagen, Gentofte & Herlev Hosp, Dept Oncol, Radiotherapy Res Unit, Herlev, Denmark. EM dana@dtu.dk NR 31 TC 1 Z9 1 U1 0 U2 0 PU SPIE-INT SOC OPTICAL ENGINEERING PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA SN 0277-786X BN 978-1-5106-0019-5 J9 PROC SPIE PY 2016 VL 9784 AR 978417 DI 10.1117/12.2216924 PG 8 WC Optics; Radiology, Nuclear Medicine & Medical Imaging SC Optics; Radiology, Nuclear Medicine & Medical Imaging GA BF5NM UT WOS:000382313300041 ER PT S AU Han, YS Jin, KH Kim, K Ye, JC AF Han, Yo Seob Jin, Kyong Hwan Kim, Kyungsang Ye, Jong Chul GP IEEE TI SPARSE-VIEW X-RAY SPECTRAL CT RECONSTRUCTION USING ANNIHILATING FILTER-BASED LOW RANK HANKEL MATRIX APPROACH SO 2016 IEEE 13TH INTERNATIONAL SYMPOSIUM ON BIOMEDICAL IMAGING (ISBI) SE IEEE International Symposium on Biomedical Imaging LA English DT Proceedings Paper CT IEEE 13th International Symposium on Biomedical Imaging (ISBI) CY APR 13-16, 2016 CL Prague, CZECH REPUBLIC SP IEEE, EMB, IEEE Signal Proc Soc, Amer Elements DE spectral computed tomography (CT); sparse-view; X-ray CT; annihilating filter; low rank Hankel matrix AB In a kVp switching-based sparse view spectral CT, each spectral image cannot be reconstructed separably by an analytic reconstruction method, because the projection views for each spectral band is too sparse. However, the underlying structure is common between the spectral bands, so there exists inter-spectral redundancies that can be exploited by the recently proposed annihilating filter-based low rank Hankel matrix approach (ALOHA). More specifically, the sparse view projection data are first rebinned in the Fourier space, from which Hankel structured matrix with missing elements are constructed for each spectral band. Thanks to the inter-spectral correlations as well as transform domain sparsity of underlying images, the concatenated Hankel structured matrix is low-ranked, and the missing Fourier data for each spectral band can be simultaneously estimated using a low rank matrix completion. To reduce the computational complexity furthermore, we exploit the Hermitian symmetry of Fourier data. Numerical experiments confirm that the proposed method outperforms the existing ones. C1 [Han, Yo Seob; Jin, Kyong Hwan; Ye, Jong Chul] Korea Adv Inst Sci & Technol, Bioimaging & Signal Proc Lab BISPL, Dept Bio & Brain Engn, Daejeon, South Korea. [Kim, Kyungsang] Massachusetts Gen Hosp, Ctr Adv Med Imaging Sci, Boston, MA 02114 USA. [Kim, Kyungsang] Harvard Med Sch, Boston, MA USA. RP Han, YS (reprint author), Korea Adv Inst Sci & Technol, Bioimaging & Signal Proc Lab BISPL, Dept Bio & Brain Engn, Daejeon, South Korea. NR 6 TC 0 Z9 0 U1 0 U2 0 PU IEEE PI NEW YORK PA 345 E 47TH ST, NEW YORK, NY 10017 USA SN 1945-7928 BN 978-1-4799-2349-6; 978-1-4799-2350-2 J9 I S BIOMED IMAGING PY 2016 BP 573 EP 576 PG 4 WC Engineering, Biomedical; Radiology, Nuclear Medicine & Medical Imaging SC Engineering; Radiology, Nuclear Medicine & Medical Imaging GA BG0MT UT WOS:000386377400136 ER PT J AU Lin, RL Garibyan, L Kimball, AB Drake, LA AF Lin, Richard L. Garibyan, Lilit Kimball, Alexandra B. Drake, Lynn A. TI Systemic causes of hair loss SO ANNALS OF MEDICINE LA English DT Review DE Alopecia; dietary supplements; hair ID SERUM FERRITIN LEVELS; ANDROGENETIC ALOPECIA; TELOGEN-EFFLUVIUM; REVERSIBLE ALOPECIA; PSYCHOSOCIAL IMPACT; IRON-DEFICIENCY; VIRUS-INFECTION; WOMEN; DIAGNOSIS; SCALP AB Hair loss is both a common chief complaint by patients and a clinical challenge for physicians, especially general practitioners, yet few dermatological problems yield as much patient satisfaction when resolved as hair loss. The diagnosis is often attributed to androgen-related hair loss, while other causes, some of which are life-threatening but treatable, are overlooked. We searched for relevant literature on hair loss and supported these findings with our clinical experience to identify seven major systemic etiologies of hair loss, ranging from infectious agents to consumption of unsafe supplements. Many causes are only described in the literature through case studies, though some original articles and meta-analyses are available. Careful history taking, proper examination techniques, and judicious use of laboratory tests are essential to reach at the correct diagnosis in a cost-effective manner when performing patient work-up. Such methodical evaluation of hair loss can result in the appropriate treatment plan and provide significant patient satisfaction.Key messagesHair loss is a common chief complaint and a difficult challenge for both general practitioners and dermatology consultants.We identified seven major categories of systemic hair loss etiology and present a framework for their clinical evaluation.A methodical approach to hair loss can result in the appropriate treatment plan and provide significant patient satisfaction. C1 [Lin, Richard L.] Harvard Med Sch, Harvard MIT Div Hlth Sci & Technol, Boston, MA USA. [Lin, Richard L.; Garibyan, Lilit; Kimball, Alexandra B.; Drake, Lynn A.] Massachusetts Gen Hosp, Dept Dermatol, 50 Staniford St 807, Boston, MA 02114 USA. RP Drake, LA (reprint author), Massachusetts Gen Hosp, Dept Dermatol, 50 Staniford St 807, Boston, MA 02114 USA. EM drake.lynn@mgh.harvard.edu NR 93 TC 0 Z9 0 U1 4 U2 4 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND SN 0785-3890 EI 1365-2060 J9 ANN MED JI Ann. Med. PY 2016 VL 48 IS 6 BP 393 EP 402 DI 10.1080/07853890.2016.1180426 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA DZ2KL UT WOS:000385670600001 PM 27145919 ER PT J AU Santeford, A Wiley, LA Park, S Bamba, S Nakamura, R Gdoura, A Ferguson, TA Rao, PK Guan, JL Saitoh, T Akira, S Xavier, R Virgin, HW Apte, RS AF Santeford, Andrea Wiley, Luke A. Park, Sunmin Bamba, Sonya Nakamura, Rei Gdoura, Abdelaziz Ferguson, Thomas A. Rao, P. Kumar Guan, Jun-Lin Saitoh, Tatsuya Akira, Shizuo Xavier, Ramnik Virgin, Herbert W. Apte, Rajendra S. TI Impaired autophagy in macrophages promotes inflammatory eye disease SO AUTOPHAGY LA English DT Article DE autophagy; eye; inflammasome; innate immunity; macrophage; uveitis ID ENDOTOXIN-INDUCED UVEITIS; IL-1-BETA PRODUCTION; SELECTIVE AUTOPHAGY; ACTIVATION; ATG16L1; PREVENTION; PROTEINS; IMMUNITY; MOUSE; CELLS AB Autophagy is critical for maintaining cellular homeostasis. Organs such as the eye and brain are immunologically privileged. Here, we demonstrate that autophagy is essential for maintaining ocular immune privilege. Deletion of multiple autophagy genes in macrophages leads to an inflammation-mediated eye disease called uveitis that can cause blindness. Loss of autophagy activates inflammasome-mediated IL1B secretion that increases disease severity. Inhibition of caspase activity by gene deletion or pharmacological means completely reverses the disease phenotype. Of interest, experimental uveitis was also increased in a model of Crohn disease, a systemic autoimmune disease in which patients often develop uveitis, offering a potential mechanistic link between macrophage autophagy and systemic disease. These findings directly implicate the homeostatic process of autophagy in blinding eye disease and identify novel pathways for therapeutic intervention in uveitis. C1 [Santeford, Andrea; Bamba, Sonya; Nakamura, Rei; Gdoura, Abdelaziz; Ferguson, Thomas A.; Rao, P. Kumar; Apte, Rajendra S.] Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, St Louis, MO 63110 USA. [Wiley, Luke A.] Univ Iowa, Dept Ophthalmol & Visual Sci, Steven W Dezii Translat Vis Res Facil, Stephen A Wynn Inst Vis Res,Carver Coll Med, Iowa City, IA USA. [Park, Sunmin; Virgin, Herbert W.] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO USA. [Guan, Jun-Lin] Univ Cincinnati, Coll Med, Dept Canc Biol, Cincinnati, OH USA. [Saitoh, Tatsuya] Univ Tokushima, Dept Inflammat Biol, Tokushima, Japan. [Saitoh, Tatsuya] Univ Tokushima, Inst Enzyme Res, Tokushima, Japan. [Akira, Shizuo] Osaka Univ, WPI Immunol Frontier Res Ctr, Host Def Lab, Osaka, Japan. [Akira, Shizuo] Osaka Univ, Microbial Dis Res Inst, Osaka, Japan. [Xavier, Ramnik] Broad Inst Massachusetts Inst Technol & Harvard U, Cambridge, MA USA. [Xavier, Ramnik] Harvard Med Sch, Massachusetts Gen Hosp, Ctr Computat & Integrat Biol, Boston, MA USA. [Xavier, Ramnik] Harvard Med Sch, Massachusetts Gen Hosp, Ctr Study Inflammatory Bowel Dis, Gastrointestinal Unit, Boston, MA USA. [Virgin, Herbert W.] Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA. [Apte, Rajendra S.] Washington Univ, Sch Med, Dept Dev Biol, St Louis, MO USA. [Apte, Rajendra S.] Washington Univ, Sch Med, Neurosci Program, St Louis, MO USA. [Apte, Rajendra S.] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA. RP Apte, RS (reprint author), 660 S Euclid Ave,Box 8096, St Louis, MO 63110 USA.; Virgin, HW (reprint author), 4939 Childrens Pl,Box 8118, St Louis, MO 63110 USA. EM virgin@wustl.edu; apte@vision.wustl.edu FU NIH [R01EY019287, DK097845]; NIH Vision Core Grant [P30EY02687]; Carl Marshall Reeves and Mildred Almen Reeves Foundation Inc. Award; Research to Prevent Blindness Inc. Career Development Award; Jeffrey Fort Innovation Fund (RSA), NIH [U19AI109725, R01AI084887] FX This work was supported by NIH Grant R01EY019287 (RSA), NIH Vision Core Grant P30EY02687, Carl Marshall Reeves and Mildred Almen Reeves Foundation Inc. Award (RSA), Research to Prevent Blindness Inc. Career Development Award and Physician Scientist Award (RSA), Jeffrey Fort Innovation Fund (RSA), NIH grants U19AI109725 and R01AI084887 (HWV), NIH Grant DK097845 (RX), and a Research to Prevent Blindness Inc. Unrestricted Grant to Washington University. Experimental support was also provided by the Speed Congenics Facility of the Rheumatic Diseases Core Center and the National Institute of Arthritis and Musculoskeletal and Skin Diseases (P30AR048335). NR 25 TC 0 Z9 0 U1 3 U2 3 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 1554-8627 EI 1554-8635 J9 AUTOPHAGY JI Autophagy PY 2016 VL 12 IS 10 BP 1876 EP 1885 DI 10.1080/15548627.2016.1207857 PG 10 WC Cell Biology SC Cell Biology GA DZ3KB UT WOS:000385744400014 PM 27463423 ER PT J AU Fisher, LB Pedrelli, P Iverson, GL Bergquist, TF Bombardier, CH Hammond, FM Hart, T Ketchum, JM Giacino, J Zafonte, R AF Fisher, Lauren B. Pedrelli, Paola Iverson, Grant L. Bergquist, Thomas F. Bombardier, Charles H. Hammond, Flora M. Hart, Tessa Ketchum, Jessica M. Giacino, Joseph Zafonte, Ross TI Prevalence of suicidal behaviour following traumatic brain injury: Longitudinal follow-up data from the NIDRR Traumatic Brain Injury Model Systems SO BRAIN INJURY LA English DT Article DE Traumatic brain injury; depression; suicide; suicidal ideation; suicide attempt; prevalence ID MAJOR DEPRESSIVE DISORDER; SPINAL-CORD-INJURY; MINOR DEPRESSION; UNITED-STATES; RISK-FACTORS; REHABILITATION; POPULATION; IDEATION; HEALTH; RATES AB Objective: This study utilized the Traumatic Brain Injury Model Systems (TBIMS) National Database to examine the prevalence of depression and suicidal behaviour in a large cohort of patients who sustained moderate-to-severe TBI.Method: Participants presented to a TBIMS acute care hospital within 72 hours of injury and received acute care and comprehensive rehabilitation in a TBIMS designated brain injury inpatient rehabilitation programme. Depression and suicidal ideation were measured with the Patient Health Questionnaire (PHQ-9). Self-reported suicide attempts during the past year were recorded at each follow-up examination, at 1, 2, 3, 10, 15 and 20 years post-injury.Results: Throughout the 20 years of follow-up, rates of depression ranged from 24.8-28.1%, suicidal ideation ranged from 7.0-10.1% and suicide attempts (past year) ranged from 0.8-1.7%. Participants who endorsed depression and/or suicidal behaviour at year 1 demonstrated consistently elevated rates of depression and suicidal behaviour 5 years after TBI.Conclusion: Compared to the general population, individuals with TBI are at greater risk for depression and suicidal behaviour many years after TBI. The significant psychiatric symptoms evidenced by individuals with TBI highlight the need for routine screening and mental health treatment in this population. C1 [Fisher, Lauren B.; Pedrelli, Paola; Giacino, Joseph] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Fisher, Lauren B.; Pedrelli, Paola] Harvard Med Sch, Dept Psychiat, Boston, MA USA. [Iverson, Grant L.; Giacino, Joseph; Zafonte, Ross] Harvard Med Sch, Dept Phys Med & Rehabil, Boston, MA USA. [Iverson, Grant L.; Giacino, Joseph; Zafonte, Ross] Spaulding Rehabil Hosp, Boston, MA USA. [Iverson, Grant L.; Zafonte, Ross] Red Sox Fdn, Boston, MA USA. [Iverson, Grant L.; Zafonte, Ross] Massachusetts Gen Hosp, Home Base Program, Boston, MA 02114 USA. [Bergquist, Thomas F.] Mayo Clin, Coll Med Rochester, Dept Psychol, Rochester, MN USA. [Bergquist, Thomas F.] Mayo Clin, Coll Med Rochester, Dept Psychiat, Rochester, MN USA. [Bergquist, Thomas F.] Mayo Clin, Coll Med Rochester, Dept Phys Med & Rehabil, Rochester, MN USA. [Bombardier, Charles H.] Univ Washington, Dept Rehabil Med, Div Clin & Neuropsychol, Seattle, WA 98195 USA. [Hammond, Flora M.] Indiana Univ Sch Med, Dept Phys Med & Rehabil, Indianapolis, IN 46202 USA. [Hammond, Flora M.] Rehabil Hosp Indiana, Indianapolis, IN USA. [Hart, Tessa] Moss Rehabil Res Inst, Elkins Pk, PA USA. [Ketchum, Jessica M.] Georgia Regents Univ, Dept Biostat & Epidemiol, Augusta, GA USA. [Zafonte, Ross] Massachusetts Gen Hosp, Dept Phys Med & Rehabil, Boston, MA 02114 USA. [Zafonte, Ross] Brigham & Womens Hosp, Dept Phys Med & Rehabil, 75 Francis St, Boston, MA 02115 USA. RP Fisher, LB (reprint author), Massachusetts Gen Hosp, Dept Psychiat, Depress Clin & Res Program, One Bowdoin Sq,6th Floor, Boston, MA 02114 USA. EM lbfisher@mgh.harvard.edu FU Department of Health and Human Services, National Institute on Disability, Independent Living and Rehabilitation Research [H133A120085, H133A 120026, H133A120028, H133A120035, H133A120037, H133A120031]; Harvard Medical School; Avanir; INTRuST Post-traumatic Stress Disorder and Traumatic Brain Injury Clinical Consortium - Department of Defense Psychological Health/Traumatic Brain Injury Research Programme [X81XWH-07-CC-CSDoD] FX The contents of this manuscript were developed under a grant from the Department of Health and Human Services, National Institute on Disability, Independent Living and Rehabilitation Research grant numbers H133A120085, H133A 120026, H133A120028, H133A120035, H133A120037 and H133A120031. However, those contents do not necessarily represent the policy of the Department of Education and you should not assume endorsement by the Federal Government. Lauren B. Fisher, PhD received a fellowship grant from Harvard Medical School to support the current work. Flora Hammond, MD, has received personal fees from Avanir for participation on the PRISM II Steering Committee and stock ownership [Stock ownership in health care companies include: ABBVIE INC SHS ($34 247 market value), ELI LILLY & CO ($14 535), GLAXOSMITHKLINE PLC ADR ($23 794), Exchange Traded Funds ($84 545) and Mutual Funds ($47 095)]. Joseph Giacino, PhD, is a member of the Advisory Board of the TBIMS National Data and Statistical Center. Dr. Zafonte and Dr. Iverson acknowledge additional support from the INTRuST Post-traumatic Stress Disorder and Traumatic Brain Injury Clinical Consortium funded by the Department of Defense Psychological Health/Traumatic Brain Injury Research Programme (X81XWH-07-CC-CSDoD). Grant Iverson, PhD, has been reimbursed by the government, professional scientific bodies and commercial organizations for discussing or presenting research relating to MTBI and sport-related concussion atmeetings, scientific conferences and symposiums. He has a clinical practice in forensic neuropsychology involving individuals who have sustained mild TBIs. He has received honorariums for serving on research panels that provide scientific peer review of programmes. He is a co-investigator, collaborator or consultant on grants relating to mild TBI funded by several organizations. For the remaining authors, no conflicts were declared. NR 33 TC 0 Z9 0 U1 1 U2 1 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 0269-9052 EI 1362-301X J9 BRAIN INJURY JI Brain Inj. PY 2016 VL 30 IS 11 BP 1311 EP 1318 DI 10.1080/02699052.2016.1195517 PG 8 WC Neurosciences; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA DZ8TP UT WOS:000386144900004 PM 27541868 ER PT J AU Milberg, W AF Milberg, William TI Manfred Frank Greiffenstein: a remembrance SO CLINICAL NEUROPSYCHOLOGIST LA English DT Biographical-Item C1 [Milberg, William] Harvard Med Sch, Dept Psychiat, Psychol, Boston, MA 02115 USA. [Milberg, William] VA Boston Healthcare, Boston Div, Res New England GRECC, Boston, MA 02130 USA. RP Milberg, W (reprint author), Harvard Med Sch, Dept Psychiat, Psychol, Boston, MA 02115 USA.; Milberg, W (reprint author), VA Boston Healthcare, Boston Div, Res New England GRECC, Boston, MA 02130 USA. EM william_milberg@hms.harvard.edu NR 1 TC 0 Z9 0 U1 0 U2 0 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 1385-4046 EI 1744-4144 J9 CLIN NEUROPSYCHOL JI Clin. Neuropsychol. PY 2016 VL 30 IS 8 BP 1389 EP 1390 DI 10.1080/13854046.2016.1244198 PG 2 WC Psychology, Clinical; Clinical Neurology; Psychology SC Psychology; Neurosciences & Neurology GA EA8NR UT WOS:000386893100018 PM 27767897 ER PT J AU Toh, WS Foldager, CB Hui, JHP Olsen, BR Spector, M AF Toh, Wei Seong Foldager, Casper Bindzus Hui, James Hoi Po Olsen, Bjorn Reino Spector, Myron TI Exploiting Stem Cell-Extracellular Matrix Interactions for Cartilage Regeneration: A Focus on Basement Membrane Molecules SO CURRENT STEM CELL RESEARCH & THERAPY LA English DT Review DE Basement membrane; cartilage; biomaterials; extracellular matrix; stem cells; pericellular matrix; tissue regeneration ID AUTOLOGOUS CHONDROCYTE IMPLANTATION; COLLAGEN TYPE-IV; ARTICULAR-CARTILAGE; CHONDROGENIC DIFFERENTIATION; PERICELLULAR MATRIX; IN-VITRO; BONE-MARROW; CHONDROITIN SULFATE; HYALURONIC-ACID; ADIPOGENIC DIFFERENTIATION AB The extracellular matrix (ECM) is a complex network of proteins and glycosaminoglycans which surrounds cells and serves a critical role in directing cell fate and functions, as well as imparting the necessary mechanical behaviour to the tissue. To achieve successful cartilage regeneration, stem cells and/or progenitor cells have to be able to undergo an orderly spatiotemporal differentiation process, along with specific changes in the ECM expression and deposition, to form a cartilage tissue with the defined hierarchical matrix organization. In the last decade, significant advances have been made in our understanding of the role of the ECM during chondrogenesis and in cartilage homeostasis following differentiation, with some unexpected findings. This review will survey the major ECM components and their interactions with relevant stem cell populations for the regeneration of cartilage. Future therapies will likely benefit from a better understanding and a more precise control of stem cell-ECM interactions implicated in the regenerative response. C1 [Toh, Wei Seong] Natl Univ Singapore, Fac Dent, 11 Lower Kent Ridge Rd, Singapore 119083, Singapore. [Toh, Wei Seong; Hui, James Hoi Po] Natl Univ Singapore, Inst Life Sci, Tissue Engn Program, 27 Med Dr, Singapore 117510, Singapore. [Foldager, Casper Bindzus] Aarhus Univ Hosp, Orthopaed Res Lab, Noerrebrogade 44,Bldg 1A, DK-8000 Aarhus C, Denmark. [Hui, James Hoi Po] Natl Univ Singapore, Natl Univ Hlth Syst, Dept Orthopaed Surg, Therapeut Tissue Engn Lab,Cartilage Repair Progra, 1E Kent Ridge Rd, Singapore 119288, Singapore. [Olsen, Bjorn Reino] Harvard Sch Dent Med, Dept Dev Biol, Boston, MA 02115 USA. [Spector, Myron] VA Boston Healthcare Syst, Tissue Engn Labs, MS 151, Boston, MA 02130 USA. [Spector, Myron] Harvard Med Sch, Brigham & Womens Hosp, Dept Orthopaed Surg, Boston, MA 02115 USA. RP Toh, WS (reprint author), Natl Univ Singapore, Fac Dent, 11 Lower Kent Ridge Rd, Singapore 119083, Singapore. EM dentohws@nus.edu.sg RI Toh, Wei Seong/K-7720-2013 OI Toh, Wei Seong/0000-0001-9147-6423 FU National University Healthcare System, National University of Singapore [R221000067133, R221000070733, R221000077733, R221000083112]; National Medical Research Council Singapore [R221000080511] FX This work was supported by grants from the National University Healthcare System, National University of Singapore (R221000067133, R221000070733, R221000077733 and R221000083112) and National Medical Research Council Singapore (R221000080511). NR 106 TC 1 Z9 1 U1 2 U2 2 PU BENTHAM SCIENCE PUBL LTD PI SHARJAH PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES SN 1574-888X EI 2212-3946 J9 CURR STEM CELL RES T JI Curr. Stem Cell Res. Ther. PY 2016 VL 11 IS 8 BP 618 EP 625 DI 10.2174/1574888X10666150723150525 PG 8 WC Cell & Tissue Engineering; Cell Biology SC Cell Biology GA EA7FD UT WOS:000386794300003 PM 26201861 ER PT J AU Hong, EK Dicianno, BE Pearlman, J Cooper, R Cooper, RA AF Hong, Eun-Kyoung Dicianno, Brad E. Pearlman, Jon Cooper, Rosemarie Cooper, Rory A. TI Comfort and stability of wheelchair backrests according to the TAWC (tool for assessing wheelchair discomfort) SO DISABILITY AND REHABILITATION-ASSISTIVE TECHNOLOGY LA English DT Article DE Assessment; backrest; comfort; discomfort; wheelchair ID SPINAL-CORD-INJURY; TECHNOLOGY AB Purpose: The goal of this study was thus to determine if people with different types of wheelchair backrests on their personal wheelchairs reported different levels of comfort as measured by the Tool for Assessing Wheelchair disComfort (TAWC). Methods: Participants were between 18 and 80 years of age and were manual wheelchair users. The TAWC was used to assess the participants' wheelchair seating discomfort levels with the wheelchair and seating systems. Results: We surveyed 131 wheelchair users to assess the comfort of their backrests on their personal wheelchairs and found a trend suggesting that rigid backrests are were less comfortable as compared with sling backrests. This finding was statistically significant in a subgroup of participants with tetraplegia. Conclusions: Although many clinicians expect rigid backrests to be more comfortable because they may provide more support, the higher discomfort ratings among rigid backrest users with tetraplegia may be due to sub-optimal shape, fit, adjustment or user preferences. C1 [Hong, Eun-Kyoung; Dicianno, Brad E.; Pearlman, Jon; Cooper, Rory A.] VA Pittsburgh Healthcare Syst, Human Engn Res Labs, Pittsburgh, PA USA. [Hong, Eun-Kyoung; Dicianno, Brad E.; Pearlman, Jon; Cooper, Rosemarie; Cooper, Rory A.] Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA USA. [Dicianno, Brad E.] Univ Pittsburgh, Sch Med, Dept Phys Med & Rehabil, Pittsburgh, PA USA. RP Cooper, RA (reprint author), Human Engn Res Labs, 6425 Penn Ave,Suite 400, Pittsburgh, PA 15206 USA. EM rcooper@pitt.edu OI Pearlman, Jon/0000-0003-0830-9136 NR 17 TC 0 Z9 0 U1 0 U2 1 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 1748-3107 EI 1748-3115 J9 DISABIL REHABIL-ASSI JI Disabil. Rehabil.-Assist. Technol. PY 2016 VL 11 IS 3 BP 223 EP 227 DI 10.3109/17483107.2014.938365 PG 5 WC Rehabilitation SC Rehabilitation GA EA2WC UT WOS:000386455500006 PM 25036985 ER PT J AU Darrah, SD Dicianno, BE Berthold, J McCoy, A Haas, M Cooper, RA AF Darrah, Shaun D. Dicianno, Brad E. Berthold, Justin McCoy, Andrew Haas, Matthew Cooper, Rory A. TI Measuring static seated pressure distributions and risk for skin pressure ulceration in ice sledge hockey players SO DISABILITY AND REHABILITATION-ASSISTIVE TECHNOLOGY LA English DT Article DE Adaptive sports; cerebral palsy; hockey; spina bifida; spinal cord injury ID DEFORMITY; SPINE AB Purpose: To determine whether sledge hockey players with physical disability have higher average seated pressures compared to non-disabled controls. Method: Fifteen age-matched controls without physical disability and 15 experimental participants with physical disability were studied using a pressure mapping device to determine risk for skin pressure ulceration and the impact of cushioning and knee angle positioning on seated pressure distributions. Results: Regardless of participant group, cushioning, or knee angle, average seated pressures exceeded clinically acceptable seated pressures. Controls had significantly higher average seated pressures than the disability group when knees were flexed, both with the cushion (p = 0.013) and without (p = 0.015). Knee extension showed significantly lower average pressures in controls, both with the cushion (p<0.001) and without (p<0.001). Placement of the cushion resulted in significantly lower average pressure in controls when knees were extended (p = 0.024) but not when flexed (p = 0.248). Placement of the cushion resulted in no difference in pressure (p = 0.443) in the disability group. Conclusions: Pressures recorded indicate high risk for skin ulceration. Cushioning was effective only in the control group with knees extended. That knee extension significantly lowered average seated pressures is important, as many sledge hockey players utilize positioning with larger knee flexion angles. C1 [Darrah, Shaun D.; Dicianno, Brad E.; Berthold, Justin; McCoy, Andrew; Haas, Matthew; Cooper, Rory A.] VA Pittsburgh Healthcare Syst, Ctr Excellence Wheelchairs & Related Technol, Pittsburgh, PA USA. [Darrah, Shaun D.; Dicianno, Brad E.; Berthold, Justin; McCoy, Andrew; Haas, Matthew; Cooper, Rory A.] Univ Pittsburgh, Med Ctr, Dept Phys Med & Rehabil, Pittsburgh, PA USA. [Dicianno, Brad E.; Cooper, Rory A.] Univ Pittsburgh, Human Engn Res Labs, Pittsburgh, PA USA. [Dicianno, Brad E.; Cooper, Rory A.] Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA USA. [McCoy, Andrew] Univ Pittsburgh, Drexel Univ, Coll Med, Pittsburgh, PA USA. [Haas, Matthew] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. [Cooper, Rory A.] Univ Pittsburgh, Swanson Sch Engn, Dept Bioengn, Pittsburgh, PA USA. RP Dicianno, BE (reprint author), Univ Pittsburgh, Med Ctr, Dept Phys Med & Rehabil, Pittsburgh, PA USA. EM dicibe@upmc.edu NR 9 TC 0 Z9 0 U1 2 U2 12 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 1748-3107 EI 1748-3115 J9 DISABIL REHABIL-ASSI JI Disabil. Rehabil.-Assist. Technol. PY 2016 VL 11 IS 3 BP 241 EP 246 DI 10.3109/17483107.2014.921939 PG 6 WC Rehabilitation SC Rehabilitation GA EA2WC UT WOS:000386455500009 PM 24875641 ER PT J AU Hong, EK Cooper, RA Pearlman, JL Hargroder, T AF Hong, Eun-Kyoung Cooper, Rory A. Pearlman, Jonathan L. Hargroder, Todd TI Design, testing and evaluation of angle-adjustable backrest hardware SO DISABILITY AND REHABILITATION-ASSISTIVE TECHNOLOGY LA English DT Article DE Adjustment; backrest; design; focus group; ISO testing; wheelchair ID SPINAL-CORD-INJURY; WHEELCHAIR PROPULSION; CONFIGURATION AB Purpose: The purpose of this study was to design and evaluate a final design prototype of angle-adjustable backrest hardware. Methods: A traditional iterative design development protocol was undertaken and completed. Before evaluation by a focus group, testing of the prototype was performed in strict accordance with ISO standards. Focus group participants were between 18 and 80 years of age, used a manual wheelchair as their primary means of mobility, and transferred independently. Individuals with pressure sores or who required of the use of specialized or custom seating for trunk support were excluded from the study. A questionnaire was administered to elicit participants' opinions on the adjustability, function and appearance of the angle-adjustable backrest device. Results: The prototype successfully met the ISO testing standards. Wheelchair users (n = 8) who evaluated the device in a focus group had an overall positive response. Things they most liked about the prototype were comfort, support (function/activities) and adjustability, while things they most disliked about the prototype were problems with string and reaching back position to adjust. Conclusions: The prototype had a positive impression from participants, however, improvements on the operation method and usability were suggested. C1 [Hong, Eun-Kyoung; Cooper, Rory A.; Pearlman, Jonathan L.] VA Pittsburgh Healthcare Syst, Human Engn Res Labs, 6425 Penn Ave,Suite 400, Pittsburgh, PA 15206 USA. [Hong, Eun-Kyoung; Cooper, Rory A.; Pearlman, Jonathan L.] Univ Pittsburgh, Dept Rehabil Sci & Technol, Pittsburgh, PA USA. [Hargroder, Todd] Accessible Designs Inc, San Antonio, TX USA. RP Cooper, RA (reprint author), VA Pittsburgh Healthcare Syst, Human Engn Res Labs, 6425 Penn Ave,Suite 400, Pittsburgh, PA 15206 USA. EM rcooper@pitt.edu FU NICHD NIH HHS [2R44HD056705-02A1] NR 12 TC 0 Z9 0 U1 0 U2 0 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 1748-3107 EI 1748-3115 J9 DISABIL REHABIL-ASSI JI Disabil. Rehabil.-Assist. Technol. PY 2016 VL 11 IS 4 BP 325 EP 332 DI 10.3109/17483107.2014.938364 PG 8 WC Rehabilitation SC Rehabilitation GA EA2WP UT WOS:000386457100008 PM 24999560 ER PT J AU Mohajer, P Shimada, YJ AF Mohajer, Pouya Shimada, Yuichi J. TI Reducing the risk of heart failure exacerbation by bariatric surgery in obese patients SO EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM LA English DT Editorial Material DE Heart failure exacerbation; obesity; bariatric surgery; self-controlled case series study; hospitalization ID NATIONAL DIABETES REGISTRY; LEFT-VENTRICULAR GEOMETRY; QUALITY-OF-LIFE; WEIGHT-LOSS; CARDIORESPIRATORY FITNESS; EJECTION FRACTION; PARADOX; IMPACT; HOSPITALIZATION; MASS C1 [Mohajer, Pouya; Shimada, Yuichi J.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Med, Div Cardiol, Boston, MA USA. RP Shimada, YJ (reprint author), Massachusetts Gen Hosp, Dept Med, Div Cardiol, 55 Fruit St,Gray Bigelow 800, Boston, MA 02114 USA. EM yshimada@partners.org NR 35 TC 0 Z9 0 U1 0 U2 0 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 1744-6651 EI 1744-8417 J9 EXPERT REV ENDOCRINO JI Expert Rev. Endocrinol. Metab. PY 2016 VL 11 IS 5 BP 369 EP 371 DI 10.1080/17446651.2016.1221339 PG 3 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA EA5WF UT WOS:000386694400002 ER PT J AU McCully, KS AF McCully, Kilmer S. TI Homocysteine, Infections, Polyamines, Oxidative Metabolism, and the Pathogenesis of Dementia and Atherosclerosis SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Review DE Adenosyl methionine; aging; atherosclerosis; cystathionine synthase; dementia; homocysteine; nitric oxide; oxidative phosphorylation; peroxynitrite; polyamines; thioretinaco ozonide ID UNFOLDED PROTEIN RESPONSE; ALZHEIMERS-DISEASE; CHEMICAL PATHOLOGY; CYSTATHIONINE SYNTHASE; CELL-DEATH; THIOLACTONE METABOLISM; NITRIC-OXIDE; HYPERHOMOCYSTEINEMIA; ADENOSYLMETHIONINE; PHOSPHORYLATION AB Hyperhomocysteinemia is a risk factor for development of dementia and Alzheimer's disease (AD), and low blood levels of folate and cobalamin are associated with hyperhomocysteinemia and AD. In elderly subjects with cognitive decline, supplementation with folate, cobalamin, and pyridoxal demonstrated reduction of cerebral atrophy in gray matter regions vulnerable to the AD process. Multiple pathogenic microbes are implicated as pathogenic factors in AD and atherosclerosis, and the deposition of amyloid-beta (A beta), phosphorylation of tau protein, neuronal injury, and apoptosis in AD are secondary to microbial infection. Glucose utilization and blood flow are reduced in AD, and these changes are accompanied by down-regulation of glucose transport, Na, K-ATPase, oxidative phosphorylation, and energy consumption. Thioretinaco ozonide, the complex formed from thioretinamide, cobalamin, ozone, and oxygen is proposed to constitute the active site of oxidative phosphorylation, catalyzing synthesis of adenosine triphosphate (ATP) from nicotinamide adenine dinucleotide (NAD(+)) and phosphate. Pathogenic microbes cause synthesis of polyamines in host cells by increasing the transfer of aminopropyl groups from adenosyl methionine to putrescine, resulting in depletion of intracellular adenosyl methionine concentrations in host cells. Depletion of adenosyl methionine causes dysregulation of methionine metabolism, hyperhomocysteinemia, reduced biosynthesis of thioretinamide and thioretinaco ozonide, decreased oxidative phosphorylation, decreased production of nitric oxide and peroxynitrite, and impaired host response to infectious microbes, contributing to the pathogenesis of dementia and atherosclerosis. C1 [McCully, Kilmer S.] Harvard Med Sch, Pathol & Lab Med Serv, VA Boston Healthcare Syst, Boston, MA USA. RP McCully, KS (reprint author), VA Boston Healthcare Syst, Pathol & Lab Med Serv, 1400 Vet Foreign Wars Pkwy, West Roxbury, MA 02132 USA. EM Kilmer.mccully@va.gov NR 62 TC 1 Z9 1 U1 0 U2 0 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 EI 1875-8908 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2016 VL 54 IS 4 BP 1283 EP 1290 DI 10.3233/JAD-160549 PG 8 WC Neurosciences SC Neurosciences & Neurology GA EA6PA UT WOS:000386749900003 PM 27567876 ER PT J AU Harel, NY Carmel, JB AF Harel, Noam Y. Carmel, Jason B. TI Paired Stimulation to Promote Lasting Augmentation of Corticospinal Circuits SO NEURAL PLASTICITY LA English DT Review ID SPINAL-CORD-INJURY; HUMAN MOTOR CORTEX; TRANSCRANIAL MAGNETIC STIMULATION; TIMING-DEPENDENT PLASTICITY; THETA-BURST STIMULATION; ELECTRICAL-STIMULATION; HETEROSYNAPTIC FACILITATION; ASSOCIATIVE STIMULATION; SYNAPTIC PLASTICITY; STROKE PATIENTS AB After injury, electrical stimulation of the nervous system can augment plasticity of spared or latent circuits through focal modulation. Pairing stimulation of two parts of a spared circuit can target modulation more specifically to the intended circuit. We discuss 3 kinds of paired stimulation in the context of the corticospinal system, because of its importance in clinical neurorehabilitation. The first uses principles of Hebbian plasticity: by altering the stimulation timing of presynaptic neurons and their postsynaptic targets, synapse function can be modulated up or down. The second form uses synchronized presynaptic inputs onto a common synaptic target. We dub this a "convergent" mechanism, because stimuli have to converge on a common target with coordinated timing. The third form induces focal modulation by tonic excitation of one region (e.g., the spinal cord) during phasic stimulation of another (e.g., motor cortex). Additionally, endogenous neural activity may be paired with exogenous electrical stimulation. This review addresses what is known about paired stimulation of the corticospinal system of both humans and animal models, emphasizes how it qualitatively differs from single-site stimulation, and discusses the gaps in knowledge that must be addressed to maximize its use and efficacy in neurorehabilitation. C1 [Harel, Noam Y.] James J Peters Vet Affairs Med Ctr, Bronx, NY 10468 USA. [Harel, Noam Y.] Icahn Sch Med Mt Sinai, New York, NY 10029 USA. [Carmel, Jason B.] Burke Med Res Inst, White Plains, NY 10605 USA. [Carmel, Jason B.] Weill Cornell Med Coll, New York, NY 10065 USA. RP Harel, NY (reprint author), James J Peters Vet Affairs Med Ctr, Bronx, NY 10468 USA.; Harel, NY (reprint author), Icahn Sch Med Mt Sinai, New York, NY 10029 USA.; Carmel, JB (reprint author), Burke Med Res Inst, White Plains, NY 10605 USA.; Carmel, JB (reprint author), Weill Cornell Med Coll, New York, NY 10065 USA. EM noam.harel@mssm.edu; jason.carmel@med.cornell.edu FU VA RRD Grants [B-0881W, B-4162C]; NY State Spinal Cord Injury Board Grants [C030090, C030171, C30599GG]; Travis Roy Foundation; NIH [1R01NS092875, 1R21EB020318, K08NS073796] FX The authors thank Asht Mishra, Ph.D., for helping in preparing Figure 1. Noam Y. Harel is supported by VA RR&D Grants B-0881W and B-4162C and NY State Spinal Cord Injury Board Grants C030090, C030171, and C30599GG. Jason B. Carmel is supported by the Travis Roy Foundation and NIH Grants 1R01NS092875, 1R21EB020318, and K08NS073796. NR 106 TC 0 Z9 0 U1 0 U2 0 PU HINDAWI PUBLISHING CORP PI NEW YORK PA 315 MADISON AVE 3RD FLR, STE 3070, NEW YORK, NY 10017 USA SN 2090-5904 EI 1687-5443 J9 NEURAL PLAST JI Neural. Plast. PY 2016 AR 7043767 DI 10.1155/2016/7043767 PG 11 WC Neurosciences SC Neurosciences & Neurology GA EA5CE UT WOS:000386633600001 ER PT J AU Yao, J Chan, J Mita, A Kundu, M Valera, SZ Unge, P Strosberg, J Wolin, E AF Yao, J. Chan, J. Mita, A. Kundu, M. Valera, S. Z. Unge, P. Strosberg, J. Wolin, E. TI Safety and Efficacy of Pasireotide LAR (PAS) in Patients with Advanced Neuroendocrine Tumors (NET): Findings of a Phase I, Multi-Center, Open-Label, Dose-Escalation Study SO NEUROENDOCRINOLOGY LA English DT Meeting Abstract CT 13th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease CY MAR 09-11, 2016 CL Barcelona, SPAIN SP ENETS DE Pasireotide; MTD C1 [Yao, J.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Chan, J.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Mita, A.; Wolin, E.] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. [Kundu, M.; Valera, S. Z.] Novartis Pharmaceut, E Hanover, NJ USA. [Unge, P.] Novartis Pharma AG, Basel, Switzerland. [Strosberg, J.] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0028-3835 EI 1423-0194 J9 NEUROENDOCRINOLOGY JI Neuroendocrinology PY 2016 VL 103 SU 1 MA K8 BP 76 EP 76 PG 1 WC Endocrinology & Metabolism; Neurosciences SC Endocrinology & Metabolism; Neurosciences & Neurology GA EA3ED UT WOS:000386481600199 ER PT J AU Singh, S Carnaghi, C Buzzoni, R Raderer, M Lahner, H Valle, J Voi, M Bubuteishvili-Pacaud, L Lincy, J Okita, N Kulke, M Strosberg, J Yao, J Pavel, M Fazio, N AF Singh, S. Carnaghi, C. Buzzoni, R. Raderer, M. Lahner, H. Valle, J. Voi, M. Bubuteishvili-Pacaud, L. Lincy, J. Okita, N. Kulke, M. Strosberg, J. Yao, J. Pavel, M. Fazio, N. TI Everolimus for Advanced, Progressive, Nonfunctional Neuroendocrine Tumors (NET) of the Gastrointestinal (GI) Tract: Efficacy and Safety from a RADIANT-4 Subgroup Analysis SO NEUROENDOCRINOLOGY LA English DT Meeting Abstract CT 13th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease CY MAR 09-11, 2016 CL Barcelona, SPAIN SP ENETS DE Everolimus; progression-free survival; gastro-intestinal NET C1 [Singh, S.] Sunnybrook Hlth Sci Ctr, Toronto, ON, Canada. [Carnaghi, C.] IRCCS Ist Clin Humanitas, Rozzano, Italy. [Buzzoni, R.] Fdn IRCCS, Ist Nazl Tumori, Milan, Italy. [Raderer, M.] Univ Klin Innere Med 1, AKH, Vienna, Austria. [Lahner, H.] Univ Klinikum Essen, Zentrum Innere Med, Essen, Germany. [Valle, J.] Univ Manchester, Christie Hosp, Inst Canc Studies, Manchester, Lancs, England. [Voi, M.] Novartis Pharmaceut, E Hanover, NJ USA. [Bubuteishvili-Pacaud, L.; Lincy, J.] Novartis Pharma AG, Basel, Switzerland. [Okita, N.] Natl Canc Ctr, Chuo Ku, Tokyo, Japan. [Kulke, M.] Dana Farber Canc Inst, Boston, MA USA. [Strosberg, J.] H Lee Moffitt Canc Ctr & Res Inst, Dept Med, Tampa, FL USA. [Yao, J.] Univ Texas MD Anderson Canc Ctr, Houston, TX USA. [Pavel, M.] Charite, Campus Virchow Klinikum, Berlin, Germany. [Fazio, N.] Ist Europeo Oncol IRCCS, Milan, Italy. NR 0 TC 1 Z9 1 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0028-3835 EI 1423-0194 J9 NEUROENDOCRINOLOGY JI Neuroendocrinology PY 2016 VL 103 SU 1 MA L20 BP 85 EP 85 PG 1 WC Endocrinology & Metabolism; Neurosciences SC Endocrinology & Metabolism; Neurosciences & Neurology GA EA3ED UT WOS:000386481600220 ER PT J AU Hrsch, D Kulke, M Caplin, M Anthony, L Bergsland, E Oberg, K Welin, S Warner, R Lombard-Bohas, C Kunz, P Valle, J Fleming, D Lapuerta, P Banks, P Pavel, M AF Hrsch, D. Kulke, M. Caplin, M. Anthony, L. Bergsland, E. Oberg, K. Welin, S. Warner, R. Lombard-Bohas, C. Kunz, P. Valle, J. Fleming, D. Lapuerta, P. Banks, P. Pavel, M. TI Efficacy and Safety of Telotristat Etiprate in Patients with Carcinoid Syndrome Not Adequately Controlled by Somatostatin Analog Therapy: Analysis of the Ongoing TELESTAR Extension Period SO NEUROENDOCRINOLOGY LA English DT Meeting Abstract CT 13th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease CY MAR 09-11, 2016 CL Barcelona, SPAIN SP ENETS DE Telotristat; Carcinoid syndrome; Tryptophan C1 [Hrsch, D.] Zent Klin Bad Berka, Bad Berka, Germany. [Kulke, M.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Caplin, M.] Royal Free Hosp, London, England. [Anthony, L.] Univ Kentucky, Lexington, KY 40506 USA. [Bergsland, E.] UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA. [Oberg, K.; Welin, S.] Uppsala Univ, Uppsala, Sweden. [Warner, R.] Icahn Sch Med Mt Sinai, New York, NY 10029 USA. [Lombard-Bohas, C.] Hosp Civils Lyon, Hop Edouard Herriot, Lyon, France. [Kunz, P.] Stanford Univ, Palo Alto, CA 94304 USA. [Valle, J.] Univ Manchester, Christie NHS Fdn Trust, Manchester, Lancs, England. [Fleming, D.] Ipsen BioSci, Cambridge, MA USA. [Lapuerta, P.; Banks, P.] Lexicon Pharmaceut Inc, The Woodlands, TX USA. [Pavel, M.] Charite, Berlin, Germany. NR 0 TC 0 Z9 0 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0028-3835 EI 1423-0194 J9 NEUROENDOCRINOLOGY JI Neuroendocrinology PY 2016 VL 103 SU 1 MA M5 BP 88 EP 88 PG 1 WC Endocrinology & Metabolism; Neurosciences SC Endocrinology & Metabolism; Neurosciences & Neurology GA EA3ED UT WOS:000386481600228 ER PT J AU Pavel, M Horsch, D Anthony, L Ervin, C Kulke, M Bergsland, E Caplin, M Oberg, K Warner, R Kunz, P Metz, D Pasieka, J Pavlakis, N DiBenedetti, D Lapuerta, P AF Pavel, M. Hoersch, D. Anthony, L. Ervin, C. Kulke, M. Bergsland, E. Caplin, M. Oberg, K. Warner, R. Kunz, P. Metz, D. Pasieka, J. Pavlakis, N. DiBenedetti, D. Lapuerta, P. TI Patient Interviews in TELESTAR, a Phase 3 Study of Telotristat Etiprate, Report Meaningful Improvement in Carcinoid Syndrome SO NEUROENDOCRINOLOGY LA English DT Meeting Abstract CT 13th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease CY MAR 09-11, 2016 CL Barcelona, SPAIN SP ENETS DE Serotonin; Bowel movement; Durable response; Treatment satisfaction C1 [Pavel, M.] Charite, Berlin, Germany. [Hoersch, D.] Zent Klin Bad Berka, Bad Berka, Germany. [Anthony, L.] Univ Kentucky, Lexington, KY 40506 USA. [Ervin, C.; DiBenedetti, D.] RTI Hlth Solut, Res Triangle Pk, NC USA. [Kulke, M.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Bergsland, E.] UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA. [Caplin, M.] Royal Free Hosp, London, England. [Oberg, K.] Uppsala Univ, Uppsala, Sweden. [Warner, R.] Icahn Sch Med Mt Sinai, New York, NY 10029 USA. [Kunz, P.] Stanford Univ, Palo Alto, CA 94304 USA. [Metz, D.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Pasieka, J.] Tom Baker Canc Ctr Calgary, Calgary, AB, Canada. [Pavlakis, N.] Royal North Shore Hosp, St Leonards, NSW, Australia. [Lapuerta, P.] Lexicon Pharmaceut Inc, The Woodlands, TX USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0028-3835 EI 1423-0194 J9 NEUROENDOCRINOLOGY JI Neuroendocrinology PY 2016 VL 103 SU 1 MA M7 BP 89 EP 89 PG 1 WC Endocrinology & Metabolism; Neurosciences SC Endocrinology & Metabolism; Neurosciences & Neurology GA EA3ED UT WOS:000386481600230 ER PT J AU Clift, A Pai, M Habib, N Senturk, H Laktakia, S Reddy, N Cicinnati, V Kaba, I Beckebaum, S Drymousis, P Kahaleh, M Malczewska, A Zanellato, A Brugge, W Frilling, A AF Clift, A. Pai, M. Habib, N. Senturk, H. Laktakia, S. Reddy, N. Cicinnati, V Kaba, I Beckebaum, S. Drymousis, P. Kahaleh, M. Malczewska, A. Zanellato, A. Brugge, W. Frilling, A. TI Endoscopic Ultrasound-Guided Radiofrequency Ablation for Pancreatic Neoplasms SO NEUROENDOCRINOLOGY LA English DT Meeting Abstract CT 13th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease CY MAR 09-11, 2016 CL Barcelona, SPAIN SP ENETS DE Ablation; Pancreas; Neuroendocrine C1 [Clift, A.; Pai, M.; Habib, N.; Drymousis, P.; Malczewska, A.; Zanellato, A.; Frilling, A.] Imperial Coll London, London, England. [Senturk, H.] Bezmi Alam Univ, Istanbul, Turkey. [Laktakia, S.; Reddy, N.] Asian Inst Gastroenterol, Hyperabad, India. [Cicinnati, V; Kaba, I; Beckebaum, S.] Univ Hosp Munster, Munster, Germany. [Kahaleh, M.] Weill Cornell Med Coll, New York, NY USA. [Malczewska, A.] Med Univ Silesia, Dept Pathophysiol & Endocrinol, Katowice, Poland. [Brugge, W.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0028-3835 EI 1423-0194 J9 NEUROENDOCRINOLOGY JI Neuroendocrinology PY 2016 VL 103 SU 1 MA N4 BP 91 EP 91 PG 1 WC Endocrinology & Metabolism; Neurosciences SC Endocrinology & Metabolism; Neurosciences & Neurology GA EA3ED UT WOS:000386481600235 ER PT J AU Strosberg, J Wolin, E Chasen, B Kulke, M Bushnell, D Caplin, M Baum, R Kunz, P Hobday, T Hendifar, A Oberg, K Sierra, ML Kwekkeboom, D Ruszniewski, P Krenning, E AF Strosberg, J. Wolin, E. Chasen, B. Kulke, M. Bushnell, D. Caplin, M. Baum, R. Kunz, P. Hobday, T. Hendifar, A. Oberg, K. Sierra, Lopera M. Kwekkeboom, D. Ruszniewski, P. Krenning, E. TI NETTER-1 Phase III in Patients with Midgut Neuroendocrine Tumors Treated with 177Lu-DOTATATE: Efficacy and Safety Results SO NEUROENDOCRINOLOGY LA English DT Meeting Abstract CT 13th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease CY MAR 09-11, 2016 CL Barcelona, SPAIN SP ENETS DE Lutathera; PRRT; NET C1 [Strosberg, J.] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA. [Wolin, E.] Markey Canc Ctr, Lexington, KY USA. [Chasen, B.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. [Kulke, M.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Bushnell, D.] Univ Iowa, Med Ctr, Iowa City, IA USA. [Caplin, M.] Royal Free Hosp, London, England. [Baum, R.] Zent Klin, Bad Berka, Germany. [Kunz, P.] Stanford Univ, Med Ctr, Stanford, CA 94305 USA. [Hobday, T.] Mayo Clin, Coll Med, Rochester, MI USA. [Hendifar, A.] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. [Oberg, K.] Uppsala Univ Hosp, Uppsala, Sweden. [Sierra, Lopera M.] Adv Accelerator Applicat, New York, NY USA. [Kwekkeboom, D.; Krenning, E.] Erasmus MC, Rotterdam, Netherlands. [Ruszniewski, P.] Hop Beaujon, Clichy, France. NR 0 TC 0 Z9 0 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0028-3835 EI 1423-0194 J9 NEUROENDOCRINOLOGY JI Neuroendocrinology PY 2016 VL 103 SU 1 MA N15 BP 95 EP 95 PG 1 WC Endocrinology & Metabolism; Neurosciences SC Endocrinology & Metabolism; Neurosciences & Neurology GA EA3ED UT WOS:000386481600246 ER PT J AU Fazio, N Buzzoni, R Delle Fave, G Tesselaar, M Wolin, E Van Cutsem, E Tomassetti, P Strosberg, J Voi, M Bubuteishvili-Pacaud, L Ridolfi, A Singh, S Pavel, M Kulke, M Yao, J AF Fazio, N. Buzzoni, R. Delle Fave, G. Tesselaar, M. Wolin, E. Van Cutsem, E. Tomassetti, P. Strosberg, J. Voi, M. Bubuteishvili-Pacaud, L. Ridolfi, A. Singh, S. Pavel, M. Kulke, M. Yao, J. TI Efficacy and Safety of Everolimus in Advanced, Progressive, Nonfunctional Neuroendocrine Tumors (NET) of the Lung: A Subgroup Analysis of the Phase 3 RADIANT-4 Study SO NEUROENDOCRINOLOGY LA English DT Meeting Abstract CT 13th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease CY MAR 09-11, 2016 CL Barcelona, SPAIN SP ENETS DE PFS; Everolimus; Lung carcinoid C1 [Fazio, N.] Ist Europeo Oncol, IRCCS, Milan, Italy. [Buzzoni, R.] Fdn IRCCS, Ist Nazl Tumori, Milan, Italy. [Delle Fave, G.] Univ Roma La Sapienza, Azienda Osped St Andrea, Rome, Italy. [Tesselaar, M.] Netherlands Canc Inst, Amsterdam, Netherlands. [Wolin, E.] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. [Van Cutsem, E.] Univ Hosp Gasthuisberg Leuven, Leuven, Belgium. [Van Cutsem, E.] Katholieke Univ Leuven, Leuven, Belgium. [Tomassetti, P.] Univ Bologna, S Orsola Malpighi Hosp, Dept Med & Surg Sci, Bologna, Italy. [Strosberg, J.] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA. [Voi, M.] Novartis Pharmaceut, E Hanover, NJ USA. [Bubuteishvili-Pacaud, L.] Novartis Pharma AG, Basel, Switzerland. [Ridolfi, A.] Novartis Pharma SAS, Rueil Malmaison, France. [Singh, S.] Sunnybrook Hlth Sci Ctr, Toronto, ON, Canada. [Pavel, M.] Charite, Virchow Klinikum, Berlin, Germany. [Kulke, M.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Yao, J.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA. NR 0 TC 1 Z9 1 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0028-3835 EI 1423-0194 J9 NEUROENDOCRINOLOGY JI Neuroendocrinology PY 2016 VL 103 SU 1 MA P1 BP 104 EP 104 PG 1 WC Endocrinology & Metabolism; Neurosciences SC Endocrinology & Metabolism; Neurosciences & Neurology GA EA3ED UT WOS:000386481600268 ER PT J AU Reidy-Lagunes, D Kulke, M Wolin, E Mirakhur, B Massien, C Caplin, M Baudin, E AF Reidy-Lagunes, D. Kulke, M. Wolin, E. Mirakhur, B. Massien, C. Caplin, M. Baudin, E. TI Design of a Phase 3, International, Prospective, Randomized, Double-Blind, Placebo (PBO) Controlled Study Assessing Efficacy and Safety of Lanreotide Autogel/Depot (LAN) 120 mg in Patients with Well-Differentiated, Advanced Typical and Atypical Lung NETs SO NEUROENDOCRINOLOGY LA English DT Meeting Abstract CT 13th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease CY MAR 09-11, 2016 CL Barcelona, SPAIN SP ENETS DE Lung NETs; Lanreotide C1 [Reidy-Lagunes, D.] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA. [Kulke, M.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Wolin, E.] Markey Canc Ctr, Lexington, KY USA. [Mirakhur, B.] Ipsen Biopharmaceut, Basking Ridge, NJ USA. [Massien, C.] Ipsen Biopharmaceut, Boulogne, France. [Caplin, M.] Royal Free Hosp, London, England. NR 0 TC 0 Z9 0 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0028-3835 EI 1423-0194 J9 NEUROENDOCRINOLOGY JI Neuroendocrinology PY 2016 VL 103 SU 1 MA R11 BP 118 EP 118 PG 1 WC Endocrinology & Metabolism; Neurosciences SC Endocrinology & Metabolism; Neurosciences & Neurology GA EA3ED UT WOS:000386481600308 ER PT J AU Moura, LMVR Carneiro, TS Cole, AJ Hsu, J Vickrey, BG Hoch, DB AF Moura, Lidia M. V. R. Carneiro, Thiago S. Cole, Andrew J. Hsu, John Vickrey, Barbara G. Hoch, Daniel B. TI Association between addressing antiseizure drug side effects and patient-reported medication adherence in epilepsy SO PATIENT PREFERENCE AND ADHERENCE LA English DT Article DE epilepsy; antiepileptic drug side effects; medication adherence ID NURSING-HOME RESIDENTS; ANTIEPILEPTIC DRUG; QUALITY MEASURES; SELF-MANAGEMENT; COMBINATION THERAPY; SEIZURE CONTROL; OLDER-ADULTS; PHONE SURVEY; CARE; NONADHERENCE AB Background and aim: Adherence to treatment is a critical component of epilepsy management. This study examines whether addressing antiepileptic drug (AED) side effects at every visit is associated with increased patient-reported medication adherence. Patients and methods: This study identified 243 adults with epilepsy who were seen at two academic outpatient neurology settings and had at least two visits over a 3-year period. Demographic and clinical characteristics were abstracted. Evidence that AED side effects were addressed was measured through 1) phone interview (patient-reported) and 2) medical records abstraction (physician-documented). Medication adherence was assessed using the validated Morisky Medication Adherence Scale-4. Complete adherence was determined as answering "no" to all questions. Results: Sixty-two (25%) patients completed the interviews. Participants and nonparticipants were comparable with respect to demographic and clinical characteristics; however, a smaller proportion of participants had a history of drug-resistant epilepsy than nonparticipants (17.7% vs 30.9%, P=0.04). Among the participants, evidence that AED side effects were addressed was present in 48 (77%) medical records and reported by 51 (82%) patients. Twenty-eight (45%) patients reported complete medication adherence. The most common reason for incomplete adherence was missed medication due to forgetfulness (n=31, 91%). There was no association between addressing AED side effects (neither physician-documented nor patient-reported) and complete medication adherence (P=0.22 and 0.20). Discussion and conclusion: Among patients with epilepsy, addressing medication side effects at every visit does not appear to increase patient-reported medication adherence. C1 [Moura, Lidia M. V. R.; Carneiro, Thiago S.; Cole, Andrew J.; Hoch, Daniel B.] Massachusetts Gen Hosp, Dept Neurol, 55 Fruit St,Wang 739D, Boston, MA 02114 USA. [Hsu, John] Massachusetts Gen Hosp, Dept Med, Mongan Inst Hlth Policy, Boston, MA 02114 USA. [Hsu, John] Harvard Med Sch, Dept Hlth Care Policy, Boston, MA USA. [Vickrey, Barbara G.] Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA. RP Moura, LMVR (reprint author), Massachusetts Gen Hosp, Dept Neurol, 55 Fruit St,Wang 739D, Boston, MA 02114 USA. EM lidia.moura@mgh.harvard.edu FU National Institutes of Health; Clinical Research Fellowship - American Brain Foundation FX The authors acknowledge Hui Zheng, PhD, for statistical consultation through the Harvard Catalyst Biostatistical Consulting Program, funded by the National Institutes of Health.; The study was funded by a 2015 Clinical Research Fellowship sponsored by the American Brain Foundation. The funding body had no role in the design of the study, in collection, analysis, and interpretation of data, and in writing the manuscript. NR 66 TC 0 Z9 0 U1 1 U2 1 PU DOVE MEDICAL PRESS LTD PI ALBANY PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND SN 1177-889X J9 PATIENT PREFER ADHER JI Patient Prefer. Adherence PY 2016 VL 10 BP 2197 EP 2207 DI 10.2147/PPA.S119973 PG 11 WC Medicine, General & Internal SC General & Internal Medicine GA EA9XK UT WOS:000386997800001 PM 27826186 ER PT J AU Williams, CS Spitz, MC Foley, JF Weaver, LK Lindblad, AS Wierzbicki, MR AF Williams, Christopher S. Spitz, Mark C. Foley, John F. Weaver, Lindell K. Lindblad, Anne S. Wierzbicki, Michael R. TI Baseline EEG abnormalities in mild traumatic brain injury from the BIMA study SO UNDERSEA AND HYPERBARIC MEDICINE LA English DT Article DE mild traumatic brain injury; EEG; slowing ID HEAD-INJURY; CONCUSSION; CARE AB The Brain Injury and Mechanisms of Action of HBO2 for Persistent Post-Concussive Symptoms after Mild Traumatic Brain Injury (BIMA), sponsored by the Department of Defense, is a randomized, double-blind, sham controlled trial of hyperbaric oxygen (HBO2) in service members with persistent post-concussive symptoms following mild TBI, undergoing comprehensive assessments. The clinical EEG was assessed by neurologists for slow wave activity, ictal/interictal epileptiform abnormalities, and background periodic discharges. There is scant literature about EEG findings in this population, so we report baseline clinical EEG results and explore associations with other evaluations, including demographics, medication, neurological assessments, and clinical MRI outcomes. Seventy-one participants were enrolled: median age 32 years, 99% male, 49% comorbid PTSD, 28% with mTBI in the previous year, 32% blast injuries only, and 73% multiple injuries. All participants reported medication use (mean medications = 8, SD = 5). Slowing was present in 39%: generalized 37%, localized 8%, both 6%. No other abnormalities were identified. Slowing was not significantly associated with demographics, medication or neurological evaluation. Participants without EEG abnormalities paradoxically had significantly higher number of white matter hyperintensities as identified on MRI (p = 0.003). EEG slowing is present in more than one-third of participants in this study without evidence of associations with demographics, medications or neurological findings. C1 [Williams, Christopher S.; Spitz, Mark C.; Foley, John F.] Lovelace Biomed Res, Albuquerque, NM USA. [Williams, Christopher S.] Univ Colorado, CHMG Neurosci, Colorado Springs, CO 80907 USA. [Spitz, Mark C.] Univ Colorado, Hlth Sci Ctr, Aurora, CO USA. [Spitz, Mark C.] Denver Vet Affairs Med Ctr, Denver, CO USA. [Foley, John F.] Intermt LDS Hosp, Rocky Mt Neurol Associates, Salt Lake City, UT USA. [Weaver, Lindell K.] Intermt Med Ctr, Div Hyperbar Med, Murray, UT 84107 USA. [Weaver, Lindell K.] Intermt LDS Hosp, Salt Lake City, UT 84143 USA. [Weaver, Lindell K.] Univ Utah, Sch Med, Dept Med, Salt Lake City, UT 84132 USA. [Lindblad, Anne S.; Wierzbicki, Michael R.] Emmes Corp, Rockville, MD USA. RP Weaver, LK (reprint author), Intermt Med Ctr, Div Hyperbar Med, Murray, UT 84107 USA.; Weaver, LK (reprint author), Intermt LDS Hosp, Salt Lake City, UT 84143 USA.; Weaver, LK (reprint author), Univ Utah, Sch Med, Dept Med, Salt Lake City, UT 84132 USA. EM lindell.weaver@imail.org FU U.S. Army Medical Materiel Development Activity FX This work was supported by the U.S. Army Medical Materiel Development Activity. Any opinions, findings and conclusions or recommendations expressed in this material are those of the authors and do not necessarily reflect the views of the U.S. Army or its subordinate activities. Because the BIMA study is still ongoing, clinical trial data summarized in this publication has not yet been locked and is therefore subject to change. NR 25 TC 1 Z9 1 U1 0 U2 0 PU UNDERSEA & HYPERBARIC MEDICAL SOC INC PI DURHAM PA 21 WEST COLONY PLACE, STE 280, DURHAM, NC 27705 USA SN 1066-2936 J9 UNDERSEA HYPERBAR M JI Undersea Hyperb. Med. PY 2016 VL 43 IS 5 SI SI BP 521 EP 530 PG 10 WC Marine & Freshwater Biology; Medicine, Research & Experimental SC Marine & Freshwater Biology; Research & Experimental Medicine GA EA8EE UT WOS:000386867300004 ER PT J AU Canbay, A Sowa, JP Syn, WK Treckmann, J AF Canbay, Ali Sowa, Jan-Peter Syn, Wing-Kin Treckmann, Juergen TI NASH Cirrhosis - the New Burden in Liver Transplantation: How Should It Be Managed? SO VISCERAL MEDICINE LA English DT Review DE Non-alcoholic fatty liver disease, NAFLD; Non-alcoholic steatohepatitis, NASH; Alcoholic steatohepatitis, ASH; Transplantation ID FREE FATTY-ACIDS; NONALCOHOLIC STEATOHEPATITIS; HEPATOCELLULAR-CARCINOMA; BARIATRIC SURGERY; DISEASE; KIDNEY; RECIPIENTS; STEATOSIS; MORTALITY; OUTCOMES AB Background: Non-alcoholic fatty liver disease (NAFLD) is a continuously increasing cause of chronic liver disease and a health burden in all populations affected by the obesity and metabolic syndrome pandemic. Cirrhotic alterations or hepatocellular carcinoma developing from NAFLD may require liver transplantation (LTx). Methods: Current literature was screened for data on LTx in the setting of NAFLD. Results: NAFLD-associated LTx is expected to increase in number and relevance during the next decade. NAFLD is part of the metabolic syndrome and thus connected to various metabolic alterations and comorbidities such as diabetes or hyperlipidemia. Moreover, NAFLD comprises an independent risk factor for cardiovascular and chronic kidney disease, which again are important risk factors for outcome of surgical interventions. Postoperative immunosuppression, possible steatosis of the liver graft, and a continued presence of metabolic alterations may lead to early recurrence of steatosis or even non-alcoholic steatohepatitis. Currently, no data are available on combined approaches of weight loss and LTx for NAFLD. Conclusion: Specific guidelines on how to manage NAFLD-associated LTx are lacking. This particular situation requires close monitoring of metabolic syndrome-associated comorbidities. NAFLD represents a novel challenge to established LTx procedures. (C) 2016 S. Karger GmbH, Freiburg C1 [Canbay, Ali; Sowa, Jan-Peter] Univ Duisburg, Univ Hosp, Dept Gastroenterol & Hepatol, Essen, Germany. [Syn, Wing-Kin] Med Univ South Carolina, Div Gastroenterol & Hepatol, Charleston, SC 29425 USA. [Syn, Wing-Kin] Ralph H Johnson Vet Affairs Med Ctr, Gastroenterol Sect, Charleston, SC USA. [Treckmann, Juergen] Univ Duisburg, Univ Hosp, Dept Gen Visceral & Transplantat Surg, Essen, Germany. RP Canbay, A (reprint author), Univ Klin Essen, Klin Gastroenterol & Hepatol, Hufelandstr 55, D-45122 Essen, Germany. EM ali.canbay@uni-due.de NR 37 TC 3 Z9 3 U1 1 U2 1 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 2297-4725 EI 2297-475X J9 VISC MED JI Visc. Med. PY 2016 VL 32 IS 4 BP 234 EP 238 DI 10.1159/000446379 PG 5 WC Surgery SC Surgery GA EB0SG UT WOS:000387055100002 PM 27722159 ER PT S AU Scaduto, DA Hu, YH Lu, YH Huang, HL Liu, JX Rinaldi, K Gindi, G Fisher, PR Zhao, W AF Scaduto, David A. Hu, Yue-Houng Lu, Yihuan Huang, Hailiang Liu, Jingxuan Rinaldi, Kim Gindi, Gene Fisher, Paul R. Zhao, Wei BE Tingberg, A Lang, K Timberg, P TI Dependence of Contrast-Enhanced Lesion Detection in Contrast-Enhanced Digital Breast Tomosynthesis on Imaging Chain Design SO BREAST IMAGING, IWDM 2016 SE Lecture Notes in Computer Science LA English DT Proceedings Paper CT 13th International Workshop on Breast Imaging (IWDM) CY JUN 19-22, 2016 CL Malmo, SWEDEN DE Contrast-enhanced digital mammography; Contrast-enhanced digital breast tomosynthesis; Digital breast tomosynthesis; X-ray imaging; SDNR ID SPECTRAL MAMMOGRAPHY; MRI; WOMEN AB Contrast-enhanced digital breast tomosynthesis (CEDBT) may improve contrast-enhanced lesion conspicuity and relative contrast quantification by improving three-dimensional visualization of lesion morphology, and reducing the integration of attenuation information along the axial direction. Improved visualization of patterns of contrast-enhancement and improved iodine quantification may help differentiate between malignant and benign enhancing lesions. The dependence of dual-energy contrast-enhanced lesion detectability on imaging chain design is investigated. Lesion detectability and relative iodine quantification is comparable for subtraction in either reconstruction or projection domains for both phantom and patient images. SART generally produces greater SDNR than FBP, and scatter correcting projections further improves SDNR. C1 [Scaduto, David A.; Huang, Hailiang; Rinaldi, Kim; Gindi, Gene; Fisher, Paul R.; Zhao, Wei] SUNY Stony Brook, Dept Radiol, Stony Brook, NY 11794 USA. [Hu, Yue-Houng] Dana Farber Canc Inst, Dept Radiat Oncol, Div Med Phys & Biophys, Boston, MA 02115 USA. [Hu, Yue-Houng] Harvard Med Sch, Boston, MA 02115 USA. [Lu, Yihuan] Yale Univ, Dept Radiol, New Haven, CT 06520 USA. [Lu, Yihuan] Yale Univ, Dept Biomed Engn, New Haven, CT 06520 USA. [Liu, Jingxuan] SUNY Stony Brook, Dept Pathol, Stony Brook, NY 11794 USA. RP Scaduto, DA (reprint author), SUNY Stony Brook, Dept Radiol, Stony Brook, NY 11794 USA. EM david.scaduto@stonybrookmedicine.edu NR 13 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER INT PUBLISHING AG PI CHAM PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND SN 0302-9743 BN 978-3-319-41546-8; 978-3-319-41545-1 J9 LECT NOTES COMPUT SC PY 2016 VL 9699 BP 136 EP 144 DI 10.1007/978-3-319-41546-8_18 PG 9 WC Computer Science, Software Engineering; Computer Science, Theory & Methods; Imaging Science & Photographic Technology; Radiology, Nuclear Medicine & Medical Imaging SC Computer Science; Imaging Science & Photographic Technology; Radiology, Nuclear Medicine & Medical Imaging GA BG0LB UT WOS:000386324200018 ER PT J AU Guan, Q Jiang, MY Wu, JH Zhai, YP Wu, Y Bao, K Zhang, WG AF Guan, Qi Jiang, Mingyang Wu, Junhui Zhai, Yanpeng Wu, Yue Bao, Kai Zhang, Weige TI Direct cycle between co-product and reactant: an approach to improve the atom economy and its application in the synthesis and protection of primary amines SO GREEN CHEMISTRY LA English DT Article ID NINGALIN B ANALOGS; GABRIEL SYNTHESIS; GREEN CHEMISTRY; EFFICIENCY; PHTHALIMIDES; GLUCOSAMINE; INHIBITORS; CATALYSIS; DESIGN; AGENTS AB Two important goals of green chemistry are to maximize the efficiency of reactants and to minimize the production of waste. In this study, a novel approach to improve the atom economy of a chemical process was developed by incorporating a direct cycle between a co-product and a reactant of the same reaction. To demonstrate this concept, recoverable 3,4-diphenylmaleic anhydride (1) was designed and used for the atom-economical synthesis of aliphatic primary amines from aqueous ammonia. In each individual cycle, only ammonia and alkyl halide were consumed, and 1 was recovered in nearly a quantitative yield. In this approach for developing atom-economical protecting agents, 1 showed good performance as a recoverable protecting agent for primary amines. The broad substrate scope, good tolerance to various reaction conditions, and high reaction and recovery rates make 1 a valuable complement to conventional primary amine protecting agents. C1 [Guan, Qi; Jiang, Mingyang; Wu, Junhui; Zhai, Yanpeng; Wu, Yue; Bao, Kai; Zhang, Weige] Shenyang Pharmaceut Univ, Key Lab Struct Based Drug Design & Discovery, Minist Educ, Shenyang 110016, Peoples R China. [Bao, Kai] Massachusetts Gen Hosp, Dept Radiol, Div Nucl Med & Mol Imaging, Gordon Ctr Med Imaging, Boston, MA 02214 USA. [Bao, Kai] Harvard Med Sch, Boston, MA 02214 USA. RP Bao, K; Zhang, WG (reprint author), Shenyang Pharmaceut Univ, Key Lab Struct Based Drug Design & Discovery, Minist Educ, Shenyang 110016, Peoples R China.; Bao, K (reprint author), Massachusetts Gen Hosp, Dept Radiol, Div Nucl Med & Mol Imaging, Gordon Ctr Med Imaging, Boston, MA 02214 USA.; Bao, K (reprint author), Harvard Med Sch, Boston, MA 02214 USA. EM baokai@syphu.edu.cn; zhangweige@syphu.edu.cn FU National ST Major Project [2012ZX09103101-060]; National Natural Science Foundation of China [81502932]; Shenyang Science & Technology Bureau Item [F13-316-1-56]; Program for Innovative Research Team of the Ministry of Education and Program for Liaoning Innovative Research Team in University FX We gratefully acknowledge the National S&T Major Project (2012ZX09103101-060), the National Natural Science Foundation of China (81502932), and the Shenyang Science & Technology Bureau Item (No. F13-316-1-56) for generous financial support. This work was also supported by Program for Innovative Research Team of the Ministry of Education and Program for Liaoning Innovative Research Team in University. We thank Professor Motomu Kanai, University of Tokyo, for helpful discussions. NR 34 TC 1 Z9 1 U1 5 U2 5 PU ROYAL SOC CHEMISTRY PI CAMBRIDGE PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND SN 1463-9262 EI 1463-9270 J9 GREEN CHEM JI Green Chem. PY 2016 VL 18 IS 21 BP 5794 EP 5799 DI 10.1039/c6gc01318j PG 6 WC Chemistry, Multidisciplinary; GREEN & SUSTAINABLE SCIENCE & TECHNOLOGY SC Chemistry; Science & Technology - Other Topics GA EA2LX UT WOS:000386425000013 ER PT J AU Gjesteby, L De Man, B Jin, YN Paganetti, H Verburg, J Giantsoudi, D Wang, G AF Gjesteby, Lars De Man, Bruno Jin, Yannan Paganetti, Harald Verburg, Joost Giantsoudi, Drosoula Wang, Ge TI Metal Artifact Reduction in CT: Where Are We After Four Decades? SO IEEE ACCESS LA English DT Article DE Biomedical imaging; computed tomography; radiation therapy; reconstruction algorithms; metal artifact reduction ID X-RAY CT; CONE-BEAM CT; DUAL-ENERGY CT; HELICAL COMPUTED-TOMOGRAPHY; IMAGE-RECONSTRUCTION; PROJECTION DATA; STREAK ARTIFACTS; HIP PROSTHESES; REFORMATTED PROJECTIONS; TRANSMISSION TOMOGRAPHY AB Methods to overcome metal artifacts in computed tomography (CT) images have been researched and developed for nearly 40 years. When X-rays pass through a metal object, depending on its size and density, different physical effects will negatively affect the measurements, most notably beam hardening, scatter, noise, and the non-linear partial volume effect. These phenomena severely degrade image quality and hinder the diagnostic power and treatment outcomes in many clinical applications. In this paper, we first review the fundamental causes of metal artifacts, categorize metal object types, and present recent trends in the CT metal artifact reduction (MAR) literature. To improve image quality and recover information about underlying structures, many methods and correction algorithms have been proposed and tested. We comprehensively review and categorize these methods into six different classes of MAR: metal implant optimization, improvements to the data acquisition process, data correction based on physics models, modifications to the reconstruction algorithm (projection completion and iterative reconstruction), and image-based post-processing. The primary goals of this paper are to identify the strengths and limitations of individual MAR methods and overall classes, and establish a relationship between types of metal objects and the classes that most effectively overcome their artifacts. The main challenges for the field of MAR continue to be cases with large, dense metal implants, as well as cases with multiple metal objects in the field of view. Severe photon starvation is difficult to compensate for with only software corrections. Hence, the future of MAR seems to be headed toward a combined approach of improving the acquisition process with dual-energy CT, higher energy X-rays, or photon-counting detectors, along with advanced reconstruction approaches. Additional outlooks are addressed, including the need for a standardized evaluation system to compare MAR methods. C1 [Gjesteby, Lars; Wang, Ge] Rensselaer Polytech Inst, Dept Biomed Engn, Biomed Imaging Ctr, Troy, NY 12180 USA. [De Man, Bruno; Jin, Yannan] Gen Elect Global Res Ctr, Image Reconstruct Lab, Niskayuna, NY 12309 USA. [Paganetti, Harald; Verburg, Joost; Giantsoudi, Drosoula] Harvard Med Sch, Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. RP Wang, G (reprint author), Rensselaer Polytech Inst, Dept Biomed Engn, Biomed Imaging Ctr, Troy, NY 12180 USA.; De Man, B (reprint author), Gen Elect Global Res Ctr, Image Reconstruct Lab, Niskayuna, NY 12309 USA. EM deman@ge.com; ge-wang@ieee.org NR 137 TC 0 Z9 0 U1 2 U2 2 PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC PI PISCATAWAY PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA SN 2169-3536 J9 IEEE ACCESS JI IEEE Access PY 2016 VL 4 BP 5826 EP 5849 DI 10.1109/ACCESS.2016.2608621 PG 24 WC Computer Science, Information Systems; Engineering, Electrical & Electronic; Telecommunications SC Computer Science; Engineering; Telecommunications GA DZ7WD UT WOS:000386078300023 ER PT J AU Akay, M Dragomir, A Akay, YM Chen, FH Post, A Jneid, H Paniagua, D Denktas, A Bozkurt, B AF Akay, Metin Dragomir, Andrei Akay, Yasemin M. Chen, Feihua Post, Allison Jneid, Hani Paniagua, David Denktas, AlI Bozkurt, Biykem TI The Assessment of Stent Effectiveness Using a Wearable Beamforming MEMS Microphone Array System SO IEEE JOURNAL OF TRANSLATIONAL ENGINEERING IN HEALTH AND MEDICINE-JTEHM LA English DT Article DE Coronary artery disease; nonlinear dynamics analysis; MEMs microphone array; approximate entropy ID CORONARY-ARTERY STENOSIS; SIROLIMUS-ELUTING STENT; DIASTOLIC MURMUR; NONINVASIVE DETECTION; APPROXIMATE ENTROPY; COMPLEXITY-MEASURES; SOURCE LOCALIZATION; STANDARD STENT; DISEASE; PHONOANGIOGRAPHY AB Studies involving turbulent flow have been carried out in many parts of the cardiovascular system, and it has been widely reported that turbulence related to stenosis (narrowing) of arteries creates audible sounds, which may be analyzed to yield information about the nature and severity of the blockage. Results so far indicate that the high frequency content of the sounds generally increases with the degree of stenosis. In this paper, we designed and built an MEMs microphone array and a signal acquisition board to improve the detection of coronary occlusions using an approach based on the recording and analysis of isolated diastolic heart sounds associated with turbulent blood flow in occluded coronary arteries. The nonlinear dynamic analysis method based on approximate entropy has been proposed for the analysis of diastolic heart sounds from patients with single coronary occlusions, before and after stent placement procedures. The nonlinear dynamic analysis (approximate entropy) measures of the diastolic heart sounds recorded from eight patients with single coronary occlusions and two normal subjects were estimated. In addition, a spectral analysis based on the fast Fourier transform was used to estimate the energy content of the recorded signals. Results suggest the presence of high nonlinear (approximate entropy) values of diastolic heart sounds associated with coronary artery disease (p < 0.01) as well as significant differences in the energy content of the heart sound signals above and below 150 Hz (p < 0.05). C1 [Akay, Metin; Dragomir, Andrei; Akay, Yasemin M.; Chen, Feihua; Post, Allison] Univ Houston, Dept Biomed Engn, Houston, TX 77204 USA. [Jneid, Hani; Paniagua, David; Denktas, AlI; Bozkurt, Biykem] DeBakey VA Med Ctr, Winters Ctr Heart Failure Res, Houston, TX 77030 USA. [Jneid, Hani; Paniagua, David; Denktas, AlI; Bozkurt, Biykem] Baylor Coll Med, Cardiovasc Res Inst, Houston, TX 77030 USA. RP Akay, M (reprint author), Univ Houston, Dept Biomed Engn, Houston, TX 77204 USA. EM makay58@gmail.com NR 56 TC 0 Z9 0 U1 1 U2 1 PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC PI PISCATAWAY PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA SN 2168-2372 J9 IEEE J TRANSL ENG HE JI IEEE J. Transl. Eng. Health Med.-JTEHM PY 2016 VL 4 AR 1900310 DI 10.1109/JTEHM.2016.2609901 PG 10 WC Engineering, Biomedical SC Engineering GA EA0CE UT WOS:000386251500001 ER PT J AU Collins, JM Reizes, O Dempsey, MK AF Collins, John M. Reizes, Ofer Dempsey, Michael K. TI Healthcare Commercialization Programs: Improving the Efficiency of Translating Healthcare Innovations From Academia Into Practice SO IEEE JOURNAL OF TRANSLATIONAL ENGINEERING IN HEALTH AND MEDICINE-JTEHM LA English DT Article DE Valley of death; I-Corps; commercialization; translational research; healthcare innovation AB Academic investigators are generating a plethora of insights and technologies that have the potential to significantly improve patient care. However, to address the imperative to improve the quality, cost and access to care with ever more constrained funding, the efficiency and the consistency with which they are translated into cost effective products and/or services need to improve. Healthcare commercialization programs (HCPs) are described and proposed as an option that institutions can add to their portfolio to improve translational research. In helping teams translate specific healthcare innovations into practice, HCPs expand the skillset of investigators and enhance an institution's innovation capacity. Lessons learned are shared from configuring and delivering HCPs, which build on the fundamentals of the National Science Foundation's Innovation Corps program, to address the unique challenges in supporting healthcare innovations and innovators. C1 [Collins, John M.; Dempsey, Michael K.] Massachusetts Gen Hosp, Consortia Improving Med Innovat & Technol, Boston, MA 02115 USA. [Reizes, Ofer] Cleveland Clin Fdn, Lerner Res Inst, Dept Cellular & Mol Med, Cleveland, OH 44195 USA. RP Collins, JM (reprint author), Massachusetts Gen Hosp, Consortia Improving Med Innovat & Technol, Boston, MA 02115 USA. EM jcollins11@partners.org FU NHLBI NIH HHS [U54 HL119810] NR 15 TC 0 Z9 0 U1 0 U2 0 PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC PI PISCATAWAY PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA SN 2168-2372 J9 IEEE J TRANSL ENG HE JI IEEE J. Transl. Eng. Health Med.-JTEHM PY 2016 VL 4 AR 3500107 DI 10.1109/JTEHM.2016.2609915 PG 7 WC Engineering, Biomedical SC Engineering GA EA0CO UT WOS:000386252700001 PM 27766188 ER PT J AU Jeun, M Park, S Lee, H Lee, KH AF Jeun, Minhong Park, Sungwook Lee, Hakho Lee, Kwan Hyi TI Highly sensitive detection of protein biomarkers via nuclear magnetic resonance biosensor with magnetically engineered nanoferrite particles SO INTERNATIONAL JOURNAL OF NANOMEDICINE LA English DT Article DE biosensor; NMR; nanoferrite particles; transverse relaxation; magnetization; onsite detection ID CARE-ASSOCIATED INFECTIONS; NANOPARTICLES; RELAXATION; DIAGNOSIS; SPHERES; CANCER; CELLS AB Magnetic-based biosensors are attractive for on-site detection of biomarkers due to the low magnetic susceptibility of biological samples. Here, we report a highly sensitive magnetic-based biosensing system that is composed of a miniaturized nuclear magnetic resonance (NMR) device and magnetically engineered nanoferrite particles (NFPs). The sensing performance, also identified as the transverse relaxation (R-2) rate, of the NMR device is directly related to the magnetic properties of the NFPs. Therefore, we developed magnetically engineered NFPs (MnMg-NFP) and used them as NMR agents to exhibit a significantly improved R-2 rate. The magnetization of the MnMg-NFPs was increased by controlling the Mn and Mg cation concentration and distribution during the synthesis process. This modification of the Mn and Mg cation directly contributed to improving the R-2 rate. The miniaturized NMR system, combined with the magnetically engineered MnMg-NFPs, successfully detected a small amount of infectious influenza A H1N1 nucleoprotein with high sensitivity and stability. C1 [Jeun, Minhong; Park, Sungwook; Lee, Kwan Hyi] Korea Inst Sci & Technol, Ctr Biomat, Biomed Res Inst, Seoul 02792, South Korea. [Park, Sungwook; Lee, Kwan Hyi] Korea Univ Sci & Technol, Dept Biomed Engn, Daejeon, South Korea. [Lee, Hakho] Harvard Med Sch, Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA USA. RP Lee, KH (reprint author), Korea Inst Sci & Technol, Ctr Biomat, Biomed Res Inst, Seoul 02792, South Korea. EM kwanhyi@kist.re.kr FU Basic Science Research Program through the National Research Foundation of Korea (NRF) - Ministry of Education [2013R1A6A3A04063923]; Bio & Medical Technology Development Program of the NRF - Korean government MSIP [2015M3A9E2029265]; Korea Health Technology R&D Project through the Korea Health Industry Development Institute - Ministry of Health and Welfare, Republic of Korea [HI15C-3078-020015] FX This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (2013R1A6A3A04063923), the Bio & Medical Technology Development Program of the NRF funded by the Korean government MSIP (2015M3A9E2029265), and Korea Health Technology R&D Project through the Korea Health Industry Development Institute funded by the Ministry of Health and Welfare, Republic of Korea (HI15C-3078-020015). NR 21 TC 0 Z9 0 U1 1 U2 1 PU DOVE MEDICAL PRESS LTD PI ALBANY PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND SN 1178-2013 J9 INT J NANOMED JI Int. J. Nanomed. PY 2016 VL 11 BP 5497 EP 5503 DI 10.2147/IJN.S118156 PG 7 WC Nanoscience & Nanotechnology; Pharmacology & Pharmacy SC Science & Technology - Other Topics; Pharmacology & Pharmacy GA DZ9WF UT WOS:000386231000003 PM 27799772 ER PT J AU Adams, ZW McCauley, JL Back, SE Flanagan, JC Hanson, RF Killeen, TK Danielson, CK AF Adams, Zachary W. McCauley, Jenna L. Back, Sudie E. Flanagan, Julianne C. Hanson, Rochelle F. Killeen, Therese K. Danielson, Carla Kmett TI Clinician Perspectives on Treating Adolescents with Co-occurring Post-Traumatic Stress Disorder, Substance Use, and Other Problems SO JOURNAL OF CHILD & ADOLESCENT SUBSTANCE ABUSE LA English DT Article DE adolescents; comorbidity; PTSD; substance use; treating adolescents ID RANDOMIZED CONTROLLED-TRIAL; MENTAL-HEALTH; NATIONAL-SURVEY; ABUSE; PTSD; TRAUMA; COMORBIDITY; RISK; CHALLENGES; DEPRESSION AB Clinicians (N = 138) who treat adolescents with co-occurring Post-Traumatic Stress Disorder (PTSD) and substance use disorder (SUD), (PTSD+SUD) were surveyed about their attitudes and practice behaviors. Most providers were trained in PTSD treatment; fewer were trained in SUD or PTSD+SUD treatments. PTSD+SUD treatment was rated more difficult than treatment of other diagnoses. Providers typically addressed symptoms of PTSD and SUD separately and sequentially, rather than with integrated approaches. There was no consensus about which clinical strategies to use with adolescent PTSD+SUD. Continued treatment development, training, and dissemination efforts are needed to equip providers with resources to deliver effective treatments to adolescents with PTSD+SUD. C1 [Adams, Zachary W.; McCauley, Jenna L.; Back, Sudie E.; Flanagan, Julianne C.; Hanson, Rochelle F.; Killeen, Therese K.; Danielson, Carla Kmett] Med Univ South Carolina, Charleston, SC USA. [Back, Sudie E.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. RP Adams, ZW (reprint author), Med Univ South Carolina, Dept Psychiat & Behav Sci, 67 President St,MSC 861, Charleston, SC 29425 USA. EM adamsz@musc.edu FU NIDA [K12 DA031794, K23 DA036566, K23 DA038257, K02 DA039229, K24 DA039783, R01DA031285, DA030143]; NIAAA [P50 AA010761]; NICHD [K12 HD 055885]; SAMHSA [1 U79SM061269]; NIH/NCATS [UL1TR000062]; NIH/NCRR [UL1 RR029882] FX The preparation of this manuscript was supported by NIDA grants K12 DA031794 (sponsoring ZWA; PIs: Kathleen Brady and Robert Malcolm), K23 DA036566 (PI: McCauley), K23 DA038257 (PI: Adams), K02 DA039229 (PI: Back), K24 DA039783 (PI: Danielson), and R01DA031285 (PI: Danielson), NIAAA grant P50 AA010761 (PI of Center: Howard Becker; PI of Clinical Component 5: Danielson), NICHD grant K12 HD 055885 (PI: Brady) and SAMHSA grant 1 U79SM061269 (PI: Rochelle Hanson). The study was also facilitated by NIH/NCATS grant UL1TR000062 (PI: Kathleen Brady) and NIH/NCRR grant UL1 RR029882 (PI: Kathleen Brady), which supports the South Carolina Clinical and Translational Research Institute (SCTR), as well as NIDA grant DA030143 (PI: Back). The funding sources did not have any involvement in the study design; collection, analysis, or interpretation of data; writing of the report; or the decision to submit the article for publication. NR 38 TC 0 Z9 0 U1 3 U2 3 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 1067-828X EI 1547-0652 J9 J CHILD ADOLES SUBST JI J. Child Adolesc. Subst. Abus. PY 2016 VL 25 IS 6 BP 575 EP 583 DI 10.1080/1067828X.2016.1153555 PG 9 WC Substance Abuse SC Substance Abuse GA EA3GF UT WOS:000386489100009 PM 27840568 ER PT J AU Mamon, D Solomon, Z Dekel, S AF Mamon, Daria Solomon, Zahava Dekel, Sharon TI Obsessive Compulsive Symptoms Predict Posttraumatic Growth: A Longitudinal Study SO JOURNAL OF LOSS & TRAUMA LA English DT Article DE Obsessive-compulsive symptoms; posttraumatic growth; posttraumatic stress disorder ID DISORDER AB Although posttraumatic growth (PTG) has received growing attention, the relationship between PTG and distress remains unclear. This longitudinal study examines the relationship between posttraumatic obsessive-compulsive (OC) symptoms and PTG. Israeli veterans were followed over 17 years using self-report questionnaires of OC symptoms, posttraumatic stress disorder (PTSD), and PTG. Hierarchical regression analyses demonstrated that OC symptoms predicted PTG, even when initial PTG levels and PTSD symptoms were controlled for in the combatants group. These preliminary findings suggest that OC symptoms may play an important role in facilitating psychological growth. Future research is warranted to explore the mechanisms responsible for this relationship. C1 [Mamon, Daria] William James Coll, Dept Clin Psychol, Newton, MA USA. [Solomon, Zahava] Tel Aviv Univ, Sch Social Work, Tel Aviv, Israel. [Solomon, Zahava] I Core Res Ctr Mass Trauma, Tel Aviv, Israel. [Dekel, Sharon] Massachusetts Gen Hosp, Charlestown, MA USA. [Dekel, Sharon] Harvard Med Sch, Dept Psychiat, Boston, MA USA. RP Dekel, S (reprint author), Massachusetts Gen Hosp East, PTSD Res Lab, 120 Second Ave, Charlestown, MA 02129 USA. EM sdekel@mgh.harvard.edu NR 19 TC 0 Z9 0 U1 1 U2 1 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 1532-5024 EI 1532-5032 J9 J LOSS TRAUMA JI J. Loss Trauma PY 2016 VL 21 IS 6 BP 484 EP 491 DI 10.1080/15325024.2015.1117931 PG 8 WC Psychology, Social SC Psychology GA DZ8HT UT WOS:000386112200003 ER PT J AU Baker, AW Keshaviah, A Horenstein, A Goetter, EM Mauro, C Reynolds, CF Zisook, S Shear, MK Simon, NM AF Baker, Amanda W. Keshaviah, Aparna Horenstein, Arielle Goetter, Elizabeth M. Mauro, Christine Reynolds, Charles F., III Zisook, Sidney Shear, M. Katherine Simon, Naomi M. TI The Role of Avoidance in Complicated Grief: A Detailed Examination of the Grief-Related Avoidance Questionnaire (GRAQ) in a Large Sample of Individuals with Complicated Grief SO JOURNAL OF LOSS & TRAUMA LA English DT Article DE Anxiety; avoidance; grief; loss; questionnaire ID SCALE; BEREAVEMENT; IMPAIRMENT; INVENTORY; SYMPTOMS; VALIDITY; TRIAL; MODEL AB Grief-related avoidance is a significant component of complicated grief, yet has rarely been formally measured in a validated fashion. Further, more work is needed to understand the impact of grief-related avoidance on symptom severity and functional impairment among individuals with complicated grief (CG). The Grief-Related Avoidance Questionnaire (GRAQ; Shear, Monk et al. 2007) was created to assess grief-related avoidance and the present analysis aimed to further develop this measure and construct by confirming the GRAQ's psychometric properties and examining loss-related predictors of avoidance. In a sample of 393 adults with CG, we found the GRAQ had high internal consistency, with a Cronbach's alpha of 0.89 and good convergent validity. While the EFA results suggest that the GRAQ may be unidimensional, a 3-factor model generally corresponded with the findings by (Shear, Monk et al. 2007), which suggested the presence of 3 subscales. Loss-related variables age, relationship to the deceased, and cause of death were all significant predictors of GRAQ scores. Our findings support that among individuals with complicated grief, avoidance is common, measurable and an important contributor to impairment. C1 [Baker, Amanda W.; Keshaviah, Aparna; Horenstein, Arielle; Goetter, Elizabeth M.; Simon, Naomi M.] Harvard Med Sch, Dept Psychiat, Massachusetts Gen Hosp, Boston, MA USA. [Mauro, Christine] Columbia Univ, Mailman Sch Publ Hlth, New York, NY USA. [Reynolds, Charles F., III] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA. [Zisook, Sidney] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA. [Shear, M. Katherine] Columbia Univ, Sch Social Work, New York, NY USA. RP Baker, AW (reprint author), One Bowdoin Sq,6th Floor, Boston, MA 02116 USA. EM awbaker@mgh.harvard.edu NR 26 TC 0 Z9 0 U1 0 U2 0 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 1532-5024 EI 1532-5032 J9 J LOSS TRAUMA JI J. Loss Trauma PY 2016 VL 21 IS 6 BP 533 EP 547 DI 10.1080/15325024.2016.1157412 PG 15 WC Psychology, Social SC Psychology GA DZ8HT UT WOS:000386112200007 ER PT J AU Zhang, YS Davoudi, F Walch, P Manbachi, A Luo, X Dell'Erba, V Miri, AK Albadawi, H Arneri, A Li, XY Wang, XY Dokmeci, MR Khademhosseini, A Oklu, R AF Zhang, Yu Shrike Davoudi, Farideh Walch, Philipp Manbachi, Amir Luo, Xuan Dell'Erba, Valeria Miri, Amir K. Albadawi, Hassan Arneri, Andrea Li, Xiaoyun Wang, Xiaoying Dokmeci, Mehmet Remzi Khademhosseini, Ali Oklu, Rahmi TI Bioprinted thrombosis-on-a-chip SO LAB ON A CHIP LA English DT Article ID DEEP-VEIN THROMBOSIS; CATHETER-DIRECTED THROMBOLYSIS; VENOUS THROMBOSIS; MICROFLUIDIC DEVICE; HEART-ASSOCIATION; TISSUE FACTOR; FEMORAL VEIN; WHOLE-BLOOD; MOUSE MODEL; DISEASE AB Pathologic thrombosis kills more people than cancer and trauma combined; it is associated with significant disability and morbidity, and represents a major healthcare burden. Despite advancements in medical therapies and imaging, there is often incomplete resolution of the thrombus. The residual thrombus can undergo fibrotic changes over time through infiltration of fibroblasts from the surrounding tissues and eventually transform into a permanent clot often associated with post-thrombotic syndrome. In order to understand the importance of cellular interactions and the impact of potential therapeutics to treat thrombosis, an in vitro platform using human cells and blood components would be beneficial. Towards achieving this aim, there have been studies utilizing the capabilities of microdevices to study the hemodynamics associated with thrombosis. In this work, we further exploited the utilization of 3D bioprinting technology, for the construction of a highly biomimetic thrombosis-on-a-chip model. The model consisted of microchannels coated with a layer of confluent human endothelium embedded in a gelatin methacryloyl (GelMA) hydrogel, where human whole blood was infused and induced to form thrombi. Continuous perfusion with tissue plasmin activator led to dissolution of non-fibrotic clots, revealing clinical relevance of the model. Further encapsulating fibroblasts in the GelMA matrix demonstrated the potential migration of these cells into the clot and subsequent deposition of collagen type I over time, facilitating fibrosis remodeling that resembled the in vivo scenario. Our study suggests that in vitro 3D bioprinted blood coagulation models can be used to study the pathology of fibrosis, and particularly, in thrombosis. This versatile platform may be conveniently extended to other vascularized fibrotic disease models. C1 [Zhang, Yu Shrike; Davoudi, Farideh; Walch, Philipp; Manbachi, Amir; Luo, Xuan; Dell'Erba, Valeria; Miri, Amir K.; Arneri, Andrea; Li, Xiaoyun; Wang, Xiaoying; Dokmeci, Mehmet Remzi; Khademhosseini, Ali; Oklu, Rahmi] Harvard Med Sch, Brigham & Womens Hosp, Dept Med, Biomat Innovat Res Ctr,Div Engn Med, Cambridge, MA 02139 USA. [Zhang, Yu Shrike; Davoudi, Farideh; Walch, Philipp; Manbachi, Amir; Luo, Xuan; Dell'Erba, Valeria; Miri, Amir K.; Arneri, Andrea; Li, Xiaoyun; Wang, Xiaoying; Dokmeci, Mehmet Remzi; Khademhosseini, Ali; Oklu, Rahmi] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA. [Zhang, Yu Shrike; Dokmeci, Mehmet Remzi; Khademhosseini, Ali] Harvard Univ, Wyss Inst Biol Inspired Engn, Boston, MA 02115 USA. [Walch, Philipp] Heidelberg Univ, Inst Pharm & Mol Biotechnol, Neuenheimer Feld 364, D-69120 Heidelberg, Germany. [Luo, Xuan] Univ Technol Compiegne, Sorbonne Univ, CNRS, UMR 7338,BMBI, Compiegne, France. [Dell'Erba, Valeria] Politecn Torino, Dept Biomed Engn, I-10129 Turin, Italy. [Albadawi, Hassan] Massachusetts Gen Hosp, Dept Surg, Div Vasc & Endovasc Surg, Boston, MA 02114 USA. [Li, Xiaoyun; Wang, Xiaoying] South China Univ Technol, State Key Lab Pulp & Paper Engn, Guangzhou 510640, Guangdong, Peoples R China. [Khademhosseini, Ali] Konkuk Univ, Coll Anim Biosci & Technol, Dept Bioind Technol, Seoul 143701, South Korea. [Khademhosseini, Ali] King Abdulaziz Univ, Dept Phys, Jeddah 21569, Saudi Arabia. [Oklu, Rahmi] Mayo Clin, Div Vasc & Intervent Radiol, Scottsdale, AZ 85259 USA. RP Khademhosseini, A; Oklu, R (reprint author), Harvard Med Sch, Brigham & Womens Hosp, Dept Med, Biomat Innovat Res Ctr,Div Engn Med, Cambridge, MA 02139 USA.; Khademhosseini, A; Oklu, R (reprint author), MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA.; Khademhosseini, A (reprint author), Harvard Univ, Wyss Inst Biol Inspired Engn, Boston, MA 02115 USA.; Khademhosseini, A (reprint author), Konkuk Univ, Coll Anim Biosci & Technol, Dept Bioind Technol, Seoul 143701, South Korea.; Khademhosseini, A (reprint author), King Abdulaziz Univ, Dept Phys, Jeddah 21569, Saudi Arabia.; Oklu, R (reprint author), Mayo Clin, Div Vasc & Intervent Radiol, Scottsdale, AZ 85259 USA. EM alik@bwh.harvard.edu; oklu.rahmi@mayo.edu FU Office of Naval Research Young National Investigator Award; National Institutes of Health [EB012597, AR057837, DE021468, HL099073, R56AI105024, AR068258, AR066193, EB022403, EB021148]; Presidential Early Career Award for Scientists and Engineers (PECASE); National Cancer Institute of the National Institutes of Health Pathway to Independence Award [1K99CA201603-01A1]; Mayo Clinic FX The authors acknowledge funding from the Office of Naval Research Young National Investigator Award, the National Institutes of Health (EB012597, AR057837, DE021468, HL099073, R56AI105024, AR068258, AR066193, EB022403, EB021148), and the Presidential Early Career Award for Scientists and Engineers (PECASE). Y. S. Z. acknowledges the National Cancer Institute of the National Institutes of Health Pathway to Independence Award (1K99CA201603-01A1). R. O. acknowledges additional support from the Mayo Clinic. NR 48 TC 1 Z9 1 U1 11 U2 11 PU ROYAL SOC CHEMISTRY PI CAMBRIDGE PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND SN 1473-0197 EI 1473-0189 J9 LAB CHIP JI Lab Chip PY 2016 VL 16 IS 21 BP 4097 EP 4105 DI 10.1039/c6lc00380j PG 9 WC Biochemical Research Methods; Chemistry, Multidisciplinary; Nanoscience & Nanotechnology SC Biochemistry & Molecular Biology; Chemistry; Science & Technology - Other Topics GA EA0XC UT WOS:000386311100005 PM 27722710 ER PT J AU Labarca, G Aravena, C Ortega, F Arenas, A Majid, A Folch, E Mehta, HJ Jantz, MA Fernandez-Bussy, S AF Labarca, Gonzalo Aravena, Carlos Ortega, Francisco Arenas, Alex Majid, Adnan Folch, Erik Mehta, Hiren J. Jantz, Michael A. Fernandez-Bussy, Sebastian TI Minimally Invasive Methods for Staging in Lung Cancer: Systematic Review and Meta-Analysis SO PULMONARY MEDICINE LA English DT Review ID TRANSBRONCHIAL NEEDLE ASPIRATION; PERIPHERAL PULMONARY-LESIONS; RANDOMIZED CONTROLLED-TRIAL; MEDIASTINAL LYMPH-NODES; ENDOBRONCHIAL ULTRASOUND; ENDOSCOPIC ULTRASOUND; GUIDE-SHEATH; EBUS-TBNA; AMERICAN-COLLEGE; EUS-FNA AB Introduction. Endobronchial ultrasound (EBUS) is a procedure that provides access to the mediastinal staging; however, EBUS cannot be used to stage all of the nodes in the mediastinum. In these cases, endoscopic ultrasound (EUS) is used for complete staging. Objective. To provide a synthesis of the evidence on the diagnostic performance of EBUS + EUS in patients undergoing mediastinal staging. Methods. Systematic review and meta-analysis to evaluate the diagnostic yield of EBUS + EUS compared with surgical staging. Two researchers performed the literature search, quality assessments, data extractions, and analyses. We produced a meta-analysis including sensitivity, specificity, and likelihood ratio analysis. Results. Twelve primary studies (1515 patients) were included; two were randomized controlled trials (RCTs) and ten were prospective trials. The pooled sensitivity for combined EBUS + EUS was 87% (CI 84-89%) and the specificity was 99% (CI 98-100%). For EBUS + EUS performed with a single bronchoscope group, the sensitivity improved to 88% (CI 83.1-91.4%) and specificity improved to 100% (CI 99-100%). Conclusion. EBUS + EUS is a highly accurate and safe procedure. The combined procedure should be considered in selected patients with lymphadenopathy noted at stations that are not traditionally accessible with conventional EBUS. C1 [Labarca, Gonzalo] Univ San Sebastian, Fac Med, Lientur 1457, Concepcion 4080871, Chile. [Labarca, Gonzalo] Complejo Asistencial Victor Rios Ruiz, Div Internal Med, Los Angeles, Chile. [Aravena, Carlos] Pontificia Univ Catolica Chile, Sch Med, Div Pulm Med, Santiago, Chile. [Ortega, Francisco] Pontificia Univ Catolica Chile, Sch Med, Div Oncol, Santiago, Chile. [Arenas, Alex] Pontificia Univ Catolica Chile, Sch Med, Div Internal Med, Santiago, Chile. [Majid, Adnan] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Div Thorac Surg, Boston, MA USA. [Majid, Adnan] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Div Intervent Pulm, Boston, MA USA. [Folch, Erik] Harvard Med Sch, Massachusetts Gen Hosp, Div Pulm & Crit Care Med, Boston, MA USA. [Mehta, Hiren J.; Jantz, Michael A.] Univ Florida, Div Pulm Crit Care & Sleep Med, Gainesville, FL USA. [Fernandez-Bussy, Sebastian] Univ Desarrollo, Clin Alemana, Unidad Neumol Intervenc, Santiago, Chile. RP Labarca, G (reprint author), Univ San Sebastian, Fac Med, Lientur 1457, Concepcion 4080871, Chile.; Labarca, G (reprint author), Complejo Asistencial Victor Rios Ruiz, Div Internal Med, Los Angeles, Chile. EM glabarcat@gmail.com OI Mehta, Hiren/0000-0001-7331-747X; Labarca, Gonzalo/0000-0002-0069-3420 NR 58 TC 0 Z9 0 U1 0 U2 0 PU HINDAWI PUBLISHING CORP PI NEW YORK PA 315 MADISON AVE 3RD FLR, STE 3070, NEW YORK, NY 10017 USA SN 2090-1836 EI 2090-1844 J9 PULM MED JI Pulm. Med. PY 2016 AR 1024709 DI 10.1155/2016/1024709 PG 11 WC Respiratory System SC Respiratory System GA EA1NL UT WOS:000386358900001 ER PT J AU Soreide, K Boermeester, MA Humes, DJ Velmahos, GC AF Soreide, Kjetil Boermeester, Marja A. Humes, David J. Velmahos, George C. TI Acute colonic diverticulitis: modern understanding of pathomechanisms, risk factors, disease burden and severity SO SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY LA English DT Review DE Diverticulitis; colonic-disorders; emergency; prevention; pathophysiology; epidemiology; severity; classification ID RANDOMIZED CLINICAL-TRIAL; UNCOMPLICATED ACUTE DIVERTICULITIS; PREVENT RECURRENT DIVERTICULITIS; ACUTE PERFORATED DIVERTICULITIS; UNITED-STATES; NONOPERATIVE MANAGEMENT; LAPAROSCOPIC LAVAGE; HOSPITAL ADMISSIONS; PROSPECTIVE COHORT; PHYSICAL-ACTIVITY AB Introduction: Conservative, non-antibiotic and non-surgical management of acute diverticulitis is currently being investigated. To better inform clinical decisions, better understanding of disease mechanisms, disease burden and severity is needed.Methods: Literature search of risk factors, pathophysiology, epidemiology and disease burden/severity reported over the last decade.Results: Acute diverticulitis is a common disease and has a high disease burden. Incidence of hospital admissions is reported around 71 per 100,000 population, with reported increase in several subpopulations over the last decades. The incidence is likely to increase further with the aging populations. Risk factors for left-sided acute diverticulitis include dietary, anthropometric and lifestyle factors. Disease mechanisms are still poorly understood, but a distinction between inflammation and infection is emerging. The integrative and complex role of the gut microbiota has become an interesting factor for both understanding the disease as well as a potential target for intervention using probiotics. Mild, self-limiting events are increasingly reported from studies of successful non-antibiotic management in a considerable number of cases. Risk markers of progression to or presence of severe, complicated disease are needed for better disease stratification. Current risk stratification by clinical, imaging or endoscopic means is imperfect and needs validation. Long-term results from minimal-invasive and comparative surgical trials may better help inform clinicians and patients.Conclusions: Over- and under-treatment as well as over- and under-diagnosis of severity is likely to continue in clinical practice due to lack of reliable, robust and universal severity and classification systems. Better understanding of pathophysiology is needed. C1 [Soreide, Kjetil] Stavanger Univ Hosp, Dept Gastrointestinal Surg, Stavanger, Norway. [Soreide, Kjetil] Univ Bergen, Dept Clin Med, Bergen, Norway. [Boermeester, Marja A.] Acad Med Ctr, Dept Surg, Amsterdam, Netherlands. [Humes, David J.] Univ Nottingham, Sch Community Hlth Sci, Div Epidemiol & Publ Hlth, Nottingham, England. [Velmahos, George C.] Massachusetts Gen Hosp, Div Trauma Emergency Surg & Surg Crit Care, Boston, MA 02114 USA. [Velmahos, George C.] Harvard Med Sch, Boston, MA USA. RP Soreide, K (reprint author), Stavanger Univ Hosp, Dept Gastrointestinal Surg, Stavanger, Norway. EM ksoreide@mac.com FU Department of Health [PDF-2012-05-431] NR 81 TC 0 Z9 0 U1 0 U2 0 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND SN 0036-5521 EI 1502-7708 J9 SCAND J GASTROENTERO JI Scand. J. Gastroenterol. PY 2016 VL 51 IS 12 BP 1416 EP 1422 DI 10.1080/00365521.2016.1218536 PG 7 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EA1ZQ UT WOS:000386391200002 PM 27539786 ER PT J AU Oldenburg, CE Le, B Huyen, HT Thien, DD Quan, NH Biello, KB Nunn, A Chan, PA Mayer, KH Mimiaga, MJ Colby, D AF Oldenburg, Catherine E. Le, Bao Hoang Thi Huyen Dinh Duc Thien Nguyen Hoang Quan Biello, Katie B. Nunn, Amy Chan, Philip A. Mayer, Kenneth H. Mimiaga, Matthew J. Colby, Donn TI Antiretroviral pre-exposure prophylaxis preferences among men who have sex with men in Vietnam: results from a nationwide cross-sectional survey SO SEXUAL HEALTH LA English DT Article ID CHI-MINH CITY; TRANSGENDER WOMEN; HIV PREVENTION; YOUNG MEN; RECTAL MICROBICIDES; RISK; ACCEPTABILITY; WORKERS; METAANALYSIS; INFECTION AB Background: The HIV/AIDS epidemic in Vietnam is concentrated in subgroups of the population, including men who have sex with men (MSM). Pre-exposure prophylaxis (PrEP) is a viable strategy for HIV prevention, but knowledge about and preferences for PrEP delivery among Vietnamese MSM are not well understood. Methods: In 2015, an online survey was conducted with recruitment via social networking websites for MSM and peer recruitment. A description of daily oral, long-acting injectable, and rectal microbicide formulations of PrEP was provided to participants. Participants were asked about their prior awareness of and interest in PrEP, and ranked their most preferred PrEP modality. Multivariable logistic regression models were used to assess factors associated with having heard of PrEP and preference for each PrEP modality. Results: Of 548 participants who answered demographic and PrEP-related questions, 26.8% had previously heard of PrEP and most (65.7%) endorsed rectal microbicides as their most preferred PrEP delivery modality. Commonly-cited perceived barriers to uptake of PrEP included concern about side-effects, perception about being HIV positive, and family or friends finding out about their sexual behaviour. In multivariable models, older participants less often endorsed rectal microbicides (adjusted odds ratio (AOR) 0.95 per year, 95% confidence interval (CI) 0.91-0.99) and more often endorsed long-acting injectables (AOR 1.08 per year, 95% CI 1.03 to 1.14) as their preferred PrEP modality. Participants who were willing to pay more for PrEP less often endorsed rectal microbicides (AOR 0.81, 95% CI 0.72-0.92) and more often endorsed long-acting injectables (AOR 1.17, 95% CI 1.01-1.35) and daily oral pills (AOR 1.16, 95% CI 1.00-1.35) as their preferred form of PrEP. Conclusions: A variety of PrEP modalities were acceptable to MSM in Vietnam, but low knowledge of PrEP may be a barrier to implementation. C1 [Oldenburg, Catherine E.; Biello, Katie B.; Mayer, Kenneth H.; Mimiaga, Matthew J.] Fenway Inst, Fenway Community Hlth, 1340 Boylston St, Boston, MA 02215 USA. [Oldenburg, Catherine E.; Biello, Katie B.; Mimiaga, Matthew J.] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, 677 Huntington Ave, Boston, MA 02115 USA. [Le, Bao; Hoang Thi Huyen; Dinh Duc Thien; Nguyen Hoang Quan; Colby, Donn] Ctr Appl Res Men & Hlth, 51-53 Vo Van Tan St,Ward 6,Dist 3, Ho Chi Minh City, Vietnam. [Nunn, Amy] Brown Univ, Sch Publ Hlth, Dept Behav & Social Sci, 121 South Main St, Providence, RI 02903 USA. [Nunn, Amy] Brown Univ, Sch Publ Hlth, Rhode Isl Publ Hlth Inst, 121 South Main St, Providence, RI 02903 USA. [Chan, Philip A.] Miriam Hosp, Div Infect Dis, 1125 N Main St, Providence, RI 02904 USA. [Mayer, Kenneth H.] Harvard TH Chan Sch Publ Hlth, Dept Global Hlth & Populat, 677 Huntington Ave, Boston, MA 02115 USA. [Mayer, Kenneth H.] Beth Israel Deaconess Med Ctr, Dept Med, 300 Brookline Ave, Boston, MA 02215 USA. [Mimiaga, Matthew J.] Massachusetts Gen Hosp, Dept Psychiat, 55 Fruit St, Boston, MA 02114 USA. [Colby, Donn] Thai Red Cross AIDS Res Ctr, SEARCH, 104 Radjumri Rd, Bangkok 10330, Thailand. RP Oldenburg, CE (reprint author), Fenway Inst, Fenway Community Hlth, 1340 Boylston St, Boston, MA 02215 USA.; Oldenburg, CE (reprint author), Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, 677 Huntington Ave, Boston, MA 02115 USA. EM ceo242@mail.harvard.edu OI Chan, Philip/0000-0003-0964-5895 NR 46 TC 0 Z9 0 U1 2 U2 2 PU CSIRO PUBLISHING PI CLAYTON PA UNIPARK, BLDG 1, LEVEL 1, 195 WELLINGTON RD, LOCKED BAG 10, CLAYTON, VIC 3168, AUSTRALIA SN 1448-5028 EI 1449-8987 J9 SEX HEALTH JI Sex Health PY 2016 VL 13 IS 5 BP 465 EP 473 DI 10.1071/SH15144 PG 9 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA DZ6YG UT WOS:000386008200009 ER PT J AU Nickel, E Hansen, A Pearlman, J Goldish, G AF Nickel, Eric Hansen, Andrew Pearlman, Jonathan Goldish, Gary TI A drive system to add standing mobility to a manual standing wheelchair SO ASSISTIVE TECHNOLOGY LA English DT Article DE accessibility; chain drive; manual; mid-wheel drive; mobile; spinal cord injury; stability; standing; wheelchair ID SPINAL-CORD-INJURY; PRESSURE; POSITION; PEOPLE AB Current manual standing wheelchairs are not mobile in the standing position. The addition of standing mobility may lead to improved health and function for the user and may increase utilization of standing wheelchairs. In this project, a chain drive system was fitted to a manual standing wheelchair, adding mobility in the standing position. The hand rims are accessible from both seated and standing positions. The prototype uses 16-inch drive wheels in front with casters in the rear. Additional anterior casters are elevated when seated for navigating obstacles and then descend when standing to create a six-wheeled base with extended anterior support. Stability testing shows the center of pressure remains within the base of support when leaning to the sides or front in both seated and standing positions. Four veterans with spinal cord injury provided feedback on the design and reported that mobility during standing was very important or extremely important to them. The veterans liked the perceived stability and mobility of the prototype and provided feedback for future refinements. For example, reducing the overall width (width from hand rim to hand rim) and weight could make this system more functional for users. C1 [Nickel, Eric; Hansen, Andrew] Minneapolis VA Hlth Care Syst, Minneapolis, MN USA. [Hansen, Andrew] Univ Minnesota, Program Rehabil Sci, Minneapolis, MN USA. [Pearlman, Jonathan] Univ Pittsburgh, Dept Rehab Sci & Technol, Pittsburgh, PA USA. [Pearlman, Jonathan] VA Pittsburgh Healthcare Syst, Human Engn Res Labs, Pittsburgh, PA USA. [Goldish, Gary] Minneapolis VA Hlth Care Syst, Extended Care & Rehabil, Minneapolis, MN USA. [Goldish, Gary] Univ Minnesota, Phys Med & Rehabil, Minneapolis, MN USA. RP Goldish, G (reprint author), Minneapolis VA Med Ctr 11M, Extended Care & Rehabil, One Vet Dr, Minneapolis, MN 55417 USA. EM Gary.Goldish@va.gov FU Paralyzed Veterans of America [2012PVA000RES0000075260]; Department of Veterans Affairs, Rehabilitation Research and Development Service FX The research reported here was supported by the Paralyzed Veterans of America grant no. 2012PVA000RES0000075260 and the Department of Veterans Affairs, Rehabilitation Research and Development Service. NR 12 TC 0 Z9 0 U1 1 U2 1 PU R E S N A PRESS PI ARLINGTON PA 1700 MOORE ST, STE 1540, ARLINGTON, VA 22209-1903 USA SN 1040-0435 EI 1949-3614 J9 ASSIST TECHNOL JI Assist. Technol. PY 2016 VL 28 IS 4 BP 218 EP 224 DI 10.1080/10400435.2016.1165757 PG 7 WC Rehabilitation SC Rehabilitation GA DY8KS UT WOS:000385379500004 ER PT J AU Belanger, HG Lange, RT Bailie, J Iverson, GL Arrieux, JP Ivins, BJ Cole, WR AF Belanger, Heather G. Lange, Rael T. Bailie, Jason Iverson, Grant L. Arrieux, Jacques P. Ivins, Brian J. Cole, Wesley R. TI Interpreting change on the neurobehavioral symptom inventory and the PTSD checklist in military personnel SO CLINICAL NEUROPSYCHOLOGIST LA English DT Article DE Traumatic brain injury; mild TBI; PTSD; military; concussion; reliable change ID TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; POSTCONCUSSION SYMPTOMS; CLINICAL-SIGNIFICANCE; CIVILIAN VERSION; SERVICE MEMBERS; NATIONAL-GUARD; NORMATIVE DATA; IRAQ; ASSOCIATIONS AB Objective: The purpose of this study was to examine the prevalence and stability of symptom reporting in a healthy military sample and to develop reliable change indices for two commonly used self-report measures in the military health care system. Participants and method: Participants were 215 U.S. active duty service members recruited from Fort Bragg, NC as normal controls as part of a larger study. Participants completed the Neurobehavioral Symptom Inventory (NSI) and Posttraumatic Checklist (PCL) twice, separated by approximately 30days. Results: Depending on the endorsement level used (i.e. ratings of mild' or greater vs. ratings of moderate' or greater), approximately 2-15% of this sample met DSM-IV symptom criteria for Postconcussional Disorder across time points, while 1-6% met DSM-IV symptom criteria for Posttraumatic Stress Disorder. Effect sizes for change from Time 1 to Time 2 on individual symptoms were small (Cohen's d=.01 to .13). The test-retest reliability for the NSI total score was r=.78 and the PCL score was r=.70. An eight-point change in symptom reporting represented reliable change on the NSI total score, with a seven-point change needed on the PCL. Conclusions: Postconcussion-like symptoms are not unique to mild TBI and are commonly reported in a healthy soldier sample. It is important for clinicians to use normative data when evaluating a service member or veteran and when evaluating the likelihood that a change in symptom reporting is reliable and clinically meaningful. C1 [Belanger, Heather G.] James A Haley VAMC, Dept Mental Hlth & Behav Sci, Tampa, FL 33612 USA. [Belanger, Heather G.] Univ S Florida, Dept Psychiat & Behav Neurosci, Tampa, FL 33620 USA. [Belanger, Heather G.; Lange, Rael T.; Bailie, Jason; Iverson, Grant L.; Arrieux, Jacques P.; Ivins, Brian J.; Cole, Wesley R.] Def & Vet Brain Injury Ctr, Silver Spring, MD 20910 USA. [Lange, Rael T.] Natl Intrepid Ctr Excellence, Bethesda, MD USA. [Lange, Rael T.] Walter Reed Natl Mil Med Ctr, Bethesda, MD USA. [Lange, Rael T.] Univ British Columbia, Vancouver, BC, Canada. [Bailie, Jason] Naval Hosp, Camp Pendleton, CA USA. [Iverson, Grant L.] Harvard Med Sch, Boston, MA USA. [Iverson, Grant L.] Spaulding Rehabil Hosp, Charlestown, MA USA. [Iverson, Grant L.] Red Sox Fdn, Boston, MA USA. [Iverson, Grant L.] Massachusetts Gen Hosp, Home Base Program, Boston, MA 02114 USA. [Arrieux, Jacques P.; Cole, Wesley R.] Womack Army Med Ctr, Ft Bragg, NC USA. RP Belanger, HG (reprint author), James A Haley VAMC, Dept Mental Hlth & Behav Sci, Tampa, FL 33612 USA.; Belanger, HG (reprint author), Univ S Florida, Dept Psychiat & Behav Neurosci, Tampa, FL 33620 USA.; Belanger, HG (reprint author), Def & Vet Brain Injury Ctr, Silver Spring, MD 20910 USA. EM Heather.Belanger@va.gov NR 40 TC 0 Z9 0 U1 2 U2 2 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 1385-4046 EI 1744-4144 J9 CLIN NEUROPSYCHOL JI Clin. Neuropsychol. PY 2016 VL 30 IS 7 BP 1063 EP 1073 DI 10.1080/13854046.2016.1193632 PG 11 WC Psychology, Clinical; Clinical Neurology; Psychology SC Psychology; Neurosciences & Neurology GA DY9FU UT WOS:000385440100009 PM 27266484 ER PT S AU Orkin, SH AF Orkin, Stuart H. GP New York Acad Sci TI Recent advances in globin research using genome-wide association studies and gene editing SO COOLEY'S ANEMIA SE Annals of the New York Academy of Sciences LA English DT Article; Proceedings Paper CT 10th Cooley's Anemia Symposium CY OCT 18-22, 2015 CL Rosemont, IL SP ApoPharma, Acceleron, Celgene, Ionis Pharmaceut, Novartis, Immucor, Pfizer, Sangamo BioSciences DE thalassemia; BCL11A; gene editing; enhancer; CRISPR ID SICKLE-CELL-DISEASE; FETAL-HEMOGLOBIN; DNA POLYMORPHISMS; BETA-THALASSEMIA; MAMMALIAN-CELLS; BCL11A; EXPRESSION; ENHANCER; LINEAGE; PROTEIN AB A long-sought goal in the hemoglobin field has been an improved understanding of the mechanisms that regulate the switch from fetal (HbF) to adult (HbA) hemoglobin during development. With such knowledge, the hope is that strategies for directed reactivation of HbF in adults could be devised as an approach to therapy for the beta-hemoglobinopathies thalassemia and sickle cell disease. Recent genome-wide association studies (GWAS) led to identification of three loci (BCL11A, HBS1L-MYB, and the beta-globin cluster itself) in which natural genetic variation is correlated with different HbF levels in populations. Here, the central role of BCL11A in control of HbF is reviewed from the perspective of how findings may be translated to gene therapy in the not-too-distant future. This summary traces the evolution of recent studies from the initial recognition of BCL11A through GWAS to identification of critical sequences in an enhancer required for its erythroid-specific expression, thereby highlighting an Achilles heel for genome editing. C1 [Orkin, Stuart H.] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA USA. [Orkin, Stuart H.] Harvard Med Sch, Boston Childrens Hosp, Boston, MA USA. [Orkin, Stuart H.] Howard Hughes Med Inst, Boston, MA 02115 USA. RP Orkin, SH (reprint author), Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA. EM Stuart_Orkin@dfci.harvard.edu FU National Heart, Lung, and Blood Institute (NHLBI); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health; Howard Hughes Medical Institute FX I am grateful to those who have contributed to the work reviewed here, including Vijay Sankaran, Guillaume Lettre, Jian Xu, Dan Bauer, Sophia Kamran, Crew Smith, Yuko Fujiwara, and Matt Canver. Work from my laboratory is supported by the National Heart, Lung, and Blood Institute (NHLBI) and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health and the Howard Hughes Medical Institute. NR 23 TC 5 Z9 5 U1 3 U2 3 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND SN 0077-8923 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 2016 VL 1368 BP 5 EP 10 DI 10.1111/nyas.13001 PG 6 WC Hematology SC Hematology GA BF6WW UT WOS:000383744400001 PM 26866328 ER PT S AU Nathan, DG AF Nathan, David G. GP New York Acad Sci TI Thalassemia: a look to the future SO COOLEY'S ANEMIA SE Annals of the New York Academy of Sciences LA English DT Article; Proceedings Paper CT 10th Cooley's Anemia Symposium CY OCT 18-22, 2015 CL Rosemont, IL SP ApoPharma, Acceleron, Celgene, Ionis Pharmaceut, Novartis, Immucor, Pfizer, Sangamo BioSciences DE thalassemia; hemoglobin; sickle cell disease; gene therapy ID MARROW TRANSPLANTATION; BETA-THALASSEMIA; ALPHA; METABOLISM; ANEMIA; GLOBIN AB To assess the future of a clinical science one must first assess the rate of accrual of understanding in the past century. From the time of Cooley's description ( 1925) to 1964, the year of the first Symposium, progress was glacial because the molecular biology revolution in medicine was in its infancy and therapy other than transfusion was impossible. But between 1964 and 2015, progress has been huge on every front. Our patients ushered in the molecular biology revolution in medicine. They have benefited from far better understanding of molecular pathophysiology, substantial improvements in transfusion and chelation, more effective stem cell transplantation, the beginnings of gene therapy, and now major advances in our capacity to reinduce fetal hemoglobin. We have only lagged in the application of prevention technology in the less developed world that suffers the most from thalassemia and sickle cell disease. We must redouble our efforts to spare patients from these cruel diseases. C1 [Nathan, David G.] Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA. RP Nathan, DG (reprint author), Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA. EM David_Nathan@dfci.harvard.edu FU New York Academy of Sciences; Cooley's Anemia Foundation FX A keynote address presented at the Tenth Cooley's Anemia Symposium, October 18-22, 2015, in Chicago, Illinois, a meeting sponsored by the New York Academy of Sciences and the Cooley's Anemia Foundation; the symposium organizers asked that I respond to the following question, What do I believe will be the future status of this fascinating but disastrous group of diseases? NR 17 TC 0 Z9 0 U1 3 U2 3 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND SN 0077-8923 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 2016 VL 1368 BP 11 EP 15 DI 10.1111/nyas.13002 PG 5 WC Hematology SC Hematology GA BF6WW UT WOS:000383744400002 PM 26866425 ER PT S AU Basak, A Sankaran, VG AF Basak, Anindita Sankaran, Vijay G. GP New York Acad Sci TI Regulation of the fetal hemoglobin silencing factor BCL11A SO COOLEY'S ANEMIA SE Annals of the New York Academy of Sciences LA English DT Article; Proceedings Paper CT 10th Cooley's Anemia Symposium CY OCT 18-22, 2015 CL Rosemont, IL SP ApoPharma, Acceleron, Celgene, Ionis Pharmaceut, Novartis, Immucor, Pfizer, Sangamo BioSciences DE fetal hemoglobin; hemoglobin switching; BCL11A; thalassemia; therapy ID SICKLE-CELL-DISEASE; GLOBIN GENE-EXPRESSION; BETA-THALASSEMIA; GAMMA-GLOBIN; RISK-FACTORS; BINDING REGION; INDUCTION; ENHANCER; ANEMIA; HYDROXYUREA AB The clinical severity of sickle cell disease and beta-thalassemia, the major disorders of beta-globin, can be ameliorated by increased production of fetal hemoglobin (HbF). Here, we provide a brief overview of the fetal-to-adult hemoglobin switch that occurs in humans shortly after birth and review our current understanding of one of the most potent known regulators of this switching process, the multiple zinc finger-containing transcription factor BCL11A. Originally identified in genome-wide association studies, multiple orthogonal lines of evidence have validated BCL11A as a key regulator of hemoglobin switching and as a promising therapeutic target for HbF induction. We discuss recent studies that have highlighted its importance in silencing the HbF-encoding genes and discuss opportunities that exist to further understand the regulation of BCL11A and its mechanism of action, which could provide new insight into opportunities to induce HbF for therapeutic purposes. C1 [Basak, Anindita; Sankaran, Vijay G.] Boston Childrens Hosp, Manton Ctr Orphan Dis Res, Div Hematol Oncol, Boston, MA USA. [Basak, Anindita; Sankaran, Vijay G.] Harvard Med Sch, Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA USA. [Basak, Anindita; Sankaran, Vijay G.] Broad Inst MIT & Harvard, Cambridge, MA USA. RP Sankaran, VG (reprint author), 3 Blackfan Circle,CLS 03001, Boston, MA 02115 USA. EM sankaran@broadinstitute.org FU NHLBI NIH HHS [R21 HL120791, U01 HL117720]; NIDDK NIH HHS [R01 DK103794] NR 51 TC 3 Z9 3 U1 3 U2 3 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND SN 0077-8923 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 2016 VL 1368 BP 25 EP 30 DI 10.1111/nyas.13024 PG 6 WC Hematology SC Hematology GA BF6WW UT WOS:000383744400004 PM 26963603 ER PT J AU Kassenbrock, A Vasdev, N Liang, SH AF Kassenbrock, Alina Vasdev, Neil Liang, Steven H. TI Selected PET Radioligands for Ion Channel Linked Neuroreceptor Imaging: Focus on GABA, NMDA and nACh Receptors SO CURRENT TOPICS IN MEDICINAL CHEMISTRY LA English DT Review DE Positron Emission Tomography; Ion Channel; gamma-Aminobutyric Acid-Benzodiazapine Receptor; Nicotinic Acetylcholine Receptor; N-Methyl-D-Aspartate Receptor ID POSITRON-EMISSION-TOMOGRAPHY; NICOTINIC ACETYLCHOLINE-RECEPTORS; D-ASPARTATE RECEPTOR; IN-VIVO EVALUATION; PLASMA-PROTEIN BINDING; LIVING HUMAN BRAIN; PRECLINICAL EVALUATION; NONHUMAN PRIMATE; RHESUS-MONKEYS; F-18-FLUOROFLUMAZENIL PET AB Positron emission tomography (PET) neuroimaging of ion channel linked receptors is a developing area of preclinical and clinical research. The present review focuses on recent advances with radiochemistry, preclinical and clinical PET imaging studies of three receptors that are actively pursued in neuropsychiatric drug discovery: namely the gamma-aminobutyric acid-benzodiazapine (GABA) receptor, nicotinic acetylcholine receptor (nAChR), and N-methyl-D-aspartate (NMDA) receptor. Recent efforts to develop new PET radioligands for these targets with improved brain uptake, selectivity, stability and pharmacokinetics are highlighted. C1 [Kassenbrock, Alina; Vasdev, Neil; Liang, Steven H.] Massachusetts Gen Hosp, Div Nucl Med & Mol Imaging, Boston, MA 02114 USA. [Kassenbrock, Alina] Northeastern Univ, Dept Chem & Chem Biol, Boston, MA 02115 USA. [Vasdev, Neil; Liang, Steven H.] Harvard Med Sch, Dept Radiol, Boston, MA USA. RP Liang, SH (reprint author), Massachusetts Gen Hosp, Dept Radiol, Div Nucl Med & Mol Imaging, Boston, MA 02114 USA.; Liang, SH (reprint author), Harvard Med Sch, Boston, MA USA. EM liang.steven@mgh.harvard.edu FU NIDA NIH HHS [K01 DA038000] NR 114 TC 1 Z9 1 U1 3 U2 4 PU BENTHAM SCIENCE PUBL LTD PI SHARJAH PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES SN 1568-0266 EI 1873-5294 J9 CURR TOP MED CHEM JI Curr. Top. Med. Chem. PY 2016 VL 16 IS 16 BP 1830 EP 1842 DI 10.2174/1568026616666160315142457 PG 13 WC Chemistry, Medicinal SC Pharmacology & Pharmacy GA DZ0LB UT WOS:000385529300005 PM 26975506 ER PT J AU Cusack, M Montgomery, AE Blonigen, D Gabrielian, S Marsh, L AF Cusack, Meagan Montgomery, Ann Elizabeth Blonigen, Daniel Gabrielian, Sonya Marsh, Laura TI Veteran Returns to Homelessness Following Exits From Permanent Supportive Housing: Health and Supportive Services Use Proximal to Exit SO FAMILIES IN SOCIETY-THE JOURNAL OF CONTEMPORARY SOCIAL SERVICES LA English DT Article ID CRITICAL TIME INTERVENTION; PUBLIC SHELTER UTILIZATION; NEW-YORK-CITY; MENTAL-ILLNESS; INDIVIDUALS; TRANSITIONS; STABILITY; DISCHARGE; PATTERNS AB Permanent supportive housing (PSH) programs have been shown to increase housing retention for "hard to house" individuals and been used to address veteran homelessness. Departures from PSH (referred to as "exits") can represent a positive outcome for some veterans, while others may return to homelessness. This study analyzed administrative and primary data to identify individual- and institutional-level factors associated with veterans' returns to homelessness following exits from a PSH program. Findings suggest that a number of factors increase the risk of a return to homelessness, including admissions to inpatient substance abuse and behavioral health treatment programs and emergency department visits both pre- and post-exit. Targeted interventions may reduce the likelihood of subsequent homelessness. C1 [Cusack, Meagan] VA Ctr Hlth Equ Res & Promot, 4100 Chester Ave,Suite 202, Philadelphia, PA 19104 USA. [Montgomery, Ann Elizabeth] VA Natl Ctr Homelessness Vet, Philadelphia, PA USA. [Blonigen, Daniel] VA Palo Hlth Care Syst, Livermore, CA USA. [Gabrielian, Sonya] VA Greater Los Angeles, Los Angeles, CA USA. [Marsh, Laura] Michael E DeBakey VA Med Ctr, Houston, TX USA. RP Cusack, M (reprint author), VA Ctr Hlth Equ Res & Promot, 4100 Chester Ave,Suite 202, Philadelphia, PA 19104 USA. EM meagan.cusack@va.gov NR 28 TC 0 Z9 0 U1 1 U2 1 PU ALLIANCE CHILDREN & FAMILIES PI MILWAUKEE PA 11700 WEST LAKE PARK DRIVE, MILWAUKEE, WI 53224 USA SN 1044-3894 EI 1945-1350 J9 FAM SOC JI Fam. Soc. PY 2016 VL 97 IS 3 BP 221 EP 229 DI 10.1606/1044-3894.2016.97.23 PG 9 WC Family Studies; Social Work SC Family Studies; Social Work GA DX9YX UT WOS:000384754400009 ER PT J AU Leslie-Mazwi, TM Hirsch, JA Falcone, GJ Schaefer, PW Lev, MH Rabinov, JD Rost, NS Schwamm, L Gonzalez, RG AF Leslie-Mazwi, Thabele M. Hirsch, Joshua A. Falcone, Guido J. Schaefer, Pamela W. Lev, Michael H. Rabinov, James D. Rost, Natalia S. Schwamm, Lee Gonzalez, R. Gilberto TI Endovascular Stroke Treatment Outcomes After Patient Selection Based on Magnetic Resonance Imaging and Clinical Criteria SO JAMA NEUROLOGY LA English DT Article ID ACUTE ISCHEMIC-STROKE; DIFFUSION/PERFUSION MISMATCH; THERAPY; MRI; THROMBECTOMY; PROFILE; VOLUME; ONSET; TIME AB IMPORTANCE Which imaging modality is optimal to select patients for endovascular stroke treatment remains unclear. OBJECTIVE To evaluate the effectiveness of specific magnetic resonance imaging (MRI) and clinical criteria in the selection of patients with acute ischemic stroke for thrombectomy. DESIGN, SETTING, AND PARTICIPANTS In this observational, single-center, prospective cohort study, we studied 72 patients with middle cerebral artery or terminal internal carotid artery occlusion using computed tomographic angiography, followed by core infarct volume determination by diffusion weighted MRI, who underwent thrombectomy after meeting institutional criteria from January 1, 2012, through December 31, 2014. In this period, 31 patients with similar ischemic strokes underwent endovascular treatment without MRI and are categorized as computed tomography only and considered in a secondary analysis. INTERVENTIONS Patients were prospectively classified as likely to benefit (LTB) or uncertain to benefit (UTB) using diffusion-weighted imaging lesion volume and clinical criteria (age, National Institutes of Health Stroke Scale score, time from onset, baseline modified Rankin Scale [mRS] score, life expectancy). MAIN OUTCOMES AND MEASURES The 90-day mRS score, with favorable defined as a 90-day mRS score of 2 or less. RESULTS Forty patients were prospectively classified as LTB and 32 as UTB. Reperfusion (71 of 103 patients) and prospective categorization as LTB (40 of 103 patients) were associated with favorable outcomes (P <.001 and P <.005, respectively). Successful reperfusion positively affected the distribution of mRS scores of the LTB cohort (P <.001). Reperfusion was achieved in 27 LTB patients (67.5%) and 24 UTB patients (75.0%) (P =.86). Favorable outcomes were obtained in 21 (52.5%) and 8 (25.0%) of LTB and UTB patients who were treated, respectively (P =.02). Favorable outcomes were observed in 20 of the 27 LTB patients (74.1%) who had successful reperfusion compared with 8 of the 24 UTB patients (33.3%) who had successful reperfusion (P =.004). The ratio of treated to screened patients was 1: 3. CONCLUSIONS AND RELEVANCE Prospective classification as LTB by MRI and clinical criteria is associated with likelihood of favorable outcome after thrombectomy, particularly if reperfusion is successful. Selection of patients using MRI compares favorably with selection using computed tomographic techniques with the distinction that a higher proportion of screened patients were treated. C1 [Leslie-Mazwi, Thabele M.; Hirsch, Joshua A.; Rabinov, James D.] Massachusetts Gen Hosp, Neuroendovasc Program, Boston, MA 02114 USA. [Falcone, Guido J.; Rost, Natalia S.; Schwamm, Lee] Massachusetts Gen Hosp, Stroke Serv, Boston, MA 02114 USA. [Schaefer, Pamela W.; Lev, Michael H.; Gonzalez, R. Gilberto] Massachusetts Gen Hosp, Neuroradiol Div, Boston, MA 02114 USA. RP Leslie-Mazwi, TM (reprint author), Massachusetts Gen Hosp, 55 Fruit St,GRB 2-241, Boston, MA 02114 USA. EM tleslie-mazwi@mgh.harvard.edu FU Medtronic and Carefusion; MLNM/Takeda Pharmaceuticals and institutional research; GE Healthcare; National Institute of Neurological Disorders and Stroke [R01 NS082285]; Massachusetts Department of Public Health, Lundbeck, and Penumbraand; National Institute of Neurological Disorders and Stroke and Genentech FX Dr Hirsch reported receiving consulting fees from Medtronic and Carefusion (spine treatment) and having stock interest in Intratech. Dr Lev reported receiving consultant fees from GE Healthcare and MLNM/Takeda Pharmaceuticals and institutional research support from GE Healthcare. Dr Rost reported receiving partial support from grant R01 NS082285 from the National Institute of Neurological Disorders and Stroke. Dr Schwamm reported receiving consultant fees from the Massachusetts Department of Public Health, Lundbeck, and Penumbraand and grants from the National Institute of Neurological Disorders and Stroke and Genentech. No other disclosures were reported. NR 20 TC 3 Z9 3 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6149 EI 2168-6157 J9 JAMA NEUROL JI JAMA Neurol. PD JAN PY 2016 VL 73 IS 1 BP 43 EP 49 DI 10.1001/jamaneurol.2015.3000 PG 7 WC Clinical Neurology SC Neurosciences & Neurology GA DZ4RZ UT WOS:000385848500008 PM 26524074 ER PT J AU Xian, Y Federspiel, JJ Grau-Sepulveda, M Hernandez, AF Schwamm, LH Bhatt, DL Smith, EE Reeves, MJ Thomas, L Webb, L Bettger, JP Laskowitz, DT Fonarow, GC Peterson, ED AF Xian, Ying Federspiel, Jerome J. Grau-Sepulveda, Maria Hernandez, Adrian F. Schwamm, Lee H. Bhatt, Deepak L. Smith, Eric E. Reeves, Mathew J. Thomas, Laine Webb, Laura Bettger, Janet Prvu Laskowitz, Daniel T. Fonarow, Gregg C. Peterson, Eric D. TI Risks and Benefits Associated With Prestroke Antiplatelet Therapy Among Patients With Acute Ischemic Stroke Treated With Intravenous Tissue Plasminogen Activator SO JAMA NEUROLOGY LA English DT Article ID RANDOMIZED CONTROLLED-TRIALS; INTRACRANIAL HEMORRHAGE; GUIDELINES-STROKE; INTRACEREBRAL HEMORRHAGE; THROMBOLYTIC THERAPY; ECASS II; OUTCOMES; PRETREATMENT; METAANALYSIS; ALTEPLASE AB IMPORTANCE Intravenous tissue plasminogen activator (tPA) is known to improve outcomes in ischemic stroke; however, many patients may have been receiving antiplatelet therapy before acute ischemic stroke and could face an increased risk for bleeding when treated with tPA. OBJECTIVE To assess the risks and benefits associated with prestroke antiplatelet therapy among patients with ischemic stroke who receive intravenous tPA. DESIGN, SETTING, AND PARTICIPANTS This observational study used data from the American Heart Association and American Stroke Association Get With the Guidelines-Stroke registry, which included 85 072 adult patients with ischemic stroke who received intravenous tPA in 1545 registry hospitals from January 1, 2009, through March 31, 2015. Data were analyzed during the same period. EXPOSURES Prestroke antiplatelet therapy before tPA administration for acute ischemic stroke. MAIN OUTCOMES AND MEASURES Symptomatic intracranial hemorrhage (sICH), in-hospital mortality, discharge ambulatory status, and modified Rankin Scale score (range, 0 [no symptoms] to 6 [death]). RESULTS Of the 85 072 registry patients, 38 844 (45.7%) were receiving antiplatelet therapy before admission; 46 228 patients (54.3%) were not. Patients receiving antiplatelet therapy were older (median [25th-75th percentile] age, 76 [65-84] vs 68 [56-80] years) and had a higher prevalence of cardiovascular risk factors. The unadjusted rate of sICH was higher in patients receiving antiplatelet therapy (5.0% vs 3.7%). After risk adjustment, prior use of antiplatelet agents remained associated with higher odds of sICH compared with no use (adjusted odds ratio [AOR], 1.18 [95% CI, 1.10-1.28]; absolute difference, + 0.68%[95% CI, 0.36%-1.01%]; number needed to harm [NNH], 147). Among patients enrolled on October 1, 2012, or later, the highest odds (95% CIs) of sICH were found in 15 116 patients receiving aspirin alone (AOR, 1.19 [1.06-1.34]; absolute difference [95% CI], + 0.68%[0.21%-1.20%]; NNH, 147) and 2397 patients receiving dual antiplatelet treatment of aspirin and clopidogrel (AOR, 1.47 [1.16-1.86]; absolute difference, + 1.67%[0.58%-3.00%]; NNH, 60). The risk for in-hospital mortality was similar between those who were and were not receiving antiplatelet therapy after adjustment (8.0% vs 6.6%; AOR, 1.00 [0.94-1.06]; nonsignificant absolute difference, -0.01% [-0.37% to 0.36%]). However, patients receiving antiplatelet therapy had a greater risk-adjusted likelihood of independent ambulation (42.1% vs 46.6%; AOR, 1.13 [1.08-1.17]; absolute difference, + 2.23%[1.55%-2.92%]; number needed to treat, 43) and better functional outcomes (modified Rankin Scale score, 0-1) at discharge (24.1% vs 27.8%; AOR, 1.14; 1.07-1.22; absolute difference, + 1.99%[0.78%-3.22%]; number needed to treat, 50). CONCLUSIONS AND RELEVANCE Among patients with an acute ischemic stroke treated with intravenous tPA, those receiving antiplatelet therapy before the stroke had a higher risk for sICH but better functional outcomes than those who were not receiving antiplatelet therapy. C1 [Xian, Ying; Grau-Sepulveda, Maria; Hernandez, Adrian F.; Thomas, Laine; Webb, Laura; Bettger, Janet Prvu; Peterson, Eric D.] Duke Clin Res Inst, 2400 Pratt St, Durham, NC 27705 USA. [Federspiel, Jerome J.] Univ N Carolina, Sch Med, Chapel Hill, NC USA. [Federspiel, Jerome J.] Johns Hopkins Sch Med, Dept Gynecol & Obstet, Baltimore, MD USA. [Schwamm, Lee H.] Massachusetts Gen Hosp, Div Neurol, Boston, MA 02114 USA. [Bhatt, Deepak L.] Brigham & Womens Hosp, Heart & Vasc Ctr, 75 Francis St, Boston, MA 02115 USA. [Bhatt, Deepak L.] Harvard Med Sch, Boston, MA USA. [Smith, Eric E.] Univ Calgary, Dept Clin Neurosci, Calgary, AB, Canada. [Smith, Eric E.] Univ Calgary, Hotchkiss Brain Inst, Calgary, AB, Canada. [Reeves, Mathew J.] Michigan State Univ, Dept Epidemiol, E Lansing, MI 48824 USA. [Laskowitz, Daniel T.] Duke Univ, Med Ctr, Div Neurol, Durham, NC 27710 USA. [Fonarow, Gregg C.] Univ Calif Los Angeles, Div Cardiol, Los Angeles, CA USA. RP Xian, Y (reprint author), Duke Clin Res Inst, 2400 Pratt St, Durham, NC 27705 USA. EM ying.xian@duke.edu FU AHA [13CRP14410024]; Janssen Pharmaceutical Companies of Johnson Johnson; Boeringher-Ingelheim; Merck; partnership of Bristol-Myers Squibb and Sanofi; AHA Pharmaceutical Roundtable FX This study was supported by award 13CRP14410024 from the AHA. The AHA-ASA GWTG-Stroke program is currently supported in part by a charitable contribution from Janssen Pharmaceutical Companies of Johnson & Johnson and has been funded in the past through support from Boeringher-Ingelheim, Merck, a partnership of Bristol-Myers Squibb and Sanofi, and the AHA Pharmaceutical Roundtable. NR 39 TC 5 Z9 5 U1 0 U2 2 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6149 EI 2168-6157 J9 JAMA NEUROL JI JAMA Neurol. PD JAN PY 2016 VL 73 IS 1 BP 50 EP 59 DI 10.1001/jamaneurol.2015.3106 PG 10 WC Clinical Neurology SC Neurosciences & Neurology GA DZ4RZ UT WOS:000385848500009 PM 26551916 ER PT J AU Biglan, KM Shoulson, I Kieburtz, K Oakes, D Kayson, E Shinaman, MA Zhao, HW Romer, M Young, A Hersch, S Penney, J Marder, K Paulsen, J Quaid, K Siemers, E Tanner, C Mallonee, W Suter, G Dubinsky, R Gray, C Nance, M Bundlie, S Radtke, D Kostyk, S Baic, C Caress, J Walker, F Hunt, V O'Neill, C Chouinard, S Factor, S Greenamyre, T Wood-Siverio, C Corey-Bloom, J Song, D Peavy, G Moskowitz, C Wesson, M Samii, A Bird, T Lipe, H Blindauer, K Marshall, F Zimmerman, C Goldstein, J Rosas, D Novak, P Caviness, J Adler, C Duffy, A Wheelock, V Tempkin, T Richman, D Seeberger, L Albin, R Chou, KL Racette, B Perlmutter, JS Perlman, S Bordelon, Y Martin, W Wieler, M Leavitt, B Raymond, L Decolongon, J Clarke, L Jankovic, J Hunter, C Hauser, RA Sanchez-Ramos, J Furtado, S Suchowersky, O Klimek, ML Guttman, M Sethna, R Feigin, A Cox, M Shannon, B Percy, A Dure, L Harrison, M Johnson, W Higgins, D Molho, E Nickerson, C Evans, S Hobson, D Singer, C Galvez-Jimenez, N Shannon, K Comella, C Ross, C Saint-Hilaire, MH Testa, C Rosenblatt, A Hogarth, P Weiner, W Como, P Kumar, R Cotto, C Stout, J Brocht, A Watts, A Eberly, S Weaver, C Foroud, T Gusella, J MacDonald, M Myers, R Fahn, S Shults, C AF Biglan, Kevin Michael Shoulson, Ira Kieburtz, Karl Oakes, David Kayson, Elise Shinaman, M. Aileen Zhao, Hongwei Romer, Megan Young, Anne Hersch, Steven Penney, Jack Marder, Karen Paulsen, Jane Quaid, Kimberly Siemers, Eric Tanner, Caroline Mallonee, William Suter, Greg Dubinsky, Richard Gray, Carolyn Nance, Martha Bundlie, Scott Radtke, Dawn Kostyk, Sandra Baic, Corrine Caress, James Walker, Francis Hunt, Victoria O'Neill, Christine Chouinard, Sylvain Factor, Stewart Greenamyre, Timothy Wood-Siverio, Cathy Corey-Bloom, Jody Song, David Peavy, Guerry Moskowitz, Carol Wesson, Melissa Samii, Ali Bird, Thomas Lipe, Hillary Blindauer, Karen Marshall, Frederick Zimmerman, Carol Goldstein, Jody Rosas, Diana Novak, Peter Caviness, John Adler, Charles Duffy, Amy Wheelock, Vicki Tempkin, Teresa Richman, David Seeberger, Lauren Albin, Roger Chou, Kelvin L. Racette, Brad Perlmutter, Joel S. Perlman, Susan Bordelon, Yvette Martin, Wayne Wieler, Marguerite Leavitt, Blair Raymond, Lynn Decolongon, Joji Clarke, Lorne Jankovic, Joseph Hunter, Christine Hauser, Robert A. Sanchez-Ramos, Juan Furtado, Sarah Suchowersky, Oksana Klimek, Mary Lou Guttman, Mark Sethna, Rustom Feigin, Andrew Cox, Marie Shannon, Barbara Percy, Alan Dure, Leon Harrison, Madaline Johnson, William Higgins, Donald Molho, Eric Nickerson, Constance Evans, Sharon Hobson, Douglas Singer, Carlos Galvez-Jimenez, Nestor Shannon, Kathleen Comella, Cynthia Ross, Christopher Saint-Hilaire, Marie H. Testa, Claudia Rosenblatt, Adam Hogarth, Penelope Weiner, William Como, Peter Kumar, Rajeev Cotto, Candace Stout, Julie Brocht, Alicia Watts, Arthur Eberly, Shirley Weaver, Christine Foroud, Tatiana Gusella, James MacDonald, Marcy Myers, Richard Fahn, Stanley Shults, Clifford CA Huntington Study Grp PHAROS Invest TI Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS) Implications for Clinical Trials SO JAMA NEUROLOGY LA English DT Article ID CAG REPEAT LENGTH; PREDICT-HD; COGNITIVE DECLINE; FLUENCY DEFICITS; TRACK-HD; DISEASE; PREMANIFEST; PROGRESSION; DIAGNOSIS; CARRIERS AB IMPORTANCE Identifying measures that are associated with the cytosine-adenine-guanine (CAG) expansion in individuals before diagnosis of Huntington disease (HD) has implications for designing clinical trials. OBJECTIVE To identify the earliest features associated with the motor diagnosis of HD in the Prospective Huntington at Risk Observational Study (PHAROS). DESIGN, SETTING, AND PARTICIPANTS A prospective, multicenter, longitudinal cohort study was conducted at 43 US and Canadian Huntington Study Group research sites from July 9, 1999, through December 17, 2009. Participants included 983 unaffected adults at risk for HD who had chosen to remain unaware of their mutation status. Baseline comparability between CAG expansion (>= 37 repeats) and nonexpansion (<37 repeats) groups was assessed. All participants and investigators were blinded to individual CAG analysis. A repeated-measures analysis adjusting for age and sex was used to assess the divergence of the linear trend between the expanded and nonexpanded groups. Data were analyzed from April 27, 2010, to September 3, 2013. EXPOSURE Huntington disease mutation status in individuals with CAG expansion vs without CAG expansion. MAIN OUTCOMES AND MEASURES Unified Huntington's Disease Rating Scale motor (score range, 0-124; higher scores indicate greater impairment), cognitive (symbol digits modality is the total number of correct responses in 90 seconds; lower scores indicate greater impairment), behavioral (score range, 0-176; higher scores indicate greater behavioral symptoms), and functional (Total Functional Capacity score range, 0-13; lower scores indicate reduced functional ability) domains were assessed at baseline and every 9 months up to a maximum of 10 years. RESULTS Among the 983 research participants at risk for HD in the longitudinal cohort, 345 (35.1%) carried the CAG expansion and 638 (64.9%) did not. The mean (SD) duration of follow-up was 5.8 (3.0) years. At baseline, participants with expansions had more impaired motor (3.0 [4.2] vs 1.9 [2.8]; P < .001), cognitive (P < .05 for all measures except Verbal Fluency, P = .52), and behavioral domain scores (9.4 [11.4] vs 6.5 [8.5]; P < .001) but not significantly different measures of functional capacity (12.9 [0.3] vs 13.0 [0.2]; P = .23). With findings reported as mean slope (95% CI), in the longitudinal analyses, participants with CAG expansions showed significant worsening in motor (0.84 [0.73 to 0.95] vs 0.03 [-0.05 to 0.11]), cognitive (-0.54 [-0.67 to -0.40] vs 0.22 [0.12 to 0.32]), and functional (-0.08 [-0.09 to -0.06] vs -0.01 [-0.02 to 0]) measures compared with those without expansion (P < .001 for all); behavioral domain scores did not diverge significantly between groups. CONCLUSIONS AND RELEVANCE Using these prospectively accrued clinical data, relatively large treatment effects would be required to mount a randomized, placebo-controlled clinical trial involving premanifest HD individuals who carry the CAG expansion. C1 [Biglan, Kevin Michael; Kieburtz, Karl; Kayson, Elise; Shinaman, M. Aileen; Marshall, Frederick; Zimmerman, Carol; Goldstein, Jody; Brocht, Alicia; Watts, Arthur; Weaver, Christine] Univ Rochester, Dept Neurol, Rochester, NY 14642 USA. [Shoulson, Ira] Georgetown Univ, Dept Neurol, Washington, DC USA. [Oakes, David; Eberly, Shirley] Univ Rochester, Dept Biostat, Rochester, NY USA. [Zhao, Hongwei] Texas A&M, Dept Epidemiol & Biostat, College Stn, TX USA. [Romer, Megan] Penn State Univ, Dept Stat, University Pk, PA 16802 USA. [Young, Anne; Hersch, Steven; Penney, Jack; Rosas, Diana; Novak, Peter; Gusella, James; MacDonald, Marcy] Massachusetts Gen Hosp, Charleston, SC USA. [Marder, Karen; Fahn, Stanley] Columbia Univ, Med Ctr, Dept Neurol, New York, NY USA. [Paulsen, Jane] Univ Iowa, Dept Psychiat & Neurol, Iowa City, IA USA. [Quaid, Kimberly; Wesson, Melissa; Foroud, Tatiana] Indiana Univ Sch Med, Dept Med & Mol Genet, Indianapolis, IN 46202 USA. [Siemers, Eric] Lilly Corp Ctr, Indianapolis, IN USA. [Tanner, Caroline] Parkinsons Inst, Sunnyvale, CA USA. [Mallonee, William] Hereditary Neurol Dis Ctr, Wichita, KS USA. [Suter, Greg; Dubinsky, Richard; Gray, Carolyn] Univ Kansas, Med Ctr, Dept Neurol, Kansas City, KS 66103 USA. [Nance, Martha; Bundlie, Scott; Radtke, Dawn] Hennepin Cty Med Ctr, Dept Neurol, Minneapolis, MN 55415 USA. [Kostyk, Sandra; Baic, Corrine] Ohio State Univ, Dept Neurol, Columbus, OH 43210 USA. [Caress, James; Walker, Francis; Hunt, Victoria; O'Neill, Christine] Wake Forest Univ, Sch Med, Winston Salem, NC 27109 USA. [Chouinard, Sylvain] Hotel Dieu Hosp CHUM, Montreal, PQ, Canada. [Factor, Stewart; Greenamyre, Timothy; Wood-Siverio, Cathy] Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA. [Corey-Bloom, Jody; Song, David; Peavy, Guerry; Shults, Clifford] Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA. [Samii, Ali; Bird, Thomas; Lipe, Hillary] Univ Washington, Dept Neurol, Seattle, WA 98195 USA. [Samii, Ali; Bird, Thomas; Lipe, Hillary] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. [Blindauer, Karen] Med Coll Wisconsin, Dept Neurol, Milwaukee, WI 53226 USA. [Caviness, John; Adler, Charles; Duffy, Amy] Mayo Clin Scottsdale, Dept Neurol, Scottsdale, AZ USA. [Wheelock, Vicki; Tempkin, Teresa; Richman, David] Univ Calif Davis, Dept Neurol, Sacramento, CA 95817 USA. [Seeberger, Lauren] Idaho Elks Rehabil Hosp, Boise, ID USA. [Albin, Roger; Chou, Kelvin L.] Univ Michigan, Dept Neurol, Ann Arbor, MI USA. [Racette, Brad; Perlmutter, Joel S.] Washington Univ, Dept Neurol, St Louis, MO USA. [Perlman, Susan; Bordelon, Yvette] Univ Calif Los Angeles, Med Ctr, Dept Neurol, Los Angeles, CA 90024 USA. [Martin, Wayne; Wieler, Marguerite] Univ Alberta, Dept Neurol, Edmonton, AB, Canada. [Leavitt, Blair; Raymond, Lynn; Decolongon, Joji; Clarke, Lorne] Univ British Columbia, Dept Neurol, Vancouver, BC, Canada. [Jankovic, Joseph; Hunter, Christine; Klimek, Mary Lou] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA. [Hauser, Robert A.; Sanchez-Ramos, Juan] Univ S Florida, Dept Neurol, Tampa, FL USA. [Furtado, Sarah; Suchowersky, Oksana] Univ Calgary, Dept Neurol, Calgary, AB, Canada. [Guttman, Mark; Sethna, Rustom] Ctr Addict & Mental Hlth, Markham, ON, Canada. [Feigin, Andrew; Cox, Marie; Shannon, Barbara] North Shore LIJ Univ Hosp, Dept Neurol, Manhasset, NY USA. [Percy, Alan; Dure, Leon] Univ Alabama Birmingham, Dept Neurobiol, Birmingham, AL USA. [Harrison, Madaline] Univ Virginia, Dept Neurol, Charlottesville, VA USA. [Johnson, William] Univ Med & Dent New Jersey, Dept Neurol, Robert Wood Johnson Med Ctr, Stratford, NJ USA. [Higgins, Donald; Molho, Eric; Nickerson, Constance; Evans, Sharon] Albany Med Coll, Dept Neurol, Albany, NY 12208 USA. [Hobson, Douglas] Winnipeg Clin, Winnipeg, MB, Canada. [Singer, Carlos; Galvez-Jimenez, Nestor] Univ Miami, Dept Neurol, Miami, FL USA. [Shannon, Kathleen; Comella, Cynthia] Rush Univ, Dept Neurol Sci, Chicago, IL 60612 USA. [Ross, Christopher] Johns Hopkins Univ, Dept Psychiat & Behav Sci, Baltimore, MD USA. [Saint-Hilaire, Marie H.; Myers, Richard] Boston Univ, Dept Neurol, Boston, MA USA. [Testa, Claudia; Rosenblatt, Adam] Virginia Commonwealth Univ, Dept Neurol, Richmond, VA 23284 USA. [Hogarth, Penelope] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Weiner, William] Univ Maryland, Sch Med, Dept Neurol, Baltimore, MD 21201 USA. [Como, Peter] US FDA, Rockville, MD 20857 USA. [Kumar, Rajeev] Rocky Mt Movement Disorders Ctr, Dept Neurol, Denver, CO USA. [Cotto, Candace] Inst Neurodegenerat Disorders, Dept Neurol, New Haven, CT USA. [Stout, Julie] Monash Univ, Clin & Cognit Neurosci Lab, Melbourne, Vic, Australia. RP Biglan, KM (reprint author), Univ Rochester, Dept Neurol, Rochester, NY 14642 USA. OI Raymond, Lynn/0000-0002-8610-1042 FU National Human Genome Research Institute; National Institutes of Health NINDS [5RO1-HG-02449]; High Q Foundation/CHDI Foundation, Inc; Huntington's Disease Society of America; Hereditary Disease Foundation; Huntington Society of Canada; Fox Family Foundation FX This research was supported by grants and awards from the National Human Genome Research Institute and grant 5RO1-HG-02449 from the National Institutes of Health NINDS (Dr Shoulson), the High Q Foundation/CHDI Foundation, Inc, the Huntington's Disease Society of America, the Hereditary Disease Foundation, the Huntington Society of Canada, and the Fox Family Foundation. NR 35 TC 1 Z9 1 U1 1 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6149 EI 2168-6157 J9 JAMA NEUROL JI JAMA Neurol. PD JAN PY 2016 VL 73 IS 1 BP 102 EP 110 DI 10.1001/jamaneurol.2015.2736 PG 9 WC Clinical Neurology SC Neurosciences & Neurology GA DZ4RZ UT WOS:000385848500015 ER PT J AU Guo, L Rezvanian, A Kukreja, L Hoveydai, R Bigio, EH Mesulam, MM El Khoury, J Geula, C AF Guo, Ling Rezvanian, Aras Kukreja, Lokesh Hoveydai, Ramez Bigio, Eileen H. Mesulam, M. -Marsel El Khoury, Joseph Geula, Changiz TI Postmortem Adult Human Microglia Proliferate in Culture to High Passage and Maintain Their Response to Amyloid-beta SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Phenotype; primary human microglia cultures; reactive oxygen species; scavenger receptor ligand ID ACETYLCHOLINESTERASE-RICH NEURONS; MACROPHAGE SCAVENGER RECEPTOR; NITRIC-OXIDE SYNTHASE; ALZHEIMERS-DISEASE; BRAIN-TISSUE; HUMAN FETAL; IN-VITRO; CELLS; PATHOGENESIS; ASTROCYTES AB Microglia are immune cells of the brain that display a range of functions. Most of our knowledge about microglia biology and function is based on cells from the rodent brain. Species variation in the complexity of the brain and differences in microglia response in the primate when compared with the rodent, require use of adult human microglia in studies of microglia biology. While methods exist for isolation of microglia from postmortem human brains, none allow culturing cells to high passage. Thus cells from the same case could not be used in parallel studies and multiple conditions. Here we report a method, which includes use of growth factors such as granulocyte macrophage colony stimulating factor, for successful culturing of adult human microglia from postmortem human brains up to 28 passages without significant loss of proliferation. Such cultures maintained their phenotype, including uptake of the scavenger receptor ligand acetylated low density lipoprotein and response to the amyloid-beta peptide, and were used to extend in vivo studies in the primate brain demonstrating that inhibition of microglia activation protects neurons from amyloid-beta toxicity. Significantly, microglia cultured from brains with pathologically confirmed Alzheimer's disease displayed the same characteristics as microglia cultured from normal aged brains. The method described here provides the scientific community with a new and reliable tool for mechanistic studies of human microglia function in health from childhood to old age, and in disease, enhancing the relevance of the findings to the human brain and neurodegenerative conditions. C1 [Rezvanian, Aras; Kukreja, Lokesh; Hoveydai, Ramez; Bigio, Eileen H.; Mesulam, M. -Marsel; Geula, Changiz] Northwestern Univ, Feinberg Sch Med, Cognit Neurol & Alzheimers Dis Ctr, Lab Cognit & Mol Morphometry, 320 E Super St,Searle 11-467, Chicago, IL 60611 USA. [Guo, Ling] Third Peoples Hosp Yunnan Prov, Kunming, Peoples R China. [El Khoury, Joseph] Harvard Med Sch, Dept Med, Boston, MA USA. [El Khoury, Joseph] Massachusetts Gen Hosp, Ctr Immunol & Inflammatory Dis, Div Infect Dis, Boston, MA 02114 USA. RP Geula, C (reprint author), Northwestern Univ, Feinberg Sch Med, Cognit Neurol & Alzheimers Dis Ctr, Lab Cognit & Mol Morphometry, 320 E Super St,Searle 11-467, Chicago, IL 60611 USA. EM c-geula@northwestern.edu FU National Institute of Neurological Disorders and Stroke [NS084210]; Dana Foundation Neuroimmunology Program; Alzheimer's Disease Fund of the Illinois Department of Public Health; Scientific Research Funding, Science and Technology Agency [2013FB045]; Provincial Education Department, Yunnan Province, China [2012Z093] FX This work was supported by the National Institute of Neurological Disorders and Stroke (NS084210), the Dana Foundation Neuroimmunology Program, the Alzheimer's Disease Fund of the Illinois Department of Public Health, and Scientific Research Funding, Science and Technology Agency (2013FB045), and Provincial Education Department (2012Z093), Yunnan Province, China. A portion of the human brain tissue used in these experiments was obtained from the Northwestern University Alzheimer's Disease Center Brain Bank (AG13854). We are grateful to Girgis Girgis for expert technical assistance. NR 36 TC 0 Z9 0 U1 0 U2 0 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 EI 1875-8908 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2016 VL 54 IS 3 BP 1157 EP 1167 DI 10.3233/JAD-160394 PG 11 WC Neurosciences SC Neurosciences & Neurology GA DZ2DF UT WOS:000385651800028 PM 27567845 ER PT J AU Perlman, MR Dawson, AE Dardis, CM Egan, T Anderson, T AF Perlman, Matthew R. Dawson, Anne E. Dardis, Christina M. Egan, Theresa Anderson, Timothy TI The Association Between Childhood Maltreatment and Coping Strategies: The Indirect Effect Through Attachment SO JOURNAL OF GENETIC PSYCHOLOGY LA English DT Article DE attachment; childhood maltreatment; coping strategies; emerging adulthood ID ADULT ATTACHMENT; SEXUAL-ABUSE; EMOTION REGULATION; DEVELOPMENTAL PSYCHOPATHOLOGY; INSECURE ATTACHMENT; STRESSFUL EVENTS; WORKING MODELS; MEDIATING ROLE; DEPRESSION; SURVIVORS AB Maladaptive coping strategies represent a potentially treatable component of psychopathologies associated with childhood abuse and neglect. Coping strategies are relatively stable constructs that may be viewed as trait-like behavioral manifestations of larger, albeit less accessible, intra- and interpersonal processes, such as activation of the attachment system. The authors investigated a potential mediational pathway from childhood maltreatment (in the form of physical and emotional abuse experiences) to coping strategies developed in emerging adulthood through attachment organization in a sample of undergraduate psychology research participants at a public Midwestern university (N = 225). Avoidant attachment patterns helped to explain the relationship between increased instances of childhood maltreatment and a decreased use of adaptive coping strategies. Further, both anxious and avoidant attachment mediated the relationship between childhood maltreatment and an increased use of maladaptive coping. By utilizing an attachment theory-informed approach as an explanatory guide, researchers and clinicians may be better able to conceptualize, study, and treat complex cases by understanding the underlying relationships between childhood maltreatment, attachment, and coping. C1 [Perlman, Matthew R.; Dawson, Anne E.; Egan, Theresa; Anderson, Timothy] Ohio Univ, Dept Psychol, 200 Porter Hall, Athens, OH 45701 USA. [Dardis, Christina M.] VA Boston Healthcare Syst, Natl Ctr PTSD, Boston, MA USA. [Dardis, Christina M.] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA. RP Perlman, MR (reprint author), Ohio Univ, Dept Psychol, 200 Porter Hall, Athens, OH 45701 USA. EM mp282313@ohio.edu NR 75 TC 0 Z9 0 U1 8 U2 8 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 0022-1325 EI 1940-0896 J9 J GENET PSYCHOL JI J. Genet. Psychol. PY 2016 VL 177 IS 5 BP 156 EP 171 DI 10.1080/00221325.2016.1220912 PG 16 WC Psychology, Developmental; Psychology; Psychology, Multidisciplinary SC Psychology GA DY8OF UT WOS:000385389000003 ER PT J AU Keeler, AM Sapp, E Chase, K Sottosanti, E Danielson, E Pfister, E Stoica, L DiFiglia, M Aronin, N Sena-Esteves, M AF Keeler, Allison M. Sapp, Ellen Chase, Kathryn Sottosanti, Emily Danielson, Eric Pfister, Edith Stoica, Lorelei DiFiglia, Marian Aronin, Neil Sena-Esteves, Miguel TI Cellular Analysis of Silencing the Huntington's Disease Gene Using AAV9 Mediated Delivery of Artificial Micro RNA into the Striatum of Q140/Q140 Mice SO JOURNAL OF HUNTINGTONS DISEASE LA English DT Article DE Huntington; AAV; microRNA; RNAscope; mRNA; in situ hybridization; Htt; huntingtin ID MOUSE MODEL; MUTANT HUNTINGTIN; EARLY MOTOR; BRAIN; EXPRESSION; NEURONS; VECTOR AB Background: The genetic mutation in Huntington's disease (HD) is a CAG repeat expansion in the coding region of the huntingtin (Htt) gene. RNAi strategies have proven effective in substantially down-regulating Htt mRNA in the striatum through delivery of siRNAs or viral vectors based on whole tissue assays, but the extent of htt mRNA lowering in individual neurons is unknown. Objective: Here we characterize the effect of an AAV9-GFP-miR(Htt) vector on Htt mRNA levels in striatal neurons of Q140/Q140 knock-in mice. Methods: HD mice received bilateral striatal injections of AAV9-GFP-miR(Htt) or AAV9-GFP at 6 or 12 weeks and striata were evaluated at 6 months of age for levels of Htt mRNA and protein and for mRNA signal within striatal neurons using RNAscope multiplex fluorescence in situ hybridization. Results: Compared to controls, the striatum of 6-month old mice treated at 6 or 12 weeks of age with AAV9-GFP-miR(Htt) showed a reduction of 40-50% in Htt mRNA and lowering of 25-40% in protein levels. The number of Htt mRNA foci in medium spiny neurons (MSNs) of untreated Q140/Q140 mice varied widely per cell (0 to 34 per cell), with similar to 10% of MSNs devoid of foci. AAV9-GFP-miR(Htt) treatment shifted the distribution toward lower numbers and the percentage of cells without foci increased to 14-20%. The average number of Htt mRNA foci per MSN was reduced by 43%. Conclusions: The findings here show that intrastriatal infusion of an AAV9-GFP-miR(Htt) vector lowers mRNA expression of Htt in striatum by similar to 50%, through a partial reduction in the number of copies of mutant Htt mRNAs per cell. These findings demonstrate at the neuronal level the variable levels of Htt mRNA expression in MSNs and the neuronal heterogeneity of RNAi dependent Htt mRNA knockdown. C1 [Keeler, Allison M.; Danielson, Eric; Stoica, Lorelei; Sena-Esteves, Miguel] Univ Massachusetts, Sch Med, Dept Neurol, Worcester, MA USA. [Keeler, Allison M.; Stoica, Lorelei; Sena-Esteves, Miguel] Univ Massachusetts, Sch Med, Horae Gene Therapy Ctr, Worcester, MA USA. [Chase, Kathryn; Sottosanti, Emily; Pfister, Edith; Aronin, Neil] Univ Massachusetts, Sch Med, Dept Med, Worcester, MA USA. [Chase, Kathryn; Sottosanti, Emily; Pfister, Edith; Aronin, Neil] Univ Massachusetts, Sch Med, RNA Therapeut Inst, Worcester, MA USA. [Sapp, Ellen; DiFiglia, Marian] Massachusetts Gen Hosp, Dept Neurol, Charlestown, MA USA. [DiFiglia, Marian] Harvard Med Sch, Boston, MA USA. RP Sena-Esteves, M (reprint author), 368 Plantat St,ASC6-2055, Worcester, MA 01605 USA. EM miguel.esteves@umassmed.edu NR 27 TC 0 Z9 0 U1 2 U2 2 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1879-6397 EI 1879-6400 J9 J HUNTINGTONS DIS JI J. Huntingtons Dis. PY 2016 VL 5 IS 3 BP 239 EP 248 DI 10.3233/JHD-160215 PG 10 WC Neurosciences SC Neurosciences & Neurology GA DZ2CM UT WOS:000385649800002 PM 27689620 ER PT J AU Vodicka, P Chase, K Iuliano, M Tousley, A Valentine, DT Sapp, E Kegel-Gleason, KB Sena-Esteves, M Aronin, N DiFiglia, M AF Vodicka, Petr Chase, Kathryn Iuliano, Maria Tousley, Adelaide Valentine, Dana T. Sapp, Ellen Kegel-Gleason, Kimberly B. Sena-Esteves, Miguel Aronin, Neil DiFiglia, Marian TI Autophagy Activation by Transcription Factor EB (TFEB) in Striatum of HDQ175/Q7 Mice SO JOURNAL OF HUNTINGTONS DISEASE LA English DT Article DE Adeno associated virus; autophagy; GRP78/BiP; huntingtin; Huntington's disease; LC3; neurodegeneration; striatum; TFEB ID TERMINAL HUNTINGTIN FRAGMENTS; MUTANT HUNTINGTIN; LYSOSOMAL BIOGENESIS; MEDIATED AUTOPHAGY; SELECTIVE UPTAKE; ALPHA-SYNUCLEIN; CELL-DEATH; PROTEINS; DISEASE; DEGRADATION AB Background: Mutant huntingtin (mHTT) is encoded by the Huntington's disease (HD) gene and its accumulation in the brain contributes to HD pathogenesis. Reducing mHTT levels through activation of the autophagosome-lysosomal pathway may have therapeutic benefit. Transcription factor EB (TFEB) regulates lysosome biogenesis and autophagy. Objective: To examine if increasing TFEB protein levels in HD mouse striatum induces autophagy and influences mHTT levels. Methods: We introduced cDNA encoding TFEB with an HA tag (TFEB-HA) under the control of neuron specific synapsin 1 promoter into the striatum of 3 month old HDQ175/Q7 mice using adeno-associated virus AAV2/9. The levels of exogenous TFEB were analyzed using qPCR andWestern blot. Proteins involved in autophagy, levels of huntingtin, and striatal-enriched proteins were examined using biochemical and/or immunohistochemical methods. Results: In HD mice expressing TFEB-HA, HA immunoreactivity distributed throughout the striatum in neuronal cell bodies and processes and preferentially in neuronal nuclei and overlapped with a loss of DARPP32 immunoreactivity. TFEB-HA mRNA and protein were detected in striatal lysates. There were increased levels of proteins involved with autophagosome/lysosome activity including LAMP-2A, LC3II, and cathepsin D and reduced levels of mutant HTT and the striatal enriched proteins DARPP32 and PDE10A. Compared to WT mice, HDQ175/Q7 mice had elevated levels of the ER stress protein GRP78/BiP and with TFEB-HA expression, increased levels of the astrocyte marker GFAP and pro-caspase 3. Conclusion: These results suggest thatTFEBexpression in the striatum ofHD(Q175/Q7) mice stimulates autophagy and lysosome activity, and lowers mHTT, but may also increase a neuronal stress response. C1 [Vodicka, Petr; Iuliano, Maria; Tousley, Adelaide; Valentine, Dana T.; Sapp, Ellen; Kegel-Gleason, Kimberly B.; DiFiglia, Marian] Massachusetts Gen Hosp, Dept Neurol, 114 16th St,Room2002, Charlestown, MA 02129 USA. [Vodicka, Petr; Iuliano, Maria; Tousley, Adelaide; Valentine, Dana T.; Sapp, Ellen; Kegel-Gleason, Kimberly B.; DiFiglia, Marian] Harvard Med Sch, Charlestown, MA USA. [Chase, Kathryn; Aronin, Neil] Univ Massachusetts, Dept Med, Worcester, MA 01605 USA. [Sena-Esteves, Miguel] Univ Massachusetts, Dept Cell Biol, Worcester, MA 01605 USA. [Sena-Esteves, Miguel] Univ Massachusetts, Sch Med, Dept Neurol, Horae Gene Therapy Ctr,Albert Sherman Ctr, Worcester, MA USA. RP DiFiglia, M (reprint author), Massachusetts Gen Hosp, Dept Neurol, 114 16th St,Room2002, Charlestown, MA 02129 USA. EM difiglia@helix.mgh.harvard.edu RI Vodicka, Petr/C-3845-2009 OI Vodicka, Petr/0000-0002-6605-9158 NR 49 TC 0 Z9 0 U1 5 U2 5 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1879-6397 EI 1879-6400 J9 J HUNTINGTONS DIS JI J. Huntingtons Dis. PY 2016 VL 5 IS 3 BP 249 EP 260 DI 10.3233/JHD-160211 PG 12 WC Neurosciences SC Neurosciences & Neurology GA DZ2CM UT WOS:000385649800003 PM 27689619 ER PT J AU Karimi, M Bahrami, S Mirshekari, H Basri, SMM Nik, AB Aref, AR Akbari, M Hamblin, MR AF Karimi, Mahdi Bahrami, Sajad Mirshekari, Hamed Basri, Seyed Masoud Moosavi Nik, Amirala Bakhshian Aref, Amir R. Akbari, Mohsen Hamblin, Michael R. TI Microfluidic systems for stem cell-based neural tissue engineering SO LAB ON A CHIP LA English DT Review ID ON-A-CHIP; 3-DIMENSIONAL EXTRACELLULAR-MATRIX; CENTRAL-NERVOUS-SYSTEM; REGENERATIVE MEDICINE; SPINAL-CORD; NEURONAL DIFFERENTIATION; STEM/PROGENITOR CELLS; NEUROSCIENCE RESEARCH; FUNCTIONAL RECOVERY; PROGENITOR CELLS AB Neural tissue engineering aims at developing novel approaches for the treatment of diseases of the nervous system, by providing a permissive environment for the growth and differentiation of neural cells. Three-dimensional (3D) cell culture systems provide a closer biomimetic environment, and promote better cell differentiation and improved cell function, than could be achieved by conventional two-dimensional (2D) culture systems. With the recent advances in the discovery and introduction of different types of stem cells for tissue engineering, microfluidic platforms have provided an improved microenvironment for the 3D-culture of stem cells. Microfluidic systems can provide more precise control over the spatiotemporal distribution of chemical and physical cues at the cellular level compared to traditional systems. Various microsystems have been designed and fabricated for the purpose of neural tissue engineering. Enhanced neural migration and differentiation, and monitoring of these processes, as well as understanding the behavior of stem cells and their microenvironment have been obtained through application of different microfluidic-based stem cell culture and tissue engineering techniques. As the technology advances it may be possible to construct a "brain-on-a-chip". In this review, we describe the basics of stem cells and tissue engineering as well as microfluidics-based tissue engineering approaches. We review recent testing of various microfluidic approaches for stem cell-based neural tissue engineering. C1 [Karimi, Mahdi; Bahrami, Sajad] Iran Univ Med Sci, Fac Adv Technol Med, Dept Med Nanotechnol, Tehran, Iran. [Bahrami, Sajad] USERN, NRA, Tehran, Iran. [Mirshekari, Hamed] Iran Univ Med Sci, ANNRG, Tehran, Iran. [Basri, Seyed Masoud Moosavi] Sharif Univ Technol, Bioenvironm Res Ctr, Tehran, Iran. [Basri, Seyed Masoud Moosavi] Shahid Beheshti Univ, Dept Civil & Environm Engn, Tehran, Iran. [Nik, Amirala Bakhshian] Univ Tehran, Dept Biomed Engn, Fac New Sci & Technol, Tehran 14174, Iran. [Aref, Amir R.] Dana Farber Canc Inst, Dept Canc Biol, Ctr Canc Syst Biol, Boston, MA 02215 USA. [Aref, Amir R.] Harvard Med Sch, Dept Genet, Boston, MA 02215 USA. [Akbari, Mohsen] Harvard Med Sch, Dept Med, Brigham & Womens Hosp, Boston, MA 02215 USA. [Akbari, Mohsen] Univ Victoria, Dept Mech Engn, Lab Innovat MicroEngn LiME, Victoria, BC, Canada. [Hamblin, Michael R.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. [Hamblin, Michael R.] Harvard Med Sch, Dept Dermatol, Boston, MA 02115 USA. [Hamblin, Michael R.] Harvard MIT Div Hlth Sci & Technol, Cambridge, MA 02139 USA. RP Karimi, M (reprint author), Iran Univ Med Sci, Fac Adv Technol Med, Dept Med Nanotechnol, Tehran, Iran.; Hamblin, MR (reprint author), Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.; Hamblin, MR (reprint author), Harvard Med Sch, Dept Dermatol, Boston, MA 02115 USA.; Hamblin, MR (reprint author), Harvard MIT Div Hlth Sci & Technol, Cambridge, MA 02139 USA. EM m_karimy2006@yahoo.com; sajadbahrami2021@yahoo.com; hamedmirshekari83@gmail.com; moosavi@europe.com; amir.bakhshian@gmail.com; Amir_aref@hms.harvard.edu; makbari@uvic.ca; hamblin@helix.mgh.harvard.edu FU US NIH grant [R01AI050875] FX Michael R Hamblin was supported by US NIH grant number R01AI050875. NR 152 TC 1 Z9 2 U1 20 U2 22 PU ROYAL SOC CHEMISTRY PI CAMBRIDGE PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND SN 1473-0197 EI 1473-0189 J9 LAB CHIP JI Lab Chip PY 2016 VL 16 IS 14 BP 2551 EP 2571 DI 10.1039/c6lc00489j PG 21 WC Biochemical Research Methods; Chemistry, Multidisciplinary; Nanoscience & Nanotechnology SC Biochemistry & Molecular Biology; Chemistry; Science & Technology - Other Topics GA DY7EE UT WOS:000385291600001 PM 27296463 ER PT J AU Vasuthasawat, A Yoo, EM Trinh, KR Lichtenstein, A Timmerman, JM Morrison, SL AF Vasuthasawat, Alex Yoo, Esther M. Trinh, Kham R. Lichtenstein, Alan Timmerman, John M. Morrison, Sherie L. TI Targeted immunotherapy using anti-CD138-interferon fusion proteins and bortezomib results in synergistic protection against multiple myeloma SO MABS LA English DT Article DE Antibody engineering; antibody immunotherapy; bortezomib; interferon; multiple myeloma ID INDEPENDENT CELL-DEATH; OXYGEN SPECIES GENERATION; ALPHA-INDUCED APOPTOSIS; IFN-ALPHA; INTERFERON-ALPHA; I INTERFERON; CANCER-CELLS; PROTEASOME INHIBITOR; ANTITUMOR ACTIVITIES; LYMPHOMA AB Although recent advances have substantially improved the management of multiple myeloma, it remains an incurable malignancy. We now demonstrate that anti-CD138 molecules genetically fused to type I interferons (IFN) synergize with the approved therapeutic bortezomib in arresting the proliferation of human multiple myeloma cell lines both in vitro and in vivo. The anti-CD138-IFN14 fusion protein was active in inducing increased expression of signal transducer and activator of transcription 1 (STAT1) and its phosphorylation while the cell death pathway induced by bortezomib included generation of reactive oxygen species. Interferon regulatory factor 4 (IRF4), an important survival factor for myeloma cells, was down regulated following combination treatment. Induction of cell death appeared to be caspase-independent because treatment with inhibitors of caspase activation did not decrease the level of cell death. The observed caspase-independent synergistic cell death involved mitochondrial membrane depolarization, and poly(ADP-ribose) polymerase-1 (PARP-1) cleavage, and resulted in enhanced induction of apoptosis. Importantly, using 2 different in vivo xenograft models, we found that combination therapy of anti-CD138-IFN14 and bortezomib was able to cure animals with established tumors (7 of 8 using OCI-My5 or 8 of 8 using NCI-H929). Thus, the combination of anti-CD138-IFN with bortezomib shows great promise as a novel therapeutic approach for the treatment of multiple myeloma, a malignancy for which there are currently no cures. C1 [Vasuthasawat, Alex; Yoo, Esther M.; Trinh, Kham R.; Morrison, Sherie L.] Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA USA. [Vasuthasawat, Alex; Yoo, Esther M.; Trinh, Kham R.; Morrison, Sherie L.] Univ Calif Los Angeles, Mol Biol Inst, Los Angeles, CA USA. [Lichtenstein, Alan] Greater Los Angeles Vet Adm Healthcare Ctr, Los Angeles, CA USA. [Lichtenstein, Alan; Timmerman, John M.] Jonsson Comprehens Canc Ctr, Los Angeles, CA 90034 USA. [Lichtenstein, Alan; Timmerman, John M.] Univ Calif Los Angeles, David Geffen Sch Med, Div Hematol & Oncol, Dept Med, Los Angeles, CA 90095 USA. RP Yoo, EM (reprint author), Univ Calif Los Angeles, Microbiol Immunol & Mol Genet, 247 BSRB,615 Charles E Young Dr East, Los Angeles, CA 90095 USA. EM eyoo@ucla.edu FU Multiple Myeloma Research Foundation; National Institutes of Health [CA162964] FX This work was supported by a Senior Research Award and the Dean Assink MMRF Senior Research Award from the Multiple Myeloma Research Foundation, and by the National Institutes of Health grant CA162964. NR 43 TC 0 Z9 0 U1 0 U2 0 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 1942-0862 EI 1942-0870 J9 MABS-AUSTIN JI mAbs PY 2016 VL 8 IS 7 BP 1386 EP 1397 DI 10.1080/19420862.2016.1207030 PG 12 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA DZ0ZY UT WOS:000385569400017 PM 27362935 ER PT J AU Liu, XH Ning, AY Chang, NC Kim, H Nissenson, R Wang, LP Feeley, BT AF Liu, Xuhui Ning, Anne Y. Chang, Nai Chen Kim, Hubert Nissenson, Robert Wang, Liping Feeley, Brian T. TI Investigating the cellular origin of rotator cuff muscle fatty infiltration and fibrosis after injury SO MLTJ-MUSCLES LIGAMENTS AND TENDONS JOURNAL LA English DT Article DE rotator cuff tear; fatty infiltration; fibrosis; fibro-adipogenic progenitors; Tie2; muscle ID SKELETAL-MUSCLE; FIBRO/ADIPOGENIC PROGENITORS; HETEROTOPIC OSSIFICATION; MESENCHYMAL PROGENITORS; SUPRASCAPULAR NERVE; RAT MODEL; TEAR; REPAIR; IDENTIFICATION; DEGENERATION AB Background: rotator cuff muscle atrophy, fibrosis and fatty infiltration are common complications after large and massive rotator cuff tears. Currently, there are no effective treatments for these muscle pathologies after injury. Furthermore, the cellular source for fibrotic and adipose tissues in rotator cuff muscle after injury remains unknown. In this study, we proposed that two groups of muscle resident progenitors, Tie2+ muscle mesenchymal progenitors and PDGFR alpha(+) fibro/adipogenic progenitor cells (FAPs), contribute significantly to rotator cuff muscle fibrosis and fatty infiltration. Methods: we tested our hypothesis using reporter mice. Rotator cuff muscles from Tie2-GFP and PDGFR alpha-GFP reporter mice were harvested at 2 and 6 weeks after unilateral massive rotator cuff tear surgeries. Immunofluorescent staining for fibroblast and adipocyte markers was conducted. Results: our results showed significant co-localization of Tie2+ cells with fibrotic markers vimentin and aSMA. In the PDGFR alpha-GFP reporter mice, GFP signal was seen in only a small fraction of cells staining positive for vimentin and aSMA. However, PDGFR alpha showed significant co-localization with adipocyte markers, including PPAR-gamma, adiponectin, and perilipin A. Oil red O staining confirmed that the mature adipocytes appearing in rotator cuff muscles after injury are also PDGFR alpha(+). Conclusion: these data demonstrated that the Tie2(+) muscle mesenchymal progenitors are the major source of fibroblasts while PDGFR alpha(+) FAPs are the major source of adipocytes in rotator cuff muscle fatty infiltration. Basic Science Study. C1 [Liu, Xuhui; Ning, Anne Y.; Kim, Hubert; Nissenson, Robert; Wang, Liping; Feeley, Brian T.] Univ Calif San Francisco, Dept Orthopaed Surg, 1700 Owens St Rm 361, San Francisco, CA 94158 USA. [Chang, Nai Chen] San Francisco VA Med Ctr, San Francisco, CA USA. RP Ning, AY (reprint author), Univ Calif San Francisco, Dept Orthopaed Surg, 1700 Owens St Rm 361, San Francisco, CA 94158 USA. EM anneyning@gmail.com FU BLRD VA [I01 BX002680] NR 29 TC 1 Z9 1 U1 0 U2 0 PU CIC EDIZIONI INT PI ROME PA CORSO TRIESTE 42, ROME, 00198, ITALY SN 2240-4554 J9 MLTJ-MUSCLE LIGAMENT JI MLTJ-Muscles Ligaments Tendons J. PD JAN-MAR PY 2016 VL 6 IS 1 BP 6 EP 15 DI 10.11138/mltj/2016.6.1.006 PG 10 WC Orthopedics SC Orthopedics GA DZ2UB UT WOS:000385696000003 PM 27331027 ER PT J AU Ahronian, LG Corcoran, RB AF Ahronian, Leanne G. Corcoran, Ryan B. TI Effective MAPK Inhibition is critical for therapeutic responses in colorectal cancer with BRAF mutations SO MOLECULAR & CELLULAR ONCOLOGY LA English DT Article DE Clinical trials; colorectal cancer; BRAF; BRAF inhibitor; ERK inhibitor; MAPK; resistance ID EGFR AB RAF inhibitor monotherapy is ineffective in BRAF-mutant colorectal cancer (CRC) but RAF inhibitor combinations have demonstrated improved efficacy, likely through superior suppression of MAPK signaling. The first identified mechanisms of acquired resistance to these combinations all promote MAPK reactivation, underscoring the MAPK pathway as a critical target in BRAF-mutant CRC. C1 [Ahronian, Leanne G.; Corcoran, Ryan B.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA. [Ahronian, Leanne G.; Corcoran, Ryan B.] Harvard Med Sch, Dept Med, Boston, MA 02115 USA. RP Corcoran, RB (reprint author), Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA.; Corcoran, RB (reprint author), Harvard Med Sch, Dept Med, Boston, MA 02115 USA. EM rbcorcoran@partners.org FU NCI NIH HHS [K08 CA166510, P50 CA127003] NR 10 TC 0 Z9 0 U1 0 U2 0 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 2372-3556 EI 2372-3548 J9 MOL CELL ONCOL JI MOL. CELL ONCOL. PD JAN PY 2016 VL 3 IS 1 AR UNSP e1048405 DI 10.1080/23723556.2015.1048405 PG 3 WC Oncology SC Oncology GA DY6OD UT WOS:000385245700041 PM 27308562 ER PT J AU Gupta, M Jardeleza, MSR Kim, I Durand, ML Kim, L Lobo, AM AF Gupta, Meenakashi Jardeleza, Maria Stephanie R. Kim, Ivana Durand, Marlene L. Kim, Leo Lobo, Ann-Marie TI Varicella Zoster Virus Necrotizing Retinitis in Two Patients with Idiopathic CD4 Lymphocytopenia SO OCULAR IMMUNOLOGY AND INFLAMMATION LA English DT Article DE Herpetic retinopathy; idiopathic CD4 lymphocytopenia; immunosuppression; progressive outer retinal necrosis ID OUTER RETINAL NECROSIS; CYTOMEGALOVIRUS RETINITIS; T-LYMPHOCYTOPENIA; HIV AB Purpose: Progressive outer retinal necrosis (PORN) associated with varicella zoster virus (VZV) is usually diagnosed in HIV positive or immunosuppressed patients. We report two cases of immunocompetent patients with necrotizing viral retinitis found to have idiopathic CD4 lymphocytopenia.Methods: Clinical presentation, examination, imaging, and laboratory testing of two patients with VZV retinitis are presented.Results: An HIV negative patient with history of herpes zoster presented with rapid loss of vision and examination consistent with PORN. PCR testing confirmed VZV. Lymphocytopenia was noted with a CD4 count of 25/mm(3). A second HIV negative patient presented with blurred vision and lid swelling and was found to have peripheral VZV retinitis confirmed by PCR. Laboratory workup revealed lymphocytopenia with a CD4 count of 133/mm(3).Conclusions: VZV necrotizing retinitis classic for PORN can occur in HIV negative patients. Idiopathic CD4 lymphocytopenia should be considered healthy patients who develop ocular infections seen in the immunocompromised. C1 [Gupta, Meenakashi] Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Boston, MA 02114 USA. [Jardeleza, Maria Stephanie R.] Univ Texas Hlth Sci Ctr San Antonio, Texas Diabet Inst, Dept Ophthalmol, San Antonio, TX 78229 USA. [Kim, Ivana; Kim, Leo] Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Retina Serv, Boston, MA 02114 USA. [Durand, Marlene L.] Massachusetts Gen Hosp, Dept Infect Dis, Boston, MA 02114 USA. [Lobo, Ann-Marie] Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Uveitis Serv, Boston, MA 02114 USA. RP Lobo, AM (reprint author), Massachusetts Eye & Ear Infirm, Ocular Immunol & Uveitis Serv, 243 Charles St, Boston, MA 02114 USA. EM alobo2@uic.edu NR 14 TC 0 Z9 0 U1 0 U2 0 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 0927-3948 EI 1744-5078 J9 OCUL IMMUNOL INFLAMM JI Ocul. Immunol. Inflamm. PY 2016 VL 24 IS 5 BP 544 EP 548 DI 10.3109/09273948.2015.1034376 PG 5 WC Ophthalmology SC Ophthalmology GA DZ0LW UT WOS:000385532100012 PM 26472486 ER PT J AU Houot, R Gaulard, P Schreiber, R Mellman, I Lambotte, O Coulie, PG Fest, T Korman, A Levy, R Shipp, M Tarte, K Kohrt, H Marabelle, A Ansell, S Watier, H van Elsas, A Balakumaran, A Vargas, FA Quezada, SA Salles, G Olive, D AF Houot, Roch Gaulard, Philippe Schreiber, Robert Mellman, Ira Lambotte, Olivier Coulie, Pierre G. Fest, Thierry Korman, Alan Levy, Ronald Shipp, Margaret Tarte, Karin Kohrt, Holbrook Marabelle, Aurelien Ansell, Stephen Watier, Herve van Elsas, Andrea Balakumaran, Arun Vargas, Frederick Arce Quezada, Sergio A. Salles, Gilles Olive, Daniel TI Immunomodulatory antibodies for the treatment of lymphoma: Report on the CALYM Workshop SO ONCOIMMUNOLOGY LA English DT Article DE Immunomodulation; immunotherapy; lymphoma; programmed cell death 1 ligand 1; programmed cell death 1 receptor ID REGULATORY T-CELLS; FC-GAMMA-RS; FOLLICULAR LYMPHOMA; CANCER-IMMUNOTHERAPY; CHECKPOINT BLOCKADE; METASTATIC MELANOMA; ANTITUMOR-ACTIVITY; LUNG-CANCER; ANTIGEN-4 BLOCKADE; HODGKINS-LYMPHOMA AB In November 2015, the CALYM Carnot Institute held a 2-d workshop to discuss the current and future development of immunomodulatory antibodies for the treatment of lymphoma. Highlights from the workshop are presented in this article. C1 [Houot, Roch] CHU Rennes, Dept Hematol, Rennes, France. [Gaulard, Philippe] Univ Paris Est, CHU Henri Mondor, Inserm U955, Dept Pathol, Creteil, France. [Schreiber, Robert] Washington Univ, Dept Pathol & Immunol, St Louis, MO USA. [Mellman, Ira] Genentech Inc, San Francisco, CA 94080 USA. [Lambotte, Olivier] Univ Paris 11, Hosp Kremlin Bicetre, Dept Clin Immunol & Internal Med, Orsay, France. [Coulie, Pierre G.] Catholic Univ Louvain, de Duve Inst, Brussels, Belgium. [Fest, Thierry] CHU Rennes, Inserm U917, Rennes, France. [Korman, Alan] Bristol Myers Squibb, Redwood City, CA USA. [Levy, Ronald] Stanford Sch Med, Stanford, CA USA. [Shipp, Margaret] Dana Farber Canc Inst, Boston, MA 02115 USA. [Tarte, Karin] CHU Rennes, Inserm U917, Rennes, France. [Kohrt, Holbrook] Stanford Sch Med, Dept Med, Stanford, CA USA. [Marabelle, Aurelien] Gustave Roussy Canc Campus, Villejuif, France. [Ansell, Stephen] Mayo Clin, Div Hematol, Rochester, MN USA. [Watier, Herve] Univ Tours, CHRU Tours, Tours, France. [Watier, Herve] CNRS, UMR7292, Tours, France. [van Elsas, Andrea] Aduro Biotech Europe, Oss, Netherlands. [Balakumaran, Arun] Merck & Co Inc, Clin Res Oncol, Kenilworth, NJ USA. [Vargas, Frederick Arce] UCL, UCL Canc Inst, London, England. [Quezada, Sergio A.] UCL, UCL Canc Inst, London, England. [Salles, Gilles] Univ Lyon 1, Hosp Civils Lyon, INSERM 1052, Dept Hematol, Lyon, France. [Olive, Daniel] Aix Marseille Univ, Inst Paoli Calmettes, Inserm UMR 1068, Marseille, France. RP Houot, R (reprint author), CHU Rennes, Dept Hematol, Rennes, France. EM roch.houot@gmail.com FU CALYM FX This manuscript reports on presentations given during the International Workshop on Immunomodulatory Antibodies for the Treatment of Lymphoma, organized by CALYM Carnot Institute (www.calym.org), on 13-14 December 2015, Paris, France. Presenters contributed significantly to the preparation of the manuscript. Editorial assistance, funded by CALYM, was provided by Duncan Pennington, International Medical Press, UK. NR 83 TC 0 Z9 0 U1 2 U2 2 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 2162-402X J9 ONCOIMMUNOLOGY JI OncoImmunology PY 2016 VL 5 IS 7 AR e1186323 DI 10.1080/2162402X.2016.1186323 PG 8 WC Oncology; Immunology SC Oncology; Immunology GA DY9WR UT WOS:000385486700031 PM 27622041 ER PT J AU Nandi, B Shapiro, M Samur, MK Pai, C Frank, NY Yoon, C Prabhala, RH Munshi, NC Gold, JS AF Nandi, Bisweswar Shapiro, Mia Samur, Mehmet K. Pai, Christine Frank, Natasha Y. Yoon, Charles Prabhala, Rao H. Munshi, Nikhil C. Gold, Jason S. TI Stromal CCR6 drives tumor growth in a murine transplantable colon cancer through recruitment of tumor-promoting macrophages SO ONCOIMMUNOLOGY LA English DT Article DE CCR6; chemokine CCL20; colorectal cancer; macrophages; mice; receptors ID CHEMOKINE RECEPTOR CCR6; COLORECTAL-CANCER; EPITHELIAL-CELLS; CARCINOMA CELLS; INTESTINAL TUMORIGENESIS; LIVER METASTASIS; INVASIVE MARGIN; EXPRESSION; INFLAMMATION; INTERLEUKIN-6 AB Interactions between the inflammatory chemokine CCL20 and its receptor CCR6 have been implicated in promoting colon cancer; however, the mechanisms behind this effect are poorly understood. We have previously demonstrated that deficiency of CCR6 is associated with decreased tumor macrophage accumulation in a model of sporadic intestinal tumorigenesis. In this study, we aimed to determine the role of stromal CCR6 expression in a murine syngeneic transplantable colon cancer model. We show that deficiency of host CCR6 is associated with decreased growth of syngeneic CCR6-expressing colon cancers. Colon cancers adoptively transplanted into CCR6-deficient mice have decreased tumor-associated macrophages without alterations in the number of monocytes in blood or bone marrow. CCL20, the unique ligand for CCR6, promotes migration of monocytes in vitro and promotes accumulation of macrophages in vivo. Depletion of tumor-associated macrophages decreases the growth of tumors in the transplantable tumor model. Macrophages infiltrating the colon cancers in this model secrete the inflammatory mediators CCL2, IL-1 alpha, IL-6 and TNF alpha. Ccl2, Il1 alpha and Il6 are consequently downregulated in tumors from CCR6-deficient mice. CCL2, IL-1 alpha and IL-6 also promote proliferation of colon cancer cells, linking the decreased macrophage migration into tumors mediated by CCL20-CCR6 interactions to the delay in tumor growth in CCR6-deficient hosts. The relevance of these findings in human colon cancer is demonstrated through correlation of CCR6 expression with that of the macrophage marker CD163 as well as that of CCL2, IL1 alpha and TNF alpha. Our findings support the exploration of targeting the CCL20-CCR6 pathway for the treatment of colon cancer. C1 [Nandi, Bisweswar; Shapiro, Mia; Pai, Christine; Prabhala, Rao H.] VA Boston Healthcare Syst, Res Serv, West Roxbury, MA USA. [Nandi, Bisweswar; Shapiro, Mia; Samur, Mehmet K.; Frank, Natasha Y.; Yoon, Charles; Munshi, Nikhil C.; Gold, Jason S.] Harvard Med Sch, Boston, MA USA. [Samur, Mehmet K.; Yoon, Charles; Prabhala, Rao H.; Munshi, Nikhil C.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Frank, Natasha Y.; Munshi, Nikhil C.] VA Boston Healthcare Syst, Med Serv, West Roxbury, MA USA. [Frank, Natasha Y.; Yoon, Charles; Gold, Jason S.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. [Gold, Jason S.] VA Boston Healthcare Syst, Surg Serv, West Roxbury, MA USA. RP Gold, JS (reprint author), VA Boston Healthcare Syst 112, 1400 VFW Pkwy, West Roxbury, MA 02132 USA. EM jgold4@partners.org FU Department of Veterans Affairs Office of Research and Development through a Career Development Award-2 FX This work was supported by the Department of Veterans Affairs Office of Research and Development through a Career Development Award-2 to JSG. NR 49 TC 1 Z9 1 U1 1 U2 1 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 2162-402X J9 ONCOIMMUNOLOGY JI OncoImmunology PY 2016 VL 5 IS 8 AR e1189052 DI 10.1080/2162402X.2016.1189052 PG 11 WC Oncology; Immunology SC Oncology; Immunology GA DZ0IW UT WOS:000385522800025 ER PT J AU Reddy, AT Lakshmi, SP Reddy, RC AF Reddy, Aravind T. Lakshmi, Sowmya P. Reddy, Raju C. TI PPAR gamma in Bacterial Infections: A Friend or Foe? SO PPAR RESEARCH LA English DT Review ID ACTIVATED-RECEPTOR-GAMMA; CHRONIC GRANULOMATOUS-DISEASE; ACUTE LUNG INJURY; 15-DEOXY-DELTA(12,14)-PROSTAGLANDIN J(2); SYSTEMIC INFLAMMATION; ALVEOLAR MACROPHAGES; POLYMICROBIAL SEPSIS; INDUCE APOPTOSIS; EXPRESSION; CELLS AB Peroxisome proliferator-activated receptor gamma (PPAR gamma) is now recognized as an important modulator of leukocyte inflammatory responses and function. Its immunoregulatory function has been studied in a variety of contexts, including bacterial infections of the lungs and central nervous system, sepsis, and conditions such as chronic granulomatous disease. Although it is generally believed that PPAR gamma activation is beneficial for the host during bacterial infections via its anti-inflammatory and antibacterial properties, PPAR gamma agonists have also been shown to dampen the host immune response and in some cases exacerbate infection by promoting leukocyte apoptosis and interfering with leukocyte migration and infiltration. In this review we discuss the role of PPAR gamma and its activation during bacterial infections, with focus on the potential of PPAR gamma agonists and perhaps antagonists as novel therapeutic modalities. We conclude that adjustment in the dosage and timing of PPAR gamma agonist administration, based on the competence of host antimicrobial defenses and the extent of inflammatory response and tissue injury, is critical for achieving the essential balance between pro- and anti-inflammatory effects on the immune system. C1 [Reddy, Aravind T.; Lakshmi, Sowmya P.; Reddy, Raju C.] Univ Pittsburgh, Sch Med, Dept Med, Div Pulm Allergy & Crit Care Med, Pittsburgh, PA 15213 USA. [Reddy, Aravind T.; Lakshmi, Sowmya P.; Reddy, Raju C.] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA. RP Reddy, RC (reprint author), Univ Pittsburgh, Sch Med, Dept Med, Div Pulm Allergy & Crit Care Med, Pittsburgh, PA 15213 USA.; Reddy, RC (reprint author), Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA. EM reddyrc@upmc.edu FU Merit Review award from the US Department of Veterans Affairs; National Institutes of Health Grants [HL093196, AI125338] FX This work was supported by a Merit Review award from the US Department of Veterans Affairs and National Institutes of Health Grants HL093196 and AI125338 (to Raju C. Reddy). NR 56 TC 0 Z9 0 U1 0 U2 0 PU HINDAWI PUBLISHING CORP PI NEW YORK PA 315 MADISON AVE 3RD FLR, STE 3070, NEW YORK, NY 10017 USA SN 1687-4757 EI 1687-4765 J9 PPAR RES JI PPAR Res. PY 2016 AR 7963540 DI 10.1155/2016/7963540 PG 7 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA DY5EN UT WOS:000385121900001 ER PT B AU Teicholz, JG AF Teicholz, Judith Guss BE Gunsberg, L Hershberg, SG TI FILLING THE ENVELOPE What Joe Lichtenberg Has Done for My Psychoanalytic Theory and Practice SO PSYCHOANALYTIC THEORY, RESEARCH, AND CLINICAL PRACTICE: READING JOSEPH D. LICHTENBERG SE Psychoanalytic Inquiry Book Series LA English DT Article; Book Chapter C1 [Teicholz, Judith Guss] Massachusetts Inst Psychoanal, Boston, MA 02131 USA. [Teicholz, Judith Guss] Harvard Med Sch, Massachusetts Gen Hosp, Psychiat & Psychol, Boston, MA USA. RP Teicholz, JG (reprint author), Massachusetts Inst Psychoanal, Boston, MA 02131 USA. NR 10 TC 0 Z9 0 U1 0 U2 0 PU ROUTLEDGE PI ABINGDON PA 2 PARK SQ, MILTON PARK, ABINGDON OX14 4RN, OXFORD, ENGLAND BN 978-1-138-90655-6; 978-0-203-86173-8; 978-0-415-87495-3 J9 PSYCHOANAL INQ BOOK PY 2016 VL 49 BP 265 EP 276 PG 12 WC Psychology, Psychoanalysis SC Psychology GA BF9EW UT WOS:000385502900025 ER PT J AU Perez, GK Cruess, DG Strauss, NM AF Perez, Giselle K. Cruess, Dean G. Strauss, Nicole M. TI A brief information-motivation-behavioral skills intervention to promote human papillomavirus vaccination among college-aged women SO PSYCHOLOGY RESEARCH AND BEHAVIOR MANAGEMENT LA English DT Article DE human papillomavirus; HPV; vaccination; cervical cancer; Gardasil; IMB ID AIDS-RISK BEHAVIOR; HPV VACCINATION; YOUNG-WOMEN; STUDENTS; PREVALENCE; INFECTION; KNOWLEDGE; ATTITUDES; RECOMMENDATION; ACCEPTABILITY AB Background: Human papillomavirus (HPV) is prevalent among college-aged women. Although HPV vaccines decrease women's risk for cervical cancer, the vaccination rates remain inadequate. Objective: This study explored the utility of an information-motivation-behavioral skills (IMB) intervention in promoting HPV vaccination knowledge, motivation, and intentions among college-aged women. Methods: In Spring/Fall 2012, 62 participants were randomly assigned to a single-session intervention or attention control and were assessed baseline, post-intervention, and at 1 month. Results: The participants demonstrated adequate baseline vaccine knowledge, low HPV/cancer knowledge, and ambivalence about the vaccination. Post-intervention, the IMB arm demonstrated increased HPV/cancer and vaccination knowledge, motivation, and intentions. There were no group differences in vaccination at 1 month; however, the odds of wanting to get vaccinated increased sevenfold in the IMB arm. Conclusion: These results provide preliminary support for an IMB-based intervention in increasing vaccination knowledge, motivation, and intentions among at-risk women. Future research examining the efficacy of longer trials with larger, diverse populations is warranted. C1 [Perez, Giselle K.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Cruess, Dean G.] Univ Connecticut, Dept Psychol, Storrs, CT USA. [Strauss, Nicole M.] Massachusetts Gen Hosp, Mongan Inst Hlth Policy, 50 Staniford St,Ninth Floor, Boston, MA 02114 USA. RP Perez, GK (reprint author), Massachusetts Gen Hosp, Mongan Inst Hlth Policy, 50 Staniford St,Ninth Floor, Boston, MA 02114 USA. EM gperez@mgh.harvard.edu NR 39 TC 0 Z9 0 U1 3 U2 3 PU DOVE MEDICAL PRESS LTD PI ALBANY PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND SN 1179-1578 J9 PSYCHOL RES BEHAV MA JI Psychol. Res. Behav. Manag. PY 2016 VL 9 BP 285 EP 296 DI 10.2147/PRBM.S112504 PG 12 WC Psychology, Clinical; Psychiatry; Psychology, Multidisciplinary SC Psychology; Psychiatry GA DY8EY UT WOS:000385362800001 PM 27799835 ER PT J AU Vogel, J Xia, JL Cauley, S Balakrishnan, V AF Vogel, James Xia, Jianlin Cauley, Stephen Balakrishnan, Venkataramanan TI SUPERFAST DIVIDE-AND-CONQUER METHOD AND PERTURBATION ANALYSIS FOR STRUCTURED EIGENVALUE SOLUTIONS SO SIAM JOURNAL ON SCIENTIFIC COMPUTING LA English DT Article DE superfast divide-and-conquer; eigenvalue decomposition; structured perturbation analysis; linear complexity; rank structure; compression ID LINEAR-EQUATIONS; SEMISEPARABLE REPRESENTATIONS; PARTICLE SIMULATIONS; HERMITIAN MATRICES; FAST ALGORITHMS; H-MATRICES; SYSTEMS; FACTORIZATION; EIGENPROBLEM; SOLVER AB We present a sup er fast divide-and-conquer method for finding all the eigenvalues as well as all the eigenvectors (in a structured form) of a class of symmetric matrices with off-diagonal ranks or numerical ranks bounded by r, as well as the approximation accuracy of the eigenvalues due to off-diagonal compression. More specifically, the complexity is O (r(2)n log n) + O (r n log(2)n), where n is the order of the matrix. Such matrices are often encountered in practical computations with banded matrices, Toeplitz matrices (in Fourier space), and certain discretized problems. They can be represented or approximated by hierarchically semiseparable (HSS) matrices. We show how to preserve the HSS structure throughout the dividing process that involves recursive updates and how to quickly perform stable eigendecompositions of the structured forms. Various other numerical issues are discussed, such as computation reuse and deflation. The structure of the eigenvector matrix is also shown. We further analyze the structured perturbation, i.e., how compression of the off-diagonal blocks impacts the accuracy of the eigenvalues. They show that rank structured methods can serve as an effective and efficient tool for approximate eigenvalue solutions with controllable accuracy. The algorithm and analysis are very useful for finding the eigendecomposition of matrices arising from some important applications and can be modified to find SVDs of nonsymmetric matrices. The efficiency and accuracy are illustrated in terms of Toeplitz and discretized matrices. Our method requires significantly fewer operations than a recent structured eigensolver, by nearly an order of magnitude. C1 [Vogel, James; Xia, Jianlin] Purdue Univ, Dept Math, W Lafayette, IN 47907 USA. [Cauley, Stephen] Harvard Univ, Massachusetts Gen Hosp, Dept Radiol, Athinoula A Martinos Ctr Biomed Imaging, Boston, MA 02129 USA. [Balakrishnan, Venkataramanan] Purdue Univ, Sch Elect & Comp Engn, W Lafayette, IN 47907 USA. RP Vogel, J (reprint author), Purdue Univ, Dept Math, W Lafayette, IN 47907 USA. EM voge113@purdue.edu; xiaj@math.purdue.edu; stcauley@nmr.mgh.harvard.edu; ragu@ecn.purdue.edu FU NSF [DMS-1255416, DMS-1115572] FX The work of the second author was supported in part by NSF CAREER Award DMS-1255416 and NSF grant DMS-1115572. NR 47 TC 1 Z9 1 U1 1 U2 1 PU SIAM PUBLICATIONS PI PHILADELPHIA PA 3600 UNIV CITY SCIENCE CENTER, PHILADELPHIA, PA 19104-2688 USA SN 1064-8275 EI 1095-7197 J9 SIAM J SCI COMPUT JI SIAM J. Sci. Comput. PY 2016 VL 38 IS 3 BP A1358 EP A1382 DI 10.1137/15M1018812 PG 25 WC Mathematics, Applied SC Mathematics GA DY7AY UT WOS:000385282800005 ER PT J AU Cronin, A Tian, L Uno, H AF Cronin, Angel Tian, Lu Uno, Hajime TI strmst2 and strmst2pw: New commands to compare survival curves using the restricted mean survival time SO STATA JOURNAL LA English DT Article DE st0451; strmst2; strmst2pw; restricted mean survival time; restricted mean time lost; survival analysis; time-to-event data ID COX REGRESSION-MODEL; PSEUDO-OBSERVATIONS; HAZARD RATIOS; INFERENCE; TRIALS; LIFE AB We present strmst2, a new command to implement k-sample comparisons using the restricted mean survival time (RMST) as the summary measure of the survival-time distribution. Unlike model-based summary measures such as the hazard ratio, the validity of which relies on the adequacy of the proportional hazards assumption, the measures based on the RMST (that is, the difference in RMST, the ratio of RMST, and the ratio of the restricted mean time lost) provide more robust and clinically interpretable results about the between-group differences. strmst2 performs analysis of covariance-type adjusted analyses for k-sample comparisons as well as the corresponding unadjusted analyses. Pairwise comparisons for the adjusted analyses are summarized using the new postestimation command strmst2pw. We briefly describe the issues of the hazard ratio, introduce details of the method for the RMST, and then illustrate how to use the new commands. C1 [Cronin, Angel; Uno, Hajime] Dana Farber Canc Inst, Div Populat Sci, Boston, MA 02115 USA. [Tian, Lu] Stanford Univ, Sch Med, Dept Biomed Data Sci, Stanford, CA 94305 USA. RP Cronin, A (reprint author), Dana Farber Canc Inst, Div Populat Sci, Boston, MA 02115 USA. EM AngelM_Cronin@dfci.harvard.edu; lutian@stanford.edu; huno@jimmy.harvard.edu NR 17 TC 0 Z9 0 U1 3 U2 3 PU STATA PRESS PI COLLEGE STATION PA 4905 LAKEWAY PARKWAY, COLLEGE STATION, TX 77845 USA SN 1536-867X J9 STATA J JI Stata J. PY 2016 VL 16 IS 3 BP 702 EP 716 PG 15 WC Social Sciences, Mathematical Methods; Statistics & Probability SC Mathematical Methods In Social Sciences; Mathematics GA DY2ZT UT WOS:000384961300010 ER PT S AU Carter, ME Divita, G Redd, A Rubin, MA Samore, MH Gupta, K Trautner, BW Gundlapalli, AV AF Carter, Marjorie E. Divita, Guy Redd, Andrew Rubin, Michael A. Samore, Matthew H. Gupta, Kalpana Trautner, Barbara W. Gundlapalli, Adi V. BE Mantas, J Hasman, A Gallos, P Kolokathi, A Househ, MS TI Finding 'Evidence of Absence' in Medical Notes: Using NLP for Clinical Inferencing SO UNIFYING THE APPLICATIONS AND FOUNDATIONS OF BIOMEDICAL AND HEALTH INFORMATICS SE Studies in Health Technology and Informatics LA English DT Proceedings Paper CT 14th Annual International Conference on Informatics, Management, and Technology in Healthcare (ICIMTH) CY JUL 01-03, 2016 CL Athens, GREECE DE Information extraction; NLP; indwelling urinary catheter AB Extracting evidence of the absence of a target of interest from medical text can be useful in clinical inferencing. The purpose of our study was to develop a natural language processing (NLP) pipelineto identify the presence of indwelling urinary catheters from electronic medical notes to aid in detection of catheter-associated urinary tract infections (CAUTI). Finding clear evidence that a patient does not have an indwelling urinary catheter is useful in making a determination regarding CAUTI. We developed a lexicon of seven core concepts to infer the absence of a urinary catheter. Of the 990,391 concepts extractedby NLP from a large corpus of 744,285 electronic medical notes from 5589 hospitalized patients, 63,516 were labeled as evidence of absence. Human review revealed three primary causes for false negatives. The lexicon and NLP pipeline were refined using this information, resulting in outputs with an acceptable false positive rate of 11%. C1 [Carter, Marjorie E.; Divita, Guy; Redd, Andrew; Rubin, Michael A.; Samore, Matthew H.; Gundlapalli, Adi V.] VA Salt Lake City Hlth Care Syst, Salt Lake City, UT 84148 USA. [Carter, Marjorie E.; Divita, Guy; Redd, Andrew; Rubin, Michael A.; Samore, Matthew H.; Gundlapalli, Adi V.] Univ Utah, Salt Lake City, UT 84112 USA. [Gupta, Kalpana] VA Boston Hlth Care Syst, Boston, MA USA. [Gupta, Kalpana] Boston Univ, Boston, MA 02215 USA. [Trautner, Barbara W.] Michael E DeBakey VA Med Ctr, Ctr Innovat Qual Effectiveness & Safety, Houston, TX USA. [Trautner, Barbara W.] Baylor Coll Med, Houston, TX 77030 USA. RP Gundlapalli, AV (reprint author), VA Salt Lake City Hlth Care Syst, Salt Lake City, UT 84148 USA.; Gundlapalli, AV (reprint author), Univ Utah, Salt Lake City, UT 84112 USA. EM Adi.Gundlapalli@hsc.utah.edu OI Redd, Andrew/0000-0002-6149-2438 FU HSRD VA [I21 HX001047] NR 4 TC 0 Z9 0 U1 0 U2 0 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 0926-9630 BN 978-1-61499-664-4; 978-1-61499-663-7 J9 STUD HEALTH TECHNOL PY 2016 VL 226 BP 79 EP 82 DI 10.3233/978-1-61499-664-4-79 PG 4 WC Health Care Sciences & Services; Medical Informatics SC Health Care Sciences & Services; Medical Informatics GA BF9CP UT WOS:000385446600018 PM 27350471 ER PT J AU Sri-on, J Nithimathachoke, A Tirrell, GP Surawongwattana, S Liu, SW AF Sri-on, Jiraporn Nithimathachoke, Adisak Tirrell, Gregory Philip Surawongwattana, Sataporn Liu, Shan Woo TI Revisits within 48 Hours to a Thai Emergency Department SO EMERGENCY MEDICINE INTERNATIONAL LA English DT Article ID ACUTE ABDOMINAL-PAIN; ATYPICAL PRESENTATIONS; REPEAT EMERGENCY; ADVERSE OUTCOMES; RETURN VISITS; PREDICTORS; DISORDERS; ELDERS AB Objective. Emergency department (ED) revisits are a common ED quality measure. This study was undertaken to ascertain the contributing factors of revisits within 48 hours to a Thai ED and to explore physician-related, illness-related, and patient-related factors behind those revisits. Methods. This study was a chart review from one tertiary care, urban Thai hospital from October 1, 2009, to September 31, 2010. We identified patients who returned to the ED within 48 hours for the same or related complaints after their initial discharge. Three physicians classified revisit as physician-related, illness-related, and patient-related factors. Results. Our study included 172 ED patients' charts. 86/172 (50%) were male and the mean age was 38 +/- 5.6 (SD) years. The ED revisits contributing factors were physician-related factors [86/172 (50.0%)], illness-related factors [61/172 (35.5%)], and patient-related factor [25/172 (14.5%)], respectively. Among revisits classified as physician-related factors, 40/86 (46.5%) revisits were due to misdiagnosis and 36/86 (41.9%) were due to suboptimal management. Abdominal pain [27/86 (31.4%)] was the majority of physician-related chief complaints, followed by fever [16/86 (18.6%)] and dyspnea [15/86 (17.4%)]. Conclusion. Misdiagnosis and suboptimal management contributed to half of the 48-hour repeat ED visits in this Thai hospital. C1 [Sri-on, Jiraporn; Tirrell, Gregory Philip] Massachusetts Gen Hosp, Emergency Dept, Five Emerson,Suite 155, Boston, MA 02114 USA. [Sri-on, Jiraporn; Nithimathachoke, Adisak; Surawongwattana, Sataporn] Navamindradhiraj Univ, Vajira Hosp, Emergency Dept, 681 Samsen Rd, Bangkok 10300, Thailand. [Liu, Shan Woo] Massachusetts Gen Hosp, Emergency Dept, 55 Fruit St,Zero Emerson Pl,Room 346, Boston, MA 02114 USA. RP Sri-on, J (reprint author), Massachusetts Gen Hosp, Emergency Dept, Five Emerson,Suite 155, Boston, MA 02114 USA.; Sri-on, J (reprint author), Navamindradhiraj Univ, Vajira Hosp, Emergency Dept, 681 Samsen Rd, Bangkok 10300, Thailand. EM jiraporn.rew@gmail.com OI Sri-on, Jiraporn/0000-0002-8853-2567 NR 26 TC 0 Z9 0 U1 0 U2 0 PU HINDAWI PUBLISHING CORP PI NEW YORK PA 315 MADISON AVE 3RD FLR, STE 3070, NEW YORK, NY 10017 USA SN 2090-2840 EI 2090-2859 J9 EMERG MED INT JI Emerg. Med. Int. PY 2016 AR 8983573 DI 10.1155/2016/8983573 PG 5 WC Emergency Medicine SC Emergency Medicine GA DY5SX UT WOS:000385164500001 ER PT B AU Vagal, A Vossough, A Lev, MH Wintermark, M AF Vagal, Achala Vossough, Arastoo Lev, Michael H. Wintermark, Max BE Newton, HB TI Central Nervous System Infarction SO HANDBOOK OF NEURO-ONCOLOGY NEUROIMAGING, 2ND EDITION LA English DT Article; Book Chapter ID ATTENUATED INVERSION-RECOVERY; CAROTID-ARTERY STENOSIS; ENHANCED MR-ANGIOGRAPHY; SPINAL-CORD INFARCTION; CEREBRAL-BLOOD-FLOW; ACUTE STROKE; MAGNETIC-RESONANCE; CT PERFUSION; INTRAARTERIAL THROMBOLYSIS; HEMORRHAGIC TRANSFORMATION C1 [Vagal, Achala] Univ Cincinnati, Med Ctr, Dept Radiol, Neuroradiol Div, Cincinnati, OH 45267 USA. [Vossough, Arastoo] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA. [Vossough, Arastoo] Hosp Univ Penn, 3400 Spruce St, Philadelphia, PA 19104 USA. [Lev, Michael H.] Massachusetts Gen Hosp, Neurovasc Lab, Boston, MA 02114 USA. [Lev, Michael H.] Harvard Med Sch, Boston, MA USA. [Wintermark, Max] Stanford Univ, Dept Radiol, Neuroradiol Div, Stanford, CA 94305 USA. RP Vagal, A (reprint author), Univ Cincinnati, Med Ctr, Dept Radiol, Neuroradiol Div, Cincinnati, OH 45267 USA. NR 56 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA BN 978-0-12-801168-3; 978-0-12-800945-1 PY 2016 BP 89 EP 98 DI 10.1016/B978-0-12-800945-1.00011-2 PG 10 WC Oncology; Clinical Neurology; Neuroimaging SC Oncology; Neurosciences & Neurology GA BF6UL UT WOS:000383718200012 ER PT B AU Arrillaga-Romany, I Monje, M Wen, PY AF Arrillaga-Romany, Isabel Monje, Michelle Wen, Patrick Y. BE Newton, HB TI Neurologic Complications of Oncologic Therapy SO HANDBOOK OF NEURO-ONCOLOGY NEUROIMAGING, 2ND EDITION LA English DT Article; Book Chapter ID ACUTE LYMPHOBLASTIC-LEUKEMIA; IFOSFAMIDE-INDUCED ENCEPHALOPATHY; RADIATION-INDUCED MENINGIOMAS; BREAST-CANCER PATIENTS; OF-THE-LITERATURE; ACUTE LYMPHOCYTIC-LEUKEMIA; WHOLE-BRAIN RADIOTHERAPY; INTRAVENOUS CYTOSINE-ARABINOSIDE; RECEIVING ADJUVANT CHEMOTHERAPY; STANDARD-DOSE CHEMOTHERAPY C1 [Arrillaga-Romany, Isabel] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. [Arrillaga-Romany, Isabel; Wen, Patrick Y.] Harvard Med Sch, Boston, MA 02115 USA. [Monje, Michelle] Stanford Sch Med, Dept Neurol, Stanford, CA USA. [Wen, Patrick Y.] Dana Farber Brigham & Womens Canc Ctr, Ctr Neurooncol, Boston, MA USA. RP Arrillaga-Romany, I (reprint author), Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.; Arrillaga-Romany, I (reprint author), Harvard Med Sch, Boston, MA 02115 USA. NR 251 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA BN 978-0-12-801168-3; 978-0-12-800945-1 PY 2016 BP 125 EP 142 DI 10.1016/B978-0-12-800945-1.00015-X PG 18 WC Oncology; Clinical Neurology; Neuroimaging SC Oncology; Neurosciences & Neurology GA BF6UL UT WOS:000383718200016 ER PT B AU Young, GS Qu, JR AF Young, Geoffrey S. Qu, Jinrong BE Newton, HB TI Advanced Magnetic Resonance Imaging of Brain Tumors SO HANDBOOK OF NEURO-ONCOLOGY NEUROIMAGING, 2ND EDITION LA English DT Article; Book Chapter ID CEREBRAL BLOOD-VOLUME; HIGH-GRADE GLIOMAS; DIFFUSION-WEIGHTED MRI; CONTRAST-ENHANCED MR; GAMMA-KNIFE RADIOSURGERY; NEWLY-DIAGNOSED GLIOBLASTOMA; RECURRENT MALIGNANT GLIOMAS; CYSTIC MASS LESIONS; DIFFERENTIAL-DIAGNOSIS; WHITE-MATTER C1 [Young, Geoffrey S.] Brigham & Womens Hosp, Dept Radiol, 75 Francis St, Boston, MA 02115 USA. [Young, Geoffrey S.] Dana Farber Canc Inst, Dept Radiol, Boston, MA 02115 USA. [Young, Geoffrey S.] Harvard Med Sch, Dept Radiol, Boston, MA 02215 USA. [Qu, Jinrong] Henan Canc Hosp, Dept Radiol, Zhengzhou, Henan, Peoples R China. RP Young, GS (reprint author), Brigham & Womens Hosp, Dept Radiol, 75 Francis St, Boston, MA 02115 USA.; Young, GS (reprint author), Dana Farber Canc Inst, Dept Radiol, Boston, MA 02115 USA.; Young, GS (reprint author), Harvard Med Sch, Dept Radiol, Boston, MA 02215 USA. NR 149 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA BN 978-0-12-801168-3; 978-0-12-800945-1 PY 2016 BP 167 EP 181 DI 10.1016/B978-0-12-800945-1.00019-7 PG 15 WC Oncology; Clinical Neurology; Neuroimaging SC Oncology; Neurosciences & Neurology GA BF6UL UT WOS:000383718200020 ER PT B AU Patel, KS Chapman, PH Bussiere, M Loeffler, JS Chen, CC AF Patel, Kunal S. Chapman, Paul H. Bussiere, Marc Loeffler, Jay S. Chen, Clark C. BE Newton, HB TI Applications of Stereotactic Radiosurgery in Neuro-Oncology SO HANDBOOK OF NEURO-ONCOLOGY NEUROIMAGING, 2ND EDITION LA English DT Article; Book Chapter ID GAMMA-KNIFE RADIOSURGERY; BRAIN RADIATION-THERAPY; HIGH-GRADE GLIOMAS; RECURRENT MALIGNANT GLIOMAS; SKULL BASE MENINGIOMAS; LONG-TERM OUTCOMES; JUGULAR FORAMEN SCHWANNOMAS; PITUITARY-ADENOMAS; GLIOBLASTOMA-MULTIFORME; CUSHINGS-DISEASE C1 [Patel, Kunal S.; Chen, Clark C.] Univ Calif San Diego, Moores Canc Ctr, Div Neurosurg, Ctr Theoret & Appl Neurooncol, San Diego, CA 92103 USA. [Chapman, Paul H.] Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA. [Chapman, Paul H.; Bussiere, Marc; Loeffler, Jay S.] Harvard Med Sch, Boston, MA USA. [Bussiere, Marc; Loeffler, Jay S.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. RP Patel, KS (reprint author), Univ Calif San Diego, Moores Canc Ctr, Div Neurosurg, Ctr Theoret & Appl Neurooncol, San Diego, CA 92103 USA. NR 170 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA BN 978-0-12-801168-3; 978-0-12-800945-1 PY 2016 BP 257 EP 271 DI 10.1016/B978-0-12-800945-1.00026-4 PG 15 WC Oncology; Clinical Neurology; Neuroimaging SC Oncology; Neurosciences & Neurology GA BF6UL UT WOS:000383718200027 ER PT B AU Welling, DB AF Welling, D. Bradley BE Newton, HB TI Intracranial Schwannomas SO HANDBOOK OF NEURO-ONCOLOGY NEUROIMAGING, 2ND EDITION LA English DT Article; Book Chapter ID GAMMA-KNIFE RADIOSURGERY; ACOUSTIC NEUROMA; NEUROFIBROMATOSIS TYPE-2; VESTIBULAR SCHWANNOMAS; STEREOTACTIC RADIOSURGERY; FACIAL-NERVE; FOLLOW-UP; NF2 GENE; MUTATIONS; MR C1 [Welling, D. Bradley] Harvard Med Sch, Dept Otol & Laryngol, Massachusetts Eye & Ear, Boston, MA 02115 USA. [Welling, D. Bradley] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Welling, DB (reprint author), Harvard Med Sch, Dept Otol & Laryngol, Massachusetts Eye & Ear, Boston, MA 02115 USA.; Welling, DB (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 61 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA BN 978-0-12-801168-3; 978-0-12-800945-1 PY 2016 BP 543 EP 554 DI 10.1016/B978-0-12-800945-1.00045-8 PG 12 WC Oncology; Clinical Neurology; Neuroimaging SC Oncology; Neurosciences & Neurology GA BF6UL UT WOS:000383718200046 ER PT B AU Yang, E Chi, SN Silvera, VM AF Yang, Edward Chi, Susan N. Silvera, Victoria Michelle BE Newton, HB TI Pineal Region Tumors SO HANDBOOK OF NEURO-ONCOLOGY NEUROIMAGING, 2ND EDITION LA English DT Article; Book Chapter ID GERM-CELL TUMORS; CENTRAL-NERVOUS-SYSTEM; RADIOLOGIC-PATHOLOGICAL CORRELATION; ADULTS CLINICAL ARTICLE; PARENCHYMAL TUMORS; NATURAL-HISTORY; PAPILLARY TUMOR; INTERMEDIATE DIFFERENTIATION; COMPUTED-TOMOGRAPHY; PROGNOSTIC FACTORS C1 [Yang, Edward; Silvera, Victoria Michelle] Boston Childrens Hosp, Dept Radiol, Boston, MA 02115 USA. [Chi, Susan N.] Dana Farber Canc Inst, Dana Farber Boston Childrens Canc & Blood Disorde, Boston, MA 02115 USA. [Chi, Susan N.] Boston Childrens Hosp, Boston, MA USA. RP Yang, E (reprint author), Boston Childrens Hosp, Dept Radiol, Boston, MA 02115 USA. NR 101 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA BN 978-0-12-801168-3; 978-0-12-800945-1 PY 2016 BP 585 EP 602 DI 10.1016/B978-0-12-800945-1.00048-3 PG 18 WC Oncology; Clinical Neurology; Neuroimaging SC Oncology; Neurosciences & Neurology GA BF6UL UT WOS:000383718200049 ER PT B AU Jordan, JT Vernino, S AF Jordan, Justin T. Vernino, Steven BE Newton, HB TI Neuroimaging in Paraneoplastic Syndromes SO HANDBOOK OF NEURO-ONCOLOGY NEUROIMAGING, 2ND EDITION LA English DT Article; Book Chapter ID NMDA-RECEPTOR ENCEPHALITIS; AUTOIMMUNE LIMBIC ENCEPHALITIS; BRAIN-STEM ENCEPHALITIS; FDG-PET; CEREBELLAR DEGENERATION; NEUROLOGICAL SYNDROMES; CLINICAL-COURSE; ANTIBODY; MYELOPATHY; DIAGNOSIS C1 [Jordan, Justin T.] Massachusetts Gen Hosp, Dept Neurol, Div Neurooncol, Boston, MA 02114 USA. [Vernino, Steven] Univ Texas Southwestern Med Ctr, Dept Neurol & Neurotherapeut, Dallas, TX USA. RP Jordan, JT (reprint author), Massachusetts Gen Hosp, Dept Neurol, Div Neurooncol, Boston, MA 02114 USA. NR 40 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA BN 978-0-12-801168-3; 978-0-12-800945-1 PY 2016 BP 811 EP 818 DI 10.1016/B978-0-12-800945-1.00063-X PG 8 WC Oncology; Clinical Neurology; Neuroimaging SC Oncology; Neurosciences & Neurology GA BF6UL UT WOS:000383718200064 ER PT J AU Yalcha, MM Black, JA Martin, LF Levendosky, AA AF Yalcha, Matthew M. Black, J. Audie Martin, Lia Field Levendosky, Alytia A. TI Effects of Prenatal and Postbirth Intimate Partner Violence on Preschool-Age Children's Dissociative Symptoms SO JOURNAL OF AGGRESSION MALTREATMENT & TRAUMA LA English DT Article DE Bayesian; children; dissociation; domestic violence; intimate partner violence ID INFANT-MOTHER ATTACHMENT; DOMESTIC VIOLENCE; TRAUMA SYMPTOMS; CHILDHOOD AB Studies on the effects of intimate partner violence (IPV) on children have typically focused on IPV to which children were exposed after their birth. However, research has also demonstrated the effect of prenatal IPV on children's psychological functioning, although this has not yet been studied with respect to dissociation. In this study, we examined the association between prenatal and postbirth IPV and dissociative symptoms among preschool-age children using a Bayesian approach to multiple regression. Results indicated that prenatal IPV predicts child dissociative symptoms over and above postbirth IPV and other negative life events that the child has experienced. These results provide further evidence for the role prenatal IPV plays in the development of child psychopathology and suggest directions for future research and intervention. C1 [Yalcha, Matthew M.] San Francisco VA Med Ctr, 4150 Clement St, San Francisco, CA 94121 USA. [Black, J. Audie] Allegheny Gen Hosp, Pittsburgh, PA 15212 USA. [Martin, Lia Field] Justice Resource Inst, Ctr Trauma, Brookline, MA USA. [Levendosky, Alytia A.] Michigan State Univ, Dept Psychol, E Lansing, MI 48824 USA. RP Yalcha, MM (reprint author), San Francisco VA Med Ctr, 4150 Clement St, San Francisco, CA 94121 USA. EM yalchster@gmail.com NR 41 TC 0 Z9 0 U1 2 U2 2 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 1092-6771 EI 1545-083X J9 J AGGRESS MALTREAT T JI J. Aggress. Maltreatment Trauma PY 2016 VL 25 IS 7 BP 741 EP 752 DI 10.1080/10926771.2016.1194937 PG 12 WC Psychology, Clinical; Criminology & Penology; Family Studies; Psychiatry SC Psychology; Criminology & Penology; Family Studies; Psychiatry GA DY3HS UT WOS:000384982200005 ER PT J AU Katz, A Dizon, DS AF Katz, Anne Dizon, Don S. TI Sexuality After Cancer: A Model for Male Survivors SO JOURNAL OF SEXUAL MEDICINE LA English DT Article DE Cancer; Sexuality; Males; Sexual Dysfunction ID LOCALIZED PROSTATE-CANCER; ANDROGEN DEPRIVATION THERAPY; RADICAL PROSTATECTOMY; TESTICULAR CANCER; ERECTILE DYSFUNCTION; PENILE CANCER; MEN; COUPLES; SEX; COMMUNICATION AB Introduction: For men with cancer, sexual dysfunction is a common issue and has a negative impact on quality of life, regardless of whether he has a partner. In general, sexuality encompasses much more than intercourse; it involves body image, identity, romantic and sexual attraction, and sexual thoughts and fantasies. Aim: Acknowledging that cancer affects multiple physical and psychosocial domains in patients, the authors propose that such changes also inform sexual function for the male survivor. Methods: An in-depth review of the literature describing alterations to sexual functioning in men with cancer was undertaken. Based on this and the clinical expertise of the authors, a new model was created and is presented. Results: This biopsychosocial model is intended to expand the understanding of male sexuality beyond a purely biomedical model that addresses dysfunction as distinct from the context of a man's life and sexual identity. Conclusion: Most data on sexual dysfunction in men with cancer are derived from those with a history of prostate cancer, although other data suggest that men with other types of malignancies are similarly affected. Unfortunately, male sexuality is often reduced to aspects of erection and performance. Acknowledging that cancer affects multiple physical and psychosocial domains in patients, the authors propose that such changes also inform sexual function for the male survivor. This biopsychosocial model might form the basis for interventions for sexual problems after cancer that includes a man and his partner as a complex whole. Copyright (C) 2016, International Society for Sexual Medicine. Published by Elsevier Inc. All rights reserved. C1 [Katz, Anne] CancerCare Manitoba, Manitoba Prostate Ctr, Winnipeg, MB, Canada. [Dizon, Don S.] Massachusetts Gen Hosp, Gillette Ctr Gynecol Oncol, Boston, MA 02114 USA. RP Katz, A (reprint author), CancerCare Manitoa, Manitoba Prostate Ctr, 675 McDermot Ave, Winnipeg, MB R3E 0V9, Canada. EM anne.katz@cancercare.mb.ca OI Katz, Anne/0000-0002-8313-1254 NR 65 TC 1 Z9 1 U1 2 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1743-6095 EI 1743-6109 J9 J SEX MED JI J. Sex. Med. PD JAN PY 2016 VL 13 IS 1 BP 70 EP 78 DI 10.1016/j.jsxm.2015.11.006 PG 9 WC Urology & Nephrology SC Urology & Nephrology GA DX9OS UT WOS:000384725600010 PM 26755089 ER PT J AU Mirheydar, H Zhou, TZ Chang, DC Hsieh, TC AF Mirheydar, Hossein Zhou, Tianzan Chang, David C. Hsieh, Tung-Chin TI Reoperation Rates for Penile Prosthetic Surgery SO JOURNAL OF SEXUAL MEDICINE LA English DT Article DE Erectile Dysfunction; Surgery; Penile Prosthetic Surgery; Reoperation; Complication ID ERECTILE DYSFUNCTION; SATISFACTION RATES; FOLLOW-UP; INFECTION; IMPLANTATION; OUTCOMES; PATIENT AB Introduction: In patients with erectile dysfunction refractory to medical treatment, placement of a penile prosthesis is an effective treatment option. Despite advancements in prosthetic design, it is not without complications requiring reoperation. Aim: To evaluate the long-term reoperation rate of penile prosthesis implantation. Methods: A longitudinal analysis of the California Office of Statewide Health Planning and Development database from 1995 to 2010 was performed. Inclusion criteria were men who underwent their first penile prosthetic surgery. Patients were excluded if they underwent explantation of a prior prosthesis at the time of their first recorded surgery. Statistical analysis was performed by Kaplan-Meier plot, hazard curve, and multivariate analysis adjusting for age, race, comorbidities, insurance status, hospital volume, and hospital teaching status. Main Outcome Measures: Primary outcome was reoperation, specified as the removal or replacement of the prosthesis. Results: In total, 7,666 patients (40,932 patient-years) were included in the study. The 5- and 10-year cumulative reoperation rates were 11.2% (CI = 10.5-12.0) and 15.7% (CI = 14.7-16.8), respectively. Malfunction and infection accounted for 57% and 27% of reoperations. Reoperation rate was highest at 1 year postoperatively and steadily decreased until 2 years postoperatively. Multivariate analysis showed higher rates of reoperation in younger men (hazard ratio [HR] = 1.51, CI = 1.12-2.05), African-American men (HR = 1.30, CI = 1.05-1.62), and Hispanic men (HR = 1.32, CI = 1.12-1.57). Of the reoperations, 22.9% were performed at a hospital different from the initial implantation. Conclusion: Reoperation rate for penile prosthetic surgery is highest in the first year postoperatively. Patients with the highest risk for reoperation were African-American, Hispanic, and younger men. Nearly one fourth of reoperations occurred at a hospital different from the initial surgery, suggesting the existing literature does not reflect the true prevalence of penile prosthetic complications. Copyright (C) 2016, International Society for Sexual Medicine. Published by Elsevier Inc. All rights reserved. C1 [Mirheydar, Hossein; Hsieh, Tung-Chin] Univ Calif San Diego Hlth, Dept Urol, San Diego, CA USA. [Zhou, Tianzan] Univ Calif San Diego, Sch Med, La Jolla, CA 92093 USA. [Chang, David C.] Harvard Med Sch, Massachusetts Gen Hosp, Codman Ctr, Boston, MA USA. RP Hsieh, TC (reprint author), UC San Diego Hlth, Dept Urol, 200 West Arbor Dr 8897, San Diego, CA 92103 USA. EM tmikehsieh@ucsd.edu NR 17 TC 1 Z9 1 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1743-6095 EI 1743-6109 J9 J SEX MED JI J. Sex. Med. PD JAN PY 2016 VL 13 IS 1 BP 129 EP 133 DI 10.1016/j.jsxm.2015.11.013 PG 5 WC Urology & Nephrology SC Urology & Nephrology GA DX9OS UT WOS:000384725600016 PM 26755095 ER PT J AU Bowman-Colin, C Salazar, LA Martins, JO AF Bowman-Colin, Christian Salazar, Luis A. Martins, Joilson O. TI The Role of Endocrine System in the Inflammatory Process SO MEDIATORS OF INFLAMMATION LA English DT Editorial Material C1 [Bowman-Colin, Christian] Dana Farber Canc Inst, Boston, MA 02115 USA. [Bowman-Colin, Christian] Harvard Med Sch, Boston, MA USA. [Salazar, Luis A.] Univ La Frontera, Ctr Mol Biol & Pharmacogenet, Fac Med, Temuco, Chile. [Martins, Joilson O.] Univ Sao Paulo, Dept Clin & Toxicol Analyses, Fac Pharmaceut Sci, Sao Paulo, SP, Brazil. RP Martins, JO (reprint author), Univ Sao Paulo, Dept Clin & Toxicol Analyses, Fac Pharmaceut Sci, Sao Paulo, SP, Brazil. EM martinsj@usp.br RI Martins, Joilson/G-4367-2011; OI Martins, Joilson/0000-0003-2630-7038; Salazar, Luis/0000-0002-5112-6944 NR 0 TC 0 Z9 0 U1 2 U2 2 PU HINDAWI PUBLISHING CORP PI NEW YORK PA 315 MADISON AVE 3RD FLR, STE 3070, NEW YORK, NY 10017 USA SN 0962-9351 EI 1466-1861 J9 MEDIAT INFLAMM JI Mediat. Inflamm. PY 2016 AR 6081752 DI 10.1155/2016/6081752 PG 2 WC Cell Biology; Immunology SC Cell Biology; Immunology GA DY6DC UT WOS:000385195400001 ER PT J AU Kelly, JF Yeterian, JD Cristello, JV Kaminer, Y Kahler, CW Timko, C AF Kelly, John F. Yeterian, Julie D. Cristello, Julie V. Kaminer, Yifrah Kahler, Christopher W. Timko, Christine TI Developing and Testing Twelve-Step Facilitation for Adolescents with Substance Use Disorder: Manual Development and Preliminary Outcomes SO SUBSTANCE ABUSE-RESEARCH AND TREATMENT LA English DT Article DE 12-step; adolescent; Alcoholics Anonymous; Narcotics Anonymous; Marijuana Anonymous; self-help; mutual-help; mutual-aid; peer support; treatment; addiction; substance use disorder ID RANDOMIZED CONTROLLED-TRIAL; CHANGING NETWORK SUPPORT; SELF-HELP GROUPS; OUTPATIENT TREATMENT; INPATIENT TREATMENT; YOUNG-PEOPLE; ALCOHOL; INVOLVEMENT; PARTICIPATION; ATTENDANCE AB Adolescent substance use disorder treatment programs are often based on the 12-step philosophy of Alcoholics Anonymous and/or link adolescents to these free resources. Despite this, no studies have developed and rigorously tested a twelve-step facilitation (TSF) intervention for young people, leaving a significant evidence gap. This study describes the first systematic development of an outpatient adolescent TSF treatment. An integrated twelve-step facilitation (iTSF) treatment incorporated TSF, motivational enhancement therapy, and cognitive behavioral therapy elements and was developed in an iterative manner with weekly feedback provided by 36 adolescents (M age 17 years [SD=1.4]; 52.8% white) with DSM-IV substance use disorder recruited from the community. Assessments were conducted at baseline and at three and six months. Participants completed 6 of 10 sessions on average (8 participants completed all 10). Notable treatment developments were the inclusion of "in-services" led by Marijuana Anonymous members, including parents in a portion of individual sessions to provide a rationale for TSF, and use of a Socratic therapeutic interaction style. Acceptability and feasibility of the treatment were excellent (treatment satisfaction was 4.29 [SD=0.59] out of 5). In keeping with TSF theory, the intervention substantially increased 12-step participation, and greater participation related to greater abstinence. iTSF is a replicable manualized treatment that can be implemented and tested in outpatient settings. Given the widespread compatibility of iTSF with the current adolescent treatment, if found efficacious, iTSF could be relatively easily adopted, implemented, and sustained and could provide an evidence-based option that could undergird current practice. C1 [Kelly, John F.; Yeterian, Julie D.; Cristello, Julie V.] Harvard Med Sch, Massachusetts Gen Hosp, Ctr Addict Med, Recovery Res Inst, Boston, MA 02115 USA. [Kaminer, Yifrah] Univ Connecticut, Dept Psychiat, Farmington, CT 06107 USA. [Kahler, Christopher W.] Brown Univ, Ctr Alcohol & Addict Studies, Sch Publ Hlth, Providence, RI 02912 USA. [Timko, Christine] VA Palo Alto Hlth Care Syst, Ctr Innovat Implementat, Livermore, CA USA. [Timko, Christine] Stanford Univ, Sch Med, Stanford, CA 94305 USA. RP Kelly, JF (reprint author), Harvard Med Sch, Massachusetts Gen Hosp, Ctr Addict Med, Recovery Res Inst, Boston, MA 02115 USA. EM jkelly11@mgh.harvard.edu FU United States National Institute on Alcohol Abuse and Alcoholism (NIAAA) [R01-AA019664] FX This study was funded by a grant from the United States National Institute on Alcohol Abuse and Alcoholism (NIAAA) R01-AA019664. The authors confirm that the funder had no influence over the study design, content of the article, or selection of this journal. NR 59 TC 1 Z9 1 U1 5 U2 5 PU LIBERTAS ACAD PI AUCKLAND PA PO BOX 300-874, ALBANY 0752, AUCKLAND, 00000, NEW ZEALAND SN 1178-2218 J9 SUBST ABUS-RES TREAT JI Subst. Abus.-Res. Treat. PY 2016 VL 10 BP 55 EP 64 DI 10.4137/SART.S39635 PG 10 WC Substance Abuse SC Substance Abuse GA DW5MD UT WOS:000383688400001 PM 27429548 ER PT J AU Ramsey, SE Rounsaville, D Hoskinson, R Park, TW Ames, EG Neirinckx, VD Friedmann, P AF Ramsey, Susan E. Rounsaville, Dan Hoskinson, Randall Park, Tae Woo Ames, Evan G. Neirinckx, Victor D. Friedmann, Peter TI The Need for Psychosocial Interventions to Facilitate the Transition to Extended-Release Naltrexone (XR-NTX) Treatment for Opioid Dependence: A Concise Review of the Literature SO SUBSTANCE ABUSE-RESEARCH AND TREATMENT LA English DT Article DE opioid dependence; XR-NTX; Acceptance and Commitment Therapy ID MULTICENTER RANDOMIZED-TRIAL; ACCEPTANCE-BASED TREATMENT; EARLY SMOKING LAPSE; METHADONE-MAINTENANCE; COMMITMENT THERAPY; DISTRESS TOLERANCE; CHRONIC PAIN; OPIATE ADDICTS; UNITED-STATES; DETOXIFICATION AB Given the increase of opioid dependence and opioid-related morbidity and mortality, improving treatment options for individuals with opioid dependence warrants increased attention. This article provides a concise review of work in this area. Remission from opioid dependence can be very difficult to sustain, particularly in the absence of opioid replacement or opioid antagonist therapy. For those who wish to transition from opioid use or opioid replacement therapy to opioid antagonist therapy, a significant challenge can be the period of withdrawal symptoms that must be endured prior to the initiation of opioid antagonist therapy. Studies that have incorporated psychosocial interventions into detoxification protocols have found that they can result in improved treatment outcomes. Interventions based on Acceptance and Commitment Therapy have shown promise in the treatment of clinical disorders that present with symptoms similar to those of opioid withdrawal and have been found to positively impact outcomes among those tapering from methadone. However, the use of an Acceptance and Commitment Therapy-based intervention has yet to be studied among opioid-dependent patients transitioning to XR-NTX, and its value to those transitioning to XR-NTX is currently unknown. C1 [Ramsey, Susan E.; Park, Tae Woo; Ames, Evan G.; Neirinckx, Victor D.] Rhode Isl Hosp, Providence, RI 02903 USA. [Ramsey, Susan E.; Park, Tae Woo] Brown Univ, Dept Psychiat & Human Behav, Warren Alpert Med Sch, Providence, RI 02912 USA. [Ramsey, Susan E.] Brown Univ, Dept Med, Warren Alpert Med Sch, Providence, RI 02912 USA. [Rounsaville, Dan] VA Boston Healthcare Syst, Brockton, MA USA. [Hoskinson, Randall; Friedmann, Peter] Baystate Hlth, Springfield, MA USA. RP Ramsey, SE (reprint author), Rhode Isl Hosp, Providence, RI 02903 USA.; Ramsey, SE (reprint author), Brown Univ, Dept Psychiat & Human Behav, Warren Alpert Med Sch, Providence, RI 02912 USA.; Ramsey, SE (reprint author), Brown Univ, Dept Med, Warren Alpert Med Sch, Providence, RI 02912 USA. EM Susan_Ramsey@Brown.edu FU National Institute on Drug Abuse of the National Institutes of Health [R34DA037797] FX Research reported in this publication was supported in part by the National Institute on Drug Abuse of the National Institutes of Health under award number R34DA037797. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The authors confirm that the funder had no influence over the study design, content of the article, or selection of this journal. NR 44 TC 0 Z9 0 U1 2 U2 2 PU LIBERTAS ACAD PI AUCKLAND PA PO BOX 300-874, ALBANY 0752, AUCKLAND, 00000, NEW ZEALAND SN 1178-2218 J9 SUBST ABUS-RES TREAT JI Subst. Abus.-Res. Treat. PY 2016 VL 10 BP 65 EP 68 DI 10.4137/SART.S39067 PG 4 WC Substance Abuse SC Substance Abuse GA DW5MD UT WOS:000383688400002 PM 27512336 ER PT J AU Aggarwal, V Waldo, SW Armstrong, EJ AF Aggarwal, Vikas Waldo, Stephen W. Armstrong, Ehrin J. TI Endovascular revascularization for aortoiliac atherosclerotic disease SO VASCULAR HEALTH AND RISK MANAGEMENT LA English DT Review DE peripheral artery disease; iliac artery; balloon expandable stent; self expanding stent; covered stent; claudication; endovascular ID ILIAC ARTERY OCCLUSIONS; EXPANDABLE STENTS; VASCULAR STENT; KISSING STENTS; OUTCOMES; ANGIOPLASTY; RECONSTRUCTION; BIFURCATION; RESTENOSIS; TRIAL AB Atherosclerotic iliac artery disease is increasingly being treated with endovascular techniques. A number of new stent technologies can be utilized with high long-term patency, including self-expanding stents, balloon-expandable stents, and covered stents, but comparative data on these stent types and in more complex lesions are lacking. This article provides a review of currently available iliac stent technologies, as well as complex procedural aspects of iliac artery interventions, including approaches to the treatment of iliac bifurcation disease, long segment occlusions, choice of stent type, and treatment of iliac artery in-stent restenosis. C1 [Aggarwal, Vikas] St Johns Hosp, Prairie Heart Inst, Springfield, IL USA. [Waldo, Stephen W.; Armstrong, Ehrin J.] Denver Vet Affairs Med Ctr, Sect Cardiol, 1055 Clermont St, Denver, CO 80220 USA. [Waldo, Stephen W.; Armstrong, Ehrin J.] Univ Colorado, Sect Cardiol, Aurora, CO USA. RP Armstrong, EJ (reprint author), Denver Vet Affairs Med Ctr, Sect Cardiol, 1055 Clermont St, Denver, CO 80220 USA. EM ehrin.armstrong@gmail.com NR 42 TC 1 Z9 1 U1 3 U2 3 PU DOVE MEDICAL PRESS LTD PI ALBANY PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND SN 1176-6344 EI 1178-2048 J9 VASC HEALTH RISK MAN JI Vasc. Health Risk Manag. PY 2016 VL 12 BP 117 EP 127 DI 10.2147/VHRM.S98721 PG 11 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA DW5PT UT WOS:000383699300002 PM 27099509 ER PT J AU Lo, ST Pantazopouos, P Medarova, Z Moore, A AF Lo, Su-Tang Pantazopouos, Pamela Medarova, Zdravka Moore, Anna TI Presentation of underglycosylated mucin 1 in pancreatic adenocarcinoma (PDAC) at early stages SO AMERICAN JOURNAL OF CANCER RESEARCH LA English DT Article DE Pancreatic cancer; underglycosylated mucin 1; tumor antigen; immunohistochemistry ID INTERFERING RNA NANODRUG; TRANSGENIC MOUSE MODEL; GENE-EXPRESSION; CANCER CELLS; RECOGNITION SYSTEMS; TUMOR PROGRESSION; OVARIAN-CANCER; BREAST-CANCER; COLON-CANCER; THERAPY AB Underglycosylated mucin 1 antigen (uMUC1) is a proven biomarker of cancer progression relevant to many malignancies including pancreatic ductal adenocarcinoma (PDAC). However, while ample evidence exists of the expression of total MUC1, little is known about the abundance of the underglycolsylated form of the antigen and its significance in disease progression. Such knowledge is important because the underglycosylated form of MUC1 is intimately linked to metastatic potential. Here, we investigated the expression uMUC1 at various stages of PDAC including pancreatic intraepithelial neoplasia (PanIN). Immunohistochemical analysis was performed on human tissue microarrays (TMAs) containing PDAC and PanIN using monoclonal antibody specific to uMUC1. uMUC1 expression was analyzed by a traditional pathological scoring system and using automatic imaging analysis software. Our results demonstrated low uMUC1 abundance in PanIN lesions and a transient increase in antigen availability in stage I PDAC, followed by decreased expression in later stages of the disease. An additional finding was that there was intermediate expression of uMUC1 in adjacent normal tissues from PDAC irrespective of the stage. These studies suggest the intriguing possibility that a pro-metastatic uMUC1 expression signature may appear at early stages of PDAC, providing an additional clue about the aggressive nature of pancreatic cancer. C1 [Lo, Su-Tang; Pantazopouos, Pamela; Medarova, Zdravka; Moore, Anna] Massachusetts Gen Hosp, Dept Radiol, MGH MIT HMS Athinoula A Martinos Ctr Biomed Imagi, Mol Imaging Lab, 13th St, Charlestown, MA 02129 USA. [Lo, Su-Tang; Pantazopouos, Pamela; Medarova, Zdravka; Moore, Anna] Harvard Med Sch, 13th St, Charlestown, MA 02129 USA. [Lo, Su-Tang] UT Southwestern Med Ctr, Adv Imaging Res Ctr, Dallas, TX 75390 USA. RP Moore, A (reprint author), Massachusetts Gen Hosp, Dept Radiol, MGH MIT HMS Athinoula A Martinos Ctr Biomed Imagi, Mol Imaging Lab, 13th St, Charlestown, MA 02129 USA.; Moore, A (reprint author), Harvard Med Sch, 13th St, Charlestown, MA 02129 USA. EM amoore@helix.mgh.harvard.edu FU National Institute of Health [R01CA-135650] FX This work was supported in part by the award from the National Institute of Health R01CA-135650 to A.M. (Contact PI) and Z.M. (Co-PI). NR 36 TC 0 Z9 0 U1 0 U2 0 PU E-CENTURY PUBLISHING CORP PI MADISON PA 40 WHITE OAKS LN, MADISON, WI 53711 USA SN 2156-6976 J9 AM J CANCER RES JI Am. J. Cancer Res. PY 2016 VL 6 IS 9 BP 1986 EP 1995 PG 10 WC Oncology SC Oncology GA DX7RK UT WOS:000384586500011 PM 27725904 ER PT J AU Turner, TH Renfroe, JB Elm, J Duppstadt-Delambo, A Hinson, VK AF Turner, T. H. Renfroe, J. B. Elm, J. Duppstadt-Delambo, A. Hinson, V. K. TI Robustness of reliable change indices to variability in Parkinson's disease with mild cognitive impairment SO APPLIED NEUROPSYCHOLOGY-ADULT LA English DT Article DE Problem solving; test construction; tests; treatment ID FLUCTUATIONS; ATTENTION; DEMENTIA; DISORDER; CRITERIA AB Ability to identify change is crucial for measuring response to interventions and tracking disease progression. Beyond psychometrics, investigations of Parkinson's disease with mild cognitive impairment (PD-MCI) must consider fluctuating medication, motor, and mental status. One solution is to employ 90% reliable change indices (RCIs) from test manuals to account for account measurement error and practice effects. The current study examined robustness of 90% RCIs for 19 commonly used executive function tests in 14 PD-MCI subjects assigned to the placebo arm of a 10-week randomized controlled trial of atomoxetine in PD-MCI. Using 90% RCIs, the typical participant showed spurious improvement on one measure, and spurious decline on another. Reliability estimates from healthy adults standardization samples and PD-MCI were similar. In contrast to healthy adult samples, practice effects were minimal in this PD-MCI group. Separate 90% RCIs based on the PD-MCI sample did not further reduce error rate. In the present study, application of 90% RCIs based on healthy adults in standardization samples effectively reduced misidentification of change in a sample of PD-MCI. Our findings support continued application of 90% RCIs when using executive function tests to assess change in neurological populations with fluctuating status. C1 [Turner, T. H.] Ralph H Johnson Vet Affairs Med Ctr, Mental Hlth Serv, Charleston, SC USA. [Turner, T. H.] Med Univ South Carolina, Dept Psychiat Behav Sci, Charleston, SC USA. [Renfroe, J. B.; Duppstadt-Delambo, A.; Hinson, V. K.] Med Univ South Carolina, Dept Neurosci, Charleston, SC USA. [Elm, J.] Med Univ South Carolina, Dept Publ Hlth Sci, Charleston, SC USA. [Hinson, V. K.] Ralph H Johnson Vet Affairs Med Ctr, Neurol Serv, Charleston, SC USA. RP Turner, TH (reprint author), Ralph H Johnson VAMC, Mental Hlth Serv 116, 109 Bee St, Charleston, SC 29401 USA. EM turnertr@musc.edu FU Michael J. Fox Foundation for Parkinson's Research FX Funding was provided by the Michael J. Fox Foundation for Parkinson's Research; NCT01738191. NR 16 TC 0 Z9 0 U1 2 U2 2 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 2327-9095 EI 2327-9109 J9 APPL NEUROPSYCH-ADUL JI Appl. Neuropsychol.-Adult PY 2016 VL 23 IS 6 BP 399 EP 402 DI 10.1080/23279095.2016.1160907 PG 4 WC Clinical Neurology; Psychology SC Neurosciences & Neurology; Psychology GA DX6XV UT WOS:000384530300002 PM 27144494 ER PT J AU Sudore, RL Barnes, DE Le, GM Ramos, R Osua, SJ Richardson, SA Boscardin, J Schillinger, D AF Sudore, Rebecca L. Barnes, Deborah E. Le, Gem M. Ramos, Roberto Osua, Stacy J. Richardson, Sarah A. Boscardin, John Schillinger, Dean TI Improving advance care planning for English-speaking and Spanish-speaking older adults: study protocol for the PREPARE randomised controlled trial SO BMJ OPEN LA English DT Article ID OF-LIFE CARE; MENTAL STATUS QUESTIONNAIRE; DECISIONAL CONFLICT SCALE; LIMITED HEALTH LITERACY; ADMINISTRATIVE DATA; ADVANCED CANCER; CONTROL PREFERENCES; COMORBIDITY INDEX; SOCIAL SUPPORT; MINI-COG AB Introduction: Advance care planning (ACP) is a process that allows patients to identify their goals for medical care. Traditionally, ACP has focused on completing advance directives; however, we have expanded the ACP paradigm to also prepare patients to communicate their wishes and make informed decisions. To this end, we created an ACP website called PREPARE (http://www.prepareforyourcare.org) to prepare diverse English-speaking and Spanish-speaking older adults for medical decision-making. Here, we describe the study protocol for a randomised controlled efficacy trial of PREPARE in a safety-net setting. The goal is to determine the efficacy of PREPARE to engage diverse English-speaking and Spanish-speaking older adults in a full spectrum of ACP behaviours. Methods and analysis: We include English-speaking and Spanish-speaking adults from an urban public hospital who are >= 55 years old, have >= 2 chronic medical conditions and have seen a primary care physician >= 2 times in the last year. Participants are randomised to the PREPARE intervention (review PREPARE and an easy-to-read advance directive) or the control arm (only the easy-to-read advance directive). The primary outcome is documentation of an advance directive and/or ACP discussion. Secondary outcomes include ACP behaviour change processes measured with validated surveys (eg, self-efficacy, readiness) and a broad range of ACP actions (eg, choosing a surrogate, identifying goals for care, discussing ACP with clinicians and/or surrogates). Using blinded outcome ascertainment, outcomes will be measured at 1 week and at 3, 6 and 12 months, and compared between study arms using mixed-effects logistic regression and mixed-effects linear, Poisson or negative binomial regression. Ethics and dissemination: This study has been approved by the appropriate Institutional Review Boards and is guided by input from patient and clinical advisory boards and a data safety monitoring board. The results of this study will be disseminated to academic and community stakeholders. C1 [Sudore, Rebecca L.; Le, Gem M.; Ramos, Roberto; Osua, Stacy J.; Richardson, Sarah A.; Boscardin, John] Univ Calif San Francisco, Dept Med, Div Geriatr, San Francisco, CA 94143 USA. [Sudore, Rebecca L.; Barnes, Deborah E.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Sudore, Rebecca L.; Le, Gem M.; Schillinger, Dean] Univ Calif San Francisco, Dept Med, Zuckerberg San Francisco Gen Hosp, Ctr Vulnerable Populat, San Francisco, CA 94143 USA. [Barnes, Deborah E.] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Barnes, Deborah E.; Boscardin, John] Univ Calif San Francisco, Dept Med, Dept Epidemiol, San Francisco, CA USA. [Barnes, Deborah E.; Boscardin, John] Univ Calif San Francisco, Dept Med, Dept Biostat, San Francisco, CA USA. [Le, Gem M.; Schillinger, Dean] Univ Calif San Francisco, Dept Med, Div Gen Internal Med, San Francisco, CA USA. [Ramos, Roberto; Osua, Stacy J.; Richardson, Sarah A.] Northern Calif Inst Res & Educ, San Francisco, CA USA. RP Sudore, RL (reprint author), Univ Calif San Francisco, Dept Med, Div Geriatr, San Francisco, CA 94143 USA.; Sudore, RL (reprint author), San Francisco VA Med Ctr, San Francisco, CA 94121 USA.; Sudore, RL (reprint author), Univ Calif San Francisco, Dept Med, Zuckerberg San Francisco Gen Hosp, Ctr Vulnerable Populat, San Francisco, CA 94143 USA. EM Rebecca.Sudore@ucsf.edu FU National Institute on Aging [R01 AG045043]; Patient-Centered Outcomes Research Institute [CDR-1306-01500] FX This work is supported by the National Institute on Aging (R01 AG045043) and the Patient-Centered Outcomes Research Institute (CDR-1306-01500). NR 81 TC 0 Z9 0 U1 4 U2 4 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 2044-6055 J9 BMJ OPEN JI BMJ Open PY 2016 VL 6 IS 7 AR e011705 DI 10.1136/bmjopen-2016-011705 PG 15 WC Medicine, General & Internal SC General & Internal Medicine GA DU5LB UT WOS:000382252100120 PM 27401363 ER PT J AU Oura, T Ko, DSC Boskovic, S O'Neil, JJ Chipashvili, V Koulmanda, M Hotta, K Kawai, K Nadazdin, O Smith, RN Cosimi, AB Kawai, T AF Oura, Tetsu Ko, Dicken S. C. Boskovic, Svjetlan O'Neil, John J. Chipashvili, Vaja Koulmanda, Maria Hotta, Kiyohiko Kawai, Kento Nadazdin, Ognjenka Smith, R. Neal Cosimi, A. B. Kawai, Tatsuo TI Kidney Versus Islet Allograft Survival After Induction of Mixed Chimerism With Combined Donor Bone Marrow Transplantation SO CELL TRANSPLANTATION LA English DT Article DE Kidney transplantation; Islet transplantation; Nonhuman primate; Mixed chimerism ID MISMATCHED RENAL-TRANSPLANTATION; NONHUMAN-PRIMATES; CYNOMOLGUS MONKEYS; MAINTENANCE IMMUNOSUPPRESSION; HEMATOPOIETIC CHIMERISM; T-CELLS; TOLERANCE AB We have previously reported successful induction of transient mixed chimerism and long-term acceptance of renal allografts in MHC mismatched nonhuman primates. In this study, we attempted to extend this tolerance induction approach to islet allografts. A total of eight recipients underwent MHC mismatched combined islet and bone marrow (BM) transplantation after induction of diabetes by streptozotocin. Three recipients were treated after a nonmyeloablative conditioning regimen that included low-dose total body and thymic irradiation, horse Atgam (ATG), six doses of anti-CD154 monoclonal antibody (mAb), and a 1-month course of cyclosporine (CyA) (Islet A). In Islet B, anti-CD8 mAb was administered in place of CyA. In Islet C, two recipients were treated with Islet B, but without ATG. The results were compared with previously reported results of eight cynomolgus monkeys that received combined kidney and BM transplantation (Kidney A) following the same conditioning regimen used in Islet A. The majority of kidney/BM recipients achieved long-term renal allograft survival after induction of transient chimerism. However, prolonged islet survival was not achieved in similarly conditioned islet/BM recipients (Islet A), despite induction of comparable levels of chimerism. In order to rule out islet allograft loss due to CyA toxicity, three recipients were treated with anti-CD8 mAb in place of CyA. Although these recipients developed significantly superior mixed chimerism and more prolonged islet allograft survival (61, 103, and 113 days), islet function was lost soon after the disappearance of chimerism. In Islet C recipients, neither prolonged chimerism nor islet survival was observed (30 and 40 days). Significant improvement of mixed chimerism induction and islet allograft survival were achieved with a CyA-free regimen that included anti-CD8 mAb. However, unlike the kidney allograft, islet allograft tolerance was not induced with transient chimerism. Induction of more durable mixed chimerism may be necessary for induction of islet allograft tolerance. C1 [Oura, Tetsu; Ko, Dicken S. C.; Boskovic, Svjetlan; Hotta, Kiyohiko; Kawai, Kento; Nadazdin, Ognjenka; Smith, R. Neal; Cosimi, A. B.; Kawai, Tatsuo] Harvard Med Sch, Massachusetts Gen Hosp, Ctr Transplantat Sci, Boston, MA USA. [O'Neil, John J.] Janssen Res & Dev Ltd Liabil Co, Raritan, NJ USA. [Chipashvili, Vaja; Koulmanda, Maria] Harvard Med Sch, Dept Med, Transplant Inst, Beth Israel Deaconess Med Ctr, Boston, MA USA. RP Kawai, T (reprint author), Harvard Med Sch, Dept Surg, Ctr Transplantat Sci, Massachusetts Gen Hosp, White 521,55 Fruit St, Boston, MA 02114 USA. EM TKAWAI@mgh.harvard.edu FU National Institute of Allergy and Infectious Disease (NIAID) [POI-HL18646, ROI A137692-05, U19 AI102405-01] FX This work was supported in part by POI-HL18646, ROI A137692-05, U19 AI102405-01, National Institute of Allergy and Infectious Disease (NIAID). This manuscript was not prepared or funded by any commercial organization. The authors declare no conflicts of interest. NR 25 TC 2 Z9 2 U1 0 U2 0 PU COGNIZANT COMMUNICATION CORP PI PUTNAM VALLEY PA 18 PEEKSKILL HOLLOW RD, PO BOX 37, PUTNAM VALLEY, NY 10579 USA SN 0963-6897 EI 1555-3892 J9 CELL TRANSPLANT JI Cell Transplant. PY 2016 VL 25 IS 7 BP 1331 EP 1341 DI 10.3727/096368915X688966 PG 11 WC Cell & Tissue Engineering; Medicine, Research & Experimental; Transplantation SC Cell Biology; Research & Experimental Medicine; Transplantation GA DY0QL UT WOS:000384801200011 PM 26337731 ER PT J AU Wang, LJ Kin, T O'Gorman, D Shapiro, AMJ Naziruddin, B Takita, M Levy, MF Posselt, AM Szot, GL Savari, O Barbaro, B McGarrigle, J Yeh, CC Oberholzer, J Lei, J Chen, T Lian, M Markmann, JF Alvarez, A Linetsky, E Ricordi, C Balamurugan, AN Loganathan, G Wilhelm, JJ Hering, BJ Bottino, R Trucco, M Liu, CY Min, Z Li, YJ Naji, A Fernandez, LA Ziemelis, M Danobeitia, JS Millis, JM Witkowski, P AF Wang, Ling-jia Kin, Tatsuya O'Gorman, Doug Shapiro, A. M. James Naziruddin, Bashoo Takita, Morihito Levy, Marlon F. Posselt, Andrew M. Szot, Gregory L. Savari, Omid Barbaro, Barbara McGarrigle, James Yeh, Chun Chieh Oberholzer, Jose Lei, Ji Chen, Tao Lian, Moh Markmann, James F. Alvarez, Alejandro Linetsky, Elina Ricordi, Camillo Balamurugan, A. N. Loganathan, Gopalakrishnan Wilhelm, Joshua J. Hering, Bernhard J. Bottino, Rita Trucco, Massimo Liu, Chengyang Min, Zaw Li, Yanjing Naji, Ali Fernandez, Luis A. Ziemelis, Martynas Danobeitia, Juan S. Millis, J. Michael Witkowski, Piotr TI A Multicenter Study: North American Islet Donor Score in Donor Pancreas Selection for Human Islet Isolation for Transplantation SO CELL TRANSPLANTATION LA English DT Article DE Islet isolation; Islet transplantation; Organ donor, Pancreas ID CLINICAL TRANSPLANTATION; ISOLATION SUCCESS; VARIABLES; LANGERHANS; OUTCOMES; REGISTRY; YIELD; RISK AB Selection of an optimal donor pancreas is the first key task for successful islet isolation. We conducted a retrospective multicenter study in 11 centers in North America to develop an islet donor scoring system using donor variables. The data set consisting of 1,056 deceased donors was used for development of a scoring system to predict islet isolation success (defined as postpurification islet yield >400,000 islet equivalents). With the aid of univariate logistic regression analyses, we developed the North American Islet Donor Score (NAIDS) ranging from 0 to 100 points. The c index in the development cohort was 0.73 (95% confidence interval 0.70-0.76). The success rate increased proportionally as the NAIDS increased, from 6.8% success in the NAIDS <50 points to 53.7% success in the NAIDS >= 80 points. We further validated the NAIDS using a separate set of data consisting of 179 islet isolations. A comparable outcome of the NAIDS was observed in the validation cohort. The NAIDS may be a useful tool for donor pancreas selection in clinical practice. Apart from its utility in clinical decision making, the NAIDS may also be used in a research setting as a standardized measurement of pancreas quality. C1 [Wang, Ling-jia; Savari, Omid; Millis, J. Michael; Witkowski, Piotr] Univ Chicago, Dept Surg, Sect Transplantat, 5841 S Maryland Ave, Chicago, IL 60637 USA. [Kin, Tatsuya; O'Gorman, Doug; Shapiro, A. M. James] Univ Alberta, Clin Islet Transplant Program, Edmonton, AB, Canada. [Kin, Tatsuya; O'Gorman, Doug; Shapiro, A. M. James] Alberta Hlth Serv, Edmonton, AB, Canada. [Naziruddin, Bashoo; Takita, Morihito; Levy, Marlon F.] Baylor Simmons Transplant Inst, Dallas, TX USA. [Posselt, Andrew M.; Szot, Gregory L.] Univ Calif San Francisco, UCSF Transplantat Surg, San Francisco, CA 94143 USA. [Barbaro, Barbara; McGarrigle, James; Yeh, Chun Chieh; Oberholzer, Jose] Univ Illinois, UIC Cell Isolat Program, Chicago, IL USA. [Lei, Ji; Chen, Tao; Lian, Moh; Markmann, James F.] Massachusetts Gen Hosp, Ctr Transplantat Sci, Boston, MA 02114 USA. [Alvarez, Alejandro; Linetsky, Elina; Ricordi, Camillo; Hering, Bernhard J.] Univ Miami, Miller Sch Med, Diabet Res Inst, cGMP Cell Proc Facil, Miami, FL 33136 USA. [Balamurugan, A. N.; Loganathan, Gopalakrishnan; Wilhelm, Joshua J.; Hering, Bernhard J.] Univ Minnesota, Schulze Diabet Inst, Minneapolis, MN USA. [Bottino, Rita; Trucco, Massimo] Allegheny Hlth Network, Inst Cellular Therapeut, Pittsburgh, PA USA. [Liu, Chengyang; Min, Zaw; Li, Yanjing; Naji, Ali] Univ Penn, Perelman Sch Med, Div Transplantat, Philadelphia, PA 19104 USA. [Fernandez, Luis A.; Ziemelis, Martynas; Danobeitia, Juan S.] Univ Wisconsin, Div Organ Transplantat, Madison, WI USA. RP Witkowski, P (reprint author), Univ Chicago, Med Ctr, Dept Surg, Div Abdominal Organ Transplantat, 5841 S Maryland Ave MC5027,Room J-517, Chicago, IL 60637 USA. EM pwitkowski@surgery.bsd.uchicago.edu FU NIH CTSA [UL1 TR000430]; DRTC Grant [P30 DK020595] FX The authors would like to thank Dr. Theodore Karrison (Director of Biostatistics Lab at the University of Chicago) for his advice on statistical analysis and Ms. Julissa Acevedo for her continued support in the establishment of the multicenter data entry in REDCap, University of Chicago. The authors also sincerely appreciate the database created by the REDCap project (grant support NIH CTSA UL1 TR000430), which is a reliable and user-friendly database. This study is supported in part by DRTC Grant No. P30 DK020595 to the University of Chicago. The authors declare no conflicts of interest. NR 36 TC 2 Z9 2 U1 0 U2 0 PU COGNIZANT COMMUNICATION CORP PI PUTNAM VALLEY PA 18 PEEKSKILL HOLLOW RD, PO BOX 37, PUTNAM VALLEY, NY 10579 USA SN 0963-6897 EI 1555-3892 J9 CELL TRANSPLANT JI Cell Transplant. PY 2016 VL 25 IS 8 BP 1515 EP 1523 DI 10.3727/096368916X691141 PG 9 WC Cell & Tissue Engineering; Medicine, Research & Experimental; Transplantation SC Cell Biology; Research & Experimental Medicine; Transplantation GA DY0QM UT WOS:000384801300008 PM 26922947 ER PT J AU Arena, R Lavie, CJ Hivert, MF Williams, MA Briggs, PD Guazzi, M AF Arena, Ross Lavie, Carl J. Hivert, Marie-France Williams, Mark A. Briggs, Paige D. Guazzi, Marco TI Who will deliver comprehensive healthy lifestyle interventions to combat non-communicable disease? Introducing the healthy lifestyle practitioner discipline SO EXPERT REVIEW OF CARDIOVASCULAR THERAPY LA English DT Review DE Obesity; physical inactivity; poor nutrition; tobacco; hypertension; diabetes; dyslipidemia; exercise; weight loss; healthy diet; smoking cessation ID AMERICAN-HEART-ASSOCIATION; SERVICES TASK-FORCE; NONHIERARCHICAL CONNECTIVITY MODEL; ACCOUNTABLE CARE ORGANIZATIONS; CARDIOVASCULAR RISK-FACTORS; ACTIVITY PROMOTION PROGRAMS; PHYSICAL-ACTIVITY; PREVENTIVE SERVICES; POLICY STATEMENT; RECOMMENDATION STATEMENT AB Unhealthy lifestyle characteristics (i.e., physical inactivity, excess body mass, poor diet, and smoking) as well as associated poor health metrics (i.e., dyslipidemia, hyperglycemia, and hypertension) are the primary reasons for the current non-communicable disease crisis. Compared to those with the poorest of lifestyles and associated health metrics, any movement toward improving lifestyle and associated health metrics improves health outcomes. To address the non-communicable disease crisis we must: 1) acknowledge that healthy lifestyle (HL) interventions are a potent medicine; and 2) move toward a healthcare system that embraces primordial as much as, if not more than, secondary prevention with a heavy focus on HL medicine. This article introduces the Healthy Lifestyle Practitioner, focused on training health professionals to deliver HL medicine. C1 [Arena, Ross] Univ Illinois, Coll Appl Sci, Dept Kinesiol & Nutr, Dept Phys Therapy, Chicago, IL 60612 USA. [Arena, Ross] Univ Illinois, Coll Appl Sci, Integrat Physiol Lab, Chicago, IL 60612 USA. [Lavie, Carl J.] Univ Queensland, Sch Med, Ochsner Clin Sch, John Ochsner Heart & Vasc Inst,Dept Cardiovasc Di, New Orleans, LA USA. [Hivert, Marie-France] Harvard Med Sch, Harvard Pilgrim Hlth Care Inst, Dept Populat Med, Boston, MA USA. [Hivert, Marie-France] Massachusetts Gen Hosp, Diabet Unit, Boston, MA 02114 USA. [Williams, Mark A.] Creighton Univ, Sch Med, Dept Med, Div Cardiol, Omaha, NE USA. [Briggs, Paige D.] Univ New Mexico, Off Inst Analyt, Albuquerque, NM 87131 USA. [Guazzi, Marco] Policlin San Donato Univ Hosp, IRCCS, Heart Failure Unit, Milan, Italy. [Guazzi, Marco] Policlin San Donato Univ Hosp, IRCCS, Cardiopulm Lab, Cardiol, Milan, Italy. RP Arena, R (reprint author), Univ Illinois, Coll Appl Hlth Sci, Dept Phys Therapy, Chicago, IL 60612 USA. EM raarena@uic.edu RI Lavie, Carl/A-6014-2011; Guazzi, Marco/J-3165-2016 OI Guazzi, Marco/0000-0002-8456-609X NR 60 TC 8 Z9 8 U1 7 U2 9 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 1477-9072 EI 1744-8344 J9 EXPERT REV CARDIOVAS JI Expert Rev. Cardiovasc. Ther. PY 2016 VL 14 IS 1 BP 15 EP 22 DI 10.1586/14779072.2016.1107477 PG 8 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DX8LI UT WOS:000384639600003 PM 26524498 ER PT J AU Bhatia, RS Alabousi, M Dudzinski, DM Weiner, RB AF Bhatia, R. Sacha Alabousi, Mostafa Dudzinski, David M. Weiner, Rory B. TI Appropriate use criteria: a review of need, development and applications SO EXPERT REVIEW OF CARDIOVASCULAR THERAPY LA English DT Review DE Quality improvement; appropriate use criteria; cardiology; echocardiography; health policy ID OF-CARDIOLOGY FOUNDATION; CARDIOVASCULAR-COMPUTED-TOMOGRAPHY; AMERICAN-HEART-ASSOCIATION; CORONARY-ARTERY-DISEASE; ACADEMIC-MEDICAL-CENTER; DECISION-SUPPORT TOOL; TRANSTHORACIC ECHOCARDIOGRAPHY; NUCLEAR-CARDIOLOGY; TASK-FORCE; MAGNETIC-RESONANCE AB The costs of healthcare in developed countries have seen a dramatic increase in tandem with the increasing utilization of diagnostic testing. As a result, Appropriate Use Criteria (AUC)-based practices have become more commonplace as a provider-driven solution to reducing unnecessary tests and procedures across various specialty societies. The AUC are meant to serve as a distinct entity from clinical guidelines to help inform clinicians of the 'appropriateness' of a diagnostic test or procedure. In this article, we discuss the development, implementation, impact, and practical applications of AUC to improve appropriate utilization by providers, healthcare institutions, payers, and policy makers. We also focus on the role of education and feedback as a potentially efficacious future method of implementation of global quality improvement and cost-mitigating strategies. AUC represent a growing quality improvement tool in cardiovascular medicine that can play an important role in reducing inappropriate testing while preserving physician autonomy. C1 [Bhatia, R. Sacha] Womens Coll Hosp, Inst Hlth Syst Solut & Virtual Care, Toronto, ON, Canada. [Bhatia, R. Sacha] Univ Hlth Network, Toronto Gen Hosp, Peter Munk Cardiac Ctr, Toronto, ON, Canada. [Bhatia, R. Sacha] Univ Toronto, Sch Med, Dept Med, Toronto, ON, Canada. [Alabousi, Mostafa] Univ Ottawa, Sch Med, Ottawa, ON, Canada. [Dudzinski, David M.; Weiner, Rory B.] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA. [Bhatia, R. Sacha] Inst Clin Evaluat Sci, Toronto, ON, Canada. [Bhatia, R. Sacha] Univ Hlth Network, Div Cardiol, Toronto, ON, Canada. [Bhatia, R. Sacha] Womens Coll Hosp, Toronto, ON, Canada. [Bhatia, R. Sacha] Univ Toronto, Med, 76 Grenville St,6th Floor, Toronto, ON M5S 1B2, Canada. RP Bhatia, RS (reprint author), Womens Coll Hosp, Inst Hlth Syst Solut & Virtual Care, Toronto, ON, Canada.; Bhatia, RS (reprint author), Inst Clin Evaluat Sci, Toronto, ON, Canada.; Bhatia, RS (reprint author), Univ Hlth Network, Div Cardiol, Toronto, ON, Canada.; Bhatia, RS (reprint author), Womens Coll Hosp, Toronto, ON, Canada.; Bhatia, RS (reprint author), Univ Toronto, Med, 76 Grenville St,6th Floor, Toronto, ON M5S 1B2, Canada. EM sacha.r.bhatia@wchospital.ca NR 57 TC 2 Z9 2 U1 2 U2 2 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 1477-9072 EI 1744-8344 J9 EXPERT REV CARDIOVAS JI Expert Rev. Cardiovasc. Ther. PY 2016 VL 14 IS 3 BP 281 EP 290 DI 10.1586/14779072.2016.1131125 PG 10 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DX8LV UT WOS:000384641100006 PM 26653710 ER PT J AU Johansen, T Venegas, JG AF Johansen, Troels Venegas, Jose Gabriel TI 3D mapping of oxygen and CO2 transport rates in the lung: a new imaging tool for use in lung surgery, intensive care and basic research SO EXPERT REVIEW OF RESPIRATORY MEDICINE LA English DT Editorial Material DE Pulmonary gas exchange; pulmonary gas transfer; oxygen; carbon dioxide; lung imaging; lung surgery C1 [Johansen, Troels] Aarhus Univ Hosp, Dept Resp Dis, Aarhus, Denmark. [Venegas, Jose Gabriel] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA. [Venegas, Jose Gabriel] Harvard Med Sch, Boston, MA 02115 USA. RP Venegas, JG (reprint author), Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA.; Venegas, JG (reprint author), Harvard Med Sch, Boston, MA 02115 USA. EM jvenegas@vqpet.mgh.harvard.edu NR 5 TC 0 Z9 0 U1 0 U2 0 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND SN 1747-6348 EI 1747-6356 J9 EXPERT REV RESP MED JI Expert Rev. Respir. Med. PY 2016 VL 10 IS 9 BP 935 EP 937 DI 10.1080/17476348.2016.1206818 PG 3 WC Respiratory System SC Respiratory System GA DX8QF UT WOS:000384653000001 PM 27348193 ER PT J AU Carleton, PF Schachter, S Parrish, JA Collins, JM Crocker, JB Dixon, RF Edgman-Levitan, S Lewandrowski, KB Stahl, JE Klapperich, C Cabodi, M Gaydos, CA Rompalo, AM Manabe, Y Wang, TH Rothman, R Geddes, CD Widdice, L Jackman, J Mathura, RA Lash, TB AF Carleton, Penny Ford Schachter, Steven Parrish, John A. Collins, John M. Crocker, J. Benjamin Dixon, Ronald F. Edgman-Levitan, Susan Lewandrowski, Kent B. Stahl, James E. Klapperich, Catherine Cabodi, Mario Gaydos, Charlotte A. Rompalo, Anne M. Manabe, Yukari Wang, Tza-Huei Rothman, Richard Geddes, Chris D. Widdice, Lea Jackman, Joany Mathura, Rishi A. Lash, Tiffani Bailey TI National Institute of Biomedical Imaging and Bioengineering Point-of-Care Technology Research Network: Advancing Precision Medicine SO IEEE JOURNAL OF TRANSLATIONAL ENGINEERING IN HEALTH AND MEDICINE-JTEHM LA English DT Article DE Point of care technologies; policy ID ISOTHERMAL AMPLIFICATION; CHLAMYDIA-TRACHOMATIS; AMBULATORY PRACTICE; CLINICAL-SAMPLES; DIAGNOSTICS; INFECTIONS; EXTRACTION; WORK; CHIP AB To advance the development of point-of-care technology (POCT), the National Institute of Biomedical Imaging and Bioengineering established the POCT Research Network (POCTRN), comprised of Centers that emphasize multidisciplinary partnerships and close facilitation to move technologies from an early stage of development into clinical testing and patient use. This paper describes the POCTRN and the three currently funded Centers as examples of academic-based organizations that support collaborations across disciplines, institutions, and geographic regions to successfully drive innovative solutions from concept to patient care. C1 [Carleton, Penny Ford; Schachter, Steven; Parrish, John A.; Collins, John M.] Consortium Improving Med Innovat & Technol, Boston, MA 02114 USA. [Carleton, Penny Ford; Schachter, Steven; Parrish, John A.; Collins, John M.; Crocker, J. Benjamin; Dixon, Ronald F.; Edgman-Levitan, Susan; Lewandrowski, Kent B.; Stahl, James E.] CIMIT Point Care Technol Res Ctr Primary Care, Boston, MA USA. [Schachter, Steven; Parrish, John A.; Crocker, J. Benjamin; Dixon, Ronald F.; Edgman-Levitan, Susan; Lewandrowski, Kent B.] Harvard Med Sch, Boston, MA 02115 USA. [Dixon, Ronald F.; Edgman-Levitan, Susan; Lewandrowski, Kent B.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Stahl, James E.] Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA. [Klapperich, Catherine; Cabodi, Mario] Boston Univ, Dept Biomed Engn, Boston, MA 02215 USA. [Klapperich, Catherine; Cabodi, Mario] BU Ctr Future Technol Canc Care, Boston, MA USA. [Gaydos, Charlotte A.; Rompalo, Anne M.; Manabe, Yukari; Wang, Tza-Huei; Rothman, Richard; Jackman, Joany] Johns Hopkins Univ, Baltimore, MD 21218 USA. [Geddes, Chris D.] Univ Maryland, College Pk, MD 20742 USA. [Widdice, Lea] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA. [Gaydos, Charlotte A.; Rompalo, Anne M.; Manabe, Yukari; Wang, Tza-Huei; Rothman, Richard; Geddes, Chris D.; Widdice, Lea; Jackman, Joany] JHU Ctr Excellence Dev & Testing Point Care Tests, Baltimore, MD USA. [Mathura, Rishi A.; Lash, Tiffani Bailey] Natl Inst Biomed Imaging & Bioengn, NIH, Bethesda, MD 20892 USA. RP Schachter, S (reprint author), Consortium Improving Med Innovat & Technol, Boston, MA 02114 USA. EM sschacht@bidmc.harvard.edu NR 30 TC 0 Z9 0 U1 0 U2 0 PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC PI PISCATAWAY PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA SN 2168-2372 J9 IEEE J TRANSL ENG HE JI IEEE J. Transl. Eng. Health Med.-JTEHM PY 2016 VL 4 AR 2800614 DI 10.1109/JTEHM.2016.2598837 PG 14 WC Engineering, Biomedical SC Engineering GA DX8OK UT WOS:000384648200001 PM 27730014 ER PT J AU Roos, LE Afifi, TO Martin, CG Pietrzak, RH Tsai, J Sareen, J AF Roos, Leslie E. Afifi, Tracie O. Martin, Christina Gamache Pietrzak, Robert H. Tsai, Jack Sareen, Jitender TI Linking Typologies of Childhood Adversity to Adult Incarceration: Findings From a Nationally Representative Sample SO AMERICAN JOURNAL OF ORTHOPSYCHIATRY LA English DT Article DE child maltreatment; adverse childhood experiences; latent class analysis; incarceration ID HOUSEHOLD DYSFUNCTION; FEMALE PRISONERS; SEXUAL-ABUSE; ALCOHOL-USE; DRUG-USE; EXPERIENCES; MALTREATMENT; WOMEN; DISORDERS; OUTCOMES AB Ecologically valid typologies of adverse child experiences (ACEs) were identified to investigate the link between ACEs and adult incarceration. In a nationally representative sample (N = 34,653, age 20+), latent class analysis (LCA) was conducted with childhood maltreatment (physical, sexual, and emotional abuse, interpersonal violence [IPV] exposure, physical neglect) and caregiver maladjustment (substance use, incarceration, mental illness, and suicidal behavior) indicators. LCA identified a 5-typology model (1. Low Adversity Risk; 2. Caregiver Substance Use, and Maltreatment Acts of Omission; 3. Physical and Emotional Maltreatment; 4. Severe Cross-Subtype Maltreatment and Caregiver Substance Use; and 5. Caregiver Maladjustment). Controlling for sociodemographics and substance use problems, logistic regression analyses determined that, compared with the Low Adversity Risk typology, all typologies (except Caregiver Maladjustment) had elevated incarceration risk (adjusted odds ratios: 1.76-4.18). Maltreatment experiences were more predictive of incarceration for women versus men. Childhood maltreatment confers risk for incarceration beyond established risk factors, but caregiver maladjustment, alone, does not. Preventative efforts should focus on understanding and targeting pathways to delinquency for individuals with childhood maltreatment. C1 [Roos, Leslie E.; Martin, Christina Gamache] Univ Oregon, Dept Psychol, Eugene, OR 97403 USA. [Roos, Leslie E.] Univ Manitoba, Dept Psychiat, Winnipeg, MB R3T 2N2, Canada. [Afifi, Tracie O.; Sareen, Jitender] Univ Manitoba, Dept Psychiat, Dept Community Hlth Sci, Winnipeg, MB R3T 2N2, Canada. [Afifi, Tracie O.] Univ Manitoba, Dept Family Social Serv, Winnipeg, MB R3T 2N2, Canada. [Pietrzak, Robert H.] VA Connecticut Healthcare Syst, US Dept Vet Affairs, Natl Ctr Posttraumat Stress Disorder, West Haven, CT USA. [Pietrzak, Robert H.; Tsai, Jack] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT 06520 USA. [Tsai, Jack] Vet Affairs New England Mental Illness Res Educ &, West Haven, CT USA. [Sareen, Jitender] Univ Manitoba, Dept Psychol, Winnipeg, MB R3T 2N2, Canada. RP Roos, LE (reprint author), 1227 Univ Oregon, Dept Psychol, Eugene, OR 97403 USA. EM leslie.roos@gmail.com OI Roos, Leslie/0000-0001-7083-4017 FU Manitoba Health Research Council (MHRC); Canadian Institutes of Health Research (CIHR); Preventing Violence Across the Lifespan (PreVAiL) Network FX Preparation of this article was supported by a Manitoba Health Research Council (MHRC) establishment award (TOA), and a Canadian Institutes of Health Research (CIHR) New Investigator award (TOA). Funding was also provided by the Preventing Violence Across the Lifespan (PreVAiL) Network (LER, TOA, and JS). NR 51 TC 0 Z9 0 U1 8 U2 8 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0002-9432 EI 1939-0025 J9 AM J ORTHOPSYCHIAT JI Am. J. Orthopsychiatr. PY 2016 VL 86 IS 5 BP 584 EP 593 DI 10.1037/ort0000144 PG 10 WC Psychiatry; Social Work SC Psychiatry; Social Work GA DX2VI UT WOS:000384229900011 PM 27078049 ER PT J AU Sardina, JL Di Stefano, B Graf, T AF Luis Sardina, Jose Di Stefano, Bruno Graf, Thomas TI How does C/EBP alpha speed up cell reprogramming? SO CELL CYCLE LA English DT Editorial Material ID TRANSDIFFERENTIATION; PLURIPOTENCY C1 [Luis Sardina, Jose; Graf, Thomas] Barcelona Inst Sci & Technol, CRG, Barcelona, Spain. [Luis Sardina, Jose; Graf, Thomas] UPF, Barcelona, Spain. [Di Stefano, Bruno] Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA. [Di Stefano, Bruno] Harvard Univ, Dept Stem Cell & Regenerat Biol, Cambridge, MA 02138 USA. [Di Stefano, Bruno] Harvard Stem Cell Inst, Cambridge, MA USA. RP Graf, T (reprint author), Ctr Genom Regulat, C Dr Aiguader 88, Barcelona 08003, Spain. EM Thomas.Graf@crg.eu NR 7 TC 0 Z9 0 U1 0 U2 0 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 1538-4101 EI 1551-4005 J9 CELL CYCLE JI Cell Cycle PY 2016 VL 15 IS 18 BP 2381 EP 2382 DI 10.1080/15384101.2016.1194138 PG 2 WC Cell Biology SC Cell Biology GA DW9ZV UT WOS:000384022200002 PM 27267161 ER PT J AU William, A Singhal, A Khurana, D Padma, MV Kaul, S Pn, S Arora, D Pannu, A Pandian, J AF William, A. Singhal, A. Khurana, D. Padma, M., V Kaul, S. Pn, S. Arora, D. Pannu, A. Pandian, J. TI Wake-Up Stroke in India: The Indo-US Stroke Project SO CEREBROVASCULAR DISEASES LA English DT Meeting Abstract ID THROMBOLYSIS C1 [William, A.; Arora, D.; Pannu, A.; Pandian, J.] Christian Med Coll & Hosp, Neurol, Ludhiana, Punjab, India. [Singhal, A.] Massachusetts Gen Hosp, Neurol, Boston, MA 02114 USA. [Khurana, D.] Postgrad Inst Med Educ & Res, Neurol, Chandigarh, India. [Padma, M., V] All India Inst Med Sci, Neurol, New Delhi, India. [Kaul, S.] Nizams Inst Med Sci, Neurol, Hydrabad, India. [Pn, S.] Sree Chitra Thirunal Inst Midecal Sci & Technol, Neurol, Trivandrum, Kerala, India. NR 4 TC 0 Z9 0 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1015-9770 EI 1421-9786 J9 CEREBROVASC DIS JI Cerebrovasc. Dis. PY 2016 VL 42 SU 1 MA P081 BP 67 EP 67 PG 1 WC Clinical Neurology; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA DS9MM UT WOS:000381107200137 ER PT J AU Pal, A Das, RS Zhang, WC Lang, MG McLaughlin, LW Szostak, JW AF Pal, Ayan Das, Rajat S. Zhang, Weicheng Lang, Megan McLaughlin, Larry W. Szostak, Jack W. TI Effect of terminal 3 '-hydroxymethyl modification of an RNA primer on nonenzymatic primer extension SO CHEMICAL COMMUNICATIONS LA English DT Article ID TEMPLATE-DIRECTED SYNTHESIS; HAIRPIN OLIGONUCLEOTIDES; NUCLEOSIDE ANALOGS; POTENTIAL INHIBITORS; CRYSTAL-STRUCTURE; GENETIC POLYMER; OLIGOMERIZATION; HIV; RIBONUCLEOTIDES; GUANOSINE AB The significance of the precise position of the hydroxyl at the 3'-end of an RNA primer for nonenzymatic template-directed primer extension is not well understood. We show that an RNA primer terminating in 3'-hydroxymethyl-2',3'- dideoxy-guanosine has greatly diminished activity, suggesting that the spatial preorganization of the terminal sugar contributes significantly to the efficiency of primer extension. C1 [Pal, Ayan; Zhang, Weicheng; Szostak, Jack W.] Massachusetts Gen Hosp, Howard Hughes Med Inst, Dept Mol Biol, 185 Cambridge St, Boston, MA 02114 USA. [Pal, Ayan; Zhang, Weicheng; Szostak, Jack W.] Massachusetts Gen Hosp, Ctr Computat & Integrat Biol, 185 Cambridge St, Boston, MA 02114 USA. [Pal, Ayan; Szostak, Jack W.] Harvard Med Sch, Dept Genet, 77 Ave Louis Pasteur, Boston, MA 02115 USA. [Das, Rajat S.; Lang, Megan; McLaughlin, Larry W.] Boston Coll, Merkert Chem Ctr, Dept Chem, 2609 Beacon St, Chestnut Hill, MA 02467 USA. [Das, Rajat S.] Alnylam Pharmaceut, 300 Third St, Cambridge, MA 02142 USA. [Zhang, Weicheng; Szostak, Jack W.] Harvard Univ, Dept Chem & Chem Biol, 12 Oxford St, Cambridge, MA 02138 USA. RP Szostak, JW (reprint author), Massachusetts Gen Hosp, Howard Hughes Med Inst, Dept Mol Biol, 185 Cambridge St, Boston, MA 02114 USA.; Szostak, JW (reprint author), Massachusetts Gen Hosp, Ctr Computat & Integrat Biol, 185 Cambridge St, Boston, MA 02114 USA.; Szostak, JW (reprint author), Harvard Med Sch, Dept Genet, 77 Ave Louis Pasteur, Boston, MA 02115 USA.; Szostak, JW (reprint author), Harvard Univ, Dept Chem & Chem Biol, 12 Oxford St, Cambridge, MA 02138 USA. EM szostak@molbio.mgh.harvard.edu FU Simons Foundation [290363] FX We thank Drs Victor Lelyveld, Wen Zhang, Noam Prywes, Neha Kamat and Mr Travis Walton for helpful discussions. J. W. S. is an Investigator of the Howard Hughes Medical Institute. This work was supported in part by a grant (290363) from the Simons Foundation to J. W. S. NR 29 TC 0 Z9 0 U1 2 U2 2 PU ROYAL SOC CHEMISTRY PI CAMBRIDGE PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND SN 1359-7345 EI 1364-548X J9 CHEM COMMUN JI Chem. Commun. PY 2016 VL 52 IS 80 BP 11905 EP 11907 DI 10.1039/c6cc06925h PG 3 WC Chemistry, Multidisciplinary SC Chemistry GA DX2MK UT WOS:000384203900007 PM 27722518 ER PT J AU Hunger, T Schnell-Inderst, P Sahakyan, N Siebert, U AF Hunger, Theresa Schnell-Inderst, Petra Sahakyan, Narine Siebert, Uwe TI USING EXPERT OPINION IN HEALTH TECHNOLOGY ASSESSMENT: A GUIDELINE REVIEW SO INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE LA English DT Review DE Health technology assessment; Expert opinion; Expert elicitation; Expert data ID COST-EFFECTIVENESS AB Objectives: External experts can be consulted at different stages of an HTA. When using vague information sources, it is particularly important to plan, analyze, and report the information processing in a standardized and transparent way. Our objective was to search and analyze recommendations regarding where and how to include expert data in HTA. Methods: We performed a systematic database search and screened the Internet pages of seventy-seven HTA organizations for guidelines, recommendations, and methods papers that address the inclusion of experts in HTA. Relevant documents were downloaded, and information was extracted in a standard form. Results were merged in tables and narrative evidence synthesis. Results: From twenty-two HTA organizations, we included forty-two documents that consider the use of expert opinion in HTA. Nearly all documents mention experts in the step of preparation of the evidence report. Six documents address their role for priority setting of topics, fifteen for scoping, twelve for the appraisal of evidence and results, another twelve documents mention experts when considering the dissemination of HTA results. During the assessment step, experts are most often asked to amend the literature search or to provide expertise for special data analyses. Another issue for external experts is to appraise the HTA results and refer them back to a clinical and social context. Little is reported on methods of expert elicitation when their input substitutes study data. Conclusions: Despite existing recommendations on the use of expert opinion in HTA, common standards for elicitation are scarce in HTA guidelines. C1 [Hunger, Theresa; Schnell-Inderst, Petra; Sahakyan, Narine; Siebert, Uwe] UMIT Univ Hlth Sci Med Informat & Technol, Dept Publ Hlth Hlth Serv Res & Hlth Technol Asses, Hall In Tirol, Austria. [Hunger, Theresa; Schnell-Inderst, Petra; Sahakyan, Narine; Siebert, Uwe] ONCOTYROL Ctr Personalized Canc Med, Div Publ Hlth Decis Modeling Hlth Technol Assessm, Innsbruck, Austria. [Siebert, Uwe] Harvard TH Chan Sch Publ Hlth, Inst Technol Assessment, Dept Hlth Policy & Management, Boston, MA 02115 USA. [Siebert, Uwe] Harvard Med Sch, Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02115 USA. RP Hunger, T (reprint author), UMIT Univ Hlth Sci Med Informat & Technol, Dept Publ Hlth Hlth Serv Res & Hlth Technol Asses, Hall In Tirol, Austria.; Hunger, T (reprint author), ONCOTYROL Ctr Personalized Canc Med, Div Publ Hlth Decis Modeling Hlth Technol Assessm, Innsbruck, Austria. EM theresa.hunger@umit.at FU Tiroler Wissenschaftsfonds [GZ: UNI - 4040/1009] FX The present work was exclusively funded by the Tiroler Wissenschaftsfonds, grant number GZ: UNI - 4040/1009. NR 56 TC 0 Z9 0 U1 0 U2 0 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0266-4623 EI 1471-6348 J9 INT J TECHNOL ASSESS JI Int. J. Technol. Assess. Health Care PY 2016 VL 32 IS 3 BP 131 EP 139 DI 10.1017/S0266462316000209 PG 9 WC Health Care Sciences & Services; Public, Environmental & Occupational Health; Medical Informatics SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Medical Informatics GA DX4HK UT WOS:000384341600007 PM 27502308 ER PT J AU Latimer, NR Henshall, C Siebert, U Bell, H AF Latimer, Nicholas R. Henshall, Chris Siebert, Uwe Bell, Helen TI TREATMENT SWITCHING: STATISTICAL AND DECISION-MAKING CHALLENGES AND APPROACHES SO INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE LA English DT Article DE Decision making; Statistical models; Survival analysis; Randomized controlled trials; Treatment switching; Treatment crossover ID RANDOMIZED CONTROLLED-TRIALS; INVERSE PROBABILITY; ECONOMIC-EVALUATION; CLINICAL-TRIALS; SURVIVAL; MODELS; RECOMMENDATIONS; NONCOMPLIANCE; CROSSOVER; BIAS AB Objectives: Treatment switching refers to the situation in a randomized controlled trial where patients switch from their randomly assigned treatment onto an alternative. Often, switching is from the control group onto the experimental treatment. In this instance, a standard intention-to-treat analysis does not identify the true comparative effectiveness of the treatments under investigation. We aim to describe statistical methods for adjusting for treatment switching in a comprehensible way for nonstatisticians, and to summarize views on these methods expressed by stakeholders at the 2014 Adelaide International Workshop on Treatment Switching in Clinical Trials. Methods: We describe three statistical methods used to adjust for treatment switching: marginal structural models, two-stage adjustment, and rank preserving structural failure time models. We draw upon discussion heard at the Adelaide International Workshop to explore the views of stakeholders on the acceptability of these methods. Results: Stakeholders noted that adjustment methods are based on assumptions, the validity of which may often be questionable. There was disagreement on the acceptability of adjustment methods, but consensus that when these are used, they should be justified rigorously. The utility of adjustment methods depends upon the decision being made and the processes used by the decision-maker. Conclusions: Treatment switching makes estimating the true comparative effect of a new treatment challenging. However, many decision-makers have reservations with adjustment methods. These, and how they affect the utility of adjustment methods, require further exploration. Further technical work is required to develop adjustment methods to meet real world needs, to enhance their acceptability to decision-makers. C1 [Latimer, Nicholas R.; Bell, Helen] Univ Sheffield, ScHARR, Sheffield S10 2TN, S Yorkshire, England. [Henshall, Chris] Brunel Univ London, Uxbridge, Middx, England. [Siebert, Uwe] UMIT Univ Hlth Sci Med Informat & Technol Oncotyr, Ctr Personalized Canc Med, Hall In Tirol, Austria. [Siebert, Uwe] Harvard TH Chan Sch Publ Hlth, Boston, MA USA. [Siebert, Uwe] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA USA. RP Latimer, NR (reprint author), Univ Sheffield, ScHARR, Sheffield S10 2TN, S Yorkshire, England. EM n.latimer@sheffield.ac.uk FU Bellberry; Amgen; AstraZeneca; Janssen; Merck Sharpe and Dohme; Pfizer; Roche FX Funding for the Adelaide Workshop was provided by Bellberry, Amgen, AstraZeneca, Janssen, Merck Sharpe and Dohme, Pfizer and Roche. Many parts of this study are based upon discussion and feedback from participants in the Adelaide Workshop. NR 22 TC 1 Z9 1 U1 0 U2 0 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0266-4623 EI 1471-6348 J9 INT J TECHNOL ASSESS JI Int. J. Technol. Assess. Health Care PY 2016 VL 32 IS 3 BP 160 EP 166 DI 10.1017/S026646231600026X PG 7 WC Health Care Sciences & Services; Public, Environmental & Occupational Health; Medical Informatics SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Medical Informatics GA DX4HK UT WOS:000384341600011 PM 27624982 ER PT J AU Varghese, M Santa-Maria, I Ho, L Ward, L Yemul, S Dubner, L Ksiezak-Reding, H Pasinetti, GM AF Varghese, Merina Santa-Maria, Ismael Ho, Lap Ward, Libby Yemul, Shrishailam Dubner, Lauren Ksiezak-Reding, Hanna Pasinetti, Giulio Maria TI Extracellular Tau Paired Helical Filaments Differentially Affect Tau Pathogenic Mechanisms in Mitotic and Post-Mitotic Cells: Implications for Mechanisms of Tau Propagation in the Brain SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Alzheimer's disease; neuropathology; proteasome; tau ID PROGRESSIVE SUPRANUCLEAR PALSY; INCLUSION-BODY FORMATION; ALZHEIMERS-DISEASE; PROTEIN-TAU; AGGRESOME FORMATION; PRIMARY NEURONS; MESSENGER-RNA; NEURODEGENERATIVE DISEASES; AUTOPHAGOSOME DYNAMICS; MICROTUBULE NUCLEATION AB The release of paired helical (PHFs) from neurons into the extracellular space may contribute to the propagation of tau pathology across brain regions in Alzheimer's disease (AD) and other tauopathies. The majority of available mechanistic studies exploring the pathologic role of extracellular PHFs are conducted in proliferating cell lines. Here, we compare how extracellular PHFs induce tauopathy in mitotic cells and in post-mitotic brain neurons. In a mitotic cell line (HEK 293T), extracellular exposure to AD PHFs leads to an intracellular "aggresomal" type deposition of tau, coincidental with redistribution of dynein, a retrograde motor protein. We also observed that PHFs impaired proteasome degradation, but not autophagy. Exposure of cells to proteasome inhibitors was sufficient to induce intracellular tau aggregate formation as well as reorganization of dynein and the intermediate filament protein, vimentin. Thus, in mitotic cells, extracellular PHFs promote cellular tau aggregation, in part, by interfering with cellular proteasome degradation processes. In contrast with our observations with proliferating cells, exposure of post-mitotic primary neuronal cultures to AD PHFs did not promote "aggresomal" tau deposition, but instead resulted in a widespread accumulation of phosphorylated tau-immunoreactive swellings in neuritic processes, characterized by disturbed cytoskeletal organization of dynein and vimentin. Collectively, our observations suggest that extracellular PHFs may contribute to the propagation of tau pathology by independent mechanisms in post-mitotic and mitotic brain cells. These outcomes indicate that in addition to post-mitotic brain neurons, mitotic brain cells should also be considered as targets for therapeutic interventions to attenuate propagation of tauopathy. C1 [Varghese, Merina; Ho, Lap; Ward, Libby; Yemul, Shrishailam; Dubner, Lauren; Ksiezak-Reding, Hanna; Pasinetti, Giulio Maria] Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA. [Varghese, Merina] Icahn Sch Med Mt Sinai, Dept Neurosci, New York, NY 10029 USA. [Varghese, Merina; Yemul, Shrishailam; Ksiezak-Reding, Hanna; Pasinetti, Giulio Maria] James J Peters Vet Affairs Med Ctr, Ctr Geriatr Res Educ & Clin, Bronx, NY USA. [Santa-Maria, Ismael] Columbia Univ, Dept Pathol & Cell Biol, Taub Inst Res Alzheimers Dis & Aging Brain, New York, NY USA. RP Pasinetti, GM (reprint author), One Gustave L Levy Pl,Box 1137, New York, NY 10029 USA. EM giulio.pasinetti@mssm.edu OI Varghese, Merina/0000-0002-1517-3903 FU CurePSP - Foundation for PSP \ CBD and Related Brain Diseases, NIH [PO1 AT004511]; MERIT Review grant from Veterans Administration; NIH-NCI [5R24 CA095823-04]; NSF Major Research Instrumentation grant [DBI-9724504]; NIH shared instrumentation grant [1 S10 RR0 9145-01] FX We would like to thank Miguel Gama-Sosa for his expertise in confocal microscopy and Shimul Begum for her effort in western blotting studies. The authors gratefully acknowledge financial as well as inspirational support from CurePSP - Foundation for PSP vertical bar CBD and Related Brain Diseases, NIH PO1 AT004511, and in part from MERIT Review grant from Veterans Administration to Dr. Pasinetti. Confocal laser scanning microscopy was performed at the James J. Peters Veterans Affairs Medical Center and conventional fluorescent microscopy at the Icahn School of Medicine at Mount Sinai-Microscopy Shared Resource Facility, supported with funding from NIH-NCI shared resources grant (5R24 CA095823-04), NSF Major Research Instrumentation grant (DBI-9724504) and NIH shared instrumentation grant (1 S10 RR0 9145-01). This material is the result of work supported in part with resources and the use of facilities at the James J. Peters Veterans Affairs Medical Center, Bronx, NY. In addition, Dr. Pasinetti holds a Career Scientist Award in the Research and Development unit and is the Director of the Basic and Biomedical Research and Training Program, GRECC, James J. Peters Veterans Affairs Medical Center. We also acknowledge that the contents of this manuscript do not represent the views of the U.S. Department of Veterans Affairs or the United States Government. NR 113 TC 0 Z9 0 U1 3 U2 3 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 EI 1875-8908 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2016 VL 54 IS 2 BP 477 EP 496 DI 10.3233/JAD-160166 PG 20 WC Neurosciences SC Neurosciences & Neurology GA DX0WO UT WOS:000384087200006 PM 27567821 ER PT J AU DeLorenzo, MC Wu, DH Yang, K Rutel, IB AF DeLorenzo, Matthew C. Wu, Dee H. Yang, Kai Rutel, Isaac B. TI RadShield: semiautomated shielding design using a floor plan driven graphical user interface SO JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS LA English DT Article DE RadShield; shielding design; radiation protection; radiation shielding; GUI ID DIAGNOSTIC-RADIOLOGY; REQUIREMENTS; ATTENUATION; MODEL AB The purpose of this study was to introduce and describe the development of RadShield, a Java-based graphical user interface (GUI), which provides a base design that uniquely performs thorough, spatially distributed calculations at many points and reports the maximum air-kerma rate and barrier thickness for each barrier pursuant to NCRP Report 147 methodology. Semiautomated shielding design calculations are validated by two approaches: a geometry-based approach and a manual approach. A series of geometry-based equations were derived giving the maximum air-kerma rate magnitude and location through a first derivative root finding approach. The second approach consisted of comparing RadShield results with those found by manual shielding design by an American Board of Radiology (ABR)-certified medical physicist for two clinical room situations: two adjacent catheterization labs, and a radiographic and fluoroscopic (R&F) exam room. RadShield's efficacy in finding the maximum air-kerma rate was compared against the geometry-based approach and the overall shielding recommendations by RadShield were compared against the medical physicist's shielding results. Percentage errors between the geometry-based approach and RadShield's approach in finding the magnitude and location of the maximum air-kerma rate was within 0.00124% and 14 mm. RadShield's barrier thickness calculations were found to be within 0.156 mm lead (Pb) and 0.150 mm lead (Pb) for the adjacent catheterization labs and R&F room examples, respectively. However, within the R&F room example, differences in locating the most sensitive calculation point on the floor plan for one of the barriers was not considered in the medical physicist's calculation and was revealed by the RadShield calculations. RadShield is shown to accurately find the maximum values of air-kerma rate and barrier thickness using NCRP Report 147 methodology. Visual inspection alone of the 2D X-ray exam distribution by a medical physicist may not be sufficient to accurately select the point of maximum air-kerma rate or barrier thickness. C1 [DeLorenzo, Matthew C.; Wu, Dee H.; Rutel, Isaac B.] Univ Oklahoma, Hlth Sci Ctr, Dept Radiol Sci, 940 NE 13th St,Nicholson Tower,Room 3904, Oklahoma City, OK 73104 USA. [Yang, Kai] Massachusetts Gen Hosp, Div Diagnost Imaging Phys, Dept Radiol, Boston, MA 02114 USA. RP DeLorenzo, MC (reprint author), Univ Oklahoma, Hlth Sci Ctr, Dept Radiol Sci, 940 NE 13th St,Nicholson Tower,Room 3904, Oklahoma City, OK 73104 USA. EM MDELORENZO@mgh.harvard.edu NR 15 TC 0 Z9 0 U1 2 U2 2 PU MULTIMED INC PI TORONTO PA 66 MARTIN ST, TORONTO, ON L9T 2R2, CANADA SN 1526-9914 J9 J APPL CLIN MED PHYS JI J. Appl. Clin. Med. Phys PY 2016 VL 17 IS 5 BP 509 EP 522 PG 14 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA DX0XX UT WOS:000384091000042 ER PT J AU Renfroe, JB Turner, TH Hinson, VK AF Renfroe, Jenna B. Turner, Travis H. Hinson, Vanessa K. TI Prevalence, impact, and management of depression and anxiety in patients with Parkinson's disease SO JOURNAL OF PARKINSONISM AND RESTLESS LEGS SYNDROME LA English DT Review DE Parkinson's disease; depression; anxiety; prevalence; treatment ID TRANSCRANIAL MAGNETIC STIMULATION; QUALITY-OF-LIFE; COGNITIVE-BEHAVIORAL THERAPY; PLACEBO-CONTROLLED TRIAL; NONMOTOR SYMPTOMS; NEUROPSYCHIATRIC SYMPTOMS; DOUBLE-BLIND; MOTOR SUBTYPES; RISK-FACTORS; DISORDERS AB Individuals with Parkinson's disease (PD) exhibit higher rates of depression and anxiety than the general and other medically disabled populations. Evidence suggests that mood and anxiety symptoms are related to disease pathology. Rates of depression and anxiety in PD vary depending on how these symptoms are measured, but they are estimated to occur in up to 40% of patients. These conditions have adverse effects on patient and caregivers' quality of life, level of disability, and mortality, with several studies suggesting greater contribution than motor symptom severity. Pharmacological and psychotherapeutic interventions, particularly in combination, have demonstrated efficacy in treating depression and anxiety in PD. However, additional randomized controlled trials are needed to better delineate when and how to best treat these disabling symptoms. C1 [Renfroe, Jenna B.; Hinson, Vanessa K.] Med Univ South Carolina, Dept Neurol, 208 B Rutledge Ave,MSC 108, Charleston, SC 29425 USA. [Turner, Travis H.] Ralph H Johnson VA Med Ctr, Mental Hlth Serv, Charleston, SC USA. [Turner, Travis H.] Med Univ South Carolina, Dept Psychiat & Behav Sci, Charleston, SC USA. [Hinson, Vanessa K.] Ralph H Johnson VA Med Ctr, Neurol Serv, Charleston, SC USA. RP Renfroe, JB (reprint author), Med Univ South Carolina, Dept Neurol, 208 B Rutledge Ave,MSC 108, Charleston, SC 29425 USA. EM renfroe@musc.edu NR 104 TC 0 Z9 0 U1 4 U2 4 PU DOVE MEDICAL PRESS LTD PI ALBANY PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND SN 1927-7733 J9 J PARKINSONISM RESTL JI J. PARKINSONISM RESTLESS LEGS SYNDR. PY 2016 VL 6 BP 15 EP 22 DI 10.2147/JPRLS.S83165 PG 8 WC Clinical Neurology SC Neurosciences & Neurology GA DX2TS UT WOS:000384224500001 ER PT J AU Tangka, FKL Subramanian, S Beebe, MC Weir, HK Trebino, D Babcock, F Ewing, J AF Tangka, Florence K. L. Subramanian, Sujha Beebe, Maggie Cole Weir, Hannah K. Trebino, Diana Babcock, Frances Ewing, Jean TI Cost of Operating Central Cancer Registries and Factors That Affect Cost: Findings From an Economic Evaluation of Centers for Disease Control and Prevention National Program of Cancer Registries SO JOURNAL OF PUBLIC HEALTH MANAGEMENT AND PRACTICE LA English DT Article DE cancer registry; cost; economics ID DRUG-ABUSE TREATMENT; DATCAP AB Context: The Centers for Disease Control and Prevention (CDC) evaluated the economics of the National Program of Cancer Registries to provide the CDC, the registries, and policy makers with the economics evidence-base to make optimal decisions about resource allocation. Cancer registry budgets are under increasing threat, and, therefore, systematic assessment of the cost will identify approaches to improve the efficiencies of this vital data collection operation and also justify the funding required to sustain registry operations. Objectives: To estimate the cost of cancer registry operations and to assess the factors affecting the cost per case reported by National Program of Cancer Registries-funded central cancer registries. Methods: We developed a Web-based cost assessment tool to collect 3 years of data (2009-2011) from each National Program of Cancer Registries-funded registry for all actual expenditures for registry activities (including those funded by other sources) and factors affecting registry operations. We used a random-effects regression model to estimate the impact of various factors on cost per cancer case reported. Results: The cost of reporting a cancer case varied across the registries. Central cancer registries that receive high-quality data from reporting sources (as measured by the percentage of records passing automatic edits) and electronic data submissions, and those that collect and report on a large volume of cases had significantly lower cost per case. The volume of cases reported had a large effect, with low-volume registries experiencing much higher cost per case than medium-or high-volume registries. Conclusions: Our results suggest that registries operate with substantial fixed or semivariable costs. Therefore, sharing fixed costs among low-volume contiguous state registries, whenever possible, and centralization of certain processes can result in economies of scale. Approaches to improve quality of data submitted and increasing electronic reporting can also reduce cost. C1 [Tangka, Florence K. L.; Weir, Hannah K.; Babcock, Frances; Ewing, Jean] Ctr Dis Control & Prevent, Div Canc Prevent & Control, 4770 Buford Hwy NE,F76, Atlanta, GA 30341 USA. [Subramanian, Sujha; Beebe, Maggie Cole; Trebino, Diana] RTI Int, Waltham, MA USA. [Trebino, Diana] Dana Farber Canc Inst, Boston, MA 02115 USA. RP Tangka, FKL (reprint author), Ctr Dis Control & Prevent, Div Canc Prevent & Control, 4770 Buford Hwy NE,F76, Atlanta, GA 30341 USA. EM ftangka@cdc.gov FU Centers for Disease Control and Prevention [200-2002-00575, 009] FX The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. Funding support for Sujha Subramanian, Maggie Cole Beebe, and Diana Trebino was provided by the Centers for Disease Control and Prevention (Contract No. 200-2002-00575, Task order 009, to RTI International). NR 14 TC 5 Z9 5 U1 2 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1078-4659 EI 1550-5022 J9 J PUBLIC HEALTH MAN JI J. Public Health Manag. Pract. PY 2016 VL 22 IS 5 BP 452 EP 460 DI 10.1097/PHH.0000000000000349 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DX2ZA UT WOS:000384241200011 PM 26642226 ER PT J AU Wheeler, SB Roberts, MC Bloom, D Reeder-Hayes, KE Espada, M Peppercorn, J Golin, CE Earp, JA AF Wheeler, Stephanie B. Roberts, Megan C. Bloom, Diane Reeder-Hayes, Katherine E. Espada, Maya Peppercorn, Jeffrey Golin, Carol E. Earp, Jo Anne TI Oncology providers' perspectives on endocrine therapy prescribing and management SO PATIENT PREFERENCE AND ADHERENCE LA English DT Article DE breast cancer; endocrine therapy; oncology; oncologist; qualitative interviews ID BREAST-CANCER SURVIVORS; NAVIGATION RESEARCH-PROGRAM; ADJUVANT TAMOXIFEN; ADHERENCE; CARE; NEEDS; WOMEN AB Purpose: Adjuvant endocrine therapy (ET) can reduce the risk of recurrence among females with hormone receptor-positive breast cancer. Overall, initiation and adherence to ET are suboptimal, though reasons are not well described. The study's objective was to better understand ET decision making, prescribing, and patient management from oncology providers' perspectives. Methods: Using purposive sampling, we recruited oncology providers who saw five or more breast cancer patients per week (n=20). We conducted 30-45-minute telephone interviews, using a semistructured guide to elicit perspectives on ET use. We used thematic content analysis to systematically identify categories of meaning and double-coded transcripts using Atlas.ti. Results: Providers recommend ET to all eligible patients except those with contraindications or other risk factors. Providers base their ET prescribing decisions on the patient's menopausal status, side effects, and comorbidities. ET is typically discussed multiple times: at the onset of breast cancer treatment and in more detail after other treatment completion. Providers felt that the associated recurrence risk reduction is the most compelling argument for patients during ET decision making. While providers rarely perceived noninitiation as a problem, nonadherence was prevalent, often due to unresolvable side effects. Conclusion: From the clinicians' perspectives, side effects from ET are the dominant factor in nonadherence. Efforts to improve adherence should focus on strategies to minimize side effects and ensure clinicians and patients are well informed regarding optimal side effect management. This finding has important implications for novel endocrine regimens that offer improved outcomes through longer duration or more intensive therapy. C1 [Wheeler, Stephanie B.; Roberts, Megan C.; Bloom, Diane; Espada, Maya] Univ North Carolina Chapel Hill, Dept Hlth Policy & Management, 135 Dauer Dr,CB7411, Chapel Hill, NC 27516 USA. [Wheeler, Stephanie B.; Reeder-Hayes, Katherine E.; Earp, Jo Anne] Univ North Carolina Chapel Hill, Lineberger Comprehens Canc Ctr, Chapel Hill, NC USA. [Reeder-Hayes, Katherine E.] Univ North Carolina Chapel Hill, Div Hematol & Oncol, Chapel Hill, NC USA. [Peppercorn, Jeffrey] Massachusetts Gen Hosp, Div Hematol Oncol, Boston, MA 02114 USA. [Golin, Carol E.; Earp, Jo Anne] Univ North Carolina Chapel Hill, Dept Hlth Behav, Chapel Hill, NC USA. [Golin, Carol E.] Univ North Carolina Chapel Hill, Dept Med, Chapel Hill, NC USA. RP Wheeler, SB (reprint author), Univ North Carolina Chapel Hill, Dept Hlth Policy & Management, 135 Dauer Dr,CB7411, Chapel Hill, NC 27516 USA. EM stephanie_wheeler@unc.edu FU American Cancer Society (ACS) [MRSG-13-157-01-CPPB]; Carolina Community Network Center to Reduce Cancer Health Disparities (CCN II) - National Cancer Institute's Center to Reduce Cancer Health Disparities through its Community Network Program Centers [U54-CA153602]; UNC Lineberger, Cancer Control Education Program [R25 CA57726]; Building Interdisciplinary Careers in Womens' Health (BIRCWH) program of the National Institutes of Health [5K12HD001441-12]; Eunice Kennedy Shriver National Institute of Child Health and Human Development [K24-HD06920] FX This research was funded by the American Cancer Society (ACS) Mentored Research Scholar Grant (MRSG-13-157-01-CPPB: "Improving Endocrine Therapy Utilization in Racially Diverse Populations"). SBW was also supported as a faculty trainee through the Carolina Community Network Center to Reduce Cancer Health Disparities (CCN II), funded by the National Cancer Institute's Center to Reduce Cancer Health Disparities through its Community Network Program Centers (U54-CA153602). JAE and MCR were supported through UNC Lineberger, Cancer Control Education Program (R25 CA57726). During the conduct of this research, KRH received funding from a career development award through the Building Interdisciplinary Careers in Womens' Health (BIRCWH) program of the National Institutes of Health (5K12HD001441-12). CEG was partially supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (K24-HD06920). NR 24 TC 1 Z9 1 U1 3 U2 3 PU DOVE MEDICAL PRESS LTD PI ALBANY PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND SN 1177-889X J9 PATIENT PREFER ADHER JI Patient Prefer. Adherence PY 2016 VL 10 BP 2007 EP 2019 DI 10.2147/PPA.S95594 PG 13 WC Medicine, General & Internal SC General & Internal Medicine GA DX7VK UT WOS:000384597300002 PM 27757021 ER PT J AU Hamblin, MR AF Hamblin, Michael R. TI Virulence profile: Michael R. Hamblin SO VIRULENCE LA English DT Editorial Material C1 [Hamblin, Michael R.] Harvard Med Sch, Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA USA. RP Hamblin, MR (reprint author), BAR 414,40 Blossom St, Boston, MA 02114 USA. EM hamblin@helix.mgh.harvard.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 2150-5594 EI 2150-5608 J9 VIRULENCE JI Virulence PY 2016 VL 7 IS 7 BP 836 EP 839 DI 10.1080/21505594.2016.1201348 PG 4 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA DX0BJ UT WOS:000384026200015 PM 27315436 ER PT S AU Detrich, HW Westerfield, M Zon, LI AF Detrich, H. William, III Westerfield, Monte Zon, Leonard I. BE Detrich, HW Westerfield, M Zon, LI TI Methods in Cell Biology The Zebrafish: Genetics, Genomics, and Transcriptomics Preface SO ZEBRAFISH: GENETICS, GENOMICS, AND TRANSCRIPTOMICS, 4TH EDITION SE Methods in Cell Biology LA English DT Editorial Material; Book Chapter C1 [Detrich, H. William, III] Northeastern Univ, Ctr Marine Sci, Nahant, MA 01908 USA. [Westerfield, Monte] Univ Oregon, Eugene, OR 97403 USA. [Zon, Leonard I.] Boston Childrens Hosp, Boston, MA USA. [Zon, Leonard I.] Harvard Stem Cell Inst, Dana Farber Canc Inst, Boston, MA USA. [Zon, Leonard I.] Harvard Med Sch, Boston, MA USA. [Zon, Leonard I.] Howard Hughes Med Inst, Boston, MA 02115 USA. [Zon, Leonard I.] Harvard Univ, Cambridge, MA 02138 USA. RP Detrich, HW (reprint author), Northeastern Univ, Ctr Marine Sci, Nahant, MA 01908 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA SN 0091-679X BN 978-0-12-803488-0; 978-0-12-803474-3 J9 METHOD CELL BIOL JI Methods Cell Biol. PY 2016 VL 135 BP XXV EP XXVI PG 2 WC Cell Biology; Genetics & Heredity SC Cell Biology; Genetics & Heredity GA BF6UH UT WOS:000383713800001 ER PT S AU Yang, S Ott, CJ Rossmann, MP Superdock, M Zon, LI Zhou, Y AF Yang, S. Ott, C. J. Rossmann, M. P. Superdock, M. Zon, L. I. Zhou, Y. BE Detrich, HW Westerfield, M Zon, LI TI Chromatin immunoprecipitation and an open chromatin assay in zebrafish erythrocytes SO ZEBRAFISH: GENETICS, GENOMICS, AND TRANSCRIPTOMICS, 4TH EDITION SE Methods in Cell Biology LA English DT Review; Book Chapter ID DNA-BINDING PROTEINS; CHIP-SEQ; VASCULAR DEVELOPMENT; HUMAN GENOME; DISEASE; MODEL; GENES; REGENERATION; TOOL; TRANSPOSITION AB Zebrafish is an excellent genetic and developmental model for the study of vertebrate development and disease. Its ability to produce an abundance of transparent, externally developed embryos has facilitated large-scale genetic and chemical screens for the identification of critical genes and chemical factors that modulate developmental pathways. These studies can have profound implications for the diagnosis and treatment of a variety of human diseases. Recent advancements in molecular and genomic studies have provided valuable tools and resources for comprehensive and high-resolution analysis of epigenomes during cell specification and lineage differentiation throughout development. In this chapter, we describe two simple methods to evaluate protein-DNA interaction and chromatin architecture in erythrocytes from adult zebrafish. These are chromatin immunoprecipitation coupled with next-generation sequencing (ChIP-seq) and an assay for transposase-accessible chromatin with high-throughput sequencing (ATAC-seq). These techniques, together with gene expression profiling, are useful for analyzing epigenomic regulation of cell specification, differentiation, and function during zebrafish development in both normal and disease models C1 [Yang, S.; Superdock, M.; Zon, L. I.; Zhou, Y.] Boston Childrens Hosp, Boston, MA 02115 USA. [Yang, S.; Ott, C. J.; Superdock, M.; Zon, L. I.; Zhou, Y.] Harvard Stem Cell Inst, Dana Farber Canc Inst, Boston, MA 02115 USA. [Yang, S.; Superdock, M.; Zon, L. I.; Zhou, Y.] Harvard Med Sch, Boston, MA 02115 USA. [Yang, S.; Superdock, M.; Zon, L. I.; Zhou, Y.] Howard Hughes Med Inst, Boston, MA 02115 USA. [Rossmann, M. P.; Zon, L. I.; Zhou, Y.] Harvard Univ, Cambridge, MA 02138 USA. RP Zhou, Y (reprint author), Boston Childrens Hosp, Boston, MA 02115 USA.; Zhou, Y (reprint author), Harvard Stem Cell Inst, Dana Farber Canc Inst, Boston, MA 02115 USA.; Zhou, Y (reprint author), Harvard Med Sch, Boston, MA 02115 USA.; Zhou, Y (reprint author), Howard Hughes Med Inst, Boston, MA 02115 USA.; Zhou, Y (reprint author), Harvard Univ, Cambridge, MA 02138 USA. EM yzhou@enders.tch.harvard.edu NR 59 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA SN 0091-679X BN 978-0-12-803488-0; 978-0-12-803474-3 J9 METHOD CELL BIOL JI Methods Cell Biol. PY 2016 VL 135 BP 387 EP 412 DI 10.1016/bs.mcb.2016.04.019 PG 26 WC Cell Biology; Genetics & Heredity SC Cell Biology; Genetics & Heredity GA BF6UH UT WOS:000383713800021 PM 27443937 ER PT J AU Williams, JS Walker, RJ Egede, LE AF Williams, Joni Strom Walker, Rebekah J. Egede, Leonard E. TI Achieving Equity in an Evolving Healthcare System: Opportunities and Challenges SO AMERICAN JOURNAL OF THE MEDICAL SCIENCES LA English DT Article DE Health disparities; Health equity ID UNITED-STATES; DISPARITIES RESEARCH; ETHNIC DISPARITIES; KIDNEY-DISEASE; ACCESS; POLICY; ISSUES; RACE; INSURANCE; COVERAGE AB For decades, disparities in health have been well documented in the United States and regrettably, remain prevalent despite evidence and appeals for their elimination. Compared with the majority, racial and ethnic minorities continue to have poorer health status and health outcomes for most chronic conditions, including diabetes mellitus, cardiovascular disease, cancer and end-stage renal disease. Many factors, such as affordability, access and diversity in the healthcare system, influence care and outcomes, creating challenges that make the task of eliminating health disparities and achieving health equity daunting and elusive. Novel strategies are needed to bring about much needed change in the complex and evolving United States healthcare system. Although not exhaustive, opportunities such as(1) developing standardized race measurements across health systems,(2) implementing effective interventions, (3) improving workforce diversity,(4) using technological advances and(5) adopting practices such as personalized medicine may serve as appropriate starting points for moving toward health equity. Over the past several decades, diversity in the U.S. population has increased significantly and is expected to increase exponentially in the near future. As the population becomes more diverse, it is important to recognize the possibilities of new and emerging disparities. It is imperative that steps are taken to eliminate the current gap in care and prevent new disparities from developing. Therefore, we present challenges and offer recommendations for facilitating the process of eliminating health disparities and achieving health equity across diverse populations. C1 [Williams, Joni Strom; Walker, Rebekah J.; Egede, Leonard E.] Med Univ South Carolina, Ctr Hlth Dispar Res, Dept Med, 135 Rutledge Ave,Room 280G, Charleston, SC 29425 USA. [Williams, Joni Strom; Egede, Leonard E.] Med Univ South Carolina, Dept Med, Charleston, SC USA. [Walker, Rebekah J.; Egede, Leonard E.] Ralph H Johnson Vet Affairs Med Ctr, HEROIC, Charleston, SC USA. RP Egede, LE (reprint author), Med Univ South Carolina, Ctr Hlth Dispar Res, Dept Med, 135 Rutledge Ave,Room 280G, Charleston, SC 29425 USA. EM egedel@musc.edu FU HSRD VA [I50 HX001229]; NIDDK NIH HHS [K24 DK093699] NR 56 TC 0 Z9 0 U1 4 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9629 EI 1538-2990 J9 AM J MED SCI JI Am. J. Med. Sci. PD JAN PY 2016 VL 351 IS 1 BP 33 EP 43 PG 11 WC Medicine, General & Internal SC General & Internal Medicine GA DV1EN UT WOS:000382663000007 PM 26802756 ER PT J AU Gibson, E Sandberg, C Fedorenko, E Bergen, L Kiran, S AF Gibson, Edward Sandberg, Chaleece Fedorenko, Evelina Bergen, Leon Kiran, Swathi TI A rational inference approach to aphasic language comprehension SO APHASIOLOGY LA English DT Article DE Language comprehension; aphasic language comprehension; rational inference; Bayesian language ID SENTENCE COMPREHENSION; SYNTACTIC COMPREHENSION; AGRAMMATIC COMPREHENSION; WORD ORDER; DEFICITS; SPEECH; BROCAS; DETERMINANTS; DISSOCIATION; PLAUSIBILITY AB Background: It has long been observed that, when confronted with an implausible sentence like The ball kicked the girl, individuals with aphasia rely more on plausibility information from world knowledge (such that a girl is likely to kick a ball, but not vice versa) than control non-impaired populations do. We here offer a novel hypothesis to explain this greater reliance on plausibility information for individuals with aphasia. The hypothesis is couched with the rational inference approach to language processing. A key idea in this approach is that to derive an interpretation for an input string, individuals combine their priors (about messages that are likely to be communicated) with their knowledge about how messages can get corrupted by noise (due to production or perception errors).Aims: We hypothesise that language comprehension in aphasia works in the same way, except with a greater amount of noise, which leads to stronger reliance on syntactic and semantic priors.Methods & Procedures: We evaluated this hypothesis in an act-out task in three groups of participants (8 individuals with aphasia, 7 older controls, 11 younger controls) on two sets of materials: (a) implausible double-object (DO)/prepositional-phrase object (PO) materials, where a single added or deleted word could lead to a plausible meaning; and (b) implausible active-passive materials, where at least two added or deleted words are needed to arrive at a plausible meaning.Outcomes & Results: We observed that, similar to controls, individuals with aphasia rely on plausibility to a greater extent in the DO/PO than in the active/passive alternation. Critically, however, as predicted, individuals with aphasia rely less on the literal syntax overall than either of the control groups, and use their world knowledge prior (plausibility) in both the active/passive and DO/PO alternations, whereas controls rely on plausibility only in the DO/PO alternation. In addition, older persons and persons with aphasia made more errors on the DO structures (which are less frequent than PO structures) independent of plausibility, thus providing evidence for reliance on a syntactic prior, the more frequent structure.Conclusions: These results are as predicted by the rational inference approach to language processing in individuals with aphasia. C1 [Gibson, Edward; Bergen, Leon] MIT, Dept Brain & Cognit Sci, E25-618, Cambridge, MA 02139 USA. [Sandberg, Chaleece] Penn State Univ, Dept Commun Sci & Disorders, State Coll, PA 16801 USA. [Fedorenko, Evelina] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Kiran, Swathi] Boston Univ, Sargent Coll Hlth & Rehabil Sci, Boston, MA 02215 USA. RP Gibson, E (reprint author), MIT, Dept Brain & Cognit Sci, E25-618, Cambridge, MA 02139 USA.; Sandberg, C (reprint author), Penn State Univ, Dept Commun Sci & Disorders, State Coll, PA 16801 USA. EM egibson@mit.edu; cws18@psu.com NR 61 TC 3 Z9 3 U1 3 U2 3 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 0268-7038 EI 1464-5041 J9 APHASIOLOGY JI Aphasiology PY 2016 VL 30 IS 11 SI SI BP 1341 EP 1360 DI 10.1080/02687038.2015.1111994 PG 20 WC Clinical Neurology SC Neurosciences & Neurology GA DW8JW UT WOS:000383902400009 ER PT S AU Langenau, D AF Langenau, David BE Langenau, DM TI Prelude: Cancer and Zebrafish SO CANCER AND ZEBRAFISH: MECHANISMS, TECHNIQUES, AND MODELS SE Advances in Experimental Medicine and Biology LA English DT Editorial Material; Book Chapter C1 [Langenau, David] Massachusetts Gen Hosp, Mol Pathol & Canc Ctr, Charlestown, MA 02129 USA. RP Langenau, D (reprint author), Massachusetts Gen Hosp, Mol Pathol & Canc Ctr, Charlestown, MA 02129 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER INT PUBLISHING AG PI CHAM PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND SN 0065-2598 BN 978-3-319-30654-4; 978-3-319-30652-0 J9 ADV EXP MED BIOL JI Adv.Exp.Med.Biol. PY 2016 VL 916 BP V EP X D2 10.1007/978-3-319-30654-4 PG 6 WC Oncology; Medicine, Research & Experimental SC Oncology; Research & Experimental Medicine GA BF6PR UT WOS:000383510100001 PM 27540621 ER PT S AU Parant, JM Yeh, JRJ AF Parant, John M. Yeh, Jing-Ruey Joanna BE Langenau, DM TI Approaches to Inactivate Genes in Zebrafish SO CANCER AND ZEBRAFISH: MECHANISMS, TECHNIQUES, AND MODELS SE Advances in Experimental Medicine and Biology LA English DT Article; Book Chapter DE CRISPR; Cas9; Zinc finger nuclease; Transcription activator-like effector nuclease; Mutagenesis; Zebrafish; Genome engineering; Cancer; Gene targeting; Homologous recombination ID ZINC-FINGER NUCLEASES; CRISPR-CAS SYSTEMS; NONPOLYPOSIS COLORECTAL-CANCER; CAUSES GENOME INSTABILITY; DNA-BINDING SPECIFICITY; POOL ENGINEERING OPEN; TARGETED MUTAGENESIS; COLON-CANCER; HOMOLOGOUS RECOMBINATION; CHROMOSOMAL DELETIONS AB Animal models of tumor initiation and tumor progression are essential components toward understanding cancer and designing/validating future therapies. Zebrafish is a powerful model for studying tumorigenesis and has been successfully exploited in drug discovery. According to the zebrafish reference genome, 82 % of disease-associated genes in the Online Mendelian Inheritance in Man (OMIM) database have clear zebrafish orthologues. Using a variety of large-scale random mutagenesis methods developed to date, zebrafish can provide a unique opportunity to identify gene mutations that may be associated with cancer predisposition. On the other hand, newer technologies enabling targeted mutagenesis can facilitate reverse cancer genetic studies and open the door for complex genetic analysis of tumorigenesis. In this chapter, we will describe the various technologies for conducting genome editing in zebrafish with special emphasis on the approaches to inactivate genes. C1 [Parant, John M.] Univ Alabama Birmingham, Sch Med, UAB Comprehens Canc Ctr, Dept Pharmacol & Toxicol, Birmingham, AL 35294 USA. [Yeh, Jing-Ruey Joanna] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Charlestown, MA 02129 USA. [Yeh, Jing-Ruey Joanna] Harvard Med Sch, Dept Med, Boston, MA 02115 USA. RP Parant, JM (reprint author), Univ Alabama Birmingham, Sch Med, UAB Comprehens Canc Ctr, Dept Pharmacol & Toxicol, Birmingham, AL 35294 USA.; Yeh, JRJ (reprint author), Massachusetts Gen Hosp, Cardiovasc Res Ctr, Charlestown, MA 02129 USA.; Yeh, JRJ (reprint author), Harvard Med Sch, Dept Med, Boston, MA 02115 USA. EM jparant@uab.edu; jyeh1@mgh.harvard.edu FU NCI NIH HHS [CA140188]; NIGMS NIH HHS [GM088040, R01 GM088040]; NINDS NIH HHS [NS092105] NR 151 TC 1 Z9 1 U1 1 U2 1 PU SPRINGER INT PUBLISHING AG PI CHAM PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND SN 0065-2598 BN 978-3-319-30654-4; 978-3-319-30652-0 J9 ADV EXP MED BIOL JI Adv.Exp.Med.Biol. PY 2016 VL 916 BP 61 EP 86 DI 10.1007/978-3-319-30654-4_3 D2 10.1007/978-3-319-30654-4 PG 26 WC Oncology; Medicine, Research & Experimental SC Oncology; Research & Experimental Medicine GA BF6PR UT WOS:000383510100004 PM 27165349 ER PT S AU Dang, M Fogley, R Zon, LI AF Dang, Michelle Fogley, Rachel Zon, Leonard I. BE Langenau, DM TI Identifying Novel Cancer Therapies Using Chemical Genetics and Zebrafish SO CANCER AND ZEBRAFISH: MECHANISMS, TECHNIQUES, AND MODELS SE Advances in Experimental Medicine and Biology LA English DT Article; Book Chapter DE Chemical screen; Chemical genetics; Zebrafish; Cancer; Drug discovery; Therapeutics ID ACUTE LYMPHOBLASTIC-LEUKEMIA; ZINC-FINGER NUCLEASES; DIFFERENT DEVELOPMENTAL-STAGES; TRANSGENIC ZEBRAFISH; SMALL MOLECULES; EMBRYONAL RHABDOMYOSARCOMA; ANTIANGIOGENIC COMPOUNDS; TARGETED MUTAGENESIS; TRIAZINE LIBRARY; EXPOSURE ROUTES AB Chemical genetics is the use of small molecules to perturb biological pathways. This technique is a powerful tool for implicating genes and pathways in developmental programs and disease, and simultaneously provides a platform for the discovery of novel therapeutics. The zebrafish is an advantageous model for in vivo high-throughput small molecule screening due to translational appeal, high fecundity, and a unique set of developmental characteristics that support genetic manipulation, chemical treatment, and phenotype detection. Chemical genetic screens in zebrafish can identify hit compounds that target oncogenic processes-including cancer initiation and maintenance, metastasis, and angiogenesis-and may serve as cancer therapies. Notably, by combining drug discovery and animal testing, in vivo screening of small molecules in zebrafish has enabled rapid translation of hit anti-cancer compounds to the clinic, especially through the repurposing of FDA-approved drugs. Future technological advancements in automation and high-powered imaging, as well as the development and characterization of new mutant and transgenic lines, will expand the scope of chemical genetics in zebrafish. C1 [Dang, Michelle; Fogley, Rachel; Zon, Leonard I.] Boston Childrens Hosp, Stem Cell Program, Boston, MA 02115 USA. [Dang, Michelle; Fogley, Rachel; Zon, Leonard I.] Boston Childrens Hosp, Div Hematol Oncol, Boston, MA 02115 USA. [Dang, Michelle; Fogley, Rachel; Zon, Leonard I.] Harvard Med Sch, Harvard Stem Cell Inst, Howard Hughes Med Inst, Dana Farber Canc Inst, 1 Blackfan Circle, Boston, MA 02115 USA. RP Zon, LI (reprint author), Boston Childrens Hosp, Stem Cell Program, Boston, MA 02115 USA.; Zon, LI (reprint author), Boston Childrens Hosp, Div Hematol Oncol, Boston, MA 02115 USA.; Zon, LI (reprint author), Harvard Med Sch, Harvard Stem Cell Inst, Howard Hughes Med Inst, Dana Farber Canc Inst, 1 Blackfan Circle, Boston, MA 02115 USA. EM mdang@fas.harvard.edu; rfogley@enders.tch.harvard.edu; zon@enders.tch.harvard.edu FU Howard Hughes Medical Institute; NCI NIH HHS [R01 CA103846] NR 76 TC 2 Z9 2 U1 0 U2 0 PU SPRINGER INT PUBLISHING AG PI CHAM PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND SN 0065-2598 BN 978-3-319-30654-4; 978-3-319-30652-0 J9 ADV EXP MED BIOL JI Adv.Exp.Med.Biol. PY 2016 VL 916 BP 103 EP 124 DI 10.1007/978-3-319-30654-4_5 D2 10.1007/978-3-319-30654-4 PG 22 WC Oncology; Medicine, Research & Experimental SC Oncology; Research & Experimental Medicine GA BF6PR UT WOS:000383510100006 PM 27165351 ER PT S AU Ignatius, MS Hayes, M Langenau, DM AF Ignatius, Myron S. Hayes, Madeline Langenau, David M. BE Langenau, DM TI In Vivo Imaging of Cancer in Zebrafish SO CANCER AND ZEBRAFISH: MECHANISMS, TECHNIQUES, AND MODELS SE Advances in Experimental Medicine and Biology LA English DT Article; Book Chapter DE Zebrafish; Cancer; Imaging; Self-renewal; Cancer stem cells ID ACUTE LYMPHOBLASTIC-LEUKEMIA; TRANSGENIC ZEBRAFISH; EMBRYONAL RHABDOMYOSARCOMA; CELL TRANSPLANTATION; VASCULAR DEVELOPMENT; TUMOR INITIATION; MUTANT ZEBRAFISH; SELF-RENEWAL; MODEL; PATHWAY AB Zebrafish cancer models have greatly advanced our understanding of malignancy in humans. This is made possible due to the unique advantages of the zebrafish model including ex vivo development and large clutch sizes, which enable large-scale genetic and chemical screens. Transparency of the embryo and the creation of adult zebrafish devoid of pigmentation (casper) have permitted unprecedented ability to dynamically visualize cancer progression in live animals. When coupled with fluorescent reporters and transgenic approaches that drive oncogenesis, it is now possible to label entire or subpopulations of cancer cells and follow cancer growth in near real-time. Here, we will highlight aspects of in vivo imaging using the zebrafish and how it has enhanced our understanding of the fundamental aspects of tumor initiation, self-renewal, neovascularization, tumor cell heterogeneity, invasion and metastasis. Importantly, we will highlight the contribution of cancer imaging in zebrafish for drug discovery. C1 [Ignatius, Myron S.; Hayes, Madeline; Langenau, David M.] Massachusetts Gen Hosp, Dept Pathol, Mol Pathol Unit, 149 13th St,6012, Charlestown, MA 02129 USA. [Ignatius, Myron S.; Hayes, Madeline; Langenau, David M.] Massachusetts Gen Hosp, Ctr Canc Res, Charlestown, MA 02129 USA. [Ignatius, Myron S.; Hayes, Madeline; Langenau, David M.] Harvard Stem Cell Inst, Boston, MA 02129 USA. RP Langenau, DM (reprint author), Massachusetts Gen Hosp, Dept Pathol, Mol Pathol Unit, 149 13th St,6012, Charlestown, MA 02129 USA.; Langenau, DM (reprint author), Massachusetts Gen Hosp, Ctr Canc Res, Charlestown, MA 02129 USA.; Langenau, DM (reprint author), Harvard Stem Cell Inst, Boston, MA 02129 USA. EM mignatius@mgh.harvard.edu; mnhayes@mgh.harvard.edu; dlangenau@mgh.harvard.edu FU NCI NIH HHS [1R01CA154923, K99CA175184, U54CA168512]; NIH HHS [R24OD016761] NR 66 TC 0 Z9 0 U1 2 U2 2 PU SPRINGER INT PUBLISHING AG PI CHAM PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND SN 0065-2598 BN 978-3-319-30654-4; 978-3-319-30652-0 J9 ADV EXP MED BIOL JI Adv.Exp.Med.Biol. PY 2016 VL 916 BP 219 EP 237 DI 10.1007/978-3-319-30654-4_10 D2 10.1007/978-3-319-30654-4 PG 19 WC Oncology; Medicine, Research & Experimental SC Oncology; Research & Experimental Medicine GA BF6PR UT WOS:000383510100011 PM 27165356 ER PT S AU Moore, JC Langenau, DM AF Moore, John C. Langenau, David M. BE Langenau, DM TI Allograft Cancer Cell Transplantation in Zebrafish SO CANCER AND ZEBRAFISH: MECHANISMS, TECHNIQUES, AND MODELS SE Advances in Experimental Medicine and Biology LA English DT Article; Book Chapter DE Zebrafish; Allogeneic transplantation; Immune compromised; Syngeneic; Engraftment ID ACUTE LYMPHOBLASTIC-LEUKEMIA; ZINC-FINGER NUCLEASES; TARGETED GENE DISRUPTION; HUMAN-MELANOMA CELLS; TRANSGENIC ZEBRAFISH; EMBRYONAL RHABDOMYOSARCOMA; DEFICIENT ZEBRAFISH; MUTANT ZEBRAFISH; CLONAL ZEBRAFISH; IMMUNE-SYSTEM AB Allogeneic cell transplantation is the transfer of cells from one individual into another of the same species and has become an indispensable technique for studying development, immunology, regeneration and cancer biology. In experimental settings, tumor cell engraftment into immunologically competent recipients has greatly increased our understanding of the mechanisms that drive self-renewal, progression and metastasis in vivo. Zebrafish have quickly emerged as a powerful genetic model of cancer that has benefited greatly from allogeneic transplantation. Efficient engraftment can be achieved by transplanting cells into either early larval stage zebrafish that have not yet developed a functional acquired immune system or adult zebrafish following radiation or chemical ablation of the immune system. Alternatively, transplantation can be completed in adult fish using either clonal syngeneic strains or newly-generated immune compromised zebrafish models that have mutations in genes required for proper immune cell function. Here, we discuss the current state of cell transplantation as it pertains to zebrafish cancer and the available models used for dissecting important processes underlying cancer. We will also use the zebrafish model to highlight the power of cell transplantation, including its capacity to dynamically assess functional heterogeneity within individual cancer cells, visualize cancer progression and evolution, assess tumor-propagating potential and self-renewal, image cancer cell invasion and dissemination and identify novel therapies for treating cancer. C1 [Moore, John C.] Massachusetts Gen Hosp, Canc Ctr & Regenerat Med, Mol Pathol Unit, 149 13th St,Off 6133, Charlestown, MA 02129 USA. [Moore, John C.] Harvard Stem Cell Inst, Cambridge, MA USA. [Langenau, David M.] Massachusetts Gen Hosp, Mol Pathol & Canc Ctr, Charlestown, MA 02129 USA. RP Langenau, DM (reprint author), Massachusetts Gen Hosp, Mol Pathol & Canc Ctr, Charlestown, MA 02129 USA. EM moore.john@mgh.harvard.edu; dlangenau@mgh.harvard.edu FU NCI NIH HHS [1R01CA154923, U54CA168512]; NIH HHS [R24OD016761] NR 97 TC 0 Z9 0 U1 2 U2 2 PU SPRINGER INT PUBLISHING AG PI CHAM PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND SN 0065-2598 BN 978-3-319-30654-4; 978-3-319-30652-0 J9 ADV EXP MED BIOL JI Adv.Exp.Med.Biol. PY 2016 VL 916 BP 265 EP 287 DI 10.1007/978-3-319-30654-4_12 D2 10.1007/978-3-319-30654-4 PG 23 WC Oncology; Medicine, Research & Experimental SC Oncology; Research & Experimental Medicine GA BF6PR UT WOS:000383510100013 PM 27165358 ER PT S AU Hwang, KL Goessling, W AF Hwang, Katie L. Goessling, Wolfram BE Langenau, DM TI Baiting for Cancer: Using the Zebrafish as a Model in Liver and Pancreatic Cancer SO CANCER AND ZEBRAFISH: MECHANISMS, TECHNIQUES, AND MODELS SE Advances in Experimental Medicine and Biology LA English DT Article; Book Chapter DE Liver development; Liver cancer; Pancreas development; Pancreas cancer; Zebrafish; Transgenesis; Mutations ID DIFFERENT DEVELOPMENTAL-STAGES; GENOME-WIDE ASSOCIATION; TRANSGENIC ZEBRAFISH; DANIO-RERIO; IN-VIVO; HEPATOCELLULAR-CARCINOMA; MUTANT ZEBRAFISH; RAS ONCOGENES; DUCTAL ADENOCARCINOMA; DNA HYPOMETHYLATION AB Liver and pancreatic cancers are amongst the leading causes of cancer death. In recent years, genetic and chemical approaches in zebrafish have elucidated cellular and molecular mechanisms of liver and pancreatic cancer formation and progression. In this chapter, we review the recent approaches and advances in the field to study both hepatocellular carcinomas and pancreatic cancer. C1 [Hwang, Katie L.] Harvard Med Sch, Med Scientist Training Program, Boston, MA USA. [Hwang, Katie L.; Goessling, Wolfram] Brigham & Womens Hosp, Div Genet, 75 Francis St, Boston, MA 02115 USA. [Goessling, Wolfram] Dana Farber Canc Inst, Gastrointestinal Canc Ctr, Boston, MA 02115 USA. [Goessling, Wolfram] Broad Inst MIT & Harvard, Cambridge, MA 02142 USA. [Goessling, Wolfram] Harvard Stem Cell Inst, Cambridge, MA 02138 USA. RP Goessling, W (reprint author), Brigham & Womens Hosp, Div Genet, 75 Francis St, Boston, MA 02115 USA.; Goessling, W (reprint author), Dana Farber Canc Inst, Gastrointestinal Canc Ctr, Boston, MA 02115 USA.; Goessling, W (reprint author), Broad Inst MIT & Harvard, Cambridge, MA 02142 USA.; Goessling, W (reprint author), Harvard Stem Cell Inst, Cambridge, MA 02138 USA. EM wolfram_goessling@dfci.harvard.edu OI Goessling, Wolfram/0000-0001-9972-1569 FU NIDDK NIH HHS [R01DK090311]; NIGMS NIH HHS [T32 GM007753] NR 89 TC 0 Z9 0 U1 1 U2 1 PU SPRINGER INT PUBLISHING AG PI CHAM PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND SN 0065-2598 BN 978-3-319-30654-4; 978-3-319-30652-0 J9 ADV EXP MED BIOL JI Adv.Exp.Med.Biol. PY 2016 VL 916 BP 391 EP 410 DI 10.1007/978-3-319-30654-4_17 D2 10.1007/978-3-319-30654-4 PG 20 WC Oncology; Medicine, Research & Experimental SC Oncology; Research & Experimental Medicine GA BF6PR UT WOS:000383510100018 PM 27165363 ER PT S AU Kaufman, CK AF Kaufman, Charles K. BE Langenau, DM TI Zebrafish Melanoma SO CANCER AND ZEBRAFISH: MECHANISMS, TECHNIQUES, AND MODELS SE Advances in Experimental Medicine and Biology LA English DT Article; Book Chapter DE Zebrafish; Melanoma; Cancer models; Transgenics; Drug discovery ID METASTATIC MELANOMA; UNTREATED MELANOMA; NEURAL CREST; BRAF; IPILIMUMAB; EXPRESSION; MUTATIONS; NIVOLUMAB; HETEROGENEITY; MULTICENTER AB Melanoma skin cancer is a potentially deadly disease in humans and has remained extremely difficult to treat once it has metastasized. In just the last 10 years, a number of models of melanoma have been developed in the zebrafish that are biologically faithful to the human disease and have already yielded important insights into the fundamental biology of melanoma and offered new potential avenues for treatment. With the diversity and breadth of the molecular genetic tools available in the zebrafish, these melanoma models will continue to be refined and expanded upon to keep pace with the rapidly evolving field of melanoma biology. C1 [Kaufman, Charles K.] Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave, Boston, MA 02115 USA. [Kaufman, Charles K.] Boston Childrens Hosp, Hematol Oncol, Boston, MA 02115 USA. RP Kaufman, CK (reprint author), Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave, Boston, MA 02115 USA.; Kaufman, CK (reprint author), Boston Childrens Hosp, Hematol Oncol, Boston, MA 02115 USA. EM ckkaufman@partners.org NR 44 TC 0 Z9 0 U1 2 U2 2 PU SPRINGER INT PUBLISHING AG PI CHAM PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND SN 0065-2598 BN 978-3-319-30654-4; 978-3-319-30652-0 J9 ADV EXP MED BIOL JI Adv.Exp.Med.Biol. PY 2016 VL 916 BP 439 EP 450 DI 10.1007/978-3-319-30654-4_19 D2 10.1007/978-3-319-30654-4 PG 12 WC Oncology; Medicine, Research & Experimental SC Oncology; Research & Experimental Medicine GA BF6PR UT WOS:000383510100020 PM 27165365 ER PT S AU Zhu, SZ Look, AT AF Zhu, Shizhen Look, A. Thomas BE Langenau, DM TI Neuroblastoma and Its Zebrafish Model SO CANCER AND ZEBRAFISH: MECHANISMS, TECHNIQUES, AND MODELS SE Advances in Experimental Medicine and Biology LA English DT Article; Book Chapter DE Zebrafish; Animal model; Neuroblastoma; Neural crest; MYCN; ALK; Transgenesis; Functional genomic ID CENTRAL HYPOVENTILATION SYNDROME; CHROMAFFIN CELL-DEVELOPMENT; AUTONOMIC NERVOUS-SYSTEM; HIGH-RISK NEUROBLASTOMA; CANCER GENE DISCOVERY; AVIAN NEURAL CREST; TRANSGENIC ZEBRAFISH; IN-VIVO; TYROSINE-HYDROXYLASE; SYMPATHETIC NEURONS AB Neuroblastoma, an important developmental tumor arising in the peripheral sympathetic nervous system (PSNS), accounts for approximately 10 % of all cancer-related deaths in children. Recent genomic analyses have identified a spectrum of genetic alterations in this tumor. Amplification of the MYCN oncogene is found in 20 % of cases and is often accompanied by mutational activation of the ALK (anaplastic lymphoma kinase) gene, suggesting their cooperation in tumor initiation and spread. Understanding how complex genetic changes function together in oncogenesis has been a continuing and daunting task in cancer research. This challenge was addressed in neuroblastoma by generating a transgenic zebrafish model that overexpresses human MYCN and activated ALK in the PSNS, leading to tumors that closely resemble human neuroblastoma and new opportunities to probe the mechanisms that underlie the pathogenesis of this tumor. For example, coexpression of activated ALK with MYCN in this model triples the penetrance of neuroblastoma and markedly accelerates tumor onset, demonstrating the interaction of these modified genes in tumor development. Further, MYCN overexpression induces adrenal sympathetic neuroblast hyperplasia, blocks chromaffin cell differentiation, and ultimately triggers a developmentally-timed apoptotic response in the hyperplastic sympathoadrenal cells. In the context of MYCN overexpression, activated ALK provides prosurvival signals that block this apoptotic response, allowing continued expansion and oncogenic transformation of hyperplastic neuroblasts, thus promoting progression to neuroblastoma. This application of the zebrafish model illustrates its value in rational assessment of the multigenic changes that define neuroblastoma pathogenesis and points the way to future studies to identify novel targets for therapeutic intervention. C1 [Zhu, Shizhen] Mayo Clin, Ctr Canc, Dept Biochem & Mol Biol, Rochester, MN 55902 USA. [Zhu, Shizhen] Mayo Clin, Ctr Individualized Med, Rochester, MN 55902 USA. [Look, A. Thomas] Harvard Med Sch, Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA. RP Zhu, SZ (reprint author), Mayo Clin, Ctr Canc, Dept Biochem & Mol Biol, Rochester, MN 55902 USA.; Zhu, SZ (reprint author), Mayo Clin, Ctr Individualized Med, Rochester, MN 55902 USA.; Look, AT (reprint author), Harvard Med Sch, Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA. EM Zhu.shizhen@mayo.edu; thomas_look@dfci.harvard.edu NR 140 TC 2 Z9 2 U1 1 U2 1 PU SPRINGER INT PUBLISHING AG PI CHAM PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND SN 0065-2598 BN 978-3-319-30654-4; 978-3-319-30652-0 J9 ADV EXP MED BIOL JI Adv.Exp.Med.Biol. PY 2016 VL 916 BP 451 EP 478 DI 10.1007/978-3-319-30654-4_20 D2 10.1007/978-3-319-30654-4 PG 28 WC Oncology; Medicine, Research & Experimental SC Oncology; Research & Experimental Medicine GA BF6PR UT WOS:000383510100021 PM 27165366 ER PT S AU Durbin, AD Ki, DH He, SN Look, AT AF Durbin, Adam D. Ki, Dong Hyuk He, Shuning Look, A. Thomas BE Langenau, DM TI Malignant Peripheral Nerve Sheath Tumors SO CANCER AND ZEBRAFISH: MECHANISMS, TECHNIQUES, AND MODELS SE Advances in Experimental Medicine and Biology LA English DT Article; Book Chapter DE Malignant peripheral nerve sheath tumor; MPNST; Zebrafish; Tumor modeling; p53; p16 INK4A; PI3K; Akt; mTOR; NF1; RAS; EGFR ID NEUROFIBROMATOSIS TYPE-I; GROWTH-FACTOR RECEPTOR; PROGRESSIVE VESTIBULAR SCHWANNOMAS; ACUTE LYMPHOBLASTIC-LEUKEMIA; VON RECKLINGHAUSENS DISEASE; SOFT-TISSUE SARCOMA; PLEXIFORM NEUROFIBROMAS; IMATINIB MESYLATE; SIGNALING PATHWAY; SUPPRESSOR GENE AB Malignant peripheral nerve sheath tumors (MPNST) are tumors derived from Schwann cells or Schwann cell precursors. Although rare overall, the incidence of MPNST has increased with improved clinical management of patients with the neurofibromatosis type 1 (NF1) tumor predisposition syndrome. Unfortunately, current treatment modalities for MPNST are limited, with no targeted therapies available and poor efficacy of conventional radiation and chemotherapeutic regimens. Many murine and zebrafish models of MPNST have been developed, which have helped to elucidate the genes and pathways that are dysregulated in MPNST tumorigenesis, including the p53, and the RB1, PI3K-Akt-mTOR, RAS-ERK and Wnt signaling pathways. Preclinical results have suggested that new therapies, including mTOR and ERK inhibitors, may synergize with conventional chemotherapy in human tumors. The discovery of new genome editing technologies, like CRISPR-cas9, and their successful application to the zebrafish model will enable rapid progress in the faithful modeling of MPNST molecular pathogenesis. The zebrafish model is especially suited for high throughput screening of new targeted therapeutics as well as drugs approved for other purposes, which may help to bring enhanced treatment modalities into human clinical trials for this devastating disease. C1 [Durbin, Adam D.; Ki, Dong Hyuk; He, Shuning; Look, A. Thomas] Harvard Med Sch, Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02215 USA. [Durbin, Adam D.; Ki, Dong Hyuk; He, Shuning; Look, A. Thomas] Boston Childrens Hosp, Div Pediat Hematol Oncol, Boston, MA 02215 USA. [Durbin, Adam D.; Look, A. Thomas] Boston Childrens Hosp, Dept Med, Boston, MA 02215 USA. RP Durbin, AD; Look, AT (reprint author), Harvard Med Sch, Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02215 USA.; Durbin, AD; Look, AT (reprint author), Boston Childrens Hosp, Div Pediat Hematol Oncol, Boston, MA 02215 USA.; Durbin, AD; Look, AT (reprint author), Boston Childrens Hosp, Dept Med, Boston, MA 02215 USA. EM adam.durbin@childrens.harvard.edu; DongH_Ki@dfci.harvard.edu; shuning_he@dfci.harvard.edu; Thomas_Look@dfci.harvard.edu NR 149 TC 1 Z9 1 U1 2 U2 2 PU SPRINGER INT PUBLISHING AG PI CHAM PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND SN 0065-2598 BN 978-3-319-30654-4; 978-3-319-30652-0 J9 ADV EXP MED BIOL JI Adv.Exp.Med.Biol. PY 2016 VL 916 BP 495 EP 530 DI 10.1007/978-3-319-30654-4_22 D2 10.1007/978-3-319-30654-4 PG 36 WC Oncology; Medicine, Research & Experimental SC Oncology; Research & Experimental Medicine GA BF6PR UT WOS:000383510100023 PM 27165368 ER PT J AU Young, MR Craft, DL AF Young, Michael R. Craft, David L. TI Pathway-Informed Classification System (PICS) for Cancer Analysis Using Gene Expression Data SO CANCER INFORMATICS LA English DT Article DE oncogenomics; systems biology; genomics-based optimization; data-mining; biological pathways ID OVARIAN-CANCER; BREAST-CANCER; RECONSTRUCTION; SIGNATURE; SURVIVAL; STAGE AB We introduce Pathway-Informed Classification System (PICS) for classifying cancers based on tumor sample gene expression levels. PICS is a computational method capable of expeditiously elucidating both known and novel biological pathway involvement specific to various cancers and uses that learned pathway information to separate patients into distinct classes. The method clearly separates a pan-cancer dataset by tissue of origin and also sub-classifies individual cancer datasets into distinct survival classes. Gene expression values are collapsed into pathway scores that reveal which biological activities are most useful for clustering cancer cohorts into subtypes. Variants of the method allow it to be used on datasets that do and do not contain non-cancerous samples. Activity levels of all types of pathways, broadly grouped into metabolic, cellular processes and signaling, and immune system, are useful for separating the pan-cancer cohort. In the clustering of specific cancer types, certain pathway types become more valuable depending on the site being studied. For lung cancer, signaling pathways dominate; for pancreatic cancer, signaling and metabolic pathways dominate; and for melanoma, immune system pathways are the most useful. This work suggests the utility of pathway-level genomic analysis and points in the direction of using pathway classification for predicting the efficacy and side effects of drugs and radiation. C1 [Young, Michael R.; Craft, David L.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02115 USA. [Young, Michael R.] Univ Massachusetts, Dept Biomed Engn & Biotechnol, Intercampus, MA 01002 USA. RP Young, MR (reprint author), Harvard Med Sch, Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02115 USA.; Young, MR (reprint author), Univ Massachusetts, Dept Biomed Engn & Biotechnol, Intercampus, MA 01002 USA. EM myoung22@mgh.harvard.edu NR 31 TC 0 Z9 0 U1 2 U2 2 PU LIBERTAS ACAD PI AUCKLAND PA PO BOX 300-874, ALBANY 0752, AUCKLAND, 00000, NEW ZEALAND SN 1176-9351 J9 CANCER INFORM JI Cancer Inform. PY 2016 VL 15 BP 151 EP 161 DI 10.4137/CIN.S40088 PG 11 WC Mathematical & Computational Biology SC Mathematical & Computational Biology GA DW9HS UT WOS:000383968400001 PM 27486299 ER PT J AU Gong, Y Zou, L Chen, DJ Chao, W AF Gong, Yu Zou, Lin Chen, Dunjin Chao, Wei TI The role of myeloid differentiation factor 88 on mitochondrial dysfunction of peritoneal leukocytes during polymicrobial sepsis SO CENTRAL EUROPEAN JOURNAL OF IMMUNOLOGY LA English DT Article DE polymicrobial sepsis; peritoneal leukocyte; mitochondrial dysfunction; MyD88 ID CARDIAC-FUNCTION; RECEPTOR 2; APOPTOSIS; ENDOTOXIN; MORTALITY; SURVIVAL; MYD88; SHOCK; MICE AB Objective: To investigate the role of myeloid differentiation factor 88 (MyD88) on mitochondrial dysfunction of peritoneal leukocytes during polymicrobial sepsis. Material and methods: Polymicrobial peritonitis, a clinically relevant mouse model of sepsis, was generated by cecum ligation and puncture (CLP) in both male C57BL/6J wild-type (WT) and MyD88 knockout (MyD88(-/-)) mice. Twenty-four hours after surgeries, peritoneal leukocytes were collected and four parameters of mitochondrial function, including total intracellular and mitochondrial ROS burst, mitochondrial membrane depolarization and ATP depletion, were measured by flow cytometry or ATP assay, and then compared. Results: Polymicrobial sepsis led to a marked mitochondrial dysfunction of peritoneal leukocytes with total intracellular and mitochondrial ROS overproduction, decreased mitochondrial membrane potential and reduced intracellular ATP production. In comparison, there was no significant difference in the extent of mitochondrial dysfunction of peritoneal leukocytes between WT and MyD88(-/-) septic mice. Conclusions: MyD88 may be not sufficient to regulate mitochondrial dysfunction of peritoneal leukocytes during polymicrobial sepsis. C1 [Gong, Yu] Guangzhou Med Univ, Affiliated Hosp 3, Biomed Res Ctr, Guangzhou, Guangdong, Peoples R China. [Gong, Yu] Guangzhou Med Univ, Affiliated Hosp 3, Key Lab Reprod & Genet Guangdong Higher Educ Inst, Dept Surg,Key Lab Major Obstet Dis Guangdong Prov, Guangzhou, Guangdong, Peoples R China. [Gong, Yu; Zou, Lin; Chao, Wei] Harvard Med Sch, Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA USA. [Chen, Dunjin] Guangzhou Med Univ, Affiliated Hosp 3, Inst Gynecol & Obstet, Key Lab Major Obstet Dis Guangdong Prov, Guangzhou, Guangdong, Peoples R China. RP Gong, Y (reprint author), Guangzhou Med Univ, Affiliated Hosp 3, 63 Duobao Rd, Guangzhou 510150, Guangdong, Peoples R China. EM shirley_gong17@hotmail.com FU Guangzhou Medical University [2011C43]; Third Affiliated Hospital of Guangzhou Medical University [2012Y20]; Department of Education of Guangdong Province [2015KQNCX137] FX This work was supported financially by Guangzhou Medical University (2011C43), the Third Affiliated Hospital of Guangzhou Medical University (2012Y20), and Department of Education of Guangdong Province (2015KQNCX137). NR 19 TC 0 Z9 0 U1 0 U2 0 PU TERMEDIA PUBLISHING HOUSE LTD PI POZNAN PA KLEEBERGA ST 2, POZNAN, 61-615, POLAND SN 1426-3912 EI 1644-4124 J9 CENT EUR J IMMUNOL JI Central Eur. J. Immunol. PY 2016 VL 41 IS 2 BP 153 EP 158 DI 10.5114/ceji.2016.60989 PG 6 WC Immunology SC Immunology GA DW0TL UT WOS:000383355600007 PM 27536200 ER PT J AU Rivin, BE Diekema, DS Mastroianni, AC Krieger, JN Klausner, JD Morris, BJ AF Rivin, Beth E. Diekema, Douglas S. Mastroianni, Anna C. Krieger, John N. Klausner, Jeffrey D. Morris, Brian J. TI Critical Evaluation of Adler's Challenge to the CDC's Male Circumcision Recommendations SO INTERNATIONAL JOURNAL OF CHILDRENS RIGHTS LA English DT Article DE male circumcision; children's rights; critical perspective; Centers for Disease Control and Prevention; policy ID URINARY-TRACT-INFECTIONS; MALE INFANT CIRCUMCISION; NEONATAL MALE CIRCUMCISION; LIDOCAINE-PRILOCAINE CREAM; SUB-SAHARAN AFRICA; SEXUAL SATISFACTION; UNITED-STATES; POLICY STATEMENT; RANDOMIZED-TRIAL; HIV PREVENTION AB We evaluate Peter Adler's challenge to the Centers for Disease Control and Prevention (CDC) draft recommendations on male circumcision (this issue, see pp. 237-262). The CDC advocates elective male circumcision (MC) to improve public health in the USA based on strong scientific evidence. In marked contrast to the CDC, Adler's criticisms depend on-speculative claims and obfuscation of the scientific data. Adler's central argument that circumcision in infancy should be delayed to allow a boy to make up his own mind as an adult fails to appreciate that circumcision later in life is a more complex operation, entails higher risk, is more likely to involve general anaesthesia and presents financial, psychological and organisational barriers. These limitations are avoided by circumcision early in infancy, when it is convenient, safe, quick, low risk, usually involves local anaesthesia and provides benefits immediately. Benefits of male circumcision include: protection against: urinary tract infections that are ten times higher in uncircumcised infants; inflammatory skin conditions; other foreskin problems; sexually transmitted infections and genital cancers in the male and his female sexual partners. Circumcision during infancy is also associated with faster healing and improved cosmetic outcomes. Circumcision does not impair sexual function or pleasure. Some authorities regard the failure to offer circumcision as unethical, just as it would be unethical to fail to encourage paediatric vaccination. Since the benefits vastly outweigh the risks, each intervention is in the best interests of the child. In conclusion, Adler's criticisms of the CDC's evidence-based male circumcision policy are flawed scientifically, ethically and legally, and should be dismissed as endangering public health and individual well-being. C1 [Rivin, Beth E.] Univ Washington, Sch Law, Seattle, WA 98195 USA. [Diekema, Douglas S.] Seattle Childrens Hosp, Treuman Katz Ctr Pediat Bioeth, Seattle, WA USA. [Mastroianni, Anna C.] Univ Washington, Urol Sect, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. [Mastroianni, Anna C.] Univ Washington, Sch Med, Seattle, WA USA. [Krieger, John N.; Klausner, Jeffrey D.] Univ Calif Los Angeles, David Geffen Sch Med, Div Infect Dis, Dept Med, Los Angeles, CA 90024 USA. [Morris, Brian J.] Univ Sydney, Sch Med Sci, Bldg F13, Sydney, NSW 2006, Australia. RP Morris, BJ (reprint author), Univ Sydney, Sch Med Sci, Bldg F13, Sydney, NSW 2006, Australia. EM brivin@uw.edu; diek@uw.edu; amastroi@uw.edu; jkrieger@uw.edu; jdklausner@mednet.ucla.edu; brian.morris@sydney.edu.au NR 156 TC 1 Z9 1 U1 3 U2 3 PU BRILL ACADEMIC PUBLISHERS PI LEIDEN PA PLANTIJNSTRAAT 2, P O BOX 9000, 2300 PA LEIDEN, NETHERLANDS SN 0927-5568 EI 1571-8182 J9 INT J CHILD RIGHTS JI Int. J. Child. Rights PY 2016 VL 24 IS 2 BP 265 EP 303 DI 10.1163/15718182-02402004 PG 39 WC Social Sciences, Interdisciplinary SC Social Sciences - Other Topics GA DW8EM UT WOS:000383886900003 ER PT J AU XinYan Shen, H Jiang, HJ Hu, D Wang, J Wu, XQ AF XinYan Shen, Huan Jiang, Hongjian Hu, Dan Wang, Jun Wu, Xinqi TI External Qi of Qigong induces apoptosis and inhibits multiple signaling pathways in colorectal cancer cells SO INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE LA English DT Meeting Abstract C1 [XinYan] Chongqing Inst Tradit Chinese Med, Chongqing, Peoples R China. [XinYan; Shen, Huan; Wang, Jun] New Med Sci Res Inst, New York, NY 10032 USA. [Jiang, Hongjian] Cardiovasc Clin Sci Fdn, Boston, MA 02111 USA. [Hu, Dan] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. [Hu, Dan; Wu, Xinqi] Harvard Med Sch, Boston, MA 02115 USA. [Wu, Xinqi] Dana Farber Canc Inst, Boston, MA 02115 USA. EM xwu1@partners.org NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPANDIDOS PUBL LTD PI ATHENS PA POB 18179, ATHENS, 116 10, GREECE SN 1107-3756 EI 1791-244X J9 INT J MOL MED JI Int. J. Mol. Med. PY 2016 VL 38 SU 1 MA 179 BP S24 EP S24 PG 1 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA DW6CC UT WOS:000383733000080 ER PT J AU Durazzo, TC Korecka, M Trojanowski, JQ Weiner, MW Hara, RO Ashford, JW Shaw, LM AF Durazzo, Timothy C. Korecka, Magdalena Trojanowski, John Q. Weiner, Michael W. Hara, Ruth O' Ashford, John W. Shaw, Leslie M. CA Alzheimer's Dis Neuroimaging Initi TI Active Cigarette Smoking in Cognitively-Normal Elders and Probable Alzheimer's Disease is Associated with Elevated Cerebrospinal Fluid Oxidative Stress Biomarkers SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Alzheimer's disease; cigarette smoking; F-2-isoprostanes; hippocampus; mild cognitive impairment ID SURFACE-BASED ANALYSIS; HUMAN CEREBRAL-CORTEX; TOBACCO-SMOKE; LIPID-PEROXIDATION; IN-VIVO; BRAIN; ISOPROSTANES; DAMAGE; F-2-ISOPROSTANES; QUANTITATION AB Neurodegenerative diseases and chronic cigarette smoking are associated with increased cerebral oxidative stress (OxS). Elevated F-2-isoprostane levels in biological fluid is a recognized marker of OxS. This study assessed the association of active cigarette smoking with F-2-isoprostane in concentrations in cognitively-normal elders (CN), and those with mild cognitive impairment (MCI) and probable Alzheimer's disease (AD). Smoking and non-smoking CN (n = 83), MCI (n = 164), and probable AD (n = 101) were compared on cerebrospinal fluid (CSF) iPF(2 alpha)-III and 8,12, iso-iPF(2 alpha)-VI F-2-isoprostane concentrations. Associations between F-2-isoprostane levels and hippocampal volumes were also evaluated. In CN and AD, smokers had higher iPF(2 alpha)-III concentration; overall, smoking AD showed the highest iPF(2 alpha)-III concentration across groups. Smoking and non-smoking MCI did not differ on iPF(2 alpha)-III concentration. No group differences were apparent on 8,12, iso-iPF(2 alpha)-VI concentration, but across AD, higher 8,12, iso-iPF(2 alpha)-VI level was related to smaller left and total hippocampal volumes. Results indicate that active cigarette smoking in CN and probable AD is associated with increased central nervous system OxS. Further investigation of factors mediating/moderating the absence of smoking effects on CSF F-2-isoprostane levels in MCI is warranted. In AD, increasing magnitude of OxS appeared to be related to smaller hippocampal volume. This study contributes additional novel information to the mounting body of evidence that cigarette smoking is associated with adverse effects on the human central nervous system across the lifespan. C1 [Durazzo, Timothy C.; Hara, Ruth O'; Ashford, John W.] Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA. [Durazzo, Timothy C.; Hara, Ruth O'; Ashford, John W.] VA Palo Alto Hlth Care Syst, Mental Illness Res Ctr, Palo Alto, CA USA. [Durazzo, Timothy C.; Hara, Ruth O'; Ashford, John W.] VA Palo Alto Hlth Care Syst, Educ Clin Ctr, Palo Alto, CA USA. [Durazzo, Timothy C.; Hara, Ruth O'; Ashford, John W.] VA Palo Alto Hlth Care Syst, Sierra Pacific War Related Illness & Injury Study, Palo Alto, CA USA. [Korecka, Magdalena; Trojanowski, John Q.] Univ Penn, Perelman Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA. [Korecka, Magdalena; Trojanowski, John Q.] Univ Penn, Perelman Sch Med, Ctr Neurodegenerat Dis Res, Philadelphia, PA 19104 USA. [Weiner, Michael W.] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA. [Weiner, Michael W.] Univ Calif San Francisco, Dept Psychol, San Francisco, CA 94143 USA. [Weiner, Michael W.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Weiner, Michael W.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA. [Shaw, Leslie M.] San Francisco VA Med Ctr, CIND, San Francisco, CA USA. RP Durazzo, TC (reprint author), VA Palo Alto Hlth Care Syst, War Related Illness Ctr, Mental Illness Res Ctr, 3801 Miranda Ave, Palo Alto, CA 94304 USA.; Durazzo, TC (reprint author), VA Palo Alto Hlth Care Syst, Injury Study Ctr, Mental Illness Res Ctr, 3801 Miranda Ave, Palo Alto, CA 94304 USA.; Durazzo, TC (reprint author), VA Palo Alto Hlth Care Syst, Educ Clin Ctr 151Y, 3801 Miranda Ave, Palo Alto, CA 94304 USA. EM tdurazzo@stanford.edu FU National Institutes of Health [NIH DA24136]; ADNI; National Institute on Aging [U01 AG024904]; National Institute of Biomedical Imaging and Bioengineering; Abbott; AstraZeneca AB; Bayer Schering Pharma AG; Bristol-Myers Squibb; Eisai Global Clinical Development; Elan Corporation; Genentech; GE Healthcare; GlaxoSmithKline; Fujirebio Europe; Johnson and Johnson; Eli Lilly and Co.; Medpace, Inc.; Merck and Co., Inc.; Novartis AG; Pfizer Inc; F. Hoffman-La Roche; Schering-Plough; Synarc, Inc.; Wyeth; NIH [P30 AG010129, K01 AG030514, R01 AG010897, R01 AG012435]; Dana Foundation; Alzheimer's Association; Alzheimer's Drug Discovery Foundation; U.S. FDA FX This work was supported by the National Institutes of Health (NIH DA24136 to TCD) and by the use of resources and facilities at the VA San Francisco and Palo Alto. All data collection and sharing for this project was supported by ADNI. ADNI1 was funded by the National Institute on Aging (U01 AG024904), the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: Abbott, AstraZeneca AB, Bayer Schering Pharma AG, Bristol-Myers Squibb, Eisai Global Clinical Development, Elan Corporation, Genentech, GE Healthcare, GlaxoSmithKline, Fujirebio Europe, Johnson and Johnson, Eli Lilly and Co., Medpace, Inc., Merck and Co., Inc., Novartis AG, Pfizer Inc, F. Hoffman-La Roche, Schering-Plough, Synarc, Inc., and Wyeth, and non-profit partners the Alzheimer's Association and Alzheimer's Drug Discovery Foundation, with participation from the U.S. FDA. Private sector contributions to ADNI are facilitated by the Foundation for the National Institutes of Health (http://www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for NeuroImaging at the University Southern California. This research was also supported by NIH grants P30 AG010129, K01 AG030514, R01 AG010897, R01 AG012435, and The Dana Foundation. The funding agencies had no role in the design and conduct of the study, collection, management, analysis, and interpretation of the data, preparation, review, or approval of the manuscript. Original data used in preparation of this article were obtained from the ADNI database (http://www.loni.usc.edu/ADNI). As such, the investigators, other than those listed, contributed to the design and implementation of ADNI and/or provided data, but did not participate in analysis or writing of this report. A complete listing of ADNI investigators can be found at: http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledg ement_List.pdf. NR 51 TC 2 Z9 2 U1 1 U2 1 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 EI 1875-8908 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2016 VL 54 IS 1 BP 99 EP 107 DI 10.3233/JAD-160413 PG 9 WC Neurosciences SC Neurosciences & Neurology GA DW7NS UT WOS:000383838400009 PM 27472882 ER PT J AU Roalf, DR Quarmley, M Mechanic-Hamilton, D Wolk, DA Arnold, SE Moberg, PJ AF Roalf, David R. Quarmley, Megan Mechanic-Hamilton, Dawn Wolk, David A. Arnold, Steven E. Moberg, Paul J. CA Alzheimer's Dis Neuroimaging Initi TI Within-Individual Variability: An Index for Subtle Change in Neurocognition in Mild Cognitive Impairment SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE ADNI; Alzheimer's disease; intra-individual variability; mild cognitive impairment; neurocognitive function ID BATTERY TOTAL SCORE; ALZHEIMERS-DISEASE; INTRAINDIVIDUAL VARIABILITY; PERFORMANCE VARIABILITY; PERSON VARIABILITY; BRAIN STRUCTURE; SCHIZOPHRENIA; DEMENTIA; CERAD; COMMON AB Background: The transition from mild cognitive impairment (MCI) to Alzheimer's disease is characterized by a decline in cognitive performance in many domains. Cognitive performance profiles in MCI are heterogeneous, however, and additional insights into markers of incipient dementia are needed. Typically, studies focus on average or mean performance, but ignore consistency of performance across domains. WIV (within-individual variability) provides an index of this consistency and is a potential marker of cognitive decline. Objective: To use neurocognitive data from the Alzheimer's Disease Neuroimaging Initiative cohort to measure neurocognitive variability. Methods: The utility of WIV was measured, in addition to global neurocognitive performance (GNP), for identifying AD and MCI. In addition, the association between changes in neurocognitive variability and diagnostic transition over 12 months was measured. Results: As expected, variability was higher in AD and MCI as compared to healthy controls; GNP was lower in both groups as compared to healthy subjects. Global neurocognitive performance alone best distinguished those with dementia from healthy older adults. Yet, for individuals with MCI, including variability along with GNP improved diagnostic classification. Variability was higher at baseline in individuals transitioning from MCI to AD over a 12-month period. Conclusion: We conclude that variability offers complementary information about neurocognitive performance in dementia, particularly in individuals with MCI, and may provide beneficial information about disease transition. C1 [Roalf, David R.; Quarmley, Megan; Mechanic-Hamilton, Dawn; Arnold, Steven E.; Moberg, Paul J.] Dept Psychiat, Philadelphia, PA USA. [Wolk, David A.; Arnold, Steven E.; Moberg, Paul J.] Dept Neurol, Philadelphia, PA USA. [Wolk, David A.; Arnold, Steven E.; Moberg, Paul J.] Univ Penn, Alzheimers Dis Ctr, Perelman Sch Med, Philadelphia, PA 19104 USA. [Arnold, Steven E.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Neurol, Boston, MA USA. RP Roalf, DR (reprint author), Hosp Univ Penn, Brain Behav Lab, Neuropsychiat Sect, Dept Psychiat, 10th Floor,Gates Bldg, Philadelphia, PA 19104 USA. EM roalf@upenn.edu FU NIA [AG10124]; NIMH [K01 MH102609]; Institute of Aging and Alzheimer's Disease Core Center Pilot Funding Program; Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health) [U01AG024904]; DOD ADNI (Department of Defense) [W81XWH-12-2-0012]; National Institute on Aging; National Institute of Biomedical Imaging and Bioengineering; AbbVie; Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; Transition Therapeutics; Canadian Institutes of Health Research; Northern California Institute for Research and Education FX This work was supported by NIA AG10124, NIMH K01 MH102609 (Dr. Roalf), and the Institute of Aging and Alzheimer's Disease Core Center Pilot Funding Program (Dr. Roalf).; Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (http://www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California. NR 45 TC 0 Z9 0 U1 5 U2 5 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 EI 1875-8908 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2016 VL 54 IS 1 BP 325 EP 335 DI 10.3233/JAD-160259 PG 11 WC Neurosciences SC Neurosciences & Neurology GA DW7NS UT WOS:000383838400030 PM 27567827 ER PT J AU Rosenberg, PB Lanctot, KL Herrmann, N Mintzer, JE Porsteinsson, AP Sun, XY Raman, R AF Rosenberg, Paul B. Lanctot, Krista L. Herrmann, Nathan Mintzer, Jacobo E. Porsteinsson, Anton P. Sun, Xiaoying Raman, Rema TI Changes in Neuropsychiatric Inventory Associated with Semagacestat Treatment of Alzheimer's Disease SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Alzheimer's disease; amyloid; clinical trial; depression; neuropsychiatry ID QUALITY-OF-LIFE; LONG-TERM-CARE; CLINICAL-TRIALS; CACHE COUNTY; SYMPTOMS; DEMENTIA; DEPRESSION; CITALOPRAM; INHIBITORS; AGITATION AB Background: In a recent report, 76 weeks' treatment with a gamma-secretase inhibitor (semagacestat) was associated with poorer cognitive outcomes in Alzheimer's disease (AD). Objective: We sought to examine the effect of semagacestat treatment on neuropsychiatric symptoms (NPS). Methods: 1,537 participants with mild to moderate AD were randomized to 76 weeks' treatment with placebo versus two doses of semagacestat. NPS were assessed with the Neuropsychiatric Inventory (NPI-Total and subdomains). Cognition was assessed with the Alzheimer's Disease Assessment Scale-Cognitive (first 11 items, ADAS11). Mixed-Model Repeated Measures was used to compare the effects of treatment assignment on change in NPI-total and subdomains over time. Survival analysis was used to assess the treatment effect on time to first worsening of NPS (NPI-Total >= 10 or NPI subdomain >= 4) for subjects with no or minor NPS at baseline. Results: Participants on high dose semagecestat (140 mg) had greater increase in NPI-Total and greater risk of incident first worsening in NPI-Total and in subdomains of aberrant motor behavior, appetite, depression/dysphoria, and sleep. ADAS11 increased more in participants whose NPI-Total increased. Conclusion: In participants with mild to moderate AD, high dose semagacestat treatment was associated with greater severity and faster worsening of NPS in a pattern resembling an agitated depression. Increased NPS was associated with cognitive decline regardless of treatment assignment. These findings suggest that greater NPS may be the result of gamma-secretase treatment and emphasize the importance of monitoring NPS as potential adverse events in trials of novel treatments for AD. C1 [Rosenberg, Paul B.] Johns Hopkins Sch Med, Div Geriatr Psychiat & Neuropsychiat, Dept Psychiat & Behav Sci, Baltimore, MD USA. [Lanctot, Krista L.] Sunnybrook Res Inst, Hurvitz Brain Sci Program, Toronto, ON, Canada. [Lanctot, Krista L.] Univ Toronto, Dept Psychiat, Toronto, ON, Canada. [Lanctot, Krista L.] Univ Toronto, Dept Pharmacol Toxicol, Toronto, ON, Canada. [Herrmann, Nathan] Sunnybrook Hlth Sci Ctr, Div Geriatr Psychiat, Toronto, ON, Canada. [Herrmann, Nathan] Univ Toronto, Div Geriatr Psychiat, Dept Psychiat, Toronto, ON, Canada. [Mintzer, Jacobo E.] Roper St Francis Clin Biotechnol Res Inst, Charleston, SC USA. [Mintzer, Jacobo E.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. [Mintzer, Jacobo E.] Med Univ South Carolina, Charleston, SC 29425 USA. [Mintzer, Jacobo E.] Univ South Carolina, Sch Internal Med, Columbia, SC 29208 USA. [Porsteinsson, Anton P.] Univ Rochester, Sch Med & Dent, Dept Psychiat, Rochester, NY 14642 USA. [Sun, Xiaoying] Univ Calif San Diego, Biostat Res Ctr, La Jolla, CA 92093 USA. [Raman, Rema] Univ Southern Calif, Keck Sch Med, ATRI, Los Angeles, CA 90033 USA. RP Rosenberg, PB (reprint author), Johns Hopkins Univ, Johns Hopkins Bayview Med Ctr, Sch Med, 5300 Alpha Commons Dr,4th Floor, Baltimore, MD 21224 USA. EM prosenb9@jhmi.edu FU Eli Lilly; University of California at San Diego FX Supported by Eli Lilly and the University of California at San Diego (the latter as a fiduciary for the Alzheimer's Disease Cooperative Study), a clinical trials consortium established by the National Institute on Aging. NR 29 TC 0 Z9 0 U1 3 U2 3 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 EI 1875-8908 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2016 VL 54 IS 1 BP 373 EP 381 DI 10.3233/JAD-151113 PG 9 WC Neurosciences SC Neurosciences & Neurology GA DW7NS UT WOS:000383838400034 PM 27567808 ER PT J AU Keane, FK Wo, JY Zhu, AX Hong, TS AF Keane, Florence K. Wo, Jennifer Y. Zhu, Andrew X. Hong, Theodore S. TI Liver-Directed Radiotherapy for Hepatocellular Carcinoma SO LIVER CANCER LA English DT Review DE Hepatocellular carcinoma; Liver-directed radiotherapy; Stereotactic body radiotherapy ID STEREOTACTIC BODY RADIOTHERAPY; PROTON-BEAM THERAPY; RADIATION-THERAPY; ABDOMINAL COMPRESSION; NORMAL TISSUE; PHASE-I; CHEMOEMBOLIZATION; TUMORS; SURVIVAL; TRIAL AB Background: The incidence of hepatocellular carcinoma (HCC) continues to increase worldwide. Many patients present with advanced disease with extensive local tumor or vascular invasion and are not candidates for traditionally curative therapies such as orthotopic liver transplantation (OLT) or resection. Radiotherapy (RT) was historically limited by its inability to deliver a tumoricidal dose; however, modern RT techniques have prompted renewed interest in the use of liver-directed RT to treat patients with primary hepatic malignancies. Summary: The aim of this review was to discuss the use of external beam RT in the treatment of HCC, with particular focus on the use of stereotactic body radiotherapy (SBRT). We review the intricacies of SBRT treatment planning and delivery. Liver-directed RT involves accurate target identification, precise and reproducible patient immobilization, and assessment of target and organ motion. We also summarize the published data on liver-directed RT, and demonstrate that it is associated with excellent local control and survival rates, particularly in patients who are not candidates for OLT or resection. Key Messages: Modern liver-directed RT is safe and effective for the treatment of HCC, particularly in patients who are not candidates for OLT or resection. Liver-directed RT, including SBRT, depends on accurate target identification, precise and reproducible patient immobilization, and assessment of target and organ motion. Further prospective studies are needed to fully delineate the role of liver-directed RT in the treatment of HCC. Copyright (C) 2016 S. Karger AG, Basel C1 [Keane, Florence K.] Harvard Med Sch, Harvard Radiat Oncol Program, Boston, MA USA. [Wo, Jennifer Y.; Hong, Theodore S.] Massachusetts Gen Hosp, Dept Radiat Oncol, 32 Fruit St,Yawkey 7, Boston, MA 02114 USA. [Zhu, Andrew X.] Massachusetts Gen Hosp, Dept Med, Div Med Oncol, Boston, MA 02114 USA. RP Hong, TS (reprint author), Massachusetts Gen Hosp, Dept Radiat Oncol, 32 Fruit St,Yawkey 7, Boston, MA 02114 USA. EM TSHong1@mgh.harvard.edu NR 41 TC 1 Z9 1 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 2235-1795 EI 1664-5553 J9 LIVER CANCER JI Liver Cancer PY 2016 VL 5 IS 3 BP 198 EP 209 DI 10.1159/000367764 PG 12 WC Oncology; Gastroenterology & Hepatology SC Oncology; Gastroenterology & Hepatology GA DV9BW UT WOS:000383235300005 PM 27493895 ER PT S AU Saytashev, I Murphy, M Osseiran, S Spence, DM Evans, CL Dantus, M AF Saytashev, Ilyas Murphy, Michael Osseiran, Sam Spence, Dana M. Evans, Conor L. Dantus, Marcos BE Periasamy, A So, PTC Konig, K TI The nature of multiphoton fluorescence from red blood cells SO MULTIPHOTON MICROSCOPY IN THE BIOMEDICAL SCIENCES XVI SE Proceedings of SPIE LA English DT Proceedings Paper CT Conference on Multiphoton Microscopy in the Biomedical Sciences XVI CY FEB 14-16, 2016 CL San Francisco, CA SP SPIE, Becker & Hickl GmbH, Carl Zeiss, Chroma Technol Corp, Coherent Inc, Semrock Inc, ISS Inc, JenLab GmbH, Leica Microsystems, Spectra Phys DE fluorescence; red blood cells; fluorescence lifetime; hemoglobin ID MICROSCOPY AB We report on the nature of multiphoton excited fluorescence observed from human erythrocytes (red blood cells RBC's) and their "ghosts" following 800nm sub-15 fs excitation. The detected optical signal is assigned as two-photon excited fluorescence from hemoglobin. Our findings are supported by wavelength-resolved fluorescence lifetime decay measurements using time-correlated single photon counting system from RBC's, their ghosts as well as in vitro samples of various fluorophores including riboflavin, NADH, NAD(P)H, hemoglobin. We find that low-energy and short-duration pulses allow two-photon imaging of RBC's, but longer more intense pulses lead to their destruction. C1 [Saytashev, Ilyas; Spence, Dana M.; Dantus, Marcos] Michigan State Univ, Dept Chem, 578 S Shaw Lane, E Lansing, MI 48824 USA. [Murphy, Michael; Evans, Conor L.] Harvard Med Sch, Massachusetts Gen Hosp, Wellman Ctr Photomed, 40 Blossom St, Boston, MA 02114 USA. [Osseiran, Sam] Harvard Mit Div Hlth Sci & Technol, Wellman Ctr Photomed, Med Engn & Med Phys, 40 Blossom St, Boston, MA 02114 USA. RP Dantus, M (reprint author), Michigan State Univ, Dept Chem, 578 S Shaw Lane, E Lansing, MI 48824 USA. EM dantus@msu.edu NR 6 TC 0 Z9 0 U1 2 U2 2 PU SPIE-INT SOC OPTICAL ENGINEERING PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA SN 0277-786X BN 978-1-62841-946-7 J9 PROC SPIE PY 2016 VL 9712 AR 97121W DI 10.1117/12.2213422 PG 4 WC Engineering, Biomedical; Microscopy; Optics SC Engineering; Microscopy; Optics GA BF6XN UT WOS:000383762200047 ER PT J AU Yozbatiran, N Keser, Z Davis, M Stampas, A O'Malley, MK Cooper-Hay, C Frontera, J Fregni, F Francisco, GE AF Yozbatiran, Nuray Keser, Zafer Davis, Matthew Stampas, Argyrios O'Malley, Marcia K. Cooper-Hay, Catherine Frontera, Joel Fregni, Felipe Francisco, Gerard E. TI Transcranial direct current stimulation (tDCS) of the primary motor cortex and robot-assisted arm training in chronic incomplete cervical spinal cord injury: A proof of concept sham-randomized clinical study SO NEUROREHABILITATION LA English DT Article DE Spinal cord injury; arm; motor recovery; non-invasive brain stimulation; rehabilitation-robotics ID NONINVASIVE CORTICAL STIMULATION; UPPER EXTREMITY; MAGNETIC STIMULATION; BRAIN-STIMULATION; CHRONIC STROKE; REORGANIZATION; EXCITABILITY; RECOVERY; TETRAPLEGIA; MODULATION AB BACKGROUND: After cervical spinal cord injury, current options for treatment of upper extremity motor functions have been limited to traditional approaches. However, there is a substantial need to explore more rigorous alternative treatments to facilitate motor recovery. OBJECTIVE: To demonstrate whether anodal-primary motor cortex (M1) excitability enhancement (with cathodal-supra orbital area) (atDCS) combined with robot-assisted arm training (R-AAT) will provide greater improvement in contralateral arm and hand motor functions compared to sham stimulation (stDCS) and R-AAT in patients with chronic, incomplete cervical spinal cord injury (iCSCI). METHODS: In this parallel-group, double-blinded, randomized and sham-controlled trial, nine participants with chronic iCSCI (AIS C and D level) were randomized to receive 10 sessions of atDCS or stDSC combined with R-AAT. Feasibility and tolerability was assessed with attrition rate and occurrence of adverse events, Changes in arm and hand function were assessed with Jebson Taylor Hand Function Test (JTHFT), Amount of Use Scale of Motor Activity Log (AOU-MAL), American Spinal Injury Association Upper Extremity Motor Score and Modified Ashworth Scale (MAS) at baseline, after treatment, and at two-month follow-up. RESULTS: None of the participants missed a treatment session or dropped-out due to adverse events related to the treatment protocol. Participants tended to perform better in JTHFT and AOU-MAL after treatment. Active group at post-treatment and two-month follow-up demonstrated better arm and hand performance compared to sham group. CONCLUSION: These preliminary findings support that modulating excitatory input of the corticospinal tracts on spinal circuits may be a promising strategy in improving arm and hand functions in persons with incomplete tetraplegia. Further study is needed to explore the underlying mechanisms of recovery. C1 [Yozbatiran, Nuray; Keser, Zafer; Davis, Matthew; Stampas, Argyrios; Cooper-Hay, Catherine; Frontera, Joel; Francisco, Gerard E.] Univ Texas Hlth Sci Ctr Houston, Dept Phys Med & Rehabil, Houston, TX 77030 USA. [Yozbatiran, Nuray; Keser, Zafer; Davis, Matthew; Stampas, Argyrios; Cooper-Hay, Catherine; Frontera, Joel; Francisco, Gerard E.] Univ Texas Hlth Sci Ctr Houston, Inst Rehabil & Res TIRR, Mem Hermann Neurorecovery Res Ctr, Houston, TX 77030 USA. [O'Malley, Marcia K.] Rice Univ, Dept Mech Engn, Houston, TX 77005 USA. [Fregni, Felipe] Harvard Med Sch, Spaulding Rehabil Hosp, Spaulding Neuromodulat Ctr, Boston, MA USA. [Fregni, Felipe] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA USA. RP Yozbatiran, N (reprint author), TIRR Mem Hermann, 1333-B Moursund St Suite 224, Houston, TX 77030 USA. EM Nuray.Yozbatiran@uth.tmc.edu FU Mission Connect a project of TIRR Foundation; Institute for Rehabilitation and Research at Memorial Hermann FX This study was supported by a pilot research grant from Mission Connect a project of TIRR Foundation and by The Institute for Rehabilitation and Research at Memorial Hermann. Also, we wish to thank Jay Karri for his kind assistance. NR 35 TC 1 Z9 1 U1 1 U2 1 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1053-8135 EI 1878-6448 J9 NEUROREHABILITATION JI Neurorehabilitation PY 2016 VL 39 IS 3 BP 401 EP 411 DI 10.3233/NRE-161371 PG 11 WC Clinical Neurology; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA DW7XA UT WOS:000383865200007 PM 27589510 ER PT B AU Kontos, N AF Kontos, Nicholas BE Moseley, DD Gala, G TI Can What's in Your Head be "All in Your Head?" Possibilities and Problems of Psychological Symptom Amplification SO PHILOSOPHY AND PSYCHIATRY: PROBLEMS, INTERSECTIONS, AND NEW PERSPECTIVES LA English DT Article; Book Chapter ID MAJOR DEPRESSIVE DISORDER; CHRONIC-FATIGUE-SYNDROME; MEDICALLY UNEXPLAINED SYMPTOMS; STAR-ASTERISK-D; PRIMARY-CARE; SOMATOFORM DISORDERS; SOMATIC SYMPTOMS; NONANXIOUS DEPRESSION; PSYCHIATRIC-DISORDERS; AMERICANS ATTITUDES C1 [Kontos, Nicholas] Harvard Med Sch, Psychiat, Boston, MA 02215 USA. [Kontos, Nicholas] Massachusetts Gen Hosp, MD Psychiat Consultat Serv, Psychosomat Med, Boston, MA 02114 USA. RP Kontos, N (reprint author), Harvard Med Sch, Psychiat, Boston, MA 02215 USA. NR 127 TC 1 Z9 1 U1 0 U2 0 PU ROUTLEDGE PI ABINGDON PA 2 PARK SQ, MILTON PARK, ABINGDON OX14 4RN, OXFORD, ENGLAND BN 978-1-315-68872-5; 978-0-415-70816-6 PY 2016 BP 7 EP 28 PG 22 WC Philosophy; Psychiatry SC Philosophy; Psychiatry GA BF6IX UT WOS:000383145100003 ER PT J AU Sugiyama, Y Sasajima, J Mizukami, Y Koizumi, K Kawamoto, T Ono, Y Karasaki, H Tanabe, H Fujiya, M Kohgo, Y AF Sugiyama, Yoshiaki Sasajima, Junpei Mizukami, Yusuke Koizumi, Kazuya Kawamoto, Toru Ono, Yusuke Karasaki, Hidenori Tanabe, Hiroki Fujiya, Mikihiro Kohgo, Yutaka TI GLI2 PROTEIN EXPRESSION LEVEL IS A FEASIBLE MARKER OF LIGAND-DEPENDENT HEDGEHOG ACTIVATION IN PANCREATIC NEOPLASMS SO POLISH JOURNAL OF PATHOLOGY LA English DT Article DE hedgehog; Gli2 protein; carcinoma; pancreatic ductal; pancreatic neoplasms; carcinogenesis ID SONIC HEDGEHOG; INTERACTING PROTEIN; MULTIINSTITUTIONAL PHASE-2; CANCER; GEMCITABINE; PATHWAY; MOUSE; ADENOCARCINOMA; TRIAL; DIFFERENTIATION AB The hedgehog pathway is known to promote proliferation of pancreatic ductal adenocarcinoma (PDA) and has been shown to restrain tumor progression. To understand how hedgehog causes these effects, we sought to carefully examine protein expression of hedgehog signaling components during different tumor stages. Genetically engineered mice, Pdx1-Cre; LSL-Kras(G12D) and Pdx1-Cre; LSL-Kras(G12D); p53(lox/+), were utilized to model distinct phases of tumorigenesis, pancreatic intraepithelial neoplasm (PanIN) and PDA. Human pancreatic specimens of intraductal papillary mucinous neoplasm (IPMN) and PDA were also employed. PanIN and IPMN lesions highly express Sonic Hedgehog, at a level that is slightly higher than that observed in PDA. GLI2 protein is also expressed in both PanIN/IPMN and PDA. Although there was no difference in the nuclear staining, the cytoplasmic GLI2 level in PDA was modest in comparison to that in PanIN/IPMN. Hedgehog interacting protein was strongly expressed in the precursors, whereas the level in PDA was significantly attenuated. There were no differences in expression of Patched1 at early and late stages. Finally, a strong correlation between Sonic Hedgehog and GLI2 staining was found in both human and murine pancreatic tumors. The results indicate that the GLI2 protein level could serve as a feasible marker of ligand-dependent hedgehog activation in pancreatic neoplasms. C1 [Sugiyama, Yoshiaki; Sasajima, Junpei; Koizumi, Kazuya; Kawamoto, Toru; Tanabe, Hiroki; Fujiya, Mikihiro; Kohgo, Yutaka] Asahikawa Med Univ, Dept Med, Div Gastroenterol & Hematol Oncol, 2-1-1-1 Midorigaoka Higashi, Asahikawa, Hokkaido 0788510, Japan. [Mizukami, Yusuke; Ono, Yusuke; Karasaki, Hidenori] Sapporo Higashi Tokushukai Hosp, Ctr Clin & Biomed Res, Sapporo, Hokkaido, Japan. [Mizukami, Yusuke] Massachusetts Gen Hosp, Ctr Canc, Ctr Canc Res, Boston, MA USA. [Mizukami, Yusuke] Harvard Med Sch, Boston, MA USA. RP Sasajima, J (reprint author), Asahikawa Med Univ, Dept Med, Div Gastroenterol & Hematol Oncol, 2-1-1-1 Midorigaoka Higashi, Asahikawa, Hokkaido 0788510, Japan. EM junsasaji@gmail.com FU Japan Society for the Promotion of Science [23701042, 22590754, 23790759] FX This work was supported by Grants-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (J.S.; 23701042, Y.M.; 22590754, K.K; 23790759). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 37 TC 0 Z9 0 U1 0 U2 0 PU VESALIUS UNIV MEDICAL PUBL PI CRACOW PA WISLISKO 1, CRACOW, 00000, POLAND SN 1233-9687 J9 POL J PATHOL JI Pol. J. Pathol. PY 2016 VL 67 IS 2 BP 136 EP 144 DI 10.5114/PJP.2016.61449 PG 9 WC Pathology SC Pathology GA DW0WY UT WOS:000383364900007 PM 27543868 ER PT J AU Kakuhikire, B Suquillo, D Atuhumuza, E Mushavi, R Perkins, JM Venkataramani, AS Weiser, SD Bangsberg, DR Tsai, AC AF Kakuhikire, Bernard Suquillo, Diego Atuhumuza, Elly Mushavi, Rumbidzai Perkins, Jessica M. Venkataramani, Atheendar S. Weiser, Sheri D. Bangsberg, David R. Tsai, Alexander C. TI A livelihood intervention to improve economic and psychosocial well-being in rural Uganda: Longitudinal pilot study SO SAHARA J-JOURNAL OF SOCIAL ASPECTS OF HIV-AIDS LA English DT Article DE HIV; poverty; social stigma; Uganda ID SUB-SAHARAN AFRICA; HIV-RELATED STIGMA; FOOD INSECURITY; INTERNALIZED STIGMA; TREATMENT EXPANSION; SOCIAL SUPPORT; SHAMBA-MAISHA; AIDS; OUTCOMES; IMPACTS AB HIV and poverty are inextricably intertwined in sub-Saharan Africa. Economic and livelihood intervention strategies have been suggested to help mitigate the adverse economic effects of HIV, but few intervention studies have focused specifically on HIV-positive persons. We conducted three pilot studies to assess a livelihood intervention consisting of an initial orientation and loan package of chickens and associated implements to create poultry microenterprises. We enrolled 15 HIV-positive and 22 HIV-negative participants and followed them for up to 18 months. Over the course of follow-up, participants achieved high chicken survival and loan repayment rates. Median monthly income increased, and severe food insecurity declined, although these changes were not statistically significant (P-values ranged from 0.11 to 0.68). In-depth interviews with a purposive sample of three HIV-positive participants identified a constellation of economic and psychosocial benefits, including improved social integration and reduced stigma. C1 [Kakuhikire, Bernard] Mbarara Univ Sci & Technol, Inst Management Sci, Mbarara, Uganda. [Suquillo, Diego] Harvard Univ, Quincy House, Cambridge, MA USA. [Atuhumuza, Elly] Infect Dis Res Collaborat, Kampala, Uganda. [Mushavi, Rumbidzai] Harvard Med Sch, Boston, MA USA. [Perkins, Jessica M.] Massachusetts Gen Hosp, Div Global Psychiat, Boston, MA 02114 USA. [Venkataramani, Atheendar S.] Harvard Med Sch, Med, Boston, MA USA. [Weiser, Sheri D.] Univ Calif San Francisco, Med, San Francisco, CA 94143 USA. [Bangsberg, David R.] Portland State Univ, Sch Publ Hlth, Oregon Hlth Sci Univ, Portland, OR 97207 USA. [Tsai, Alexander C.] Harvard Med Sch, Psychiat, Boston, MA 02115 USA. RP Tsai, AC (reprint author), Harvard Med Sch, Psychiat, Boston, MA 02115 USA. EM actsai@partners.org FU Sullivan Family Foundation; Tim and Jane Meyer Family Foundation; U.S. National Institutes of Health (NIH) [K23MH096620, K24MH087227]; Friends of a Healthy Uganda FX This study was funded by the Sullivan Family Foundation, the Tim and Jane Meyer Family Foundation, the U.S. National Institutes of Health (NIH) K23MH096620 and K24MH087227, and Friends of a Healthy Uganda. NR 58 TC 1 Z9 1 U1 1 U2 1 PU SA MEDICAL ASSOC HEALTH & MEDICAL PUBL GROUP PI CLAREMONT PA 21 DREYER ST, 4TH FLOOR, SANCLARE BLDG, CLAREMONT, 7700, SOUTH AFRICA SN 1729-0376 EI 1813-4424 J9 SAHARA J-J SOC ASP H JI Sahara J-J. Soc. Asp. HIV/AIDS PY 2016 VL 13 IS 1 BP 162 EP 169 DI 10.1080/17290376.2016.1230072 PG 8 WC Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA DV9AH UT WOS:000383231200018 PM 27619011 ER PT J AU Lauffenburger, JC Gagne, JJ Song, ZR Brill, G Choudhry, NK AF Lauffenburger, Julie C. Gagne, Joshua J. Song, Zirui Brill, Gregory Choudhry, Niteesh K. TI Potentially disruptive life events: what are the immediate impacts on chronic disease management? A case-crossover analysis SO BMJ OPEN LA English DT Article ID MEDICATION ADHERENCE; MYOCARDIAL-INFARCTION; NONADHERENCE; ASSOCIATION; PREDICTORS; PHYSICIAN; THERAPY; DESIGN; COHORT; CHAOS AB Objective: To explore the association between unexpected potentially disruptive life events in a patient or family member that may challenge an individual's ability to take medications as prescribed and the discontinuation of evidence-based medications for common, chronic conditions. Understanding the relationship between medication adherence and life stressors, especially those that can be identified using administrative data, may help identify patients at risk of non-adherence. Design: Observational self-controlled case-crossover design. Setting: Individuals in a nationally representative US commercial health insurance database. Participants: Adult individuals who initiated an oral hypoglycaemic, antihypertensive and/or statin and subsequently stopped the medication for >= 90 days. Main outcome measure: Potentially disruptive life events among patients and their family members measured in the 30 days just before the medication was discontinued ('hazard period') compared with the 30 days before this period ('control period'). These events included personal injury, hospitalisation, emergency room visits, changes in insurance coverage, acute stress or acute anxiety. Results: Among the 326 519 patients meeting study criteria who discontinued their chronic disease medications, 88 896 (27.2%) experienced at least one potentially disruptive life event. Newly experiencing an injury (OR: 1.26, 95% CI 1.12 to 1.42), an emergency room visit (OR: 1.19, 95% CI 1.13 to 1.26) and acute stress (OR: 1.19, 95% CI 1.08 to 1.31) were associated with discontinuation. Life events among patients' family members did not appear to be associated with medication discontinuation or occurred less frequently just prior to discontinuation. Conclusions: Potentially disruptive life events among individuals identified using routinely collected claims data are associated with discontinuation of chronic disease medications. Awareness of these events may help providers or payers identify patients at risk of non-adherence to maximise patient outcomes. C1 [Lauffenburger, Julie C.; Gagne, Joshua J.; Brill, Gregory; Choudhry, Niteesh K.] Brigham & Womens Hosp, Dept Med, Div Pharmacoepidemiol & Pharmacoecon, 75 Francis St, Boston, MA 02115 USA. [Lauffenburger, Julie C.; Gagne, Joshua J.; Brill, Gregory; Choudhry, Niteesh K.] Harvard Med Sch, Boston, MA 02115 USA. [Lauffenburger, Julie C.; Choudhry, Niteesh K.] Brigham & Womens Hosp, Dept Med, Ctr Healthcare Delivery Sci, 75 Francis St, Boston, MA 02115 USA. [Song, Zirui] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. RP Lauffenburger, JC (reprint author), Brigham & Womens Hosp, Dept Med, Div Pharmacoepidemiol & Pharmacoecon, 75 Francis St, Boston, MA 02115 USA.; Lauffenburger, JC (reprint author), Harvard Med Sch, Boston, MA 02115 USA.; Lauffenburger, JC (reprint author), Brigham & Womens Hosp, Dept Med, Ctr Healthcare Delivery Sci, 75 Francis St, Boston, MA 02115 USA. EM jlauffenburger@bwh.harvard.edu OI Lauffenburger, Julie/0000-0002-4940-4140 NR 26 TC 0 Z9 0 U1 0 U2 0 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 2044-6055 J9 BMJ OPEN JI BMJ Open PY 2016 VL 6 IS 8 AR e010958 DI 10.1136/bmjopen-2015-010958 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA DU6PI UT WOS:000382336700089 PM 27491664 ER PT J AU Rauh, SP Heymans, MW Mehr, DR Kruse, RL Lane, P Kowall, NW Volicer, L van der Steen, JT AF Rauh, Simone P. Heymans, Martijn W. Mehr, David R. Kruse, Robin L. Lane, Patricia Kowall, Neil W. Volicer, Ladislav van der Steen, Jenny T. TI Predicting mortality in patients treated differently: updating and external validation of a prediction model for nursing home residents with dementia and lower respiratory infections SO BMJ OPEN LA English DT Article ID ANTIBIOTIC-TREATMENT; PNEUMONIA; IMPACT; DEATH; RECLASSIFICATION; PERFORMANCE; SEVERITY; RISK AB Objective: To evaluate whether a model that was previously developed to predict 14-day mortality for nursing home residents with dementia and lower respiratory tract infection who received antibiotics could be applied to residents who were not treated with antibiotics. Specifically, in this same data set, to update the model using recalibration methods; and subsequently examine the historical, geographical, methodological and spectrum transportability through external validation of the updated model. Design: 1 cohort study was used to develop the prediction model, and 4 cohort studies from 2 countries were used for the external validation of the model. Setting: Nursing homes in the Netherlands and the USA. Participants: 157 untreated residents were included in the development of the model; 239 untreated residents were included in the external validation cohorts. Outcome: Model performance was evaluated by assessing discrimination: area under the receiver operating characteristic curves; and calibration: Hosmer and Lemeshow goodness-of-fit statistics and calibration graphs. Further, reclassification tables allowed for a comparison of patient classifications between models. Results: The original prediction model applied to the untreated residents, who were sicker, showed excellent discrimination but poor calibration, underestimating mortality. Adjusting the intercept improved calibration. Recalibrating the slope did not substantially improve the performance of the model. Applying the updated model to the other 4 data sets resulted in acceptable discrimination. Calibration was inadequate only in one data set that differed substantially from the other data sets in case-mix. Adjusting the intercept for this population again improved calibration. Conclusions: The discriminative performance of the model seems robust for differences between settings. To improve calibration, we recommend adjusting the intercept when applying the model in settings where different mortality rates are expected. An impact study may evaluate the usefulness of the two prediction models for treated and untreated residents and whether it supports decision-making in clinical practice. C1 [Rauh, Simone P.; Heymans, Martijn W.] Vrije Univ Amsterdam Med Ctr, Dept Epidemiol & Biostat, Amsterdam, Netherlands. [Rauh, Simone P.; Heymans, Martijn W.] Vrije Univ Amsterdam Med Ctr, EMGO Inst Hlth & Care Res, Amsterdam, Netherlands. [Mehr, David R.; Kruse, Robin L.] Univ Missouri, Sch Med, Dept Family & Community Med, Columbia, MO USA. [Lane, Patricia] Edith Nourse Rogers Mem Vet Adm Hosp, Geriatr Res Educ Clin Ctr, Bedford, MA USA. [Kowall, Neil W.] VA Boston Healthcare Syst, Dept Vet Affairs, Boston, MA USA. [Kowall, Neil W.] Boston Univ, Alzheimer Dis Ctr, BU Sch Med, Boston, MA 02215 USA. [Volicer, Ladislav] Univ S Florida, Sch Aging Studies, Tampa, FL USA. [van der Steen, Jenny T.] Leiden Univ, Dept Publ Hlth & Primary Care, Med Ctr, Leiden, Netherlands. [van der Steen, Jenny T.] Radboud Univ Nijmegen, Dept Primary & Community Care, Med Ctr, Nijmegen, Netherlands. RP Rauh, SP (reprint author), Vrije Univ Amsterdam Med Ctr, Dept Epidemiol & Biostat, Amsterdam, Netherlands.; Rauh, SP (reprint author), Vrije Univ Amsterdam Med Ctr, EMGO Inst Hlth & Care Res, Amsterdam, Netherlands. EM s.rauh@vumc.nl FU Netherlands Organisation for Scientific Research (NWO) under the Innovational Research Incentives Scheme, Vidi [917.11.339]; Dutch Ministry of Healthcare, Welfare and Sport [37851, 37852, 37853, 37832]; Society 'Het Zonnehuis'; Agency for Healthcare Quality and Research [HS08551]; Robert Wood Johnson Foundation; 'Stichting Wetenschaps Bevordering Verpleeghuiszorg' (Society Promoting Scientific Research in Nursing Home Care) (SWBV); Department of Veterans Affairs; NIH Center [P30 AG13846]; Netherlands Organisation for Scientific Research (NWO) [Veni 916.66.073]; ZonMw the Netherlands Organisation for Health Research and Development [1151.0001]; VU University Medical Center, EMGO Institute for Health and Care Research, Department of General Practice & Elderly Care Medicine; Department of Public and Occupational Health, Amsterdam, The Netherlands FX This work was supported by the Netherlands Organisation for Scientific Research (NWO), career award for JTvdS under the Innovational Research Incentives Scheme, Vidi grant number 917.11.339. The Dutch Pneumonia Study was originally funded by the Dutch Ministry of Healthcare, Welfare and Sport (grant numbers. 37851, 37852, 37853, 37832) and the Society 'Het Zonnehuis'. The Missouri LRI Study was originally funded by the Agency for Healthcare Quality and Research (grant HS08551) and a Generalist Physician Faculty Scholars Award to DRM from the Robert Wood Johnson Foundation. The Dutch 2006-2007 study was originally funded by 'Stichting Wetenschaps Bevordering Verpleeghuiszorg' (Society Promoting Scientific Research in Nursing Home Care) (SWBV). The Bedford US Study was originally funded by the Department of Veterans Affairs and NIH Center (grant P30 AG13846). The DEOLD study was originally supported by a career award for JTvdS of the Netherlands Organisation for Scientific Research (NWO; Veni 916.66.073), by ZonMw the Netherlands Organisation for Health Research and Development (grant number 1151.0001) and by the VU University Medical Center, EMGO Institute for Health and Care Research, Department of General Practice & Elderly Care Medicine and Department of Public and Occupational Health, Amsterdam, The Netherlands. The funders had no role in the study design, data collection, data synthesis, data interpretation or writing of the report. NR 31 TC 0 Z9 0 U1 1 U2 1 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 2044-6055 J9 BMJ OPEN JI BMJ Open PY 2016 VL 6 IS 8 AR e011380 DI 10.1136/bmjopen-2016-011380 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA DU6PI UT WOS:000382336700126 PM 27577584 ER PT J AU Yasuda, H Hagiwara, Y Watase, H Hasegawa, K AF Yasuda, Hideto Hagiwara, Yusuke Watase, Hiroko Hasegawa, Kohei CA Japanese Emergency Med Network Inv TI Nocturnal emergency department visits, duration of symptoms and risk of hospitalisation among adults with asthma exacerbations: a multicentre observational study SO BMJ OPEN LA English DT Article ID CHILDREN; ADMISSION; DEATHS AB Objectives: We sought to compare the characteristics of patients with asthma presenting to the emergency department (ED) during the night-time with those of patients presenting at other times of the day, and to determine whether the time of ED presentation is associated with the risk of hospitalisation. Design and setting: A multicentre chart review study of 23 EDs across Japan. Participants: Patients aged 18-54 years with a history of physician-diagnosed asthma, presented to the ED between January 2009 and December 2011 Outcome measures: The outcome of interest was hospitalisation, including admissions to an observation unit, inpatient unit and intensive care unit. Results: Among the 1354 patients (30.1% in the night-time group vs 69.9% in the other time group) included in this study, the median age was 34 years and similar to 40% were male. Overall 145 patients (10.7%) were hospitalised. Patients in the night-time group were more likely to have a shorter duration of symptoms (<= 3 hours) before ED presentation than those in the other time group (25.9% in night-time vs 13.4% in other times; p<0.001). In contrast, there were no significant differences in respiratory rate, initial peak expiratory flow or ED asthma treatment between the two groups (p>0.05). Similarly, the risk of hospitalisation did not differ between the two groups (11.3% in night-time vs 10.5% in other times; p=0.65). In a multivariable model adjusting for potential confounders, the risk of hospitalisation in the night-time group was not statistically different from the other time group (OR, 1.10; 95% CI 0.74 to 1.61; p=0.63). Conclusions: This multicentre study in Japan demonstrated no significant difference in the risk of hospitalisations according to the time of ED presentation. C1 [Yasuda, Hideto] Japanese Red Cross Musashino Hosp, Dept Emergency & Crit Care Med, Intens Care Unit, Tokyo, Japan. [Yasuda, Hideto] Kaneda Med Ctr, Dept Intens Care Med, Chiba, Japan. [Hagiwara, Yusuke] Tokyo Metropolitan Childrens Med Ctr, Dept Pediat Emergency & Crit Care Med, Tokyo, Japan. [Watase, Hiroko] Univ Washington, Dept Radiol, Seattle, WA 98195 USA. [Hasegawa, Kohei] Harvard Med Sch, Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA USA. RP Yasuda, H (reprint author), Japanese Red Cross Musashino Hosp, Dept Emergency & Crit Care Med, Intens Care Unit, Tokyo, Japan.; Yasuda, H (reprint author), Kaneda Med Ctr, Dept Intens Care Med, Chiba, Japan. EM yasuda.hideto@kameda.jp FU St. Luke's Life Science Institute (Tokyo, Japan) FX This study was supported by a grant from St. Luke's Life Science Institute (Tokyo, Japan). NR 20 TC 0 Z9 0 U1 0 U2 0 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 2044-6055 J9 BMJ OPEN JI BMJ Open PY 2016 VL 6 IS 8 AR e010670 DI 10.1136/bmjopen-2015-010670 PG 5 WC Medicine, General & Internal SC General & Internal Medicine GA DU6PI UT WOS:000382336700171 ER PT J AU Klein, E Goering, S Gagne, J Shea, CV Franklin, R Zorowitz, S Dougherty, DD Widge, AS AF Klein, Eran Goering, Sara Gagne, Josh Shea, Conor V. Franklin, Rachel Zorowitz, Samuel Dougherty, Darin D. Widge, Alik S. TI Brain-computer interface-based control of closed-loop brain stimulation: attitudes and ethical considerations SO BRAIN-COMPUTER INTERFACES LA English DT Article DE deep brain stimulation; ethics; closed-loop; patient-controlled; end-user perspectives ID TREATMENT-RESISTANT DEPRESSION; VENTRAL CAPSULE/VENTRAL STRIATUM; USERS WANT OPINIONS; THERAPEUTIC MISCONCEPTION; POTENTIAL USERS; PSYCHOSURGERY; TECHNOLOGY; CHALLENGES; PRIORITIES; TRIAL AB Patients who have undergone deep brain stimulation (DBS) for emerging indications have unique perspectives on ethical challenges that may shape trial design and identify key design features for BCI-driven DBS systems. DBS research in cognitive and emotional disorders has generated significant ethical interest. Much of this work has focused on developing ethical guidelines and recommendations for open-loop DBS systems. While early trials of open-loop DBS for depression gave disappointing results, research is moving toward clinical trials with closed-loop or patient-controllable DBS systems that may modulate aspects of personality and emotion. Though user-centered design is an increasingly important principle in neurotechnology, the perspectives of implanted individuals on ethical issues raised by DBS are poorly understood. We solicited those perspectives through a focus group and set of qualitative interviews of participants in trials of DBS for depression and obsessive-compulsive disorder. We identified four major themes: control over device function, authentic self, relationship effects, and meaningful consent. Each has implications for the design of closed-loop systems for non-motor disorders. C1 [Klein, Eran; Goering, Sara] Univ Washington, Ctr Sensorimotor Neural Engn, Seattle, WA 98195 USA. [Klein, Eran; Goering, Sara] Univ Washington, Dept Philosophy, Seattle, WA 98195 USA. [Klein, Eran] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. [Gagne, Josh] Dana Farber Canc Inst, Survey & Data Management Core, Boston, MA 02115 USA. [Shea, Conor V.; Franklin, Rachel; Zorowitz, Samuel; Dougherty, Darin D.; Widge, Alik S.] Massachusetts Gen Hosp, Dept Psychiat, Div Neurotherapeut, Boston, MA 02114 USA. [Shea, Conor V.; Franklin, Rachel; Zorowitz, Samuel; Dougherty, Darin D.; Widge, Alik S.] Harvard Med Sch, Dept Psychiat, Boston, MA USA. [Widge, Alik S.] MIT, Picower Inst Learning & Memory, Boston, MA USA. RP Klein, E (reprint author), Univ Washington, Ctr Sensorimotor Neural Engn, Seattle, WA 98195 USA.; Klein, E (reprint author), Univ Washington, Dept Philosophy, Seattle, WA 98195 USA.; Klein, E (reprint author), Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA. EM kleineuw@uw.edu NR 58 TC 0 Z9 0 U1 1 U2 1 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND SN 2326-263X EI 2326-2621 J9 BRAIN-COMPUT INTERFA JI Brain Comput. Interfaces PY 2016 VL 3 IS 3 BP 140 EP 148 DI 10.1080/2326263X.2016.1207497 PG 9 WC Neurosciences SC Neurosciences & Neurology GA DV3VX UT WOS:000382853700004 ER PT J AU Ong, MK Romano, PS Edgington, S Auerbach, AD Black, JT Escarce, JJ Ganiats, TG Greenfield, S Kimchi, A Fonarow, GC AF Ong, M. K. Romano, P. S. Edgington, S. Auerbach, A. D. Black, J. T. Escarce, J. J. Ganiats, T. G. Greenfield, S. Kimchi, A. Fonarow, G. C. TI EFFECTIVENESS OF REMOTE PATIENT MONITORING AFTER DISCHARGE OF HOSPITALIZED PATIENTS WITH HEART FAILURE: THE BETTER EFFECTIVENESS AFTER TRANSITION-HEART FAILURE (BEAT-HF) RANDOMIZED CLINICAL TRIAL SO CARDIOLOGY LA English DT Meeting Abstract C1 [Ong, M. K.; Edgington, S.; Escarce, J. J.; Fonarow, G. C.] Univ Calif Los Angeles, Los Angeles, CA USA. [Romano, P. S.] Univ Calif Davis, Davis, CA 95616 USA. [Greenfield, S.] Univ Calif Irvine, Irvine, CA USA. [Ganiats, T. G.] Univ Calif San Diego, San Diego, CA 92103 USA. [Auerbach, A. D.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Black, J. T.; Kimchi, A.] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. [Escarce, J. J.] Univ Miami, RAND Corp, Coral Gables, FL 33124 USA. [Ganiats, T. G.] Univ Miami, Coral Gables, FL 33124 USA. [Ong, M. K.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0008-6312 EI 1421-9751 J9 CARDIOLOGY JI Cardiology PY 2016 VL 134 SU 1 MA 008 BP 21 EP 21 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DV6NH UT WOS:000383053200009 ER PT J AU Ko, D Riles, EM Marcos, EG Magnani, JW Lubitz, SA Lin, H Long, MT Schnabel, RB McManus, DD Ellinor, PT Ramachandran, VS Wang, TJ Gerszten, RE Benjamin, EJ Yin, X Rienstra, M AF Ko, D. Riles, E. M. Marcos, E. G. Magnani, J. W. Lubitz, S. A. Lin, H. Long, M. T. Schnabel, R. B. McManus, D. D. Ellinor, P. T. Ramachandran, V. S. Wang, T. J. Gerszten, R. E. Benjamin, E. J. Yin, X. Rienstra, M. TI METABOLOMIC PROFILING IN RELATION TO NEW-ONSET ATRIAL FIBRILLATION IN THE COMMUNITY: THE FRAMINGHAM HEART STUDY SO CARDIOLOGY LA English DT Meeting Abstract C1 [Ko, D.] Boston Univ, Sch Med, Boston Med Ctr, Dept Internal Med,Sect Gen Internal Med, Boston, MA 02118 USA. [Riles, E. M.; Magnani, J. W.; Ramachandran, V. S.; Benjamin, E. J.] Boston Univ, Sch Med, Boston Med Ctr, Dept Internal Med,Sect Cardiovasc Med, Boston, MA 02118 USA. [Ramachandran, V. S.; Benjamin, E. J.] Boston Univ, Sch Med, Boston Med Ctr, Sect Prevent Med,Dept Internal Med, Boston, MA 02118 USA. [Long, M. T.] Boston Univ, Sch Med, Boston Med Ctr, Sect Gastroenterol,Dept Internal Med, Boston, MA 02118 USA. [Ko, D.; Ramachandran, V. S.; Benjamin, E. J.] Boston Univ, Sch Med, Whitaker Cardiovasc Inst, Boston, MA 02118 USA. [Ko, D.] Boston Univ, Sch Med, Clin & Translat Sci Inst, Boston, MA 02118 USA. [Marcos, E. G.; Rienstra, M.] Univ Groningen, Univ Med Ctr Groningen, Dept Cardiol, NL-9700 AB Groningen, Netherlands. [Lubitz, S. A.; Ellinor, P. T.; Gerszten, R. E.] Harvard Med Sch, Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA USA. [Lubitz, S. A.; Ellinor, P. T.] Harvard Med Sch, Massachusetts Gen Hosp, Cardiac Arrhythmia Serv, Boston, MA USA. [Lin, H.; Ramachandran, V. S.; Benjamin, E. J.; Yin, X.] Boston Univ, Framingham, MA USA. [Lin, H.; Ramachandran, V. S.; Benjamin, E. J.; Yin, X.] NHLBI, Framingham Heart Study, Framingham, MA USA. [Schnabel, R. B.] Univ Heart Ctr Hamburg Eppendorf, Dept Gen & Intervent Cardiol, Hamburg, Germany. [McManus, D. D.] Univ Massachusetts, Sch Med, Div Cardiovasc Med, Worcester, MA USA. [Wang, T. J.] Vanderbilt Univ, Div Cardiovasc Med, 221 Kirkland Hall, Nashville, TN 37235 USA. [Yin, X.] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02118 USA. [Ramachandran, V. S.; Benjamin, E. J.] Boston Univ, Sch Publ Hlth, Epidemiol, Boston, MA 02118 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0008-6312 EI 1421-9751 J9 CARDIOLOGY JI Cardiology PY 2016 VL 134 SU 1 MA 212 BP 225 EP 225 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DV6NH UT WOS:000383053200213 ER PT J AU Rachmin, I Amsalem, E Golomb, E Beeri, R Gilon, D Min, G Foo, RSY Fisher, DE Razin, E Tshori, S AF Rachmin, I. Amsalem, E. Golomb, E. Beeri, R. Gilon, D. Min, G. Foo, R. S. Y. Fisher, D. E. Razin, E. Tshori, S. TI MITF SWITCHES FROM ACTIVATOR TO REPRESSOR OF ERBIN EXPRESSION DURING CARDIAC HYPERTROPHY SO CARDIOLOGY LA English DT Meeting Abstract C1 [Rachmin, I.; Amsalem, E.; Razin, E.] Hebrew Univ Jerusalem, Inst Med Res Israel Canada, Sch Med, Dept Biochem & Mol Biol, Jerusalem, Israel. [Golomb, E.] Shaare Zedek Med Ctr, Dept Pathol, Jerusalem, Israel. [Min, G.] Scripps Res Inst, Dept Canc Biol, Jupiter, FL USA. Hadassah Hebrew Univ, Med Ctr, Sharett Inst Oncol, Jerusalem, Israel. [Foo, R. S. Y.] Natl Univ Singapore, Cardiovasc Res Inst, Ctr Translat Med, Singapore, Singapore. [Fisher, D. E.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Dermatol, Cutaneous Biol Res Ctr, Boston, MA USA. [Tshori, S.] Hadassah Hebrew Univ, Med Ctr, Dept Nucl Med, Jerusalem, Israel. [Beeri, R.; Gilon, D.] Hadassah Hebrew Univ, Med Ctr, Inst Heart, Jerusalem, Israel. [Rachmin, I.] Harvard Univ, Harvard Stem Cell Inst, Dept Stem Cell & Regenerat Biol, Cambridge, MA 02138 USA. [Rachmin, I.] Brigham & Womens Hosp, Dept Med, Div Cardiovasc, Boston, MA 02115 USA. [Rachmin, I.] Harvard Med Sch, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0008-6312 EI 1421-9751 J9 CARDIOLOGY JI Cardiology PY 2016 VL 134 SU 1 MA 227 BP 240 EP 240 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DV6NH UT WOS:000383053200228 ER PT J AU Rafael, A Starobinska, EI Bartko, P Levine, RA Lubitz, SA Milan, DJ AF Rafael, A. Starobinska, E. I. Bartko, P. Levine, R. A. Lubitz, S. A. Milan, D. J. TI DELINEATING THE ASSOCIATION OF MITRAL VALVE PROLAPSE AND SUDDEN CARDIAC DEATH SO CARDIOLOGY LA English DT Meeting Abstract C1 [Rafael, A.; Bartko, P.; Levine, R. A.; Lubitz, S. A.; Milan, D. J.] Massachusetts Gen Hosp, Dept Cardiol, Boston, MA 02114 USA. [Starobinska, E. I.] Univ Arizona, Coll Med Phoenix, Phoenix, AZ USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0008-6312 EI 1421-9751 J9 CARDIOLOGY JI Cardiology PY 2016 VL 134 SU 1 MA 260 BP 273 EP 273 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DV6NH UT WOS:000383053200261 ER PT J AU Patel, YR Kurgansky, KE Imran, TF Orkaby, AR Cho, K Gagnon, DR Ho, Y Gaziano, JM Djousse, L Joseph, J AF Patel, Y. R. Kurgansky, K. E. Imran, T. F. Orkaby, A. R. Cho, K. Gagnon, D. R. Ho, Y. Gaziano, J. M. Djousse, L. Joseph, J. TI RACIAL DIFFERENCES IN CLINICAL CHARACTERISTICS OF HEART FAILURE WITH PRESERVED EJECTION FRACTION SO CARDIOLOGY LA English DT Meeting Abstract C1 [Patel, Y. R.; Kurgansky, K. E.; Imran, T. F.; Orkaby, A. R.; Cho, K.; Gagnon, D. R.; Ho, Y.; Gaziano, J. M.; Djousse, L.; Joseph, J.] Boston VA Healthcare Syst, Boston, MA USA. [Patel, Y. R.; Imran, T. F.; Orkaby, A. R.; Gaziano, J. M.; Djousse, L.; Joseph, J.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. [Patel, Y. R.; Imran, T. F.; Orkaby, A. R.; Gaziano, J. M.; Djousse, L.; Joseph, J.] Harvard Med Sch, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0008-6312 EI 1421-9751 J9 CARDIOLOGY JI Cardiology PY 2016 VL 134 SU 1 MA 411 BP 424 EP 424 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DV6NH UT WOS:000383053200411 ER PT J AU Del Gobbo, LC Zhang, X Wang, L Sesso, HD Manson, JE Pradhan, A Song, Y AF Del Gobbo, L. C. Zhang, X. Wang, L. Sesso, H. D. Manson, J. E. Pradhan, A. Song, Y. TI SERUM MAGNESIUM AND IMPAIRED FASTING GLUCOSE IN NON-DIABETIC ADULTS SO CARDIOLOGY LA English DT Meeting Abstract C1 [Del Gobbo, L. C.] Stanford Univ, Dept Med, Div Cardiovasc Med, Stanford, CA 94305 USA. [Zhang, X.; Song, Y.] Indiana Univ, Richard M Fairbanks Sch Publ Hlth, Dept Epidemiol, Indianapolis, IN 46204 USA. [Wang, L.; Sesso, H. D.; Manson, J. E.; Pradhan, A.] Harvard Med Sch, Brigham & Womens Hosp, Div Prevent Med, Boston, MA USA. [Pradhan, A.] VA Boston Healthcare Syst, Div Cardiovasc Med, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0008-6312 EI 1421-9751 J9 CARDIOLOGY JI Cardiology PY 2016 VL 134 SU 1 MA 433 BP 446 EP 446 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DV6NH UT WOS:000383053200433 ER PT J AU Le Tonqueze, O Kollu, S Lee, S Al-Salah, M Truesdell, SS Vasudevan, S AF Le Tonqueze, O. Kollu, S. Lee, S. Al-Salah, M. Truesdell, S. S. Vasudevan, S. TI Regulation of monocyte induced cell migration by the RNA binding protein, FXR1 SO CELL CYCLE LA English DT Article DE cell migration; chemokines; FXR1; gene expression; monocyte; mRNA ID MENTAL-RETARDATION PROTEIN; FRAGILE-X-SYNDROME; AU-RICH ELEMENTS; XENOPUS-LAEVIS; MESSENGER-RNAS; UP-REGULATION; TNF-ALPHA; TRANSLATION; EXPRESSION; CANCER AB FXR1 belongs to a family of RNA-binding proteins that play critical roles in post-transcriptional regulation of gene expression in immunity, development and cancer. FXR1 is associated with regulation of specific mRNAs in myocytes and macrophages. In quiescent cells (> 24h of extended serum-starvation, approximate to 30-48h or more), a spliced isoform of FXR1, FXR1a, promotes translation of the cytokine TNF, independent of the effects of RNA levels. Here we examined the role of FXR1 in THP1 human monocytic leukemic cells that were grown in serum, as well as in early (24h) serum-starvation conditions that demonstrates differences in gene expression mechanisms and is distinct from quiescent (> 24h extended serum-starvation) cells. Global RNA profiling, conducted to investigate the role of FXR1 on mRNA levels, revealed that FXR1 affects levels of specific mRNAs in serum-grown and in early 24h serum-starvation conditions. FXR1 decreases levels of several mRNAs, including as previously identified, CDKN1A (p21CIP1 or p21) mRNA in serum-grown cells. Interestingly, we find that FXR1 positively regulates mRNA levels of specific cytokines and chemokines in serum-grown and in early 24h serum-starvation conditions. These include IL1 and CCL2 that control cell migration. Accordingly, depletion and overexpression of FXR1 decreased and increased levels of CCL2 mRNA. Consistent with the reduced levels of IL1, CCL2 and other chemokines upon FXR1 depletion, our data reveal that depletion of FXR1 decreases the ability of these cells to induce cell migration of neighboring monocytic cells. These data reveal a new role of FXR1 in controlling induction of monocyte migration. C1 [Le Tonqueze, O.; Kollu, S.; Lee, S.; Al-Salah, M.; Truesdell, S. S.; Vasudevan, S.] Harvard Med Sch, Massachusetts Gen Hosp, Ctr Canc Res, 185 Cambridge St,CPZN 4202, Boston, MA 02114 USA. [Le Tonqueze, O.] Univ Calif San Francisco, Sch Med, San Francisco, CA 94158 USA. RP Vasudevan, S (reprint author), Harvard Med Sch, Massachusetts Gen Hosp, Ctr Canc Res, 185 Cambridge St,CPZN 4202, Boston, MA 02114 USA. EM vasudevan.shobha@mgh.harvard.edu FU MGH start-up funds; MGH Interim Support; V Foundation; Leukemia & Lymphoma Society New Idea Award; NIGMS [GM100202]; Fund for Medical Discovery postdoctoral fellowship FX This work was supported by MGH start-up funds, MGH Interim Support, V Foundation, the Leukemia & Lymphoma Society New Idea Award and GM100202 from NIGMS awarded to SV. SL is supported by the Fund for Medical Discovery postdoctoral fellowship. NR 43 TC 1 Z9 1 U1 1 U2 1 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 1538-4101 EI 1551-4005 J9 CELL CYCLE JI Cell Cycle PY 2016 VL 15 IS 14 BP 1874 EP 1882 DI 10.1080/15384101.2016.1189040 PG 9 WC Cell Biology SC Cell Biology GA DU5DJ UT WOS:000382232100015 PM 27229378 ER PT J AU DonGiovanni, D Vaina, LM AF DonGiovanni, Danilo Vaina, Lucia Maria TI Select and Cluster: A Method for Finding Functional Networks of Clustered Voxels in fMRI SO COMPUTATIONAL INTELLIGENCE AND NEUROSCIENCE LA English DT Article ID PRINCIPAL COMPONENT ANALYSIS; SUPPORT VECTOR MACHINE; HUMAN VISUAL-CORTEX; RESTING-STATE DATA; MRI DATA; BLIND SEPARATION; HUMAN BRAIN; CONNECTIVITY; IMAGES; PARCELLATION AB Extracting functional connectivity patterns among cortical regions in fMRI datasets is a challenge stimulating the development of effective data-driven or model based techniques. Here, we present a novel data-driven method for the extraction of significantly connected functional ROIs directly from the preprocessed fMRI data without relying on a priori knowledge of the expected activations. This method finds spatially compact groups of voxels which show a homogeneous pattern of significant connectivity with other regions in the brain. The method, called Select and Cluster (S&C), consists of two steps: first, a dimensionality reduction step based on a blind multiresolution pairwise correlation by which the subset of all cortical voxels with significant mutual correlation is selected and the second step in which the selected voxels are grouped into spatially compact and functionally homogeneous ROIs by means of a Support Vector Clustering (SVC) algorithm. The S&C method is described in detail. Its performance assessed on simulated and experimental fMRI data is compared to other methods commonly used in functional connectivity analyses, such as Independent Component Analysis (ICA) or clustering. S&C method simplifies the extraction of functional networks in fMRI by identifying automatically spatially compact groups of voxels (ROIs) involved in whole brain scale activation networks. C1 [DonGiovanni, Danilo] ENEA, Unita Tecn Fus, Via Enrico Fermi 45, I-00040 Frascati, Italy. [Vaina, Lucia Maria] Boston Univ, Dept Biomed Engn, 44 Cummington Mall, Boston, MA 02215 USA. [Vaina, Lucia Maria] Massachusetts Gen Hosp, Harvard Med Sch, Dept Neurol, 175 Cambridge St, Boston, MA 02114 USA. RP Vaina, LM (reprint author), Boston Univ, Dept Biomed Engn, 44 Cummington Mall, Boston, MA 02215 USA.; Vaina, LM (reprint author), Massachusetts Gen Hosp, Harvard Med Sch, Dept Neurol, 175 Cambridge St, Boston, MA 02114 USA. EM vaina@bu.edu FU NSF Grant [1545668] FX This work was supported in part by the NSF Grant 1545668 to Lucia Maria Vaina. The authors thank Dr. Richard Mitchell for kindly providing software for computationally efficient clique extraction. NR 64 TC 0 Z9 0 U1 0 U2 0 PU HINDAWI PUBLISHING CORP PI NEW YORK PA 315 MADISON AVE 3RD FLR, STE 3070, NEW YORK, NY 10017 USA SN 1687-5265 EI 1687-5273 J9 COMPUT INTEL NEUROSC JI Comput. Intell. Neurosci. PY 2016 AR 4705162 DI 10.1155/2016/4705162 PG 19 WC Mathematical & Computational Biology; Neurosciences SC Mathematical & Computational Biology; Neurosciences & Neurology GA DV6PL UT WOS:000383059000001 ER PT J AU Sun, HB Greenland, JR Kopchaliiska, D Gae, DD Singer, JP Golden, JA Hays, SR Calabrese, D Kukreja, J Rajalingam, R AF Sun, Haibo Greenland, John R. Kopchaliiska, Dessislava Gae, David D. Singer, Jonathan P. Golden, Jeffrey A. Hays, Steven R. Calabrese, Daniel Kukreja, Jasleen Rajalingam, Raja TI RECIPIENT FCGR3A-158V HOMOZYGOUS GENOTYPE IS ASSOCIATED WITH AN INCREASED RISK OF CHRONIC LUNG ALLOGRAFT DYSFUNCTION. SO HUMAN IMMUNOLOGY LA English DT Meeting Abstract CT 42nd Annual Meeting of the American-Society-for-Histocompatibility-and-Immunogenetics CY SEP 26-30, 2016 CL St Louis, MO SP Amer Soc Histocompatibil & Immunogenet C1 [Sun, Haibo; Kopchaliiska, Dessislava; Gae, David D.; Rajalingam, Raja] Univ Calif San Francisco, Dept Surg, Immunogenet & Transplantat Lab, San Francisco, CA USA. [Greenland, John R.; Singer, Jonathan P.; Golden, Jeffrey A.; Hays, Steven R.; Calabrese, Daniel] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Greenland, John R.] San Francisco VA Med Ctr, Med Serv, San Francisco, CA USA. [Kukreja, Jasleen] Univ Calif San Francisco, Dept Surg, Div Cardiothorac Surg, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0198-8859 EI 1879-1166 J9 HUM IMMUNOL JI Hum. Immunol. PY 2016 VL 77 SU 1 MA OR24 BP 19 EP 20 PG 2 WC Immunology SC Immunology GA DW0EK UT WOS:000383313500025 ER PT J AU Goto, T Camargo, CA Hasegawa, K AF Goto, Tadahiro Camargo, Carlos A., Jr. Hasegawa, Kohei TI Fractional exhaled nitric oxide levels in asthma-COPD overlap syndrome: analysis of the National Health and Nutrition Examination Survey, 2007-2012 SO INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE LA English DT Article DE COPD; asthma-COPD overlap syndrome; fractional exhaled nitric oxide ID OBSTRUCTIVE PULMONARY-DISEASE; US POPULATION; FEATURES AB Purpose: Recent studies propose T(H)2-mediated inflammation in patients with asthma-chronic obstructive pulmonary disease (COPD) overlap syndrome (ACOS). However, little is known about whether fractional exhaled nitric oxide (FeNO) differs between patients with ACOS and those with COPD alone. To address this knowledge gap, a nationally representative sample was analyzed to determine the difference in FeNO levels between patients with ACOS and those with COPD alone in the US population. Patients and methods: This is a cross-sectional analysis of the National Health and Nutrition Examination Survey from 2007 through 2012. All subjects aged >= 40 years with COPD were identified. ACOS was defined as self-reported wheezing in past 12 months plus bronchodilator response (forced expiratory volume increase of >200 mL and >12%) or self-reported physician diagnosis of asthma. Results: A total of 197 subjects with COPD were identified in the National Health and Nutrition Examination Survey. Of these, 23% met the criteria of ACOS. The FeNO level was higher in subjects with ACOS compared with those with COPD alone in both unadjusted (mean 21.2 ppb vs 13.0 ppb; difference, 8.2 [95% CI, 0.2 to 16.2]; P=0.045) and adjusted (difference, 8.2 [95% CI, 0.9 to 15.5]; P=0.03) analyses. Although there was no significant difference among current smokers, the FeNO level was significantly higher in non-current smokers with ACOS than nonsmokers with COPD alone (mean 31.9 ppb vs 20.3 ppb; adjusted difference, 20.5 [95% CI, 4.4 to 36.6]; P=0.02). In a sensitivity analysis using an alternative definition of ACOS, the results did not change materially. The diagnostic value of FeNO to discriminate ACOS from COPD alone was not sufficient, with the area under the curve of 0.63 (95% CI, 0.54 to 0.72). Conclusion: By using nationally representative US data, it was found that 23% of COPD subjects met the ACOS criteria and also that the FeNO level was higher in subjects with ACOS compared with those with COPD alone, particularly in non-current smokers. C1 [Goto, Tadahiro; Camargo, Carlos A., Jr.; Hasegawa, Kohei] Harvard Med Sch, Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA USA. RP Goto, T (reprint author), Massachusetts Gen Hosp, Dept Emergency Med, 125 Nashua St,Suite 920, Boston, MA 02114 USA. EM tgoto1@mgh.harvard.edu FU Agency for Healthcare Research and Quality (Rockville, MD, USA) [R01 HS023305]; St Luke's Life Science Institute; Uehara Kinen Memorial Foundation FX This study was supported by the grant R01 HS023305 from the Agency for Healthcare Research and Quality (Rockville, MD, USA). The content of this manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the Agency for Healthcare Research and Quality. Dr Goto was supported by a grant from St Luke's Life Science Institute and Uehara Kinen Memorial Foundation. The abstract of this paper was presented at the AJRCCM Conference on May 17, 2016, as a poster presentation. NR 18 TC 0 Z9 0 U1 0 U2 0 PU DOVE MEDICAL PRESS LTD PI ALBANY PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND SN 1178-2005 J9 INT J CHRONIC OBSTR JI Int. J. Chronic Obstr. Pulm. Dis. PY 2016 VL 11 BP 2149 EP 2155 DI 10.2147/COPD.S110879 PG 7 WC Respiratory System SC Respiratory System GA DV8LR UT WOS:000383189000001 PM 27660432 ER PT J AU Pickett, EK Koffie, RM Wegmann, S Henstridge, CM Herrmann, AG Colom-Cadena, M Lleo, A Kay, KR Vaught, M Soberman, R Walsh, DM Hyman, BT Spires-Jones, TL AF Pickett, Eleanor K. Koffie, Robert M. Wegmann, Susanne Henstridge, Christopher M. Herrmann, Abigail G. Colom-Cadena, Marti Lleo, Alberto Kay, Kevin R. Vaught, Melissa Soberman, Roy Walsh, Dominic M. Hyman, Bradley T. Spires-Jones, Tara L. TI Non-Fibrillar Oligomeric Amyloid-beta within Synapses SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Alzheimer's disease; amyloid-beta; array tomography; synapses ID ALZHEIMERS-DISEASE BRAIN; SOLUBLE A-BETA; MOUSE MODEL; PRION PROTEIN; FIBRILLAR OLIGOMERS; SIGNALING PATHWAY; NATURAL OLIGOMERS; ARRAY TOMOGRAPHY; TRANSGENIC MICE; INHIBITION AB Alzheimer's disease (AD) is characterized by memory loss, insidious cognitive decline, profound neurodegeneration, and the extracellular accumulation of amyloid-beta (A beta) peptide in senile plaques and intracellular accumulation of tau in neurofibrillary tangles. Loss and dysfunction of synapses are believed to underlie the devastating cognitive decline in AD. A large amount of evidence suggests that oligomeric forms of A beta associated with senile plaques are toxic to synapses, but the precise sub-synaptic localization of A beta and which forms are synaptotoxic remain unknown. Here, we characterize the sub-synaptic localization of A beta oligomers using three high-resolution imaging techniques, stochastic optical reconstruction microscopy, immunogold electron microscopy, and Forster resonance energy transfer in a plaque-bearing mouse model of AD. With all three techniques, we observe oligomeric A beta inside synaptic terminals. Further, we tested a panel of A beta antibodies using the relatively high-throughput array tomography technique to determine which forms are present in synapses. Our results show that different oligomeric A beta species are present in synapses and highlight the potential of array tomography for rapid testing of aggregation state specific A beta antibodies in brain tissue. C1 [Pickett, Eleanor K.; Henstridge, Christopher M.; Herrmann, Abigail G.; Spires-Jones, Tara L.] Univ Edinburgh, Ctr Cognit & Neural Syst, Ctr Dementia Prevent, Edinburgh, Midlothian, Scotland. [Pickett, Eleanor K.; Henstridge, Christopher M.; Herrmann, Abigail G.; Spires-Jones, Tara L.] Euan MacDonald Ctr Motor Neurone Dis Res, Edinburgh, Midlothian, Scotland. [Koffie, Robert M.; Wegmann, Susanne; Kay, Kevin R.; Vaught, Melissa; Soberman, Roy; Hyman, Bradley T.] Massachusetts Gen Hosp, Charlestown, MA USA. [Koffie, Robert M.; Wegmann, Susanne; Kay, Kevin R.; Vaught, Melissa; Soberman, Roy; Hyman, Bradley T.] Harvard Med Sch, Charlestown, MA USA. [Colom-Cadena, Marti; Lleo, Alberto] Univ Autonoma Barcelona, Hosp St Pau, Inst Invest Biomed St Pau, Dept Neurol, Barcelona, Spain. [Colom-Cadena, Marti; Lleo, Alberto] Ctr Invest Biomed Red Enfermedades Neurodegenerat, Madrid, Spain. [Walsh, Dominic M.] Brigham & Womens Hosp, Ctr Neurol Dis, Lab Neurodegenerat Res, Boston, MA 02115 USA. [Walsh, Dominic M.] Harvard Inst Med, Harvard Med Sch, Boston, MA 02115 USA. RP Spires-Jones, TL (reprint author), Ctr Cognit & Neural Syst, 1 George Sq, Edinburgh EH8 9JZ, Midlothian, Scotland. EM Tara.Spires-Jones@ed.ac.uk FU Alzheimer's Society; Alzheimer's Research UK; Scottish Government; University of Edinburgh Wellcome Trust ISSF; Instituto de Salud Carlos III [PI14/01561]; "Marato TV3" grants [20142610]; DMW from the National Institutes of Health [AG046275] FX Funding provided by Alzheimer's Society, Alzheimer's Research UK and the Scottish Government, a University of Edinburgh Wellcome Trust ISSF, Instituto de Salud Carlos III (PI14/01561), "Marato TV3" grants (20142610), and an anonymous foundation. This work was supported by grants to DMW from the National Institutes of Health (AG046275). We would like to thank Virginia Lee for providing NAB61 antibody, Charles Glabe for OC antibody, and Marian DiFiglia for access to the Philly Dake Electron Microscopy Core. NR 46 TC 0 Z9 0 U1 6 U2 6 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 EI 1875-8908 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2016 VL 53 IS 3 BP 787 EP 800 DI 10.3233/JAD-160007 PG 14 WC Neurosciences SC Neurosciences & Neurology GA DV7WE UT WOS:000383148100003 PM 27258414 ER PT J AU Hsu, DC Mormino, EC Schultz, AP Amariglio, RE Donovan, NJ Rentz, DM Johnson, KA Sperling, RA Marshall, GA AF Hsu, David C. Mormino, Elizabeth C. Schultz, Aaron P. Amariglio, Rebecca E. Donovan, Nancy J. Rentz, Dorene M. Johnson, Keith A. Sperling, Reisa A. Marshall, Gad A. CA Harvard Aging Brain Study TI Lower Late-Life Body-Mass Index is Associated with Higher Cortical Amyloid Burden in Clinically Normal Elderly SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Alzheimer's disease; amyloid; apolipoprotein E; body mass index; clinically normal elderly; Pittsburgh compound B; positron emission tomography ID ALZHEIMER-DISEASE BIOMARKERS; OLDER-ADULTS; WEIGHT-LOSS; COGNITIVE IMPAIRMENT; NORMAL INDIVIDUALS; INCIDENT DEMENTIA; BRAIN PATHOLOGY; RISK; OBESITY; DECLINE AB Background: Lower body-mass index (BMI) in late life has been associated with an increased risk of dementia, and weight loss has been associated with more rapid decline in Alzheimer's disease (AD) dementia. Objective: To explore the association between BMI and cortical amyloid burden in clinically normal (CN) elderly at risk for AD dementia. Methods: Cross-sectional analyses were completed using baseline data from the Harvard Aging Brain Study, consisting of 280 community-dwelling CN older adults aged 62-90. Assessments included medical histories and physical exam, Pittsburgh compound B (PiB) positron emission tomography (PET) amyloid imaging, and apolipoprotein E epsilon 4 (APOE4) genotyping. For the primary analysis, a general linear regression model was used to evaluate the association of BMI with PiB retention. Covariates included age, sex, years of education, and APOE4 carrier status. Secondary analyses were performed for BMI subdivisions (normal, overweight, obese), APOE4 carriers, and BMIxAPOE4 interaction. Results: In the primary analysis, greater PiB retention was associated with lower BMI (beta = -0.14, p = 0.02). In the secondary analyses, APOE4 carrier status (beta = -0.27, p = 0.02) and normal BMI (beta = -0.25, p = 0.01), as opposed to overweight or obese BMI, were associated with greater PiB retention. The BMIxAPOE4 interaction was also significant (beta = -0.14, p = 0.04). Conclusions: This finding offers new insight into the role of BMI at the preclinical stage of AD, wherein lower BMI late in life is associated with greater cortical amyloid burden. Future studies are needed to elucidate the mechanism behind this association, especially in those with lower BMI who are APOE4 carriers. C1 [Hsu, David C.; Donovan, Nancy J.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Psychiat, Boston, MA USA. [Mormino, Elizabeth C.; Schultz, Aaron P.; Amariglio, Rebecca E.; Rentz, Dorene M.; Johnson, Keith A.; Sperling, Reisa A.; Marshall, Gad A.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Neurol, Boston, MA USA. [Johnson, Keith A.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Radiol, Boston, MA USA. [Hsu, David C.; Amariglio, Rebecca E.; Donovan, Nancy J.; Rentz, Dorene M.; Johnson, Keith A.; Sperling, Reisa A.; Marshall, Gad A.] Harvard Med Sch, Brigham & Womens Hosp, Ctr Alzheimer Res & Treatment, Dept Neurol, Boston, MA USA. [Donovan, Nancy J.; Rentz, Dorene M.] Harvard Med Sch, Brigham & Womens Hosp, Dept Psychiat, Boston, MA USA. [Hsu, David C.] Mercy Med Grp, Dept Psychiat, Sacramento, CA USA. RP Marshall, GA (reprint author), Brigham & Womens Hosp, Ctr Alzheimer Res & Treatment, 221 Longwood Ave,BL-104H, Boston, MA 02115 USA. EM gamarshall@partners.org FU Harvard Aging Brain Study [NIH/NIA P01 AG036694, R01 AG037497, R01 AG046396]; Massachusetts Alzheimer's Disease Research Center [P50AG005134]; [K23 AG033634]; [K24 AG035007] FX This study was supported by the Harvard Aging Brain Study (NIH/NIA P01 AG036694, R01 AG037497, and R01 AG046396), K23 AG033634, K24 AG035007, and the Massachusetts Alzheimer's Disease Research Center (P50AG005134). The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript. NR 44 TC 0 Z9 0 U1 0 U2 0 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 EI 1875-8908 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2016 VL 53 IS 3 BP 1097 EP 1105 DI 10.3233/JAD-150987 PG 9 WC Neurosciences SC Neurosciences & Neurology GA DV7WE UT WOS:000383148100026 PM 27340843 ER PT J AU Wilker, EH Martinez-Ramirez, S Kloog, I Schwartz, J Mostofsky, E Koutrakis, P Mittleman, MA Viswanathan, A AF Wilker, Elissa H. Martinez-Ramirez, Sergi Kloog, Itai Schwartz, Joel Mostofsky, Elizabeth Koutrakis, Petros Mittleman, Murray A. Viswanathan, Anand TI Fine Particulate Matter, Residential Proximity to Major Roads, and Markers of Small Vessel Disease in a Memory Study Population SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Air pollution; microbleeds; small vessel disease; white matter hyperintensities ID LONG-TERM EXPOSURE; CEREBRAL AMYLOID ANGIOPATHY; AEROSOL OPTICAL DEPTH; AMBIENT AIR-POLLUTION; COGNITIVE FUNCTION; PM2.5 EXPOSURES; BRAIN STRUCTURE; MICROBLEEDS; ATHEROSCLEROSIS; ASSOCIATION AB Background: Long-term exposure to ambient air pollution has been associated with impaired cognitive function and vascular disease in older adults, but little is known about these associations among people with concerns about memory loss. Objective: To examine associations between exposures to fine particulate matter and residential proximity to major roads and markers of small vessel disease. Methods: From 2004-2010, 236 participants in the Massachusetts Alzheimer's Disease Research Center Longitudinal Cohort participated in neuroimaging studies. Residential proximity to major roads and estimated 2003 residential annual average of fine particulate air pollution (PM2.5) were linked to measures of brain parenchymal fraction (BPF), white matter hyperintensities (WMH), and cerebral microbleeds. Associations were modeled using linear and logistic regression and adjusted for clinical and lifestyle factors. Results: In this population (median age [interquartile range] = 74 [ 12], 57% female) living in a region with median 2003 PM2.5 annual average below the current Environmental Protection Agency (EPA) standard, there were no associations between living closer to a major roadway or for a 2 mu g/m(3) increment in PM2.5 and smaller BPF, greater WMH volume, or a higher odds of microbleeds. However, a 2 mu g/m(3) increment in PM2.5 was associated with -0.19 (95% Confidence Interval (CI): -0.37, -0.005) lower natural log-transformed WMH volume. Other associations had wide confidence intervals. Conclusions: In this population, where median 2003 estimated PM2.5 levels were below the current EPA standard, we observed no pattern of association between residential proximity to major roads or 2003 average PM2.5 and greater burden of small vessel disease or neurodegeneration. C1 [Wilker, Elissa H.; Mostofsky, Elizabeth; Mittleman, Murray A.] Beth Israel Deaconess Med Ctr, Div Cardiovasc, 330 Brookline Ave, Boston, MA 02215 USA. [Wilker, Elissa H.; Schwartz, Joel; Mostofsky, Elizabeth; Mittleman, Murray A.] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA. [Wilker, Elissa H.; Schwartz, Joel; Koutrakis, Petros; Mittleman, Murray A.] Harvard TH Chan Sch Publ Hlth, Dept Environm Hlth, Boston, MA USA. [Martinez-Ramirez, Sergi; Viswanathan, Anand] Massachusetts Gen Hosp, Dept Neurol, Hemorrhag Stroke Res Grp, Boston, MA 02114 USA. [Kloog, Itai] Ben Gurion Univ Negev, Dept Geog & Environm Dev, Beer Sheva, Israel. RP Wilker, EH (reprint author), Beth Israel Deaconess Med Ctr, W-MS 443,375 Longwood Ave, Boston, MA 02215 USA. EM ewilker@bidmc.harvard.edu FU NIH [UL1TR000170, K99ES022243, KL2 TR001100]; NIA grant [5P50AG005134]; USEPA [RD-83479801] FX This publication was made possible by NIH grants UL1TR000170, K99ES022243, KL2 TR001100 NIA grant 5P50AG005134, USEPA grant RD-83479801. Its contents are solely the responsibility of the grantee and do not necessarily represent the official views of the USEPA. Further, USEPA does not endorse the purchase of any commercial products or services mentioned in the publication. NR 47 TC 1 Z9 1 U1 2 U2 2 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 EI 1875-8908 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2016 VL 53 IS 4 BP 1315 EP 1323 DI 10.3233/JAD-151143 PG 9 WC Neurosciences SC Neurosciences & Neurology GA DV7WT UT WOS:000383149600007 PM 27372639 ER PT J AU Ronquillo, JG Baer, MR Lester, WT AF Ronquillo, Jay Geronimo Baer, Merritt Rachel Lester, William T. TI Sex-specific patterns and differences in dementia and Alzheimer's disease using informatics approaches SO JOURNAL OF WOMEN & AGING LA English DT Article DE Alzheimer's disease; biomedical informatics; data analytics; dementia; sex and gender ID BIG-DATA; HEALTH-CARE; PREDICTION; RECORDS; FUTURE; GENDER; MODEL; NIH AB The National Institutes of Health Office of Research on Women's Health recently highlighted the critical need for explicitly addressing sex differences in biomedical research, including Alzheimer's disease and dementia. The purpose of our study was to perform a sex-stratified analysis of cognitive impairment using diverse medical, clinical, and genetic factors of unprecedented scale and scope by applying informatics approaches to three large Alzheimer's databases. Analyses suggested females were 1.5 times more likely than males to have a documented diagnosis of probable Alzheimer's disease, and several other factors fell along sex-specific lines and were possibly associated with severity of cognitive impairment. C1 [Ronquillo, Jay Geronimo; Baer, Merritt Rachel] Grinformatics, 5501 Merchants View Sq 190, Haymarket, VA 20169 USA. [Lester, William T.] Massachusetts Gen Hosp, Lab Comp Sci, Boston, MA 02114 USA. [Lester, William T.] Harvard Med Sch, Boston, MA USA. RP Ronquillo, JG (reprint author), Grinformatics, 5501 Merchants View Sq 190, Haymarket, VA 20169 USA. EM jgr@grinformatics.com FU NIA [U01 AG016976, P30 AG019610, P30 AG013846, P50 AG008702, P50 AG025688, P30 AG010133, P50 AG005146, P50 AG005134, P50 AG016574, P50 AG005138, P30 AG008051]; NIH [U01 AG024904, P30 AG010129, K01 AG030514]; NIBIB; Abbott; Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Amorfix Life Sciences Ltd.; AstraZeneca; Bayer HealthCare; BioClinica, Inc.; Biogen Idec Inc.; Bristol-Myers Squibb Company; Eisai Inc.; Elan Pharmaceuticals Inc.; Eli Lilly and Company; F. Hoffmann-La Roche Ltd; Genentech, Inc.; GE Healthcare; Innogenetics; N.V.; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC; Medpace, Inc.; Merck Co., Inc.; Meso Scale Diagnostics, LLC; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Servier; Synarc Inc.; Takeda Pharmaceutical Company; Canadian Institutes of Health Research; NIA/NIH [U01 AG016976]; National Institute of Aging [P30 AG010129, P30 AG013854, P30 AG008017, P30 AG010161, P50 AG016573, P50 AG016570, P50 AG005131, P50 AG023501, P30 AG035982, P30 AG028383, P30 AG010124, P50 AG005133, P50 AG005142, P30 AG012300, P50 AG005136, P50 AG033514, P50 AG005681] FX The NACC database was funded by NIA Grant U01 AG016976. The ADNI database was funded by NIH Grant U01 AG024904.; ADNI is funded by the NIA, NIBIB, and through generous contributions from the following: Abbott; Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Amorfix Life Sciences Ltd.; AstraZeneca; Bayer HealthCare; BioClinica, Inc.; Biogen Idec Inc.; Bristol-Myers Squibb Company; Eisai Inc.; Elan Pharmaceuticals Inc.; Eli Lilly and Company; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; GE Healthcare; Innogenetics, N.V.; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC; Medpace, Inc.; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Servier; Synarc Inc.; and Takeda Pharmaceutical Company. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of California, Los Angeles. This research was also supported by NIH grants P30 AG010129 and K01 AG030514.; The NACC database is funded by NIA/NIH Grant U01 AG016976. NACC data are contributed by the NIA-funded ADCs: P30 AG019610 (PI Eric Reiman, MD), P30 AG013846 (PI Neil Kowall, MD), P50 AG008702 (PI Scott Small, MD), P50 AG025688 (PI Allan Levey, MD, PhD), P30 AG010133 (PI Andrew Saykin, PsyD), P50 AG005146 (PI Marilyn Albert, PhD), P50 AG005134 (PI Bradley Hyman, MD, PhD), P50 AG016574 (PI Ronald Petersen, MD, PhD), P50 AG005138 (PI Mary Sano, PhD), P30 AG008051 (PI Steven Ferris, PhD), P30 AG013854 (PI M. Marsel Mesulam, MD), P30 AG008017 (PI Jeffrey Kaye, MD), P30 AG010161 (PI David Bennett, MD), P30 AG010129 (PI Charles DeCarli, MD), P50 AG016573 (PI Frank LaFerla, PhD), P50 AG016570 (PI David Teplow, PhD), P50 AG005131 (PI Douglas Galasko, MD), P50 AG023501 (PI Bruce Miller, MD), P30 AG035982 (PI Russell Swerdlow, MD), P30 AG028383 (PI Linda Van Eldik, PhD), P30 AG010124 (PI John Trojanowski, MD, PhD), P50 AG005133 (PI Oscar L~pez, MD), P50 AG005142 (PI Helena Chui, MD), P30 AG012300 (PI Roger Rosenberg, MD), P50 AG005136 (PI Thomas Montine, MD, PhD), P50 AG033514 (PI Sanjay Asthana, MD, FRCP), and P50 AG005681 (PI John Morris, MD). NR 30 TC 1 Z9 1 U1 4 U2 4 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 0895-2841 EI 1540-7322 J9 J WOMEN AGING JI J. Women Aging PY 2016 VL 28 IS 5 BP 403 EP 411 DI 10.1080/08952841.2015.1018038 PG 9 WC Gerontology; Women's Studies SC Geriatrics & Gerontology; Women's Studies GA DT6FN UT WOS:000381579200007 PM 27105335 ER PT J AU Shukla, C Basheer, R AF Shukla, Charu Basheer, Radhika TI Metabolic signals in sleep regulation: recent insights SO NATURE AND SCIENCE OF SLEEP LA English DT Review DE sleep; energy balance; hypothalamus; metabolism; homeostasis ID BROWN ADIPOSE-TISSUE; OREXIN-KNOCKOUT MICE; MELANIN-CONCENTRATING HORMONE; LATERAL HYPOTHALAMIC AREA; FOOD-INTAKE; HYPOCRETIN OREXIN; ENERGY-BALANCE; CIRCADIAN MISALIGNMENT; SYMPATHETIC ACTIVITY; GHRELIN LEVELS AB Sleep and energy balance are essential for health. The two processes act in concert to regulate central and peripheral homeostasis. During sleep, energy is conserved due to suspended activity, movement, and sensory responses, and is redirected to restore and replenish proteins and their assemblies into cellular structures. During wakefulness, various energy-demanding activities lead to hunger. Thus, hunger promotes arousal, and subsequent feeding, followed by satiety that promotes sleep via changes in neuroendocrine or neuropeptide signals. These signals overlap with circuits of sleep-wakefulness, feeding, and energy expenditure. Here, we will briefly review the literature that describes the interplay between the circadian system, sleep-wake, and feeding-fasting cycles that are needed to maintain energy balance and a healthy metabolic profile. In doing so, we describe the neuroendocrine, hormonal/peptide signals that integrate sleep and feeding behavior with energy metabolism. C1 [Shukla, Charu; Basheer, Radhika] Harvard Med Sch, VA Boston Healthcare Syst, Dept Psychiat, 1400 VFW Pkwy, West Roxbury, MA 02132 USA. RP Basheer, R (reprint author), Harvard Med Sch, VA Boston Healthcare Syst, Dept Psychiat, 1400 VFW Pkwy, West Roxbury, MA 02132 USA. EM radhika_basheer@hms.harvard.edu FU BLRD VA [I01 BX001404]; NIMH NIH HHS [R01 MH039683]; NINDS NIH HHS [R21 NS079866] NR 163 TC 2 Z9 3 U1 3 U2 3 PU DOVE MEDICAL PRESS LTD PI ALBANY PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND SN 1179-1608 J9 NAT SCI SLEEP JI NAT. SCI. SLEEP PY 2016 VL 8 BP 9 EP 20 DI 10.2147/NSS.S62365 PG 12 WC Clinical Neurology SC Neurosciences & Neurology GA DU3TZ UT WOS:000382136400002 PM 26793010 ER PT J AU Brown, K Poppe, A Kaminetzky, CP Wipf, JA Woods, NF AF Brown, Kameka Poppe, Anne Kaminetzky, Catherine P. Wipf, Joyce A. Woods, Nancy Fugate TI Reflections of the Veterans Administration Puget Sound Health Care System Regional Nurse Practitioner Residency Forum SO NURSING FORUM LA English DT Article DE Education; interprofessional education; professional issue; workforce ID EDUCATION AB PROBLEM. There is a proliferation of advanced practice residency programs. However, there is no uniform model of developing and evaluating program success. METHODS. An information forum was convened by Veterans Health Administration Puget Sound Health Care System's Center for Primary Care Education on September 17, 2013, in Seattle, Washington, to explore critical aspects of residency models. The three objectives of this forum were to develop a shared understanding of key elements needed to support nurse practitioner residencies; define the unique needs of nurse practitioner trainees who are interested in applying for a residency; and examine the viability of designing a replicable nurse practitioner residency model benchmarking stakeholder best practices. FINDINGS. This article describes the organization of the forum and summarizes the presentations during the program. The companion article explores key recommendations from the forum related to future development of residency "toolkits" to aid in future evaluation and accreditation. CONCLUSION. As nurse practitioner residencies continue to develop and evolve, more is needed in the area of structure and alignment. C1 [Brown, Kameka] VA Northern Calif Hlth Care Syst, Primary Care Serv, Seattle, WA USA. [Brown, Kameka; Woods, Nancy Fugate] Univ Washington, Sch Nursing, Seattle, WA 98195 USA. [Poppe, Anne; Wipf, Joyce A.] VA Puget Sound Hlth Care Syst, Ctr Excellence Primary Care Educ, 1660 S Columbian Way S-123-COE, Seattle, WA 98108 USA. [Kaminetzky, Catherine P.] VA Puget Sound Hlth Care Syst, Educ, Seattle, WA USA. [Kaminetzky, Catherine P.; Wipf, Joyce A.] Univ Washington, Sch Med, Seattle, WA USA. RP Brown, K (reprint author), VA Puget Sound Hlth Care Syst, Ctr Excellence Primary Care Educ, 1660 S Columbian Way S-123-COE, Seattle, WA 98108 USA. EM kameka.brown@va.gov NR 14 TC 2 Z9 2 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0029-6473 EI 1744-6198 J9 NURS FORUM JI Nurs. Forum PD JAN-MAR PY 2016 VL 51 IS 1 BP 70 EP 76 DI 10.1111/nuf.12127 PG 7 WC Nursing SC Nursing GA DU4GX UT WOS:000382172000009 PM 25737307 ER PT J AU Ebrahimiadib, N Roohipour, R Karkhaneh, R Farahani, A Esfahani, MR Khodabande, A Zarei, M Taheri, A Fouladi, MI Yaseri, M Modjtahedi, BS AF Ebrahimiadib, Nazanin Roohipour, Ramak Karkhaneh, Reza Farahani, Afsar Esfahani, Mohammad Riazi Khodabande, Alireza Zarei, Mohammad Taheri, Arash Fouladi, Marjan Imani Yaseri, Mehdi Modjtahedi, Bobeck S. TI Internet-based versus Conventional Referral System for Retinopathy of Prematurity Screening in Iran SO OPHTHALMIC EPIDEMIOLOGY LA English DT Article DE Internet-based; Iran; referral; retinopathy of prematurity; screening ID RISK-FACTORS; INFANTS; POPULATION; BABIES AB Purpose: To compare the efficacy of an internet-based versus traditional referral system for retinopathy of prematurity (ROP) screening in Iran. Methods: Two referral screening systems were compared in this prospective observational study. Group A (internet-based) comprised premature babies who were registered into an online system for screening. Their appointments were scheduled automatically based on standardized criteria. Group B (conventional) comprised premature babies whose referrals were based on oral or written recommendations. Babies were referred based on standard criteria (gestational age, GA, <37 weeks or birth weight < 3000 g). Results: A total of 2115 neonates were screened between October 2011 and October 2012. From these 1896 met the inclusion criteria (group A n = 856, group B n = 1040). Time of first examination for neonates with GA27 weeks was 30.07 +/- 2.72 weeks postmenstrual age in group A and 3 8.52 +/- 7.03 weeks in group B (p = 0.049), and for neonates with GA>27 weeks was 4.86 +/- 1.77 and 8.16 +/- 4.93 weeks after birth in groups A and B, respectively (p < 0.001). All registered babies in group A attended their first screening exam. One case (0.1%) of advanced ROP developed in group A (in a patient with poor follow-up compliance), whereas advanced stages of ROP were seen in 26 cases (2.5%) in group B (p < 0.001). Conclusion: An internet-based registration system for ROP screening resulted in fewer cases of delayed first examination and resulted in fewer babies with advanced ROP. C1 [Ebrahimiadib, Nazanin; Modjtahedi, Bobeck S.] Harvard Med Sch, Dept Ophthalmol, Retina Serv, Massachusetts Eye & Ear Infirm, Boston, MA USA. [Roohipour, Ramak; Karkhaneh, Reza; Farahani, Afsar; Esfahani, Mohammad Riazi; Khodabande, Alireza; Zarei, Mohammad; Taheri, Arash; Fouladi, Marjan Imani] Univ Tehran Med Sci, Farabi Eye Hosp, Eye Res Ctr, Qazvin Sq,South Kargar St, Tehran 1336616351, Iran. [Yaseri, Mehdi] Univ Tehran Med Sci, Dept Epidemiol & Biostat, Tehran, Iran. RP Roohipour, R (reprint author), Univ Tehran Med Sci, Farabi Eye Hosp, Eye Res Ctr, Qazvin Sq,South Kargar St, Tehran 1336616351, Iran. EM ramakroohipour@yahoo.com OI Khodabande, Alireza/0000-0002-3957-7515; Yaseri, Mehdi/0000-0002-4066-873X; Taheri, Arash/0000-0003-4068-7575 NR 24 TC 0 Z9 0 U1 1 U2 1 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 0928-6586 EI 1744-5086 J9 OPHTHAL EPIDEMIOL JI Ophthalmic Epidemiol. PY 2016 VL 23 IS 5 BP 292 EP 297 DI 10.3109/09286586.2015.1136653 PG 6 WC Ophthalmology SC Ophthalmology GA DV5FN UT WOS:000382952200003 PM 27267654 ER PT J AU Reddy, AT Lakshmi, SP Reddy, RC AF Reddy, Aravind T. Lakshmi, Sowmya P. Reddy, Raju C. TI PPAR gamma as a Novel Therapeutic Target in Lung Cancer SO PPAR RESEARCH LA English DT Review ID ACTIVATED-RECEPTOR-GAMMA; EPITHELIAL-MESENCHYMAL TRANSITION; NITRATED FATTY-ACIDS; CELL-GROWTH; TUMOR PROGRESSION; CARCINOMA-CELLS; PULMONARY-FIBROSIS; GENE-EXPRESSION; COLON-CANCER; LIGANDS AB Lung cancer is the leading cause of cancer-related death, with more than half the patients having advanced-stage disease at the time of initial diagnosis and thus facing a poor prognosis. This dire situation poses a need for new approaches in prevention and treatment. Peroxisome proliferator-activated receptor gamma (PPAR gamma) is a ligand-activated transcription factor belonging to the nuclear hormone receptor superfamily. Its involvement in adipocyte differentiation and glucose and lipid homeostasis is well-recognized, but accumulating evidence now suggests that PPAR gamma may also function as a tumor suppressor, inhibiting development of primary tumors and metastases in lung cancer and other malignancies. Besides having prodifferentiation, antiproliferative, and proapoptotic effects, PPAR gamma agonists have been shown to prevent cancer cells from acquiring the migratory and invasive capabilities essential for successful metastasis. Angiogenesis and secretion of certain matrix metalloproteinases and extracellular matrix proteins within the tumor microenvironment are also regulated by PPAR gamma. This review of the current literature highlights the potential of PPAR gamma agonists as novel therapeutic modalities in lung cancer, either as monotherapy or in combination with standard cytotoxic chemotherapy. C1 [Reddy, Aravind T.; Lakshmi, Sowmya P.; Reddy, Raju C.] Univ Pittsburgh, Sch Med, Dept Med, Div Pulm Allergy & Crit Care Med, Pittsburgh, PA 15213 USA. [Reddy, Aravind T.; Lakshmi, Sowmya P.; Reddy, Raju C.] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA. RP Reddy, RC (reprint author), Univ Pittsburgh, Sch Med, Dept Med, Div Pulm Allergy & Crit Care Med, Pittsburgh, PA 15213 USA.; Reddy, RC (reprint author), Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA. EM reddyrc@upmc.edu FU U.S. Department of Veterans Affairs; National Institutes of Health [HL093196, AI125338] FX This work was supported by a Merit Review award from the U.S. Department of Veterans Affairs and National Institutes of Health grants HL093196 and AI125338 (to Raju C. Reddy). NR 63 TC 0 Z9 0 U1 1 U2 1 PU HINDAWI PUBLISHING CORP PI NEW YORK PA 315 MADISON AVE 3RD FLR, STE 3070, NEW YORK, NY 10017 USA SN 1687-4757 EI 1687-4765 J9 PPAR RES JI PPAR Res. PY 2016 AR 8972570 DI 10.1155/2016/8972570 PG 7 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA DW2MV UT WOS:000383477400001 ER PT J AU Falk, MJ Gai, XW Shigematsu, M Vilardo, E Takase, R McCormick, E Christian, T Place, E Pierce, EA Consugar, M Gamper, HB Rossmanith, W Hou, YM AF Falk, Marni J. Gai, Xiaowu Shigematsu, Megumi Vilardo, Elisa Takase, Ryuichi McCormick, Elizabeth Christian, Thomas Place, Emily Pierce, Eric A. Consugar, Mark Gamper, Howard B. Rossmanith, Walter Hou, Ya-Ming TI A novel HSD17B10 mutation impairing the activities of the mitochondrial RNase P complex causes X-linked intractable epilepsy and neurodevelopmental regression SO RNA BIOLOGY LA English DT Article DE HSD10 disease; PRORP; SDR5C1; 17 beta-hydroxysteroid dehydrogenase type 10; TRMT10C ID COENZYME-A DEHYDROGENASE; MENTAL-RETARDATION; 3-HYDROXYACYL-COA DEHYDROGENASE; FUNCTIONAL ASSIGNMENTS; ALCOHOL-DEHYDROGENASE; ISOLEUCINE METABOLISM; ABNORMAL-BEHAVIOR; INBORN-ERRORS; HSD10 DISEASE; DEFICIENCY AB We report a Caucasian boy with intractable epilepsy and global developmental delay. Whole-exome sequencing identified the likely genetic etiology as a novel p.K212E mutation in the X-linked gene HSD17B10 for mitochondrial short-chain dehydrogenase/reductase SDR5C1. Mutations in HSD17B10 cause the HSD10 disease, traditionally classified as a metabolic disorder due to the role of SDR5C1 in fatty and amino acid metabolism. However, SDR5C1 is also an essential subunit of human mitochondrial RNase P, the enzyme responsible for 50-processing and methylation of purine-9 of mitochondrial tRNAs. Here we show that the p.K212E mutation impairs the SDR5C1-dependent mitochondrial RNase P activities, and suggest that the pathogenicity of p.K212E is due to a general mitochondrial dysfunction caused by reduction in SDR5C1-dependent maturation of mitochondrial tRNAs. C1 [Falk, Marni J.; McCormick, Elizabeth; Place, Emily] Childrens Hosp Philadelphia, Dept Pediat, Div Human Genet, Philadelphia, PA 19104 USA. [Falk, Marni J.] Univ Penn, Dept Pediat, Perelman Sch Med, Philadelphia, PA 19104 USA. [Gai, Xiaowu] Childrens Hosp Los Angeles, Ctr Personalized Med, Los Angeles, CA 90027 USA. [Shigematsu, Megumi; Takase, Ryuichi; Christian, Thomas; Gamper, Howard B.; Hou, Ya-Ming] Thomas Jefferson Univ, Dept Biochem & Mol Biol, Philadelphia, PA 19107 USA. [Vilardo, Elisa; Rossmanith, Walter] Med Univ Vienna, Ctr Anat & Cell Biol, Vienna, Austria. [Place, Emily; Pierce, Eric A.; Consugar, Mark] Harvard Med Sch, Massachusetts Eye & Ear Infirm, Boston, MA USA. RP Falk, MJ (reprint author), Childrens Hosp Philadelphia, Dept Pediat, Div Human Genet, Philadelphia, PA 19104 USA.; Falk, MJ (reprint author), Univ Penn, Dept Pediat, Perelman Sch Med, Philadelphia, PA 19104 USA.; Hou, YM (reprint author), Thomas Jefferson Univ, Dept Biochem & Mol Biol, Philadelphia, PA 19107 USA. EM falkm@email.chop.edu; ya-ming.hou@jefferson.edu OI Hou, Ya-Ming/0000-0001-6546-2597; Rossmanith, Walter/0000-0003-2337-2248; Pierce, Eric/0000-0002-2354-4102 FU National Institutes of Health [U01-GM108972, R01-GM114343, R03-DK082446, R01-EY012910, P30EY014104-MEEI]; Austrian Science Fund (FWF) [P25983] FX We thank the patienet's family for their participation and Dr. Isao Masuda for his helpful discussion. This work was funded in part by the National Institutes of Health (U01-GM108972 and R01-GM114343 to Y.M.H., R03-DK082446 to M.J.F., R01-EY012910 to E.A.P., and P30EY014104-MEEI core support), and by the Austrian Science Fund (FWF) [P25983] to W.R. The content is solely the responsibility of the authors, and does not necessarily represent the official views of the sponsors, and is not influenced by the sponsors. NR 51 TC 0 Z9 0 U1 0 U2 0 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 1547-6286 EI 1555-8584 J9 RNA BIOL JI RNA Biol. PY 2016 VL 13 IS 5 BP 477 EP 485 DI 10.1080/15476286.2016.1159381 PG 9 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA DV5HJ UT WOS:000382957600002 PM 26950678 ER PT J AU Katz, LS Park, SE Cojucar, G Huffman, C Douglas, S AF Katz, Lori S. Park, Sam E. Cojucar, Geta Huffman, Cristi Douglas, Sarah TI Improved Attachment Style for Female Veterans Who Graduated Warrior Renew Sexual Trauma Treatment SO VIOLENCE AND VICTIMS LA English DT Article DE sexual trauma; women veterans; military sexual trauma; holographic reprocessing ID POSTTRAUMATIC-STRESS-DISORDER; INTIMATE PARTNER VIOLENCE; WOMEN VETERANS; MENTAL-HEALTH; PSYCHOTHERAPY/; ADULTS; ABUSE; PTSD AB The Warrior Renew sexual trauma treatment program proposes to target perceived attachment style and the internal working models of interpersonal relationships. This study examined scores on the Relationships Scales Questionnaire and Brief Symptom Inventory pre- and post-treatment in a sample of 62 female veterans who graduated the program. Findings revealed that graduates of Warrior Renew reported significant decreases in fearful and dismissive insecure attachment and significant increases in secure attachment. Scores were significantly correlated with symptoms. Findings lend support to an upward spiral hypothesis associated with long-term positive outcomes found in previous research on Warrior Renew. C1 [Katz, Lori S.] Univ Southern Calif, VA Puget Sound Hlth Care Syst, Los Angeles, CA USA. [Park, Sam E.; Cojucar, Geta; Huffman, Cristi; Douglas, Sarah] VA Long Beach Healthcare Syst, Long Beach, CA USA. RP Katz, LS (reprint author), VA Puget Sound Hlth Care Syst, 9600 Vet Dr SW, Tacoma, WA 98493 USA. EM Lorikmail@yahoo.com NR 41 TC 1 Z9 1 U1 2 U2 2 PU SPRINGER PUBLISHING CO PI NEW YORK PA 11 WEST 42ND STREET, NEW YORK, NY 10036 USA SN 0886-6708 EI 1945-7073 J9 VIOLENCE VICTIMS JI Violence Vict. PY 2016 VL 31 IS 4 BP 680 EP 691 DI 10.1891/0886-6708.VV-D-14-00182 PG 12 WC Criminology & Penology SC Criminology & Penology GA DV7PJ UT WOS:000383128300006 PM 27302913 ER PT J AU Dorner, SC Camargo, CA Schuur, JD Raja, AS AF Dorner, Stephen C. Camargo, Carlos A., Jr. Schuur, Jeremiah D. Raja, Ali S. TI Access to In-Network Emergency Physicians and Emergency Departments Within Federally Qualified Health Plans in 2015 SO WESTERN JOURNAL OF EMERGENCY MEDICINE LA English DT Article DE Health Policy; Health Reform; Insurance; Emergency Medicine AB Introduction: Under regulations established by the Affordable Care Act, insurance plans must meet minimum standards in order to be sold through the federal Marketplace. These standards to become a qualified health plan (QHP) include maintaining a provider network sufficient to assure access to services. However, the complexity of emergency physician (EP) employment practices - in which the EPs frequently serve as independent contractors of emergency departments, independently establish insurance contracts, etc. - and regulations governing insurance repayment may hinder the application of network adequacy standards to emergency medicine. As such, we hypothesized the existence of QHPs without in-network access to EPs. The objective is to identify whether there are QHPs without in-network access to EPs using information available through the federal Marketplace and publicly available provider directories. Results: In a national sample of Marketplace plans, we found that one in five provider networks lacks identifiable in-network EPs. QHPs lacking EPs spanned nearly half (44%) of the 34 states using the federal Marketplace. Conclusion: Our data suggest that the present regulatory framework governing network adequacy is not generalizable to emergency care, representing a missed opportunity to protect patient access to in-network physicians. These findings and the current regulations governing insurance payment to EPs dis-incentivize the creation of adequate physician networks, incentivize the practice of balance billing, and shift the cost burden to patients. C1 [Dorner, Stephen C.] Vanderbilt Univ, Sch Med, Dept Emergency Med, Nashville, TN 37212 USA. [Dorner, Stephen C.] Harvard TH Chan Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA USA. [Camargo, Carlos A., Jr.; Raja, Ali S.] Massachusetts Gen Hosp, Dept Emergency Med, 55 Fruit St, Boston, MA 02114 USA. [Schuur, Jeremiah D.] Harvard Med Sch, Brigham & Womens Hosp, Dept Emergency Med, Boston, MA USA. RP Dorner, SC (reprint author), Massachusetts Gen Hosp, Dept Emergency Med, 55 Fruit St, Boston, MA 02114 USA. EM stephen.dorner@post.harvard.edu NR 9 TC 1 Z9 1 U1 2 U2 2 PU WESTJEM PI ORANGE PA C/O SHAHRAM LOTFIPOUR, MD, MPH, 333 CITY BLVD W STE 640, RT 128-01, ORANGE, CA 92868 USA SN 1936-900X EI 1936-9018 J9 WEST J EMERG MED JI West. J. Emerg. Med. PD JAN PY 2016 VL 17 IS 1 BP 18 EP 21 DI 10.5811/westjem.2015.12.29188 PG 4 WC Emergency Medicine SC Emergency Medicine GA DV3PX UT WOS:000382836400004 PM 26823925 ER PT J AU Hasegawa, K Stoll, SJ Ahn, J Kysia, RF Sullivan, AF Camargo, CA AF Hasegawa, Kohei Stoll, Samantha J. Ahn, Jason Kysia, Rashid F. Sullivan, Ashley F. Camargo, Carlos A., Jr. TI Association of Insurance Status with Severity and Management in ED Patients with Asthma Exacerbation SO WESTERN JOURNAL OF EMERGENCY MEDICINE LA English DT Article DE Acute asthma; Insurance; Disparity; Public Health; Race; Management; Severity ID EMERGENCY-DEPARTMENT PATIENTS; CARE; QUALITY; ADULTS; CHILDREN; HOSPITALIZATION; DISPARITIES; RISK AB Introduction: Previous studies have demonstrated an association of low socioeconomic status with frequent asthma exacerbations. However, there have been no recent multicenter efforts to examine the relationship of insurance status - a proxy for socioeconomic status - with asthma severity and management in adults. The objective is to investigate chronic and acute asthma management disparities by insurance status among adults requiring emergency department (ED) treatment in the United States. Methods: We conducted a multicenter chart review study (48 EDs in 23 U.S. states) on ED patients, aged 18-54 years, with acute asthma between 2011 and 2012. Each site underwent training (lecture, practice charts, certification) before reviewing randomly selected charts. We categorized patients into three groups based on their primary health insurance: private, public, and no insurance. Outcome measures were chronic asthma severity (as measured by >= 2 ED visits in one-year period) and management prior to the index ED visit, acute asthma management in the ED, and prescription at ED discharge. Results: The analytic cohort comprised 1,928 ED patients with acute asthma. Among these, 33% had private insurance, 40% had public insurance, and 27% had no insurance. Compared to patients with private insurance, those with public insurance or no insurance were more likely to have >= 2 ED visits during the preceding year (35%, 49%, and 45%, respectively; p< 0.001). Despite the higher chronic severity, those with no insurance were less likely to have guideline-recommended chronic asthma care -i.e., lower use of inhaled corticosteroids (ICS [41%, 41%, and 29%; p< 0.001]) and asthma specialist care (9%, 10%, and 4%; p< 0.001). By contrast, there were no significant differences in acute asthma management in the ED -e.g., use of systemic corticosteroids (75%, 79%, and 78%; p=0.08) or initiation of ICS at ED discharge (12%, 12%, and 14%; p=0.57) - by insurance status. Conclusion: In this multicenter observational study of ED patients with acute asthma, we found significant discrepancies in chronic asthma severity and management by insurance status. By contrast, there were no differences in acute asthma management among the insurance groups. C1 [Hasegawa, Kohei; Ahn, Jason; Sullivan, Ashley F.; Camargo, Carlos A., Jr.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA. [Stoll, Samantha J.] North Shore Med Ctr, Dept Emergency Med, Salem, MA USA. [Kysia, Rashid F.] John H Stroger Jr Hosp Cook Cty, Dept Emergency Med, Chicago, IL USA. RP Hasegawa, K (reprint author), 125 Nashua St,Suite 920, Boston, MA 02446 USA. EM khasegawa1@partners.org NR 26 TC 1 Z9 1 U1 1 U2 1 PU WESTJEM PI ORANGE PA C/O SHAHRAM LOTFIPOUR, MD, MPH, 333 CITY BLVD W STE 640, RT 128-01, ORANGE, CA 92868 USA SN 1936-900X EI 1936-9018 J9 WEST J EMERG MED JI West. J. Emerg. Med. PD JAN PY 2016 VL 17 IS 1 BP 22 EP 27 DI 10.5811/westjem.2015.11.28715 PG 6 WC Emergency Medicine SC Emergency Medicine GA DV3PX UT WOS:000382836400005 PM 26823926 ER PT J AU Rafael, A Mela, T Milan, DJ AF Rafael, Allon Mela, Theofanie Milan, David J. TI Mitral Valve Prolapse and Sudden Cardiac Death Risk SO CARDIOLOGY LA English DT Meeting Abstract C1 [Rafael, Allon; Mela, Theofanie; Milan, David J.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0008-6312 EI 1421-9751 J9 CARDIOLOGY JI Cardiology PY 2016 VL 134 IS 2 BP 273 EP 274 PG 2 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DL6UB UT WOS:000375773900268 ER PT J AU Lynn, DD Umari, T Dunnick, CA Dellavalle, RP AF Lynn, Darren D. Umari, Tamara Dunnick, Cory A. Dellavalle, Robert P. TI The epidemiology of acne vulgaris in late adolescence SO ADOLESCENT HEALTH MEDICINE AND THERAPEUTICS LA English DT Review DE review; epidemiology; GBD; hormones; diet ID GLYCEMIC-LOAD DIET; GROWTH-FACTOR-I; ORAL-CONTRACEPTIVES; AFRICAN-AMERICAN; RETINOID THERAPY; IMPROVE OUTCOMES; CONTROLLED-TRIAL; GLOBAL ALLIANCE; FEMALE-PATIENTS; HIGH-SCHOOL AB Importance: Acne vulgaris is the most common skin condition affecting late adolescents across the globe. Although prior studies have evaluated epidemiologic patterns of acne vulgaris in various ethnicities and regions, adequate understanding of the worldwide burden of the disease associated with patients in their late adolescence (15-19-year olds) remains lacking. Objective: To assess the global burden of the disease associated with acne vulgaris for late adolescents (15-19-year olds) and provide an overview of the epidemiology, pathophysiology, and treatment options for acne in this population. Design: Database summary study. Setting: Global Burden of Disease Study 2010 database. Participants: Global Burden of Disease regions comprised countries with prevalence of acne vulgaris between the ages of 15 and 19 years. Main outcomes and measures: Geographic region-level disability-adjusted life year rates (per 100,000 persons) associated with acne vulgaris in years 1990 through 2010. Median percentage change in disability-adjusted life year rates was estimated for each region across the specified study period. Conclusion and relevance: Acne vulgaris-associated disease burden exhibits global distribution and has continued to grow in prevalence over time within this population. This continued growth suggests an unmet dermatologic need worldwide for this disorder and potential opportunities for improved access and delivery of dermatologic care. Our analysis of the literature reveals numerous opportunities for enhanced patient care. To that end, we highlight some of the effective and promising treatments currently available and address important factors, such as sex, nationality, genetics, pathophysiology, and diet, as they relate to acne vulgaris in late adolescence. C1 [Lynn, Darren D.; Umari, Tamara] Univ Colorado, Sch Med, Dept Dermatol, Aurora, CO USA. [Dunnick, Cory A.; Dellavalle, Robert P.] Univ Colorado, Dept Dermatol, Anschutz Med Campus, Aurora, CO USA. [Dunnick, Cory A.; Dellavalle, Robert P.] US Dept Vet Affairs, Eastern Colorado Hlth Care Syst, Dermatol Serv, Denver, CO USA. [Dellavalle, Robert P.] Univ Colorado, Colorado Sch Publ Hlth, Dept Epidemiol, Anschutz Med Campus, Aurora, CO USA. RP Dellavalle, RP (reprint author), US Dept Vet Affairs, Med Ctr, Dermatol Serv, 1055 Clermont St,Box 165, Denver, CO 80220 USA. EM robert.dellavalle@ucdenver.edu NR 97 TC 5 Z9 5 U1 4 U2 5 PU DOVE MEDICAL PRESS LTD PI ALBANY PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND SN 1179-318X J9 ADOLESC HEALTH MED T JI ADOLESC. HEALTH MED. THER. PY 2016 VL 7 BP 13 EP 25 DI 10.2147/AHMT.S55832 PG 13 WC Pediatrics SC Pediatrics GA DU4UD UT WOS:000382207200001 PM 26955297 ER PT J AU Eneanya, ND Wenger, JB Waite, K Crittenden, S Hazar, DB Volandes, A Temel, JS Thadhani, R Paasche-Orlow, MK AF Eneanya, Nwamaka D. Wenger, Julia B. Waite, Katherine Crittenden, Stanley Hazar, Derya B. Volandes, Angelo Temel, Jennifer S. Thadhani, Ravi Paasche-Orlow, Michael K. TI Racial Disparities in End-of-Life Communication and Preferences among Chronic Kidney Disease Patients SO AMERICAN JOURNAL OF NEPHROLOGY LA English DT Article DE Racial disparities; End-of-life; Chronic kidney disease ID HOSPITAL CARDIOPULMONARY-RESUSCITATION; RANDOMIZED CONTROLLED-TRIAL; DIALYSIS PATIENTS; ELDERLY-PATIENTS; MAINTENANCE DIALYSIS; TREATMENT INTENSITY; CARE PREFERENCES; OLDER-ADULTS; OUTCOMES; PERSPECTIVES AB Background: Previous studies on end-of-life (EOL) care among patients with chronic kidney disease (CKD) have been largely limited to White hemodialysis patients. In this study, we sought to explore racial variability in EOL communication, care preferences and advance care planning (ACP) among patients with advanced CKD prior to decisions regarding the initiation of dialysis. Methods: We performed a cross-sectional study between 2013 and 2015 of Black and White patients with stage IV or V CKD (per the Modified Diet in Renal Disease estimation of GFR < 30 ml/min/1.73 m(2)) from 2 academic centers in Boston. We assessed experiences with EOL communication, ACP, EOL care preferences, hospice knowledge, spiritual/religious and cultural beliefs, and distrust of providers. Results: Among 152 participants, 41% were Black. Black patients were younger, had less education, and lower income than White patients (all p < 0.01). Black patients also had less knowledge of hospice compared to White patients (17 vs. 61%, p < 0.01). A small fraction of patients (8%) reported having EOL discussions with their nephrologists and the majority had no advance directives. In multivariable analyses, Blacks were more likely to have not communicated EOL preferences (adjusted OR 2.70, 95% CI 1.08-6.76) and more likely to prefer life-extending treatments (adjusted OR 3.06, 95% CI 1.23-7.60) versus Whites. Conclusions: As Black and White patients with advanced CKD differ in areas of EOL communication, preferences, and hospice knowledge, future efforts should aim to improve patient understanding and promote informed decision-making. (C) 2016 S. Karger AG, Basel C1 [Eneanya, Nwamaka D.; Wenger, Julia B.; Hazar, Derya B.; Thadhani, Ravi] Harvard Med Sch, Massachusetts Gen Hosp, Dept Internal Med, Div Nephrol, Boston, MA USA. [Volandes, Angelo] Harvard Med Sch, Massachusetts Gen Hosp, Dept Internal Med, Div Gen Med, Boston, MA USA. [Temel, Jennifer S.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Internal Med, Div Hematol & Oncol, Boston, MA USA. [Waite, Katherine; Paasche-Orlow, Michael K.] Boston Univ, Sch Med, Boston Med Ctr, Gen Internal Med Sect, Boston, MA 02118 USA. [Crittenden, Stanley] Boston Univ, Sch Med, Boston Med Ctr, Div Nephrol, Boston, MA 02118 USA. RP Eneanya, ND (reprint author), Dept Internal Med, Div Nephrol, 165 Cambridge St,Suite 302, Boston, MA 02114 USA. EM Aeneanya@partners.org FU American Society of Nephrology Foundation; National Institute of Diabetes and Digestive and Kidney Diseases [K24-DK094872] FX We thank Sarah M. Doughtery for her assistance with patient recruitment and data entry. This study was supported by a grant from the American Society of Nephrology Foundation for Kidney Research Ben J. Lipps Research Fellowship Program (PI - Eneanya) and a mentorship grant from the National Institute of Diabetes and Digestive and Kidney Diseases K24-DK094872 (PI - Thadhani). NR 43 TC 0 Z9 0 U1 2 U2 2 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0250-8095 EI 1421-9670 J9 AM J NEPHROL JI Am. J. Nephrol. PY 2016 VL 44 IS 1 BP 46 EP 53 DI 10.1159/000447097 PG 8 WC Urology & Nephrology SC Urology & Nephrology GA DV2EI UT WOS:000382733200007 PM 27351650 ER PT J AU Guillemette, L Allard, C Lacroix, M Patenaude, J Battista, MC Doyon, M Moreau, J Menard, J Bouchard, L Ardilouze, JL Perron, P Hivert, MF AF Guillemette, Laetitia Allard, Catherine Lacroix, Marilyn Patenaude, Julie Battista, Marie-Claude Doyon, Myriam Moreau, Julie Menard, Julie Bouchard, Luigi Ardilouze, Jean-Luc Perron, Patrice Hivert, Marie-France TI Genetics of Glucose regulation in Gestation and Growth (Gen3G): a prospective prebirth cohort of mother-child pairs in Sherbrooke, Canada SO BMJ OPEN LA English DT Article ID INSULIN-RESISTANCE; DIABETES-MELLITUS; VITAMIN-D; TNF-ALPHA; HUMAN-PREGNANCY; 1ST TRIMESTER; HIGHER RISK; WOMEN; ASSOCIATION; SENSITIVITY AB Purpose: We initiated the Genetics of Glucose regulation in Gestation and Growth (Gen3G) prospective cohort to increase our understanding of biological, environmental and genetic determinants of glucose regulation during pregnancy and their impact on fetal development. Participants: Between January 2010 and June 2013, we invited pregnant women aged >= 18 years old who visited the blood sampling in pregnancy clinic in Sherbrooke for their first trimester clinical blood samples: 1034 women accepted to participate in our cohort study. Findings to date: At first and second trimester, we collected demographics and lifestyle questionnaires, anthropometry measures (including fat and lean mass estimated using bioimpedance), blood pressure, and blood samples. At second trimester, women completed a full 75 g oral glucose tolerance test and we collected additional blood samples. At delivery, we collected cord blood and placenta samples; obstetrical and neonatal clinical data were abstracted from electronic medical records. We also collected buffy coats and extracted DNA from maternal and/or offspring samples (placenta and blood cells) to pursue genetic and epigenetic hypotheses. So far, we have found that low adiponectin and low vitamin D maternal levels in first trimester predict higher risk of developing gestational diabetes. Future plans: We are now in the phase of prospective follow-up of mothers and offspring 3 and 5 years postdelivery to investigate the consequences of maternal dysglycaemia during pregnancy on offspring adiposity and metabolic profile. C1 [Guillemette, Laetitia; Lacroix, Marilyn; Patenaude, Julie; Battista, Marie-Claude; Ardilouze, Jean-Luc; Perron, Patrice; Hivert, Marie-France] Univ Sherbrooke, Fac Med & Life Sci, Dept Med, Sherbrooke, PQ, Canada. [Allard, Catherine] Univ Sherbrooke, Fac Sci, Dept Math, Sherbrooke, PQ, Canada. [Doyon, Myriam; Moreau, Julie; Menard, Julie; Bouchard, Luigi; Ardilouze, Jean-Luc; Perron, Patrice; Hivert, Marie-France] CHU Sherbrooke, Ctr Rech, Sherbrooke, PQ, Canada. [Bouchard, Luigi] Univ Sherbrooke, Fac Med & Life Sci, Dept Biochem, Sherbrooke, PQ, Canada. [Bouchard, Luigi] Chicoutimi Hosp, ECOGENE 21, Saguenay, PQ, Canada. [Bouchard, Luigi] Chicoutimi Hosp, Lipid Clin, Saguenay, PQ, Canada. [Hivert, Marie-France] Harvard Med Sch, Harvard Pilgrim Hlth Care Inst, Dept Populat Med, Boston, MA USA. [Hivert, Marie-France] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Hivert, MF (reprint author), Univ Sherbrooke, Fac Med & Life Sci, Dept Med, Sherbrooke, PQ, Canada.; Hivert, MF (reprint author), CHU Sherbrooke, Ctr Rech, Sherbrooke, PQ, Canada.; Hivert, MF (reprint author), Harvard Med Sch, Harvard Pilgrim Hlth Care Inst, Dept Populat Med, Boston, MA USA.; Hivert, MF (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. EM marie-france_hivert@harvardpilgrim.org FU Fonds de recherche du Quebec en sante (FRQ-S) [20697]; Canadian Institute of Health Reseach (CIHR) [MOP 115071]; Diabete Quebec grant; Canadian Diabetes Association [OG-3-08-2622-JA]; FRQ-S; Canadian Diabetes Association; Maud Menten Award from CIHR-Institute of Genetics; Diabete Quebec internship awards; CIHR Master's training award [299295]; FRQ-S [27029, 27113, 29033, 27499] FX This work was supported by a Fonds de recherche du Quebec en sante (FRQ-S) operating grant (to M-FH, grant #20697); a Canadian Institute of Health Reseach (CIHR) Operating grant (to M-FH grant #MOP 115071); a Diabete Quebec grant (to PP) and a Canadian Diabetes Association operating grant (to J-LA, grant #OG-3-08-2622-JA). LB is a junior research scholar from the FRQ-S and a member of the FRQ-S-funded Centre de recherche du CHUS. M-FH was a FRQ-S Junior 1 research scholar and received a Clinical Scientist Award by the Canadian Diabetes Association and the Maud Menten Award from the CIHR-Institute of Genetics. J-LA is a FRQ-S Junior 2 research scholar. Analyses were supported by Diabete Quebec internship awards (to LG, ML, JP), CIHR Master's training award (#299295 to CA), and FRQ-S Master's (#27029 to LG; #27113 to CA; #29033 to JP) and Doctoral training award (#27499 to ML). NR 31 TC 4 Z9 4 U1 2 U2 2 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 2044-6055 J9 BMJ OPEN JI BMJ Open PY 2016 VL 6 IS 2 DI 10.1136/bmjopen-2015-010031 PG 13 WC Medicine, General & Internal SC General & Internal Medicine GA DT5HX UT WOS:000381514500083 ER PT J AU Nakanishi, N Goto, T Ikeda, T Kasai, A AF Nakanishi, Nobuto Goto, Tadahiro Ikeda, Tomoya Kasai, Atsunobu TI Does T wave inversion in lead aVL predict mid-segment left anterior descending lesions in acute coronary syndrome? A retrospective study SO BMJ OPEN LA English DT Article ID ACUTE MYOCARDIAL-INFARCTION; RECIPROCAL CHANGES; ST-SEGMENT; ELECTROCARDIOGRAM; CARDIOLOGY; ELEVATION; DIAGNOSIS AB Objectives: Limited data are available regarding the predictive value of electrocardiographic T wave inversion in lead aVL for mid-segment left anterior descending (MLAD) lesions among patients with acute coronary syndrome (ACS). Setting: Retrospective single-centre study, using a prospectively-collected coronary angiography database from January 2012 to December 2013. Participants: We included consecutive adult patients with ACS who underwent urgent percutaneous coronary intervention (PCI) within 24 h after arriving at the hospital. We excluded patients who did not undergo an ECG before PCI, patients with proximal MLAD occlusion and patients diagnosed with vasospastic angina. Primary and secondary outcome measures: The primary outcome was MLAD lesion >50%. The other outcome of interest was MLAD lesion as a cause of ACS. First, we evaluated the diagnostic values of T wave inversion in lead aVL regardless of other T wave changes for each outcome. Second, we evaluated the diagnostic values of isolated T wave inversion in lead aVL. Results: Overall, 219 patients were eligible for the analysis. T wave inversion in lead aVL regardless of other T wave changes had a sensitivity of 32.9%, specificity of 48.2%, positive predictive value of 27.6% and negative predictive value of 54.5% for predicting MLAD lesions. Isolated T wave inversion in lead aVL had a sensitivity of 9.8%, specificity of 86.9%, positive predictive value of 30.8% and negative predictive value of 61.7% for predicting MLAD lesions. These diagnostic values did not change materially when focusing on patients with MLAD lesion as the cause. Conclusions: While T wave inversion in lead aVL regardless of other T wave changes had low diagnostic values for predicting MLAD lesions, isolated T wave inversion in lead aVL had a high specificity. Our inferences underscore the importance of a cautious interpretation of T wave inversion in lead aVL among patients with ACS. C1 [Nakanishi, Nobuto; Ikeda, Tomoya; Kasai, Atsunobu] Ise Red Cross Hosp, Dept Cardiol, Ise, Mie, Japan. [Goto, Tadahiro] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA. RP Nakanishi, N (reprint author), Ise Red Cross Hosp, Dept Cardiol, Ise, Mie, Japan. EM nobuto_nakanishi@ise.jrc.or.jp NR 14 TC 0 Z9 0 U1 0 U2 0 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 2044-6055 J9 BMJ OPEN JI BMJ Open PY 2016 VL 6 IS 2 AR e010268 DI 10.1136/bmjopen-2015-010268 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA DT5HX UT WOS:000381514500110 PM 26832434 ER PT J AU Tramontano, AC Sheehan, DF McMahon, PM Dowling, EC Holford, TR Ryczak, K Lesko, SM Levy, DT Kong, CY AF Tramontano, Angela C. Sheehan, Deirdre F. McMahon, Pamela M. Dowling, Emily C. Holford, Theodore R. Ryczak, Karen Lesko, Samuel M. Levy, David T. Kong, Chung Yin TI Evaluating the impacts of screening and smoking cessation programmes on lung cancer in a high-burden region of the USA: a simulation modelling study SO BMJ OPEN LA English DT Article ID UNITED-STATES; TOBACCO USE; MORTALITY; POLICIES; TRIAL AB Objective: While the US Preventive Services Task Force has issued recommendations for lung cancer screening, its effectiveness at reducing lung cancer burden may vary at local levels due to regional variations in smoking behaviour. Our objective was to use an existing model to determine the impacts of lung cancer screening alone or in addition to increased smoking cessation in a US region with a relatively high smoking prevalence and lung cancer incidence. Setting: Computer-based simulation model. Participants: Simulated population of individuals 55 and older based on smoking prevalence and census data from Northeast Pennsylvania. Interventions: Hypothetical lung cancer control from 2014 to 2050 through (1) screening with CT, (2) intensified smoking cessation or (3) a combination strategy. Primary and secondary outcome measures: Primary outcomes were lung cancer mortality rates. Secondary outcomes included number of people eligible for screening and number of radiation-induced lung cancers. Results: Combining lung cancer screening with increased smoking cessation would yield an estimated 8.1% reduction in cumulative lung cancer mortality by 2050. Our model estimated that the number of screening-eligible individuals would progressively decrease over time, indicating declining benefit of a screening-only programme. Lung cancer screening achieved a greater mortality reduction in earlier years, but was later surpassed by smoking cessation. Conclusions: Combining smoking cessation programmes with lung cancer screening would provide the most benefit to a population, especially considering the growing proportion of patients ineligible for screening based on current recommendations. C1 [Tramontano, Angela C.; Sheehan, Deirdre F.; McMahon, Pamela M.; Dowling, Emily C.; Kong, Chung Yin] Massachusetts Gen Hosp, Inst Technol Assessment, Boston, MA 02114 USA. [McMahon, Pamela M.; Kong, Chung Yin] Harvard Med Sch, Boston, MA 02115 USA. [Holford, Theodore R.] Yale Univ, Sch Publ Hlth, Dept Biostat, New Haven, CT USA. [Ryczak, Karen; Lesko, Samuel M.] Northeast Reg Canc Inst, Scranton, PA USA. [Levy, David T.] Georgetown Univ, Lombardi Comprehens Canc Ctr, Washington, DC USA. RP Kong, CY (reprint author), Massachusetts Gen Hosp, Inst Technol Assessment, Boston, MA 02114 USA.; Kong, CY (reprint author), Harvard Med Sch, Boston, MA 02115 USA. EM joey@mgh-ita.org FU National Cancer Institute, National Institutes of Health [U01CA152956, K25CA133141]; Centers for Disease Control and Prevention FX This work was supported by the National Cancer Institute, National Institutes of Health grants to the CISNET Lung group (U01CA152956) and to CYK (K25CA133141) and funding from the Centers for Disease Control and Prevention. NR 31 TC 1 Z9 1 U1 2 U2 2 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 2044-6055 J9 BMJ OPEN JI BMJ Open PY 2016 VL 6 IS 2 DI 10.1136/bmjopen-2015-010227 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA DT5HX UT WOS:000381514500104 ER PT J AU Eliades, P Miller, DM Miao, BC Kumar, R Taylor, M Buch, S Srinivasa, SP Flaherty, KT Tsao, H AF Eliades, Philip Miller, David M. Miao, Benchun Kumar, Raj Taylor, Michael Buch, Shama Srinivasa, Sreesha P. Flaherty, Keith T. Tsao, Hensin TI A novel multi-CDK inhibitor P1446A-05 restricts melanoma growth and produces synergistic effects in combination with MAPK pathway inhibitors SO CANCER BIOLOGY & THERAPY LA English DT Article DE Cell cycle; MAPK pathways; melanoma; multi-CDK inhibitor; synergy ID CYCLIN-DEPENDENT KINASES; CELL-CYCLE; ANTAGONISM; TARGETS; CANCER; LINES AB Nearly 100% of melanomas have a defect in the p16(INK4A):cyclin D-CDK4/6:RB pathway, leading to abnormal cell cycle control and unregulated cellular proliferation. Here, we report that P1446A-05, a novel multi-CDK inhibitor has significant inhibitory activity against cutaneous and uveal melanoma. Mechanistic studies revealed that P1446A-05 inhibits phosphorylation targets of CDK members, and induces cell cycle arrest and apoptosis irrespective of melanoma genotype or phenotype. Additionally, we show preclinical evidence that P1446A-05 can synergize with other small molecule inhibitors previously studied in melanoma. Collectively, these data demonstrate that targeting cell cycle and transcriptional CDKs with a small molecule multi-CDK inhibitor is a viable approach for developing novel anti-melanoma therapeutics. C1 [Eliades, Philip; Miller, David M.; Miao, Benchun; Kumar, Raj; Taylor, Michael; Tsao, Hensin] Harvard Med Sch, Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02115 USA. [Eliades, Philip; Miller, David M.; Miao, Benchun; Kumar, Raj; Taylor, Michael; Tsao, Hensin] Harvard Med Sch, Massachusetts Gen Hosp, Dept Dermatol, Boston, MA 02115 USA. [Eliades, Philip] Tufts Univ, Sch Med, Boston, MA 02111 USA. [Miller, David M.] Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA. [Buch, Shama; Srinivasa, Sreesha P.] Piramal Enterprises Ltd, Bombay, Maharashtra, India. [Flaherty, Keith T.] Harvard Med Sch, Massachusetts Gen Hosp, Div Hematol Oncol, Canc Ctr, Boston, MA USA. RP Tsao, H (reprint author), Harvard Med Sch, Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02115 USA.; Tsao, H (reprint author), Harvard Med Sch, Massachusetts Gen Hosp, Dept Dermatol, Boston, MA 02115 USA. EM HTSAO@mgh.harvard.edu NR 25 TC 0 Z9 0 U1 1 U2 1 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 1538-4047 EI 1555-8576 J9 CANCER BIOL THER JI Cancer Biol. Ther. PY 2016 VL 17 IS 7 BP 778 EP 784 DI 10.1080/15384047.2016.1139267 PG 7 WC Oncology SC Oncology GA DT2IW UT WOS:000381305000011 PM 26810603 ER PT J AU Rotstein, BH Liang, SH Placzek, MS Hooker, JM Gee, AD Dolle, F Wilson, AA Vasdev, N AF Rotstein, Benjamin H. Liang, Steven H. Placzek, Michael S. Hooker, Jacob M. Gee, Antony D. Dolle, Frederic Wilson, Alan A. Vasdev, Neil TI C-11 = O bonds made easily for positron emission tomography radiopharmaceuticals SO CHEMICAL SOCIETY REVIEWS LA English DT Review ID ACID AMIDE HYDROLASE; KAPPA-OPIOID RECEPTOR; MONOAMINE-OXIDASE-B; IN-VIVO EVALUATION; PRELIMINARY SCINTIGRAPHIC EVALUATION; CHEMOTHERAPEUTIC AGENT BCNU; CAPTIVE SOLVENT METHOD; HIGH-AFFINITY STATE; FATTY-ACID; HUMAN-BRAIN AB The positron-emitting radionuclide carbon-11 (C-11, t(1/2) = 20.3 min) possesses the unique potential for radiolabeling of any biological, naturally occurring, or synthetic organic molecule for in vivo positron emission tomography (PET) imaging. Carbon-11 is most often incorporated into small molecules by methylation of alcohol, thiol, amine or carboxylic acid precursors using [C-11] methyl iodide or [C-11] methyl triflate (generated from [C-11] carbon dioxide or [C-11]methane). Consequently, small molecules that lack an easily substituted C-11-methyl group are often considered to have non-obvious strategies for radiolabeling and require a more customized approach. [C-11] Carbon dioxide itself, [C-11] carbon monoxide, [C-11] cyanide, and [C-11] phosgene represent alternative reactants to enable C-11-carbonylation. Methodologies developed for preparation of C-11-carbonyl groups have had a tremendous impact on the development of novel PET tracers and provided key tools for clinical research. C-11-Carbonyl radiopharmaceuticals based on labeled carboxylic acids, amides, carbamates and ureas now account for a substantial number of important imaging agents that have seen translation to higher species and clinical research of previously inaccessible targets, which is a testament to the creativity, utility and practicality of the underlying radiochemistry. C1 [Rotstein, Benjamin H.; Liang, Steven H.; Vasdev, Neil] Massachusetts Gen Hosp, Harvard Med Sch, Boston, MA 02114 USA. [Placzek, Michael S.; Hooker, Jacob M.] MGH, HMS, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA. [Placzek, Michael S.] McLean Hosp, Belmont, MA 02178 USA. [Gee, Antony D.] Kings Coll London, London, England. [Wilson, Alan A.] Univ Paris Saclay, CEA Inst Imagerie Biomed, Serv Hosp Frederic Joliot, Orsay, France. [Wilson, Alan A.] Ctr Addict & Mental Hlth, Toronto, ON, Canada. RP Vasdev, N (reprint author), Massachusetts Gen Hosp, Harvard Med Sch, Boston, MA 02114 USA. EM vasdev.neil@mgh.harvard.edu OI Rotstein, Benjamin/0000-0001-9707-9357 FU CEA-I2BM intramural programs; European Union's Seventh Framework Programme [FP7] INMiND [HEALTH-F2-2011-278850]; France Life Imaging [ANR-11-INBS-0006] FX Part of the work presented herein was supported by CEA-I2BM intramural programs, as well as the European Union's Seventh Framework Programme [FP7/2007-2013] INMiND (Grant agreement no HEALTH-F2-2011-278850) and France Life Imaging (Grant agreement no ANR-11-INBS-0006). NR 215 TC 5 Z9 5 U1 12 U2 12 PU ROYAL SOC CHEMISTRY PI CAMBRIDGE PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND SN 0306-0012 EI 1460-4744 J9 CHEM SOC REV JI Chem. Soc. Rev. PY 2016 VL 45 IS 17 BP 4708 EP 4726 DI 10.1039/c6cs00310a PG 19 WC Chemistry, Multidisciplinary SC Chemistry GA DU2EJ UT WOS:000382023500005 PM 27276357 ER PT J AU Baig, KRKK Wilcox, CM AF Baig, Kondal Rao Kyanam Kabir Wilcox, Charles Melbern TI Translational and clinical perspectives on sphincter of Oddi dysfunction SO CLINICAL AND EXPERIMENTAL GASTROENTEROLOGY LA English DT Review DE SOD; abdominal pain; pancreatitis; sphincter dysfunction; abnormal liver tests; biliary dilation ID ENDOSCOPIC SPHINCTEROTOMY; BOTULINUM TOXIN; SUSPECTED SPHINCTER; BILIARY PAIN; CHOLECYSTECTOMY; TRIAL; MANOMETRY; CHOLECYSTOKININ; MICROLITHIASIS; GALLBLADDER AB Sphincter of Oddi dysfunction is a complex pathophysiologic entity that is associated with significant morbidity causing abdominal pain, nausea, and vomiting. The purpose of this review is to describe the anatomy and physiology of the sphincter of Oddi, to understand the pathologic mechanisms thought to be responsible for symptomatology, review recent major studies, explore endoscopic and pharmacologic therapies and their efficacy, and to explore future research avenues. C1 [Wilcox, Charles Melbern] Univ Alabama Birmingham, Div Gastroenterol & Hepatol, 1720 Second Ave South,BDB 380, Birmingham, AL 35294 USA. Birmingham VA Med Ctr, Birmingham, AL USA. RP Wilcox, CM (reprint author), Univ Alabama Birmingham, Div Gastroenterol & Hepatol, 1720 Second Ave South,BDB 380, Birmingham, AL 35294 USA. EM melw@uab.edu NR 36 TC 0 Z9 0 U1 2 U2 2 PU DOVE MEDICAL PRESS LTD PI ALBANY PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND SN 1178-7023 J9 CLIN EXP GASTROENTER JI Clin. Exp. Gastroenterol. PY 2016 VL 9 BP 191 EP 195 DI 10.2147/CEG.S84018 PG 5 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DU6KP UT WOS:000382323800001 ER PT J AU Reddy, DN Yonekawa, Y Thomas, BJ Nudleman, ED Williams, GA AF Reddy, Devasis N. Yonekawa, Yoshihiro Thomas, Benjamin J. Nudleman, Eric D. Williams, George A. TI Long-term surgical outcomes of retinal detachment in patients with Stickler syndrome SO CLINICAL OPHTHALMOLOGY LA English DT Article DE pediatric retina; proliferative vitreoretinopathy; retina; scleral buckle; vitrectomy; vitreoretinal surgery ID MOLECULAR-GENETICS; KEY AB Purpose: The aim of the study was to present the long-term anatomical and visual outcomes of retinal detachment repair in patients with Stickler syndrome. Patients and methods: This study is a retrospective, interventional, consecutive case series of patients with Stickler syndrome undergoing retinal reattachment surgery from 2009 to 2014 at the Associated Retinal Consultants, William Beaumont Hospital. Results: Sixteen eyes from 13 patients were identified. Patients underwent a mean of 3.1 surgical interventions (range: 1-13) with a mean postoperative follow-up of 94 months (range: 5-313 months). Twelve eyes (75%) developed proliferative vitreoretinopathy. Retinal reattachment was achieved in 100% of eyes, with ten eyes (63%) requiring silicone oil tamponade at final follow-up. Mean preoperative visual acuity (VA) was 20/914, which improved to 20/796 at final follow-up (P=0.81). There was a significant correlation between presenting and final VA (P<0.001), and patients with poorer presenting VA were more likely to require silicone oil tamponade at final follow-up (P=0.04). Conclusion: Repair of retinal detachment in patients with Stickler syndrome often requires multiple surgeries, and visual outcomes are variable. Presenting VA is significantly predictive of long-term VA outcomes. C1 [Reddy, Devasis N.; Yonekawa, Yoshihiro; Thomas, Benjamin J.; Williams, George A.] Oakland Univ, William Beaumont Sch Med, Rochester, MI 48063 USA. [Yonekawa, Yoshihiro; Thomas, Benjamin J.; Williams, George A.] William Beaumont Hosp, Associated Retinal Consultants, 3535 West Thirteen Mile Rd,Suite 344, Royal Oak, MI 48073 USA. [Yonekawa, Yoshihiro] Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA. [Yonekawa, Yoshihiro] Harvard Med Sch, Boston Childrens Hosp, Boston, MA USA. [Thomas, Benjamin J.] Florida Retina Inst, Jacksonville, FL USA. [Nudleman, Eric D.] Univ Calif San Diego, Sch Med, Shiley Eye Inst, San Diego, CA 92103 USA. RP Williams, GA (reprint author), William Beaumont Hosp, Associated Retinal Consultants, 3535 West Thirteen Mile Rd,Suite 344, Royal Oak, MI 48073 USA. EM george_williams@beaumont.org NR 11 TC 0 Z9 0 U1 0 U2 0 PU DOVE MEDICAL PRESS LTD PI ALBANY PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND SN 1177-5483 J9 CLIN OPHTHALMOL JI Clin. Ophthalmol. PY 2016 VL 10 BP 1531 EP 1534 DI 10.2147/OPTH.S111526 PG 4 WC Ophthalmology SC Ophthalmology GA DT6GR UT WOS:000381582700001 PM 27574392 ER PT J AU Fernandes, TL Felix, ECR Bessa, F Luna, NMS Sugimoto, D Greve, JMD Hernandez, AJ AF Fernandes, Tiago Lazzaretti Rodrigues Felix, Ellen Cristina Bessa, Felipe Luna, Natalia M. S. Sugimoto, Dai D'Andrea Greve, Julia Maria Hernandez, Arnaldo Jose TI Evaluation of static and dynamic balance in athletes with anterior cruciate ligament injury - A controlled study SO CLINICS LA English DT Article DE Anterior Cruciate Ligament; Postural Balance; Knee ID POSTURAL CONTROL; MUSCLE STRENGTH; ACL INJURY; FUNCTIONAL PERFORMANCE; RECONSTRUCTED KNEES; HOP PERFORMANCE; SINGLE; INDIVIDUALS; SWAY; INSTABILITY AB OBJECTIVES: Anterior cruciate ligament injury leads to adaptive responses to maintain postural control. However, there is no consensus regarding whether leg dominance also affects postural control in athletes with anterior cruciate ligament injury. The purpose of this study was to evaluate dynamic and static postural control among athletes with and without anterior cruciate ligament injury to the dominant leg. METHODS: Twenty-eight athletes, twenty-one males and seven females aged 15-45 years, were allocated to one of two groups: the anterior cruciate ligament injury group (26 +/- 3 years) or the control group without anterior cruciate ligament injury (25 +/- 6.5 years). All subjects performed one legged stance tests under eyes open and eyes closed conditions and squat and kick movement tests using a postural control protocol (AccuSway(Plus) force platform, Massachusetts). The center of pressure displacement and speed were measured by the force platform. In addition, the distance traveled on the single-leg hop test was assessed as an objective measure of function. RESULTS: Significantly greater mediolateral sway was found under the eyes closed condition (p=0.04) and during squat movement (p=0.01) in the anterior cruciate ligament injury group than in the control group. Analysis of the single-leg hop test results showed no difference between the groups (p=0.73). CONCLUSION: Athletes with anterior cruciate ligament injury had greater mediolateral displacement of the center of pressure toward the dominant leg under the eyes closed condition and during squat movement compared to control athletes. C1 [Fernandes, Tiago Lazzaretti; Rodrigues Felix, Ellen Cristina; Bessa, Felipe; Luna, Natalia M. S.; D'Andrea Greve, Julia Maria; Hernandez, Arnaldo Jose] Univ Sao Paulo, Fac Med, Inst Ortopedia & Traumatol, Grp Med Esporte FIFA, Sao Paulo, SP, Brazil. [Fernandes, Tiago Lazzaretti; Rodrigues Felix, Ellen Cristina; Bessa, Felipe; Luna, Natalia M. S.; D'Andrea Greve, Julia Maria; Hernandez, Arnaldo Jose] Univ Sao Paulo, Fac Med, Inst Ortopedia & Traumatol, Lab Cinesiol LEM, Sao Paulo, SP, Brazil. [Fernandes, Tiago Lazzaretti] Harvard Med Sch, Massachusetts Gen Hosp, Dept Orthoped Surg, Bioengn Lab, Boston, MA 02115 USA. [Sugimoto, Dai] Boston Childrens Hosp, Dept Orthoped, Div Sports Med, Boston, MA USA. [Sugimoto, Dai] Micheli Ctr Sports Injury Prevent, Waltham, MA USA. RP Fernandes, TL (reprint author), Univ Sao Paulo, Fac Med, Inst Ortopedia & Traumatol, Grp Med Esporte FIFA, Sao Paulo, SP, Brazil.; Fernandes, TL (reprint author), Univ Sao Paulo, Fac Med, Inst Ortopedia & Traumatol, Lab Cinesiol LEM, Sao Paulo, SP, Brazil.; Fernandes, TL (reprint author), Harvard Med Sch, Massachusetts Gen Hosp, Dept Orthoped Surg, Bioengn Lab, Boston, MA 02115 USA. EM tiago.lazzaretti@usp.br NR 27 TC 0 Z9 0 U1 9 U2 9 PU HOSPITAL CLINICAS, UNIV SAO PAULO PI SAO PAULO PA FAC MEDICINA, UNIV SAO PAULO, SAO PAULO, SP 00000, BRAZIL SN 1807-5932 EI 1980-5322 J9 CLINICS JI Clinics PY 2016 VL 71 IS 8 BP 425 EP 429 DI 10.6061/clinics/2016(08)03 PG 5 WC Medicine, General & Internal SC General & Internal Medicine GA DV4CK UT WOS:000382872200003 PM 27626471 ER PT J AU Galamb, O Kalmar, A Peterfia, B Csabai, I Bodor, A Ribli, D Krenacs, T Patai, AV Wichmann, B Bartak, BK Toth, K Valcz, G Spisak, S Tulassay, Z Molnar, B AF Galamb, Orsolya Kalmar, Alexandra Peterfia, Balint Csabai, Istvan Bodor, Andras Ribli, Dezso Krenacs, Tibor Patai, Arpad V. Wichmann, Barnabas Bartak, Barbara Kinga Toth, Kinga Valcz, Gabor Spisak, Sandor Tulassay, Zsolt Molnar, Bela TI Aberrant DNA methylation of WNT pathway genes in the development and progression of CIMP-negative colorectal cancer SO EPIGENETICS LA English DT Article DE Adenoma; -catenin mutation; APC; colorectal cancer; promoter and gene body methylation; gene expression; whole methylome analysis; WNT signaling pathway ID MESSENGER-RNA EXPRESSION; PROMOTER METHYLATION; SIGNALING PATHWAY; BODY METHYLATION; CELL-LINES; ADENOMA; HYPERMETHYLATION; SUPPRESSOR; PHENOTYPE; CARCINOGENESIS AB The WNT signaling pathway has an essential role in colorectal carcinogenesis and progression, which involves a cascade of genetic and epigenetic changes. We aimed to analyze DNA methylation affecting the WNT pathway genes in colorectal carcinogenesis in promoter and gene body regions using whole methylome analysis in 9 colorectal cancer, 15 adenoma, and 6 normal tumor adjacent tissue (NAT) samples by methyl capture sequencing. Functional methylation was confirmed on 5-aza-2-deoxycytidine-treated colorectal cancer cell line datasets. In parallel with the DNA methylation analysis, mutations of WNT pathway genes (APC, -catenin/CTNNB1) were analyzed by 454 sequencing on GS Junior platform. Most differentially methylated CpG sites were localized in gene body regions (95% of WNT pathway genes). In the promoter regions, 33 of the 160 analyzed WNT pathway genes were differentially methylated in colorectal cancer vs. normal, including hypermethylated AXIN2, CHP1, PRICKLE1, SFRP1, SFRP2, SOX17, and hypomethylated CACYBP, CTNNB1, MYC; 44 genes in adenoma vs. NAT; and 41 genes in colorectal cancer vs. adenoma comparisons. Hypermethylation of AXIN2, DKK1, VANGL1, and WNT5A gene promoters was higher, while those of SOX17, PRICKLE1, DAAM2, and MYC was lower in colon carcinoma compared to adenoma. Inverse correlation between expression and methylation was confirmed in 23 genes, including APC, CHP1, PRICKLE1, PSEN1, and SFRP1. Differential methylation affected both canonical and noncanonical WNT pathway genes in colorectal normal-adenoma-carcinoma sequence. Aberrant DNA methylation appears already in adenomas as an early event of colorectal carcinogenesis. C1 [Galamb, Orsolya; Wichmann, Barnabas; Valcz, Gabor; Tulassay, Zsolt; Molnar, Bela] Hungarian Acad Sci, Mol Med Res Grp, Budapest, Hungary. [Kalmar, Alexandra; Peterfia, Balint; Patai, Arpad V.; Bartak, Barbara Kinga; Toth, Kinga; Tulassay, Zsolt] Semmelweis Univ, Dept Internal Med 2, Univ Szentkiralyi Str 46, H-1088 Budapest, Hungary. [Csabai, Istvan; Bodor, Andras; Ribli, Dezso] Eotvos Lorand Univ, Dept Phys Complex Syst, Budapest, Hungary. [Krenacs, Tibor] Semmelweis Univ, Dept Pathol & Expt Canc Res 1, Budapest, Hungary. [Krenacs, Tibor] Semmelweis Univ, Tumor Progress Res Grp, Hungarian Acad Sci, Budapest, Hungary. [Spisak, Sandor] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. RP Galamb, O (reprint author), Semmelweis Univ, Dept Internal Med 2, Univ Szentkiralyi Str 46, H-1088 Budapest, Hungary. EM orsg1@yahoo.com OI Csabai, Istvan/0000-0001-9232-9898 FU National Research, Development and Innovation Office [KMR-12-1-2012-0216]; Hungarian Scientific Research Fund [OTKA-K111743] FX This study was supported by the National Research, Development and Innovation Office (KMR-12-1-2012-0216 grant) and the validation study by the Hungarian Scientific Research Fund (OTKA-K111743 grant). NR 65 TC 2 Z9 2 U1 5 U2 5 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 1559-2294 EI 1559-2308 J9 EPIGENETICS-US JI Epigenetics PY 2016 VL 11 IS 8 BP 588 EP 602 DI 10.1080/15592294.2016.1190894 PG 15 WC Biochemistry & Molecular Biology; Genetics & Heredity SC Biochemistry & Molecular Biology; Genetics & Heredity GA DU7GB UT WOS:000382380500004 PM 27245242 ER PT J AU Thordardottir, EB Valdimarsdottir, UA Hansdottir, I Hauksdottir, A Dyregrov, A Shipherd, JC Elklit, A Resnick, H Gudmundsdottir, B AF Thordardottir, Edda Bjork Valdimarsdottir, Unnur Anna Hansdottir, Ingunn Hauksdottir, Arna Dyregrov, Atle Shipherd, Jillian C. Elklit, Ask Resnick, Heidi Gudmundsdottir, Berglind TI Sixteen-year follow-up of childhood avalanche survivors SO EUROPEAN JOURNAL OF PSYCHOTRAUMATOLOGY LA English DT Article DE Children; disaster; avalanche; posttraumatic stress disorder; long-term follow-up ID POSTTRAUMATIC-STRESS-DISORDER; HURRICANE KATRINA; PTSD SYMPTOMS; RISK-FACTORS; DISASTER; CHILDREN; ADOLESCENTS; METAANALYSIS; EXPOSURE; EVENTS AB Background: Every year a substantial number of children are affected by natural disasters worldwide. However, data are scarce on long-term psychological impact of natural disasters on children's health. Identifying risk factors and outcomes associated with the long-term sequelae of posttraumatic stress disorder (PTSD) can provide a gateway to recovery as well as enhancement of preventive measures. Objective: Among childhood avalanche survivors, we aimed to investigate risk factors for PTSD symptoms and the relationship between socioeconomic status (SES) and PTSD symptoms in adulthood. Methods: Childhood survivors (aged 2-19 at the time of exposure) of two avalanches were identified through nationwide registers 16 years later. The Posttraumatic Diagnostic Scale was used to assess current PTSD symptoms. One-way ANOVA was used to explore PTSD symptoms by background and trauma-specific factors, as well as associations with current SES. Predictors of PTSD symptoms were examined by multivariable regression analysis. Results: Response rate was 66% (108/163). Results from univariate ANOVA analysis revealed that female sex was associated with PTSD symptoms (F = 5.96, p < 0.05). When adjusted for age and sex, PTSD symptoms were associated with lower education (F = 7.62, p < 0.001), poor financial status (F = 12.21, p < 0.001), and unemployment and/or disability (F = 3.04, p < 0.05). In a multivariable regression model, when adjusting for age and sex, lack of social support (t = 4.22, p < 0.001) and traumatic reactions of caregivers (t = 2.49, p < 0.05) in the aftermath of the disaster independently predicted PTSD 16 years post-trauma. Conclusions: Lingering PTSD symptoms after childhood exposure to a disaster may negatively influence socioeconomic development in adulthood. Strengthening children's support systems post-disaster may prevent the long-term sequelae of symptoms. C1 [Thordardottir, Edda Bjork; Valdimarsdottir, Unnur Anna; Hauksdottir, Arna] Univ Iceland, Sch Hlth Sci, Ctr Publ Hlth Sci, Fac Med, Reykjavik, Iceland. [Valdimarsdottir, Unnur Anna] Harvard Sch Publ Hlth, Dept Epidemiol, Boston, MA USA. [Valdimarsdottir, Unnur Anna] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden. [Hansdottir, Ingunn] Univ Iceland, Sch Hlth Sci, Fac Psychol, Reykjavik, Iceland. [Dyregrov, Atle] Ctr Crisis Psychol, Bergen, Norway. [Dyregrov, Atle] Univ Bergen, Fac Psychol, Dept Clin Psychol, Bergen, Norway. [Shipherd, Jillian C.] VA Boston Healthcare Syst, Natl Ctr PTSD, Boston, MA USA. [Shipherd, Jillian C.] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA. [Elklit, Ask] Univ Southern Denmark, Dept Psychol, Odense, Denmark. [Elklit, Ask] Univ Ulster, Dept Psychol, Derry, Londonderry, North Ireland. [Resnick, Heidi] Med Univ South Carolina, Dept Psychiat & Behav Sci, Charleston, SC USA. [Gudmundsdottir, Berglind] Landspitali, Mental Hlth Serv, Reykjavik, Iceland. [Gudmundsdottir, Berglind] Univ Iceland, Sch Hlth Sci, Fac Med, Reykjavik, Iceland. RP Thordardottir, EB (reprint author), Univ Iceland, Ctr Publ Hlth Sci, IS-101 Reykjavik, Iceland. EM eddat@hi.is FU University of Iceland Research Fund; Icelandic Research Fund for Graduate Students (Rannis); Landspitali University Hospital Research Fund; Nordic Centre of Excellence for Resilience and Societal Security (NORDRESS) -Nordic Societal Security Programme FX This study was funded by the University of Iceland Research Fund, the Icelandic Research Fund for Graduate Students (Rannis), the Landspitali University Hospital Research Fund, and the Nordic Centre of Excellence for Resilience and Societal Security (NORDRESS), which is funded by the Nordic Societal Security Programme. NR 46 TC 0 Z9 0 U1 4 U2 4 PU CO-ACTION PUBLISHING PI JARFALLA PA RIPVAGEN 7, JARFALLA, SE-175 64, SWEDEN SN 2000-8066 J9 EUR J PSYCHOTRAUMATO JI Eur. J. Psychotraumatol. PY 2016 VL 7 AR 30995 DI 10.3402/ejpt.v7.30995 PG 9 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA DU6EY UT WOS:000382308100001 PM 27534741 ER PT J AU Miller, JJ Curry, WT Cahill, DP Dietrich, J AF Miller, Julie J. Curry, William T. Cahill, Dan P. Dietrich, Joerg TI Perspectives on investigational drugs and immunotherapies for glioblastoma SO EXPERT OPINION ON INVESTIGATIONAL DRUGS LA English DT Editorial Material DE Glioblastoma; IDH; immunotherapy; immune checkpoint inhibition; vaccination ID MALIGNANT GLIOMA; IDH1; CELLS; DIFFERENTIATION; INHIBITION; GROWTH C1 [Miller, Julie J.; Curry, William T.; Cahill, Dan P.; Dietrich, Joerg] Massachusetts Gen Hosp, Ctr Canc, Stephen E & Catherine Pappas Ctr Neurooncol, Boston, MA 02114 USA. [Miller, Julie J.; Dietrich, Joerg] Harvard Med Sch, Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02115 USA. [Curry, William T.; Cahill, Dan P.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA USA. RP Dietrich, J (reprint author), Massachusetts Gen Hosp, Ctr Canc, Stephen E & Catherine Pappas Ctr Neurooncol, Boston, MA 02114 USA.; Dietrich, J (reprint author), Harvard Med Sch, Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02115 USA. EM jdietrich1@partners.org OI Cahill, Daniel/0000-0003-2552-6546 FU NCI NIH HHS [R01 CA190901] NR 20 TC 0 Z9 0 U1 1 U2 1 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND SN 1354-3784 EI 1744-7658 J9 EXPERT OPIN INV DRUG JI Expert Opin. Investig. Drugs PY 2016 VL 25 IS 9 BP 1007 EP 1009 DI 10.1080/13543784.2016.1213242 PG 3 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA DU1SO UT WOS:000381989600001 PM 27415034 ER PT J AU Farzaei, MH Bahramsoltani, R Abdolghaffari, AH Sodagari, HR Esfahani, SA Rezaei, N AF Farzaei, Mohammad Hosein Bahramsoltani, Roodabeh Abdolghaffari, Amir Hossein Sodagari, Hamid Reza Esfahani, Shadi A. Rezaei, Nima TI A mechanistic review on plant-derived natural compounds as dietary supplements for prevention of inflammatory bowel disease SO EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY LA English DT Review DE Inflammatory bowel diseases; herbal medicine; prevention; dietary supplement; oxidative stress ID ACTIVE ULCERATIVE-COLITIS; PLACEBO-CONTROLLED TRIAL; TRINITROBENZENESULFONIC ACID MODEL; OF-THE-LITERATURE; CROHNS-DISEASE; DOUBLE-BLIND; TNF-ALPHA; OXIDATIVE STRESS; GUT MICROBIOTA; NITRIC-OXIDE AB Inflammatory bowel disease (IBD) is a recurrent idiopathic inflammatory condition, characterized by disruption of the gut mucosal barrier. This mechanistic review aims to highlight the significance of plant-derived natural compounds as dietary supplements, which can be used in addition to restricted conventional options for the prevention of IBD and induction of remission. Various clinical trials confirmed the effectiveness and tolerability of natural supplements in patients with IBD. Mounting evidence suggests that these natural compounds perform their protective and therapeutic effect on IBD through numerous molecular mechanisms, including anti-inflammatory and immunoregulatory, anti-oxidative stress, modulation of intracellular signaling transduction pathways, as well as improving gut microbiota. In conclusion, natural products can be considered as dietary supplements with therapeutic potential for IBD, provided that their safety and efficacy is confirmed in future well-designed clinical trials with adequate sample size. C1 [Farzaei, Mohammad Hosein] Kermanshah Univ Med Sci, Pharmaceut Sci Res Ctr, Kermanshah, Iran. [Farzaei, Mohammad Hosein] Kermanshah Univ Med Sci, Med Biol Res Ctr, Kermanshah, Iran. [Bahramsoltani, Roodabeh] Univ Tehran Med Sci, Fac Pharm, Tehran, Iran. [Abdolghaffari, Amir Hossein] ACECR, Inst Med Plants, Med Plants Res Ctr, Karaj, Iran. [Abdolghaffari, Amir Hossein] Univ Tehran Med Sci, Int Campus ICTUMS, Tehran, Iran. [Sodagari, Hamid Reza] Islamic Azad Univ, Karaj Branch, Young Researchers & Elite Club, Karaj, Iran. [Esfahani, Shadi A.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Radiol, Boston, MA USA. [Rezaei, Nima] Univ Tehran Med Sci, Childrens Med Ctr, Res Ctr Immunodeficiencies, Tehran, Iran. [Rezaei, Nima] Univ Tehran Med Sci, Sch Med, Dept Immunol, Tehran, Iran. [Rezaei, Nima] USERN, NIIMA, Tehran, Iran. [Abdolghaffari, Amir Hossein] Alborz Univ Med Sci, Fac Pharm, Dept Pharmacol & Toxicol, Karaj, Iran. RP Rezaei, N (reprint author), Childrens Med Ctr, Dr Gharib St,Keshavarz Blvd, Tehran 14194, Iran. EM rezaei_nima@tums.ac.ir OI Abdolghaffari, Amir Hossein/0000-0001-9961-9097 NR 128 TC 0 Z9 0 U1 3 U2 5 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND SN 1747-4124 EI 1747-4132 J9 EXPERT REV GASTROENT JI Expert Rev. Gastroenterol. Hepatol. PY 2016 VL 10 IS 6 BP 745 EP 758 DI 10.1586/17474124.2016.1145546 PG 14 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DT2NT UT WOS:000381317700011 PM 26799847 ER PT J AU Hollenbeak, CS Weinstock, RS Cibula, D Delahanty, LM Trief, PM AF Hollenbeak, Christopher S. Weinstock, Ruth S. Cibula, Donald Delahanty, Linda M. Trief, Paula M. TI Cost-effectiveness of SHINE: A Telephone Translation of the Diabetes Prevention Program SO HEALTH SERVICES INSIGHTS LA English DT Article DE diabetes; diabetes prevention program; cost-effectiveness anlaysis ID LIFE-STYLE INTERVENTION; WEIGHT-LOSS; METABOLIC SYNDROME; HIGH-RISK; QUALITY; REDUCTION; COMMUNITY; METFORMIN; OUTCOMES; DISEASE AB BACKGROUND: The Support, Health Information, Nutrition, and Exercise (SHINE) trial recently showed that a telephone adaptation of the Diabetes Prevention Program (DPP) lifestyle intervention was effective in reducing weight among patients with metabolic syndrome. The aim of this study is to determine whether a conference call (CC) adaptation was cost effective relative to an individual call (IC) adaptation of the DPP lifestyle intervention in the primary care setting. METHODS: We performed a stochastic cost-effectiveness analysis alongside a clinical trial comparing two telephone adaptations of the DPP lifestyle intervention. The primary outcomes were incremental cost-effectiveness ratios estimated for weight loss, body mass index (BMI), waist circumference, and quality-adjusted life years (QALYs). Costs were estimated from the perspective of society and included direct medical costs, indirect costs, and intervention costs. RESULTS: After one year, participants receiving the CC intervention accumulated fewer costs ($2,831 vs. $2,933) than the IC group, lost more weight (6.2 kg vs. 5.1 kg), had greater reduction in BMI (2.1 vs. 1.9), and had greater reduction in waist circumference (6.5 cm vs. 5.9 cm). However, participants in the CC group had fewer QALYs than those in the IC group (0.635 vs. 0.646). The incremental cost-effectiveness ratio for CC vs. IC was $9,250/QALY, with a 48% probability of being cost-effective at a willingness-to-pay of $100,000/QALY. CONCLUSIONS: CC delivery of the DPP was cost effective relative to IC delivery in the first year in terms of cost per clinical measure (weight lost, BMI, and waist circumference) but not in terms of cost per QALY, most likely because of the short time horizon. C1 [Hollenbeak, Christopher S.] Penn State Univ, Coll Med, Dept Surg, Hershey, PA 17033 USA. [Hollenbeak, Christopher S.] Penn State Univ, Coll Med, Dept Publ Hlth Sci, Hershey, PA 17033 USA. [Weinstock, Ruth S.] SUNY Upstate Med Univ, Dept Med, Syracuse, NY 13210 USA. [Weinstock, Ruth S.] SUNY Upstate Med Univ, Dept Neurosci & Physiol, Syracuse, NY 13210 USA. [Cibula, Donald] SUNY Upstate Med Univ, Dept Publ Hlth & Prevent Med, Syracuse, NY 13210 USA. [Delahanty, Linda M.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. [Trief, Paula M.] SUNY Upstate Med Univ, Dept Med, Syracuse, NY 13210 USA. [Trief, Paula M.] SUNY Upstate Med Univ, Dept Psychiat & Behav Sci, Syracuse, NY 13210 USA. [Trief, Paula M.] SUNY Upstate Med Univ, Dept Orthoped Surg, Syracuse, NY 13210 USA. RP Hollenbeak, CS (reprint author), Penn State Univ, Coll Med, Dept Surg, Hershey, PA 17033 USA.; Hollenbeak, CS (reprint author), Penn State Univ, Coll Med, Dept Publ Hlth Sci, Hershey, PA 17033 USA. EM chollenbeak@psu.edu FU NIH/NIDDK [R18-DK078553] FX This study was funded by NIH/NIDDK R18-DK078553. The authors confirm that the funder had no influence over the study design, content of the article, or selection of this journal. NR 32 TC 0 Z9 0 U1 0 U2 0 PU LIBERTAS ACAD PI AUCKLAND PA PO BOX 300-874, ALBANY 0752, AUCKLAND, 00000, NEW ZEALAND SN 1178-6329 J9 HEALTH SERV INSIGHTS JI HEALTH SERV. INSIGHTS PY 2016 VL 9 DI 10.4137/HSI.S39084 PG 8 WC Health Care Sciences & Services SC Health Care Sciences & Services GA DV5QL UT WOS:000382982600001 ER PT J AU De Man, R Wang, G Kalra, MK Otrakji, A Hsieh, S Pelc, N AF De Man, Ruben Wang, Ge Kalra, Mannudeep K. Otrakji, Alexi Hsieh, Scott Pelc, Norbert TI Upper-Bound on Dose Reduction in CT Reconstruction for Nodule Detection SO IEEE ACCESS LA English DT Article DE Computed tomography; radiation dose; cancer ID AFFIRMED ITERATIVE RECONSTRUCTION; IMAGE QUALITY; RADIATION AB The success of X-ray computed tomography (CT) as a widespread medical diagnosis tool has led to concerns about possible harm due to the increased average radiation dose to the population. A highly effective way to reduce CT radiation dose is to use iterative image reconstruction. All major CT vendors now offer iterative reconstruction solutions and claim that they can achieve the desired image quality at only a fraction of the dose level needed with conventional filtered backprojection (FBP) reconstruction. In this paper, we empirically estimate the upper bound on the achievable dose reduction in CT reconstruction in the context of a clinical detection task. We do this based on a series of patient lung CT data sets, with and without nodules, for a large number of random noise realizations. We analyze lesion detectability in the FBP images, in which case performance is lost due to the sub-optimal reconstruction. We compare this to lesion detectability directly in the raw data domain, where by definition, all information is still available with specific location information. This, therefore, represents the best scenario any reconstruction algorithm could achieve from raw data without additional prior information. The results indicate that a threefold dose reduction is feasible relative to FBP reconstruction: specifically, the upper bound on dose reduction was estimated at 62.5% for 90% detection accuracy and 66.2% for 80% detection accuracy. Statistical weighting is responsible for approximately half of that benefit. C1 [De Man, Ruben; Wang, Ge] Rensselaer Polytech Inst, Dept Biomed Engn, Troy, NY 12180 USA. [Kalra, Mannudeep K.; Otrakji, Alexi] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. [Hsieh, Scott; Pelc, Norbert] Stanford Univ, Dept Radiol, Stanford, CA 94305 USA. RP De Man, R (reprint author), Rensselaer Polytech Inst, Dept Biomed Engn, Troy, NY 12180 USA. EM rubendeman@gmail.com NR 16 TC 0 Z9 0 U1 2 U2 2 PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC PI PISCATAWAY PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA SN 2169-3536 J9 IEEE ACCESS JI IEEE Access PY 2016 VL 4 BP 4247 EP 4253 DI 10.1109/ACCESS.2016.2592941 PG 7 WC Computer Science, Information Systems; Engineering, Electrical & Electronic; Telecommunications SC Computer Science; Engineering; Telecommunications GA DV2UM UT WOS:000382777400027 ER PT J AU Weininger, S Jaffe, MB Robkin, M Rausch, T Arney, D Goldman, JM AF Weininger, Sandy Jaffe, Michael B. Robkin, Michael Rausch, Tracy Arney, David Goldman, Julian M. TI The Importance of State and Context in Safe Interoperable Medical Systems SO IEEE JOURNAL OF TRANSLATIONAL ENGINEERING IN HEALTH AND MEDICINE-JTEHM LA English DT Article DE Safety; interoperability; state; context AB This paper describes why "device state" and "patient context" information are necessary components of device models for safe interoperability. This paper includes a discussion of the importance of describing the roles of devices with respect to interactions (including human user workflows involving devices, and device to device communication) within a system, particularly those intended for use at the point-of-care, and how this role information is communicated. In addition, it describes the importance of clinical scenarios in creating device models for interoperable devices. C1 [Weininger, Sandy] FDA CDRH, Off Sci & Engn Labs, Silver Spring, MD 20993 USA. [Jaffe, Michael B.; Arney, David; Goldman, Julian M.] Massachusetts Gen Hosp, Dept Anesthesia, MDPnP Program, Boston, MA 02114 USA. [Robkin, Michael] Anakena Solut Inc, Woodland Hills, CA 91367 USA. [Rausch, Tracy] DocBox Inc, Newton, MA 02460 USA. RP Weininger, S (reprint author), FDA CDRH, Off Sci & Engn Labs, Silver Spring, MD 20993 USA. EM sandy.weininger@fda.hhs.gov NR 24 TC 1 Z9 1 U1 0 U2 0 PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC PI PISCATAWAY PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA SN 2168-2372 J9 IEEE J TRANSL ENG HE JI IEEE J. Transl. Eng. Health Med.-JTEHM PY 2016 VL 4 AR 2800110 DI 10.1109/JTEHM.2016.2596283 PG 10 WC Engineering, Biomedical SC Engineering GA DV2TZ UT WOS:000382775900001 PM 27730013 ER PT J AU Kullgren, JT Williams, GC Resnicow, K An, LC Rothberg, A Volpp, KG Heisler, M AF Kullgren, Jeffrey T. Williams, Geoffrey C. Resnicow, Kenneth An, Lawrence C. Rothberg, Amy Volpp, Kevin G. Heisler, Michele TI The promise of tailoring incentives for healthy behaviors SO INTERNATIONAL JOURNAL OF WORKPLACE HEALTH MANAGEMENT LA English DT Article DE Self-determination theory; Behaviour change; Behavioural economics; Financial incentives; Employee behaviour; Workplace wellness; Motivation psychology; Behaviour modification; Health promotion; Wellness interventions ID SELF-DETERMINATION THEORY; RANDOMIZED CONTROLLED-TRIAL; FINANCIAL INCENTIVES; WEIGHT-LOSS; INTRINSIC MOTIVATION; PHYSICAL-ACTIVITY; SMOKING-CESSATION; VEGETABLE INTERVENTION; AUTONOMY SUPPORT; EXERCISE AB Purpose - The purpose of this paper is to describe how tailoring financial incentives for healthy behaviors to employees' goals, values, and aspirations might improve the efficacy of incentives. Design/methodology/approach - The authors integrate insights from self-determination theory (SDT) with principles from behavioral economics in the design of financial incentives by linking how incentives could help meet an employee's life goals, values, or aspirations. Findings - Tailored financial incentives could be more effective than standard incentives in promoting autonomous motivation necessary to initiate healthy behaviors and sustain them after incentives are removed. Research limitations/implications - Previous efforts to improve the design of financial incentives have tested different incentive designs that vary the size, schedule, timing, and target of incentives. The strategy for tailoring incentives builds on strong evidence that difficult behavior changes are more successful when integrated with important life goals and values. The authors outline necessary research to examine the effectiveness of this approach among at-risk employees. Practical implications - Instead of offering simple financial rewards for engaging in healthy behaviors, existing programs could leverage incentives to promote employees' autonomous motivation for sustained health improvements. Social implications - Effective application of these concepts could lead to programs more effective at improving health, potentially at lower cost. Originality/value - The approach for the first time integrates key insights from SDT, behavioral economics, and tailoring to turn an extrinsic reward for behavior change into an internalized, self-sustaining motivator for long-term engagement in risk-reducing behaviors. C1 [Kullgren, Jeffrey T.; Heisler, Michele] VA Ann Arbor Healthcare Syst, VA Ctr Clin Management Res, Ann Arbor, MI 48105 USA. [Kullgren, Jeffrey T.; An, Lawrence C.; Rothberg, Amy; Heisler, Michele] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA. [Williams, Geoffrey C.] Univ Rochester, Dept Med, Rochester, NY USA. [Williams, Geoffrey C.] Univ Rochester, Dept Clin Social Sci Psychol, Rochester, NY USA. [Resnicow, Kenneth] Univ Michigan, Dept Hlth Behav & Hlth Educ, Ann Arbor, MI 48109 USA. [Volpp, Kevin G.] Philadelphia VA Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Volpp, Kevin G.] Univ Penn, Dept Med, Philadelphia, PA 19104 USA. [Volpp, Kevin G.] Univ Penn, Dept Hlth Care Management, Philadelphia, PA 19104 USA. RP Kullgren, JT (reprint author), VA Ann Arbor Healthcare Syst, VA Ctr Clin Management Res, Ann Arbor, MI 48105 USA.; Kullgren, JT (reprint author), Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA. EM jkullgre@med.umich.edu NR 59 TC 0 Z9 0 U1 13 U2 14 PU EMERALD GROUP PUBLISHING LTD PI BINGLEY PA HOWARD HOUSE, WAGON LANE, BINGLEY BD16 1WA, W YORKSHIRE, ENGLAND SN 1753-8351 EI 1753-836X J9 INT J WORKPLACE HEAL JI Int. J. Workplace Health Manag. PY 2016 VL 9 IS 1 BP 2 EP 16 DI 10.1108/IJWHM-12-2014-0060 PG 15 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DU9QR UT WOS:000382553100001 ER PT J AU Chasser, YM AF Chasser, Yvonne M. TI Profiles of Youths With PTSD and Addiction SO JOURNAL OF CHILD & ADOLESCENT SUBSTANCE ABUSE LA English DT Article DE addiction; adolescent; post-traumatic stress disorder; substance use disorder ID POSTTRAUMATIC-STRESS-DISORDER; MENTAL-HEALTH PROBLEMS; SUBSTANCE-ABUSE; ADOLESCENTS; PREDICTORS; COMORBIDITY; WOMEN AB Objective: Understanding the relationship between PTSD and addiction in adolescents may dramatically improve evidence-based practice in child psychiatry. We hypothesized that in a sample of substance addicted youth, PTSD would correlate with (1) female gender and racial minority status, (2) preference for anxiolytic substances, (3) higher burden of self injury and suicide attempts, and (4) earlier age of first use. Methods: One-hundred and ninety-five adolescents (52% female, ages 14-18) were court-referred to residential treatment and assessed at intake. Multi-informant data regarding Axis I diagnostic status and other clinical variables were collected via rater-administered, semi-structured interviews; medical chart review; and youth, parent, and clinician reports. Differences between subjects were evaluated using Fisher's exact test for binary variables or Kruskal-Wallis Chi-Square Test. Results: Substance dependent youth with comorbid PTSD were significantly more likely to be female and Latino. PTSD was correlated with preference for alcohol, narcotics, tranquilizers and inhalants. In addition, PTSD was correlated with higher burden of self-injury and suicidal behavior. Youth with PTSD were also more likely to have begun using before age 13 and reported that PTSD symptoms preceded first use. Conclusions: Girls and Latinos may be particularly vulnerable in developing comorbid substance dependence and PTSD. Drug preferences among youth with PTSD may reflect tendencies to target symptoms such as hypervigilance and anxiety. The recognition and early intervention among youth with trauma could prevent early first use and eventual substance dependency. C1 [Chasser, Yvonne M.] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Chasser, YM (reprint author), Massachusetts Gen Hosp, Dept Psychiat, 55 Fruit St,Wang 8, Boston, MA 02135 USA. EM yvonne.chasser@gmail.com NR 22 TC 0 Z9 0 U1 3 U2 3 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 1067-828X EI 1547-0652 J9 J CHILD ADOLES SUBST JI J. Child Adolesc. Subst. Abus. PY 2016 VL 25 IS 5 BP 448 EP 454 DI 10.1080/1067828X.2015.1081115 PG 7 WC Substance Abuse SC Substance Abuse GA DV2RC UT WOS:000382767500007 PM 28377669 ER PT J AU Vaquero, S Bossio, C Bellani, S Martino, N Zucchetti, E Lanzani, G Antognazza, MR AF Vaquero, Susana Bossio, Caterina Bellani, Sebastiano Martino, Nicola Zucchetti, Elena Lanzani, Guglielmo Antognazza, Maria Rosa TI Conjugated polymers for the optical control of the electrical activity of living cells SO JOURNAL OF MATERIALS CHEMISTRY B LA English DT Article ID LIGHT-EMITTING DIODE; FIBRONECTIN ADSORPTION; QCM-D; PROTEIN ADSORPTION; BLUE-LIGHT; THIN-FILMS; INTERFACE; STIMULATION; SURFACES; ADHESION AB The possibility to optically excite the electrical activity of living cells by using exogenous absorbers is gaining more and more interest in the neuroscience and biotechnology community. Conjugated polymers, inherently sensitive to visible light, were recently proposed as candidates to this goal. To date, however, only one polymer type, namely regio- regular poly-3-hexylthiophene, has been tested as the active material. In this work four different conjugated polymers, regarded as prototypes of their category, are investigated as photoactive bio-interfaces. The selected materials have different absorption spectra, morphology, light emission efficiency and charge transport properties. We analyze their key-enabling properties, such as electrochemical stability, surface morphology, wettability, sterilization compatibility, interaction with protein adhesion layers and toxicity, throughout all the necessary steps for the realization of an efficient bio-optical interface. We demonstrate that all considered polymers are characterized by good biocompatibility and cell seeding properties, and can optimally sustain thermal sterilization. Conversely, electrochemical stability and cell photostimulation efficacy can vary a lot among different materials, and should be carefully evaluated case by case. Reported results represent the starting point for the implementation of bio-polymer interfaces sensitive to different colors and, in perspective, for the realization of a three-chromatic artificial visual prosthesis. C1 [Vaquero, Susana; Bossio, Caterina; Bellani, Sebastiano; Martino, Nicola; Zucchetti, Elena; Lanzani, Guglielmo; Antognazza, Maria Rosa] IIT PoliMi, Ctr Nana Sci & Technol, Via Pascoli 70-3, I-20133 Milan, Italy. [Bellani, Sebastiano; Martino, Nicola; Zucchetti, Elena; Lanzani, Guglielmo] Politecn Milan, Dip Fis, Pzza L da Vinci 32, I-20133 Milan, Italy. [Bellani, Sebastiano] Ist Italiano Tecnol, Via Morego 30, I-16163 Genoa, Italy. [Martino, Nicola] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. [Martino, Nicola] Harvard Med Sch, Boston, MA USA. RP Lanzani, G; Antognazza, MR (reprint author), IIT PoliMi, Ctr Nana Sci & Technol, Via Pascoli 70-3, I-20133 Milan, Italy.; Lanzani, G (reprint author), Politecn Milan, Dip Fis, Pzza L da Vinci 32, I-20133 Milan, Italy. EM guglielmo.lanzani@iit.it; mariarosa.antognazza@iit.it FU EU [FP7-PEOPLE-212-ITN 316832-OLIMPIA]; Telethon - Italy [GGP12033, GGP14022]; Fondazione Cariplo [2013-0738] FX This work was supported by EU through project FP7-PEOPLE-212-ITN 316832-OLIMPIA, Telethon - Italy (grants GGP12033 and GGP14022), Fondazione Cariplo (grant ID 2013-0738). NR 61 TC 1 Z9 1 U1 11 U2 11 PU ROYAL SOC CHEMISTRY PI CAMBRIDGE PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND SN 2050-750X EI 2050-7518 J9 J MATER CHEM B JI J. Mat. Chem. B PY 2016 VL 4 IS 31 BP 5272 EP 5283 DI 10.1039/c6tb01129b PG 12 WC Materials Science, Biomaterials SC Materials Science GA DT4FN UT WOS:000381435600009 ER PT J AU Matlow, A Chan, MK Bohnen, JD Blumenthal, DM Sanchez-Mendiola, M Meschino, DD Samson, LM Busari, J AF Matlow, Anne Chan, Ming-Ka Bohnen, Jordan David Blumenthal, Daniel Mark Sanchez-Mendiola, Melchor Meschino, Diane de Camps Samson, Lindy Michelle Busari, Jamiu TI Collaborating internationally on physician leadership education: first steps SO LEADERSHIP IN HEALTH SERVICES LA English DT Article DE International; Health leadership competencies; Doctors; Education; Leadership curriculum ID HEALTH-CARE; MEDICAL-EDUCATION; CHALLENGES AB Purpose - Physicians are often ill-equipped for the leadership activities their work demands. In part, this is due to a gap in traditional medical education. An emergent international network is developing a globally relevant leadership curriculum for postgraduate medical education. The purpose of this article is to share key learnings from this process to date. Design/methodology/approach - The Toronto International Summit on Leadership Education for Physicians (TISLEP) was hosted by the Royal College of Physicians and Surgeons of Canada, and the University of Toronto's Faculty of Medicine and Institute of Health Policy, Management and Evaluation. Of 64 attendees from eight countries, 34 joined working groups to develop leadership competencies. The CanMEDS Competency Framework, stage of learner development and venue of learning formed the scaffold for the work. Emotional intelligence was selected as the topic to test the feasibility of fruitful international collaboration; results were presented at TISLEP 2015. Findings - Dedicated international stakeholders engaged actively and constructively through defined working groups to develop a globally relevant, competency-based curriculum for physician leadership education. Eleven principles are recommended for consideration in physician leadership curriculum development. Defining common language and taxonomy is essential for a harmonized product. The importance of establishing an international network to support implementation, evaluation, sustainability and dissemination of the work was underscored. Originality/value - International stakeholders are collaborating successfully on a graduated, competency- based leadership curriculum for postgraduate medical learners. The final product will be available for adaptation to local needs. An international physician leadership education network is being developed to support and expand the work underway. C1 [Matlow, Anne] Univ Toronto, Toronto, ON, Canada. [Chan, Ming-Ka] Univ Manitoba, Dept Paediat & Child Hlth, Winnipeg, MB, Canada. [Chan, Ming-Ka] Royal Coll Phys & Surg Canada, Ottawa, ON, Canada. [Bohnen, Jordan David] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA. [Blumenthal, Daniel Mark] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA. [Sanchez-Mendiola, Melchor] Univ Nacl Autonoma Mexico, Fac Med, Dept Med Educ, Mexico City, DF, Mexico. [Meschino, Diane de Camps] Univ Toronto, Dept Psychiat, Toronto, ON, Canada. [Samson, Lindy Michelle] Univ Ottawa, Dept Pediat, Ottawa, ON, Canada. [Busari, Jamiu] Zuyderland Med Ctr, Dept Pediat, Heerlen, Netherlands. [Busari, Jamiu] Maastricht Univ, Dept Educ Dev & Res, Maastricht, Netherlands. RP Matlow, A (reprint author), Univ Toronto, Toronto, ON, Canada. EM anne.matlow@utoronto.ca NR 30 TC 0 Z9 0 U1 1 U2 1 PU EMERALD GROUP PUBLISHING LTD PI BINGLEY PA HOWARD HOUSE, WAGON LANE, BINGLEY BD16 1WA, W YORKSHIRE, ENGLAND SN 1188-3669 EI 1751-1887 J9 LEADERSH HEALTH SERV JI Leadersh. Health Serv. PY 2016 VL 29 IS 3 BP 220 EP 230 DI 10.1108/LHS-12-2015-0049 PG 11 WC Health Policy & Services SC Health Care Sciences & Services GA DT4IY UT WOS:000381444600002 PM 27397745 ER PT J AU Chan, MK Meschino, DD Dath, D Busari, J Bohnen, JD Samson, LM Matlow, A Sanchez-Mendiola, M AF Chan, Ming-Ka Meschino, Diane de Camps Dath, Deepak Busari, Jamiu Bohnen, Jordan David Samson, Lindy Michelle Matlow, Anne Sanchez-Mendiola, Melchor TI Collaborating internationally on physician leadership development: why now? SO LEADERSHIP IN HEALTH SERVICES LA English DT Article DE Health leadership competencies; Health education; Doctors; International; Competency-based ID MEDICAL RESIDENTS; EDUCATION AB Purpose - This paper aims to highlight the importance of leadership development for all physicians within a competency-based medical education (CBME) framework. It describes the importance of timely international collaboration as a key strategy in promoting physician leadership development. Design/methodology/approach - The paper explores published and Grey literature around physician leadership development and proposes that international collaboration will meet the expanding call for development of leadership competencies in postgraduate medical learners. Two grounding frameworks were used: complexity science supports adding physician leadership training to the current momentum of CBME adoption, and relational cultural theory supports the engagement of diverse stakeholders in multiple jurisdictions around the world to ensure inclusivity in leadership education development. Findings - An international collaborative identified key insights regarding the need to frame physician leadership education within a competency-based model. Practical implications - International collaboration can be a vehicle for developing a globally relevant, generalizable physician leadership curriculum. This model can be expanded to encourage innovation, scholarship and program evaluation. Originality/value - Acompetency-based leadership development curriculum is being designed by an international collaborative. The curriculum is based on established leadership and education frameworks. The international collaboration model provides opportunities for ongoing sharing, networking and diversification. C1 [Chan, Ming-Ka] Univ Manitoba, Dept Paediat & Child Hlth, Winnipeg, MB, Canada. [Chan, Ming-Ka; Dath, Deepak] Royal Coll Phys & Surg Canada, Ottawa, ON, Canada. [Meschino, Diane de Camps] Univ Toronto, Dept Psychiat, Toronto, ON, Canada. [Dath, Deepak] McMaster Univ, Dept Surg, Hamilton, ON, Canada. [Busari, Jamiu] Zuyderland Med Ctr, Dept Pediat, Heerlen, Netherlands. [Busari, Jamiu] Maastricht Univ, Dept Educ Dev & Res, Maastricht, Netherlands. [Bohnen, Jordan David] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA. [Bohnen, Jordan David] Harvard Med Sch, Boston, MA USA. [Samson, Lindy Michelle] Univ Ottawa, Dept Pediat, Ottawa, ON, Canada. [Matlow, Anne] Univ Toronto, Toronto, ON, Canada. [Sanchez-Mendiola, Melchor] Univ Nacl Autonoma Mexico, Fac Med, Dept Med Educ, Mexico City, DF, Mexico. RP Chan, MK (reprint author), Univ Manitoba, Dept Paediat & Child Hlth, Winnipeg, MB, Canada.; Chan, MK (reprint author), Royal Coll Phys & Surg Canada, Ottawa, ON, Canada. EM Ming-Ka.Chan@umanitoba.ca NR 37 TC 0 Z9 0 U1 2 U2 2 PU EMERALD GROUP PUBLISHING LTD PI BINGLEY PA HOWARD HOUSE, WAGON LANE, BINGLEY BD16 1WA, W YORKSHIRE, ENGLAND SN 1188-3669 EI 1751-1887 J9 LEADERSH HEALTH SERV JI Leadersh. Health Serv. PY 2016 VL 29 IS 3 BP 231 EP 239 DI 10.1108/LHS-12-2015-0050 PG 9 WC Health Policy & Services SC Health Care Sciences & Services GA DT4IY UT WOS:000381444600003 PM 27397746 ER PT J AU Szostak, JW AF Szostak, Jack W. TI ON THE ORIGIN OF LIFE SO MEDICINA-BUENOS AIRES LA English DT Article DE RNA replication cycle; protocells; ribozymes; geothermal activity; concentrated cyanide AB The origin of life is a very rich field, filled with possibilities and ripe for discovery. RNA replication requires chemical energy and vesicle division is easy to do with mechanical energy. These requirements point to a surface lake, perhaps at some time following the period of concentrated cyanide chemistry that gave rise to nucleotides, amino acids and (maybe) fatty acids. A second requirement follows specifically from the nature of the RNA replication cycle, which requires generally cool to moderate temperatures for the copying chemistry, punctuated by brief periods of high temperature for strand separation. Remarkably, lakes in a geothermal active area provide just such a fluctuating temperature environment, because lakes similar to Yellowstone can be generally cool (even ice covered in winter), but they contain numerous hydrothermal vents that emit streams of hot water. Protocells in such an environment would occasionally be swept into these hot water streams, where the transient high temperature exposure would cause RNA strand separation. However, the protocells would be quickly mixed with surrounding cold water, and would therefore cool quickly, before their delicate RNA molecules could be destroyed by heat. Because of the combination of favorable chemical and physical environments, this could be the most likely scenario for the early Earth environment that nurtured the origin of life. C1 [Szostak, Jack W.] Harvard Med Sch, Howard Hughes Med Inst, Boston, MA 02115 USA. [Szostak, Jack W.] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Szostak, JW (reprint author), Harvard Med Sch, Howard Hughes Med Inst, Boston, MA 02115 USA.; Szostak, JW (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 7 TC 0 Z9 0 U1 22 U2 22 PU MEDICINA (BUENOS AIRES) PI BUENOS AIRES PA DONATO ALVAREZ 3150, 1427 BUENOS AIRES, ARGENTINA SN 0025-7680 EI 1669-9106 J9 MEDICINA-BUENOS AIRE JI Med.-Buenos Aires PY 2016 VL 76 IS 4 BP 199 EP 203 PG 5 WC Medicine, General & Internal SC General & Internal Medicine GA DV4OB UT WOS:000382903800001 PM 27576276 ER PT J AU Zoltowska, KM Maesako, M Berezovska, O AF Zoltowska, Katarzyna Marta Maesako, Masato Berezovska, Oksana TI Interrelationship between Changes in the Amyloid beta 42/40 Ratio and Presenilin 1 Conformation SO MOLECULAR MEDICINE LA English DT Article ID GAMMA-SECRETASE MODULATORS; ALZHEIMERS-DISEASE; A-BETA; TRANSMEMBRANE DOMAIN; MOUSE MODEL; CALCIUM; BRAIN; PEPTIDES; PLAQUES; AGGREGATION AB The ratio of the longer (A beta 42/A beta 43) to shorter (A beta 40) species is a critical factor determining amyloid fibril formation, neurotoxicity and progression of the amyloid pathology in Alzheimer's disease. The relative levels of the different A beta species are affected by activity and conformation of the.-secretase complex catalytic component presenilin 1 (PS1). The enzyme exists in a dynamic equilibrium of the conformational states, with so-called "close" conformation associated with the shift of the.-secretase cleavage toward the production of longer, neurotoxic A beta species. In the current study, fluorescence lifetime imaging microscopy, spectral Forster resonance energy transfer, calcium imaging and cytotoxicity assays were utilized to explore a reciprocal link between the A beta 42 and A beta 40 peptides present at various ratios and PS1 conformation in primary neurons. We report that exposure to A beta peptides at a relatively high ratio of A beta 42/40 causes conformational change within the PS1 subdomain architecture toward the pathogenic "closed" state. Mechanistically, the A beta 42/40 peptides present at the relatively high ratio increase intracellular calcium levels, which were shown to trigger pathogenic PS1 conformation. This indicates that there is a reciprocal cross-talk between the extracellular A beta peptides and PS1 conformation within a neuron, with A beta 40 showing some protective effect. The pathogenic shift within the PS1 domain architecture may further shift the production of A beta peptides toward the longer, neurotoxic A beta species. These findings link elevated calcium, A beta 42 and PS1/gamma-secretase conformation, and offer possible mechanistic explanation of the impending exacerbation of the amyloid pathology. C1 [Zoltowska, Katarzyna Marta; Maesako, Masato; Berezovska, Oksana] Harvard Med Sch, Massachusetts Gen Hosp, MassGen Inst Neurodegenerat Dis, Dept Neurol, 114 16th St, Charlestown, MA 02129 USA. RP Berezovska, O (reprint author), Harvard Med Sch, Massachusetts Gen Hosp, MassGen Inst Neurodegenerat Dis, Dept Neurol, 114 16th St, Charlestown, MA 02129 USA. EM oberezovska@partners.org NR 37 TC 2 Z9 2 U1 2 U2 2 PU FEINSTEIN INST MED RES PI MANHASSET PA 350 COMMUNITY DR, MANHASSET, NY 11030 USA SN 1076-1551 EI 1528-3658 J9 MOL MED JI Mol. Med. PY 2016 VL 22 BP 329 EP 337 DI 10.2119/molmed.2016.00127 PG 9 WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine GA DU7IF UT WOS:000382386700001 ER PT J AU Abbott, SM Videnovic, A AF Abbott, Sabra M. Videnovic, Aleksandar TI Chronic sleep disturbance and neural injury: links to neurodegenerative disease SO NATURE AND SCIENCE OF SLEEP LA English DT Review DE sleep; neurodegeneration; Alzheimer's disease; Parkinson's disease; Huntington's disease ID EXCESSIVE DAYTIME SLEEPINESS; TRANSGENIC MOUSE MODEL; HYPOCRETIN OREXIN LOSS; LONG-TERM EFFICACY; PARKINSONS-DISEASE; ALZHEIMERS-DISEASE; HUNTINGTONS-DISEASE; COGNITIVE IMPAIRMENT; CEREBROSPINAL-FLUID; CIRCADIAN-RHYTHMS AB Sleep-wake disruption is frequently observed and often one of the earliest reported symptoms of many neurodegenerative disorders. This provides insight into the underlying pathophysiology of these disorders, as sleep-wake abnormalities are often accompanied by neurodegenerative or neurotransmitter changes. However, in addition to being a symptom of the underlying neurodegenerative condition, there is also emerging evidence that sleep disturbance itself may contribute to the development and facilitate the progression of several of these disorders. Due to its impact both as an early symptom and as a potential factor contributing to ongoing neurodegeneration, the sleep-wake cycle is an ideal target for further study for potential interventions not only to lessen the burden of these diseases but also to slow their progression. In this review, we will highlight the sleep phenotypes associated with some of the major neurodegenerative disorders, focusing on the circadian disruption associated with Alzheimer's disease, the rapid eye movement behavior disorder and sleep fragmentation associated with Parkinson's disease, and the insomnia and circadian dysregulation associated with Huntington's disease. C1 [Abbott, Sabra M.] Northwestern Feinberg Sch Med, Dept Neurol, 710 N Lake Shore Dr,Abbott Hall 524, Chicago, IL 60611 USA. [Videnovic, Aleksandar] Harvard Med Sch, Massachusetts Gen Hosp, Dept Neurol, 165 Cambridge St,Suite 600, Boston, MA 02114 USA. RP Abbott, SM (reprint author), Northwestern Feinberg Sch Med, Dept Neurol, 710 N Lake Shore Dr,Abbott Hall 524, Chicago, IL 60611 USA.; Videnovic, A (reprint author), Harvard Med Sch, Massachusetts Gen Hosp, Dept Neurol, 165 Cambridge St,Suite 600, Boston, MA 02114 USA. EM sabra.abbott@northwestern.edu; avidenovic@mgh.harvard.edu FU NINDS NIH HHS [K23 NS072283] NR 69 TC 2 Z9 2 U1 5 U2 9 PU DOVE MEDICAL PRESS LTD PI ALBANY PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND SN 1179-1608 J9 NAT SCI SLEEP JI NAT. SCI. SLEEP PY 2016 VL 8 BP 55 EP 61 DI 10.2147/NSS.S78947 PG 7 WC Clinical Neurology SC Neurosciences & Neurology GA DU6IB UT WOS:000382316800001 PM 26869817 ER PT J AU Gold, AK Sylvia, LG AF Gold, Alexandra K. Sylvia, Louisa G. TI The role of sleep in bipolar disorder SO NATURE AND SCIENCE OF SLEEP LA English DT Review DE bipolar disorder; circadian rhythms; sleep-wake homeostasis ID MAJOR DEPRESSIVE DISORDER; CIRCADIAN-RHYTHMS; SUPRACHIASMATIC NUCLEUS; EUTHYMIC BIPOLAR; MOOD DISORDERS; PHASE ADVANCE; WAKE CYCLE; UNIPOLAR; DEPRIVATION; DISTURBANCE AB Bipolar disorder is a serious mental illness characterized by alternating periods of elevated and depressed mood. Sleep disturbances in bipolar disorder are present during all stages of the condition and exert a negative impact on overall course, quality of life, and treatment outcomes. We examine the partnership between circadian system (process C) functioning and sleep-wake homeostasis (process S) on optimal sleep functioning and explore the role of disruptions in both systems on sleep disturbances in bipolar disorder. A convergence of evidence suggests that sleep problems in bipolar disorder result from dysregulation across both process C and process S systems. Biomarkers of depressive episodes include heightened fragmentation of rapid eye movement (REM) sleep, reduced REM latency, increased REM density, and a greater percentage of awakenings, while biomarkers of manic episodes include reduced REM latency, greater percentage of stage I sleep, increased REM density, discontinuous sleep patterns, shortened total sleep time, and a greater time awake in bed. These findings highlight the importance of targeting novel treatments for sleep disturbance in bipolar disorder. C1 [Gold, Alexandra K.; Sylvia, Louisa G.] Massachusetts Gen Hosp, Dept Psychiat, 50 Staniford St,Suite 580, Boston, MA 02114 USA. [Sylvia, Louisa G.] Harvard Med Sch, Boston, MA USA. RP Gold, AK (reprint author), Massachusetts Gen Hosp, Dept Psychiat, 50 Staniford St,Suite 580, Boston, MA 02114 USA. EM alexandrakategold@gmail.com NR 89 TC 0 Z9 0 U1 6 U2 6 PU DOVE MEDICAL PRESS LTD PI ALBANY PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND SN 1179-1608 J9 NAT SCI SLEEP JI NAT. SCI. SLEEP PY 2016 VL 8 BP 207 EP 214 DI 10.2147/NSS.S85754 PG 8 WC Clinical Neurology SC Neurosciences & Neurology GA DU6IM UT WOS:000382317900001 PM 27418862 ER PT J AU Moro, M Gannon, K Lovell, K Merlino, M Mojica, J Bianchi, MT AF Moro, Marilyn Gannon, Karen Lovell, Kathy Merlino, Margaret Mojica, James Bianchi, Matt T. TI Clinical predictors of central sleep apnea evoked by positive airway pressure titration SO NATURE AND SCIENCE OF SLEEP LA English DT Article DE risk; prediction; central apnea; complex apnea; emergent; titration ID RANDOMIZED CONTROLLED-TRIAL; CONGESTIVE-HEART-FAILURE; ADAPTIVE SERVOVENTILATION; PRACTICE PARAMETERS; JAPANESE PATIENTS; COMPLEX; PREVALENCE; THERAPY; STROKE; ADULTS AB Purpose: Treatment-emergent central sleep apnea (TECSA), also called complex apnea, occurs in 5%-15% of sleep apnea patients during positive airway pressure (PAP) therapy, but the clinical predictors are not well understood. The goal of this study was to explore possible predictors in a clinical sleep laboratory cohort, which may highlight those at risk during clinical management. Methods: We retrospectively analyzed 728 patients who underwent PAP titration (n = 422 split-night; n 306 two-night). Demographics and self-reported medical comorbidities, medications, and behaviors as well as standard physiological parameters from the polysomnography (PSG) data were analyzed. We used regression analysis to assess predictors of binary presence or absence of central apnea index (CAI) >= 5 during split-night PSG (SN-PSG) versus full-night PSG (FN-PSG) titrations. Results: CAI >= 5 was present in 24.2% of SN-PSG and 11.4% of FN-PSG patients during titration. Male sex, maximum continuous positive airway pressure, and use of bilevel positive airway pressure were predictors of TECSA, and rapid eye movement dominance was a negative predictor, for both SN-PSG and FN-PSG patients. Self-reported narcotics were a positive predictor of TECSA, and the time spent in stage N2 sleep was a negative predictor only for SN-PSG patients. Self-reported history of stroke and the CAI during the diagnostic recording predicted TECSA only for FN-PSG patients. Conclusion: Clinical predictors of treatment-evoked central apnea spanned demographic, medical history, sleep physiology, and titration factors. Improved predictive models may be increasingly important as diagnostic and therapeutic modalities move away from the laboratory setting, even as PSG remains the gold standard for characterizing primary central apnea and TECSA. C1 [Moro, Marilyn; Gannon, Karen; Lovell, Kathy; Merlino, Margaret; Bianchi, Matt T.] Massachusetts Gen Hosp, Dept Neurol, Wang 720,55 Fruit St, Boston, MA 02114 USA. [Mojica, James] Massachusetts Gen Hosp, Pulm & Crit Care Med, Boston, MA 02114 USA. [Bianchi, Matt T.] Harvard Med Sch, Div Sleep Med, Boston, MA USA. RP Bianchi, MT (reprint author), Massachusetts Gen Hosp, Dept Neurol, Wang 720,55 Fruit St, Boston, MA 02114 USA. EM mtbianchi@partners.org NR 36 TC 0 Z9 0 U1 2 U2 2 PU DOVE MEDICAL PRESS LTD PI ALBANY PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND SN 1179-1608 J9 NAT SCI SLEEP JI NAT. SCI. SLEEP PY 2016 VL 8 BP 259 EP 266 DI 10.2147/NSS.S110032 PG 8 WC Clinical Neurology SC Neurosciences & Neurology GA DU6IP UT WOS:000382318200002 PM 27555802 ER PT J AU Moro, M Goparaju, B Castillo, J Alameddine, Y Bianchi, MT AF Moro, Marilyn Goparaju, Balaji Castillo, Jelina Alameddine, Yvonne Bianchi, Matt T. TI Periodic limb movements of sleep: empirical and theoretical evidence supporting objective at-home monitoring SO NATURE AND SCIENCE OF SLEEP LA English DT Article DE periodic limb movements; polysomnography; predictors; sleep; decision analysis; cost-effectiveness; diagnostic ID RESTLESS LEGS SYNDROME; TO-NIGHT VARIABILITY; HEART-RATE-VARIABILITY; PARKINSONS-DISEASE; BLOOD-PRESSURE; CARDIOVASCULAR-DISEASE; RISK-FACTORS; DISORDER; APNEA; PREVALENCE AB Introduction: Periodic limb movements of sleep (PLMS) may increase cardiovascular and cerebrovascular morbidity. However, most people with PLMS are either asymptomatic or have nonspecific symptoms. Therefore, predicting elevated PLMS in the absence of restless legs syndrome remains an important clinical challenge. Methods: We undertook a retrospective analysis of demographic data, subjective symptoms, and objective polysomnography (PSG) findings in a clinical cohort with or without obstructive sleep apnea (OSA) from our laboratory (n=443 with OSA, n=209 without OSA). Correlation analysis and regression modeling were performed to determine predictors of periodic limb movement index (PLMI). Markov decision analysis with TreeAge software compared strategies to detect PLMS: in-laboratory PSG, at-home testing, and a clinical prediction tool based on the regression analysis. Results: Elevated PLMI values (>15 per hour) were observed in >25% of patients. PLMI values in No-OSA patients correlated with age, sex, self-reported nocturnal leg jerks, restless legs syndrome symptoms, and hypertension. In OSA patients, PLMI correlated only with age and self-reported psychiatric medications. Regression models indicated only a modest predictive value of demographics, symptoms, and clinical history. Decision modeling suggests that at-home testing is favored as the pretest probability of PLMS increases, given plausible assumptions regarding PLMS morbidity, costs, and assumed benefits of pharmacological therapy. Conclusion: Although elevated PLMI values were commonly observed, routinely acquired clinical information had only weak predictive utility. As the clinical importance of elevated PLMI continues to evolve, it is likely that objective measures such as PSG or at-home PLMS monitors will prove increasingly important for clinical and research endeavors. C1 [Moro, Marilyn; Goparaju, Balaji; Castillo, Jelina; Alameddine, Yvonne; Bianchi, Matt T.] Massachusetts Gen Hosp, Dept Neurol, 55 Fruit St, Boston, MA 02114 USA. [Bianchi, Matt T.] Harvard Med Sch, Div Sleep Med, Boston, MA USA. RP Bianchi, MT (reprint author), Massachusetts Gen Hosp, Dept Neurol, 55 Fruit St, Boston, MA 02114 USA. EM mtbianchi@partners.org NR 72 TC 0 Z9 0 U1 2 U2 2 PU DOVE MEDICAL PRESS LTD PI ALBANY PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND SN 1179-1608 J9 NAT SCI SLEEP JI NAT. SCI. SLEEP PY 2016 VL 8 BP 277 EP 289 DI 10.2147/NSS.S101753 PG 13 WC Clinical Neurology SC Neurosciences & Neurology GA DU6IR UT WOS:000382318500001 PM 27540316 ER PT J AU Francis, R Ariga, J Al Mutawa, S Soparkar, P Mascarenhas, AK AF Francis, Roy Ariga, Jitendra Al Mutawa, Sabiha Soparkar, Pramod Mascarenhas, Ana Karina TI Five-year Sealant Retention and Efficacy in a Multi-operated School-based Oral Health Programme in Kuwait SO ORAL HEALTH & PREVENTIVE DENTISTRY LA English DT Article DE caries prevention; fissure sealant; retention effectiveness; school sealant programme ID 1ST PERMANENT MOLARS; RESIN-BASED SEALANT; FISSURE SEALANTS; SINGLE APPLICATION; DENTAL-CARIES; GLASS-IONOMER; PREVENTION; PIT; OCCLUSAL; PERFORMANCE AB Purpose: To evaluate sealant retention in a multi-operator school-based oral health programme and sealant efficacy in preventing caries in a high caries-risk population. Materials and Methods: Sealant retention and caries status in previously placed sealants on permanent first molars were evaluated in 503 children ages 6 to 8 years at 20 primary schools. A total of 2538 sealants were applied on 876 first permanent molars and evaluated for retention and efficacy in preventing caries from 2002 to 2007. These sealants were placed on occlusal and buccal or palatal surfaces using a standard protocol after isolation with rubber-dam or cotton roll. Caries was scored in teeth in which the sealants were partially or completely lost. Result: 1752 sealants (69%) were examined at the end of the fifth year, with 58.3% of the sealants completely retained, 7.4% partially lost, 19% completely lost, 6.2% resealed and 9.1% restored. Only 3.1% of the previously sealed teeth were carious and 87.8% of previously sealed teeth were caries free. In multivariate analysis, occlusal surfaces were 2.0 times more likely to retain a sealant than were the buccal and palatal pits (p < 0.0001). No differences in sealant retention vs caries by arch, or teeth isolated using rubber-dam vs cotton roll were seen. Conclusion: The present study shows the effectiveness of sealants in caries prevention in a multi-operator school sealant programme, and provides evidence supporting their use in such programmes for high-caries populations. C1 [Francis, Roy; Ariga, Jitendra; Al Mutawa, Sabiha] Sch Oral Hlth Programme, PB 5338, Salmiya 22064, Kuwait. [Al Mutawa, Sabiha] Dept Dent, Kuwait, Kuwait. [Soparkar, Pramod] Forsyth Inst, Cambridge, MA USA. [Mascarenhas, Ana Karina] Nova Southeastern Univ, Coll Dent Med, Res, Ft Lauderdale, FL USA. RP Francis, R (reprint author), Sch Oral Hlth Programme, PB 5338, Salmiya 22064, Kuwait. EM royfrancisp@gmail.com NR 39 TC 0 Z9 0 U1 2 U2 2 PU QUINTESSENCE PUBLISHING CO INC PI HANOVER PARK PA 4350 CHANDLER DRIVE, HANOVER PARK, IL 60133 USA SN 1602-1622 EI 1757-9996 J9 ORAL HLTH PREV DENT JI Oral Health Prev. Dent. PY 2016 VL 14 IS 4 BP 349 EP 354 DI 10.3290/j.ohpd.a35617 PG 6 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA DT4KL UT WOS:000381448600008 PM 26870848 ER PT J AU Hong, FX Blonquist, TM Halpenny, B Berry, DL AF Hong, Fangxin Blonquist, Traci M. Halpenny, Barbara Berry, Donna L. TI Patient-reported symptom distress, and most bothersome issues, before and during cancer treatment SO PATIENT-RELATED OUTCOME MEASURES LA English DT Article DE symptom distress; perceived bother; SDS-15; prediction; most bothersome issues ID QUALITY-OF-LIFE; PROSTATE-CANCER; OLDER-ADULTS; CHEMOTHERAPY; PREVALENCE; RESPONSES; VISITS; TRIAL; MEN AB Introduction: Frequently reported symptoms and treatment side effects may not be the most bothersome issues to patients with cancer. The purpose of this study was to investigate patient-reported symptom distress and bothersome issues among participants with cancer. Methods: Participants completed the Symptom Distress Scale-15 before treatment (T1) and during cancer treatment (T2) and reported up to two most bothersome issues among symptoms rated with moderate-to-severe distress. We compared symptom ratings and perceived bother and explored two approaches predicting patients' most bothersome issues: worst absolute symptom score or worst change from pretreatment. Results: Significantly, (P=0.0002) more patients reported moderate-to-severe distress at T2 for eight of 13 symptoms. At T1, 81% of patients reported one and 56% reported multiple symptoms with moderate-to-severe distress, while at T2, 89% reported one and 69% reported multiple symptoms with moderate-to-severe distress. Impact on sexual activity/interest, pain, fatigue, and insomnia were the most prevalent symptoms with moderate-to-severe distress. Fatigue, pain, and insomnia were perceived most often as bothersome. When one symptom was rated moderate-to-severe, predictive accuracy of the absolute score was 46% and 48% (T1 & T2) and 38% with the change score (T2-T1). When two or more symptoms were rated moderate-to-severe, predictive accuracy of the absolute score was 76% and 79% (T1 & T2) and 70% with the change score (T2-T1). Conclusion: More patients experienced moderate-to-severe symptom distress after treatment initiation. Patient identification of bothersome issues could not be assumed based on prevalence of symptoms reported with moderate-to-severe distress. The absolute symptom distress scores identified patients' most bothersome issues with good accuracy, outperforming change scores. C1 [Hong, Fangxin; Blonquist, Traci M.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [Hong, Fangxin] Harvard Sch Publ Hlth, Dept Biostat, Boston, MA USA. [Halpenny, Barbara; Berry, Donna L.] Dana Farber Canc Inst, Phyllis F Cantor Ctr, Dept Nursing & Patient Care Serv, Boston, MA 02115 USA. [Berry, Donna L.] Harvard Med Sch, Dept Med, Boston, MA USA. RP Hong, FX (reprint author), Harvard Sch Publ Hlth, Dana Farber Canc Inst, Dept Biostat & Computat Biol, 450 Brookline Ave,Mailstop CLSB 11007, Boston, MA 02115 USA. EM fxhong@jimmy.harvard.edu FU NINR NIH HHS [R01 NR008726] NR 26 TC 0 Z9 0 U1 2 U2 2 PU DOVE MEDICAL PRESS LTD PI ALBANY PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND SN 1179-271X J9 PATIENT-RELAT OUTCOM JI PATIENT-RELAT. OUTCOME MEAS. PY 2016 VL 7 BP 127 EP 135 DI 10.2147/PROM.S95593 PG 9 WC Health Care Sciences & Services SC Health Care Sciences & Services GA DV4EU UT WOS:000382879000001 PM 27672346 ER PT J AU Sabatine, MS Underberg, JA Koren, M Baum, SJ AF Sabatine, Marc S. Underberg, James A. Koren, Michael Baum, Seth J. TI Focus on PCSK9 Inhibitors: From Genetics to Clinical Practice: Highlights from a CME symposium held at the Cardiometabolic Health Congress (CMHC) Sheraton Boston Hotel, Boston, MA, USA, 23 October 2015 SO POSTGRADUATE MEDICINE LA English DT Article DE PCSK9 inhibitors; LDL-C; lipid disorders; familial hypercholesterolemia; statin intolerance ID PLACEBO-CONTROLLED TRIAL; SUBTILISIN/KEXIN TYPE 9; HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA; MONOCLONAL-ANTIBODY; DOUBLE-BLIND; ENDOPLASMIC-RETICULUM; CARDIOVASCULAR EVENTS; REDUCING LIPIDS; CHOLESTEROL; EFFICACY AB Elevation of low-density lipoprotein cholesterol (LDL-C) is an important cause of atherosclerotic cardiovascular disease (ASCVD). Over the years, clinical outcome studies with LDL-C lowering agents have revealed that reducing LCL-C levels is effective in reducing rates of major ASCVD events. Although secondary factors play a role in clinical expression, severe lipid disorders often have a strong genetic component. Genetic revelations have provided novel targets for improving LDL-C management in high-risk individuals. Most recently, researchers have explored how the inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9) alters LDL metabolism and lowers LDL-C levels to achieve lipid goals and potentially reduce ASCVD risk in patients with severe lipid disorders, including familial hypercholesterolemia (FH). This CMHC Spotlight article summarizes the clinical evidence demonstrating the safety, tolerability, and efficacy of PCSK9 inhibitors in lowering LDL-C levels. Reductions in LDL-C levels by PCSK9 inhibitors alone in patients who are statin intolerant or combined with maximally tolerated statins in patients with severe lipid disorders demonstrate the potential for reduced morbidity and mortality associated with ASCVD. C1 [Sabatine, Marc S.] Brigham & Womens Hosp, TIMI Study Grp, Div Cardiovasc Med, 75 Francis St, Boston, MA 02115 USA. [Sabatine, Marc S.] Harvard Med Sch, Dept Med, Boston, MA USA. [Underberg, James A.] NYU, Sch Med, Ctr CVD Prevent, Bellevue Hosp Lipid Clin, New York, NY USA. [Koren, Michael] Jacksonville Ctr Clin Res, Jacksonville, FL USA. [Koren, Michael] Acad Phys Clin Res, Jacksonville, FL USA. [Baum, Seth J.] MB Clin Res, Glen Ellyn, IL USA. [Baum, Seth J.] Amer Soc Prevent Cardiol, Jacksonville, FL USA. [Baum, Seth J.] FH Fdn, Jacksonville, FL USA. RP Sabatine, MS (reprint author), Brigham & Womens Hosp, TIMI Study Grp, Div Cardiovasc Med, 75 Francis St, Boston, MA 02115 USA.; Sabatine, MS (reprint author), Harvard Med Sch, Dept Med, Boston, MA USA. EM msabatine@partners.org FU Amgen; Abbott Laboratories; AstraZeneca; Critical Diagnostics; Daiichi Sankyo; Eisai; Gilead; GlaxoSmithKline; Intarcia; Merck; Roche Diagnostics; Sanofi-Aventis; Takeda; Alnylam; Cubist; CVS Caremark; Pfizer; Kowa; Aegerion; Novartis; Esperion; Liposcience; Amarin; Aegerion Pharmaceuticals Inc.; Genzyme FX This paper was funded by Amgen, through support provided to the 2015 Cardiometabolic Health Congress (CMHC); editorial support was arranged by CMHC. Editorial support was provided by Paul Cerrato, Robert E. Lamb, and Erin Franceschini. MS Sabatine has received grants/research support from Abbott Laboratories, Amgen, AstraZeneca, Critical Diagnostics, Daiichi Sankyo, Eisai, Gilead, GlaxoSmithKline, Intarcia, Merck, Roche Diagnostics, Sanofi-Aventis and Takeda, as well as consulting fees from Alnylam, Amgen, AstraZeneca, Cubist, CVS Caremark, Intarcia and Merck. JA Underberg has received grants/research support from Pfizer, Kowa and Aegerion, as well as consulting fees from Amgen, Sanofi, Novartis, Esperion, Liposcience and Amarin, and he has been on the Speakers' Bureau for Merck, Amarin, Sanofi, Genzyme, Kowa and AstraZeneca. M Koren has received grants/research support from Sanofi, Regeneron, Amgen and Pfizer, and been on the Speakers' Bureau for Sanofi, Regeneron and Amgen. SJ Baum has received consulting fees from Merck, AstraZeneca, Aegerion Pharmaceuticals Inc., Genzyme and Sanofi, and been on the Speakers' Bureau for Merck, AstraZeneca, Aegerion Pharmaceuticals Inc., Genzyme and Sanofi. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. NR 36 TC 0 Z9 0 U1 1 U2 1 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND SN 0032-5481 EI 1941-9260 J9 POSTGRAD MED JI Postgrad. Med. PY 2016 VL 128 SU 1 BP 31 EP 39 DI 10.1080/00325481.2016.1208895 PG 9 WC Medicine, General & Internal SC General & Internal Medicine GA DT4AH UT WOS:000381421800004 PM 27422124 ER PT J AU Pi-Sunyer, X Shanahan, W Fain, R Ma, T Garvey, WT AF Pi-Sunyer, Xavier Shanahan, William Fain, Randi Ma, Tony Garvey, W. Timothy TI Impact of lorcaserin on glycemic control in overweight and obese patients with type 2 diabetes: analysis of week 52 responders and nonresponders SO POSTGRADUATE MEDICINE LA English DT Article DE Obesity; overweight; diabetes mellitus; weight loss; lorcaserin ID NEURONS REGULATE ENERGY; SEROTONIN 2C RECEPTORS; WEIGHT-LOSS; CLINICAL ENDOCRINOLOGISTS; AMERICAN ASSOCIATION; GLUCOSE-HOMEOSTASIS; UNITED-STATES; MANAGEMENT; MELLITUS; TRIAL AB Objectives: Treatment guidelines for type 2 diabetes mellitus (T2DM) suggest weight loss as a means to maintain glycemic control. Lorcaserin has been approved for chronic weight management in the United States as an adjunct to a reduced-calorie diet and exercise, and the previous phase 3 Behavioral Modification and Lorcaserin for Obesity and Overweight Management in Diabetes Mellitus (BLOOM-DM) study has shown that, in addition to weight loss, lorcaserin is associated with improvements in glycemic parameters. In this post hoc analysis of the BLOOM-DM trial, the relationship between responder status (patients achieving 5% weight loss at Week 52) and glycemic and cardiometabolic parameters is evaluated.Methods: Data are presented for patients receiving lorcaserin 10mg twice daily or placebo for 52 weeks.Results: More than twice as many patients receiving lorcaserin plus diet and exercise counseling were classified as Week 52 responders compared to those receiving diet and exercise counseling alone (37.5% vs. 16.1%, respectively; p<0.001), and lorcaserin Week 52 responders had greater improvements vs. placebo Week 52 responders in FPG (-38.1mg/dL vs. -26.0mg/dL) and HbA1c (-1.3% vs. -1.0%). Furthermore, more lorcaserin-treated Week 52 responders decreased the number of concomitant oral antidiabetic medications (OADs) used, and fewer increased the number of OADs used, compared to placebo. Unexpectedly, lorcaserin Week 52 nonresponders also had substantial reductions in glycemic levels, despite very modest weight loss.Conclusions: These data support lorcaserin use in overweight and obese patients with T2DM to promote weight loss and facilitate glycemic control.Clinical trial registration: www.clinicaltrials.gov identifier is NCT00603291 C1 [Pi-Sunyer, Xavier] Columbia Univ, Med Ctr, Div Endocrinol, New York, NY USA. [Shanahan, William] Arena Pharmaceut Inc, Div Preclin & Clin Drug Dev, San Diego, CA USA. [Fain, Randi; Ma, Tony] Eisai Inc, Global Neurosci Business Unit, Woodcliff Lake, NJ USA. [Garvey, W. Timothy] Univ Alabama Birmingham, Dept Nutr Sci, Birmingham, AL 35294 USA. [Garvey, W. Timothy] Birmingham VA Med Ctr, Birmingham, AL USA. RP Pi-Sunyer, X (reprint author), Columbia Univ, Med Ctr, New York Obes Nutr Res Ctr, Russ Berrie Pavil,1150 St Nicholas Ave, New York, NY 10032 USA. EM fxp1@columbia.edu FU Arena Pharmaceuticals, Inc.; Eisai Inc. FX The BLOOM-DM study was funded by Arena Pharmaceuticals, Inc., and this post hoc analysis was funded by Eisai Inc. Editorial support was provided by Medicus International New York and Imprint Publication Science, New York, NY, USA, with funding from Eisai Inc. X Pi-Sunyer is on Scientific Advisory Committees for Lilly, Novo Nordisk, Vivus, Eisai, and Zafgen. WT Garvey has served on advisory boards for Eisai Inc., Novo Nordisk, Daiichi-Sankyo, Liposcience, Vivus, Takeda, Janssen, Boehringer Ingelheim, and AstraZeneca; and has conducted research for Eisai Inc., Merck, Sanofi, AstraZeneca, Weight Watchers, Pfizer, Lexicon, Elcelyx Therapeutics, and Novo Nordisk. T Ma and R Fain are former employees of Eisai Inc. W Shanahan is a former employee of Arena Pharmaceuticals, Inc. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. NR 34 TC 0 Z9 0 U1 2 U2 2 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND SN 0032-5481 EI 1941-9260 J9 POSTGRAD MED JI Postgrad. Med. PY 2016 VL 128 IS 6 BP 591 EP 597 DI 10.1080/00325481.2016.1208618 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA DU7GO UT WOS:000382382000009 PM 27389084 ER PT J AU Gordon, AJ Saba, SK AF Gordon, Adam J. Saba, Shaddy K. TI Confronting the opioid epidemic through publication, promotion, and dissemination of evidence-based addiction scholarship SO SUBSTANCE ABUSE LA English DT Editorial Material ID CHRONIC PAIN; PRESCRIBING OPIOIDS; CDC GUIDELINE; UNITED-STATES; STIGMA C1 [Gordon, Adam J.] Univ Pittsburgh, Div Gen Internal Med, Pittsburgh, PA 15240 USA. [Gordon, Adam J.] VA Pittsburgh Healthcare Syst, CHERP, Pittsburgh, PA 15240 USA. [Gordon, Adam J.; Saba, Shaddy K.] VA Pittsburgh Healthcare Syst, VA Off Acad Affiliat, Interdisciplinary Addict Program Educ & Res VIPER, Pittsburgh, PA 15240 USA. RP Gordon, AJ (reprint author), Univ Pittsburgh, Univ Dr C Mailcode 151-C, Pittsburgh, PA 15240 USA.; Gordon, AJ (reprint author), VA Pittsburgh Healthcare Syst, Univ Dr C Mailcode 151-C, Pittsburgh, PA 15240 USA. EM gordona@medschool.pitt.edu NR 6 TC 0 Z9 0 U1 0 U2 0 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 0889-7077 EI 1547-0164 J9 SUBST ABUS JI Subst. Abus. PY 2016 VL 37 IS 3 BP 379 EP 380 DI 10.1080/08897077.2016.1208988 PG 2 WC Substance Abuse SC Substance Abuse GA DV2RW UT WOS:000382769800001 PM 27712565 ER PT J AU Clark, BJ Rubinsky, AD Ho, PM Au, DH Chavez, LJ Moss, M Bradley, KA AF Clark, Brendan J. Rubinsky, Anna D. Ho, P. Michael Au, David H. Chavez, Laura J. Moss, Marc Bradley, Katharine A. TI Alcohol screening scores and the risk of intensive care unit admission and hospital readmission SO SUBSTANCE ABUSE LA English DT Article DE Alcohol abuse; alcohol consumption; alcohol-related disorders; intensive care units; patient readmission; health care utilization ID RESPIRATORY-DISTRESS-SYNDROME; MULTIPLE ORGAN DYSFUNCTION; SERVICES TASK-FORCE; USE DISORDERS; BRIEF INTERVENTION; MECHANICAL VENTILATION; CONSUMPTION QUESTIONS; CONTROLLED-TRIAL; SEPTIC SHOCK; AUDIT-C AB Background: The association between alcohol misuse and the need for intensive care unit admission as well as hospital readmission among those discharged from the hospital following a critical illness is unclear. This study sought to determine whether alcohol misuse was associated with (1) admission to an intensive care unit (ICU) among a cohort of patients receiving outpatient care and (2) hospital readmission among those discharged from the hospital following critical illness. Methods: This was a retrospective cohort study conducted with data from 24 Veterans Affairs (VA) health care facilities between 2004 and 2007. Scores on the Alcohol Use Disorders Identification TestConsumption (AUDIT-C) questionnaire were used to identify patients with past-year abstinence, lower-risk alcohol use, moderate alcohol misuse, or severe alcohol misuse. The primary outcome was admission to a VA intensive care unit within the year following administration of the AUDIT-C. In an analysis focused on patients discharged from the ICU, the 2 main outcomes were hospital readmission within 1year and within 30days. Results: Among 486,115 veterans receiving outpatient care, the adjusted probability of ICU admission within 1year was 2.0% (95% confidence interval [CI]: 1.7%-2.3%) for abstinent patients, 1.6% (95% CI: 1.3%-1.8%) for patients with lower-risk alcohol use, 1.8% (1.4%-2.3%) for patients with moderate alcohol misuse, and 2.5% (2.0%-2.9%) for patients with severe alcohol misuse. Among the 9,030 patients discharged from an ICU, the adjusted probability of hospital readmission within 1year was 48% (46%-49%) in abstinent patients, 44% (42%-45%) in patients with lower-risk alcohol use, 42% (39%-45%) in patients with moderate alcohol misuse, and 55% (49%-60%) in patients with severe alcohol misuse. Conclusions: Alcohol misuse may represent a modifiable risk factor for a cycle of ICU admission and subsequent hospital readmission. C1 [Clark, Brendan J.; Moss, Marc] Univ Colorado, Div Pulm Sci & Crit Care Med, RC2,Box C272,9th Floor,12700 East 19th Ave, Aurora, CO 80045 USA. [Rubinsky, Anna D.; Bradley, Katharine A.] Dept Vet Affairs Puget Sound Hlth Care Syst, Ctr Excellence Subst Abuse Treatment & Educ, Seattle, WA USA. [Rubinsky, Anna D.; Au, David H.; Chavez, Laura J.; Bradley, Katharine A.] Dept Vet Affairs Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA USA. [Ho, P. Michael] Denver VA Med Ctr, Div Cardiol, Dept Med, Denver, CO USA. [Ho, P. Michael] Univ Colorado, Div Cardiol, Dept Med, Aurora, CO 80045 USA. [Bradley, Katharine A.] Grp Hlth Res Inst, Seattle, WA USA. RP Clark, BJ (reprint author), Univ Colorado, Div Pulm Sci & Crit Care Med, RC2,Box C272,9th Floor,12700 East 19th Ave, Aurora, CO 80045 USA. EM Brendan.clark@ucdenver.edu FU Merit Review Award [. IIR 08-314]; United States Department of Veterans Affairs Health Services Research and Development Program; Center of Excellence for Substance Abuse Treatment and Education; NIH/NCATS Colorado CTSI [UL1 TR001082]; National Institute on Alcohol Abuse and Alcoholism [K23 AA 021814]; National Heart Lung and Blood Institute [K24 HL 089223]; Agency for Healthcare Research and Quality [R36 HS 022800]; VA Information Resource Center [SDR 02-237, SDR 98-004] FX This work was supported by Merit Review Award no. IIR 08-314 from the United States Department of Veterans Affairs Health Services Research and Development Program, the Center of Excellence for Substance Abuse Treatment and Education, NIH/NCATS Colorado CTSI Grant Number UL1 TR001082, the National Institute on Alcohol Abuse and Alcoholism (K23 AA 021814), the National Heart Lung and Blood Institute (K24 HL 089223), and the Agency for Healthcare Research and Quality (R36 HS 022800). Support for VA/CMS data is provided by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research and Development, VA Information Resource Center (project numbers SDR 02-237 and 98-004). The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs, the United States Government, or any of the authors' institutions. The funding agencies were not involved in the design of this study, analysis of data, or preparation of the manuscript. The authors declare that they have no conflicts of interest. NR 62 TC 1 Z9 1 U1 2 U2 2 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 0889-7077 EI 1547-0164 J9 SUBST ABUS JI Subst. Abus. PY 2016 VL 37 IS 3 BP 466 EP 473 DI 10.1080/08897077.2015.1137259 PG 8 WC Substance Abuse SC Substance Abuse GA DV2RW UT WOS:000382769800015 PM 26730984 ER PT J AU Gakis, G Efstathiou, JA Daneshmand, S Keegan, KA Clayman, RH Hrbacek, J Ali-El-Dein, B Zaid, HB Schubert, T Mischinger, J Todenhofer, T Galland, S Olugbade, K Rink, M Fritsche, HM Burger, M Chang, SS Babjuk, M Thalmann, GN Stenzl, A Morgan, TM AF Gakis, Georgios Efstathiou, Jason A. Daneshmand, Siamak Keegan, Kirk A. Clayman, Rebecca H. Hrbacek, Jan Ali-El-Dein, Bedeir Zaid, Harras B. Schubert, Tina Mischinger, Johannes Todenhoefer, Tilman Galland, Sigolene Olugbade, Kola, Jr. Rink, Michael Fritsche, Hans-Martin Burger, Maximilian Chang, Sam S. Babjuk, Marko Thalmann, George N. Stenzl, Arnulf Morgan, Todd M. TI Oncological Outcomes of Patients with Concomitant Bladder and Urethral Carcinoma SO UROLOGIA INTERNATIONALIS LA English DT Article DE Bladder cancer; Lymph node; Prognosis; Radical cystectomy; Risk factor; Survival; Urethra ID INTERNATIONAL COLLABORATION; PROGNOSTIC-FACTORS; URINARY-BLADDER; CANCER; SURVIVAL; TUMORS; TRACT AB Introduction: The study aimed to investigate oncological outcomes of patients with concomitant bladder cancer (BC) and urethral carcinoma. Methods: This is a multicenter series of 110 patients (74 men, 36 women) diagnosed with urethral carcinoma at 10 referral centers between 1993 and 2012. Kaplan Meier analysis was used to investigate the impact of BC on survival, and Cox regression multivariable analysis was performed to identify predictors of recurrence. Results: Synchronous BC was diagnosed in 13 (12%) patients, and the median follow-up was 21 months (interquartile range 4-48). Urethral cancers were of higher grade in patients with synchronous BC compared to patients with non-synchronous BC (p = 0.020). Patients with synchronous BC exhibited significantly inferior 3-year recurrence-free survival (RFS) compared to patients with non-synchronous BC (63.2 vs. 34.4%; p = 0.026). In multivariable analysis, inferior RFS was associated with clinically advanced nodal stage (p < 0.001), proximal tumor location (p < 0.001) and synchronous BC (p = 0.020). Conclusion: The synchronous presence of BC in patients diagnosed with urethral carcinoma has a significant adverse impact on RFS and should be an impetus for a multimodal approach. (C) 2016 5. Karger AG, Basel C1 [Olugbade, Kola, Jr.; Morgan, Todd M.] Univ Michigan, Dept Urol, Ann Arbor, MI 48109 USA. [Efstathiou, Jason A.; Clayman, Rebecca H.; Galland, Sigolene] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA USA. [Daneshmand, Siamak] USC Norris Comprehens Canc Ctr, Inst Urol, Los Angeles, CA USA. [Keegan, Kirk A.; Zaid, Harras B.; Chang, Sam S.] Vanderbilt Univ, Med Ctr, Dept Urol Surg, Nashville, TN USA. [Hrbacek, Jan; Babjuk, Marko] Charles Univ Prague, Fac Med 2, Dept Urol, Prague, Czech Republic. [Ali-El-Dein, Bedeir] Mansoura Clin, Urol & Nephrol Ctr, Mansoura, Egypt. [Gakis, Georgios; Schubert, Tina; Mischinger, Johannes; Todenhoefer, Tilman; Stenzl, Arnulf] Univ Tubingen, Dept Urol, Tubingen, Germany. [Rink, Michael] Univ Med Ctr Hamburg Eppendorf, Dept Urol, Hamburg, Germany. [Fritsche, Hans-Martin; Burger, Maximilian] Univ Hosp Regensburg, Dept Urol, Regensburg, Germany. [Thalmann, George N.] Univ Hosp Bern, Dept Urol, Bern, Switzerland. RP Gakis, G (reprint author), Univ Tubingen, Univ Hosp Tubingen, Dept Urol, Hoppe Seyler Str 3, DE-72076 Tubingen, Germany. EM georgios.gakis@googlemail.com NR 13 TC 0 Z9 0 U1 1 U2 1 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0042-1138 EI 1423-0399 J9 UROL INT JI Urol.Int. PY 2016 VL 97 IS 2 BP 134 EP 141 DI 10.1159/000448335 PG 8 WC Urology & Nephrology SC Urology & Nephrology GA DV1VZ UT WOS:000382711500002 PM 27462702 ER PT J AU Mifflin, J AF Mifflin, Jeffrey TI The Journey of "A Good Type": From Artistry to Ethnography in Early Japanese Photography SO VISUAL ANTHROPOLOGY LA English DT Book Review C1 [Mifflin, Jeffrey] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Mifflin, J (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. EM jmifflin@partners.org NR 1 TC 0 Z9 0 U1 0 U2 0 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 0894-9468 EI 1545-5920 J9 VIS ANTHROPOL JI Vis. Anthropol. PY 2016 VL 29 IS 4-5 BP 460 EP 462 DI 10.1080/08949468.2016.1192437 PG 3 WC Anthropology SC Anthropology GA DT3TR UT WOS:000381404400009 ER PT J AU Canterberry, M Peltier, MR Brady, KT Hanlon, CA AF Canterberry, Melanie Peltier, MacKenzie R. Brady, Kathleen T. Hanlon, Colleen A. TI Attenuated neural response to emotional cues in cocaine-dependence: a preliminary analysis of gender differences SO AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE LA English DT Article DE Cocaine; emotion; fMRI; addiction; gender ID SUBSTANCE USE DISORDERS; FUNCTIONAL NEUROANATOMY; PREFRONTAL CORTEX; CHOICE PROCEDURE; NEGATIVE AFFECT; SEX-DIFFERENCES; DRUG-ADDICTION; ACTIVATION; FMRI; METAANALYSIS AB Background: Cocaine users often report a loss of arousal for nondrug-related stimuli, which may contribute to their response to drug-related rewards. However, little is known about users' neural reactivity to emotional nondrug-related stimuli and the potential influence of gender. Objectives: Test the hypotheses that cocaine-dependent individuals have an attenuated neural response to arousing stimuli relative to controls and that this difference is amplified in women. Methods: The brain response to typically arousing positive and negative images as well as neutral images from the International Affective Picture System was measured in 40 individuals (20 non-treatment seeking cocaine-dependent and 20 age- and gender-matched control participants; 50% of whom were women). Images were displayed for 4 s each in blocks of five across two 270-second runs. General linear models assessed within and between group activation differences for the emotional images. Results: Cocaine-dependent individuals had a significantly lower response to typically arousing positive and negative images than controls, with attenuated neural activity present in the medial prefrontal cortex (mPFC) and anterior cingulate cortex (ACC). Analyses by gender revealed less mPFC/ACC activation among female users, but not males, for both positive and negative images. Conclusion: The dampened neural response to typically arousing stimuli among cocaine-dependent polydrug users suggests decreased salience processing for nondrug stimuli, particularly among female users. This decreased responding is consistent with data from other substance using populations and suggests that this may be a general feature of addiction. Amplifying the neural response to naturally arousing nondrug-related reinforcers may present an opportunity for unique behavioral and brain stimulation therapies. C1 [Canterberry, Melanie; Peltier, MacKenzie R.; Brady, Kathleen T.; Hanlon, Colleen A.] Med Univ South Carolina, Dept Psychiat & Behav Sci, Charleston, SC USA. [Peltier, MacKenzie R.] Louisiana State Univ, Dept Psychol, Baton Rouge, LA 70803 USA. [Brady, Kathleen T.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Hanlon, CA (reprint author), Med Univ South Carolina, Dept Psychiat, 67 President St,Room 502 North, Charleston, SC 29425 USA. EM hanlon@musc.edu FU National Institutes of Health [F32DA036329, K01DA0267756] FX The effort for this research was supported by the National Institutes of Health (F32DA036329 to MC and K01DA0267756 to CAH). NR 53 TC 0 Z9 0 U1 0 U2 0 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 0095-2990 EI 1097-9891 J9 AM J DRUG ALCOHOL AB JI Am. J. Drug Alcohol Abuse PY 2016 VL 42 IS 5 BP 577 EP 586 DI 10.1080/00952990.2016.1192183 PG 10 WC Psychology, Clinical; Substance Abuse SC Psychology; Substance Abuse GA DU7XX UT WOS:000382429000013 PM 27441590 ER PT J AU Pinder, LF Nelson, BD Eckardt, M Goodman, A AF Pinder, Leeya F. Nelson, Brett D. Eckardt, Melody Goodman, Annekathryn TI A Public Health Priority: Disparities in Gynecologic Cancer Research for African-Born Women in the United States SO CLINICAL MEDICINE INSIGHTS-WOMENS HEALTH LA English DT Article DE maternal health; refugee health; African-born immigrants; immigrant health; cancer screening; research disparities ID BARRIERS; CARE; PARTICIPATION; IMMIGRANTS; ACCESS AB African-born immigrants comprise one of the fastest growing populations in the U.S., nearly doubling its population size in recent years. However, it is also one of the most underrepresented groups in health-care research, especially research focused on gynecologic and breast malignancies. While the opportunity exists for access to an advanced health-care system, as immigrants migrate to the U.S., they encounter the same health-care inequalities that are faced by the native-born population based on ethnicity and social class, potentiated by limitations of health literacy and lack of familiarity with U.S. health systems. Given the continued influx of African-born immigrants in the U.S., we sought to understand the representation of this population in cervical and breast cancer research, recognizing the population's high risk for these diseases at baseline while residing in their native countries. We determined that there is limited research in these diseases that disproportionately affect them; yet, there are identifiable and potentially modifiable factors that contribute to this paucity of evidence. This clinical commentary seeks to underscore the clear lack of research available involving African-born immigrants with respect to gynecologic and breast malignancies in the existing literature, demonstrate the need for more robust research in this population, and provide fundamental insights into barriers and solutions critical to the continued health of this growing population. C1 [Pinder, Leeya F.; Nelson, Brett D.; Eckardt, Melody] Massachusetts Gen Hosp, Dept Emergency Med, Div Global Hlth & Human Rights, Boston, MA 02114 USA. [Pinder, Leeya F.; Nelson, Brett D.; Eckardt, Melody; Goodman, Annekathryn] Harvard Med Sch, Boston, MA 02115 USA. [Pinder, Leeya F.] Boston Univ, Sch Med, Dept Obstet & Gynecol, Boston, MA 02118 USA. [Goodman, Annekathryn] Massachusetts Gen Hosp, Dept Obstet & Gynecol, Div Gynecol Oncol, Boston, MA 02114 USA. RP Pinder, LF (reprint author), Massachusetts Gen Hosp, Dept Emergency Med, Div Global Hlth & Human Rights, Boston, MA 02114 USA.; Pinder, LF (reprint author), Harvard Med Sch, Boston, MA 02115 USA.; Pinder, LF (reprint author), Boston Univ, Sch Med, Dept Obstet & Gynecol, Boston, MA 02118 USA. EM leeyapinder@gmail.com OI Nelson, Brett/0000-0002-5049-1798 NR 23 TC 0 Z9 0 U1 0 U2 0 PU LIBERTAS ACAD PI AUCKLAND PA PO BOX 300-874, ALBANY 0752, AUCKLAND, 00000, NEW ZEALAND SN 1179-562X J9 CLIN MED INSIGHTS-WO JI Clin. Med. Insights-Womens Health PY 2016 VL 9 BP 21 EP 26 DI 10.4137/CMWH.S39867 PG 6 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA DU7GA UT WOS:000382380400001 PM 27499654 ER PT S AU Ciarlo, CA Zon, LI AF Ciarlo, C. A. Zon, L. I. BE Detrich, HW Westerfield, M Zon, LI TI Embryonic cell culture in zebrafish SO ZEBRAFISH: CELLULAR AND DEVELOPMENTAL BIOLOGY, PT A: CELLULAR BIOLOGY, 4TH EDITION SE Methods in Cell Biology LA English DT Review; Book Chapter ID MYOGENESIS; LINE AB Zebrafish embryonic cell cultures have many useful properties that make them complementary to intact embryos for a wide range of studies. Embryonic cell cultures allow for maintenance of transient cell populations, control of chemical and mechanical cues received by cells, and facile chemical screening. Zebrafish cells can be cultured in either heterogeneous or homogeneous cultures from a wide range of developmental time points. Here we describe two methods with particular applicability to chemical screening: a method for the culture of blastomeres for directed differentiation toward the myogenic lineage and a method for the culture of neural crest cells in heterogeneous cultures from early somitogenesis embryos. C1 [Ciarlo, C. A.] Harvard Med Sch, Boston, MA 02115 USA. [Ciarlo, C. A.; Zon, L. I.] Childrens Hosp, 300 Longwood Ave, Boston, MA 02115 USA. [Zon, L. I.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Zon, L. I.] Harvard Univ, Cambridge, MA 02138 USA. RP Ciarlo, CA (reprint author), Harvard Med Sch, Boston, MA 02115 USA.; Ciarlo, CA (reprint author), Childrens Hosp, 300 Longwood Ave, Boston, MA 02115 USA. EM caciarlo@enders.tch.harvard.edu FU NCI NIH HHS [R01 CA103846] NR 9 TC 0 Z9 0 U1 6 U2 6 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA SN 0091-679X BN 978-0-12-803489-7; 978-0-12-803475-0 J9 METHOD CELL BIOL JI Methods Cell Biol. PY 2016 VL 133 BP 1 EP 10 DI 10.1016/bs.mcb.2016.02.010 PG 10 WC Cell Biology; Marine & Freshwater Biology SC Cell Biology; Marine & Freshwater Biology GA BF5OS UT WOS:000382401100002 PM 27263406 ER PT S AU Detrich, HW Westerfield, M Zon, LI AF Detrich, H. William, III Westerfield, Monte Zon, Leonard I. BE Detrich, HW Westerfield, M Zon, LI TI Methods in Cell Biology The Zebrafish: Cellular and Developmental Biology, Part A Cellular Biology Volume 133 Preface SO ZEBRAFISH: CELLULAR AND DEVELOPMENTAL BIOLOGY, PT A: CELLULAR BIOLOGY, 4TH EDITION SE Methods in Cell Biology LA English DT Editorial Material; Book Chapter C1 [Detrich, H. William, III] Northeastern Univ, Ctr Marine Sci, Nahant, MA 01908 USA. [Westerfield, Monte] Univ Oregon, Eugene, OR 97403 USA. [Zon, Leonard I.] Childrens Hosp, 300 Longwood Ave, Boston, MA 02115 USA. [Zon, Leonard I.] Dana Farber Canc Inst, Boston, MA 02115 USA. [Zon, Leonard I.] Harvard Univ, Cambridge, MA 02138 USA. RP Detrich, HW (reprint author), Northeastern Univ, Ctr Marine Sci, Nahant, MA 01908 USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA SN 0091-679X BN 978-0-12-803489-7; 978-0-12-803475-0 J9 METHOD CELL BIOL JI Methods Cell Biol. PY 2016 VL 133 BP XV EP XVI PG 2 WC Cell Biology; Marine & Freshwater Biology SC Cell Biology; Marine & Freshwater Biology GA BF5OS UT WOS:000382401100001 ER PT S AU Drummond, IA Davidson, AJ AF Drummond, I. A. Davidson, A. J. BE Detrich, HW Westerfield, M Zon, LI TI Zebrafish kidney development SO ZEBRAFISH: CELLULAR AND DEVELOPMENTAL BIOLOGY, PT B: DEVELOPMENTAL BIOLOGY SE Methods in Cell Biology LA English DT Review; Book Chapter ID RETINOIC ACID; NEPHRON SEGMENTATION; SLIT DIAPHRAGM; PODOCYTE DIFFERENTIATION; INTERMEDIATE MESODERM; DEVELOPING PRONEPHROS; TRANSGENIC ZEBRAFISH; EXPRESSION ANALYSIS; CL COTRANSPORTER; GENE-EXPRESSION AB The kidney of the zebrafish shares many features with other vertebrate kidneys including the human kidney. Similar cell types and shared developmental and patterning mechanisms make the zebrafish pronephros a valuable model for kidney organogenesis. Here we review recent advances in studies of zebrafish pronephric development and provide experimental protocols to analyze kidney cell types and structures, measure nephron function, live image kidney cells in vivo, and probe mechanisms of kidney regeneration after injury. C1 [Drummond, I. A.] Massachusetts Gen Hosp, Charlestown, MA 02129 USA. [Davidson, A. J.] Univ Auckland, Auckland, New Zealand. RP Drummond, IA (reprint author), Massachusetts Gen Hosp, Charlestown, MA 02129 USA. EM idrummond@mgh.harvard.edu NR 117 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA SN 0091-679X BN 978-0-12-805206-8 J9 METHOD CELL BIOL JI Methods Cell Biol. PY 2016 VL 134 BP 391 EP 429 DI 10.1016/bs.mcb.2016.03.041 PG 39 WC Cell Biology; Marine & Freshwater Biology SC Cell Biology; Marine & Freshwater Biology GA BF5LE UT WOS:000382187900013 PM 27312500 ER PT S AU Wojciechowska, S van Rooijen, E Ceol, C Patton, EE White, RM AF Wojciechowska, S. van Rooijen, E. Ceol, C. Patton, E. E. White, R. M. BE Detrich, HW Westerfield, M Zon, LI TI Generation and analysis of zebrafish melanoma models SO ZEBRAFISH: CELLULAR AND DEVELOPMENTAL BIOLOGY, PT B: DEVELOPMENTAL BIOLOGY SE Methods in Cell Biology LA English DT Review; Book Chapter ID IN-VIVO; METASTATIC MELANOMA; BRAF MUTATIONS; MITF MUTATION; NEURAL-CREST; RESISTANCE; PATHWAY; CANCER; INHIBITION; PREDISPOSES AB The rapid emergence of the zebrafish as a cancer model has been aided by advances in genetic, chemical, and imaging technologies. Melanoma in particular highlights both the power and challenges associated with cancer modeling in zebrafish. This chapter focuses on the lessons that have emerged from the melanoma models as paradigmatic of what will apply to nearly all cancer models in the zebrafish system. We specifically focus on methodologies related to germline and mosaic transgenic melanoma generation, and how these can be used to deeply interrogate additional cooperating oncogenes or tumor suppressors. These transgenic tumors can in turn be used to generate zebrafish-specific, stable melanoma cell lines which can be fluorescently labeled, modified by cDNA/CRISPR techniques, and used for detailed in vivo imaging of cancer progression in real time. These zebrafish melanoma models are beginning to elucidate both cell intrinsic and microenvironmental factors in melanoma that have broader implications for human disease. We envision that nearly all of the techniques described here can be applied to other zebrafish cancer models, and likely expanded beyond what we describe here. C1 [Wojciechowska, S.; Patton, E. E.] Univ Edinburgh, MRC Human Genet Unit, Edinburgh EH8 9YL, Midlothian, Scotland. [Wojciechowska, S.; Patton, E. E.] Univ Edinburgh, Canc Res UK Ctr, Inst Genet & Mol Med, Edinburgh EH8 9YL, Midlothian, Scotland. [van Rooijen, E.] Boston Childrens Hosp, Stem Cell Program, Boston, MA USA. [van Rooijen, E.] Boston Childrens Hosp, Div Pediat Hematol Oncol, Boston, MA USA. [van Rooijen, E.] Howard Hughes Med Inst, Dana Farber Canc Inst, Boston, MD USA. [van Rooijen, E.] Harvard Med Sch, Boston, MA USA. [Ceol, C.] Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA USA. [Ceol, C.] Univ Massachusetts, Sch Med, Dept Mol Cell & Canc Biol, Worcester, MA USA. [White, R. M.] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA. RP Patton, EE (reprint author), Univ Edinburgh, MRC Human Genet Unit, Edinburgh EH8 9YL, Midlothian, Scotland.; Patton, EE (reprint author), Univ Edinburgh, Canc Res UK Ctr, Inst Genet & Mol Med, Edinburgh EH8 9YL, Midlothian, Scotland.; White, RM (reprint author), Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA. EM e.patton@igmm.ed.ac.uk; whiter@mskcc.org FU Medical Research Council [MC_PC_U127585840] NR 36 TC 0 Z9 0 U1 2 U2 3 PU ELSEVIER ACADEMIC PRESS INC PI SAN DIEGO PA 525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA SN 0091-679X BN 978-0-12-805206-8 J9 METHOD CELL BIOL JI Methods Cell Biol. PY 2016 VL 134 BP 531 EP 549 DI 10.1016/bs.mcb.2016.03.008 PG 19 WC Cell Biology; Marine & Freshwater Biology SC Cell Biology; Marine & Freshwater Biology GA BF5LE UT WOS:000382187900017 PM 27312504 ER PT J AU Deek, MP Nagarajan, S Kim, S Ahmed, I Paul, S Scher, ED Listo, M Chen, A Aisner, J Hussain, S Haffty, BG Jabbour, SK AF Deek, Matthew P. Nagarajan, Sairaman Kim, Sinae Ahmed, Inaya Paul, Shiby Scher, Eli D. Listo, Matthew Chen, Andrew Aisner, Joseph Hussain, Sabiha Haffty, Bruce G. Jabbour, Salma K. TI Clinical characteristics and dose-volume histogram parameters associated with the development of pleural effusions in non-small cell lung cancer patients treated with chemoradiation therapy SO ACTA ONCOLOGICA LA English DT Article ID CONCURRENT CHEMORADIOTHERAPY; RADIATION PNEUMONITIS; HEART EXPOSURE; RISK-FACTOR; RADIOTHERAPY; IRRADIATION AB Background: To investigate descriptive characteristics and dose metric (DM) parameters associated with development of pleural effusions (PlEf) in non-small cell lung cancer (NSCLC) treated with definitive chemoradiation therapy (CRT).Materials and methods: We retrospectively assessed treatment records and follow-up imaging of 66 NSCLC patients to identify PlEf formation after CRT. PlEf association between mean heart dose (MHD), mean lung dose (MLD), heart V-5-V-60 (HV), and lung V-5-V-60 (LV) were evaluated using Cox Proportional Hazard Models.Results: A total of 52% (34 of 66 patients) of our population developed PlEf and the actuarial rates at 6 months, 12 months, and 18 months were 7%, 30%, and 42%, respectively. Median time to diagnosis was five months (range 0.06-27 months). The majority of PlEfs were grade one (67%) and developed at a median of four (0.06-13) months, followed by grade two (15%) at a median 11 (5-12) months, and grade three (18%) at a median of 11 (3-27) months. On multivariate analysis, increasing HV5-HV50, LV5-LV50, MHD, and MLD were associated with greater risk of PlEf. Higher grade PlEf was also associated with higher doses of radiation to the heart, while lung DM parameters were not significantly associated with higher PlEf grades. At five-months post-CRT, MHD of 25Gy was associated with a 100% chance of grade one PlEf, an 82% risk of grade two PlEf, and a 19% risk of grade three PlEf.Conclusions: Post-CRT PlEf is common in NSCLC with the majority being grade one. Increasing heart and lung irradiation was associated with increased risk of PlEf. Increasing heart irradiation also correlated with development of increasing grades of PlEf. The impact of potential cardiopulmonary toxicity and resultant PlEfs after CRT requires additional study. C1 [Deek, Matthew P.; Ahmed, Inaya; Paul, Shiby; Scher, Eli D.; Chen, Andrew; Haffty, Bruce G.; Jabbour, Salma K.] Rutgers State Univ, Rutgers Canc Inst New Jersey, Robert Wood Johnson Med Sch, Dept Radiat Oncol, New Brunswick, NJ USA. [Nagarajan, Sairaman] Massachusetts Gen Hosp, Harvard MGH Ctr Genom, Boston, MA 02114 USA. [Kim, Sinae] Rutgers State Univ, Sch Publ Hlth, Dept Biostat, New Brunswick, NJ USA. [Listo, Matthew] Rutgers State Univ, New Jersey Med Sch, Dept Med, Newark, NJ USA. [Aisner, Joseph] Rutgers State Univ, Rutgers Canc Inst New Jersey, Robert Wood Johnson Med Sch, Div Med Oncol, New Brunswick, NJ USA. [Hussain, Sabiha] Rutgers State Univ, Robert Wood Johnson Med Sch, Dept Med, Div Pulm & Crit Care Med, New Brunswick, NJ USA. RP Jabbour, SK (reprint author), Rutgers Canc Inst New Jersey, 195 Little Albany St, New Brunswick, NJ 08903 USA. EM jabbousk@cinj.rutgers.edu NR 25 TC 0 Z9 0 U1 0 U2 0 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND SN 0284-186X EI 1651-226X J9 ACTA ONCOL JI Acta Oncol. PY 2016 VL 55 IS 8 BP 1029 EP 1035 DI 10.1080/0284186X.2016.1176248 PG 7 WC Oncology SC Oncology GA DS9KW UT WOS:000381102800013 PM 27219912 ER PT S AU Primo, VA Arboleda-Velasquez, JF AF Primo, Vincent A. Arboleda-Velasquez, Joseph F. BE Martin, SG Hewett, PW TI Isolation and Transfection of Primary Culture Bovine Retinal Pericytes SO ANGIOGENESIS PROTOCOLS, 3RD EDITION SE Methods in Molecular Biology LA English DT Article; Book Chapter DE Pericyte; Isolation; Bovine; Retina; Primary culture ID ENDOTHELIAL-CELLS; SMOOTH-MUSCLE; MOUSE-BRAIN; IN-VIVO; MARKERS AB This protocol describes an enzymatic approach for isolating homogeneous cultures of pericytes from retinas of bovine source. In summary, retinas are dissected, washed, digested, filtered, cultured in specific media to select for pericytes, and finally expanded for a low passage culture of about 14 million bovine retinal pericytes (BRP) within 4-6 weeks. This protocol also describes a liposomal-based technique for transfection of BRPs. C1 [Primo, Vincent A.] Univ Turin, Canc Inst Candiolo FPO IRCCS, Turin, Italy. [Primo, Vincent A.] Univ Turin, Dept Oncol, Turin, Italy. [Arboleda-Velasquez, Joseph F.] Harvard Med Sch, Mass Eye & Ear Infirm, Schepens Eye Res Inst, Dept Ophthalmol, Boston, MA 02115 USA. RP Primo, VA (reprint author), Univ Turin, Canc Inst Candiolo FPO IRCCS, Turin, Italy.; Primo, VA (reprint author), Univ Turin, Dept Oncol, Turin, Italy. NR 20 TC 0 Z9 0 U1 0 U2 0 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA SN 1064-3745 BN 978-1-4939-3628-1; 978-1-4939-3626-7 J9 METHODS MOL BIOL JI Methods Mol. Biol. PY 2016 VL 1430 BP 107 EP 117 DI 10.1007/978-1-4939-3628-1_7 D2 10.1007/978-1-4939-3628-1 PG 11 WC Biochemical Research Methods; Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA BF4XS UT WOS:000381762600008 PM 27172949 ER PT J AU Howard, M Bonham, AJ Heyland, DK Sudore, R Fassbender, K Robinson, CA McKenzie, M Elston, D You, JJ AF Howard, Michelle Bonham, Aaron J. Heyland, Daren K. Sudore, Rebecca Fassbender, Konrad Robinson, Carole A. McKenzie, Michael Elston, Dawn You, John J. TI Measuring engagement in advance care planning: a cross-sectional multicentre feasibility study SO BMJ OPEN LA English DT Article DE advance care planning; communication; survey; measurement ID OF-LIFE CARE; DECISION-MAKING; FAMILY SATISFACTION; ELDERLY-PATIENTS; MEASURE PATIENT; END; QUESTIONNAIRE; VALIDATION AB Objectives To assess the feasibility, acceptability and clinical sensibility of a novel survey, the advance care planning (ACP) Engagement Survey, in various healthcare settings. Setting A target sample of 50 patients from each of primary care, hospital, cancer care and dialysis care settings. Participants A convenience sample of patients without cognitive impairment who could speak and read English was recruited. Patients 50 and older were eligible in primary care; patients 80 and older or 55 and older with clinical markers of advanced chronic disease were recruited in hospital; patients aged 19 and older were recruited in cancer and renal dialysis centres. Outcomes We assessed feasibility, acceptability and clinical sensibility of the ACP Engagement Survey using a 6-point scale. The ACP Engagement Survey measures ACP processes (knowledge, contemplation, self-efficacy and readiness) on 5-point Likert scales and actions (yes/no). Results 196 patients (38-96years old, 50.5% women) participated. Mean (SD) time to administer was 48.8 +/- 19.6min. Mean acceptability scores ranged from 3.2 +/- 1.3 in hospital to 4.7 +/- 0.9 in primary care, and mean relevance ranged from 3.5 +/- 1.0 in hospital to 4.9 +/- 0.9 in dialysis centres (p<0.001 for both). The mean process score was 3.1 +/- 0.6 and the mean action score was 11.2 +/- 5.6 (of a possible 25). Conclusions The ACP Engagement Survey demonstrated feasibility and acceptability in outpatient settings but was less feasible and acceptable among hospitalised patients due to length. A shorter version may improve feasibility. Engagement in ACP was low to moderate. C1 [Howard, Michelle; Elston, Dawn] McMaster Univ, Dept Family Med, Hamilton, ON, Canada. [Bonham, Aaron J.; You, John J.] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada. [Heyland, Daren K.] Kingston Gen Hosp, Clin Evaluat Res Unit, Kingston, ON, Canada. [Heyland, Daren K.] Queens Univ, Dept Publ Hlth, Kingston, ON, Canada. [Sudore, Rebecca] San Francisco VA Med Ctr, San Francisco, CA USA. [Sudore, Rebecca] Univ Calif San Francisco, Dept Med, Div Geriatr, San Francisco, CA USA. [Fassbender, Konrad] Covenant Hlth Palliat Inst, Edmonton, AB, Canada. [Robinson, Carole A.] Univ British Columbia, Sch Nursing, Kelowna, BC, Canada. [McKenzie, Michael] British Columbia Canc Agcy, Vancouver Canc Ctr, Radiat Therapy Program, Vancouver, BC, Canada. [You, John J.] McMaster Univ, Med, Hamilton, ON, Canada. RP Howard, M (reprint author), McMaster Univ, Dept Family Med, Hamilton, ON, Canada. EM mhoward@mcmaster.ca NR 17 TC 0 Z9 0 U1 1 U2 1 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 2044-6055 J9 BMJ OPEN JI BMJ Open PY 2016 VL 6 IS 6 AR e010375 DI 10.1136/bmjopen-2015-010375 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA DR9ST UT WOS:000380237100031 PM 27338877 ER PT J AU Mashamba-Thompson, TP Drain, PK Sartorius, B AF Mashamba-Thompson, T. P. Drain, P. K. Sartorius, B. TI Evaluating the accessibility and utility of HIV-related point-of-care diagnostics for maternal health in rural South Africa: a study protocol SO BMJ OPEN LA English DT Article DE Point-of-care diagnostics; Maternal health outcomes; Primary health care ID INFECTION; SETTINGS; TESTS AB Introduction Poor healthcare access is a major barrier to receiving antenatal care and a cause of high maternal mortality in South Africa (SA). Point-of-care' (POC) diagnostics is a powerful emerging healthcare approach to improve healthcare access. This study focuses on evaluating the accessibility and utility of POC diagnostics for maternal health in rural SA primary healthcare (PHC) clinics in order to generate a model framework of implementation of POC diagnostics in rural South African clinics. Method and analyses We will use several research methods, including a systematic review, quasi-experiments, survey, key informant interviews and audits. We will conduct a systematic review and experimental study to determine the impact of POC diagnostics on maternal health. We will perform a cross-sectional case study of 100 randomly selected rural primary healthcare clinics in KwaZulu-Natal to measure the context and patterns of POC diagnostics access and usage by maternal health providers and patients. We will conduct interviews with relevant key stakeholders to determine the reasons for POC deficiencies regarding accessibility and utility of HIV-related POC diagnostics for maternal health. We will also conduct a vertical audit to investigate all the quality aspects of POC diagnostic services including diagnostic accuracy in a select number of clinics. On the basis of information gathered, we will propose a model framework for improved implementation of POC diagnostics in rural South African public healthcare clinics. Statistical (Stata-13) and thematic (NVIVO) data analysis will be used in this study. Ethics and dissemination The study protocol was approved by the Ethics Committee of the University of KwaZulu-Natal (BE 484/14) and the KwaZulu-Natal Department of Health based on the Helsinki Declaration (HRKM 40/15). Findings of this study will be disseminated electronically and in print. They will be presented to conferences related to HIV/AIDS, diagnostics, maternal health and strengthening of health systems. C1 [Mashamba-Thompson, T. P.; Sartorius, B.] Univ KwaZulu Natal, Sch Nursing & Publ Hlth, Discipline Publ Hlth Med, Durban, South Africa. [Drain, P. K.] Univ Washington, Int Clincial Res Ctr, Dept Global Hlth, Seattle, WA 98195 USA. [Drain, P. K.] Univ Washington, Dept Med, Div Infect Dis, Seattle, WA USA. [Drain, P. K.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Surg, Boston, MA USA. RP Mashamba-Thompson, TP (reprint author), Univ KwaZulu Natal, Sch Nursing & Publ Hlth, Discipline Publ Hlth Med, Durban, South Africa. EM Mashamba-Thompson@ukzn.ac.za FU University of KwaZulu-Natal; South African Centre of Excellence for Epidemiology and Modelling Analysis; African Population and Health Research Centre FX University of KwaZulu-Natal (grant: College of Health Sciences Research Scholarship); South African Centre of Excellence for Epidemiology and Modelling Analysis (grant: PhD scholarhip); African Population and Health Research Centre (grant: 2015 African Doctorate Dissertation Fellowship). NR 31 TC 0 Z9 0 U1 0 U2 0 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 2044-6055 J9 BMJ OPEN JI BMJ Open PY 2016 VL 6 IS 6 AR e011155 DI 10.1136/bmjopen-2016-011155 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA DR9ST UT WOS:000380237100105 PM 27354074 ER PT J AU Ravnskov, U Diamond, DM Hama, R Hamazaki, T Hammarskjold, B Hynes, N Kendrick, M Langsjoen, PH Malhotra, A Mascitelli, L McCully, KS Ogushi, Y Okuyama, H Rosch, PJ Schersten, T Sultan, S Sundberg, R AF Ravnskov, Uffe Diamond, David M. Hama, Rokura Hamazaki, Tomohito Hammarskjold, Bjoern Hynes, Niamh Kendrick, Malcolm Langsjoen, Peter H. Malhotra, Aseem Mascitelli, Luca McCully, Kilmer S. Ogushi, Yoichi Okuyama, Harumi Rosch, Paul J. Schersten, Tore Sultan, Sherif Sundberg, Ralf TI Lack of an association or an inverse association between low-density-lipoprotein cholesterol and mortality in the elderly: a systematic review SO BMJ OPEN LA English DT Review DE Risk factor; LDL-cholesterol; cardiovascular mortality; total mortality; elderly; GERIATRIC MEDICINE; PREVENTIVE MEDICINE; EPIDEMIOLOGY ID ALL-CAUSE MORTALITY; CORONARY-ARTERY-DISEASE; CARDIOVASCULAR-DISEASE; MYOCARDIAL-INFARCTION; PLASMA-LIPIDS; PROSPECTIVE COHORT; BLOOD CHOLESTEROL; OLDER-PEOPLE; SERUM-LIPIDS; RISK-FACTORS AB Objective It is well known that total cholesterol becomes less of a risk factor or not at all for all-cause and cardiovascular (CV) mortality with increasing age, but as little is known as to whether low-density lipoprotein cholesterol (LDL-C), one component of total cholesterol, is associated with mortality in the elderly, we decided to investigate this issue. Setting, participants and outcome measures We sought PubMed for cohort studies, where LDL-C had been investigated as a risk factor for all-cause and/or CV mortality in individuals 60years from the general population. Results We identified 19 cohort studies including 30 cohorts with a total of 68094 elderly people, where all-cause mortality was recorded in 28 cohorts and CV mortality in 9 cohorts. Inverse association between all-cause mortality and LDL-C was seen in 16 cohorts (in 14 with statistical significance) representing 92% of the number of participants, where this association was recorded. In the rest, no association was found. In two cohorts, CV mortality was highest in the lowest LDL-C quartile and with statistical significance; in seven cohorts, no association was found. Conclusions High LDL-C is inversely associated with mortality in most people over 60years. This finding is inconsistent with the cholesterol hypothesis (ie, that cholesterol, particularly LDL-C, is inherently atherogenic). Since elderly people with high LDL-C live as long or longer than those with low LDL-C, our analysis provides reason to question the validity of the cholesterol hypothesis. Moreover, our study provides the rationale for a re-evaluation of guidelines recommending pharmacological reduction of LDL-C in the elderly as a component of cardiovascular disease prevention strategies. C1 [Ravnskov, Uffe] Magle Stora Kyrkogata 9, S-22350 Lund, Sweden. [Diamond, David M.] Univ S Florida, Dept Psychol, Dept Mol Pharmacol & Physiol, Ctr Preclin & Clin Res PTSD, Tampa, FL USA. [Hama, Rokura] NPO Japan Inst Pharmacovigilance, Osaka, Japan. [Hamazaki, Tomohito] Toyama Univ, Toyama Jonan Onsen Daini Hosp, Dept Internal Med, Toyama, Japan. [Hammarskjold, Bjoern] Stromstad Acad, Stromstad, Sweden. [Hynes, Niamh; Sultan, Sherif] Univ Hosp Galway, Western Vasc Inst, Galway, Ireland. [Hynes, Niamh; Sultan, Sherif] Natl Univ Ireland, Galway Clin, Galway, Ireland. [Hynes, Niamh; Sultan, Sherif] Royal Coll Surg Ireland, Affiliated Hosp, Galway, Ireland. [Kendrick, Malcolm] Macclesfield Hosp, East Cheshire Trust, Macclesfield, Cheshire, England. [Langsjoen, Peter H.] Solo Practice Cardiol, Tyler, TX 75701 USA. [Malhotra, Aseem] Frimley Pk Hosp, Dept Cardiol, Portsmouth Rd, Frimley GU16 7UJ, Surrey, England. [Mascitelli, Luca] Comando Brigata Alpina Julia Multinatl Land Force, Med Serv, Udine, Italy. [McCully, Kilmer S.] VA Boston Healthcare Syst, Pathol & Lab Med Serv, West Roxbury, MA USA. [McCully, Kilmer S.] Harvard Med Sch, Boston, MA USA. [Ogushi, Yoichi] Tokai Univ, Hiratsuka, Kanagawa 2540807, Japan. [Okuyama, Harumi] Nagoya City Univ, Nagoya, Aichi, Japan. [Okuyama, Harumi] Kinjo Gakuin Univ, Inst Consumer Sci & Human Life, Nagoya, Aichi, Japan. [Rosch, Paul J.] New York Med Coll, Valhalla, NY 10595 USA. [Rosch, Paul J.] Amer Inst Stress, Yonkers, NY USA. [Schersten, Tore] Univ Gothenburg, Sahlgrens Acad, Gothenburg, Sweden. [Schersten, Tore] Columbia Univ, New York, NY 10027 USA. [Sundberg, Ralf] Slottsstadens Lakarhus, Gothenburg, Sweden. RP Ravnskov, U (reprint author), Magle Stora Kyrkogata 9, S-22350 Lund, Sweden. EM ravnskov@tele2.se FU Western Vascular Institute FX The study has been supported by a grant from Western Vascular Institute. NR 40 TC 8 Z9 8 U1 8 U2 9 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 2044-6055 J9 BMJ OPEN JI BMJ Open PY 2016 VL 6 IS 6 AR e010401 DI 10.1136/bmjopen-2015-010401 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA DR9ST UT WOS:000380237100035 PM 27292972 ER PT J AU Wentworth, K Hsing, A Urrutia, A Zhu, Y Horvai, AE Bastepe, M Hsiao, EC AF Wentworth, Kelly Hsing, Alyssa Urrutia, Ashley Zhu, Yan Horvai, Andrew E. Bastepe, Murat Hsiao, Edward C. TI A Novel T55A Variant of G(s)alpha Associated with Impaired cAMP Production, Bone Fragility, and Osteolysis SO CASE REPORTS IN ENDOCRINOLOGY LA English DT Article ID STIMULATORY G-PROTEIN; ALBRIGHTS HEREDITARY OSTEODYSTROPHY; PSEUDOHYPOPARATHYROIDISM TYPE 1A; ADENYLYL-CYCLASE; ALPHA-SUBUNIT; GNAS1 GENE; MUTATIONS; DISORDERS AB G-protein coupled receptors (GPCRs) mediate a wide spectrum of biological activities. The GNAS complex locus encodes the stimulatory alpha subunit of the guanine nucleotide binding protein (G(s)alpha) and regulates production of the second messenger cyclic AMP (cAMP). Loss-of-function GNAS mutations classically lead to Albright's Hereditary Osteodystrophy (AHO) and pseudohypoparathyroidism, often with significant effects on bone formation and mineral metabolism. We present the case of a child who exhibits clinical features of osteolysis, multiple childhood fractures, and neonatal SIADH. Exome sequencing revealed a novel de novo heterozygous missense mutation of GNAS (c.163A= 55 years) for functional MRI (fMRI) as part of the Early Detection of Angiopathy Network (EDAN) Study. Cerebrovascular reactivity parameters (i.e., amplitude and time to peak responses) were assessed in response to visual stimulation using fMRI. Student's t-test and linear regression were used to compare fMRI parameters in participants with and without microbleeds. Results: Amplitude and time to peak responses did not differ between participants with and without microbleeds (respectively, p = 0.179 and p = 0.555). Participants with microbleeds had slightly higher amplitude responses compared to participants without microbleeds. After excluding individuals with mixed microbleeds (i.e., lobar and non-lobar microbleeds), we found no significant difference in cerebrovascular reactivity for persons with a single microbleed or multiple microbleeds compared to persons without microbleeds. Conclusions: In the general population, lobar microbleeds may not relate to impaired cerebrovascular reactivity. In asymptomatic individuals, lobar microbleeds may either reflect less advanced CAA pathology insufficient to cause functional vascular impairment, or reflect vascular pathology other than CAA. C1 [Akoudad, Saloua; Hofman, Albert; Ikram, M. Arfan; Vernooij, Meike W.] Erasmus MC Univ Med Ctr, Dept Epidemiol, Rotterdam, Netherlands. [Akoudad, Saloua; Ikram, M. Arfan; Vernooij, Meike W.] Erasmus MC Univ Med Ctr, Dept Radiol, Rotterdam, Netherlands. [Akoudad, Saloua; Koudstaal, Peter J.; Ikram, M. Arfan] Erasmus MC Univ Med Ctr, Dept Neurol, Rotterdam, Netherlands. [Gurol, M. Edip; Fotiadis, Panagiotis; Greenberg, Steven M.] Massachusetts Gen Hosp, Dept Neurol, Hemorrhag Stroke Res Grp, Boston, MA 02114 USA. RP Vernooij, MW (reprint author), Erasmus MC, Univ Med Ctr, Off Secretariat Epidemiol, Na28-18,Postbus 2040, NL-3000 CA Rotterdam, Netherlands. EM m.vernooij@erasmusmc.nl FU US National Institutes of Health [R01 NS070834]; "Early Detection of Cerebral Amyloid Angiopathy" grant; Erasmus University Rotterdam; Netherlands Organization for Scientific Research (NWO); Netherlands Organization for Health Research and Development (ZonMW); Research Institute for Diseases in the Elderly (RIDE); Netherlands Genomics Initiative; Ministry of Education, Culture and Science; Ministry of Health, Welfare and Sports; European Commission (DG XII); Municipality of Rotterdam; Erasmus MC University Medical Center; Netherlands Heart Foundation; Netherlands Organization for Health Research and Development; Internationaal Parkinson Fonds; Internationale Stichting Alzheimer Onderzoek [12533] FX This study was funded by the US National Institutes of Health R01 NS070834, the "Early Detection of Cerebral Amyloid Angiopathy" grant.; The Rotterdam Study is supported by the Erasmus MC University Medical Center and Erasmus University Rotterdam, the Netherlands Organization for Scientific Research (NWO), the Netherlands Organization for Health Research and Development (ZonMW), the Research Institute for Diseases in the Elderly (RIDE), the Netherlands Genomics Initiative, the Ministry of Education, Culture and Science, the Ministry of Health, Welfare and Sports, the European Commission (DG XII), and the Municipality of Rotterdam. The current study is further supported by a research fellowship (MWV) from Erasmus MC University Medical Center; the Netherlands Heart Foundation; Netherlands Organization for Health Research and Development; Internationaal Parkinson Fonds, and Internationale Stichting Alzheimer Onderzoek (grant 12533). The funding sources had no influence on study design, collection, management, analysis, and interpretation of the data and preparation, review, or approval of the manuscript. NR 29 TC 0 Z9 0 U1 2 U2 2 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 EI 1875-8908 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2016 VL 53 IS 2 BP 497 EP 503 DI 10.3233/JAD-151130 PG 7 WC Neurosciences SC Neurosciences & Neurology GA DT0XY UT WOS:000381207500011 PM 27163807 ER PT J AU Kantarci, K Lowe, VJ Lesnick, TG Tosakulwong, N Bailey, KR Fields, JA Shuster, LT Zuk, SM Senjem, ML Mielke, MM Gleason, C Jack, CR Rocca, WA Miller, VM AF Kantarci, Kejal Lowe, Val J. Lesnick, Timothy G. Tosakulwong, Nirubol Bailey, Kent R. Fields, Julie A. Shuster, Lynne T. Zuk, Samantha M. Senjem, Matthew L. Mielke, Michelle M. Gleason, Carey Jack, Clifford R., Jr. Rocca, Walter A. Miller, Virginia M. TI Early Postmenopausal Transdermal 17 beta-Estradiol Therapy and Amyloid-beta Deposition SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Alzheimer's disease; amyloid-beta; cognitive function; estrogen; hormone therapy; menopause; PET; prevention ID CONJUGATED EQUINE ESTROGENS; HORMONE REPLACEMENT THERAPY; MILD COGNITIVE IMPAIRMENT; ALZHEIMERS-DISEASE; APOLIPOPROTEIN-E; CACHE COUNTY; WOMEN; RISK; DEMENTIA; APOE AB Background: It remains controversial whether hormone therapy in recently postmenopausal women modifies the risk of Alzheimer's disease (AD). Objective: To investigate the effects of hormone therapy on amyloid-beta deposition in recently postmenopausal women. Methods: Participants within 5-36 months past menopause in the Kronos Early Estrogen Prevention Study, a randomized, double blinded placebo-controlled clinical trial, were randomized to: 1) 0.45 mg/day oral conjugated equine estrogens (CEE); 2) 50 mu g/day transdermal 17 beta-estradiol; or 3) placebo pills and patch for four years. Oral progesterone (200 mg/day) was given to active treatment groups for 12 days each month. C-11 Pittsburgh compound B (PiB) PET imaging was performed in 68 of the 118 participants at Mayo Clinic approximately seven years post randomization and three years after stopping randomized treatment. PiB Standard unit value ratio (SUVR) was calculated. Results: Women (age = 52-65) randomized to transdermal 17 beta-estradiol (n = 21) had lower PiB SUVR compared to placebo (n = 30) after adjusting for age [odds ratio (95% CI) = 0.31(0.11-0.83)]. In the APOE epsilon 4 carriers, transdermal 17 beta-estradiol treated women (n = 10) had lower PiB SUVR compared to either placebo (n = 5) [odds ratio (95% CI) = 0.04(0.004-0.44)], or the oral CEE treated group (n = 3) [odds ratio (95% CI) = 0.01(0.0006-0.23)] after adjusting for age. Hormone therapy was not associated with PiB SUVR in the APOE epsilon 4 non-carriers. Conclusion: In this pilot study, transdermal 17 beta-estradiol therapy in recently postmenopausal women was associated with a reduced amyloid-beta deposition, particularly in APOE epsilon 4 carriers. This finding may have important implications for the prevention of AD in postmenopausal women, and needs to be confirmed in a larger sample. C1 [Kantarci, Kejal; Lowe, Val J.; Zuk, Samantha M.; Jack, Clifford R., Jr.] Mayo Clin, Dept Radiol, 200 First St SW, Rochester, MN 55905 USA. [Lesnick, Timothy G.; Tosakulwong, Nirubol; Bailey, Kent R.; Mielke, Michelle M.; Rocca, Walter A.] Mayo Clin, Dept Hlth Sci Res, Rochester, MN USA. [Fields, Julie A.] Mayo Clin, Dept Psychiat & Psychol, Rochester, MN USA. [Shuster, Lynne T.] Mayo Clin, Dept Internal Med, Rochester, MN USA. [Senjem, Matthew L.] Mayo Clin, Dept Informat Technol, Rochester, MN USA. [Mielke, Michelle M.; Rocca, Walter A.] Mayo Clin, Dept Neurol, Rochester, MN USA. [Gleason, Carey] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Madison, WI USA. [Gleason, Carey] William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Madison, WI USA. [Miller, Virginia M.] Mayo Clin, Dept Surg, Rochester, MN USA. [Miller, Virginia M.] Mayo Clin, Dept Physiol, Rochester, MN USA. [Miller, Virginia M.] Mayo Clin, Dept Biomed Engn, Rochester, MN USA. RP Kantarci, K (reprint author), Mayo Clin, Dept Radiol, 200 First St SW, Rochester, MN 55905 USA. EM kantarci.kejal@mayo.edu FU Aurora Foundation; NIH [NS66147, AG029624, AG44170] FX This study is funded by the Aurora Foundation to the Kronos Longevity Research Institute, NIH (NS66147, AG029624 and AG44170). The authors thank Ms. Kim Jensen for consenting and scheduling of the participants. The authors do not have any conflicts of interest related to the submitted work. The funding sources had no role in study design, collection, analysis, interpretation, or decision to submit this paper. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication. NR 44 TC 4 Z9 4 U1 2 U2 2 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 EI 1875-8908 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2016 VL 53 IS 2 BP 547 EP 556 DI 10.3233/JAD-160258 PG 10 WC Neurosciences SC Neurosciences & Neurology GA DT0XY UT WOS:000381207500015 PM 27163830 ER PT J AU Hanseeuw, B Dricot, L Lhommel, R Quenon, L Ivanoiu, A AF Hanseeuw, Bernard Dricot, Laurence Lhommel, Renaud Quenon, Lisa Ivanoiu, Adrian TI Patients with Amyloid-Negative Mild Cognitive Impairment have Cortical Hypometabolism but the Hippocampus is Preserved SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Alzheimer's disease; amyloid; F-18-flutemetamol; FDG-PET; hippocampus; magnetic resonance imaging; mild cognitive impairment; neocortex; PALZ score ID DISEASE CONSORTIUM EADC; PET IMAGE-ANALYSIS; ALZHEIMERS-DISEASE; FDG-PET; GLUCOSE-METABOLISM; ELDERLY SUBJECTS; AMNESTIC MCI; HUMAN BRAIN; PROGRESSION; AD AB Background: Patients with mild cognitive impairment (MCI) are at risk for Alzheimer's dementia but the presence of amyloid (A beta) strongly increases this risk. In clinical settings, when A beta status is not available, different neurodegenerative markers are used to characterize MCI. The accuracy of these markers to discriminate between A beta- and A beta+ MCI is not yet determined. Objective: To compare different markers of neurodegeneration in A beta- and A beta+ MCI, with an A beta- elderly control (EC) group. Methods: Patients with MCI (n = 39) and EC (n = 28) underwent MRI, F-18-FDG PET, and A beta PET (F-18-flutemetamol). We compared FDG and MRI biomarker values in cortical and hippocampal regions of interest, and using voxel-wise surface maps. We computed ROC curves discriminating between the three groups for each biomarker. Results: All biomarker values were reduced in A beta+ MCI compared to EC (p < 0.001). A beta- MCI had low cortical metabolism (p = 0.002), but hippocampal volume, cortical thickness, and hippocampal metabolism were not significantly different between A beta- MCI and EC (p > 0.40). Cortical metabolism best discriminated between MCI and EC (AUC=0.92/0.86, A beta+/A beta-) while hippocampal volume best discriminated between A beta- MCI and A beta+ MCI (AUC = 0.79). Conclusions: Cortical hypometabolism was observed in both A beta- MCI and A beta+ MCI whereas hippocampal atrophy was mostly found in A beta+ MCI. For MCI patients without available A beta information, hippocampal atrophy is thus more informative about A beta status than cortical hypometabolism. C1 [Hanseeuw, Bernard; Quenon, Lisa; Ivanoiu, Adrian] St Luc Univ Hosp, Dept Neurol, Av Hippocrate 10, B-1200 Brussels, Belgium. [Hanseeuw, Bernard; Dricot, Laurence; Quenon, Lisa; Ivanoiu, Adrian] Catholic Univ Louvain, Inst Neurosci, Brussels, Belgium. [Hanseeuw, Bernard] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. [Hanseeuw, Bernard] Martinos Ctr Biomed Imaging, Boston, MA USA. [Lhommel, Renaud] St Luc Univ Hosp, Dept Nucl Med, Brussels, Belgium. RP Hanseeuw, B (reprint author), St Luc Univ Hosp, Dept Neurol, Av Hippocrate 10, B-1200 Brussels, Belgium. EM bernard.hanseeuw@uclouvain.be FU Belgian American Education Foundation; Belgian Neurological Society; Saint-Luc Foundation FX This study was made possible thanks to the generous funding help of: the Belgian American Education Foundation, the Belgian Neurological Society and the Saint-Luc Foundation. We are also grateful to the firm GE Healthcare Ltd. for having supplied the [18F]-flutemetamol for the PET scan imaging according to an agreement with our Clinic. NR 50 TC 0 Z9 0 U1 2 U2 2 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 EI 1875-8908 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2016 VL 53 IS 2 BP 651 EP 660 DI 10.3233/JAD-160204 PG 10 WC Neurosciences SC Neurosciences & Neurology GA DT0XY UT WOS:000381207500022 PM 27232217 ER PT J AU Robinaugh, DJ Mauro, C Bui, E Stone, L Shah, R Wang, YJ Skritskaya, NA Reynolds, CF Zisook, S O'Connor, MF Shear, K Simon, NM AF Robinaugh, Donald J. Mauro, Christine Bui, Eric Stone, Lauren Shah, Riva Wang, Yuanjia Skritskaya, Natalia A. Reynolds, Charles F. Zisook, Sidney O'Connor, Mary-Frances Shear, Katherine Simon, Naomi M. TI Yearning and Its Measurement in Complicated Grief SO JOURNAL OF LOSS & TRAUMA LA English DT Article DE Assessment; bereavement; complicated grief; longing; yearning ID BEREAVEMENT; DEPRESSION; VALIDITY; INVENTORY; DISORDER; SCALE AB Persistent intense yearning for the deceased is a core clinical feature of complicated grief (CG) that distinguishes it from other mental disorders that develop following loss. The Yearning in Situations of Loss Scale (YSL) is a recently developed assessment of yearning. To assess the psychometric properties of the YSL in those with CG, we administered the YSL, Inventory of Complicated Grief, and Quick Inventory of Depression Symptomatology to 303 treatment-seeking bereaved adults with CG. Our results suggest the YSL is a reliable assessment with acceptable convergent and discriminant validity as a measure of yearning in those with CG. C1 [Robinaugh, Donald J.] Harvard Univ, Dept Psychol, Boston, MA 02115 USA. [Robinaugh, Donald J.; Bui, Eric; Stone, Lauren; Shah, Riva; Simon, Naomi M.] Massachusetts Gen Hosp, Dept Psychiat, 1 Bowdoin Sq,Room 644, Boston, MA 02114 USA. [Mauro, Christine; Wang, Yuanjia] Columbia Univ, Dept Biostat, Mailman Sch Publ Hlth, New York, NY USA. [Skritskaya, Natalia A.; Shear, Katherine] Columbia Univ, Sch Social Work, New York, NY USA. [Reynolds, Charles F.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA. [Zisook, Sidney] Univ Calif San Diego, San Diego, CA 92103 USA. [Zisook, Sidney] San Diego VA Healthcare Syst, San Diego, CA USA. [O'Connor, Mary-Frances] Univ Arizona, Dept Psychol, Tucson, AZ 85721 USA. RP Robinaugh, DJ (reprint author), Massachusetts Gen Hosp, Dept Psychiat, 1 Bowdoin Sq,Room 644, Boston, MA 02114 USA. EM drobinaugh@partners.org NR 20 TC 0 Z9 0 U1 2 U2 2 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 1532-5024 EI 1532-5032 J9 J LOSS TRAUMA JI J. Loss Trauma PY 2016 VL 21 IS 5 BP 410 EP 420 DI 10.1080/15325024.2015.1110447 PG 11 WC Psychology, Social SC Psychology GA DS9KA UT WOS:000381100300007 ER PT J AU Gow, DW Olson, BB AF Gow, David W., Jr. Olson, Bruna B. TI Sentential influences on acoustic-phonetic processing: a Granger causality analysis of multimodal imaging data SO LANGUAGE COGNITION AND NEUROSCIENCE LA English DT Article DE Speech perception; semantic context effect; sentential context effect; modularity; top-down processing ID SUPERIOR TEMPORAL GYRUS; SPOKEN-WORD RECOGNITION; SPEECH-PERCEPTION; CORTICAL ORGANIZATION; TOP-DOWN; LANGUAGE COMPREHENSION; PHONEMIC RESTORATION; PREFRONTAL CORTEX; BRAIN POTENTIALS; FRONTAL GYRUS AB Sentential context influences the way that listeners identify phonetically ambiguous or perceptual degraded speech sounds. Unfortunately, inherent inferential limitations on the interpretation of behavioural or BOLD imaging results make it unclear whether context influences perceptual processing directly, or acts at a post-perceptual decision stage. In this paper, we use Kalman-filter enabled Granger causation analysis of MRI-constrained MEG/EEG data to distinguish between these possibilities. Using a retrospective probe verification task, we found that sentential context strongly affected the interpretation of words with ambiguous initial voicing (e.g. DUSK-TUSK). This behavioural context effect coincided with increased influence by brain regions associated with lexical representation on regions associated with acoustic-phonetic processing. These results support an interactive view of sentence context effects on speech perception. C1 [Gow, David W., Jr.; Olson, Bruna B.] Massachusetts Gen Hosp, Neuropsychol Lab, 175 Cambridge St,CPZ S340, Boston, MA 02114 USA. [Gow, David W., Jr.] Salem State Univ, Dept Psychol, 352 Lafayette St, Salem, MA 01970 USA. [Gow, David W., Jr.; Olson, Bruna B.] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, 149 Thirteenth St, Charlestown, MA 02129 USA. [Gow, David W., Jr.] Harvard Mit Div Hlth Sci & Technol, 77 Massachusetts Ave,E25-519, Cambridge, MA 02139 USA. RP Gow, DW (reprint author), Massachusetts Gen Hosp, Neuropsychol Lab, 175 Cambridge St,CPZ S340, Boston, MA 02114 USA.; Gow, DW (reprint author), Salem State Univ, Dept Psychol, 352 Lafayette St, Salem, MA 01970 USA.; Gow, DW (reprint author), Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, 149 Thirteenth St, Charlestown, MA 02129 USA.; Gow, DW (reprint author), Harvard Mit Div Hlth Sci & Technol, 77 Massachusetts Ave,E25-519, Cambridge, MA 02139 USA. EM gow@helix.mgh.harvard.edu FU National Institute of Deafness and Communicative Disorders [R01 DC003108]; NCRR Regional Resource [41RR14075]; MIND Institute FX This work was supported by the National Institute of Deafness and Communicative Disorders [grant number R01 DC003108] and benefited from support from the MIND Institute and the NCRR Regional Resource [grant number 41RR14075] for the development of technology and analysis tools at the Athinoula A. Martinos Center for Biomedical Imaging. NR 74 TC 4 Z9 4 U1 2 U2 2 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 2327-3798 EI 2327-3801 J9 LANG COGN NEUROSCI JI Lang. Cogn. Neurosci. PY 2016 VL 31 IS 7 BP 841 EP 855 DI 10.1080/23273798.2015.1029498 PG 15 WC Audiology & Speech-Language Pathology; Behavioral Sciences; Linguistics; Psychology, Experimental SC Audiology & Speech-Language Pathology; Behavioral Sciences; Linguistics; Psychology GA DT2FH UT WOS:000381295700001 PM 27595118 ER PT J AU Gow, DW Olson, BB AF Gow, David W., Jr. Olson, Bruna B. TI Using effective connectivity analyses to understand processing architecture: response to commentaries by Samuel, Spivey and McQueen, Eisner and Norris SO LANGUAGE COGNITION AND NEUROSCIENCE LA English DT Article DE Modularity; effective connectivity; speech perception; localisation; sentential context ID DOMAIN-SPECIFIC INTERFERENCE; GRANGER CAUSALITY ANALYSIS; SUPERIOR TEMPORAL GYRUS; VERBAL WORKING-MEMORY; AUDITORY IMAGERY; SPEECH-PERCEPTION; CORTICAL ORGANIZATION; LEXICAL ACTIVATION; WORD RECOGNITION; OUTPUT BUFFER C1 [Gow, David W., Jr.] Massachusetts Gen Hosp, Neuropsychol Lab, Boston, MA 02114 USA. [Gow, David W., Jr.] Salem State Univ, Dept Psychol, Salem, MA 01970 USA. [Gow, David W., Jr.] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA. [Gow, David W., Jr.] Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA. [Olson, Bruna B.] Univ Massachusetts, Sch Med, Worcester, MA USA. RP Gow, DW (reprint author), Massachusetts Gen Hosp, Neuropsychol Lab, Boston, MA 02114 USA.; Gow, DW (reprint author), Salem State Univ, Dept Psychol, Salem, MA 01970 USA.; Gow, DW (reprint author), Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA.; Gow, DW (reprint author), Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA. EM gow@helix.mgh.harvard.edu FU National Institute of Deafness and Communicative Disorders [R01 DC003108]; NCRR Regional Resource Grant [41RR14075] FX This work was originally supported by the National Institute of Deafness and Communicative Disorders [R01 DC003108] and benefited from support from the Mind Research Network and the NCRR Regional Resource Grant [41RR14075] for the development of technology and analysis tools at the Athinoula A. Martinos Center for Biomedical Imaging. NR 68 TC 1 Z9 1 U1 4 U2 4 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 2327-3798 EI 2327-3801 J9 LANG COGN NEUROSCI JI Lang. Cogn. Neurosci. PY 2016 VL 31 IS 7 BP 869 EP 875 DI 10.1080/23273798.2016.1192656 PG 7 WC Audiology & Speech-Language Pathology; Behavioral Sciences; Linguistics; Psychology, Experimental SC Audiology & Speech-Language Pathology; Behavioral Sciences; Linguistics; Psychology GA DT2FH UT WOS:000381295700005 PM 28090547 ER PT J AU Carvajal, FJ Mattison, HA Cerpa, W AF Carvajal, Francisco J. Mattison, Hayley A. Cerpa, Waldo TI Role of NMDA Receptor-Mediated Glutamatergic Signaling in Chronic and Acute Neuropathologies SO NEURAL PLASTICITY LA English DT Review ID TRAUMATIC BRAIN-INJURY; AMYOTROPHIC-LATERAL-SCLEROSIS; D-ASPARTATE RECEPTORS; PROTEIN-KINASE-II; MAJOR DEPRESSIVE DISORDER; ASTERISK-D REPORT; CONTROLLED CORTICAL IMPACT; TYROSINE-PHOSPHATASE STEP; MOTOR-NEURON DEGENERATION; RAT HIPPOCAMPAL-NEURONS AB N-Methyl-D-aspartate receptors (NMDARs) have two opposing roles in the brain. On the one hand, NMDARs control critical events in the formation and development of synaptic organization and synaptic plasticity. On the other hand, the overactivation of NMDARs can promote neuronal death in neuropathological conditions. Ca2+ influx acts as a primary modulator after NMDAR channel activation. An imbalance in Ca2+ homeostasis is associated with several neurological diseases including schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis. These chronic conditions have a lengthy progression depending on internal and external factors. External factors such as acute episodes of brain damage are associated with an earlier onset of several of these chronic mental conditions. Here, we will review some of the current evidence of how traumatic brain injury can hasten the onset of several neurological conditions, focusing on the role of NMDAR distribution and the functional consequences in calcium homeostasis associated with synaptic dysfunction and neuronal death present in this group of chronic diseases. C1 [Carvajal, Francisco J.; Cerpa, Waldo] Pontificia Univ Catolica Chile, Fac Ciencias Biol, Dept Biol Celular & Mol, Lab Func & Patol Neuronal, Santiago 8331150, Chile. [Mattison, Hayley A.] Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA. RP Cerpa, W (reprint author), Pontificia Univ Catolica Chile, Fac Ciencias Biol, Dept Biol Celular & Mol, Lab Func & Patol Neuronal, Santiago 8331150, Chile. EM wcerpa@bio.puc.cl FU Fondo Nacional de Desarrollo Cientifico, Tecnologico (Fondecyt) [11121206]; Proyecto Asociativo CONICYT (anillo) [ACT1411]; CONICYT (anillo) [ACT1411]; CONICYT FX This work was supported through grant from Fondo Nacional de Desarrollo Cientifico, Tecnologico (Fondecyt) 11121206 to WC and Proyecto Asociativo CONICYT (anillo ACT1411) and predoctoral fellowship from CONICYT to FJC. NR 249 TC 1 Z9 1 U1 4 U2 4 PU HINDAWI PUBLISHING CORP PI NEW YORK PA 315 MADISON AVE 3RD FLR, STE 3070, NEW YORK, NY 10017 USA SN 2090-5904 EI 1687-5443 J9 NEURAL PLAST JI Neural. Plast. PY 2016 AR 2701526 DI 10.1155/2016/2701526 PG 20 WC Neurosciences SC Neurosciences & Neurology GA DU3TC UT WOS:000382134100001 ER PT J AU Jakobiec, FA Ramsey, DJ Stagner, AM Wu, DM Yoon, MK AF Jakobiec, Frederick A. Ramsey, David J. Stagner, Anna M. Wu, David M. Yoon, Michael K. TI Pulmonary Adenocarcinoma Metastatic to the Choroid Diagnosed by Biopsy of an Extrascleral Nodule SO OCULAR ONCOLOGY AND PATHOLOGY LA English DT Article DE Choroid; Orbit; Lung carcinoma; Metastasis; Immunohistochemistry ID CELL LUNG-CANCER; OCULAR METASTASES; CILIARY BODY; CARCINOMA; EYE; FREQUENCY; TUMOR; UVEAL AB Purpose/Background: To report a patient with orbital extension of a choroidal metastasis produced by a pulmonary adenocarcinoma which was diagnosed by biopsy of the extrascleral nodule. Methods: Clinical history and imaging studies (including fundus photography, autofluorescence, fluorescein angiography, B-scan, and orbital MRI) were reviewed along with histopathologic and immunohistochemical studies. Results: A 60-year-old woman presented with decreased vision in the right eye. Fundus examination revealed a leopard-spotted choroidal lesion and associated serous retinal detachment. Imaging disclosed an enhancing orbital lesion abutting the sclera near the choroidal mass, which had spread outside of the eye. Histopathology revealed lumen-forming cells elaborating mucin. The cells were immunohistochemically positive for epithelial membrane antigen, thyroid transcription factor 1, and cytokeratin 7 and negative for cytokeratin 20. This was consistent with a pulmonary adenocarcinoma. Widespread metastases were subsequently found. Conclusions: This is the first detailed case report of a successful biopsy of the orbital extension of an essentially posterior intraocular tumor. Such a maneuver permits a much more generous tissue sample than a needle biopsy. In the current case, a large tissue sample provided the basis for complete immunohistochemical evaluation, leading to the diagnosis of an intraocular metastatic mucin-producing adenocarcinoma of lung origin. (C) 2015 S. Karger AG, Basel C1 [Jakobiec, Frederick A.; Ramsey, David J.; Stagner, Anna M.; Wu, David M.; Yoon, Michael K.] Harvard Med Sch, Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Boston, MA USA. [Jakobiec, Frederick A.; Stagner, Anna M.] Massachusetts Eye & Ear Infirm, David G Cogan Lab Ophthalm Pathol, Suite 328,243 Charles St, Boston, MA 02114 USA. RP Jakobiec, FA (reprint author), Massachusetts Eye & Ear Infirm, David G Cogan Lab Ophthalm Pathol, Suite 328,243 Charles St, Boston, MA 02114 USA. EM Fred_Jakobiec@meei.harvard.edu NR 22 TC 0 Z9 0 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 2296-4681 EI 2296-4657 J9 OCUL ONCOL PATHOL JI Ocul. Oncol. Pathol. PY 2016 VL 2 IS 1 BP 24 EP 28 DI 10.1159/000430098 PG 5 WC Ophthalmology SC Ophthalmology GA DT7VR UT WOS:000381696800006 PM 27171574 ER PT J AU Korkmaz, H Yao, W Korkmaz, M Bleier, BS AF Korkmaz, Hakan Yao, William Korkmaz, Mukadder Bleier, Benjamin S. TI Benefit of Preoperative Oral Steroids during Sinus Surgery when Utilizing Concentrated Topical Epinephrine SO ORL-JOURNAL FOR OTO-RHINO-LARYNGOLOGY HEAD AND NECK SURGERY LA English DT Article DE Sinusitis; Steroid; Surgical blood loss; Surgical time; Intranasal surgery; Epinephrine; Chronic rhinosinusitis; Oral steroid; Intraoperative bleeding; Length of surgery; Endoscopic sinus surgery; Concentrated epinephrine ID CHRONIC-RHINOSINUSITIS; NASAL POLYPOSIS; SYSTEMIC STEROIDS; METAANALYSIS; HEMOSTASIS; ADRENALINE AB Background/Aims: Oral steroids have been advocated in the preoperative setting as a means of reducing intraoperative blood loss and surgical time during sinus surgery. The purpose of this study was to analyze the impact of preoperative oral steroid administration on intraoperative bleeding and surgical duration when coupled with concentrated topical epinephrine. Methods: The medical records of 302 patients who underwent bilateral 'full house' sinus surgery were reviewed. Concentrated topical epinephrine and inhalational anesthesia was used in all patients. Surgical duration and estimated blood loss were compared between the preoperative steroid-exposed and steroid-naive groups. chi(2) and Student's t tests were used for statistical analysis. Results: One hundred and forty-two patients were exposed to steroid, while the remaining 160 were steroid naive. No significant differences were found with respect to surgical time between the steroid-exposed (96.91 +/- 25.97 min) and steroid-naive patients (91.24 +/- 32.29 min, p = 0.100). The steroid-exposed group demonstrated a marginally increased blood loss (66.03 +/- 55.81 ml) as compared to steroid-naive patients (55.00 +/- 38.71 ml, p = 0.048). Conclusion: When coupled with intraoperative concentrated topical epinephrine use, preoperative oral steroid administration provides no clinically significant benefit with respect to reduced intraoperative bleeding or surgical duration. (C) 2016 S. Karger AG, Basel C1 [Korkmaz, Hakan; Korkmaz, Mukadder] Ordu Univ, Dept Otorhinolaryngol, Fac Med, Ordu, Turkey. [Yao, William; Bleier, Benjamin S.] Harvard Med Sch, Massachusetts Eye & Ear Infirm, Dept Otolaryngol, Boston, MA USA. RP Korkmaz, H (reprint author), Ordu Univ Egitim & Arastirma Hastanesi, TR-52200 Ordu, Turkey. EM hakankorkmaz@hotmail.com NR 32 TC 0 Z9 0 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0301-1569 EI 1423-0275 J9 ORL J OTO-RHINO-LARY JI ORL-J. Oto-Rhino-Laryngol. Head Neck Surg. PY 2016 VL 78 IS 4 BP 216 EP 222 DI 10.1159/000446806 PG 7 WC Otorhinolaryngology SC Otorhinolaryngology GA DU0KS UT WOS:000381893300006 PM 27383647 ER PT S AU Munos, B Baker, PC Bot, BM Crouthamel, M de Vries, G Ferguson, I Hixson, JD Malek, LA Mastrototaro, JJ Misra, V Ozcan, A Sacks, L Wang, P AF Munos, Bernard Baker, Pamela C. Bot, Brian M. Crouthamel, Michelle de Vries, Glen Ferguson, Ian Hixson, John D. Malek, Linda A. Mastrototaro, John J. Misra, Veena Ozcan, Aydogan Sacks, Leonard Wang, Pei GP Annals New York Acad Sci TI Mobile health: the power of wearables, sensors, and apps to transform clinical trials SO SPECIAL ISSUE: ANNALS REPORTS, VOL 1375 SE Annals of the New York Academy of Sciences LA English DT Article; Book Chapter DE biosensors; mobile technology; wireless; medical device; health care; data; clinical study ID ON-CHIP MICROSCOPY AB Mobile technology has become a ubiquitous part of everyday life, and the practical utility of mobile devices for improving human health is only now being realized. Wireless medical sensors, or mobile biosensors, are one such technology that is allowing the accumulation of real-time biometric data that may hold valuable clues for treating even some of the most devastating human diseases. From wearable gadgets to sophisticated implantable medical devices, the information retrieved from mobile technology has the potential to revolutionize how clinical research is conducted and how disease therapies are delivered in the coming years. Encompassing the fields of science and engineering, analytics, health care, business, and government, this report explores the promise that wearable biosensors, along with integrated mobile apps, hold for improving the quality of patient care and clinical outcomes. The discussion focuses on groundbreaking device innovation, data optimization and validation, commercial platform integration, clinical implementation and regulation, and the broad societal implications of using mobile health technologies. C1 [Munos, Bernard] Milken Inst, FasterCures, Washington, DC 20005 USA. [Baker, Pamela C.] Questex Media Grp LLC, FierceBigData, Newton, MA USA. [Bot, Brian M.] Sage Bionetworks, Seattle, WA USA. [Crouthamel, Michelle] GlaxoSmithKline, Collegeville, PA USA. [de Vries, Glen] Medidata Solut, New York, NY USA. [Ferguson, Ian] ARM, San Francisco, CA USA. [Hixson, John D.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA. [Hixson, John D.] San Francisco VA Med Ctr, San Francisco, CA USA. [Malek, Linda A.] Moses & Singer LLP, Healthcare & Privacy & Cybersecur Practices, New York, NY USA. [Mastrototaro, John J.] Medtronic PLC, Los Angeles, CA USA. [Misra, Veena] North Carolina State Univ, NSF Nanosyst Engn Res Ctr NERC Adv Self Powered S, Raleigh, NC USA. [Ozcan, Aydogan] Univ Calif Los Angeles, Calif NanoSyst Inst, Los Angeles, CA USA. [Ozcan, Aydogan] Univ Calif Los Angeles, Dept Bioengn, Los Angeles, CA USA. [Ozcan, Aydogan] Univ Calif Los Angeles, Dept Elect Engn, Los Angeles, CA 90024 USA. [Sacks, Leonard] US FDA, Silver Spring, MD USA. [Wang, Pei] Icahn Sch Med Mt Sinai, New York, NY 10029 USA. RP Munos, B (reprint author), Milken Inst, FasterCures, Washington, DC 20005 USA. EM annals@nyas.org RI Emchi, Karma/Q-1952-2016 NR 40 TC 1 Z9 1 U1 14 U2 14 PU BLACKWELL SCIENCE PUBL PI OXFORD PA OSNEY MEAD, OXFORD OX2 0EL, ENGLAND SN 0077-8923 J9 ANN NY ACAD SCI JI Ann.NY Acad.Sci. PY 2016 VL 1375 BP 3 EP 18 DI 10.1111/nyas.13117 PG 16 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA BF5HR UT WOS:000382005200001 PM 27384501 ER PT J AU Wolach, O Stone, R AF Wolach, Ofir Stone, Richard TI Autoimmunity and inflammation in Myelodysplastic Syndromes SO ACTA HAEMATOLOGICA LA English DT Review DE Autoimmune and inflammatory conditions; Connective tissue diseases; Myelodysplastic syndrome ID REGULATORY T-CELLS; ACUTE MYELOID-LEUKEMIA; NECROSIS-FACTOR-ALPHA; CHRONIC MYELOMONOCYTIC LEUKEMIA; OF-THE-LITERATURE; AUTOLOGOUS LYMPHOCYTES; MONOCLONAL-ANTIBODY; INTESTINAL ULCERS; SUPPRESSOR-CELLS; INTERFERON-GAMMA AB Autoimmune and inflammatory conditions (AICs) are encountered in up to 25% of patients with myelodysplastic syndromes (MDS). A wide range of AICs have been reported in association with MDS and can range from limited clinical manifestations to systemic diseases affecting multiple organs. Vasculitides, connective tissue diseases, and inflammatory arthritis are frequently reported in different studies; noninfectious fever and constitutional symptoms at presentation are common. Associations between AICs and specific MDS characteristics vary by study, but the available data suggest that AICs cluster more often in younger patients with higher-risk MDS. In general, AICs do not seem to confer worse survival, although certain AICs may be associated with adverse outcome (e.g. vasculitis) or progression of MDS (Sweet's syndrome). Nonetheless, these complications may have a significant impact on quality of life and affect the timing and type of MDS-directed therapy. The mainstay of management of these complications in the short term relies on immunosuppressive drugs. Increasing evidence suggests that hypomethylating agents.may be effective in treating these complications and reduce steroid dependence. While the pathogenesis of AICs is incompletely understood, growing appreciation of cellular immune deregulation, cytokine hypersecretion, and the genetic heterogeneity underlying MDS may improve our understanding of common pathways linking MDS, inflammation, and autoimmunity. (C) 2016 S. Karger AG, Basel C1 [Wolach, Ofir; Stone, Richard] Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave, Boston, MA 02115 USA. RP Wolach, O (reprint author), Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave, Boston, MA 02115 USA. EM Ofir_wolaj@dfci.harvard.edu NR 72 TC 0 Z9 0 U1 1 U2 1 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0001-5792 EI 1421-9662 J9 ACTA HAEMATOL-BASEL JI Acta Haematol. PY 2016 VL 136 IS 2 BP 108 EP 117 DI 10.1159/000446062 PG 10 WC Hematology SC Hematology GA DT8WR UT WOS:000381776900007 PM 27337745 ER PT J AU Tseng, YH AF Tseng, Yu-Hua TI Shades of brown: an introduction for the special focus issue of Adipocyte on "brown and beige/brite adipocytes" INTRODUCTION SO ADIPOCYTE LA English DT Editorial Material DE brown adipocyte; beige/brite adipocyte; thermogenic adipocyte C1 [Tseng, Yu-Hua] Harvard Med Sch, Joslin Diabet Ctr, Sect Integrat Physiol & Metab, Boston, MA 02115 USA. RP Tseng, YH (reprint author), Harvard Med Sch, Joslin Diabet Ctr, Sect Integrat Physiol & Metab, Boston, MA 02115 USA. EM Yu-Hua.Tseng@joslin.harvard.edu NR 0 TC 0 Z9 0 U1 2 U2 2 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 2162-3945 EI 2162-397X J9 ADIPOCYTE JI Adipocyte PY 2016 VL 5 IS 2 SI SI BP 97 EP 97 DI 10.1080/21623945.2016.1194132 PG 1 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA DT7RE UT WOS:000381683100001 ER PT J AU Stanford, KI Goodyear, LJ AF Stanford, Kristin I. Goodyear, Laurie J. TI Exercise regulation of adipose tissue SO ADIPOCYTE LA English DT Article DE beiging; brown adipose tissue; exercise; myokines; white adipose tissue ID HIGH-FAT DIET; MESSENGER-RNA EXPRESSION; PHYSICALLY TRAINED RATS; SKELETAL-MUSCLE MASS; BROWN ADIPOCYTES; WHITE FAT; THERMOGENIC CAPACITY; INSULIN SENSITIVITY; ENERGY-EXPENDITURE; GLUCOSE-TRANSPORT AB Exercise training results in adaptations to numerous organ systems and offers protection against metabolic disorders including obesity and type 2 diabetes, and recent reports suggest that adipose tissue may play a role in these beneficial effects of exercise on overall health. Multiple studies have investigated the effects of exercise training on both white adipose tissue (WAT) and brown adipose tissue (BAT), as well as the induction of beige adipocytes. Studies from both rodents and humans show that there are exercise training-induced changes in WAT including decreased cell size and lipid content, and increased mitochondrial activity. In rodents, exercise training causes an increased beiging of WAT. Whether exercise training causes a beiging of human scWAT, as well as which factors contribute to the exercise-induced beiging of WAT are areas of current investigation. Studies investigating the effects of exercise training on BAT mass and function have yielded conflicting data, and hence, is another area of intensive investigation. This review will focus on studies aimed at elucidating the mechanisms regulating exercise training induced-adaptations to adipose tissue. C1 [Stanford, Kristin I.] Ohio State Univ, Wexner Med Ctr, Dept Physiol & Cell Biol, Dorothy M Davis Heart & Lung Res Inst, Columbus, OH 43210 USA. [Goodyear, Laurie J.] Harvard Med Sch, Joslin Diabet Ctr, Sect Integrat Physiol & Metab, Boston, MA USA. [Goodyear, Laurie J.] Harvard Med Sch, Brigham & Womens Hosp, Dept Med, Boston, MA USA. RP Stanford, KI (reprint author), 460 W 12th Ave,BRT Rm 314, Columbus, OH 43210 USA. EM kristin.stanford@osumc.edu FU NIDDK NIH HHS [K01 DK105109, T32 DK007260] NR 76 TC 3 Z9 3 U1 2 U2 3 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 2162-3945 EI 2162-397X J9 ADIPOCYTE JI Adipocyte PY 2016 VL 5 IS 2 SI SI BP 153 EP 162 DI 10.1080/21623945.2016.1191307 PG 10 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA DT7RE UT WOS:000381683100006 PM 27386159 ER PT J AU Chaudhury, S Brown, FL Kirk, CM Mukunzi, S Nyirandagijimana, B Mukandanga, J Ukundineza, C Godfrey, K Ng, LC Brennan, RT Betancourt, TS AF Chaudhury, Sumona Brown, Felicity L. Kirk, Catherine M. Mukunzi, Sylvere Nyirandagijimana, Beatha Mukandanga, Josee Ukundineza, Christian Godfrey, Kalisa Ng, Lauren C. Brennan, Robert T. Betancourt, Theresa S. TI Exploring the potential of a family-based prevention intervention to reduce alcohol use and violence within HIV-affected families in Rwanda SO AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV LA English DT Article DE Children affected by HIV; AIDS; resilience; IPV; alcohol; Rwanda; family-based prevention ID INTIMATE PARTNER VIOLENCE; STUDIES DEPRESSION SCALE; MENTAL-HEALTH; CHILDREN; AFRICAN; RESILIENCE; HIV/AIDS; RISK; COUNTRIES; SETTINGS AB HIV-affected families report higher rates of harmful alcohol use, intimate partner violence (IPV) and family conflict, which can have detrimental effects on children. Few evidence-based interventions exist to address these complex issues in Sub-Saharan Africa. This mixed methods study explores the potential of a family-based intervention to reduce IPV, family conflict and problems related to alcohol use to promote child mental health and family functioning within HIV-affected families in post-genocide Rwanda. A family home-visiting, evidence-based intervention designed to identify and enhance resilience and communication in families to promote mental health in children was adapted and developed for use in this context for families affected by caregiver HIV in Rwanda. The intervention was adapted and developed through a series of pilot study phases prior to being tested in open and randomized controlled trials (RCTs) in Rwanda for families affected by caregiver HIV. Quantitative and qualitative data from the RCT are explored here using a mixed methods approach to integrate findings. Reductions in alcohol use and IPV among caregivers are supported by qualitative reports of improved family functioning, lower levels of violence and problem drinking as well as improved child mental health, among the intervention group. This mixed methods analysis supports the potential of family-based interventions to reduce adverse caregiver behaviors as a major mechanism for improving child well-being. Further studies to examine these mechanisms in well-powered trials are needed to extend the evidence-base on the promise of family-based intervention for use in low- and middle-income countries. C1 [Chaudhury, Sumona] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA. [Brown, Felicity L.; Kirk, Catherine M.; Brennan, Robert T.; Betancourt, Theresa S.] Harvard TH Chan Sch Publ Hlth, Dept Global Hlth & Populat, Boston, MA 02115 USA. [Mukunzi, Sylvere; Mukandanga, Josee; Ukundineza, Christian; Godfrey, Kalisa] FXB Rwanda, Kigali, Rwanda. [Nyirandagijimana, Beatha] MPH, Partners Hlth Inshuti Mu Buzima, Kigali, Rwanda. [Ng, Lauren C.] Massachusetts Gen Hosp, Div Global Psychiat, ScD, Boston, MA 02114 USA. RP Betancourt, TS (reprint author), Harvard TH Chan Sch Publ Hlth, Dept Global Hlth & Populat, Boston, MA 02115 USA. EM theresa_betancourt@harvard.edu FU National Institute of Mental Health [R34 MH084679]; Peter C. Alderman Foundation Junior Faculty Development Grant, through the Harvard TH Chan School of Public Health; Peter C. Alderman Foundation Junior Faculty Development Grant, through Julie Henry, Harvard Center on the Developing Child; Harvard Career Incubator Fund; Harvard Center for AIDS Research; Endeavour Queen Elizabeth II Diamond Jubilee fellowship [4764_2015] FX This study was funded by a grant from the National Institute of Mental Health [R34 MH084679] and supported by the Peter C. Alderman Foundation Junior Faculty Development Grant, through the Harvard TH Chan School of Public Health and through Julie Henry, Harvard Center on the Developing Child, Harvard Career Incubator Fund, Harvard Center for AIDS Research and an Endeavour Queen Elizabeth II Diamond Jubilee fellowship under [grant number 4764_2015 (FB)]. NR 48 TC 1 Z9 1 U1 1 U2 1 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 0954-0121 EI 1360-0451 J9 AIDS CARE JI Aids Care-Psychol. Socio-Med. Asp. Aids-Hiv PY 2016 VL 28 SU 2 SI SI BP 118 EP 129 DI 10.1080/09540121.2016.1176686 PG 12 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychology, Multidisciplinary; Respiratory System; Social Sciences, Biomedical SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychology; Respiratory System; Biomedical Social Sciences GA DS5AT UT WOS:000380793600016 PM 27392007 ER PT J AU Gaudin, R Knipfer, C Henningsen, A Smeets, R Heiland, M Hadlock, T AF Gaudin, Robert Knipfer, Christian Henningsen, Anders Smeets, Ralf Heiland, Max Hadlock, Tessa TI Approaches to Peripheral Nerve Repair: Generations of Biomaterial Conduits Yielding to Replacing Autologous Nerve Grafts in Craniomaxillofacial Surgery SO BIOMED RESEARCH INTERNATIONAL LA English DT Review ID RAT SCIATIC-NERVE; CILIARY NEUROTROPHIC FACTOR; NEURAL STEM-CELLS; MOTONEURONS IN-VIVO; ELECTRICAL-STIMULATION PROMOTES; DENATURED MUSCLE-TISSUE; DYING-BACK PROCESS; AXONAL REGENERATION; GROWTH-FACTOR; SCHWANN-CELL AB Peripheral nerve injury is a common clinical entity, which may arise due to traumatic, tumorous, or even iatrogenic injury in craniomaxillofacial surgery. Despite advances in biomaterials and techniques over the past several decades, reconstruction of nerve gaps remains a challenge. Autografts are the gold standard for nerve reconstruction. Using autografts, there is donor site morbidity, subsequent sensory deficit, and potential for neuroma development and infection. Moreover, the need for a second surgical site and limited availability of donor nerves remain a challenge. Thus, increasing efforts have been directed to develop artificial nerve guidance conduits (ANCs) as new methods to replace autografts in the future. Various synthetic conduit materials have been tested in vitro and in vivo, and several first- and second-generation conduits are FDA approved and available for purchase, while third-generation conduits still remain in experimental stages. This paper reviews the current treatment options, summarizes the published literature, and assesses future prospects for the repair of peripheral nerve injury in craniomaxillofacial surgery with a particular focus on facial nerve regeneration. C1 [Gaudin, Robert; Hadlock, Tessa] Harvard Med Sch, Massachusetts Eye & Ear Infirm, Dept Otolaryngol Head & Neck Surg, Div Facial Plast & Reconstruct Surg, 243 Charles St, Boston, MA 02114 USA. [Knipfer, Christian; Smeets, Ralf; Heiland, Max] Univ Med Ctr Hamburg Eppendorf, Dept Oral & Maxillofacial Surg, Martinistr 52, D-20246 Hamburg, Germany. [Henningsen, Anders] Bundeswehrkrankenhaus Hamburg, Dept Oral & Maxillofacial Surg, Lesserstr 180, D-22049 Hamburg, Germany. RP Gaudin, R (reprint author), Harvard Med Sch, Massachusetts Eye & Ear Infirm, Dept Otolaryngol Head & Neck Surg, Div Facial Plast & Reconstruct Surg, 243 Charles St, Boston, MA 02114 USA. EM robert-a-gaudin@t-online.de OI Heiland, Max/0000-0002-4987-2913 NR 248 TC 0 Z9 0 U1 6 U2 7 PU HINDAWI PUBLISHING CORP PI NEW YORK PA 315 MADISON AVE 3RD FLR, STE 3070, NEW YORK, NY 10017 USA SN 2314-6133 EI 2314-6141 J9 BIOMED RES INT JI Biomed Res. Int. PY 2016 AR 3856262 DI 10.1155/2016/3856262 PG 18 WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental SC Biotechnology & Applied Microbiology; Research & Experimental Medicine GA DT3WK UT WOS:000381411700001 ER PT J AU Zimmerman, A Flahive, JM Hertl, M Cosimi, AB Saidi, RF AF Zimmerman, A. Flahive, J. M. Hertl, M. Cosimi, A. B. Saidi, R. F. TI Outcomes of Full-Right-Full-Left Split Liver Transplantation in Adults in the USA: A Propensity-Score Matched Analysis SO INTERNATIONAL JOURNAL OF ORGAN TRANSPLANTATION MEDICINE LA English DT Article DE Liver transplantation; Waiting Lists; Mortality; Allograft survival; Patient survival; Survival analysis ID SINGLE-CENTER EXPERIENCE; ONE DONOR LIVER; LIVING-DONOR; RECIPIENTS; GRAFTS AB Background: Splitting a liver for utilization in adult/pediatric recipients has been shown to decrease mortality on the wait list without increasing the overall risk of long-term graft failure compared to a whole graft. However, splitting a single donor organ for two adult recipients, full-right-full-left split liver transplantation (FRFLSLT), to overcome organ shortage is still considered controversial. Objective: This study assessed the outcome of FRFLSLT comparing full-right (FR) and full-left (FL) with whole liver (WL) allografts in adults (1998-2010) using UNOS standard transplant analysis and research (STAR) file. Methods: Unadjusted allograft and patient survival were estimated using Kaplan-Meier survival curves. Adjusted analyses of survival were conducted controlling for propensity for WL allograft. Results: There were 83,313 cases of WL, 651 FR and 117 FL. Significant differences were evident in the unadjusted cohort between recipients who received FR and FL including donor, cold ischemic time, and days on transplant waiting list. Use of FL allograft resulted in a trend toward lower graft and patient survival compared to WL and FR, which was not statistically significant (p=0.07). In the matched cohort, FL hemiliver allograft had no detrimental effect on the allograft or patient survival after split liver transplantation when compared to FR and WL. Conclusion: After adjusting for donor and recipient characteristics, there was no difference in allograft or patient survival with the use of FL, FR, or WL after liver transplantation in adults. FRFLSLT is a valuable and safe option to expand the donor pool. C1 [Zimmerman, A.; Saidi, R. F.] Brown Univ, Alpert Med Sch, Dept Surg, Div Organ Transplantat, 593 Eddy St,APC 921, Providence, RI 02903 USA. [Flahive, J. M.] Univ Massachusetts, Sch Med, Ctr Outcomes Res, Dept Surg, Worcester, MA USA. [Hertl, M.] Rush Univ, Med Ctr, Dept Surg, Div Transplantat, Chicago, IL USA. [Cosimi, A. B.] Massachusetts Gen Hosp, Harvard Med Sch, Dept Surg, Transplantat Unit, Boston, MA USA. RP Saidi, RF (reprint author), Brown Univ, Alpert Med Sch, Dept Surg, Div Organ Transplantat, 593 Eddy St,APC 921, Providence, RI 02903 USA. EM Reza_Saidi@Brown.edu NR 23 TC 0 Z9 0 U1 2 U2 2 PU AVICENNA ORGAN TRANSPLANT CENTER PI FARS PA PHASE 2, DOKOHAK RD, SADRA TOWN, SHIRAZ, FARS, 71994-67985, IRAN SN 2008-6490 EI 2008-6482 J9 INT J TRANSPLANT MED JI Int. J. Organ Transplant. Med. PY 2016 VL 7 IS 2 BP 69 EP 76 PG 8 WC Transplantation SC Transplantation GA DS4PO UT WOS:000380763200002 ER PT J AU Menchon, JM van Ameringen, M Dell'Osso, B Denys, D Figee, M Grant, JE Hollander, E Marazziti, D Nicolini, H Pallanti, S Ruck, C Shavitt, R Stein, DJ Andersson, E Bipeta, R Cath, DC Drummond, L Feusner, J Geller, DA Hranov, G Lochner, C Matsunaga, H McCabe, RE Mpavaenda, D Nakamae, T O'Kearney, R Pasquini, M Rivera, RP Poyurovsky, M Real, E do Rosario, MC Soreni, N Swinson, RP Vulink, N Zohar, J Fineberg, N AF Menchon, Jose M. van Ameringen, Michael Dell'Osso, Bernardo Denys, Damiaan Figee, Martijn Grant, Jon E. Hollander, Eric Marazziti, Donatella Nicolini, Humberto Pallanti, Stefano Ruck, Christian Shavitt, Roseli Stein, Dan J. Andersson, Erik Bipeta, Rajshekhar Cath, Danielle C. Drummond, Lynne Feusner, Jamie Geller, Daniel A. Hranov, Georgi Lochner, Christine Matsunaga, Hisato McCabe, Randy E. Mpavaenda, Davis Nakamae, Takashi O'Kearney, Richard Pasquini, Massimo Rivera, Ricardo Perez Poyurovsky, Michael Real, Eva Conceicao do Rosario, Maria Soreni, Noam Swinson, Richard P. Vulink, Nienke Zohar, Joseph Fineberg, Naomi TI Standards of care for obsessive-compulsive disorder centres SO INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE LA English DT Article DE Accreditation standards; obsessive-compulsive disorder; OCD units; standards of care ID POSTTRAUMATIC-STRESS-DISORDER; PHARMACOLOGICAL-TREATMENT; ANXIETY DISORDERS; RELIABILITY; GUIDELINES; SCALE AB In recent years, many assessment and care units for obsessive-compulsive disorder (OCD) have been set up in order to detect, diagnose and to properly manage this complex disorder, but there is no consensus regarding the key functions that these units should perform. The International College of Obsessive-Compulsive Spectrum Disorders (ICOCS) together with the Obsessive Compulsive and Related Disorders Network (OCRN) of the European College of Neuropsychopharmacology (ECNP) and the Anxiety and Obsessive Compulsive Disorders Section of the World Psychiaric Association (WPA) has developed a standards of care programme for OCD centres. The goals of this collaborative initiative are promoting basic standards, improving the quality of clinical care and enhance the validity and reliability of research results provided by different facilities and countries. C1 [Menchon, Jose M.; Real, Eva] Bellvitge Univ Hosp, Psychiat Dept, IDIBELL, Barcelona, Spain. [Menchon, Jose M.; Real, Eva] Carlos III Hlth Inst, CIBERSAM, Madrid, Spain. [Menchon, Jose M.] Univ Barcelona, Sch Med, Dept Clin Sci, Barcelona, Spain. [van Ameringen, Michael; McCabe, Randy E.; Soreni, Noam; Swinson, Richard P.] McMaster Univ, Dept Psychiat & Behav Neurosci, Hamilton, ON, Canada. [Dell'Osso, Bernardo] Univ Milan, Dept Psychiat, Milan, Italy. [Dell'Osso, Bernardo] Fdn IRCCS Ca Granda Policlin, Milan, Italy. [Denys, Damiaan; Figee, Martijn; Vulink, Nienke] Univ Amsterdam, Dept Psychiat, Acad Med Ctr, Amsterdam, Netherlands. [Denys, Damiaan] Brain & Cognit, Amsterdam, Netherlands. [Denys, Damiaan] Netherlands Inst Neurosci, Amsterdam, Netherlands. [Denys, Damiaan] Royal Netherlands Acad Arts & Sci, Amsterdam, Netherlands. [Grant, Jon E.] Univ Chicago, Dept Psychiat & Behav Neurosci, Chicago, IL 60637 USA. [Hollander, Eric] Albert Einstein Coll Med, Dept Psychiat & Behav Sci, New York, NY USA. [Hollander, Eric] Montefiore Med Ctr, Bronx, NY 10467 USA. [Marazziti, Donatella] Univ Pisa, Sez Psichiat, Dipartimento Med Clin & Sperimentale, Pisa, Italy. [Nicolini, Humberto] Natl Inst Genom Med, Mexico City, DF, Mexico. [Nicolini, Humberto] Carracci Med Grp, Mexico City, DF, Mexico. [Pallanti, Stefano] UC Davis Hlth Syst, Psychiat & Behav Sci, Sacramento, CA USA. [Pallanti, Stefano] Ist Neurosci, Florence, Italy. [Ruck, Christian; Andersson, Erik] Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden. [Shavitt, Roseli] Univ Sao Paulo, Sch Med, Dept & Inst Psychiat, Sao Paulo, Brazil. [Stein, Dan J.] Univ Cape Town, Psychiat & Mental Hlth Dept, Cape Town, South Africa. [Stein, Dan J.] Groote Schuur Hosp, Cape Town, South Africa. [Stein, Dan J.; Lochner, Christine] MRC Unit Anxiety & Stress Disorders, Cape Town, South Africa. [Bipeta, Rajshekhar] Gandhi Med Coll & Hosp, Hyderabad, Andhra Pradesh, India. [Cath, Danielle C.] Univ Utrecht, Dept Clin Psychol, Utrecht, Netherlands. [Drummond, Lynne] South West London & St Georges Mental Hlth NHS Tr, London, England. [Drummond, Lynne] St Georges Univ London, London, England. [Feusner, Jamie] Semel Inst Neurosci & Human Behav, Los Angeles, CA 90024 USA. [Feusner, Jamie] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Geller, Daniel A.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Geller, Daniel A.] Harvard Med Sch, Boston, MA USA. [Hranov, Georgi] Med Univ, Sofia, Bulgaria. [Lochner, Christine] Univ Stellenbosch, Dept Psychiat, Stellenbosch, South Africa. [Matsunaga, Hisato] Hyogo Coll Med, Dept Neuropsychiat, Nishinomiya, Hyogo, Japan. [McCabe, Randy E.] St Josephs Healthcare Hamilton, Anxiety Treatment & Res Ctr, Hamilton, ON, Canada. [Mpavaenda, Davis; Fineberg, Naomi] Hertfordshire Partnership Univ NHS Fdn Trust, Abbots Langley, Herts, England. [Nakamae, Takashi] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Psychiat, Kyoto, Japan. [O'Kearney, Richard] Australian Natl Univ, Res Sch Psychol, Canberra, ACT, Australia. [Pasquini, Massimo] Sapienza Univ Rome, Dept Neurol & Psychiat, Rome, Italy. [Rivera, Ricardo Perez] Bio Behav Inst, Buenos Aires, DF, Argentina. [Poyurovsky, Michael] Technion, Israel Inst Technol, Haifa, Israel. [Conceicao do Rosario, Maria] Fed Univ Sao Paulo UNIFESP, Dept Psychiat, Child & Adolescent Psychiat Unit UPIA, Sao Paulo, Brazil. [Soreni, Noam] St Josephs HealthCare, Anxiety Treatment & Res Ctr, Pediat OCD Consultat Serv, Hamilton, ON, Canada. [Zohar, Joseph] Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel. RP Menchon, JM (reprint author), Bellvitge Univ Hosp, Psychiat Dept, IDIBELL, Barcelona, Spain.; Menchon, JM (reprint author), Carlos III Hlth Inst, CIBERSAM, Madrid, Spain.; Menchon, JM (reprint author), Univ Barcelona, Sch Med, Dept Clin Sci, Barcelona, Spain. EM jmenchon@bellvitgehospital.cat RI Stein, Dan/A-1752-2008; OI Stein, Dan/0000-0001-7218-7810; Bipeta, Rajshekhar/0000-0001-6808-1183; O'Kearney, Richard/0000-0002-7839-7920 FU International College of Obsessive-Compulsive Spectrum Disorders (ICOCS); European College of Neuropsychopharmacology (ECNP) FX N. Fineberg received financial support to attend scientific meetings from the International College of Obsessive-Compulsive Spectrum Disorders (ICOCS) and the European College of Neuropsychopharmacology (ECNP). N. Fineberg and E. Hollander are Associate Editors of International Journal of Psychiatry in Clinical Practice, and J. Zohar, J. E. Grant and S. Pallanti are part of the Editorial Advisory Board of the same journal. NR 10 TC 0 Z9 0 U1 1 U2 2 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND SN 1365-1501 EI 1471-1788 J9 INT J PSYCHIAT CLIN JI Int. J. Psychiat. Clin. PY 2016 VL 20 IS 3 BP 204 EP 208 DI 10.1080/13651501.2016.1197275 PG 5 WC Psychiatry SC Psychiatry GA DR8JK UT WOS:000380144000015 PM 27359333 ER PT J AU Chen, MY Kalra, MK Yun, WB Cong, WX Yang, QS Nguyen, T Wei, BA Wang, G AF Chen, Mianyi Kalra, Mannudeep K. Yun, Wenbing Cong, Wenxiang Yang, Qingsong Nguyen, Terry Wei, Biao Wang, Ge TI A mixed reality approach for stereo-tomographic quantification of lung nodules SO JOURNAL OF X-RAY SCIENCE AND TECHNOLOGY LA English DT Article DE Mixed reality; stereo imaging; lung nodule; detection; qualification ID CANCER AB To reduce the radiation dose and the equipment cost associated with lung CT screening, in this paper we propose a mixed reality based nodule measurement method with an active shutter stereo imaging system. Without involving hundreds of projection views and subsequent image reconstruction, we generated two projections of an iteratively placed ellipsoidal volume in the field of view and merging these synthetic projections with two original CT projections. We then demonstrated the feasibility of measuring the position and size of a nodule by observing whether projections of an ellipsoidal volume and the nodule are overlapped from a human observer's visual perception through the active shutter 3D vision glasses. The average errors of measured nodule parameters are less than 1 mm in the simulated experiment with 8 viewers. Hence, it could measure real nodules accurately in the experiments with physically measured projections. C1 [Chen, Mianyi; Wei, Biao] Chongqing Univ, Minist Educ, Key Lab Optoelect Technol & Syst, Chongqing, Peoples R China. [Chen, Mianyi; Cong, Wenxiang; Yang, Qingsong; Nguyen, Terry; Wang, Ge] Rensselaer Polytech Inst, Dept Biomed Engn, Troy, NY 12180 USA. [Kalra, Mannudeep K.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA USA. [Yun, Wenbing] Sigray Inc, Concord, CA USA. RP Wang, G (reprint author), Rensselaer Polytech Inst, Dept Biomed Engn, Troy, NY 12180 USA. EM wangg6@rpi.edu FU NIH [R01 EB016977, U01 EB017140]; National Natural Science Foundation of China [61401049]; Fundamental Research Funds for the Central Universities [CDJZR14125501]; Chongqing strategic industry key generic technology innovation project [cstc2015zdcy-ztzxX0002]; Graduate Innovative Research Projects of Chongqing [CYB14024] FX This work was supported by NIH under Grants R01 EB016977 and U01 EB017140, and partly by the National Natural Science Foundation of China (No. 61401049), the Fundamental Research Funds for the Central Universities (No. CDJZR14125501), Chongqing strategic industry key generic technology innovation project (No. cstc2015zdcy-ztzxX0002) and Graduate Innovative Research Projects of Chongqing (No. CYB14024). NR 11 TC 1 Z9 1 U1 0 U2 0 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 0895-3996 EI 1095-9114 J9 J X-RAY SCI TECHNOL JI J. X-Ray Sci. Technol. PY 2016 VL 24 IS 4 BP 615 EP 625 DI 10.3233/XST-160578 PG 11 WC Instruments & Instrumentation; Optics; Physics, Applied SC Instruments & Instrumentation; Optics; Physics GA DT7EE UT WOS:000381649100009 PM 27232199 ER PT S AU Joukov, V Walter, JC De Nicolo, A AF Joukov, Vladimir Walter, Johannes C. De Nicolo, Arcangela BE Chang, P Ohi, R TI Assays to Study Mitotic Centrosome and Spindle Pole Assembly and Regulation SO MITOTIC SPINDLE: METHODS AND PROTOCOLS SE Methods in Molecular Biology LA English DT Article; Book Chapter DE Mitosis; Spindle assembly; Spindle pole; Centrosome; Pericentriolar material; Microtubule-organizing center; Cep192; Xenopus egg extract; Cell-free system ID XENOPUS EGG EXTRACTS; FUNCTION IN-VITRO; GTP-BOUND RAN; MICROTUBULE NUCLEATION; SELF-ORGANIZATION; AURORA; ACTIVATION; INHIBITOR; PROTEIN; CYCLE AB Faithful chromosome segregation during cell division requires proper bipolar spindle assembly and critically depends on spindle pole integrity. In most animal cells, spindle poles form as the result of the concerted action of various factors operating in two independent pathways of microtubule assembly mediated by chromatin/RanGTP and by centrosomes. Mutation or deregulation of a number of spindle pole-organizing proteins has been linked to human diseases, including cancer and microcephaly. Our knowledge on how the spindle pole-organizing factors function at the molecular level and cooperate with one another is still quite limited. As the list of these factors expands, so does the need for the development of experimental approaches to study their function. Cell-free extracts from Xenopus laevis eggs have played an instrumental role in the dissection of the mechanisms of bipolar spindle assembly and have recently allowed the reconstitution of the key steps of the centrosome-driven microtubule nucleation pathway (Joukov et al., Mol Cell 55:578-591, 2014). Here we describe assays to study both centrosome-dependent and centrosome-independent spindle pole formation in Xenopus egg extracts. We also provide experimental procedures for the use of artificial centrosomes, such as microbeads coated with an anti-Aurora A antibody or a recombinant fragment of the Cep192 protein, to model and study centrosome maturation in egg extract. In addition, we detail the protocol for a microtubule regrowth assay that allows assessment of the centrosome-driven spindle microtubule assembly in mammalian cells. C1 [Joukov, Vladimir] Harvard Med Sch, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA. [Walter, Johannes C.] Harvard Med Sch, Dept Biol Chem & Mol Pharmacol, Howard Hughes Med Inst, Boston, MA 02115 USA. [De Nicolo, Arcangela] Harvard Med Sch, Dept Med, Boston, MA 02115 USA. [De Nicolo, Arcangela] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA. RP Joukov, V (reprint author), Harvard Med Sch, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA. NR 33 TC 0 Z9 0 U1 0 U2 0 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA SN 1064-3745 BN 978-1-4939-3542-0; 978-1-4939-3540-6 J9 METHODS MOL BIOL JI Methods Mol. Biol. PY 2016 VL 1413 BP 207 EP 235 DI 10.1007/978-1-4939-3542-0_14 D2 10.1007/978-1-4939-3542-0 PG 29 WC Biochemical Research Methods; Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA BF4SA UT WOS:000381638300015 PM 27193852 ER PT S AU Emerman, AB Jambhekar, A Blower, MD AF Emerman, Amy B. Jambhekar, Ashwini Blower, Michael D. BE Chang, P Ohi, R TI Identification and Characterization of Mitotic Spindle-Localized Transcripts SO MITOTIC SPINDLE: METHODS AND PROTOCOLS SE Methods in Molecular Biology LA English DT Article; Book Chapter DE RNA localization; Mitotic Spindle; Xenopus laevis; RNaseA ID MESSENGER-RNAS; CHROMOSOME SEGREGATION; GENOME; TRANSLATION; EXTRACTS; REVEALS; OOCYTES; SEQ AB RNAs associate with the mitotic spindle in a variety of organisms, where they can spatially regulate protein production, ensure their proper segregation during cell division, or perform translation-independent roles in spindle formation. The identifi cation of spindle-associated RNAs is an important fi rst step in understanding the biological consequences of this phenomenon. In this chapter, we describe a method to use Xenopus laevis egg extracts to assemble and isolate mitotic spindles and to identify the spindle-associated RNAs. The method described here can be used in combination with immunodepletions, the addition of inhibitors, or other perturbations to investigate factors that affect RNA localization to the spindle. Finally, we describe a method to assess the consequences of ablating RNA in the extract on spindle formation. C1 [Emerman, Amy B.; Jambhekar, Ashwini; Blower, Michael D.] Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA. [Emerman, Amy B.; Jambhekar, Ashwini; Blower, Michael D.] Harvard Med Sch, Dept Genet, Boston, MA 02115 USA. RP Emerman, AB (reprint author), Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA.; Emerman, AB (reprint author), Harvard Med Sch, Dept Genet, Boston, MA 02115 USA. NR 28 TC 0 Z9 0 U1 0 U2 0 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA SN 1064-3745 BN 978-1-4939-3542-0; 978-1-4939-3540-6 J9 METHODS MOL BIOL JI Methods Mol. Biol. PY 2016 VL 1413 BP 303 EP 324 DI 10.1007/978-1-4939-3542-0_19 D2 10.1007/978-1-4939-3542-0 PG 22 WC Biochemical Research Methods; Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA BF4SA UT WOS:000381638300020 PM 27193857 ER PT S AU Kwon, M AF Kwon, Mijung BE Chang, P Ohi, R TI Using Cell Culture Models of Centrosome Amplification to Study Centrosome Clustering in Cancer SO MITOTIC SPINDLE: METHODS AND PROTOCOLS SE Methods in Molecular Biology LA English DT Article; Book Chapter DE Centrosome; Mitosis; Cancer; Multipolar spindle; Cell division; Extra centrosomes; Aneuploidy; Selective cancer therapeutics; Centrosome amplification ID EXTRA CENTROSOMES; CHROMOSOMAL INSTABILITY; RETRACTION FIBERS; MITOTIC SPINDLE; MITOSIS; KINASE; HSET; DUPLICATION; BIOGENESIS; INHIBITOR AB The link between centrosome amplification and cancer has been recognized for more than a century, raising many key questions about the biology of both normal and cancer cells. In particular, the presence of extra centrosomes imposes a great challenge to a dividing cell by increasing the likelihood of catastrophic multipolar divisions. Only recently have we begun to understand how cancer cells successfully divide by clustering their extra centrosomes for bipolar division. Several hurdles to dissecting centrosome clustering include limitations in the methodologies used to quantify centrosome amplification, and the lack of appropriate cell culture models. Here, we describe how to accurately assess centrosome number and create isogenic cell lines with or without centrosome amplification. We then describe how imaging of cell division in these cell culture models leads to identification of the molecular machinery uniquely required for cells with extra centrosomes. These approaches have led to the identification of molecular targets for selective cancer therapeutics that can kill cancer cells with extra centrosomes without affecting normal cells with two centrosomes. We further anticipate that the approaches described here will be broadly applicable for studying the causes and consequences of centrosome amplification in a variety of contexts across cancer pathophysiology, such as cell migration and metastasis. C1 [Kwon, Mijung] Dana Farber Canc Inst, Howard Hughes Med Inst, Dept Pediat Oncol, Boston, MA 02115 USA. [Kwon, Mijung] Harvard Med Sch, Dept Cell Biol, Boston, MA 02115 USA. RP Kwon, M (reprint author), Dana Farber Canc Inst, Howard Hughes Med Inst, Dept Pediat Oncol, Boston, MA 02115 USA.; Kwon, M (reprint author), Harvard Med Sch, Dept Cell Biol, Boston, MA 02115 USA. NR 40 TC 0 Z9 0 U1 1 U2 1 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA SN 1064-3745 BN 978-1-4939-3542-0; 978-1-4939-3540-6 J9 METHODS MOL BIOL JI Methods Mol. Biol. PY 2016 VL 1413 BP 367 EP 392 DI 10.1007/978-1-4939-3542-0_23 D2 10.1007/978-1-4939-3542-0 PG 26 WC Biochemical Research Methods; Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA BF4SA UT WOS:000381638300024 PM 27193861 ER PT J AU Patel, AV Miller, JB Nath, R Shih, HA Yoon, MK Freitag, SK Papaliodis, G Chen, TC Eliott, D Kim, IK AF Patel, Avni V. Miller, John B. Nath, Rajneesh Shih, Helen A. Yoon, Michael K. Freitag, Suzanne K. Papaliodis, George Chen, Teresa C. Eliott, Dean Kim, Ivana K. TI Unilateral Eye Findings: A Rare Herald of Acute Leukemia SO OCULAR ONCOLOGY AND PATHOLOGY LA English DT Article DE Choroidal infiltration; Leukemia; Ocular manifestations of leukemia; Ocular oncology; Radiation ID EXUDATIVE RETINAL-DETACHMENT; ACUTE LYMPHOBLASTIC-LEUKEMIA; CHOROIDAL INFILTRATION; LYMPHOCYTIC-LEUKEMIA; MYELOGENOUS LEUKEMIA; INVOLVEMENT; REMISSION AB Background/Aim: Unilateral choroidal infiltration as the initial manifestation of leukemic relapse in adults is rare, particularly after an extended period of remission. This report describes this unique ophthalmic presentation, highlights the associated diagnostic challenges, and reviews the literature. Methods: Two cases are described and an extensive literature review was conducted. Results: A 59-year-old male with acute lymphoid leukemia, in remission for 18 months, presented with unilateral scleritis, exudative retinal detachment, and choroidal thickening. A 57-year-old male with a history of acute myeloid leukemia, in remission for 4 years, presented with unilateral choroidal thickening leading to secondary angle closure. In both cases, there was a significant lag from the onset of eye symptoms to establishing a systemic diagnosis of acute leukemia, leading to a delay in definitive systemic treatment, despite a high suspicion of disease based on ophthalmic findings. Conclusions: These two cases illustrate the fundus findings consistent with leukemic choroidal infiltration that can represent the first sign of relapsed leukemia. The successful treatment of these patients hinges on collaboration between ophthalmologists and oncologists to optimize patient outcomes, highlighting the need for both groups to be aware of this rare ophthalmic presentation. (C) 2016 S. Karger AG, Basel C1 [Patel, Avni V.; Miller, John B.; Yoon, Michael K.; Freitag, Suzanne K.; Papaliodis, George; Chen, Teresa C.; Eliott, Dean; Kim, Ivana K.] Harvard Med Sch, Dept Ophthalmol, Boston, MA USA. [Miller, John B.; Eliott, Dean; Kim, Ivana K.] Massachusetts Eye & Ear Infirm, Retina Serv, Boston, MA 02114 USA. [Nath, Rajneesh] UMass Mem Med Ctr, Dept Hematol Oncol, Worcester, MA USA. [Nath, Rajneesh] Univ Massachusetts, Sch Med, Worcester, MA USA. [Shih, Helen A.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. [Shih, Helen A.] Harvard Med Sch, Boston, MA USA. [Yoon, Michael K.; Freitag, Suzanne K.] Massachusetts Eye & Ear Infirm, Dept Ophthalm Plast Surg, Boston, MA 02114 USA. [Papaliodis, George] Massachusetts Eye & Ear Infirm, Ocular Immunol & Uveitis Serv, Boston, MA 02114 USA. [Chen, Teresa C.] Massachusetts Eye & Ear Infirm, Glaucoma Serv, Boston, MA 02114 USA. RP Kim, IK (reprint author), Massachusetts Eye & Ear Infirm, 243 Charles St, Boston, MA 02114 USA. EM ivana_kim@meei.harvard.edu NR 24 TC 0 Z9 0 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 2296-4681 EI 2296-4657 J9 OCUL ONCOL PATHOL JI Ocul. Oncol. Pathol. PY 2016 VL 2 IS 3 BP 166 EP 170 DI 10.1159/000442951 PG 5 WC Ophthalmology SC Ophthalmology GA DT7VZ UT WOS:000381697600011 PM 27239459 ER PT S AU Jia, F Liu, SW Wu, MX Chen, XY AF Jia, Feng Liu, Shengwu Wu, Mei X. Chen, Xinyuan BE Thomas, S TI Micro-fractional Epidermal Powder Delivery for Skin Vaccination SO VACCINE DESIGN: METHODS AND PROTOCOLS, VOL 2: VACCINES FOR VETERINARY DISEASES SE Methods in Molecular Biology LA English DT Article; Book Chapter ID RANDOMIZED CONTROLLED SAFETY; SEASONAL INFLUENZA VACCINE; MICROINJECTION SYSTEM; IMMUNOGENICITY TRIAL; ADULTS; IMMUNIZATION; ADJUVANT C1 [Jia, Feng; Liu, Shengwu; Wu, Mei X.; Chen, Xinyuan] Harvard Med Sch, Massachusetts Gen Hosp, Dept Dermatol, Wellman Ctr Photomed, Boston, MA 02115 USA. [Chen, Xinyuan] Univ Rhode Isl, Coll Pharm, Biomed & Pharmaceut Sci, Kingston, RI 02881 USA. RP Jia, F (reprint author), Harvard Med Sch, Massachusetts Gen Hosp, Dept Dermatol, Wellman Ctr Photomed, Boston, MA 02115 USA. FU NIAID NIH HHS [AI089779, AI107678, R21 AI107678]; NIDA NIH HHS [R00 DA033371, DA028378, DA033371] NR 16 TC 1 Z9 1 U1 1 U2 1 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA SN 1064-3745 BN 978-1-4939-3389-1; 978-1-4939-3388-4 J9 METHODS MOL BIOL JI Methods Mol. Biol. PY 2016 VL 1404 BP 715 EP 723 DI 10.1007/978-1-4939-3389-1_46 D2 10.1007/978-1-4939-3389-1 PG 9 WC Biochemical Research Methods; Biochemistry & Molecular Biology; Veterinary Sciences SC Biochemistry & Molecular Biology; Veterinary Sciences GA BF4SY UT WOS:000381644700047 PM 27076332 ER PT J AU Cangelosi, AL Yilmaz, OH AF Cangelosi, Andrew L. Yilmaz, Omer H. TI High fat diet and stem cells: Linking diet to intestinal tumor formation SO CELL CYCLE LA English DT Editorial Material ID CANCER C1 [Cangelosi, Andrew L.; Yilmaz, Omer H.] MIT, Dept Biol, Cambridge, MA USA. [Yilmaz, Omer H.] MIT, David H Koch Inst Integrat Canc Res, 77 Massachusetts Ave, Cambridge, MA 02139 USA. [Yilmaz, Omer H.] Broad Inst Harvard & MIT, Cambridge, MA USA. [Yilmaz, Omer H.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Yilmaz, Omer H.] Harvard Med Sch, Boston, MA USA. RP Yilmaz, OH (reprint author), MIT, 77 Massachusetts Ave, Cambridge, MA 02139 USA. EM ohyilmaz@mit.edu FU NIGMS NIH HHS [T32 GM007287] NR 5 TC 0 Z9 0 U1 0 U2 0 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 1538-4101 EI 1551-4005 J9 CELL CYCLE JI Cell Cycle PY 2016 VL 15 IS 13 BP 1657 EP 1658 DI 10.1080/15384101.2016.1175275 PG 2 WC Cell Biology SC Cell Biology GA DR8FA UT WOS:000380132600003 PM 27097128 ER PT J AU Menietti, E Xu, XY Ostano, P Joseph, JM Lefort, K Dotto, GP AF Menietti, Elena Xu, Xiaoying Ostano, Paola Joseph, Jean-Marc Lefort, Karine Dotto, G. Paolo TI Negative control of CSL gene transcription by stress/DNA damage response and p53 SO CELL CYCLE LA English DT Article DE CSL/RBPJ kappa; dermal fibroblasts; individual variations in gene transcription; p53; UVA/DNA damage response ID CANCER-ASSOCIATED FIBROBLASTS; MULTIFOCAL EPITHELIAL TUMORS; CHIP-SEQ; FIELD CANCERIZATION; BINDING-SITES; DNA-DAMAGE; CELL-FATE; EXPRESSION; NOTCH; ACTIVATION AB CSL is a key transcriptional repressor and mediator of Notch signaling. Despite wide interest in CSL, mechanisms responsible for its own regulation are little studied. CSL down-modulation in human dermal fibroblasts (HDFs) leads to conversion into cancer associated fibroblasts (CAF), promoting keratinocyte tumors. We show here that CSL transcript levels differ among HDF strains from different individuals, with negative correlation with genes involved in DNA damage/repair. CSL expression is negatively regulated by stress/DNA damage caused by UVA, Reactive Oxygen Species (ROS), smoke extract, and doxorubicin treatment. P53, a key effector of the DNA damage response, negatively controls CSL gene transcription, through suppression of CSL promoter activity and, indirectly, by increased p21 expression. CSL was previously shown to bind p53 suppressing its activity. The present findings indicate that p53, in turn, decreases CSL expression, which can serve to enhance p53 activity in acute DNA damage response of cells. C1 [Menietti, Elena; Xu, Xiaoying; Lefort, Karine; Dotto, G. Paolo] Univ Lausanne, Dept Biochem, Chemin Boveresses 155, CH-1066 Epalinges, Switzerland. [Ostano, Paola] Edo & Elvo Tempia Valenta Fdn, Canc Genom Lab, Biella, Italy. [Joseph, Jean-Marc] Univ Hosp CHUV, Dept Pediat Surg, Lausanne, Switzerland. [Lefort, Karine] Univ Hosp CHUV, Dept Dermatol, Lausanne, Switzerland. [Dotto, G. Paolo] Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Charlestown, MA USA. RP Lefort, K; Dotto, GP (reprint author), Univ Lausanne, Dept Biochem, Chemin Boveresses 155, CH-1066 Epalinges, Switzerland. EM karine.lefort@unil.ch; paolo.dotto@unil.ch FU Swiss National Science Foundation [310030_156191/1]; National Institute of Arthritis and Musculoskeletal and Skin Diseases [R01AR039190, R01AR064786]; European Research Council [26075083]; Swiss Cancer League [OCS-2922-02-2012, KFS-3301-08-2013]; ISREC; Lauretana S.P.A. FX This work was supported by grants from the Swiss National Science Foundation (310030_156191/1), the National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01AR039190; R01AR064786; the content not necessarily representing the official views of NIH), European Research Council (26075083) and Swiss Cancer League (OCS-2922-02-2012 and KFS-3301-08-2013). E. Menietti was supported by a grant from ISREC and P. Ostano by a grant from Lauretana S.P.A. NR 57 TC 0 Z9 0 U1 2 U2 2 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 1538-4101 EI 1551-4005 J9 CELL CYCLE JI Cell Cycle PY 2016 VL 15 IS 13 BP 1767 EP 1778 DI 10.1080/15384101.2016.1186317 PG 12 WC Cell Biology SC Cell Biology GA DR8FA UT WOS:000380132600018 PM 27163456 ER PT J AU Singh, K Zimmerman, AW AF Singh, Kanwaljit Zimmerman, Andrew W. TI Sulforaphane Treatment of Young Men with Autism Spectrum Disorder SO CNS & Neurological Disorders-Drug Targets LA English DT Article DE ASD; Autism; Fever effect; Sulforaphane ID HEAT-SHOCK RESPONSE; PHARMACOLOGICAL INDUCTION; UP-REGULATION; CHILDREN; INJURY; CELLS; ACTIVATION; EXPRESSION; STRESS; BRAIN AB Autism Spectrum Disorder (ASD) comprises a heterogeneous group of neurodevelopmental disorders that begin in early childhood. They are characterized by differences in behavior and delays in communication and affect at least 1% of children. Observational studies have now confirmed that behaviors of a substantial percentage of children with autism tend to improve with the onset of febrile illness, which might be the downstream effects of altered metabolic pathways involving increased expression of heat shock proteins (HSP) and cellular stress responses. Sulforaphane, a phytochemical derived from a number of cruciferous vegetables, most notably broccoli sprouts, has metabolic effects that in some ways resemble that of fever. This review paper discusses this "fever effect" and the intracellular effects of sulforaphane as well as the results of our recent clinical trial of sulforaphane in young adults with autism. The accompanying review by Liu et al. describes the cellular actions of sulforaphane and potential biomarkers in the study of ASD. C1 [Singh, Kanwaljit; Zimmerman, Andrew W.] Univ Massachusetts, Sch Med, Dept Pediat Neurol, Worcester, MA USA. [Zimmerman, Andrew W.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. RP Zimmerman, AW (reprint author), Univ Massachusetts, Sch Med, UMass Mem Med Ctr, 55 Lake Ave, Worcester, MA 01655 USA. EM Andrew.Zimmerman@umassmemorial.org NR 41 TC 3 Z9 3 U1 1 U2 1 PU BENTHAM SCIENCE PUBL PI BUSUM PA PO BOX 294, BUSUM, 1400 AG, NETHERLANDS SN 1871-5273 EI 1996-3181 J9 CNS NEUROL DISORD-DR JI CNS Neurol. Disord.-Drug Targets PY 2016 VL 15 IS 5 BP 597 EP 601 DI 10.2174/1871527315666160413122525 PG 5 WC Neurosciences; Pharmacology & Pharmacy SC Neurosciences & Neurology; Pharmacology & Pharmacy GA DS2EU UT WOS:000380566300010 PM 27071786 ER PT J AU Liu, N Yu, ZY Gao, XM Song, YS Yuan, J Xun, Y Wang, TT Yan, F Yuan, SS Zhang, J Xiang, SL Lo, EH Wang, XY AF Liu, Ning Yu, Zhanyang Gao, Xiumei Song, Yun S. Yuan, Jing Xun, Yu Wang, Tingting Yan, Feng Yuan, Shishan Zhang, Jian Xiang, Shuanglin Lo, Eng H. Wang, Xiaoying TI Establishment of Cell-Based Neuroglobin Promoter Reporter Assay for Neuroprotective Compounds Screening SO CNS & Neurological Disorders-Drug Targets LA English DT Article DE High-throughput screening; luciferase reporter assay; neurodegeneration; neuroglobin (Ngb); neuroprotection; Ngb promoter; primary neuron ID ISCHEMIC-STROKE; TRANSCRIPTIONAL REGULATION; CEREBRAL-ISCHEMIA; GENE-EXPRESSION; IN-VIVO; BRAIN; NEURONS; CREB; 17-BETA-ESTRADIOL; PATHWAY AB Neuroglobin (Ngb) has been demonstrated to be neuroprotective against stroke and neurodegenerative diseases, thus upregulating Ngb might be a novel approach for neuroprotection. In this study we aimed to establish cell-based Ngb reporter systems for screening neuroprotective compounds targeting Ngb upregulation. We developed both mouse and human stable Ngb reporter systems containing a luciferase reporter gene directed by mouse and human Ngb promoter, respectively. To validate these reporter systems, we used them to screen a pool of natural plant compounds. RT-PCR was used to verify the Ngb-upregulating effects of selected compounds, and neurotoxicity assay was used to test their neuroprotection effects in primary cultured neurons. We identified polydatin, genistein, daidzein, biochanin A and formononetin that can upregulate both mouse and human Ngb promoter activity. RT-PCR confirmed that polydatin, genistein and formononetin significantly increased Ngb mRNA expression in primary neurons. Furthermore, formononetin significantly decreased oxygen-glucose deprivation (OGD)-induced neurotoxicity. Moreover, inhibition of cAMP response element-binding protein (CREB) showed that CREB is required for formononetin-induced Ngb upregulation. These results suggest that these Ngb reporter systems are suitable for neuroprotective compound screening, which will be used to screen larger compound libraries for more potent neuroprotectants. This preliminary study will facilitate the development of Ngb-targeted therapeutics for stroke and neurodegenerative diseases. C1 [Liu, Ning; Yuan, Jing; Xun, Yu; Wang, Tingting; Yan, Feng; Yuan, Shishan; Zhang, Jian; Xiang, Shuanglin] Hunan Normal Univ, Coll Life Sci, Coll Med, Key Lab Prot Chem & Dev Biol State,Educ Minist Ch, Changsha, Hunan, Peoples R China. [Liu, Ning; Yu, Zhanyang; Lo, Eng H.; Wang, Xiaoying] Harvard Med Sch, Massachusetts Gen Hosp, Dept Neurol & Radiol, Neurosci Program,Neuroprotect Res Lab, Boston, MA USA. [Gao, Xiumei] Tianjin Univ Tradit Chinese Med, Tianjin State Key Lab Modern Chinese Med, Tianjin, Peoples R China. [Song, Yun S.] Sookmyung Womens Univ, Coll Pharm, Coll Sci, Seoul 140742, South Korea. RP Xiang, SL (reprint author), Hunan Normal Univ, Coll Life Sci, Key Lab Prot Chem & Dev Biol, State Educ Minist China, Changsha 410081, Hunan, Peoples R China.; Wang, XY (reprint author), Massachusetts Gen Hosp, Dept Neurol, Neuroprotect Res Lab, 149 13th St,Room 2411A, Charlestown, MA 02129 USA.; Wang, XY (reprint author), Massachusetts Gen Hosp, Dept Radiol, Neuroprotect Res Lab, 149 13th St,Room 2411A, Charlestown, MA 02129 USA. EM xshlin@hunnu.edu.cn; wangxi@helix.mgh.harvard.edu FU China Postdoctoral Science Foundation [2014M552139]; American Heart Association Scientist Development Grant [15SDG25550035]; NIH [R01-NS049476] FX This work was supported in part by the China Postdoctoral Science Foundation (2014M552139) (to N. Liu), American Heart Association Scientist Development Grant (15SDG25550035) (to Z. Yu), and NIH Grant R01-NS049476 (to X. Wang). NR 36 TC 1 Z9 1 U1 0 U2 0 PU BENTHAM SCIENCE PUBL PI BUSUM PA PO BOX 294, BUSUM, 1400 AG, NETHERLANDS SN 1871-5273 EI 1996-3181 J9 CNS NEUROL DISORD-DR JI CNS Neurol. Disord.-Drug Targets PY 2016 VL 15 IS 5 BP 629 EP 639 DI 10.2174/1871527315666160321105612 PG 11 WC Neurosciences; Pharmacology & Pharmacy SC Neurosciences & Neurology; Pharmacology & Pharmacy GA DS2EU UT WOS:000380566300014 PM 26996171 ER PT J AU Zorick, T Smith, J AF Zorick, Todd Smith, Jason TI Generalized Information Equilibrium Approaches to EEG Sleep Stage Discrimination SO Computational and Mathematical Methods in Medicine LA English DT Article ID FUNCTIONAL-STATE; BRAIN AB Recent advances in neuroscience have raised the hypothesis that the underlying pattern of neuronal activation which results in electroencephalography (EEG) signals is via power-law distributed neuronal avalanches, while EEG signals are nonstationary. Therefore, spectral analysis of EEG may miss many properties inherent in such signals. A complete understanding of such dynamical systems requires knowledge of the underlying nonequilibrium thermodynamics. In recent work by Fielitz and Borchardt (2011, 2014), the concept of information equilibrium (IE) in information transfer processes has successfully characterized many different systems far from thermodynamic equilibrium. We utilized a publicly available database of polysomnogram EEG data from fourteen subjects with eight different one-minute tracings of sleep stage 2 and waking and an overlapping set of eleven subjects with eight different one-minute tracings of sleep stage 3. We applied principles of IE to model EEG as a system that transfers (equilibrates) information from the time domain to scalp-recorded voltages. We find that waking consciousness is readily distinguished from sleep stages 2 and 3 by several differences in mean information transfer constants. Principles of IE applied to EEG may therefore prove to be useful in the study of changes in brain function more generally. C1 [Zorick, Todd] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Psychiat, Los Angeles, CA 90073 USA. [Zorick, Todd] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. [Smith, Jason] Boeing Co, Seattle, WA 98124 USA. RP Zorick, T (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Dept Psychiat, Los Angeles, CA 90073 USA.; Zorick, T (reprint author), Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. EM tzorick@mednet.ucla.edu FU United States Veterans Administration Career Development Award [I01 BX007080] FX Todd Zorick is supported by a United States Veterans Administration Career Development Award no. I01 BX007080. The authors thank Drs. P. Fielitz and G. Borchardt for helpful discussions and comments on the paper. NR 31 TC 0 Z9 0 U1 2 U2 2 PU HINDAWI PUBLISHING CORP PI NEW YORK PA 315 MADISON AVE 3RD FLR, STE 3070, NEW YORK, NY 10017 USA SN 1748-670X EI 1748-6718 J9 COMPUT MATH METHOD M JI Comput. Math. Method Med. PY 2016 AR 6450126 DI 10.1155/2016/6450126 PG 8 WC Mathematical & Computational Biology SC Mathematical & Computational Biology GA DS3PI UT WOS:000380694700001 ER PT J AU Moaven, O Raziee, H Bowne, W Abbaszadegan, MR Fuchs, BC AF Moaven, Omeed Raziee, Hamid Bowne, Wilbur Abbaszadegan, Mohammad Reza Fuchs, Bryan C. TI Disease Biomarkers in Gastrointestinal Malignancies SO DISEASE MARKERS LA English DT Editorial Material ID COLORECTAL-CANCER; MULTIPLE-MYELOMA; AMERICAN SOCIETY; TUMOR-MARKERS; GUIDELINES; OVARIAN; UPDATE; HM1.24 C1 [Moaven, Omeed] Univ Alabama Birmingham, Dept Surg, Birmingham, AL 35233 USA. [Raziee, Hamid] Univ Toronto, Dept Radiat Oncol, Toronto, ON M5G 2M9, Canada. [Bowne, Wilbur] Drexel Univ, Dept Surg, Philadelphia, PA 19102 USA. [Abbaszadegan, Mohammad Reza] Mashhad Univ Med Sci, Med Genet Res Ctr, Mashhad 91967, Iran. [Fuchs, Bryan C.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA. RP Moaven, O (reprint author), Univ Alabama Birmingham, Dept Surg, Birmingham, AL 35233 USA. EM omeedmoaven@gmail.com OI Moaven, Omeed/0000-0002-0560-0457 NR 13 TC 0 Z9 0 U1 1 U2 1 PU HINDAWI PUBLISHING CORP PI NEW YORK PA 315 MADISON AVE 3RD FLR, STE 3070, NEW YORK, NY 10017 USA SN 0278-0240 EI 1875-8630 J9 DIS MARKERS JI Dis. Markers PY 2016 BP 1 EP 3 AR 4714910 DI 10.1155/2016/4714910 PG 3 WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine, Research & Experimental; Pathology SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research & Experimental Medicine; Pathology GA DR5PE UT WOS:000379954100001 ER PT J AU Hart, JE Morse, L Tun, CG Brown, R Garshick, E AF Hart, Jaime E. Morse, Leslie Tun, Carlos G. Brown, Robert Garshick, Eric TI Cross-sectional associations of pulmonary function with systemic inflammation and oxidative stress in individuals with chronic spinal cord injury SO JOURNAL OF SPINAL CORD MEDICINE LA English DT Article DE Pulmonary function; Inflammation; Oxidative stress; Spinal cord injury ID C-REACTIVE PROTEIN; LUNG-FUNCTION DECLINE; SKELETAL-MUSCLE; LIPID-PEROXIDATION; GENERAL-POPULATION; BODY-COMPOSITION; COPD; DISEASE; VOLUMES; MARKERS AB Context/Objective: Systemic inflammation, and to a lesser extent oxidative stress, have been associated with reduced pulmonary function. Our objective was to evaluate the associations between biomarkers of inflammation (C-reactive protein (CRP), interleukin-6 (IL-6)) and novel makers of global oxidative stress (fluorescent oxidation products (FLOx)) with spirometric and lung volume measures in individuals with chronic spinal cord injury (SCI). Design: Cross-sectional study. Setting: Veterans Affairs Medical Center. Participants: One-hundred thirty-seven men with chronic SCI participating in an epidemiologic study. Methods: Participants provided a blood sample, completed health questionnaires, and underwent pulmonary function testing, including helium dilution measurement of functional residual capacity (FRC). General linear models were used to model associations between increasing quartiles of inflammation or oxidative stress with each outcome measure, after adjustment for a number of potential confounders. Outcome Measures: Percent-predicted forced vital capacity in one second (FEV1), percent-predicted forced vital capacity (FVC), FEV1/FVC, percent-predicted residual volume (RV), percent-predicted FRC, and percent-predicted total lung capacity (TLC). Results: After adjustment for a number of confounders, participants with higher levels of CRP and IL-6 had lower percent-predicted FEV1 and FVC measurements. There were no clear patterns of association with any of the oxidative stress biomarkers or other outcome measures. Conclusion: Increased systemic inflammation was associated with reductions in FEV1 and FVC independent of a number of covariates. Although the mechanism is uncertain, these results suggest that reductions in pulmonary function in SCI are associated with systemic inflammation. C1 [Hart, Jaime E.; Garshick, Eric] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, 75 Francis St, Boston, MA 02115 USA. [Hart, Jaime E.; Garshick, Eric] Harvard Med Sch, Boston, MA USA. [Hart, Jaime E.] Harvard TH Chan Sch Publ Hlth, Dept Environm Hlth, Exposure Epidemiol & Risk Program, Boston, MA USA. [Morse, Leslie] Harvard Med Sch, Spaulding Rehabil Hosp, Spaulding Harvard SCI Model Syst, Charlestown, MA USA. [Morse, Leslie] Harvard Med Sch, Dept Phys Med & Rehabil, Charlestown, MA USA. [Tun, Carlos G.] VA Boston Healthcare Syst, Rehabil Med Serv, West Roxbury, MA USA. [Brown, Robert] Massachusetts Gen Hosp, Pulm & Crit Care Med Unit, Boston, MA 02114 USA. [Brown, Robert] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. [Garshick, Eric] VA Boston Healthcare Syst, Med Serv, Pulm & Crit Care Med Sect, West Roxbury, MA USA. RP Garshick, E (reprint author), VA Boston Healthcare Syst, 1400 VFW Pkwy, West Roxbury, MA 02132 USA. EM Eric.Garshick@va.gov FU Office of Research and Development, Rehabilitation Research and Development [B6618R]; Massachusetts Veterans Epidemiology Research and Information Center, Cooperative Studies Program, Department of Veterans Affairs; National Institute of Child Health and Human Development [R01HD042141, R21HD057030]; National Institute of Arthritis and Musculoskeletal and Skin Diseases [R01AR059270]; Department of Education, National Institute on Disability and Rehabilitation Research [H133N110010] FX This research was funded by grants from: Office of Research and Development, Rehabilitation Research and Development [Merit Review Grant B6618R] and Massachusetts Veterans Epidemiology Research and Information Center, Cooperative Studies Program, Department of Veterans Affairs; National Institute of Child Health and Human Development [R01HD042141] and [R21HD057030]; National Institute of Arthritis and Musculoskeletal and Skin Diseases [R01AR059270], Department of Education, National Institute on Disability and Rehabilitation Research [H133N110010]. The funding sources had no role in the development of the research or in the preparation of the manuscript. NR 60 TC 2 Z9 2 U1 0 U2 0 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND SN 1079-0268 EI 2045-7723 J9 J SPINAL CORD MED JI J. Spinal Cord. Med. PY 2016 VL 39 IS 3 BP 344 EP 352 DI 10.1179/2045772315Y.000000045 PG 9 WC Clinical Neurology SC Neurosciences & Neurology GA DS0LK UT WOS:000380286900015 PM 26180939 ER PT J AU Shaffer, KM Kim, Y Carver, CS AF Shaffer, Kelly M. Kim, Youngmee Carver, Charles S. TI Physical and mental health trajectories of cancer patients and caregivers across the year post-diagnosis: a dyadic investigation SO PSYCHOLOGY & HEALTH LA English DT Article DE cancer; caregiving; physical health; mental health; actor partner interdependence model; latent growth model ID QUALITY-OF-LIFE; COVARIANCE STRUCTURE-ANALYSIS; LONGITUDINAL FOLLOW-UP; CORONARY-HEART-DISEASE; BREAST-CANCER; PSYCHOLOGICAL DISTRESS; SPOUSAL CAREGIVERS; FAMILY CAREGIVERS; SYMPTOM PREVALENCE; CHRONIC ILLNESS AB Objective: Evidence suggests interdependence between cancer patients' and their caregivers' physical and mental health. However, the extent to which caregivers' health relates to their patients' recovery, or patients' health affects their caregivers' outcomes, is largely unknown. This dyadic investigation reports the relations between cancer patients' and their caregivers' physical and mental health trajectories during the year following diagnosis.Design: Ninety-two colorectal cancer patient-caregiver dyads completed questionnaires at 2, 6 and 12 months post-diagnosis.Outcome measures: Self-reported physical and mental health using the Medical Outcomes Study Short Form Health Survey-12.Results: Patients reported improved physical health over the year following their diagnosis, whereas caregivers reported declining physical health. Patients with lower mental health at diagnosis had stagnated physical health recovery. Caregivers' physical health declined most noticeably among those reporting low mental health at diagnosis and whose patients reported low physical health at diagnosis.Conclusion: Findings suggest targeting health interventions to cancer patients and caregivers reporting poor mental health at diagnosis may mitigate their long-term physical morbidity. Limited evidence of dyadic interdependence between patients' and caregivers' physical and mental health trajectories suggests future studies are warranted to identify psychosocial and medical characteristics moderating the relations between patients' and caregivers' health. C1 [Shaffer, Kelly M.; Kim, Youngmee; Carver, Charles S.] Univ Miami, Dept Psychol, POB 248185, Coral Gables, FL 33124 USA. [Shaffer, Kelly M.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Kim, Youngmee; Carver, Charles S.] Stanford Univ, Ctr Adv Study Behav Sci, Stanford, CA 94305 USA. RP Shaffer, KM (reprint author), Univ Miami, Dept Psychol, POB 248185, Coral Gables, FL 33124 USA.; Shaffer, KM (reprint author), Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. EM kmshaffer@mgh.harvard.edu OI Shaffer, Kelly/0000-0002-9749-8006 FU American Cancer Society National Home Office; National Cancer Institute [1 F31 CA189431-01A1] FX This work was supported by the American Cancer Society National Home Office, intramural research, and the National Cancer Institute [grant number 1 F31 CA189431-01A1]. NR 74 TC 1 Z9 1 U1 3 U2 3 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND SN 0887-0446 EI 1476-8321 J9 PSYCHOL HEALTH JI Psychol. Health PY 2016 VL 31 IS 6 BP 655 EP 674 DI 10.1080/08870446.2015.1131826 PG 20 WC Public, Environmental & Occupational Health; Psychology, Multidisciplinary SC Public, Environmental & Occupational Health; Psychology GA DS0IL UT WOS:000380278800002 PM 26680247 ER PT J AU Sparer, EH Catalano, PJ Herrick, RF Dennerlein, JT AF Sparer, Emily H. Catalano, Paul J. Herrick, Robert F. Dennerlein, Jack T. TI Improving safety climate through a communication and recognition program for construction: a mixed-methods study SO SCANDINAVIAN JOURNAL OF WORK ENVIRONMENT & HEALTH LA English DT Article DE B-SAFE; construction industry; construction worker; hazard control; health and safety; safety incentive program; safety intervention ID PERFORMANCE; BEHAVIOR; INCENTIVES; INJURIES; VALIDITY; LENGTH; SITES; UNION AB Objectives This study aimed to evaluate the efficacy of a safety communication and recognition program (B-SAFE), designed to encourage improvement of physical working conditions and hazard reduction in construction. Methods A matched pair cluster randomized controlled trial was conducted on eight worksites (four received the B-SAFE intervention, four served as control sites) for approximately five months per site. Pre- and post-exposure worker surveys were collected at all sites (N = 615, pre-exposure response rate of 74%, post-exposure response rate of 88%). Multi-level mixed-effect regression models evaluated the effect of B-SAFE on safety climate as assessed from surveys. Focus groups (N = 6-8 workers/site) were conducted following data collection. Transcripts were coded and analyzed for thematic content using Atlas.ti (version 6). Results The mean safety climate score at intervention sites, as measured on a 0-50 point scale, increased 0.5 points (1%) between pre- and post-B-SAFE exposure, compared to control sites that decreased 0.8 points (1.6%). The intervention effect size was 1.64 (3.28%) (P-value = 0.01) when adjusted for month the worker started on-site, total length of time on-site, as well as individual characteristics (trade, title, age, and race/ethnicity). At intervention sites, workers noted increased levels of safety awareness, communication, and teamwork compared to control sites. Conclusions B-SAFE led to many positive changes, including an improvement in safety climate, awareness, teambuilding, and communication. B-SAFE was a simple intervention that engaged workers through effective communication infrastructures and had a significant, positive effect on worksite safety. C1 [Sparer, Emily H.; Herrick, Robert F.; Dennerlein, Jack T.] Harvard TH Chan Sch Publ Hlth, Dept Environm Hlth, Boston, MA USA. [Sparer, Emily H.] Harvard TH Chan Sch Publ Hlth, Dept Social & Behav Sci, Boston, MA USA. [Catalano, Paul J.] Harvard TH Chan Sch Publ Hlth, Dept Biostat, Boston, MA USA. [Catalano, Paul J.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA. [Dennerlein, Jack T.] Northeastern Univ, Dept Phys Therapy Movement & Rehabil Sci, Bouve Coll Hlth Sci, 301 Robinson Hall,360 Huntington Ave, Boston, MA 02115 USA. RP Dennerlein, JT (reprint author), Northeastern Univ, Dept Phys Therapy Movement & Rehabil Sci, Bouve Coll Hlth Sci, 301 Robinson Hall,360 Huntington Ave, Boston, MA 02115 USA. EM j.dennerlein@northeastern.edu OI Sparer, Emily/0000-0002-9896-7345 FU Center for Construction Research and Training (CPWR) [U60OH009762]; National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health [T32AR055885]; National Institute for Occupational Safety and Health (NIOSH); NIOSH/ERC at Harvard University [T42OH008416] FX The Center for Construction Research and Training (CPWR) supported this research under grant number U60OH009762. Additional support was provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health under award number T32AR055885 and the National Institute for Occupational Safety and Health (NIOSH) and the NIOSH/ERC at Harvard University grant (T42OH008416). The content is solely the responsibility of the authors and does not necessarily represent the official views of the CPWR, NIOSH, or NIH. The authors thank Kincaid Lowe, Mia Goldwasser, Kristen Ironside, Dana Baarsvik, and Andrea Sheldon from Northeastern University for help with data collection, Jeffrey Katz of Brigham and Woman's Hospital and Harvard Medical School for his invaluable help with the psychometrics, and all of the construction companies and workers in the Boston area that participated in the study NR 27 TC 0 Z9 0 U1 4 U2 8 PU SCANDINAVIAN JOURNAL WORK ENVIRONMENT & HEALTH PI HELSINKI PA TOPELIUKSENKATU 41A, SF-00250 HELSINKI, FINLAND SN 0355-3140 EI 1795-990X J9 SCAND J WORK ENV HEA JI Scand. J. Work Environ. Health PY 2016 VL 42 IS 4 BP 329 EP 337 DI 10.5271/sjweh.3569 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DR9QP UT WOS:000380231500009 PM 27158914 ER PT J AU Hunnicutt, JL Aaron, SE Embry, AE Cence, B Morgan, P Bowden, MG Gregory, CM AF Hunnicutt, Jennifer L. Aaron, Stacey E. Embry, Aaron E. Cence, Brian Morgan, Patrick Bowden, Mark G. Gregory, Chris M. TI The Effects of POWER Training in Young and Older Adults after Stroke SO Stroke Research and Treatment LA English DT Article ID GAIT SPEED; PHYSICAL PERFORMANCE; LEG POWER; REHABILITATION; RELIABILITY; POSTSTROKE; MOBILITY; TORQUE AB Background. Approximately 35,000 strokes occur annually in adults below the age of 40, and there is disappointingly little data describing their responses to rehabilitation. The purpose of this analysis was to determine the effects of Poststroke Optimization of Walking using Explosive Resistance (POWER) training in young (<40 years) and older (>60 years) adults and to describe relationships between training-induced improvements in muscular and locomotor function. Methods. Data was analyzed from 16 individuals with chronic stroke who participated in 24 sessions of POWER training. Outcomes included muscle power generation, self-selected walking speed (SSWS), 6-minute walk test, Fugl-Meyer motor assessment, Berg Balance Scale, and Dynamic Gait Index. Results. There were no significant differences between groups at baseline. Within-group comparisons revealed significant improvements in paretic and nonparetic knee extensor muscle power generation in both groups. Additionally, young participants significantly improved SSWS. Improvements in SSWS were more strongly associated with improvements in power generation on both sides in young versus older participants. Conclusions. Younger adults after stroke seem to preferentially benefit from POWER training, particularly when increasing gait speed is a rehabilitation goal. Future research should aim to further understand age-related differences in response to training to provide optimal treatments for all individuals following stroke. C1 [Hunnicutt, Jennifer L.; Aaron, Stacey E.; Embry, Aaron E.; Cence, Brian; Morgan, Patrick; Bowden, Mark G.; Gregory, Chris M.] Med Univ South Carolina, Coll Hlth Profess, Dept Hlth Sci & Res, 77 President St,MSC 700, Charleston, SC 29425 USA. [Embry, Aaron E.; Bowden, Mark G.; Gregory, Chris M.] Med Univ South Carolina, Coll Hlth Profess, Div Phys Therapy, 151-B Rutledge Ave,MSC 962, Charleston, SC 29425 USA. [Embry, Aaron E.; Cence, Brian; Bowden, Mark G.; Gregory, Chris M.] Ralph H Johnson VA Med Ctr, 109 Bee St, Charleston, SC 29401 USA. RP Hunnicutt, JL (reprint author), Med Univ South Carolina, Coll Hlth Profess, Dept Hlth Sci & Res, 77 President St,MSC 700, Charleston, SC 29425 USA. EM hunnicuj@musc.edu NR 19 TC 0 Z9 0 U1 3 U2 3 PU HINDAWI PUBLISHING CORP PI NEW YORK PA 315 MADISON AVE 3RD FLR, STE 3070, NEW YORK, NY 10017 USA SN 2090-8105 EI 2042-0056 J9 STROKE RES TREAT JI Stroke Res. Treat. PY 2016 AR 7316250 DI 10.1155/2016/7316250 PG 5 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA DT0EV UT WOS:000381156800001 ER PT J AU Longstaff, L Lai, P Glover, A White, M AF Longstaff, L. Lai, P. Glover, A. White, M. TI An evaluation of the effect of pre-operative anaemia on postoperative complications in a low resource setting SO ANAESTHESIA LA English DT Meeting Abstract CT Winter Scientific Meeting of the Association-of-Anaesthetists-of-Great-Britain-and-Ireland (AAGBI) CY JAN 13-15, 2016 CL London, ENGLAND SP Assoc Anaesthetists Great Britain & Ireland C1 [Longstaff, L.; Glover, A.; White, M.] Mercy Ships, Lindale, TX USA. [Lai, P.] Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 4 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0003-2409 EI 1365-2044 J9 ANAESTHESIA JI Anaesthesia PD JAN PY 2016 VL 71 SU 2 SI SI MA 125 BP 70 EP 70 PG 1 WC Anesthesiology SC Anesthesiology GA DR7TP UT WOS:000380102900118 ER PT J AU Owoyele, BV Yakubu, MT Treister, R AF Owoyele, Bamidele V. Yakubu, Musa T. Treister, Roi TI Pain and Inflammation: Update on Emerging Phytotherapy, Zootherapy, and Nutritional Therapies SO EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE LA English DT Editorial Material C1 [Owoyele, Bamidele V.] Univ Ilorin, Dept Physiol, Neurosci & Inflammat Res Unit, Ilorin 240003, Nigeria. [Yakubu, Musa T.] Univ Ilorin, Dept Biochem, Phytomed Toxicol & Reprod Res Lab, Ilorin 240003, Nigeria. [Treister, Roi] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. [Treister, Roi] Harvard Med Sch, Boston, MA 02114 USA. RP Owoyele, BV (reprint author), Univ Ilorin, Dept Physiol, Neurosci & Inflammat Res Unit, Ilorin 240003, Nigeria. EM deleyele@gmail.com OI Owoyele, Bamidele/0000-0003-3503-9338 NR 0 TC 0 Z9 0 U1 0 U2 0 PU HINDAWI PUBLISHING CORP PI NEW YORK PA 315 MADISON AVE 3RD FLR, STE 3070, NEW YORK, NY 10017 USA SN 1741-427X EI 1741-4288 J9 EVID-BASED COMPL ALT JI Evid.-based Complement Altern. Med. PY 2016 AR 2520371 DI 10.1155/2016/2520371 PG 1 WC Integrative & Complementary Medicine SC Integrative & Complementary Medicine GA DS3ST UT WOS:000380703700001 ER PT J AU Leichsenring, F Ablon, S Barber, JP Beutel, M Gibbons, MBC Crits-Christoph, P Klein, S Leweke, F Steinert, C Wiltink, J Salzer, S AF Leichsenring, Falk Ablon, Stuart Barber, Jacques P. Beutel, Manfred Gibbons, Mary Beth Connolly Crits-Christoph, Paul Klein, Susanne Leweke, Frank Steinert, Christiane Wiltink, Joerg Salzer, Simone TI Developing a prototype for short-term psychodynamic (supportive-expressive) therapy: An empirical study with the psychotherapy process Q-set SO PSYCHOTHERAPY RESEARCH LA English DT Article DE supportive-expressive therapy; short-term psychodynamic psychotherapy; psychotherapy process Q-sort; psychotherapeutic processes; mechanisms of change ID COGNITIVE-BEHAVIORAL THERAPY; SOCIAL ANXIETY DISORDER; CONTROLLED-TRIAL; UNIFIED PROTOCOL; DEPRESSION AB Objective: A Psychotherapy Process Q-set (PQS) prototype characteristic of short-term psychodynamic therapy (STPP) does not yet exist. Method: Experts in supportive-expressive (SE) therapy used the 100-Item PQS questionnaire to rate an ideal short-term SE therapy. Results: Agreement between raters was high (Cronbach's alpha=0.94). The prototype for SE therapy showed a significant correlation with the psychoanalytic prototype, but with 28% of variance explained, the majority of variance of the former was not explained by the latter or vice versa. Furthermore, the SE prototype showed significant correlations with the cognitive-behavioral prototype and the prototype of interpersonal therapy by Ablon and Jones (r=0.69, 0.43). Conclusions: We recommend using the PQS prototype presented here for future process research on STPP. C1 [Leichsenring, Falk; Klein, Susanne; Leweke, Frank; Steinert, Christiane] Univ Giessen, Dept Psychosomat & Psychotherapy, Giessen, Germany. [Ablon, Stuart] Massachusetts Gen Hosp, Dept Psychiat, Newton, MA USA. [Barber, Jacques P.] Adelphi Univ, Derner Inst Adv Psychol Studies, Garden City, NY USA. [Beutel, Manfred; Wiltink, Joerg] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Clin Psychosomat Med & Psychotherapy, Mainz, Germany. [Gibbons, Mary Beth Connolly; Crits-Christoph, Paul] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. [Salzer, Simone] Univ Gottingen, Dept Psychosomat Med & Psychotherapy, Gottingen, Germany. RP Leichsenring, F (reprint author), Univ Giessen, Dept Psychosomat & Psychotherapy, Giessen, Germany. EM falk.leichsenring@psycho.med.uni-giessen.de NR 30 TC 1 Z9 1 U1 2 U2 3 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 1050-3307 EI 1468-4381 J9 PSYCHOTHER RES JI Psychother. Res. PY 2016 VL 26 IS 4 BP 500 EP 510 DI 10.1080/10503307.2015.1051160 PG 11 WC Psychology, Clinical SC Psychology GA DR7BZ UT WOS:000380056300011 PM 26218673 ER PT S AU Hayes, TB Anderson, LL Beasley, VR de Solla, SR Iguchi, T Ingraham, H Kestemont, P Kniewald, J Kniewald, Z Langlois, VS Luquei, EH Mccoy, KA Munoz-De-Toro, M Oka, T Oliveira, CA Orton, F Ruby, S Suzawa, M Tavera-Mendoza, LE Trudeau, VL Victor-Costa, AB Willingham, E AF Hayes, Tyrone B. Anderson, Lloyd L. Beasley, Val R. de Solla, Shane R. Iguchi, Taisen Ingraham, Holly Kestemont, Patrick Kniewald, Jasna Kniewald, Zlatko Langlois, Valerie S. Luquei, Enrique H. McCoy, Krista A. Munoz-de-Toro, Monica Oka, Tomohiro Oliveira, Cleida A. Orton, Frances Ruby, Sylvia Suzawa, Miyuki Tavera-Mendoza, Luz E. Trudeau, Vance L. Victor-Costa, Anna Bolivar Willingham, Emily BE Androcec, V TI Demasculinization and Feminization of Male Gonads by Atrazine: Consistent Effects Across Vertebrate Classes SO ANNUAL 2015 OF THE CROATIAN ACADEMY OF ENGINEERING SE Annual of the Croatian Academy of Engineering LA English DT Article; Book Chapter DE Atrazine; Gonads; Endocrine disruptor ID SPRAGUE-DAWLEY RATS; ADRENOCORTICAL CARCINOMA-CELLS; AROMATASE CYP19 ACTIVITY; TADPOLE XENOPUS-LAEVIS; NORTHERN LEOPARD FROG; S-TRIAZINE HERBICIDES; MALE WISTAR RATS; RANA-PIPIENS; IN-VITRO; SEXUAL-DIFFERENTIATION AB Atrazine is the most commonly detected pesticide contaminant of ground water, surface water, and pre- cipitation. Atrazine is also an endocrine disruptor that, among other effects, alters male reproductive tissues when animals are exposed during development. Here, we apply the nine so-called "Hill criteria" (Strength, Consistency, Specificity, Temporality, Biological Gradient, Plausibility, Coherence, Experiment, and Analogy) for establishing cause-effect relationships to examine the evidence for atrazine as an endocrine disruptor that demasculinizes and feminizes the gonads of male vertebrates. We present exper- imental evidence that the effects of atrazine on male development are consistent across all vertebrate classes examined and we present a state of the art summary of the mechanisms by which atrazine acts as an endocrine disruptor to produce these effects. Atrazine demasculinizes male gonads producing testicular lesions associated with reduced germ cell numbers in teleost fish, amphibians, reptiles, and mammals, and induces partial and/or complete fern- inization in fish, amphibians, and reptiles. These effects are strong (statistically significant), consistent across vertebrate classes, and specific. Reductions in androgen levels and the induction of estrogen syn- thesis - demonstrated in fish, amphibians, reptiles, and mammals - represent plausible and coherent mechanisms that explain these effects. Biological gradients are observed in several of the cited studies, although threshold doses and patterns vary among species. Given that the effects on the male gonads described in all of these experimental studies occurred only after atrazine exposure, temporality is also met here. Thus the case for atrazine as an endocrine disruptor that demasculinizes and feminizes male vertebrates meets all nine of the "Hill criteria". Article submitted for the special issue on Endocrine diruptors. C1 [Hayes, Tyrone B.] Univ Calif Berkeley, Museum Vertebrate Zool, Grp Endocrinol Energy & Resources Grp, Lab Integrat Studies Amphibian Biol Mol Toxicol, Berkeley, CA 94720 USA. [Hayes, Tyrone B.] Univ Calif Berkeley, Dept Integrat Biol, Berkeley, CA 94720 USA. [Anderson, Lloyd L.] Univ Sci & Technol, Coll Vet Med Iowa State, Biomed Sci, Coll Agr & Life,Dept Anim Sci, 2356 Kildee Hall, Ames, IA 50011 USA. [Beasley, Val R.] Univ Illinois, Coll Vet Med, Dept Comparat Biosci, Envirovet Program Wildlife & Ecosyst Hlth, 2001 S Lincoln Ave, Urbana, IL 61802 USA. [de Solla, Shane R.] Environm Canada, Wildlife & Landscape Sci Directorate, 867 Lakeshore Rd, Burlington, ON L7R 4A6, Canada. [Iguchi, Taisen] Natl Inst Basic Biol, 5-1 Higashiyama, Okazaki, Aichi 4448787, Japan. [Ingraham, Holly; Suzawa, Miyuki] Univ Calif San Francisco, Rock Hall,Room 284E,1550 4th St, San Francisco, CA 94143 USA. [Kestemont, Patrick] Univ Namur FUNDP, Unit Res Organism Biol, Rue Bruxelles 61, B-5000 Namur, Belgium. [Kniewald, Jasna; Kniewald, Zlatko] Univ Zagreb, Fac Food Technol & Biotechnol, Pierotti St 6, Zagreb, Croatia. [Langlois, Valerie S.] Royal Mil Coll Canada, Dept Chem & Chem Engn, Stn Forces, POB 17 000, Kingston, ON K7K 7B4, Canada. [Luquei, Enrique H.; Munoz-de-Toro, Monica] Univ Nacl Litoral, Sch Biochem & Biol Sci, Lab Endocrinol & Tumores Hormonodependientes, Santa Fe, Argentina. [McCoy, Krista A.] Univ S Florida, Integrat Biol Dept, Tampa, FL 33620 USA. [Oka, Tomohiro] IDEA Consultants Inc, Inst Environm Ecol, 1334-5 Riemon, Shizuoka 4210212, Japan. [Oliveira, Cleida A.; Victor-Costa, Anna Bolivar] Univ Fed Minas Gerais, Dept Morphol, Cx Postal 486, BR-31270901 Belo Horizonte, MG, Brazil. [Orton, Frances] Sch Pharm, Ctr Toxicol, 29-39 Brunswick Sq, London WC1N 1AX, England. [Ruby, Sylvia] Concordia Univ, Dept Biol, Montreal, PQ H3G 1M8, Canada. [Tavera-Mendoza, Luz E.] Harvard Med Sch, Dana Faber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Trudeau, Vance L.] Univ Ottawa, Dept Biol, Ctr Adv Res Environm Genom, 20 Marie Curie, Ottawa, ON K1N 6N5, Canada. [Willingham, Emily] 6811 Cypress Pt N, Austin, TX 78746 USA. RP Hayes, TB (reprint author), Univ Calif Berkeley, Museum Vertebrate Zool, Grp Endocrinol Energy & Resources Grp, Lab Integrat Studies Amphibian Biol Mol Toxicol, Berkeley, CA 94720 USA.; Hayes, TB (reprint author), Univ Calif Berkeley, Dept Integrat Biol, Berkeley, CA 94720 USA. NR 142 TC 0 Z9 0 U1 16 U2 22 PU CROATIAN ACADEMY ENGINEERING PI ZAGREB PA KACICEVA 28, ZAGREB, 10000, CROATIA SN 1332-3482 J9 ANNU CROAT ACAD ENG PY 2016 BP 257 EP 278 DI 10.1016/j.jsbmb.2011.03.015 PG 22 WC Engineering, Multidisciplinary SC Engineering GA BF0UG UT WOS:000379450000015 ER PT J AU Britton, PC Kopacz, MS Stephens, B Bossarte, RM AF Britton, Peter C. Kopacz, Marek S. Stephens, Brady Bossarte, Robert M. TI Veterans Crisis Line Callers With and Without Prior VHA Service Use SO ARCHIVES OF SUICIDE RESEARCH LA English DT Article DE suicide; telephone counseling; veterans ID SUICIDE-PREVENTION; HEALTH; RISK AB This study examines differences between Veterans with and without prior Veterans Health Administration service use who received a clinical referral from the Veterans' Crisis Line. Differences between groups were identified using data taken from 13,444 calls and medical records. Approximately 91% of Veterans had a history of service use and 9% did not. Callers with prior service use were older, had more mental health disorders, made in-person contact more quickly, and used more outpatient mental healthcare. Those without prior service use were younger, had more mental health problems, and presented for care later. Callers with suicide-related diagnoses had high rates of service contact. These groups represent different subpopulations with unique healthcare needs and practices. C1 [Britton, Peter C.; Kopacz, Marek S.; Stephens, Brady] US Dept Vet Affairs, VISN Ctr Excellence Suicide Prevent 2, Canandaigua, NY USA. [Britton, Peter C.] Univ Rochester, Sch Med & Dent, Dept Psychiat, Rochester, NY USA. [Bossarte, Robert M.] US Dept Vet Affairs, Postdeployment Hlth Serv, Washington, DC USA. RP Britton, PC (reprint author), Canandaigua VA Med Ctr, Ctr Excellence Suicide Prevent, 400 Ft Hill Ave, Canandaigua, NY 14424 USA. EM peter.britton@va.gov FU Department of Veterans Affairs Office of Research Development, Clinical Science Research and Development (CSRD) [IK2CX000641] FX This paper was funded in part by a Career Development Award (IK2CX000641) from the Department of Veterans Affairs Office of Research Development, Clinical Science Research and Development (CSR&D). NR 17 TC 0 Z9 0 U1 0 U2 0 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 1381-1118 EI 1543-6136 J9 ARCH SUICIDE RES JI Arch. Suicide Res. PY 2016 VL 20 IS 3 BP 314 EP 322 DI 10.1080/13811118.2015.1017681 PG 9 WC Psychiatry; Psychology; Psychology, Multidisciplinary SC Psychiatry; Psychology GA DR2KY UT WOS:000379734600002 PM 26649615 ER PT J AU El Gaamouch, F Jing, P Xia, JH Cai, DM AF El Gaamouch, Farida Jing, Ping Xia, Jiahong Cai, Dongming TI Alzheimer's Disease Risk Genes and Lipid Regulators SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Review DE Alzheimer's disease; apolipoproteins; lipids; amyloid; cholesterol; phospholipids ID AMYLOID-BETA-PEPTIDE; HIGH-DENSITY-LIPOPROTEIN; APOLIPOPROTEIN-E POLYMORPHISM; CELLULAR CHOLESTEROL EFFLUX; MILD COGNITIVE IMPAIRMENT; ISOFORM-SPECIFIC BINDING; CENTRAL-NERVOUS-SYSTEM; PEROXIDATION IN-VIVO; BLOOD-BRAIN-BARRIER; A-BETA AB Brain lipid homeostasis plays an important role in Alzheimer's disease (AD) and other neurodegenerative disorders. Aggregation of amyloid-beta peptide is one of the major events in AD. The complex interplay between lipids and amyloid-beta accumulation has been intensively investigated. The proportions of lipid components including phospholipids, sphingolipids, and cholesterol are roughly similar across different brain regions under physiological conditions. However, disruption of brain lipid homeostasis has been described in AD and implicated in disease pathogenesis. Moreover, studies suggest that analysis of lipid composition in plasma and cerebrospinal fluid could improve our understanding of the disease development and progression, which could potentially serve as disease biomarkers and prognostic indicators for AD therapies. Here, we summarize the functional roles of AD risk genes and lipid regulators that modulate brain lipid homeostasis including different lipid species, lipid complexes, and lipid transporters, particularly their effects on amyloid processing, clearance, and aggregation, as well as neuro-toxicities that contribute to AD pathogenesis. C1 [El Gaamouch, Farida; Cai, Dongming] James J Peters VA Med Ctr, Res & Dev, Bronx, NY USA. [El Gaamouch, Farida; Cai, Dongming] Icahn Sch Med Mt Sinai, Dept Neurol, Alzheimer Dis Res Ctr, New York, NY 10029 USA. [Jing, Ping; Xia, Jiahong; Cai, Dongming] Cent Hosp Wuhan, Wuhan, Peoples R China. RP Cai, DM (reprint author), 130W Kings Bridge Rd, Bronx, NY 10468 USA. EM dongming.cai@mssm.edu OI Cai, Dongming/0000-0002-0601-6826 FU Alzheimer's Association [NIRP14-304720]; Department of Veteran Affairs RRDSPiRE [1I21RX001558-01A1]; NIH R01 [1R01AG048923-01] FX We thank Dr. Minghao Zhong, Gregory Elder, and Christopher Cardozo for critical reading of the manuscript. This work was supported in whole or in part, by funding from the Alzheimer's Association (NIRP14-304720), Department of Veteran Affairs RR&DSPiRE (1I21RX001558-01A1), and NIH R01 (1R01AG048923-01) for DC. NR 195 TC 0 Z9 0 U1 8 U2 9 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 EI 1875-8908 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2016 VL 53 IS 1 BP 15 EP 29 DI 10.3233/JAD-160169 PG 15 WC Neurosciences SC Neurosciences & Neurology GA DR2NW UT WOS:000379742200002 PM 27128373 ER PT J AU Neugroschl, J Sewell, M De La Fuente, A Umpierre, M Luo, XD Sano, M AF Neugroschl, Judith Sewell, Margaret De La Fuente, Angelica Umpierre, Mari Luo, Xiaodong Sano, Mary TI Attitudes and Perceptions of Research in Aging and Dementia in an Urban Minority Population SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Attitude; dementia; elderly; memory; minority; research ID ALZHEIMER-DISEASE; RESEARCH PARTICIPATION; BIOMEDICAL-RESEARCH; AFRICAN-AMERICANS; WILLINGNESS; LATINOS; PEOPLE; RISK AB In dementia trials, minority participation is low. We assessed attitudes toward research in a community based urban poor minority sample of elderly adults attending senior center talks using the 7-item Research Attitudes Questionnaire (RAQ). Presentations on cognitive aging were given at senior centers, and 123 attendees completed the RAQ-7. On trust and safety questions, a significant minority (42-48%) responded neutrally or negatively. Encouragingly, on questions concerning the importance of research, 72-81% answered positively. More work can be done to capitalize on these findings to engage and foster trust, and this can be a focus of outreach. C1 [Neugroschl, Judith; Sewell, Margaret; De La Fuente, Angelica; Umpierre, Mari; Luo, Xiaodong; Sano, Mary] Icahn Sch Med Mt Sinai, Alzheimers Dis Res Ctr, New York, NY 10029 USA. [Sano, Mary] James J Peters VA Med Ctr, Bronx, NY USA. [De La Fuente, Angelica] Yeshiva Univ, Ferkauf Grad Sch, Bronx, NY USA. RP Neugroschl, J (reprint author), Mt Sinai Dept Psychiat, 1 Gustave Levy Pl Box 1230, New York, NY 10029 USA. EM Judith.neugroschl@mssm.edu FU Ichan School of Medicine, The Alzheimer's Disease Research Center (ADRC) [U01 P50 AG005138]; New York State Alzheimer's Disease Assistance Center at Mount Sinai (ADAC) [C020360] FX This work was supported by the Ichan School of Medicine, The Alzheimer's Disease Research Center (ADRC: U01 P50 AG005138) and the New York State Alzheimer's Disease Assistance Center at Mount Sinai (ADAC: C020360). NR 14 TC 0 Z9 0 U1 3 U2 3 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 EI 1875-8908 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2016 VL 53 IS 1 BP 69 EP 72 DI 10.3233/JAD-151072 PG 4 WC Neurosciences SC Neurosciences & Neurology GA DR2NW UT WOS:000379742200005 PM 27128368 ER PT J AU Paholpak, P Li-Jung, L Carr, DR Jimenez, E Barrows, RJ Sabodash, V Mendez, MF AF Paholpak, Pongsatorn Li-Jung, Liang Carr, Drew R. Jimenez, Elvira Barrows, Robin J. Sabodash, Valeiry Mendez, Mario F. TI Prolonged Visual Facial Grasp in Frontotemporal Dementia SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE Alzheimer's disease; eye movements; frontotemporal dementia; social behavior ID LOBAR DEGENERATION; ALZHEIMERS-DISEASE; BEHAVIORAL-VARIANT; SEMANTIC DEMENTIA; GAZE; RECOGNITION; DYSFUNCTION; CRITERIA; EMOTION; ATROPHY AB Background: Gaze and eye contact is a critical aspect of social interaction. Patients with behavioral variant frontotemporal dementia (bvFTD) may exhibit abnormally prolonged stare toward human faces. Objective: To study characteristics of social gaze in patients with bvFTD compared to age and education matched-patients with early-onset Alzheimer's disease (eAD) and healthy controls (HC). Method: Fifty picture stimuli were presented to each participant (bvFTD = 12, eAD = 18, HC=13). Each stimuli contained two properties: face (facial versus non-facial) and valence (positive, negative, and neutral). The "facial" stimuli contained human faces. The participants Visual Fixation Time (VFT) was measured for each picture stimuli of interest (per facial expressions on the Facial Action Coding System). A linear mixed-effects regression model with participant-level of random effects was used to compare VFTs between groups. Results: The patients with bvFTD showed significantly prolonged VFTs to faces than the patients with eAD and the HC, regardless of valence (all p < 0.01). There were no differences in VFTs for non-facial stimuli between patients with bvFTD and eAD. However, patients with bvFTD and eAD had significantly prolonged VFTs to negative non-facial stimuli than the HC (p = 0.006 and 0.019, respectively). Conclusion: Patients with bvFTD exhibited a prolonged stare toward human faces. This prolonged visual facial grasp may contribute to the disturbed social interactions of patients with bvFTD and can help distinguish them from those with Alzheimer's disease and other conditions. Additionally, both dementia groups tended to stare at negative stimuli whether faces or non-faces. C1 [Paholpak, Pongsatorn; Carr, Drew R.; Jimenez, Elvira; Barrows, Robin J.; Sabodash, Valeiry; Mendez, Mario F.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90024 USA. [Jimenez, Elvira; Mendez, Mario F.] Univ Calif Los Angeles, David Geffen Sch Med, Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. [Li-Jung, Liang; Jimenez, Elvira; Mendez, Mario F.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90024 USA. [Barrows, Robin J.] Greater Los Angeles VA Healthcare Syst, West Los Angeles, CA USA. [Paholpak, Pongsatorn] Khon Kaen Univ, Dept Psychiat, Khon Kaen, Thailand. RP Paholpak, P (reprint author), West Angeles Los VA Healthcare Ctr, Neurobehav Serv 116AF, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM ppaholpak@yahoo.com FU National Institute on Aging (NIA) [5R01AG034499-05]; VA GRECC Advanced Fellowship in Geriatrics FX This work was performed at the Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095 and at Greater Los Angeles VA Healthcare System, West Los Angeles, CA 90073. It was supported by grant 5R01AG034499-05 from the National Institute on Aging (NIA). A.R. Carr is funded by the VA GRECC Advanced Fellowship in Geriatrics. NR 29 TC 0 Z9 0 U1 0 U2 0 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 EI 1875-8908 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2016 VL 53 IS 1 BP 327 EP 335 DI 10.3233/JAD-150864 PG 9 WC Neurosciences SC Neurosciences & Neurology GA DR2NW UT WOS:000379742200028 PM 27163801 ER PT J AU Benboujja, F Garcia, JA Beaudette, K Strupler, M Hartnick, CJ Boudoux, C AF Benboujja, Fouzi Garcia, Jordan A. Beaudette, Kathy Strupler, Mathias Hartnick, Christopher J. Boudoux, Caroline TI Intraoperative imaging of pediatric vocal fold lesions using optical coherence tomography SO JOURNAL OF BIOMEDICAL OPTICS LA English DT Article DE optical coherence tomography; vocal fold; pediatric; benign laryngeal lesions ID IN-VIVO; TISSUE COAGULATION; NODULES; BENIGN; RANGE; LASER; DYSPHONIA; DIAGNOSIS; PATHOLOGY; MUCOSA AB Optical coherence tomography (OCT) has been previously identified as a promising tool for exploring laryngeal pathologies in adults. Here, we present an OCT handheld probe dedicated to imaging the unique geometry involved in pediatric laryngoscopy. A vertical cavity surface emitting laser-based wavelength-swept OCT system operating at 60 frames per second was coupled to the probe to acquire three-dimensional (3-D) volumes in vivo. In order to evaluate the performance of the proposed probe and system, we imaged pediatric vocal fold lesions of patients going under direct laryngoscopy. Through this in vivo study, we extracted OCT features characterizing each pediatric vocal fold lesion, which shows a great potential for noninvasive laryngeal lesion discrimination. We believe OCT vocal fold examination in 3-D will result in improved knowledge of the pediatric anatomy and could aid in managing pediatric laryngeal diseases. (C) The Authors. Published by SPIE under a Creative Commons Attribution 3.0 Unported License. Distribution or reproduction of this work in whole or in part requires full attribution of the original publication, including its DOI. C1 [Benboujja, Fouzi; Beaudette, Kathy; Strupler, Mathias; Boudoux, Caroline] Polytech Montreal, Dept Engn Phys, POB 6079 Stn Ctr Ville, Montreal, PQ H3C 3A7, Canada. [Garcia, Jordan A.; Hartnick, Christopher J.; Boudoux, Caroline] Harvard Med Sch, Massachusetts Eye & Ear Infirm, Dept Otolaryngol, 243 Charles St, Boston, MA 02114 USA. RP Boudoux, C (reprint author), Polytech Montreal, Dept Engn Phys, POB 6079 Stn Ctr Ville, Montreal, PQ H3C 3A7, Canada.; Boudoux, C (reprint author), Harvard Med Sch, Massachusetts Eye & Ear Infirm, Dept Otolaryngol, 243 Charles St, Boston, MA 02114 USA. EM caroline.boudoux@polymtl.ca FU NSERC [341555-13] FX The authors would like to thank Dr. Anjul Loiacono and Dr. Shahidul Islam for their contribution in adapting the VSCEL system for clinical use, as well as Dr. William Faquin, director of the Head and Neck Pathology Unit, for the analysis of histology sections. We further thank Martin Guernon, Yves Leblanc, and Evgueni Babian for the fabrication of custom parts. This research is supported in part by the NSERC Discovery Grant (341555-13). NR 42 TC 2 Z9 2 U1 0 U2 1 PU SPIE-SOC PHOTO-OPTICAL INSTRUMENTATION ENGINEERS PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98225 USA SN 1083-3668 EI 1560-2281 J9 J BIOMED OPT JI J. Biomed. Opt. PD JAN PY 2016 VL 21 IS 1 AR 016007 DI 10.1117/1.JBO.21.1.016007 PG 10 WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine & Medical Imaging SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine & Medical Imaging GA DR6UJ UT WOS:000380036500021 PM 26780225 ER PT J AU Nouizi, F Luk, A Thayer, D Lin, YT Ha, S Gulsen, G AF Nouizi, Farouk Luk, Alex Thayer, Dave Lin, Yuting Ha, Seunghoon Gulsen, Gultekin TI Experimental validation of a high-resolution diffuse optical imaging modality: photomagnetic imaging SO JOURNAL OF BIOMEDICAL OPTICS LA English DT Article DE image reconstruction techniques; inverse problems; light propagation in tissues; medical and biological imaging ID BREAST-CANCER; NEOADJUVANT CHEMOTHERAPY; MR-THERMOMETRY; TOMOGRAPHY; SPECTROSCOPY; RECONSTRUCTION; PARAMETERS; MEDICINE; WOMEN; FMRI AB We present experimental results that validate our imaging technique termed photomagnetic imaging (PMI). PMI illuminates the medium under investigation with a near-infrared light and measures the induced temperature increase using magnetic resonance imaging. A multiphysics solver combining light and heat propagation is used to model spatiotemporal distribution of temperature increase. Furthermore, a dedicated PMI reconstruction algorithm has been developed to reveal high-resolution optical absorption maps from temperature measurements. Being able to perform measurements at any point within the medium, PMI overcomes the limitations of conventional diffuse optical imaging. We present experimental results obtained on agarose phantoms mimicking biological tissue with inclusions having either different sizes or absorption contrasts, located at various depths. The reconstructed images show that PMI can successfully resolve these inclusions with high resolution and recover their absorption coefficient with high-quantitative accuracy. Even a 1-mm inclusion located 6-mm deep is recovered successfully and its absorption coefficient is underestimated by only 32%. The improved PMI system presented here successfully operates under the maximum skin exposure limits defined by the American National Standards Institute, which opens up the exciting possibility of its future clinical use for diagnostic purposes. (C) 2016 Society of Photo-Optical Instrumentation Engineers (SPIE) C1 [Nouizi, Farouk; Luk, Alex; Thayer, Dave; Lin, Yuting; Ha, Seunghoon; Gulsen, Gultekin] Univ Calif Irvine, Dept Radiol Sci, Tu & Yuen Ctr Funct Oncoimaging, 164 Irvine Hall, Irvine, CA 92717 USA. [Thayer, Dave] Washington Univ, Mallinckrodt Inst Radiol, 510 South Kingshighway Blvd, St Louis, MO 63110 USA. [Lin, Yuting] Massachusetts Gen Hosp, 55 Fruit St, Boston, MA 02144 USA. [Lin, Yuting] Harvard Med Sch, Dept Radiat Oncol, 55 Fruit St, Boston, MA 02144 USA. [Ha, Seunghoon] Philips Healthcare, N27 West 23676 Paul Rd, Pewaukee, WI 53072 USA. RP Nouizi, F (reprint author), Univ Calif Irvine, Dept Radiol Sci, Tu & Yuen Ctr Funct Oncoimaging, 164 Irvine Hall, Irvine, CA 92717 USA. EM fnouizi@uci.edu FU Fulbright grant [F311F31CA171745, 1R21CA191389, R21EB013387, R01EB008716, P30CA062203] FX This research was supported in part by the Fulbright grant awarded to Farouk Nouizi, National Institutes of Health Grant Nos. F311F31CA171745, 1R21CA191389, R21EB013387, R01EB008716, and P30CA062203. NR 46 TC 3 Z9 3 U1 2 U2 4 PU SPIE-SOC PHOTO-OPTICAL INSTRUMENTATION ENGINEERS PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98225 USA SN 1083-3668 EI 1560-2281 J9 J BIOMED OPT JI J. Biomed. Opt. PD JAN PY 2016 VL 21 IS 1 AR 016009 DI 10.1117/1.JBO.21.1.016009 PG 9 WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine & Medical Imaging SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine & Medical Imaging GA DR6UJ UT WOS:000380036500023 PM 26790644 ER PT J AU Zimmermann, BB Fang, QQ Boas, DA Carp, SA AF Zimmermann, Bernhard B. Fang, Qianqian Boas, David A. Carp, Stefan A. TI Frequency domain near-infrared multiwavelength imager design using high-speed, direct analog-to-digital conversion SO JOURNAL OF BIOMEDICAL OPTICS LA English DT Article DE radio frequency; diffuse; near-infrared; light; full sampling; field-programmable gate array; absolute optical property; breast cancer ID DIFFUSE OPTICAL TOMOGRAPHY; BREAST-CANCER; IN-VIVO; SCATTERING MEDIA; SPECTROSCOPY; SYSTEM; ABSORPTION; TISSUE; MUSCLE; BRAIN AB Frequency domain near-infrared spectroscopy (FD-NIRS) has proven to be a reliable method for quantification of tissue absolute optical properties. We present a full-sampling direct analog-to-digital conversion FD-NIR imager. While we developed this instrument with a focus on high-speed optical breast tomographic imaging, the proposed design is suitable for a wide-range of biophotonic applications where fast, accurate quantification of absolute optical properties is needed. Simultaneous dual wavelength operation at 685 and 830 nm is achieved by concurrent 67.5 and 75 MHz frequency modulation of each laser source, respectively, followed by digitization using a high-speed (180 MS/s) 16-bit A/D converter and hybrid FPGA-assisted demodulation. The instrument supports 25 source locations and features 20 concurrently operating detectors. The noise floor of the instrument was measured at <1.4 pW/root Hz, and a dynamic range of 115+ dB, corresponding to nearly six orders of magnitude, has been demonstrated. Titration experiments consisting of 200 different absorption and scattering values were conducted to demonstrate accurate optical property quantification over the entire range of physiologically expected values. (C) 2016 Society of Photo-Optical Instrumentation Engineers (SPIE) C1 [Zimmermann, Bernhard B.; Boas, David A.; Carp, Stefan A.] Harvard Med Sch, Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Bldg 149,13th St, Charlestown, MA 02129 USA. [Zimmermann, Bernhard B.] MIT, Dept Elect Engn & Comp Sci, 77 Massachusetts Ave, Cambridge, MA 02139 USA. [Fang, Qianqian] Northeastern Univ, Dept Bioengn, 360 Huntington Ave, Boston, MA 02115 USA. RP Carp, SA (reprint author), Harvard Med Sch, Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Bldg 149,13th St, Charlestown, MA 02129 USA. EM carp@nmr.mgh.harvard.edu FU National Institutes of Health [R01-CA142575, R01-CA097305, R01-CA187595, R00-EB011889] FX This work has been funded by National Institutes of Health grants R01-CA142575, R01-CA097305, R01-CA187595, and R00-EB011889. The authors thank Joe Stadtmiller, Robert Dewsnap, Ron Altman, William Johnson, and Arthur DiMartino at TechEn Incorporated for collaborative efforts in developing the instrument. NR 32 TC 1 Z9 1 U1 2 U2 4 PU SPIE-SOC PHOTO-OPTICAL INSTRUMENTATION ENGINEERS PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98225 USA SN 1083-3668 EI 1560-2281 J9 J BIOMED OPT JI J. Biomed. Opt. PD JAN PY 2016 VL 21 IS 1 AR 016010 DI 10.1117/1.JBO.21.1.016010 PG 8 WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine & Medical Imaging SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine & Medical Imaging GA DR6UJ UT WOS:000380036500024 PM 26813081 ER PT J AU Chaiboonchoe, A Ghamsari, L Dohai, B Ng, P Khraiwesh, B Jaiswal, A Jijakli, K Koussa, J Nelson, DR Cai, H Yang, XP Chang, RL Papin, J Yu, HY Balaji, S Salehi-Ashtiani, K AF Chaiboonchoe, Amphun Ghamsari, Lila Dohai, Bushra Ng, Patrick Khraiwesh, Basel Jaiswal, Ashish Jijakli, Kenan Koussa, Joseph Nelson, David R. Cai, Hong Yang, Xinping Chang, Roger L. Papin, Jason Yu, Haiyuan Balaji, Santhanam Salehi-Ashtiani, Kourosh TI Systems level analysis of the Chlamydomonas reinhardtii metabolic network reveals variability in evolutionary co-conservation SO MOLECULAR BIOSYSTEMS LA English DT Article ID FITNESS LANDSCAPES; BIOCHEMICAL NETWORKS; FUNCTIONAL MODULES; ESCHERICHIA-COLI; ENZYME EVOLUTION; RNA-SEQ; PROTEIN; ORGANIZATION; EXPRESSION; EPISTASIS AB Metabolic networks, which are mathematical representations of organismal metabolism, are reconstructed to provide computational platforms to guide metabolic engineering experiments and explore fundamental questions on metabolism. Systems level analyses, such as interrogation of phylogenetic relationships within the network, can provide further guidance on the modification of metabolic circuitries. Chlamydomonas reinhardtii, a biofuel relevant green alga that has retained key genes with plant, animal, and protist affinities, serves as an ideal model organism to investigate the interplay between gene function and phylogenetic affinities at multiple organizational levels. Here, using detailed topological and functional analyses, coupled with transcriptomics studies on a metabolic network that we have reconstructed for C. reinhardtii, we show that network connectivity has a significant concordance with the co-conservation of genes; however, a distinction between topological and functional relationships is observable within the network. Dynamic and static modes of co-conservation were defined and observed in a subset of gene-pairs across the network topologically. In contrast, genes with predicted synthetic interactions, or genes involved in coupled reactions, show significant enrichment for both shorter and longer phylogenetic distances. Based on our results, we propose that the metabolic network of C. reinhardtii is assembled with an architecture to minimize phylogenetic profile distances topologically, while it includes an expansion of such distances for functionally interacting genes. This arrangement may increase the robustness of C. reinhardtii's network in dealing with varied environmental challenges that the species may face. The defined evolutionary constraints within the network, which identify important pairings of genes in metabolism, may offer guidance on synthetic biology approaches to optimize the production of desirable metabolites. C1 [Chaiboonchoe, Amphun; Dohai, Bushra; Khraiwesh, Basel; Jaiswal, Ashish; Jijakli, Kenan; Koussa, Joseph; Nelson, David R.; Cai, Hong; Balaji, Santhanam; Salehi-Ashtiani, Kourosh] New York Univ Abu Dhabi, Div Sci & Math, Lab Algal Syst & Synthet Biol, Abu Dhabi, U Arab Emirates. [Chaiboonchoe, Amphun; Dohai, Bushra; Khraiwesh, Basel; Jaiswal, Ashish; Jijakli, Kenan; Koussa, Joseph; Nelson, David R.; Cai, Hong; Balaji, Santhanam; Salehi-Ashtiani, Kourosh] New York Univ Abu Dhabi Inst, CGSB, Abu Dhabi, U Arab Emirates. [Ghamsari, Lila; Yang, Xinping; Balaji, Santhanam; Salehi-Ashtiani, Kourosh] Harvard Med Sch, CCSB, Boston, MA 02115 USA. [Ghamsari, Lila; Yang, Xinping; Balaji, Santhanam; Salehi-Ashtiani, Kourosh] Harvard Med Sch, Dept Canc Biol, Dana Farber Canc Inst, Boston, MA 02115 USA. [Ghamsari, Lila; Yang, Xinping; Balaji, Santhanam; Salehi-Ashtiani, Kourosh] Harvard Med Sch, Dept Genet, Boston, MA 02115 USA. [Ng, Patrick; Yu, Haiyuan] Cornell Univ, Dept Biol Stat & Computat Biol, Ithaca, NY 14850 USA. [Ng, Patrick; Yu, Haiyuan] Cornell Univ, Weill Inst Cell & Mol, Ithaca, NY 14850 USA. [Chang, Roger L.] Harvard Med Sch, Dept Syst Biol, Boston, MA USA. [Papin, Jason] Univ Virginia, Dept Biomed Engn, Charlottesville, VA 22904 USA. [Balaji, Santhanam] MRC Lab Mol Biol, Cambridge, England. [Ghamsari, Lila] Genocea Biosci, 100 Acorn Pk Dr, Cambridge, MA USA. [Cai, Hong] BGI Shenzhen, Shenzhen 518083, Peoples R China. [Yang, Xinping] Southern Med Univ, Nanfang Hosp, Dept Obstet, Guangzhou 510515, Peoples R China. [Yang, Xinping] Southern Med Univ, Nanfang Hosp, Dept Gynecol, Guangzhou 510515, Peoples R China. RP Balaji, S; Salehi-Ashtiani, K (reprint author), New York Univ Abu Dhabi, Div Sci & Math, Lab Algal Syst & Synthet Biol, Abu Dhabi, U Arab Emirates.; Balaji, S; Salehi-Ashtiani, K (reprint author), New York Univ Abu Dhabi Inst, CGSB, Abu Dhabi, U Arab Emirates.; Balaji, S; Salehi-Ashtiani, K (reprint author), Harvard Med Sch, CCSB, Boston, MA 02115 USA.; Balaji, S; Salehi-Ashtiani, K (reprint author), Harvard Med Sch, Dept Canc Biol, Dana Farber Canc Inst, Boston, MA 02115 USA.; Balaji, S; Salehi-Ashtiani, K (reprint author), Harvard Med Sch, Dept Genet, Boston, MA 02115 USA.; Yu, HY (reprint author), Cornell Univ, Dept Biol Stat & Computat Biol, Ithaca, NY 14850 USA.; Yu, HY (reprint author), Cornell Univ, Weill Inst Cell & Mol, Ithaca, NY 14850 USA.; Papin, J (reprint author), Univ Virginia, Dept Biomed Engn, Charlottesville, VA 22904 USA.; Balaji, S (reprint author), MRC Lab Mol Biol, Cambridge, England. EM papin@virginia.edu; haiyuan.yu@cornell.edu; bsanthan@mrc-lmb.cam.ac.uk; ksa3@nyu.edu OI Khraiwesh, Basel/0000-0001-7026-1263 FU New York University Abu Dhabi Research funds [AD060]; New York University Abu Dhabi Institute grant [G1205-1205i]; Office of Science (Biological and Environmental Research), US Department of Energy [DE-FG02-07ER64496]; Dana-Farber Cancer Institute Strategic Initiative; US National Institute of General Medical Sciences Grants [GM097358, GM104424, GM088244]; Gordon and Betty Moore Foundation Life Sciences Research Foundation postdoctoral fellowship [GBMF 2550.04]; UK Medical Research Council fund [U105185859] FX This research was supported by New York University Abu Dhabi Research funds AD060 (to K. S.-A.); New York University Abu Dhabi Institute grant G1205-1205i (to K. S.-A.); the Office of Science (Biological and Environmental Research), US Department of Energy, Grant DE-FG02-07ER64496 (to K. S.-A. and J. P.); Institute Sponsored Research funds from the Dana-Farber Cancer Institute Strategic Initiative; US National Institute of General Medical Sciences Grants GM097358 and GM104424 (to H. Y.), and GM088244 (to J. P.); and Gordon and Betty Moore Foundation GBMF 2550.04 Life Sciences Research Foundation postdoctoral fellowship (to R. L. C.). SB acknowledges the UK Medical Research Council fund (U105185859) for support. We thank Khaled Hazzouri for his comments on the manuscript and the anonymous reviewers for their insightful comments and suggestions. NR 63 TC 1 Z9 1 U1 1 U2 1 PU ROYAL SOC CHEMISTRY PI CAMBRIDGE PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND SN 1742-206X EI 1742-2051 J9 MOL BIOSYST JI Mol. Biosyst. PY 2016 VL 12 IS 8 BP 2394 EP 2407 DI 10.1039/c6mb00237d PG 14 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA DR4LM UT WOS:000379873100007 PM 27357594 ER PT S AU Li, ZX Roussakis, E Keeley, E Apiou-Sbirlea, G Birngruber, R Huang, C Evans, CL AF Li, Zongxi Roussakis, Emmanuel Keeley, Emily Apiou-Sbirlea, Gabriela Birngruber, Reginald Huang, Christene Evans, Conor L. BE Cote, GL TI A wearable conformal bandage for non-invasive two-dimensional imaging of skin oxygenation SO OPTICAL DIAGNOSTICS AND SENSING XVI: TOWARD POINT-OF-CARE DIAGNOSTICS SE Proceedings of SPIE LA English DT Proceedings Paper CT Conference on Optical Diagnostics and Sensing XVI - Toward Point-of-Care Diagnostics CY FEB 15-16, 2016 CL San Francisco, CA SP SPIE C1 [Li, Zongxi; Roussakis, Emmanuel; Apiou-Sbirlea, Gabriela; Huang, Christene; Evans, Conor L.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Keeley, Emily] MIT, Cambridge, MA 02139 USA. [Birngruber, Reginald] Univ Lubeck, Lubeck, Germany. RP Li, ZX (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPIE-INT SOC OPTICAL ENGINEERING PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA SN 0277-786X BN 978-1-62841-949-8 J9 PROC SPIE PY 2016 VL 9715 AR 97150R DI 10.1117/12.2211887 PG 1 WC Optics; Radiology, Nuclear Medicine & Medical Imaging SC Optics; Radiology, Nuclear Medicine & Medical Imaging GA BF0ZW UT WOS:000379998400022 ER PT J AU Zhang, YS Zhu, YB Chen, J Wang, YC Sherwood, ME Murray, CK Vrahas, MS Hooper, DC Hamblin, MR Dai, TH AF Zhang, Yunsong Zhu, Yingbo Chen, Jia Wang, Yucheng Sherwood, Margaret E. Murray, Clinton K. Vrahas, Mark S. Hooper, David C. Hamblin, Michael R. Dai, Tianhong TI Antimicrobial blue light inactivation of Candida albicans: In vitro and in vivo studies SO VIRULENCE LA English DT Article DE antimicrobial blue light; bioluminescence imagining; burn; candida albicans; endogenous photosensitizer; mouse model ID RESISTANT STAPHYLOCOCCUS-AUREUS; ULTRAVIOLET C IRRADIATION; HELICOBACTER-PYLORI; WOUND INFECTIONS; BURN INFECTION; VISIBLE-LIGHT; 470-NM LIGHT; 405-NM LIGHT; BACTERIA; MICE AB Fungal infections are a common cause of morbidity, mortality and cost in critical care populations. The increasing emergence of antimicrobial resistance necessitates the development of new therapeutic approaches for fungal infections. In the present study, we investigated the effectiveness of an innovative approach, antimicrobial blue light (aBL), for inactivation of Candida albicansin vitro and in infected mouse burns. A bioluminescent strain of C. albicans was used. The susceptibilities to aBL (415nm) were compared between C. albicans and human keratinocytes. The potential development of aBL resistance by C. albicans was investigated via 10 serial passages of C. albicans on aBL exposure. For the animal study, a mouse model of thermal burn infected with the bioluminescent C. albicans strain was used. aBL was delivered to mouse burns approximately 12h after fungal inoculation. Bioluminescence imaging was performed to monitor in real time the extent of infection in mice. The results obtained from the studies demonstrated that C. albicans was approximately 42-fold more susceptible to aBL than human keratinocytes. Serial passaging of C. albicans on aBL exposure implied a tendency of reduced aBL susceptibility of C. albicans with increasing numbers of passages; however, no statistically significant difference was observed in the post-aBL survival rate of C. albicans between the first and the last passage (P>0.05). A single exposure of 432 J/cm(2) aBL reduced the fungal burden in infected mouse burns by 1.75-log(10) (P=0.015). Taken together, our findings suggest aBL is a potential therapeutic for C. albicans infections. C1 [Zhang, Yunsong] Second Peoples Hosp Guangdong Prov, Dept Plast Surg & Cosmet, Guangzhou, Guangdong, Peoples R China. [Zhang, Yunsong; Zhu, Yingbo; Chen, Jia; Wang, Yucheng; Sherwood, Margaret E.; Hamblin, Michael R.; Dai, Tianhong] Massachusetts Gen Hosp, Wellman Ctr Photomed, BAR 404B,55 Fruit St, Boston, MA 02114 USA. [Zhang, Yunsong; Chen, Jia; Wang, Yucheng; Hamblin, Michael R.; Dai, Tianhong] Harvard Med Sch, Dept Dermatol, Boston, MA USA. [Zhu, Yingbo] Tongji Univ, Sch Med, Shanghai, Peoples R China. [Chen, Jia] Shanghai Dermatol Hosp, Shanghai, Peoples R China. [Wang, Yucheng] Chinese Peoples Liberat Army Gen Hosp, Dept Laser Med, Beijing, Peoples R China. [Murray, Clinton K.] Brooke Army Med Ctr, Infect Dis Serv, Ft Sam Houston, TX 78234 USA. [Vrahas, Mark S.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Orthoped Surg, Boston, MA USA. [Hooper, David C.] Harvard Med Sch, Massachusetts Gen Hosp, Div Infect Dis, Boston, MA USA. [Hamblin, Michael R.] Harvard Div Hlth Sci & Technol, Cambridge, MA USA. RP Dai, TH (reprint author), Massachusetts Gen Hosp, Wellman Ctr Photomed, BAR 404B,55 Fruit St, Boston, MA 02114 USA. EM tdai@mgh.harvard.edu FU CIMIT under U.S. Army Medical Research Acquisition Activity Cooperative Agreement [CIMIT] [14-1894] FX This work was supported by CIMIT under U.S. Army Medical Research Acquisition Activity Cooperative Agreement [CIMIT No. 14-1894]. The information contained herein does not necessarily reflect the position or policy of the Government, and no official endorsement should be inferred. NR 54 TC 0 Z9 0 U1 3 U2 4 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 2150-5594 EI 2150-5608 J9 VIRULENCE JI Virulence PY 2016 VL 7 IS 5 BP 536 EP 545 DI 10.1080/21505594.2016.1155015 PG 10 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA DR6JF UT WOS:000380007500009 PM 26909654 ER PT J AU Singh, T Prasad, R Katiyar, SK AF Singh, Tripti Prasad, Ram Katiyar, Santosh K. TI Therapeutic intervention of silymarin on the migration of non-small cell lung cancer cells is associated with the axis of multiple molecular targets including class 1 HDACs, ZEB1 expression, and restoration of miR-203 and E-cadherin expression SO AMERICAN JOURNAL OF CANCER RESEARCH LA English DT Article DE Silymarin; non-small cell lung cancer cells; cancer cell migration; HDACs; miR-203; E-cadherin; ZEB1 transcription factor ID HISTONE DEACETYLASE INHIBITORS; DOWN-REGULATION; CYCLE ARREST; IN-VIVO; MICRORNAS; ANGIOGENESIS; PROMOTES; INVASION; STEMNESS; PROGRESS AB Lung cancer and its metastasis is the leading cause of cancer-related mortality world-wide. Non-small cell lung cancer (NSCLC) accounts for about 90% of total lung cancer cases. Despite advancements in therapeutic approaches, only limited improvement has been achieved. Therefore, alternative strategies are required for the management of lung cancer. Here we report the chemotherapeutic effect of silymarin, a phytochemical from milk thistle plant (Silybum marianum L. Gaertn.), on NSCLC cell migration using metastatic human NSCLC cell lines (A549, H1299 and H460) together with the molecular targets underlying these effects. Using an in vitro cell migration assay, we found that treatment of human NSCLC cells (A549, H1299 and H460) with silymarin (0, 5, 10 and 20 mu g/mL) for 24 h resulted in concentration-dependent inhibition of cell migration, which was associated with the inhibition of histone deacetylase (HDAC) activity and reduced levels of class 1 HDAC proteins (HDAC1, HDAC2, HDAC3 and HDAC8) and concomitant increases in the levels of histone acetyltransferase activity (HAT). Known HDAC inhibitors (sodium butyrate and trichostatin A) exhibited similar patterns of therapeutic effects on the lung cancer cells. Treatment of A549 and H460 cells with silymarin reduced the expression of the transcription factor ZEB1 and restored expression of E-cadherin. The siRNA knockdown of ZEB1 also reduced the expression of HDAC proteins and enhanced re-expression of the levels of E-cadherin in NSCLC cells. MicroRNA-203 (miR-203) acts as a tumor suppressor, regulates tumor cell invasion and is repressed by ZEB1 in cancer cells. Silymarin treatment restored the levels of miR-203 in NSCLC cells. These findings indicate that silymarin can effectively inhibit lung cancer cell migration and provide a coherent model of its mechanism of action suggesting that silymarin may be an important therapeutic option for the prevention or treatment of lung cancer metastasis when administered either alone or with standard cancer therapeutic drugs. C1 [Singh, Tripti; Prasad, Ram; Katiyar, Santosh K.] Univ Alabama Birmingham, Dept Dermatol, 1670 Univ Blvd,Volker Hall 557, Birmingham, AL 35294 USA. [Katiyar, Santosh K.] Univ Alabama Birmingham, Dept Environm Hlth Sci, Birmingham, AL 35294 USA. [Katiyar, Santosh K.] Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL 35294 USA. [Katiyar, Santosh K.] Birmingham Vet Affairs Med Ctr, Birmingham, AL 35294 USA. RP Katiyar, SK (reprint author), Univ Alabama Birmingham, Dept Dermatol, 1670 Univ Blvd,Volker Hall 557, Birmingham, AL 35294 USA. EM skatiyar@uab.edu FU Veterans Administration Merit Review Award [1IO1 BX001410] FX This work was financially supported by the Veterans Administration Merit Review Award (1IO1 BX001410) to S.K.K. The funding agency had no roles in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 37 TC 0 Z9 0 U1 0 U2 0 PU E-CENTURY PUBLISHING CORP PI MADISON PA 40 WHITE OAKS LN, MADISON, WI 53711 USA SN 2156-6976 J9 AM J CANCER RES JI Am. J. Cancer Res. PY 2016 VL 6 IS 6 BP 1287 EP 1301 PG 15 WC Oncology SC Oncology GA DQ8GX UT WOS:000379448200007 PM 27429844 ER PT S AU Sheynkman, GM Shortreed, MR Cesnik, AJ Smith, LM AF Sheynkman, Gloria M. Shortreed, Michael R. Cesnik, Anthony J. Smith, Lloyd M. BE Bohn, PW Pemberton, JE TI Proteogenomics: Integrating Next-Generation Sequencing and Mass Spectrometry to Characterize Human Proteomic Variation SO ANNUAL REVIEW OF ANALYTICAL CHEMISTRY, VOL 9 SE Annual Review of Analytical Chemistry LA English DT Article; Book Chapter DE customized protein databases; genetic variation; isoforms; polymorphism; proteomics; sample-specific databases; proteoform; single amino acid variant; novel splice junction; alternative splicing ID RNA-SEQ DATA; SINGLE NUCLEOTIDE POLYMORPHISMS; PROTEIN-CODING-REGIONS; OPEN READING FRAMES; CANCER-CELL-LINES; SHOTGUN PROTEOMICS; HUMAN TRANSCRIPTOME; HUMAN GENOME; VARIANT PEPTIDES; COMPUTATIONAL ANALYSIS AB Mass spectrometry-based proteomics has emerged as the leading method for detection, quantification, and characterization of proteins. Nearly all proteomic workflows rely on proteomic databases to identify peptides and proteins, but these databases typically contain a generic set of proteins that lack variations unique to a given sample, precluding their detection. Fortunately, proteogenomics enables the detection of such proteomic variations and can be defined, broadly, as the use of nucleotide sequences to generate candidate protein sequences for mass spectrometry database searching. Proteogenomics is experiencing heightened significance due to two developments: (a) advances in DNA sequencing technologies that have made complete sequencing of human genomes and transcriptomes routine, and (b) the unveiling of the tremendous complexity of the human proteome as expressed at the levels of genes, cells, tissues, individuals, and populations. We review here the field of human proteogenomics, with an emphasis on its history, current implementations, the types of proteomic variations it reveals, and several important applications. C1 [Sheynkman, Gloria M.] Dana Farber Canc Inst, CCSB, Boston, MA 02215 USA. [Sheynkman, Gloria M.] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02215 USA. [Sheynkman, Gloria M.] Harvard Med Sch, Dept Genet, Boston, MA 02115 USA. [Sheynkman, Gloria M.; Shortreed, Michael R.; Cesnik, Anthony J.; Smith, Lloyd M.] Univ Wisconsin, Dept Chem, 1101 Univ Ave, Madison, WI 53706 USA. [Smith, Lloyd M.] Univ Wisconsin, Genome Ctr Wisconsin, Madison, WI 53706 USA. RP Sheynkman, GM (reprint author), Dana Farber Canc Inst, CCSB, Boston, MA 02215 USA.; Sheynkman, GM (reprint author), Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02215 USA.; Sheynkman, GM (reprint author), Harvard Med Sch, Dept Genet, Boston, MA 02115 USA.; Sheynkman, GM (reprint author), Univ Wisconsin, Dept Chem, 1101 Univ Ave, Madison, WI 53706 USA. EM gloriam_sheynkman@dfci.harvard.edu; mshort@chem.wisc.edu; cesnik@wisc.edu; smith@chem.wisc.edu FU NCI NIH HHS [R01 CA193481, T32 CA009361]; NIGMS NIH HHS [R01 GM114292]; NLM NIH HHS [T15 LM007359] NR 168 TC 2 Z9 3 U1 5 U2 7 PU ANNUAL REVIEWS PI PALO ALTO PA 4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0897 USA SN 1936-1327 BN 978-0-8243-4409-2 J9 ANNU REV ANAL CHEM JI Annu. Rev. Anal. Chem. PY 2016 VL 9 BP 521 EP 545 DI 10.1146/annurev-anchem-071015-041722 PG 25 WC Chemistry, Analytical; Spectroscopy SC Chemistry; Spectroscopy GA BF0QS UT WOS:000379328100023 PM 27049631 ER PT J AU Goldstein, G He, JB Ruthven, L Walker, J AF Goldstein, Gerald He, Jibo Ruthven, Leslie Walker, Jon TI An introduction to the Ruthven Impairment Assessment (RIA): A stability study SO APPLIED NEUROPSYCHOLOGY-ADULT LA English DT Article DE Assessment; computerized testing; test reliability ID HIGH-ALTITUDE; DYSFUNCTION; BATTERY AB The Ruthven Impairment Assessment (RIA) is introduced as a new neurocognitive test for the evaluation of complex attentional, reasoning, and working-memory abilities. It contains 5 subtests and is administered by computer within 15min. The subtests include measures of simple and complex attention, working memory, sequential reasoning, and problem-solving abilities. A clock is presented on the computer screen and the participant is instructed to use the space bar or a mouse to respond to the test items. Scores include reaction time and accuracy measures. The present study evaluates the stability of the RIA in healthy, normal individuals by repeating the procedure 3 times and comparing performance with analyses of variance (ANOVAs). The ANOVA results with 1 exception were nonsignificant, indicating that the RIA scores are stable in normal individuals and do not fluctuate significantly across testing. C1 [Goldstein, Gerald] VA Pittsburgh Healthcare Syst, Mental Illness Res Educ & Clin Ctr, Univ Dr, Pittsburgh, PA 15240 USA. [He, Jibo] Wichita State Univ, Dept Psychol, Wichita, KS 67208 USA. [Ruthven, Leslie] Preferred Mental Management Inc, Wichita, KS USA. [Walker, Jon] VA Pittsburgh Healthcare Syst, Res Serv, Pittsburgh, PA USA. RP Goldstein, G (reprint author), VA Pittsburgh Healthcare Syst, Mental Illness Res Educ & Clin Ctr, Univ Dr, Pittsburgh, PA 15240 USA. EM ggold@nb.net FU Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development; VISN 4 Mental Illness Research, Education, and Clinical Center, VA Pittsburgh Healthcare System FX This article is based on work supported in part by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development. The project was funded by infrastructure support funding from the VISN 4 Mental Illness Research, Education, and Clinical Center (Director: D. Oslin; Pittsburgh Site Director: G. Haas), VA Pittsburgh Healthcare System. NR 16 TC 0 Z9 0 U1 0 U2 0 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 2327-9095 EI 2327-9109 J9 APPL NEUROPSYCH-ADUL JI Appl. Neuropsychol.-Adult PY 2016 VL 23 IS 4 BP 302 EP 308 DI 10.1080/23279095.2015.1079715 PG 7 WC Clinical Neurology; Psychology SC Neurosciences & Neurology; Psychology GA DQ7XA UT WOS:000379420300007 PM 26943004 ER PT J AU Xin, SJ Ye, L Man, G Lv, CZ Elias, PM Man, MQ AF Xin, Shujun Ye, Li Man, George Lv, Chengzhi Elias, Peter M. Man, Mao-Qiang TI Heavy Cigarette Smokers in a Chinese Population Display a Compromised Permeability Barrier SO BIOMED RESEARCH INTERNATIONAL LA English DT Article ID ENVIRONMENTAL TOBACCO-SMOKE; PROINFLAMMATORY CYTOKINE RELEASE; STRATUM-CORNEUM HYDRATION; ALVEOLAR EPITHELIAL-CELLS; ATOPIC-DERMATITIS; SKIN BARRIER; HUMAN KERATINOCYTES; HIP FRACTURE; ALLERGIC SENSITIZATION; EPIDERMAL BARRIER AB Cigarette smoking is associated with various cutaneous disorders with defective permeability. Yet, whether cigarette smoking influences epidermal permeability barrier function is largely unknown. Here, we measured skin biophysical properties, including permeability barrier homeostasis, stratum corneum (SC) integrity, SC hydration, skin surface pH, and skin melanin/erythema index, in cigarette smokers. A total of 99 male volunteers were enrolled in this study. Smokers were categorized as light-to-moderate (<20 cigarettes/day) or heavy smokers (>= 20 cigarettes/day). An MPA5 was used to measure SC hydration and skin melanin/erythema index on the dorsal hand, forehead, and cheek. Basal transepidermal water loss (TEWL) and barrier recovery rates were assessed on the forearm. A Skin-pH-Meter pH900 was used to measure skin surface pH. Our results showed that heavy cigarette smokers exhibited delayed barrier recovery after acute abrogation (1.02% +/- 13.06 versus 16.48% +/- 6.07), and barrier recovery rates correlated negatively with the number of daily cigarettes consumption (p = 0.0087). Changes in biophysical parameters in cigarette smokers varied with body sites. In conclusion, heavy cigarette smokers display compromised permeability barrier homeostasis, which could contribute, in part, to the increased prevalence of certain cutaneous disorders characterized by defective permeability. Thus, improving epidermal permeability barrier should be considered for heavy cigarette smokers. C1 [Xin, Shujun; Ye, Li; Lv, Chengzhi] Dalian Skin Dis Hosp, Dalian 116021, Liaoning, Peoples R China. [Man, George; Elias, Peter M.; Man, Mao-Qiang] San Francisco VA Med Ctr, Dermatol Serv, San Francisco, CA 94121 USA. [Man, George; Elias, Peter M.; Man, Mao-Qiang] Univ Calif San Francisco, San Francisco, CA 94121 USA. RP Lv, CZ (reprint author), Dalian Skin Dis Hosp, Dalian 116021, Liaoning, Peoples R China.; Man, MQ (reprint author), San Francisco VA Med Ctr, Dermatol Serv, San Francisco, CA 94121 USA.; Man, MQ (reprint author), Univ Calif San Francisco, San Francisco, CA 94121 USA. EM dlpfb@126.com; mqman@hotmail.com NR 74 TC 1 Z9 1 U1 0 U2 0 PU HINDAWI PUBLISHING CORP PI NEW YORK PA 315 MADISON AVE 3RD FLR, STE 3070, NEW YORK, NY 10017 USA SN 2314-6133 EI 2314-6141 J9 BIOMED RES INT JI Biomed Res. Int. PY 2016 AR 9704598 DI 10.1155/2016/9704598 PG 7 WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental SC Biotechnology & Applied Microbiology; Research & Experimental Medicine GA DR2VO UT WOS:000379762200001 ER PT J AU Guo, JS Wang, XY Lu, X Jing, RR Li, JQ Li, CL Wang, DG Bi, BB Chen, XJ Wang, FQ Sun, SN Gong, J Azadzoi, KM Yang, JH AF Guo, Jisheng Wang, Xiaoyue Lu, Xin Jing, Ruirui Li, Junqiang Li, CuiLing Wang, Daoguang Bi, Baibin Chen, Xinjun Wang, Fengqin Sun, Shengnan Gong, Jing Azadzoi, Kazem M. Yang, Jing-Hua TI Unraveling molecular effects of ADAR1 overexpression in HEK293T cells by label-free quantitative proteomics SO CELL CYCLE LA English DT Article DE ADAR1; biotechnology; cell proliferation; mass spectrometry; proteomics; protein translation ID EDITING ENZYME ADAR1; ADENOSINE-DEAMINASE; DOWN-REGULATION; NUCLEAR EXPORT; RNA; PROLIFERATION; INTERFERON; EXPRESSION; GENE; COMPLEX AB ADAR1 is a double-stranded RNA (dsRNA) editing enzyme that specifically converts adenosine to inosine. ADAR1 is ubiquitously expressed in eukaryotes and participate in various cellular processes such as differentiation, proliferation and immune responses. We report here a new proteomics study of HEK293T cells with and without ADAR1 overexpression. The up- and down-regulated proteins by ADAR1 overexpression are identified by liquid chromatography-tandem mass spectrometry (LC-MS/MS) followed by label-free protein quantification. Totally 1,495 proteins (FDR < 0.01) are identified, among which 211 are up- and 159 are down-regulated for at least 1.5-fold (n =3, p < 0.05). Gene ontology analysis reveals that these ADAR1-regulated proteins are involved in protein translation and cell cycle regulation. Bioinformatics analysis identifies a closely related network consistent for the protein translation machinery and a tightly connected network through proliferating cell nuclear antigen (PCNA)-interactions. Up-regulation of the proteins in the PCNA-mediated cell proliferation network is confirmed by Western blotting. In addition, ADAR1 overexpression is confirmed to increase cell proliferation in HEK293T cells and A549 cells. We conclude that ADAR1 overexpression modulates the protein translation and cell cycle networks through PCNA-mediated protein-protein interaction to promote cell proliferation in HEK293 cells. C1 [Guo, Jisheng; Wang, Xiaoyue; Lu, Xin; Jing, Ruirui; Li, Junqiang; Li, CuiLing; Wang, Daoguang; Bi, Baibin; Chen, Xinjun; Wang, Fengqin; Sun, Shengnan; Gong, Jing; Yang, Jing-Hua] Shandong Univ, Sch Med, Canc Res Ctr, Jinan, Peoples R China. [Azadzoi, Kazem M.; Yang, Jing-Hua] Boston Univ, Sch Med, Dept Surg, VA Boston Healthcare Syst, Boston, MA 02118 USA. [Azadzoi, Kazem M.; Yang, Jing-Hua] Boston Univ, Sch Med, Dept Urol, VA Boston Healthcare Syst, Boston, MA 02118 USA. RP Yang, JH (reprint author), Shandong Univ, Sch Med, Canc Res Ctr, Jinan, Peoples R China.; Yang, JH (reprint author), Boston Univ, Sch Med, Dept Surg, VA Boston Healthcare Syst, Boston, MA 02118 USA.; Yang, JH (reprint author), Boston Univ, Sch Med, Dept Urol, VA Boston Healthcare Syst, Boston, MA 02118 USA. EM jyang@bu.edu FU National Natural Science Foundation of China [31471322, 30928031]; Shandong Province Major Science and Technology Project [2015ZDXX0802A02] FX This work was supported by grants from the National Natural Science Foundation of China (#31471322 and #30928031) and Shandong Province Major Science and Technology Project (2015ZDXX0802A02). NR 39 TC 0 Z9 0 U1 3 U2 3 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 1538-4101 EI 1551-4005 J9 CELL CYCLE JI Cell Cycle PY 2016 VL 15 IS 12 BP 1591 EP 1601 DI 10.1080/15384101.2016.1176657 PG 11 WC Cell Biology SC Cell Biology GA DR2OM UT WOS:000379743800014 PM 27104882 ER PT J AU Chang, AM Bjonnes, AC Aeschbach, D Buxton, OM Gooley, JJ Anderson, C Van Reen, E Cain, SW Czeisler, CA Duffy, JF Lockley, SW Shea, SA Scheer, FAJL Saxena, R AF Chang, Anne-Marie Bjonnes, Andrew C. Aeschbach, Daniel Buxton, Orfeu M. Gooley, Joshua J. Anderson, Clare Van Reen, Eliza Cain, Sean W. Czeisler, Charles A. Duffy, Jeanne F. Lockley, Steven W. Shea, Steven A. Scheer, Frank A. J. L. Saxena, Richa TI Circadian gene variants influence sleep and the sleep electroencephalogram in humans SO CHRONOBIOLOGY INTERNATIONAL LA English DT Article DE Circadian genes; sleep EEG; slow-wave sleep; slow-wave activity ID YOUNG-ADULTS; EEG; ASSOCIATION; POLYMORPHISM; RISK; METAANALYSIS; HOMEOSTASIS; INTENSITY; SECRETION; DURATION AB The sleep electroencephalogram (EEG) is highly heritable in humans and yet little is known about the genetic basis of inter-individual differences in sleep architecture. The aim of this study was to identify associations between candidate circadian gene variants and the polysomnogram, recorded under highly controlled laboratory conditions during a baseline, overnight, 8 h sleep opportunity. A candidate gene approach was employed to analyze single-nucleotide polymorphisms from five circadian-related genes in a two-phase analysis of 84 healthy young adults (28 F; 23.21 +/- 2.97 years) of European ancestry. A common variant in Period2 (PER2) was associated with 20 min less slow-wave sleep (SWS) in carriers of the minor allele than in noncarriers, representing a 22% reduction in SWS duration. Moreover, spectral analysis in a subset of participants (n = 37) showed the same PER2 polymorphism was associated with reduced EEG power density in the low delta range (0.25-1.0 Hz) during non-REM sleep and lower slow-wave activity (0.75-4.5 Hz) in the early part of the sleep episode. These results indicate the involvement of PER2 in the homeostatic process of sleep. Additionally, a rare variant in Melatonin Receptor 1B was associated with longer REM sleep latency, with minor allele carriers exhibiting an average of 65 min (87%) longer latency from sleep onset to REM sleep, compared to noncarriers. These findings suggest that circadian-related genes can modulate sleep architecture and the sleep EEG, including specific parameters previously implicated in the homeostatic regulation of sleep. C1 [Chang, Anne-Marie; Aeschbach, Daniel; Buxton, Orfeu M.; Gooley, Joshua J.; Anderson, Clare; Van Reen, Eliza; Cain, Sean W.; Czeisler, Charles A.; Duffy, Jeanne F.; Lockley, Steven W.; Shea, Steven A.; Scheer, Frank A. J. L.; Saxena, Richa] Brigham & Womens Hosp, Div Sleep & Circadian Disorders, Dept Med, 75 Francis St, Boston, MA 02115 USA. [Chang, Anne-Marie; Aeschbach, Daniel; Buxton, Orfeu M.; Gooley, Joshua J.; Anderson, Clare; Van Reen, Eliza; Cain, Sean W.; Czeisler, Charles A.; Duffy, Jeanne F.; Lockley, Steven W.; Shea, Steven A.; Scheer, Frank A. J. L.; Saxena, Richa] Brigham & Womens Hosp, Dept Neurol, 75 Francis St, Boston, MA 02115 USA. [Chang, Anne-Marie; Aeschbach, Daniel; Buxton, Orfeu M.; Gooley, Joshua J.; Anderson, Clare; Van Reen, Eliza; Cain, Sean W.; Czeisler, Charles A.; Duffy, Jeanne F.; Lockley, Steven W.; Shea, Steven A.; Scheer, Frank A. J. L.; Saxena, Richa] Harvard Med Sch, Div Sleep Med, Boston, MA USA. [Chang, Anne-Marie; Bjonnes, Andrew C.; Saxena, Richa] Broad Inst Harvard & Massachusetts Inst Technol, Med & Populat Genet, Cambridge, MA USA. [Chang, Anne-Marie; Buxton, Orfeu M.] Penn State Univ, Dept Biobehav Hlth, University Pk, PA 16802 USA. [Bjonnes, Andrew C.; Saxena, Richa] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA. [Bjonnes, Andrew C.; Saxena, Richa] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA. [Aeschbach, Daniel] German Aerosp Ctr, Inst Aerosp Med, Cologne, Germany. [Buxton, Orfeu M.] Harvard Sch Publ Hlth, Dept Social & Behav Sci, Boston, MA USA. [Shea, Steven A.] Oregon Hlth & Sci Univ, Oregon Inst Occupat Hlth Sci, Portland, OR 97201 USA. RP Chang, AM (reprint author), Penn State Univ, Dept Biobehav Hlth, 221 Biobehav Hlth Bldg, State Coll, PA 16801 USA. EM amchang@psu.edu OI Cain, Sean/0000-0002-8385-1550 FU National Institute of Health (NIH) grant [R21-DK089378]; pilot grant from Harvard Catalyst, Harvard Clinical and Translational Science Center [UL1 RR025758]; Harvard University; NIH grant [HL080978, MH045130, HL077453, K01-HL115458, K24-HL076446]; National Space Biomedical Research Institute (NSBRI) grant [HPF01601]; BWH General Clinical Research Center [NIH M01-02635]; BWH Faculty Career Development Award; German Aerospace Center; Harvard Catalyst Pilot Grant [R21-DK089378, R01-DK102696, R21-HL121728]; National Institutes of Health; Sunovion [ESRC-0004, ESRC-0977]; Teva; Takeda Pharmaceuticals North America; Scientific Advisory Board of Matsutani America; Wake Forest University Medical Center (NC); American Academy of Craniofacial Pain; NHLBI; NIDDK; National Postdoctoral Association; Oklahoma State University; Oregon Health Sciences University; SUNY Downstate Medical Center; American Diabetes Association; New York University; VicRoads; Sanofi-Aventis; Brown Medical School/Rhode Island Hospital; Ausmed; Cephalon; National Football League Charities; ResMed; Philips Respironics; APSS (Associated Professional Sleep Societies); AWHONN (Association of Women's Health, Obstetric and Neonatal Nurses); Harvard School of Public Health; Hokkaido University Graduate School of Medicine; Japan Society for Occupational Health; Society of Thoracic Surgeons; University of Washington; World Federation of Sleep Research and Sleep Medicine Societies; WME Entertainment LLC; American Academy of Sleep Medicine; Boehringer Ingelheim Pharmaceuticals, Inc.; Cephalon, Inc.; GlaxoSmithKline; Hypnion; Jazz Pharmaceuticals; Jordan's Furniture; Merck Co.; Pfizer, Inc.; Respironics, Inc.; Sanofi-Aventis, Inc.; Sealy, Inc.; Sepracor, Inc.; Simmons; Sleep Health Centers LLC; Spring Aire; Takeda Pharmaceuticals; Tempur-Pedic; Sepracor; Naturebright; Sound Oasis; Thomas Jefferson University; Wyle Integrated Science and Engineering (NASA); Blackrock; Cowen Co; Endurant Capital Management; Far West Capital Management; Fidelity; Frankel Group; Impax Laboratories; Kearney Venture Partners; Lazard Capital Markets; New Horizon Capital; Perceptive Advisors; Polar Capital; ResearchWorks Inc; Wyvern Funds; Optalert, Pty, Melbourne, Australia; iSLEEP, Pty, Melbourne, Australia; Biological Illuminations LLC; Philips Lighting; Vanda Pharmaceuticals FX This study was funded by National Institute of Health (NIH) grant R21-DK089378, a pilot grant from Harvard Catalyst, Harvard Clinical and Translational Science Center (UL1 RR025758) and financial contributions from Harvard University. Additional funding was provided by NIH grants HL080978, MH045130 and HL077453; National Space Biomedical Research Institute (NSBRI) grant HPF01601; the BWH General Clinical Research Center (NIH M01-02635); and a BWH Faculty Career Development Award to AMC. AMC was supported in part by NIH grant K01-HL115458. DA was supported in part by the German Aerospace Center. SAS was supported in part by NIH grant K24-HL076446. FAJLS and RS were supported by a Harvard Catalyst Pilot Grant, R21-DK089378, R01-DK102696 and R21-HL121728. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH, Harvard Catalyst, Harvard University and its affiliated academic healthcare centers, NSBRI or BWH.; Dr. Buxton reports research grant support from the National Institutes of Health outside of the submitted work; consulting with Matsutani America (scientific advisory board) and Harvard T.H. Chan School of Public Health. Travel support and honoraria for speaking from American Academy of Craniofacial Pain; Chevron; New York University; Academy of Nutrition and Dietetics; and Harvard T.H. Chan School of Public Health. Dr. Buxton received two investigator-initiated grants from Sepracor Inc (now Sunovion; ESRC-0004 and ESRC-0977, ClinicalTrials.gov Identifiers NCT00555750, NCT00900159), and two investigator-initiated grants from Cephalon Inc (now Teva; ClinicalTrials.gov Identifier: NCT00895570). OMB received Speaker's Bureau, CME and non-CME lecture honoraria and an unrestricted educational grant from Takeda Pharmaceuticals North America. OMB serves as a consultant and expert witness for Dinsmore LLC, consulting fees for serving on the Scientific Advisory Board of Matsutani America, and consulting fees from the Wake Forest University Medical Center (NC). OMB received speaking fees and/or travel support for speaking from American Academy of Craniofacial Pain, NHLBI, NIDDK, National Postdoctoral Association, Oklahoma State University, Oregon Health Sciences University, SUNY Downstate Medical Center, American Diabetes Association, and New York University.; Dr. Anderson has served as consultant to the Rail, Bus and Tram Union. National Transport Commission (Australia) and VicPolice. She has also received research support from VicRoads and Sanofi-Aventis, and has received lecturing fees from Brown Medical School/Rhode Island Hospital and Ausmed.; Dr. Czeisler has received consulting fees from or served as a paid member of scientific advisory boards for: Bombardier, Inc.; Boston Bruins; Boston Celtics; Boston Red Sox; Cephalon, Inc. (acquired by Teva Pharmaceutical Industries Ltd. October 2011); Koninklijke Philips Electronics, N.V. (acquired Respironics, Inc. March 2008); Michael Jackson's mother and children; Novartis; Sleep Multimedia, Inc.; United Parcel Service (UPS); Vanda Pharmaceuticals, Inc.; and Zeo Inc. CAC owns an equity interest in Apple; Lifetrac, Inc.; Microsoft; Somnus Therapeutics, Inc.; Vanda Pharmaceuticals, Inc., and Zeo Inc., and received royalties from McGraw Hill, Penguin Press/Houghton Mifflin Harcourt, and Philips Respironics, Inc. He has also received research support from Cephalon, National Football League Charities, ResMed and Philips Respironics; and has received lecture fees from APSS (Associated Professional Sleep Societies); AWHONN (Association of Women's Health, Obstetric and Neonatal Nurses); Harvard School of Public Health; Hokkaido University Graduate School of Medicine; Japan Society for Occupational Health; Society of Thoracic Surgeons; University of Washington; the World Federation of Sleep Research and Sleep Medicine Societies and WME Entertainment LLC. CAC has also received research prizes with monetary awards from the American Academy of Sleep Medicine. The Harvard Medical School Division of Sleep Medicine (HMS/DSM), which CAC directs, has received unrestricted research and educational gifts and endowment funds from: Boehringer Ingelheim Pharmaceuticals, Inc., Cephalon, Inc., George H. Kidder, Esq., Gerald McGinnis, GlaxoSmithKline, Herbert Lee, Hypnion, Jazz Pharmaceuticals, Jordan's Furniture, Merck & Co., Inc., Peter C. Farrell, Ph.D., Pfizer, ResMed, Respironics, Inc., Sanofi-Aventis, Inc., Sealy, Inc., Sepracor, Inc., Simmons, Sleep Health Centers LLC, Spring Aire, Takeda Pharmaceuticals and Tempur-Pedic. The HMS/DSM has received gifts from many outside organizations and individuals including: Cephalon, Inc., Committee for Interns and Residents, Eisai, Inc., Farrell Family Foundation, Fisher & Paykel Healthcare Corporation, Gerald McGinnis, Jazz Pharmaceuticals, Jordan's Furniture, Lilly USA, LLC, Neurocare Center for Sleep, NeuroScience, Novartis Consumer Health, Philips-Respironics, Inc., Praxair US Homecare, Purdue Pharma, ResMed Foundation, Safeway, Sanofi-Aventis, Inc., Select Comfort Corporation, Sleep HealthCenters LLC, Somaxon Pharmaceuticals, Transcept Pharmaceuticals, United Healthcare, Vanda Pharmaceuticals, Inc., Wake Up Narcolepsy, Inc., Watermark Medical, Weight Watchers International, YMCA of the USA and Zeo, Inc. The HMS/DSM Sleep and Health Education Program has received Educational Grant funding from Cephalon, Inc., Takeda Pharmaceuticals, Sanofi-Aventis, Inc. and Sepracor, Inc. CAC is the incumbent of an endowed professorship provided to Harvard University by Cephalon, Inc. and holds a number of process patents in the field of sleep/circadian rhythms (e.g., photic resetting of the human circadian pacemaker). Since 1985, CAC has also served as an expert witness on various legal cases related to sleep and/or circadian rhythms.; Dr. Lockley has received consulting fees from Naturebright, Sound Oasis, Thomas Jefferson University and Wyle Integrated Science and Engineering (NASA), Blackrock, Cowen & Co, Endurant Capital Management, Far West Capital Management, Fidelity, Frankel Group, Impax Laboratories, Kearney Venture Partners, Lazard Capital Markets, New Horizon Capital, Perceptive Advisors, Polar Capital, ResearchWorks Inc, and Wyvern Funds. He has also received unrestricted equipment gifts from Biological Illuminations LLC, Bionetics Corporation, and Philips Lighting; an unrestricted monetary gift from Swinburne University of Technology, Australia; a fellowship gift from Optalert, Pty, Melbourne, Australia; equity in iSLEEP, Pty, Melbourne, Australia; and advance author payment and royalties from Oxford University Press and from Elsevier. SWL has received honoraria and/or travel and accommodation support from 8th International Conference on Managing Fatigue; 14th Annual Tennessee Perfusion Conference; Brown University; Connecticut Business & Industry Association Health and Safety Conference; Emergency Services Steering Committee; Estee Lauder; Harvard University; Lighting Science Group Corp; Massachusetts General Hospital; MediCom Worldwide, Inc (CME); Midwest Lighting Institute; National Research Council Canada; New England College of Occupational and Environmental Medicine; Ontario Association of Fire Chiefs; Rio Tinto; UMass Memorial; Woolcock Institute of Medical Research; and Wyle Integrated Science and Engineering. He has received investigator-initiated research grants from Biological Illuminations LLC, Philips Lighting, and Vanda Pharmaceuticals and has served as a paid expert on behalf of six public bodies in arbitration hearings related to sleep, circadian rhythms and work hours in firefighters and police. NR 42 TC 1 Z9 1 U1 2 U2 2 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 0742-0528 EI 1525-6073 J9 CHRONOBIOL INT JI Chronobiol. Int. PY 2016 VL 33 IS 5 BP 561 EP 573 DI 10.3109/07420528.2016.1167078 PG 13 WC Biology; Physiology SC Life Sciences & Biomedicine - Other Topics; Physiology GA DR3CA UT WOS:000379779000009 PM 27089043 ER PT J AU Palanisami, A Khan, S Erdem, SS Hasan, T AF Palanisami, Akilan Khan, Shazia Erdem, Sultan Sibel Hasan, Tayyaba TI Guiding Empiric Treatment for Serious Bacterial Infections via Point of Care beta-Lactamase Characterization SO IEEE JOURNAL OF TRANSLATIONAL ENGINEERING IN HEALTH AND MEDICINE-JTEHM LA English DT Article DE Antibiotic resistance; beta-lactamase; microfluidic; point of care ID ESCHERICHIA-COLI; CEREBROSPINAL-FLUID; CHANGING EPIDEMIOLOGY; NEONATAL MENINGITIS; INFANTS YOUNGER; FEBRILE INFANTS; RAPID DETECTION; RESISTANCE; PATHOGENS; CHILDREN AB Fever is one of the most common symptoms of illness in infants and represents a clinical challenge due to the potential for serious bacterial infection. As delayed treatment for these infections has been correlated with increased morbidity and mortality, broad-spectrum beta-lactam antibiotics are often prescribed while waiting for microbiological lab results (1-3 days). However, the spread of antibiotic resistance via the beta-lactamase enzyme, which can destroy beta-lactam antibiotics, has confounded this paradigm; empiric antibiotic regimens are increasingly unable to cover all potential bacterial pathogens, leaving some infants effectively untreated until the pathogen is characterized. This can lead to lifelong sequela or death. Here, we introduce a fluorescent, microfluidic assay that can characterize beta-lactamase derived antibiotic susceptibility in 20 min with a sensitivity suitable for direct human specimens. The protocol is extensible, and the antibiotic spectrum investigated can be feasibly adapted for the pathogens of regional relevance. This new assay fills an important need by providing the clinician with hitherto unavailable point of care information for treatment guidance in an inexpensive and simple diagnostic format. C1 [Palanisami, Akilan; Khan, Shazia; Erdem, Sultan Sibel; Hasan, Tayyaba] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. [Khan, Shazia] Elsevier, Cambridge, MA 02139 USA. [Erdem, Sultan Sibel] Istanbul Medipol Univ, Inst Sch Med, TR-34810 Istanbul, Turkey. [Erdem, Sultan Sibel] Istanbul Medipol Univ, Regenerat & Restorat Med Res Ctr, TR-34810 Istanbul, Turkey. RP Hasan, T (reprint author), Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. EM thasan@mgh.harvard.edu NR 40 TC 1 Z9 1 U1 0 U2 0 PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC PI PISCATAWAY PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA SN 2168-2372 J9 IEEE J TRANSL ENG HE JI IEEE J. Transl. Eng. Health Med.-JTEHM PY 2016 VL 4 AR 2800410 DI 10.1109/JTEHM.2016.2573305 PG 10 WC Engineering, Biomedical SC Engineering GA DR4EY UT WOS:000379855500001 PM 27602307 ER PT J AU Wu, XH Burivong, W Ma, DQ Edelman, JD Richardson, ML Chen, H Stern, EJ AF Wu, Xiaohua Burivong, Wanaporn Ma, Daqing Edelman, Jeffrey D. Richardson, Michael L. Chen, Hui Stern, Eric J. TI CT findings of native lung after single lung transplantation in patients with idiopathic pulmonary fibrosis: long-term outcomes SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE LA English DT Article DE Lung transplant; idiopathic interstitial pneumonia; usual interstitial pneumonia; computed tomography; progression ID USUAL INTERSTITIAL PNEUMONIA; RESOLUTION COMPUTED-TOMOGRAPHY; THIN-SECTION CT; SERIAL EVALUATION; PROGRESSION; DIAGNOSIS; PROGNOSIS AB To evaluate the progression of native lung fibrosis on thin-section computed tomography (CT) scans from patients with IPF after SLT, we retrospectively studied thin-section CT findings of the patients who survived more than 3 years. Three radiologists independently reviewed serial CT images from 12 patients who underwent SLT for IPF. Initial CT scans were performed up to 7 months before SLT or <= 12 months after SLT, and follow-up CT scan were performed >36 months after SLT. CT measurements of the total lung volume were performed on native lungs. CT scores were evaluated for native lung findings for each thin-section CT, including the fibrosis score (FS), ground-glass opacity score (GGS), and traction bronchiectasis score (TBS). Twelve patients survived 43-110 months after SLT. In the native lung, the FS and TBS values were positively correlated with time. Rates of increase in the FS and TBS values were 0.300/year and 0.147/year, respectively. The GGS showed a slight negative correlation with the lung volume from the CT reconstruction. Rates of decrease of the GGS and lung volume measurements were 0.307/year and 5.47%/year, respectively. The results show that despite more powerful immunosuppression, fibrosis of native lung continues to progress in patients who receive SLT for IPF. C1 [Wu, Xiaohua; Ma, Daqing] Capital Med Univ, Beijing Friendship Hosp, Dept Radiol, Beijing 100050, Peoples R China. [Wu, Xiaohua; Burivong, Wanaporn; Stern, Eric J.] Univ Washington, Dept Radiol, Seattle, WA 98105 USA. [Burivong, Wanaporn] Srinakharinwirot Univ, Dept Radiol, HRH Princess Maha Chakri Sirindhorn Med Ctr, Fac Med, Nakorn Nayok 26120, Thailand. [Edelman, Jeffrey D.] Univ Washington, Dept Med, VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. [Richardson, Michael L.] Univ Washington, Dept Radiol, UW Roosevelt Radiol, Seattle, WA 98105 USA. [Chen, Hui] Capital Med Univ, Sch Biomed Engn, Beijing 100060, Peoples R China. RP Ma, DQ (reprint author), Capital Med Univ, Beijing Friendship Hosp, Dept Radiol, Beijing 100050, Peoples R China.; Stern, EJ (reprint author), Univ Washington, Dept Radiol, Seattle, WA 98105 USA. EM madaqing@vip.163.com; estern@uw.edu NR 21 TC 0 Z9 0 U1 1 U2 1 PU E-CENTURY PUBLISHING CORP PI MADISON PA 40 WHITE OAKS LN, MADISON, WI 53711 USA SN 1940-5901 J9 INT J CLIN EXP MED JI Int. J. Clin. Exp. Med. PY 2016 VL 9 IS 6 BP 9087 EP 9093 PG 7 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA DQ4EF UT WOS:000379156000023 ER PT J AU Abroms, M Sher, L AF Abroms, Mark Sher, Leo TI Dual Disorders and Suicide SO JOURNAL OF DUAL DIAGNOSIS LA English DT Letter ID DEPENDENCE C1 [Abroms, Mark] Mt Sinai St Lukes Roosevelt Hosp Ctr, 1090 Amsterdam Ave, New York, NY 10027 USA. [Abroms, Mark; Sher, Leo] Icahn Sch Med Mt Sinai, New York, NY 10029 USA. [Sher, Leo] James J Peters Vet Adm Med Ctr, New York, NY USA. RP Abroms, M (reprint author), Mt Sinai St Lukes Roosevelt Hosp Ctr, 1090 Amsterdam Ave, New York, NY 10027 USA. EM maabroms@chpnet.org NR 10 TC 1 Z9 1 U1 0 U2 0 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 1550-4263 EI 1550-4271 J9 J DUAL DIAGN JI J. Dual Diagn. PY 2016 VL 12 IS 2 BP 148 EP 149 DI 10.1080/15504263.2016.1172898 PG 2 WC Psychology, Clinical; Substance Abuse; Psychiatry SC Psychology; Substance Abuse; Psychiatry GA DR0QW UT WOS:000379613000006 PM 27064735 ER PT J AU Hartman, ML Goodson, JM Shi, P Vargas, J Yaskell, T Stephens, D Cugini, M Hasturk, H Barake, R Alsmadi, O Al-Mutawa, S Ariga, J Soparkar, P Behbehani, J Behbehani, K Welty, F AF Hartman, Mor-Li Goodson, J. Max Shi, Ping Vargas, Jorel Yaskell, Tina Stephens, Danielle Cugini, Maryann Hasturk, Hatice Barake, Roula Alsmadi, Osama Al-Mutawa, Sabiha Ariga, Jitendra Soparkar, Pramod Behbehani, Jawad Behbehani, Kazem Welty, Francine TI Unhealthy Phenotype as Indicated by Salivary Biomarkers: Glucose, Insulin, VEGF-A, and IL-12p70 in Obese Kuwaiti Adolescents SO JOURNAL OF OBESITY LA English DT Article ID CHILDREN; CHILDHOOD; SAMPLE; HEALTH AB Objective. Here, we investigated the relationships between obesity and the salivary concentrations of insulin, glucose, and 20 metabolic biomarkers in Kuwaiti adolescents. Previously, we have shown that certain salivary metabolic markers can act as surrogates for blood concentrations. Methods. Salivary samples of whole saliva were collected from 8,317 adolescents. Salivary glucose concentration was measured by a high-sensitivity glucose oxidase method implemented on a robotic chemical analyzer. The concentration of salivary insulin and 20 other metabolic biomarkers was assayed in 744 randomly selected saliva samples by multiplexed bead-based immunoassay. Results. Obesity was seen in 26.5% of the adolescents. Salivary insulin predicting hyperinsulinemia occurred in 4.3% of normal-weight adolescents, 8.3% of overweight adolescents, and 25.7% of obese adolescents (p < 0.0001). Salivary glucose predicting hyperglycemia was found in only 3% of obese children and was not predictive (p = 0.89). Elevated salivary glucose and insulin occurring together was associated with elevated vascular endothelial growth factor and reduced salivary interleukin-12. Conclusion. Considering the surrogate nature of salivary insulin and glucose, this study suggests that elevated insulin may be a dominant sign of metabolic disease in adolescent populations. It also appears that a proangiogenic environment may accompany elevated glucose in obese adolescents. C1 [Hartman, Mor-Li; Goodson, J. Max; Shi, Ping; Vargas, Jorel; Yaskell, Tina; Stephens, Danielle; Cugini, Maryann; Hasturk, Hatice; Soparkar, Pramod] Forsyth Inst, Dept Appl Oral Sci, Cambridge, MA 02142 USA. [Barake, Roula] Dasman Diabet Inst, Dept Nutr, Dasman 15462, Kuwait. [Alsmadi, Osama] Dasman Diabet Inst, Genome Ctr, Dasman 15462, Kuwait. [Al-Mutawa, Sabiha; Ariga, Jitendra] Minist Hlth, Safat 13001, Kuwait. [Behbehani, Jawad] Kuwait Univ, Fac Dent, Safat 13060, Kuwait. [Behbehani, Kazem] Dasman Diabet Inst, Dasman 15462, Kuwait. [Welty, Francine] Beth Israel Deaconess Med Ctr, Div Cardiol, Boston, MA 02215 USA. RP Hartman, ML (reprint author), Forsyth Inst, Dept Appl Oral Sci, Cambridge, MA 02142 USA. EM mhartman@forsyth.org NR 29 TC 0 Z9 0 U1 1 U2 1 PU HINDAWI PUBLISHING CORP PI NEW YORK PA 315 MADISON AVE 3RD FLR, STE 3070, NEW YORK, NY 10017 USA SN 2090-0708 EI 2090-0716 J9 J OBES JI J. Obes. PY 2016 AR UNSP 6860240 DI 10.1155/2016/6860240 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA DQ8CF UT WOS:000379436000001 ER PT J AU Khaleghi, M Cheng, JT Furlong, C Rosowski, JJ AF Khaleghi, Morteza Cheng, Jeffrey Tao Furlong, Cosme Rosowski, John J. TI In-plane and out-of-plane motions of the human tympanic membrane SO JOURNAL OF THE ACOUSTICAL SOCIETY OF AMERICA LA English DT Article ID STROBOSCOPIC HOLOGRAPHY; SURFACE; SHAPE; EARDRUM; FIELD; MODEL AB Computer-controlled digital holographic techniques are developed and used to measure shape and four-dimensional nano-scale displacements of the surface of the tympanic membrane (TM) in cadaveric human ears in response to tonal sounds. The combination of these measurements (shape and sound-induced motions) allows the calculation of the out-of-plane (perpendicular to the surface) and in-plane (tangential) motion components at over 1 000 000 points on the TM surface with a high-degree of accuracy and sensitivity. A general conclusion is that the in-plane motion components are 10-20 dB smaller than the out-of-plane motions. These conditions are most often compromised with higher-frequency sound stimuli where the overall displacements are smaller, or the spatial density of holographic fringes is higher, both of which increase the uncertainty of the measurements. The results are consistent with the TM acting as a Kirchhoff-Love's thin shell dominated by out-of-plane motion with little in-plane motion, at least with stimulus frequencies up to 8 kHz. (C) 2016 Acoustical Society of America. C1 [Khaleghi, Morteza; Furlong, Cosme] Worcester Polytech Inst, Ctr Holog Studies & Laser MicromechaTron CHSLT, Dept Mech Engn, 100 Inst Rd, Worcester, MA 01609 USA. [Cheng, Jeffrey Tao; Rosowski, John J.] Harvard Med Sch, Dept Otol & Laryngol, Massachusetts Eye & Ear Infirm, Eaton Peabody Lab, 243 Charles St, Boston, MA 02114 USA. [Khaleghi, Morteza] Earlens Corp, 4045 Campbell Ave, Menlo Pk, CA 94025 USA. [Rosowski, John J.] MIT, Hlth Sci & Technol, 77 Massachusetts Ave,E25-518, Cambridge, MA 02139 USA. RP Rosowski, JJ (reprint author), Harvard Med Sch, Dept Otol & Laryngol, Massachusetts Eye & Ear Infirm, Eaton Peabody Lab, 243 Charles St, Boston, MA 02114 USA. EM John_Rosowski@meei.harvard.edu FU National Institute on Deafness and other Communication Disorders (NIDCD); Massachusetts Eye and Ear Infirmary (MEEI); Mechanical Engineering Department at Worcester Polytechnic Institute FX This work was supported by the National Institute on Deafness and other Communication Disorders (NIDCD), Massachusetts Eye and Ear Infirmary (MEEI), and the Mechanical Engineering Department at Worcester Polytechnic Institute. We also acknowledge the support of all of the members of the CHSLT labs at Worcester Polytechnic Institute (WPI) and Eaton-Peabody labs at MEEI, in particular, Jeremie Guignard and Mike Ravicz. NR 32 TC 2 Z9 2 U1 1 U2 1 PU ACOUSTICAL SOC AMER AMER INST PHYSICS PI MELVILLE PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA SN 0001-4966 EI 1520-8524 J9 J ACOUST SOC AM JI J. Acoust. Soc. Am. PD JAN PY 2016 VL 139 IS 1 BP 104 EP 117 DI 10.1121/1.4935386 PG 14 WC Acoustics; Audiology & Speech-Language Pathology SC Acoustics; Audiology & Speech-Language Pathology GA DQ9ZO UT WOS:000379568000013 PM 26827009 ER PT S AU Spring, BQ Sears, RB Zheng, LZ Mai, ZM Watanabe, R Villa, E Hasan, T AF Spring, Bryan Q. Sears, R. Bryan Zheng, Lei Z. Mai, Zhiming Watanabe, Reika Villa, Elizabeth Hasan, Tayyaba BE Pogue, BW Gioux, S TI Optical probes for molecular-guided surgery: Using photomedicine to prevent recurrence in the surgical bed (Conference Presentation) SO MOLECULAR-GUIDED SURGERY: MOLECULES, DEVICES, AND APPLICATIONS II SE Proceedings of SPIE LA English DT Proceedings Paper CT Conference on Molecular-Guided Surgery - Molecules, Devices, and Applications II CY FEB 13-14, 2016 CL San Francisco, CA SP SPIE, Fluoptics, Intuitive Surg, LI COR Biosciences, Mauna Kea Technol, Modulated Imaging, Novadaq, PerkinElmer Healthcare, SurgiMab C1 [Spring, Bryan Q.; Sears, R. Bryan; Zheng, Lei Z.; Mai, Zhiming; Hasan, Tayyaba] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Watanabe, Reika; Villa, Elizabeth] Univ Calif San Diego, San Diego, CA 92103 USA. RP Spring, BQ (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPIE-INT SOC OPTICAL ENGINEERING PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA SN 0277-786X BN 978-1-62841-930-6 J9 PROC SPIE PY 2016 VL 9696 AR 96960B DI 10.1117/12.2213885 PG 1 WC Optics; Surgery SC Optics; Surgery GA BF0QL UT WOS:000379313700009 ER PT J AU Holt, DJ Boeke, EA Coombs, G DeCross, SN Cassidy, BS Stufflebeam, S Rauch, SL Tootell, RBH AF Holt, Daphne J. Boeke, Emily A. Coombs, Garth, III DeCross, Stephanie N. Cassidy, Brittany S. Stufflebeam, Steven Rauch, Scott L. Tootell, Roger B. H. TI Abnormalities in personal space and parietal-frontal function in schizophrenia (vol 9, pg 233, 2015) SO NEUROIMAGE-CLINICAL LA English DT Correction C1 [Holt, Daphne J.; Boeke, Emily A.; Coombs, Garth, III; DeCross, Stephanie N.; Cassidy, Brittany S.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Holt, Daphne J.; Stufflebeam, Steven; Rauch, Scott L.; Tootell, Roger B. H.] Harvard Med Sch, Boston, MA USA. [Holt, Daphne J.; Boeke, Emily A.; Coombs, Garth, III; DeCross, Stephanie N.; Cassidy, Brittany S.; Stufflebeam, Steven; Tootell, Roger B. H.] Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA. [Stufflebeam, Steven; Tootell, Roger B. H.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. [Rauch, Scott L.] McLean Hosp, 115 Mill St, Belmont, MA 02178 USA. RP Holt, DJ (reprint author), Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. NR 1 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 2213-1582 J9 NEUROIMAGE-CLIN JI NeuroImage-Clin. PY 2016 VL 11 BP 538 EP 538 DI 10.1016/j.nicl.2016.03.018 PG 1 WC Neuroimaging SC Neurosciences & Neurology GA DQ9BD UT WOS:000379504500059 ER PT J AU Becerra, L Veggeberg, R Prescot, A Jensen, JE Renshaw, P Scrivani, S Spierings, ELH Burstein, R Borsook, D AF Becerra, L. Veggeberg, R. Prescot, A. Jensen, J. E. Renshaw, P. Scrivani, S. Spierings, E. L. H. Burstein, R. Borsook, D. TI A 'complex' of brain metabolites distinguish altered chemistry in the cingulate cortex of episodic migraine patients SO NEUROIMAGE-CLINICAL LA English DT Article DE Magnetic resonance spectroscopy (MRS); Excitatory neurotransmitters; Interictal migraine; Anterior cingulate cortex (ACC); 2D J-resolved; Central sensitization ID PROTON MR SPECTROSCOPY; MAGNETIC-RESONANCE-SPECTROSCOPY; OBSESSIVE-COMPULSIVE DISORDER; RESTING-STATE NETWORK; N-ACETYLASPARTATE; IN-VIVO; RECEPTOR-BINDING; GLUTAMINE LEVELS; GABA PLUS; AURA AB Despite the prevalence of migraine, the pathophysiology of the disease remains unclear. Current understanding of migraine has alluded to the possibility of a hyperexcitable brain. The aim of the current study is to investigate human brain metabolite differences in the anterior cingulate cortex (ACC) during the interictal phase in migraine patients. We hypothesized that there may be differences in levels of excitatory neurotransmitters and/or their derivatives in the migraine cohort in support of the theory of hyperexcitability in migraine. 2D J-resolved proton magnetic resonance spectroscopy (H-1-MRS) data were acquired on a 3 Tesla (3 T) MRI from a voxel placed over the ACC of 32 migraine patients (MP; 23 females, 9 males, age 33 +/- 9.6 years) and 33 healthy controls (HC; 25 females, 8males, age 32 +/- 9.6 years). Amplitude correlation matrices were constructed for each subject to evaluate metabolite discriminability. ProFit-estimated metabolite peak areas were normalized to a water reference signal to assess subject differences. The initial analysis of variance (ANOVA) was performed to test for group differences for all metabolites/creatine (Cre) ratios between healthy controls and migraineurs but showed no statistically significant differences. In addition, we used a multivariate approach to distinguish migraineurs from healthy subjects based on the metabolite/Cre ratio. A quadratic discriminant analysis (QDA) model was used to identify 3 metabolite ratios sufficient to minimize minimum classification error (MCE). The 3 selected metabolite ratios were aspartate (Asp)/Cre, N-acetyl aspartate (NAA)/Cre, and glutamine (Gln)/Cre. These findings are in support of a 'complex' of metabolite alterations, which may underlie changes in neuronal chemistry in the migraine brain. Furthermore, the parallel changes in the three-metabolite 'complex' may confer more subtle but biological processes that are ongoing. The data also support the current theory that the migraine brain is hyperexcitable even in the interictal state. (C) 2016 The Authors. Published by Elsevier Inc. C1 [Becerra, L.; Veggeberg, R.; Borsook, D.] Harvard Med Sch, Boston Childrens Hosp, Dept Anesthesia Crit Care & Pain Med, PAIN Grp,Ctr Pain & Brain, Waltham, MA USA. [Becerra, L.] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA. [Becerra, L.; Borsook, D.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Psychiat, Charlestown, MA 02114 USA. [Becerra, L.; Borsook, D.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Radiol, Charlestown, MA 02114 USA. [Veggeberg, R.; Jensen, J. E.; Borsook, D.] Harvard Med Sch, McLean Hosp, Brain Imaging Ctr, Belmont, MA USA. [Prescot, A.] Univ Utah, Sch Med, Dept Radiol, Salt Lake City, UT USA. [Renshaw, P.] Univ Utah, Dept Psychiat, Salt Lake City, UT USA. [Scrivani, S.] Massachusetts Gen Hosp, Dept Oral & Maxillofacial Surg, Boston, MA 02114 USA. [Spierings, E. L. H.] Tufts Med Ctr, Dept Neurol, Boston, MA USA. [Burstein, R.] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Anesthesia & Crit Care, Boston, MA USA. [Renshaw, P.] VISN 19 MIRECC, Salt Lake City, UT USA. RP Borsook, D (reprint author), Boston Childrens Hosp, Ctr Pain & Brain, 1 Autumn St, Boston, MA 02115 USA. EM david.borsook@childrens.harvard.edu FU National Institutes of Health (NIH) [RO1 NS073977, K24 NS064050] FX Research reported in this publication was supported by the National Institutes of Health (NIH) award number RO1 NS073977 and K24 NS064050. NR 81 TC 1 Z9 1 U1 3 U2 4 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 2213-1582 J9 NEUROIMAGE-CLIN JI NeuroImage-Clin. PY 2016 VL 11 BP 588 EP 594 DI 10.1016/j.nicl.2016.03.020 PG 7 WC Neuroimaging SC Neurosciences & Neurology GA DQ9BD UT WOS:000379504500065 PM 27158591 ER PT J AU Budhrani-Shani, P Berry, DL Arcari, P Langevin, H Wayne, PM AF Budhrani-Shani, Pinky Berry, Donna L. Arcari, Patricia Langevin, Helene Wayne, Peter M. TI Mind-Body Exercises for Nurses with Chronic Low Back Pain: An Evidence-Based Review SO NURSING RESEARCH AND PRACTICE LA English DT Review ID RANDOMIZED CONTROLLED-TRIAL; TAI-CHI EXERCISE; COGNITIVE-BEHAVIORAL THERAPY; EVIDENCE-INFORMED MANAGEMENT; OLDER-ADULTS; RISK-FACTORS; MUSCULOSKELETAL DISORDERS; POSTURAL CONTROL; SELF-CARE; RHEUMATOID-ARTHRITIS AB Background. Chronic low back pain (CLBP) among nurses is a growing health concern. The multimodal nature of mind-body exercises has potential to impact physiological and psychological processes associated with chronic pain, affording possible advantages over conventional unimodal therapies. This paper summarizes the prevalence of and risk factors for CLBP among nurses, reviews the effectiveness in treating pain and disability of mind-body exercises (yoga and tai chi) for CLBP among the general and nursing population, and describes implications. Methods. Articles, published during or prior to 2015, were systematically identified through the PubMed/MEDLINE, Web of Science, and ScienceDirect databases using the following search terms: nurses, mind-body, integrative, biopsychosocial, yoga, tai chi, back pain, and/or risk factors. Results. Prevalence estimates of CLBP among nurses ranged from 50% to 80%. Associated risk factors for CLBP included lifestyle and physical, psychological, psychosocial, and occupational factors. No published studies were identified that evaluated yoga or tai chi for nurses with CLBP. Studies in the general population suggested that these interventions are effective in reducing pain and disability and may improve factors/processes predictive of CLBP. Conclusion. This review suggests that evaluating the impact of multimodal interventions such as yoga and tai chi for nurses with CLBP warrants investigation. C1 [Budhrani-Shani, Pinky] Texas Womans Univ, Nelda C Stark Coll Nursing, Houston, TX 77030 USA. [Budhrani-Shani, Pinky; Berry, Donna L.] Dana Farber Harvard Canc Ctr, Phyllis F Cantor Ctr Res Nursing & Patient Care S, Boston, MA 02215 USA. [Arcari, Patricia] Dana Farber Canc Inst, Boston, MA 02215 USA. [Langevin, Helene; Wayne, Peter M.] Harvard Med Sch, Brigham & Womens Hosp, Osher Ctr Integrat Med, Boston, MA 02115 USA. RP Budhrani-Shani, P (reprint author), Texas Womans Univ, Nelda C Stark Coll Nursing, Houston, TX 77030 USA.; Budhrani-Shani, P (reprint author), Dana Farber Harvard Canc Ctr, Phyllis F Cantor Ctr Res Nursing & Patient Care S, Boston, MA 02215 USA. EM pbudhrani@twu.edu NR 110 TC 0 Z9 0 U1 12 U2 12 PU HINDAWI PUBLISHING CORP PI NEW YORK PA 315 MADISON AVE 3RD FLR, STE 3070, NEW YORK, NY 10017 USA SN 2090-1429 EI 2090-1437 J9 NURS RES PRACT JI Nurs. Res. Pract. PY 2016 AR 9018036 DI 10.1155/2016/9018036 PG 10 WC Nursing SC Nursing GA DR4JM UT WOS:000379867700001 ER PT J AU Jee, JE Lim, J Ong, YS Oon, J Gao, LQ Choi, HS Lee, SS AF Jee, Joo-Eun Lim, Jaehong Ong, Yong Siang Oon, Jessica Gao, Liqian Choi, Hak Soo Lee, Su Seong TI An efficient strategy to enhance binding affinity and specificity of a known isozyme inhibitor SO ORGANIC & BIOMOLECULAR CHEMISTRY LA English DT Article ID CARBONIC-ANHYDRASE-II; PEPTIDE LIBRARIES; SELECTIVE-INHIBITION; SMALL MOLECULES; IX; AGENTS; IDENTIFICATION; DISCOVERY; CAPTURE; LIGANDS AB The binding profile of a known inhibitor, benzenesulfonamide, against a family of carbonic anhydrase isozymes was efficiently enhanced via high-throughput screening of customized combinatorial one-bead-one-compound peptide libraries modified with the inhibitor molecule. The screening of the conjugate libraries recognized subtle variations in the microenvironments of the target enzyme and thus facilitated the identification of short peptide sequences that bind selectively to a close proximity of the active site. The identified peptide portions contributed significantly to the overall binding of the conjugate peptides with greatly enhanced affinity as well as improved specificity towards the target isozyme. The interactions between the inhibitors and the isozymes were validated by surface plasmon resonance (SPR), pull-down assay and enzymatic activity measurement. This high-throughput approach proved useful and efficient to enhance the binding profile of known inhibitors and may apply to developing effective inhibitors for a wide range of isozyme families. C1 [Jee, Joo-Eun; Lim, Jaehong; Ong, Yong Siang; Oon, Jessica; Gao, Liqian; Lee, Su Seong] Inst Bioengn & Nanotechnol, 31 Biopolis Way, Singapore 138669, Singapore. [Choi, Hak Soo] Massachusetts Gen Hosp, Dept Radiol, Gordon Ctr Med Imaging, 55 Fruit St,White 427, Boston, MA 02114 USA. [Choi, Hak Soo] Harvard Med Sch, 55 Fruit St,White 427, Boston, MA 02114 USA. RP Choi, HS (reprint author), Massachusetts Gen Hosp, Dept Radiol, Gordon Ctr Med Imaging, 55 Fruit St,White 427, Boston, MA 02114 USA.; Choi, HS (reprint author), Harvard Med Sch, 55 Fruit St,White 427, Boston, MA 02114 USA. EM hchoi12@mgh.harvard.edu; sslee@ibn.a-star.edu.sg RI Lee, Su Seong/B-8485-2014 OI Lee, Su Seong/0000-0002-2968-5707 FU Institute of Bioengineering and Nanotechnology (Biomedical Research Council (BMRC)); Agency for science, Technology and Research (A*STAR); BMRC-Science and Engineering Research Council Diagnostics Grant (A*STAR); National Institutes of Health: NIBIB [R01-EB-011523] FX This work was supported by the Institute of Bioengineering and Nanotechnology (Biomedical Research Council (BMRC)), Agency for science, Technology and Research (A*STAR), BMRC-Science and Engineering Research Council Diagnostics Grant (A*STAR), and the National Institutes of Health: NIBIB grant #R01-EB-011523 (HSC). NR 41 TC 0 Z9 0 U1 3 U2 4 PU ROYAL SOC CHEMISTRY PI CAMBRIDGE PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND SN 1477-0520 EI 1477-0539 J9 ORG BIOMOL CHEM JI Org. Biomol. Chem. PY 2016 VL 14 IS 28 BP 6833 EP 6839 DI 10.1039/c6ob01104g PG 7 WC Chemistry, Organic SC Chemistry GA DQ8AX UT WOS:000379432600027 PM 27339902 ER PT B AU Reder, LS Franco, RA AF Reder, Lindsay S. Franco, Ramon A., Jr. BE Costello, D Sandhu, G TI Benign vocal fold lesions SO PRACTICAL LARYNGOLOGY LA English DT Article; Book Chapter ID GRANULAR-CELL TUMORS; TITANYL PHOSPHATE LASER; SULCUS VOCALIS; RESPIRATORY PAPILLOMATOSIS; LARYNGEAL AMYLOIDOSIS; RHEUMATOID-ARTHRITIS; BOTULINUM TOXIN; DYE-LASER; NODULES; MANAGEMENT C1 [Reder, Lindsay S.] Univ Southern Calif Keck, Dept Otolaryngol Head & Neck Surg, USC Keck Sch Med, Los Angeles, CA 90089 USA. [Franco, Ramon A., Jr.] Havard Med Sch, Boston, MA USA. [Franco, Ramon A., Jr.] Massachusetts Eye & Ear Infirm, Voice & Speech Lab, Boston, MA 02114 USA. RP Reder, LS (reprint author), Univ Southern Calif Keck, Dept Otolaryngol Head & Neck Surg, USC Keck Sch Med, Los Angeles, CA 90089 USA. NR 54 TC 0 Z9 0 U1 0 U2 0 PU CRC PRESS-TAYLOR & FRANCIS GROUP PI BOCA RATON PA 6000 BROKEN SOUND PARKWAY NW, STE 300, BOCA RATON, FL 33487-2742 USA BN 978-1-4441-8367-2; 978-1-4441-8366-5 PY 2016 BP 27 EP 44 PG 18 WC Otorhinolaryngology SC Otorhinolaryngology GA BF0WC UT WOS:000379470800006 ER PT J AU McCaskill, GM Bolland, KA Burgio, KL Leeper, J AF McCaskill, Gina M. Bolland, Kathleen A. Burgio, Kathryn L. Leeper, James TI Development and validation of a diabetes self-management instrument for older African-Americans SO SOCIAL WORK IN HEALTH CARE LA English DT Article DE Diabetes self-management; instrument validation; older African-Americans ID QUALITY-OF-LIFE; HEALTH LITERACY; CARE PROFILE; ADULTS; SCALE; ASSOCIATION; DISPARITIES; WOMEN; DISTRESS; EFFICACY AB The objective of this study was to develop and validate a new diabetes self-management instrument for older African-Americans 65 years of age and older. The Self-Care Utility Geriatric African-American Rating (SUGAAR) was developed using the American Diabetes Association's standards for the management of type 2 diabetes in older adults and cognitive interviews with older African-Americans. The instrument underwent extensive review by a panel of experts, two rounds of cognitive interviews, and a pilot test before it was administered in an interview format to 125 community-dwelling older African-Americans. The instrument demonstrated content validity and significant, but modest, convergent validity with items from an established diabetes self-management instrument. Social workers and health care professionals can use the SUGARR to assess diabetes self-management and to identify areas for education and support for older African-Americans with type 2 diabetes. C1 [McCaskill, Gina M.; Burgio, Kathryn L.] US Dept Vet Affairs, Birmingham Atlanta Geriatr Res Educ & Clin Ctr GR, Birmingham, AL USA. [McCaskill, Gina M.; Burgio, Kathryn L.] Univ Alabama Birmingham, Sch Med, Comprehens Ctr Hlth Aging, Birmingham, AL USA. [Bolland, Kathleen A.] Univ Alabama, Sch Social Work, Tuscaloosa, AL USA. [Leeper, James] Univ Alabama, Dept Community & Rural Med, Tuscaloosa, AL USA. RP McCaskill, GM (reprint author), Birmingham VAMC, 700 S 19th St, Birmingham, AL 35233 USA. EM gina.mccaskill@va.gov FU John A. Hartford Foundation Geriatric Social Work Initiative; Birmingham/Atlanta Geriatric Research, Education, and Clinical Center (GRECC), Department of Veterans Affairs, Birmingham VA Medical Center, Birmingham, Alabama FX This work was supported by a dissertation award from the John A. Hartford Foundation Geriatric Social Work Initiative and the Birmingham/Atlanta Geriatric Research, Education, and Clinical Center (GRECC), Department of Veterans Affairs, Birmingham VA Medical Center, Birmingham, Alabama. The content is solely the responsibility of the authors and does not necessarily represent the official views of the U.S. Department of Veterans Affairs. NR 48 TC 0 Z9 0 U1 5 U2 8 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 0098-1389 EI 1541-034X J9 SOC WORK HEALTH CARE JI Soc. Work Health Care PY 2016 VL 55 IS 5 BP 381 EP 394 DI 10.1080/00981389.2015.1129012 PG 14 WC Social Work SC Social Work GA DR1VW UT WOS:000379694000003 PM 27045578 ER PT J AU Gordon, AJ AF Gordon, Adam J. TI Integrating policy and research into addiction practice, AMERSA abstracts, and an appreciation to our reviewers SO SUBSTANCE ABUSE LA English DT Editorial Material ID ADOLESCENT SUBSTANCE USE C1 [Gordon, Adam J.] Univ Pittsburgh, Sch Med, Div Gen Internal Med, Sect Treatment Res & Educ Addict Med, Pittsburgh, PA USA. [Gordon, Adam J.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, 151-C Univ Dr C, Pittsburgh, PA 15215 USA. RP Gordon, AJ (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, 151-C Univ Dr C, Pittsburgh, PA 15215 USA. EM gordona@medschool.pitt.edu NR 13 TC 0 Z9 0 U1 0 U2 0 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 0889-7077 EI 1547-0164 J9 SUBST ABUS JI Subst. Abus. PY 2016 VL 37 IS 2 BP 271 EP 275 DI 10.1080/08897077.2016.1170091 PG 5 WC Substance Abuse SC Substance Abuse GA DR1WH UT WOS:000379695100001 PM 27168047 ER PT J AU Kaminer, Y Gordon, AJ AF Kaminer, Yifrah Gordon, Adam J. TI The blind side of addiction: A call for increased awareness of developmentally informed youth addiction scholarship SO SUBSTANCE ABUSE LA English DT Editorial Material ID SUBSTANCE USE DISORDERS; CANNABIS USE; BRIEF INTERVENTION; NATIONAL-SURVEY; CURRICULUM; RESIDENTS; EDUCATION C1 [Kaminer, Yifrah] Univ Connecticut, Ctr Hlth, Dept Psychiat, Alcohol Res Ctr, Farmington, CT 06032 USA. [Kaminer, Yifrah] Univ Connecticut, Ctr Hlth, Dept Pediat, Alcohol Res Ctr, Farmington, CT USA. [Gordon, Adam J.] Univ Pittsburgh, Div Gen Internal Med, Pittsburgh, PA USA. [Gordon, Adam J.] VA Pittsburgh Healthcare Syst, CHERP, Pittsburgh, PA USA. RP Kaminer, Y (reprint author), Univ Connecticut, Sch Med, Farmington, CT 06030 USA. EM kaminer@uchc.edu NR 16 TC 0 Z9 0 U1 1 U2 1 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 0889-7077 EI 1547-0164 J9 SUBST ABUS JI Subst. Abus. PY 2016 VL 37 IS 2 BP 276 EP 277 DI 10.1080/08897077.2016.1167808 PG 2 WC Substance Abuse SC Substance Abuse GA DR1WH UT WOS:000379695100002 PM 27168048 ER PT J AU Dumas, O Abramovitz, L Wiley, AS Cozier, YC Camargo, CA AF Dumas, Orianne Abramovitz, Lisa Wiley, Aleta S. Cozier, Yvette C. Camargo, Carlos A., Jr. TI Epidemiology of Sarcoidosis in a Prospective Cohort Study of US Women SO ANNALS OF THE AMERICAN THORACIC SOCIETY LA English DT Article AB Rationale: Sarcoidosis is a systemic granulomatous and inflammatory disorder that most often involves the lungs but also affects many other organs. Data on sarcoidosis from large epidemiological studies remain scarce. Objectives: To evaluate the baseline prevalence and 22-year incidence of sarcoidosis and their associations with demographic and geographic characteristics in a large cohort of U.S. women. Methods: The Nurses' Health Study II is a prospective cohort study of U.S. female nurses enrolled in 1989 (aged 25-44 yr, n = 116,430). Data on major illnesses were collected through biennial questionnaires (1989-2011). Cases were identified by the nurses' self-report of physician-diagnosed sarcoidosis. Associations of demographic and geographic characteristics with sarcoidosis were evaluated by logistic regression and Cox models. Measurements and Main Results: A total of 377 sarcoidosis cases were identified. The baseline prevalence was 100/100,000 women. The average annual incidence rate was 11/100,000 during 2,275,028 person-years of follow up. Incidence rate increased with age (P = 0.003), from 9 to 15/100,000 in women aged less than 35 to 55 or more years, respectively. Black women had a higher prevalence (odds ratio, 5.24; 95% confidence interval, 2.87-9.55) and incidence (hazard ratio, 3.80; 95% confidence interval, 2.31-6.24) than white women. Across U.S. regions, more than twofold differences were observed in sarcoidosis prevalence and incidence, with consistently higher rates in the Northeast. Conclusions: We provide recent national data on the epidemiology of sarcoidosis among U.S. women. Important differences in prevalence and incidence were observed across U.S. regions. Large epidemiological studies are needed to better understand the causes of the observed demographic and geographic differences in sarcoidosis. C1 [Dumas, Orianne; Abramovitz, Lisa; Wiley, Aleta S.; Camargo, Carlos A., Jr.] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, 75 Francis St, Boston, MA 02115 USA. [Dumas, Orianne; Abramovitz, Lisa; Wiley, Aleta S.; Camargo, Carlos A., Jr.] Harvard Med Sch, Boston, MA USA. [Dumas, Orianne; Camargo, Carlos A., Jr.] Massachusetts Gen Hosp, Dept Emergency Med, 125 Nashua St,Suite 920, Boston, MA 02114 USA. [Cozier, Yvette C.] Boston Univ, Slone Epidemiol Ctr, Boston, MA 02215 USA. RP Camargo, CA (reprint author), Massachusetts Gen Hosp, Dept Emergency Med, 125 Nashua St,Suite 920, Boston, MA 02114 USA. EM ccamargo@partners.org FU National Institutes of Health [UM1 CA176726] FX Supported by National Institutes of Health grant UM1 CA176726. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. NR 0 TC 5 Z9 5 U1 0 U2 2 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1546-3222 EI 2325-6621 J9 ANN AM THORAC SOC JI Ann. Am. Thoracic Society PD JAN PY 2016 VL 13 IS 1 BP 67 EP 71 DI 10.1513/AnnalsATS.201508-568BC PG 5 WC Respiratory System SC Respiratory System GA DQ4DM UT WOS:000379154100011 PM 26501211 ER PT J AU Margolis, ML AF Margolis, Mitchell L. TI Lung Cancer Screening Kit with LUNG-RADS, Version 3.0 SO ANNALS OF THE AMERICAN THORACIC SOCIETY LA English DT Editorial Material C1 [Margolis, Mitchell L.] Univ Penn, Philadelphia Vet Affairs Med Ctr, Pulm Sect, Philadelphia, PA 19104 USA. RP Margolis, ML (reprint author), Philadelphia Vet Affairs Med Ctr, Pulm Sect, 3900 Woodland Ave, Philadelphia, PA 19104 USA. EM mitchell.margolis@va.gov NR 0 TC 0 Z9 0 U1 3 U2 3 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1546-3222 EI 2325-6621 J9 ANN AM THORAC SOC JI Ann. Am. Thoracic Society PD JAN PY 2016 VL 13 IS 1 BP 145 EP 145 DI 10.1513/AnnalsATS.201510-720OT PG 1 WC Respiratory System SC Respiratory System GA DQ4DM UT WOS:000379154100029 PM 26730876 ER PT J AU Barroso-Sousa, R Shapiro, GI Tolaney, SM AF Barroso-Sousa, Romualdo Shapiro, Geoffrey I. Tolaney, Sara M. TI Clinical Development of the CDK4/6 Inhibitors Ribociclib and Abemaciclib in Breast Cancer SO BREAST CARE LA English DT Review DE Breast cancer; Cyclin-dependent kinase; Palbociclib; Abemaciclib; Ribociclib ID RETINOBLASTOMA PROTEIN; PALBOCICLIB; THERAPY; PHOSPHORYLATION; COMBINATION; HALLMARKS; CDK6 AB Clinical and preclinical data support a significant role for inhibitors of the cyclin-dependent kinases (CDKs) 4 and 6 in the treatment of patients with breast cancer. Recently, based on data showing improvement in progression-free survival, the use of palbociclib (Ibrance; Pfizer, Inc.) in combination with endocrine agents was approved to treat patients with hormone receptor-positive advanced disease. Importantly, 2 other CDK4/6 inhibitors, abemaciclib (LY2835219; Lilly) and ribociclib (LEE011; Novartis), are in the late stage of clinical development. In this review, we will focus on clinical data on these 2 new drugs, highlighting their differences compared to palbociclib in terms of single-agent activity, central nervous system penetration, and common adverse events. In addition, we will present the ongoing clinical trials and discuss future directions in the field. (C) 2016 S. Karger GmbH, Freiburg C1 [Barroso-Sousa, Romualdo; Tolaney, Sara M.] Dana Farber Canc Inst, Breast Oncol Program, Dept Med Oncol, Boston, MA 02115 USA. [Barroso-Sousa, Romualdo; Shapiro, Geoffrey I.; Tolaney, Sara M.] Harvard Med Sch, Boston, MA USA. [Shapiro, Geoffrey I.; Tolaney, Sara M.] Dana Farber Canc Inst, Dept Med Oncol, Early Drug Dev Ctr, Boston, MA 02115 USA. RP Tolaney, SM (reprint author), Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave,Yawkey 1257, Boston, MA 02215 USA. EM sara_tolaney@dfci.harvard.edu FU Lilly; Novartis; Pfizer FX Sara Tolaney and Geoffrey Shapiro both have received research funding from Lilly, Novartis, and Pfizer. NR 30 TC 4 Z9 4 U1 6 U2 6 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1661-3791 EI 1661-3805 J9 BREAST CARE JI Breast Care PY 2016 VL 11 IS 3 BP 167 EP 173 DI 10.1159/000447284 PG 7 WC Oncology; Obstetrics & Gynecology SC Oncology; Obstetrics & Gynecology GA DQ4IU UT WOS:000379168300002 PM 27493615 ER PT J AU Rotstein, BH Wang, L Liu, RY Patteson, J Kwan, EE Vasdev, N Liang, SH AF Rotstein, Benjamin H. Wang, Lu Liu, Richard Y. Patteson, Jon Kwan, Eugene E. Vasdev, Neil Liang, Steven H. TI Mechanistic studies and radiofluorination of structurally diverse pharmaceuticals with spirocyclic iodonium(III) ylides SO CHEMICAL SCIENCE LA English DT Article ID ELECTRON-RICH ARENES; DIARYLIODONIUM-SALTS; OXIDATIVE FLUORINATION; ACTIVATED PRECURSORS; CONCERTED MECHANISM; EXTRUSION REACTIONS; R2I-F IODINE(III); F-18 FLUORIDE; LATE-STAGE; AB-INITIO AB Synthesis of non-activated electron-rich and sterically hindered F-18-arenes remains a major challenge due to limitations of existing radiofluorination methodologies. Herein, we report on our mechanistic investigations of spirocyclic iodonium(III) ylide precursors for arene radiofluorination, including their reactivity, selectivity, and stability with no-carrier-added [F-18] fluoride. Benchmark calculations at the G2[ECP] level indicate that pseudorotation and reductive elimination at iodine(III) can be modeled well by appropriately selected dispersion-corrected density functional methods. Modeling of the reaction pathways show that fluoride-iodonium(III) adduct intermediates are strongly activated and highly regioselective for reductive elimination of the desired [F-18]fluoroarenes (difference in barriers, Delta Delta G(double dagger) > 25 kcal mol(-1)). The advantage of spirocyclic auxiliaries is further supported by NMR spectroscopy studies, which bolster evidence for underlying decomposition processes which can be overcome for radiofluorination of iodonium(III) precursors. Using a novel adamantyl auxiliary, sterically hindered iodonium ylides have been developed to enable highly efficient radiofluorination of electron-rich arenes, including fragments of pharmaceutically relevant nitrogen-containing heterocycles and tertiary amines. Furthermore, this methodology has been applied for the syntheses of the radiopharmaceuticals 6-[F-18] fluoro-meta-tyrosine ([F-18]FMT, 11 +/- 1% isolated radiochemical yield, non-decay-corrected (RCY, n.d.c.), n = 3), and meta-[F-18] fluorobenzylguanidine ([F-18]mFBG, 14 +/- 1% isolated RCY, n.d.c., n = 3) which cannot be directly radiolabeled using conventional nucleophilic aromatic substitution with [F-18] fluoride. C1 [Rotstein, Benjamin H.; Wang, Lu; Patteson, Jon; Vasdev, Neil; Liang, Steven H.] Massachusetts Gen Hosp, Div Nucl Med & Mol Imaging, 55 Fruit St, Boston, MA 02114 USA. [Rotstein, Benjamin H.; Wang, Lu; Patteson, Jon; Vasdev, Neil; Liang, Steven H.] Massachusetts Gen Hosp, Gordon Ctr Med Imaging, 55 Fruit St, Boston, MA 02114 USA. [Rotstein, Benjamin H.; Vasdev, Neil; Liang, Steven H.] Harvard Univ, Sch Med, Dept Radiol, 55 Fruit St, Boston, MA 02114 USA. [Liu, Richard Y.; Kwan, Eugene E.] Harvard Univ, Dept Chem & Chem Biol, 12 Oxford St, Cambridge, MA 02138 USA. RP Vasdev, N; Liang, SH (reprint author), Massachusetts Gen Hosp, Div Nucl Med & Mol Imaging, 55 Fruit St, Boston, MA 02114 USA.; Vasdev, N; Liang, SH (reprint author), Massachusetts Gen Hosp, Gordon Ctr Med Imaging, 55 Fruit St, Boston, MA 02114 USA.; Vasdev, N; Liang, SH (reprint author), Harvard Univ, Sch Med, Dept Radiol, 55 Fruit St, Boston, MA 02114 USA. EM vasdev.neil@mgh.harvard.edu; liang.steven@mgh.harvard.edu OI Rotstein, Benjamin/0000-0001-9707-9357 FU NIH [NIH/NIDA K01DA038000] FX We would like to thank the staff at the radiochemistry program, Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital, MA, USA for their support with cyclotron operation, radioisotope production and radiosynthesis. We thank Dr Thomas J. Brady and Dr Thomas Lee Collier for helpful discussions. S.H.L is a recipient of an NIH career development award (NIH/NIDA K01DA038000). NR 55 TC 9 Z9 9 U1 9 U2 15 PU ROYAL SOC CHEMISTRY PI CAMBRIDGE PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND SN 2041-6520 EI 2041-6539 J9 CHEM SCI JI Chem. Sci. PY 2016 VL 7 IS 7 BP 4407 EP 4417 DI 10.1039/c6sc00197a PG 11 WC Chemistry, Multidisciplinary SC Chemistry GA DP7YL UT WOS:000378715000055 PM 27540460 ER PT J AU Okubo, Y Torrey, H Butterworth, J Zheng, H Faustman, DL AF Okubo, Yoshiaki Torrey, Heather Butterworth, John Zheng, Hui Faustman, Denise L. TI Treg activation defect in type 1 diabetes: correction with TNFR2 agonism SO CLINICAL & TRANSLATIONAL IMMUNOLOGY LA English DT Article ID REGULATORY T-CELLS; BLOOD LYMPHOCYTE SUBPOPULATIONS; AGE-RELATED-CHANGES; PERIPHERAL-BLOOD; C-PEPTIDE; CANCER PATIENTS; RECEPTOR 2; EXPRESSION; SUPPRESSION; MELLITUS AB Activated T-regulatory cells (aTregs) prevent or halt various forms of autoimmunity. We show that type 1 diabetics (T1D) have a Treg activation defect through an increase in resting Tregs (rTregs, CD4(+)CD25(+)Foxp3(+)CD45RA) and decrease in aTregs (CD4(+)CD25(+)Foxp3(+)CD45RO) (n=55 T1D, n=45 controls, P=0.01). The activation defect persists life long in T1D subjects (T1D=45, controls=45, P=0.01, P=0.04). Lower numbers of aTregs had clinical significance because they were associated with a trend for less residual C-peptide secretion from the pancreas (P=0.08), and poorer HbA1C control (P=0.03). In humans, the tumor necrosis factor receptor 2 (TNFR2) is obligatory for Treg induction, maintenance and expansion of aTregs. TNFR2 agonism is a method for stimulating Treg conversion from resting to activated. Using two separate in vitro expansion protocols, TNFR2 agonism corrected the T1D activation defect by triggering conversion of rTregs into aTregs (n=54 T1D, P<0.001). TNFR2 agonism was superior to standard protocols and TNF in proliferating Tregs. In T1D, TNFR2 agonist-expanded Tregs were homogeneous and functionally potent by virtue of suppressing autologous cytotoxic T cells in a dose-dependent manner comparable to controls. Targeting the TNFR2 receptor for Treg expansion in vitro demonstrates a means to correct the activation defect in T1D. C1 [Okubo, Yoshiaki; Torrey, Heather; Butterworth, John; Faustman, Denise L.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Immunobiol, Bldg 149 13th St,Room 3602, Boston, MA USA. [Zheng, Hui] Massachusetts Gen Hosp, Dept Biostat, Boston, MA 02114 USA. RP Faustman, DL (reprint author), Harvard Med Sch, Massachusetts Gen Hosp, Dept Immunobiol, Bldg 149 13th St,Room 3602, Boston, MA USA. EM faustman@helix.mgh.harvard.edu NR 41 TC 1 Z9 1 U1 2 U2 2 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 2050-0068 J9 CLIN TRANSL IMMUNOL JI Clin. Transl. Immunol. PD JAN PY 2016 VL 5 AR e56 DI 10.1038/cti.2015.43 PG 9 WC Immunology SC Immunology GA DQ6NJ UT WOS:000379321600002 PM 26900470 ER PT S AU Kashany, ZH Ahn, S Nia, HT Tshikudi, DM Grodzinsky, A Jain, RK Nadkarni, SK AF Kashany, Zeinab Hajjarian Ahn, Shawn Nia, Hadi Tavakoli Tshikudi, Diane M. Grodzinsky, Alan Jain, Rakesh K. Nadkarni, Seemantini K. BE Tuchin, VV Larin, KV Leahy, MJ Wang, RK TI Laser speckle micro rheology for micro-mechanical mapping of biomaterials (Conference Presentation) SO DYNAMICS AND FLUCTUATIONS IN BIOMEDICAL PHOTONICS XIII SE Proceedings of SPIE LA English DT Proceedings Paper CT Conference on Dynamics and Fluctuations in Biomedical Photonics XIII CY FEB 14-15, 2016 CL San Francisco, CA SP SPIE C1 [Kashany, Zeinab Hajjarian; Nia, Hadi Tavakoli; Nadkarni, Seemantini K.] Harvard Med Sch, Boston, MA 02115 USA. [Ahn, Shawn] Univ Illinois, Champaign, IL USA. [Tshikudi, Diane M.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Grodzinsky, Alan] MIT, Cambridge, MA 02139 USA. RP Kashany, ZH (reprint author), Harvard Med Sch, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPIE-INT SOC OPTICAL ENGINEERING PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA SN 0277-786X BN 978-1-62841-941-2 J9 PROC SPIE PY 2016 VL 9707 AR 970702 DI 10.1117/12.2213761 PG 1 WC Engineering, Biomedical; Optics; Radiology, Nuclear Medicine & Medical Imaging SC Engineering; Optics; Radiology, Nuclear Medicine & Medical Imaging GA BF0JQ UT WOS:000378916800002 ER PT J AU Dorton, BJ Vitonis, AF Feldman, S AF Dorton, Benjamin J. Vitonis, Allison F. Feldman, Sarah TI Identification of potential missed opportunities for human papillomavirus (HPV) vaccination in women referred to an academic colposcopy clinic for evaluation of abnormal cervical cytology SO HUMAN VACCINES & IMMUNOTHERAPEUTICS LA English DT Article DE abnormal cervical cytology; cervical cancer; colposcopy; human papillomavirus vaccination; provider counseling ID 2006 CONSENSUS GUIDELINES; CANCER SCREENING-TESTS; UNITED-STATES; INTRAEPITHELIAL NEOPLASIA; MANAGEMENT; COVERAGE; ADOLESCENTS; PRECURSORS; DISEASES AB Objective: To identify possible predictors of missed opportunities for human papillomavirus (HPV) counseling and vaccination prior to presentation at an academic colposcopy clinic. Materials and Methods: We examined the characteristics of 638 vaccinated and 1,024 unvaccinated age-eligible patients using data from a patient registry of women presenting for colposcopic evaluation between 2/26/2007 and 3/10/2014 who were aged 26 or less at presentation. Demographics, smoking history, pregnancy history, sexually transmitted infections (STIs), sexual history, contraception use, immunosuppression, and medical problems were compared between HPV vaccinated and unvaccinated women. Multivariable logistic regression models included age, race, language, marital status, insurance type, lifetime number of sexual partners, other medical illnesses, number of pregnancies, contraception use, history of STIs, and smoking history to determine predictors of HPV vaccination. Results: In multivariable analysis, race, marital status, and language were not significantly associated with HPV vaccination. Women with fewer pregnancies were more likely to be vaccinated (p-trend <0.0001). Vaccinated women were more likely to have other medical illnesses (OR=1.44, 95% CI=1.13-1.83) and be aware of their HPV status (OR=1.75, 95% CI= 1.40-2.18). Conclusions: In this study, greater number of pregnancies was associated with lower vaccination rates as compared to women who had never been pregnant. Reproductive health visits, such as postpartum and family planning visits, represent an ideal opportunity to educate women about HPV and the importance of vaccination, and should be an area of focus to improve current HPV vaccination rates. C1 [Dorton, Benjamin J.; Vitonis, Allison F.; Feldman, Sarah] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. [Feldman, Sarah] Dana Farber Canc Inst, Boston, MA 02115 USA. RP Dorton, BJ (reprint author), Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. EM bdorts9@gmail.com NR 26 TC 0 Z9 0 U1 0 U2 0 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 2164-5515 EI 2164-554X J9 HUM VACC IMMUNOTHER JI Human Vaccines Immunother. PY 2016 VL 12 IS 6 SI SI BP 1639 EP 1645 DI 10.1080/21645515.2015.1110658 PG 7 WC Biotechnology & Applied Microbiology; Immunology SC Biotechnology & Applied Microbiology; Immunology GA DQ5QH UT WOS:000379259400052 PM 26839185 ER PT J AU Spencer, AE Faraone, SV Bogucki, OE Pope, AL Uchida, M Milad, MR Spencer, TJ Woodworth, KY Biederman, J AF Spencer, Andrea E. Faraone, Stephen V. Bogucki, Olivia E. Pope, Amanda L. Uchida, Mai Milad, Mohammed R. Spencer, Thomas J. Woodworth, K. Yvonne Biederman, Joseph TI Examinmg the Association Between Posttraumatic Stress Disorder and Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta Analysis SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article ID DEFICIT HYPERACTIVITY DISORDER; COMORBIDITY SURVEY REPLICATION; SEXUALLY-ABUSED-CHILDREN; PSYCHIATRIC COMORBIDITY; DOPAMINE TRANSPORTER; PRESCHOOL-CHILDREN; NICOTINE EXPOSURE; FEAR EXTINCTION; ADULT ADHD; PTSD AB Objective: To conduct a systematic review and meta-analysis examining the relationship between attention-deficit/hyperactivity disorder (ADHD) and posttraumatic stress disorder (PTSD). Data Sources: We reviewed literature through PubMed and PsycINFO without a specified date range, utilizing the search (posttraumatic stress disorder OR PTSD) AND (ADHO OR attention deficit hyperactivity disorder OR ADD OR attention deficit disorder OR hyperkinetic syndrome OR minimal brain dysfunction). References from relevant articles were reviewed. Study Selection: We identified 402 articles; 28 met criteria. We included original human research in English that operationalized diagnoses of ADHD and PTSD, evaluated the relationship between the disorders, and included controls. We excluded articles that failed to differentiate ADHD or PTSD from nonspecific or subsyndromal deficits or failed to compare their relationship. Data Extraction: We extracted sample size, age, diagnostic methods, design, referral status, control type, and number of subjects with and without ADHD and PTSD alone and combined. We computed meta-analyses for 22 studies examining ADHD in PTSD and PTSD in ADHD using a random effects model and meta-analytic regression. We assessed for heterogeneity and publication bias and adjusted for intrastudy clustering. Results:The relative risk (RR) for PTSD in ADHD was 2.9 (P <. 0005); in samples using healthy controls, the RR was 3.7 (P .001); and in samples using traumatized controls, the RR was 1.6 (P = .003). The RR for ADHD in PTSD was 1.7 (P < .0005); in samples using traumatized controls, the RR was 2.1 (P < .0005). The association was not significant in samples using psychiatric controls. Conclusions: Results indicate a bidirectional association between ADHD and PTSD, suggesting clinical implications and highlighting the need for neurobiological research that examines the mechanisms underlying this connection. C1 [Spencer, Andrea E.; Bogucki, Olivia E.; Pope, Amanda L.; Uchida, Mai; Spencer, Thomas J.; Woodworth, K. Yvonne; Biederman, Joseph] Massachusetts Gen Hosp, Clin & Res Programs Pediat Psychopharmacol & Adul, 55 Fruit St,Warren 625, Boston, MA 02114 USA. [Faraone, Stephen V.] SUNY Upstate Med Univ, Dept Psychiat, Syracuse, NY 13210 USA. [Faraone, Stephen V.] SUNY Upstate Med Univ, Dept Neurosci & Physiol, Syracuse, NY 13210 USA. [Spencer, Andrea E.; Milad, Mohammed R.; Spencer, Thomas J.; Biederman, Joseph] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Spencer, Andrea E.; Milad, Mohammed R.; Spencer, Thomas J.; Biederman, Joseph] Harvard Med Sch, Boston, MA USA. RP Spencer, AE (reprint author), Massachusetts Gen Hosp, Clin & Res Programs Pediat Psychopharmacol & Adul, 55 Fruit St,Warren 625, Boston, MA 02114 USA. EM aespencer@partners.org FU Pediatric Psychopharmacology Council Fund of Massachusetts General Hospital, Boston FX Supported in part by the Pediatric Psychopharmacology Council Fund of Massachusetts General Hospital, Boston. NR 60 TC 2 Z9 2 U1 3 U2 4 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 752870, MEMPHIS, TN 38175-2870 USA SN 0160-6689 EI 1555-2101 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PD JAN PY 2016 VL 77 IS 1 BP 72 EP 83 DI 10.4088/JCP.14r09479 PG 12 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA DQ5MU UT WOS:000379250300015 PM 26114394 ER PT J AU Nierenberg, AA McElroy, SL Friedman, ES Ketter, TA Shelton, RC Deckersbach, T McInnis, MG Bowden, CL Tohen, M Kocsis, JH Calabrese, JR Kinrys, G Bobo, WV Singh, V Kamali, M Kemp, D Brody, B Reilly-Harrington, NA Sylvia, LG Shesler, LW Bernstein, EE Schoenfeld, D Rabideau, DJ Leon, AC Faraone, S Thase, ME AF Nierenberg, Andrew A. McElroy, Susan L. Friedman, Edward S. Ketter, Terence A. Shelton, Richard C. Deckersbach, Thilo McInnis, Melvin G. Bowden, Charles L. Tohen, Mauricio Kocsis, James H. Calabrese, Joseph R. Kinrys, Gustavo Bobo, William V. Singh, Vivek Kamali, Masoud Kemp, David Brody, Benjamin Reilly-Harrington, Noreen A. Sylvia, Louisa G. Shesler, Leah W. Bernstein, Emily E. Schoenfeld, David Rabideau, Dustin J. Leon, Andrew C. Faraone, Stephen Thase, Michael E. TI Bipolar CHOICE (Clinical Health Outcomes Initiative in Comparative Effectiveness): A Pragmatic 6-Month Trial of Lithium Versus Quetiapine for Bipolar Disorder SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article ID INTERNATIONAL NEUROPSYCHIATRIC INTERVIEW; PLACEBO-CONTROLLED TRIAL; I-DISORDER; UNITED-STATES; DOUBLE-BLIND; SYMPTOMS SCALE; MISSING DATA; DSM-IV; DEPRESSION; MAINTENANCE AB Background: Bipolar disorder is among the 10 most disabling medical conditions worldwide While lithium has been used extensively for bipolar disorder since the 1970s, second -generation antipsychotics (SGAs) have supplanted lithium since 1998. To date, no randomized comparative-effectiveness study has compared lithium and any SGA. Method: Within the duration of the study (September 2010 -September 2013), participants with bipolar I or H disorder (D5M-IV-Trt) were randomized for 6 months to receive lithium (n =240) or quetiapine In =242). Lithium and quetiapine were combined with other medications for bipolar disorder consistent with typical clinical practice (adjunctive personalized treatment [APT], excluding any SGA for the lithium+ APT group and excluding lithium or any other SGA for the quetiapine+ APT group). Coprimary outcome measures included Clinical Global Impressions-Efficacy Index (CGI-EI) and necessary clinical adjustments, which measured number of changes in adjunctive personalized treatment. Secondary measures included a full range of symptoms, cardiovascular risk, functioning, quality of life, suicidal ideation and behavior, and adverse events. Results: Participants improved across all measures, and over 20% had a sustained response. Primary (CGI-El, P=.59; necessary clinical adjustments, P=.15) and secondary outcome changes were not statistically significantly different between the 2 groups. For participants with greater manic/hypomanic symptoms, CGI-EI changes were significantly more favorable with quetiapine+ APT (P-.02). Among those with anxiety, the lithium + APT group had fewer necessary clinical adjustments per month (P=.02). Lithium was better tolerated than quetiapine in terms of the burden of side effects frequency (P=.05), intensity (P =.01), and impairment (P=.01). Conclusions: Despite adequate power to detect clinically meaningful differences, we found outcomes with lithium +APT and quetiapine+ APT were not significantly different across 6 months of treatment for bipolar disorder. C1 [Nierenberg, Andrew A.; Deckersbach, Thilo; Kinrys, Gustavo; Reilly-Harrington, Noreen A.; Sylvia, Louisa G.; Shesler, Leah W.; Bernstein, Emily E.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. [Nierenberg, Andrew A.; Deckersbach, Thilo; Kinrys, Gustavo; Reilly-Harrington, Noreen A.; Sylvia, Louisa G.] Harvard Med Sch, Boston, MA USA. [McElroy, Susan L.] Univ Cincinnati, Coll Med, Dept Psychiat & Behav Neurosci, Cincinnati, OH USA. [McElroy, Susan L.] Lindner Ctr HOPE, Mason, OH USA. [Friedman, Edward S.] Univ Pittsburgh, Dept Psychiat, Med Ctr, Pittsburgh, PA USA. [Ketter, Terence A.] Stanford Univ, Dept Psychiat & Behav Sci, Sch Med, Stanford, CA 94305 USA. [Shelton, Richard C.] Univ Alabama Birmingham, Dept Psychiat, Birmingham, AL USA. [McInnis, Melvin G.; Kamali, Masoud] Univ Michigan, Dept Psychiat, Ann Arbor, MI 48109 USA. [Bowden, Charles L.; Singh, Vivek] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA. [Tohen, Mauricio] Univ New Mexico, Hlth Sci Ctr, Dept Psychiat, Albuquerque, NM 87131 USA. [Kocsis, James H.; Brody, Benjamin; Leon, Andrew C.] Weill Cornell Med Coll, Dept Psychiat, New York, NY USA. [Calabrese, Joseph R.; Kemp, David] Case Western Reserve Univ, Dept Psychiat, Cleveland, OH 44106 USA. [Bobo, William V.] Mayo Clin, Dept Psychiat & Psychol, Rochester, MN USA. [Schoenfeld, David; Rabideau, Dustin J.] Massachusetts Gen Hosp, Dept Biostat, Boston, MA 02114 USA. [Faraone, Stephen] SUNY Upstate Med Univ, Dept Psychiat, Syracuse, NY 13210 USA. [Faraone, Stephen] SUNY Upstate Med Univ, Dept Neurosci & Physiol, Syracuse, NY 13210 USA. [Thase, Michael E.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. RP Nierenberg, AA (reprint author), Massachusetts Gen Hosp, 50 Staniford St,Ste 580, Boston, MA 02114 USA. EM anierenberg@mgh.harvard.edu FU Agency for Healthcare Research and Quality (AHRQ) [1R01HS019371] FX Agency for Healthcare Research and Quality (AHRQ): 1R01HS019371. NR 41 TC 7 Z9 7 U1 2 U2 3 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 752870, MEMPHIS, TN 38175-2870 USA SN 0160-6689 EI 1555-2101 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PD JAN PY 2016 VL 77 IS 1 BP 90 EP 99 DI 10.4088/JCP.14m09349 PG 10 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA DQ5MU UT WOS:000379250300017 PM 26845264 ER PT J AU Deckersbach, T Nierenberg, AA McInnis, MG Salcedo, S Bernstein, EE Kemp, DE Shelton, RC McElroy, SL Sylvia, LG Kocsis, JH Bobo, WV Friedman, ES Singh, V Tohen, M Bowden, CL Ketter, TA Calabrese, JR Thase, ME Reilly-Harrington, NA Rabideau, DJ Kinrys, G Kamali, M AF Deckersbach, Thilo Nierenberg, Andrew A. McInnis, Melvin G. Salcedo, Stephanie Bernstein, Emily E. Kemp, David E. Shelton, Richard C. McElroy, Susan L. Sylvia, Louisa G. Kocsis, James H. Bobo, William V. Friedman, Edward S. Singh, Vivek Tohen, Mauricio Bowden, Charles L. Ketter, Terence A. Calabrese, Joseph R. Thase, Michael E. Reilly-Harrington, Noreen A. Rabideau, Dustin J. Kinrys, Gustavo Kamali, Masoud TI Baseline Disabiltiy and Poor Functioning in Bipolar Disorder Predict Worse Outcomes: Results From the Bipolar CHOICE Study SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article ID QUALITY-OF-LIFE; INTERNATIONAL NEUROPSYCHIATRIC INTERVIEW; FOLLOW-UP; DEPRESSIVE SYMPTOMS; DSM-IV; IMPACT; POPULATION; IMPAIRMENT; RECOVERY; HEALTH AB Objective:To examine the effects of treatment on functioning impairments and quality of life and assess baseline functioning and employment status as predictors of treatment response in symptomatic individuals from the Bipolar Clinical Health Outcomes Initiative in Comparative Effectiveness (Bipolar CHOICE) study. Method: Bipolar CHOICE was an 11-site, 6-month randomized effectiveness study comparing lithium to quetiapine, each with adjunctive personalized treatments (APTs). We examined post hoc (1) the effects of treatment on functioning, (2) how changes in functioning differed between treatment responders and nonresponders, and (3) whether functioning and employment status mediated treatment response in 482 participants with 125M-AfTR bipolar I or II disorder from September 2010 to September 2013. Results: Treatment was associated with significant improvements in functioning and quality of life, regardless of treatment group (P values <.0001). Responders showed greater improvements in quality of life (Quality of Life Enjoyment and Satisfaction Questionnaire P values <.05) and functioning (Longitudinal Interval Follow-up Evaluation -Range of Impaired Functioning Tool P values <.05) than nonresponders. Unemployed or disabled participants at baseline had significantly greater illness severity at baseline than employed participants (P values <.05). Over the study duration, employed participants reported greater improvements in physical health and quality of life in leisure activities than both unemployed and disabled participants (P values <.05). Individuals who saw greater improvement in functioning and quality of life tended to show greater improvements in depressive and anxiety symptoms (P values.0001), as well as overall illness severity (P values <.001). Early (8 weeks) and very early (4 weeks) clinical changes in mood symptoms predicted changes in functioning and quality of life at 6 months (P values <.001. Conclusions: Prior disability status was associated with a worse treatment response and prospective illness course. Results implicate functioning and employment status as important markers of illness severity and likelihood of recovery in bipolar disorder, suggesting that interventions that target functional impairment may improve outcomes. C1 [Deckersbach, Thilo; Nierenberg, Andrew A.; Sylvia, Louisa G.; Reilly-Harrington, Noreen A.; Kinrys, Gustavo] Massachusetts Gen Hosp, Dept Psychiat, 50 Staniford St,Ste 580, Boston, MA 02114 USA. [Deckersbach, Thilo; Nierenberg, Andrew A.; Sylvia, Louisa G.; Reilly-Harrington, Noreen A.] Harvard Med Sch, Boston, MA USA. [McInnis, Melvin G.; Kamali, Masoud] Univ Michigan, Dept Psychiat, Ann Arbor, MI 48109 USA. [Salcedo, Stephanie] Univ N Carolina, Dept Psychol & Neurosci, Chapel Hill, NC USA. [Bernstein, Emily E.] Harvard Univ, Dept Psychol, 33 Kirkland St, Cambridge, MA 02138 USA. [Kemp, David E.; Calabrese, Joseph R.] Case Western Reserve Univ, Dept Psychiat, Cleveland, OH 44106 USA. [Shelton, Richard C.] Univ Alabama Birmingham, Dept Psychiat, Birmingham, AL USA. [McElroy, Susan L.] Univ Cincinnati, Coll Med, Dept Psychiat & Behav Neurosci, Cincinnati, OH USA. [McElroy, Susan L.] Lindner Ctr HOPE, Mason, OH USA. [Kocsis, James H.] Weill Cornell Med Coll, Dept Psychiat, New York, NY USA. [Bobo, William V.] Mayo Clin, Dept Psychiat & Psychol, Rochester, MN USA. [Friedman, Edward S.] Univ Pittsburgh, Med Ctr, Dept Psychiat, Pittsburgh, PA USA. [Singh, Vivek; Bowden, Charles L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA. [Tohen, Mauricio] Univ New Mexico, Hlth Sci Ctr, Dept Psychiat, Albuquerque, NM 87131 USA. [Ketter, Terence A.] Stanford Univ, Dept Psychiat & Behav Sci, Sch Med, Stanford, CA 94305 USA. [Thase, Michael E.] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA. [Rabideau, Dustin J.] Massachusetts Gen Hosp, Dept Biostat, Boston, MA 02114 USA. RP Deckersbach, T (reprint author), Massachusetts Gen Hosp, Dept Psychiat, 50 Staniford St,Ste 580, Boston, MA 02114 USA. EM tdeckersbach@partners.org FU Agency for Healthcare Research and Quality (AHRQ) [1R01HS019371-01] FX This study was funded by the Agency for Healthcare Research and Quality (AHRQ), 1R01HS019371-01. NR 46 TC 2 Z9 2 U1 2 U2 2 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 752870, MEMPHIS, TN 38175-2870 USA SN 0160-6689 EI 1555-2101 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PD JAN PY 2016 VL 77 IS 1 BP 100 EP + DI 10.4088/JCP74m09210 PG 17 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA DQ5MU UT WOS:000379250300018 PM 26845265 ER PT J AU Dimitrov, DH Lee, S Yantis, J Honaker, C Braida, N Walss-Bass, C AF Dimitrov, Dimitre H. Lee, Shuko Yantis, Jesse Honaker, Craig Braida, Nicole Walss-Bass, Consuelo TI ElevatSerumed Levels of High-Sensitivity C-Reactive Proteins Are Associated With Severe Delusional Symptoms in a Subgroup of Patients With Schizophrenia SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Letter ID PSYCHOPATHOLOGY C1 [Dimitrov, Dimitre H.; Lee, Shuko; Yantis, Jesse; Honaker, Craig; Braida, Nicole] South Texas Vet Hlth Care Syst, San Antonio, TX 78228 USA. [Dimitrov, Dimitre H.; Braida, Nicole; Walss-Bass, Consuelo] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA. [Walss-Bass, Consuelo] Univ Texas Hlth Sci Ctr Houston, Dept Psychiat & Behav Sci, Houston, TX 77030 USA. RP Dimitrov, DH (reprint author), South Texas Vet Hlth Care Syst, San Antonio, TX 78228 USA.; Dimitrov, DH (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA. EM dimitre.dimitrov@va.gov NR 7 TC 3 Z9 3 U1 1 U2 1 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 752870, MEMPHIS, TN 38175-2870 USA SN 0160-6689 EI 1555-2101 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PD JAN PY 2016 VL 77 IS 1 BP 131 EP U175 DI 10.4088/JCP.15109833 PG 2 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA DQ5MU UT WOS:000379250300023 PM 26845270 ER PT J AU Papakostas, GI AF Papakostas, George I. TI Identifying Patients With Depression Who Require a Change in Treatment and Implementing That Change SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Article ID REUPTAKE INHIBITOR; RESISTANT DEPRESSION; SEXUAL DYSFUNCTION; MAJOR DEPRESSION; CLINICAL-TRIAL; DISORDER; ANTIDEPRESSANT; SYMPTOMS; VALIDITY; SCALE AB Creating an effective treatment regimen for patients diagnosed with major depressive disorder (MDD) can be a challenge for clinicians. With each treatment trial, only 20% to 30% of patients achieve remission, and many of those who do reach remission experience residual symptoms. Patients with treatment-resistant depression or with residual symptoms are candidates for a change in treatment. Other patients requiring treatment changes are those who experience intolerable adverse effects and those who experience an illness recurrence. Because early detection can lead to improved outcomes, clinicians must be vigilant about assessing patients to identify when one or more of these situations occur. Clinicians must also communicate effectively with their patients to ensure that they understand the treatment strategies, goals, and potential adverse effects; have realistic expectations of treatment; and express their treatment preferences. Timely and appropriate treatment adjustment is necessary to help patients with MDD achieve recovery. C1 [Papakostas, George I.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Papakostas, George I.] Harvard Med Sch, Boston, MA USA. RP Papakostas, GI (reprint author), 15 Parkman St WACC 812, Boston, MA 02114 USA. EM gpapakostas@partners.org FU AstraZeneca; Bristol-Myers Squibb; Forest; National Institute of Mental Health; Neuralstem; Pamlab; Pfizer; Ridge Diagnostics; Sunovion; Tal Medical; Theracos FX Dr Papakostas has served as a consultant for Abbott, AstraZeneca, Avanir, Axsome,* Brainsway, Bristol-Myers Squibb, Cephalon, Dey, Eli Lilly, Genentech,* GlaxoSmithKline, Evotec, Lundbeck, Inflabloc, Janssen,* Jazz, Johnson & Johnson,* Methylation Sciences, Novartis, One Carbon Therapeutics,* Osmotica,* Otsuka, Pamlab, Pfizer, Pierre Fabre, Ridge Diagnostics (formerly known as Precision Human Biolaboratories), Shire, Sunovion, Takeda, Theracos, and Wyeth; has received honoraria from Abbott, AstraZeneca, Avanir, Bristol-Myers Squibb, Brainsway, Cephalon, Dey, Eli Lilly, Evotec, Forest, GlaxoSmithKline, Inflabloc, Jazz, Lundbeck, Medichem, Meiji Seika, Novartis, Otsuka, Pamlab, Pfizer, Pierre Fabre, Ridge Diagnostics, Shire, Sunovion, Takeda, Theracos, Titan, and Wyeth; and has received grant support* from AstraZeneca, Bristol-Myers Squibb, Forest, the National Institute of Mental Health, Neuralstem, Pamlab, Pfizer, Ridge Diagnostics, Sunovion, Tal Medical, and Theracos. NR 54 TC 1 Z9 1 U1 2 U2 2 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 752870, MEMPHIS, TN 38175-2870 USA SN 0160-6689 EI 1555-2101 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PY 2016 VL 77 SU 1 DI 10.4088/JCP.14077su1c.03 PG 6 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA DQ5ND UT WOS:000379251200003 ER PT J AU Vodicka, P Chase, K Iuliano, M Valentine, DT Sapp, E Lu, BX Kegel-Gleason, KB Sena-Esteves, M Aronin, N DiFiglia, M AF Vodicka, Petr Chase, Kathryn Iuliano, Maria Valentine, Dana T. Sapp, Ellen Lu, Boxun Kegel-Gleason, Kimberly B. Sena-Esteves, Miguel Aronin, Neil DiFiglia, Marian TI Effects of Exogenous NUB1 Expression in the Striatum of HDQ175/Q7 Mice SO JOURNAL OF HUNTINGTONS DISEASE LA English DT Article DE Adeno-associated virus; aggregates; huntingtin; Huntington's disease; neurodegeneration; NUB1; NUB1L; P62; striatum ID DISEASE-MODEL MICE; LEWY BODY DISEASE; HUNTINGTONS-DISEASE; PROTEASOMAL DEGRADATION; PHOSPHODIESTERASE 10A; ALPHA-SYNUCLEIN; MESSENGER-RNA; PROTEIN; BRAIN; INCLUSIONS AB Background: Reducing mutant huntingtin (mHTT) in neurons may be a therapy for Huntington's disease (HD). Elevating NUB1 protein reduced mHTT levels in cell and fly models of HD through a proteasome dependent mechanism. Objective: To examine the effects of augmenting NUB1 in HD mouse striatum on mHTT levels. Methods: Striata of HDQ175/Q7 mice were injected at 3 months of age with recombinant AAV2/9 coding for NUB1 or GFP under the control of the neuron specific human synapsin 1 promoter and examined 6 months post-injection for levels of huntingtin, the striatal markers DARPP32 and PDE10A, the astrocyte marker GFAP, and the autophagy and mHTT aggregate marker P62 using immunolabeling of brain sections and Western blot assay of striatal subcellular fractions. Results: By Western blot human HD brain had only one of the two variants of NUB1 present in human control brain. In striatum of WT and HD mice NUB1 was localized in medium size neurons and enriched in the nucleus of large neurons. In the striatum of NUB1 injected HD mice, there was widespread neuronal distribution of exogenous NUB1 labeling and protein levels were similar to 2.5-fold endogenous levels. DARPP32 and GFAP distribution and levels were unchanged but PDE10A levels were lower in crude homogenates and P62 was increased in nuclear enriched P1 fractions. Elevating NUB1 did not change levels of full-length mHTT or the number and size of mHTT (S830) positive nuclear inclusions. Conclusion: Findings suggest that increasing NUB1 protein in striatal neurons of HDQ175/Q7 mice in vivo may be relatively safe but is ineffective in reducing mHTT. Increased NUB1 expression in HD striatum alters PDE10A and P62 which are known to be influenced by mHTT. C1 [Vodicka, Petr; Iuliano, Maria; Valentine, Dana T.; Sapp, Ellen; Lu, Boxun; Kegel-Gleason, Kimberly B.; DiFiglia, Marian] Massachusetts Gen Hosp, Dept Neurol, Charlestown, MA USA. [Vodicka, Petr; Iuliano, Maria; Valentine, Dana T.; Sapp, Ellen; Lu, Boxun; Kegel-Gleason, Kimberly B.; DiFiglia, Marian] Harvard Med Sch, Charlestown, MA USA. [Chase, Kathryn; Aronin, Neil] Univ Massachusetts, Sch Med, Dept Med, Worcester, MA USA. [Chase, Kathryn; Aronin, Neil] Univ Massachusetts, Sch Med, RNA Therapeut Inst, Worcester, MA USA. [Lu, Boxun] Fudan Univ, Sch Life Sci, State Key Lab Med Neurobiol, Shanghai, Peoples R China. [Sena-Esteves, Miguel] Univ Massachusetts, Sch Med, Dept Neurol, Gene Therapy Ctr, Worcester, MA USA. RP DiFiglia, M (reprint author), Massachusetts Gen Hosp, Dept Neurol, MassGen Inst Neurodegenerat MIND, 114 16th St,Room 2002, Charlestown, MA 02129 USA. EM difiglia@helix.mgh.harvard.edu RI Vodicka, Petr/C-3845-2009 OI Vodicka, Petr/0000-0002-6605-9158 NR 46 TC 1 Z9 1 U1 1 U2 3 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1879-6397 EI 1879-6400 J9 J HUNTINGTONS DIS JI J. Huntingtons Dis. PY 2016 VL 5 IS 2 BP 163 EP 174 DI 10.3233/JHD-160195 PG 12 WC Neurosciences SC Neurosciences & Neurology GA DQ2MW UT WOS:000379037400003 PM 27314618 ER PT J AU Demers, M Wong, SL Martinod, K Gallant, M Cabral, JE Wang, YM Wagner, DD AF Demers, Melanie Wong, Siu Ling Martinod, Kimberly Gallant, Maureen Cabral, Jessica E. Wang, Yanming Wagner, Denisa D. TI Priming of neutrophils toward NETosis promotes tumor growth SO ONCOIMMUNOLOGY LA English DT Article DE Cancer; G-CSF; neutrophils; NETs; tumor growth ID EXTRACELLULAR TRAP FORMATION; CANCER-ASSOCIATED THROMBOSIS; COLONY-STIMULATING FACTOR; INNATE IMMUNITY; NET FORMATION; DNA TRAPS; MYELOPEROXIDASE; PROGRESSION; CELLS; PAD4 AB Neutrophils play a major role in cancer biology and both pro- and antitumoral functions of tumor-infiltrating neutrophils have been described. We have shown that tumors, by releasing G-CSF into the bloodstream, prime circulating neutrophils to form neutrophil extracellular traps (NETs) and we have detected the presence of NETs within the tumor microenvironment. Here, we report, using PAD4-deficient mice with a defect in neutrophil chromatin decondensation and NET formation, that the priming of neutrophils toward NETosis favors tumor growth. Interestingly, in a tumor model that does not release G-CSF and in which neutrophils are not primed for NETosis, PAD4-deficiency did not reduce tumor growth. However, supplying exogenous G-CSF to the wild-type (WT) host promoted intratumoral NETosis and tumor growth. Taken together, our results suggest that the priming of neutrophils for NETosis by the tumor or its environment leads to the accumulation of intratumoral NETs and a growth advantage to the tumor. Our work unveiled a pro-tumoral role for NETs which strengthens their potential as a new target in the fight against cancer. C1 [Demers, Melanie; Wong, Siu Ling; Martinod, Kimberly; Gallant, Maureen; Cabral, Jessica E.; Wagner, Denisa D.] Boston Childrens Hosp, Program Cellular & Mol Med, Boston, MA 02115 USA. [Demers, Melanie; Wong, Siu Ling; Martinod, Kimberly; Wagner, Denisa D.] Harvard Med Sch, Dept Pediat, Boston, MA 02115 USA. [Wang, Yanming] Penn State Univ, Dept Biochem & Mol Biol, Ctr Eukaryot Gene Regulat, University Pk, PA 16802 USA. [Wagner, Denisa D.] Boston Childrens Hosp, Div Hematol Oncol, Boston, MA 02115 USA. RP Wagner, DD (reprint author), Boston Childrens Hosp, Program Cellular & Mol Med, Boston, MA 02115 USA.; Wagner, DD (reprint author), Harvard Med Sch, Dept Pediat, Boston, MA 02115 USA.; Wagner, DD (reprint author), Boston Childrens Hosp, Div Hematol Oncol, Boston, MA 02115 USA. EM denisa.wagner@childrens.harvard.edu OI Martinod, Kimberly/0000-0002-1026-6107 FU National Heart, Lung, and Blood Institute of the National Institutes of Health [R01HL102101] FX This work was supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health grant R01HL102101 (to D.D.W.). NR 38 TC 2 Z9 2 U1 5 U2 6 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 2162-402X J9 ONCOIMMUNOLOGY JI OncoImmunology PY 2016 VL 5 IS 5 AR e1134073 DI 10.1080/2162402X.2015.1134073 PG 9 WC Oncology; Immunology SC Oncology; Immunology GA DQ4GN UT WOS:000379162200044 PM 27467952 ER PT J AU Johnson, DB Lovly, CM Sullivan, RJ Carvajal, RD Sosman, JA AF Johnson, Douglas B. Lovly, Christine M. Sullivan, Ryan J. Carvajal, Richard D. Sosman, Jeffrey A. TI Melanoma driver mutations and immune therapy SO ONCOIMMUNOLOGY LA English DT Editorial Material ID NRAS MUTATIONS; ANTIBODY; CANCER AB Melanoma harbors recurrent oncogenic driver mutations in BRAF and NRAS, but these mutations' impact on immunotherapy outcomes is unclear. We assessed 229 patients treated with immunotherapy, and found that clinical outcomes were largely superior in those with NRAS mutations. Herein, we discuss our findings and their implications for melanoma therapeutics. C1 [Johnson, Douglas B.; Lovly, Christine M.; Sosman, Jeffrey A.] Vanderbilt Univ, Med Ctr, Nashville, TN 37235 USA. [Johnson, Douglas B.; Lovly, Christine M.; Sosman, Jeffrey A.] Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA. [Sullivan, Ryan J.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Carvajal, Richard D.] Columbia Univ, Med Ctr, New York, NY USA. RP Johnson, DB (reprint author), Vanderbilt Univ, Med Ctr, Nashville, TN 37235 USA.; Johnson, DB (reprint author), Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA. EM douglas.b.johnson@vanderbilt.edu NR 10 TC 0 Z9 0 U1 0 U2 0 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 2162-402X J9 ONCOIMMUNOLOGY JI OncoImmunology PY 2016 VL 5 IS 5 AR e1051299 DI 10.1080/2162402X.2015.1051299 PG 2 WC Oncology; Immunology SC Oncology; Immunology GA DQ4GN UT WOS:000379162200001 PM 27467925 ER PT J AU Mikucki, ME Skitzki, JJ Frelinger, JG Odunsi, K Gajewski, TF Luster, AD Evans, SS AF Mikucki, Maryann E. Skitzki, Joseph J. Frelinger, John G. Odunsi, Kunle Gajewski, Thomas F. Luster, Andrew D. Evans, Sharon S. TI Unlocking tumor vascular barriers with CXCR3: Implications for cancer immunotherapy SO ONCOIMMUNOLOGY LA English DT Editorial Material DE Adoptive T cell transfer; cancer immunotherapy; chemokine receptor; CXCR3; T cell trafficking; tumor vessels AB Promising cancer immunotherapeutics depend on mobilization of cytotoxic T cells across tumor vascular barriers through mechanisms that are poorly understood. Recently, we discovered that the CXCR3 chemokine receptor uniquely functions as the master-regulator of cytotoxic CD8(+) T cell extravasation and tumor control despite the multiplicity of chemokines available in the tumor landscape. C1 [Mikucki, Maryann E.; Skitzki, Joseph J.; Evans, Sharon S.] Roswell Pk Canc Inst, Dept Immunol, Buffalo, NY 14263 USA. [Skitzki, Joseph J.] Roswell Pk Canc Inst, Dept Surg Oncol, Buffalo, NY 14263 USA. [Frelinger, John G.] Univ Rochester, Med Ctr, Dept Microbiol & Immunol, Rochester, NY 14642 USA. [Frelinger, John G.] Wilmot Canc Ctr, Rochester, NY USA. [Odunsi, Kunle] Roswell Pk Canc Inst, Ctr Immunotherapy, Buffalo, NY 14263 USA. [Odunsi, Kunle] Roswell Pk Canc Inst, Dept Gynecol Oncol, Buffalo, NY 14263 USA. [Gajewski, Thomas F.] Univ Chicago, Dept Med, 5841 S Maryland Ave, Chicago, IL 60637 USA. [Gajewski, Thomas F.] Univ Chicago, Dept Pathol, 5841 S Maryland Ave, Chicago, IL 60637 USA. [Gajewski, Thomas F.] Univ Chicago, Ctr Comprehens Canc, Chicago, IL 60637 USA. [Gajewski, Thomas F.] Univ Chicago, Comm Immunol, Chicago, IL 60637 USA. [Luster, Andrew D.] Harvard Med Sch, Massachusetts Gen Hosp, Div Rheumatol Allergy & Immunol, Ctr Immunol & Inflammatory Dis, Boston, MA USA. RP Evans, SS (reprint author), Roswell Pk Canc Inst, Dept Immunol, Buffalo, NY 14263 USA. EM sharon.evans@roswellpark.org FU NCI NIH HHS [P30 CA016056] NR 10 TC 0 Z9 0 U1 1 U2 1 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 2162-402X J9 ONCOIMMUNOLOGY JI OncoImmunology PY 2016 VL 5 IS 5 AR e1116675 DI 10.1080/2162402X.2015.1116675 PG 3 WC Oncology; Immunology SC Oncology; Immunology GA DQ4GN UT WOS:000379162200012 PM 27467928 ER PT J AU Pathania, D Im, H Kilcoyne, A Sohani, AR Fexon, L Pivovarov, M Abramson, JS Randall, TC Chabner, BA Weissleder, R Lee, H Castro, CM AF Pathania, Divya Im, Hyungsoon Kilcoyne, Aoife Sohani, Aliyah R. Fexon, Lioubov Pivovarov, Misha Abramson, Jeremy S. Randall, Thomas C. Chabner, Bruce A. Weissleder, Ralph Lee, Hakho Castro, Cesar M. TI Holographic Assessment of Lymphoma Tissue (HALT) for Global Oncology Field Applications SO THERANOSTICS LA English DT Article DE Cancer diagnostics; Smartphone testing; Point-of-care diagnostics; global oncology ID SUB-SAHARAN AFRICA; CANCER; AIDS AB Low-cost, rapid and accurate detection technologies are key requisites to cope with the growing global cancer challenges. The need is particularly pronounced in resource-limited settings where treatment opportunities are often missed due to the absence of timely diagnoses. We herein describe a Holographic Assessment of Lymphoma Tissue (HALT) system that adopts a smartphone as the basis for molecular cancer diagnostics. The system detects malignant lymphoma cells labeled with marker-specific microbeads that produce unique holographic signatures. Importantly, we optimized HALT to detect lymphomas in fine-needle aspirates from superficial lymph nodes, procedures that align with the minimally invasive biopsy needs of resource-constrained regions. We equipped the platform to directly address the practical needs of employing novel technologies for "real world" use. The HALT assay generated readouts in < 1.5 h and demonstrated good agreement with standard cytology and surgical pathology. C1 [Pathania, Divya; Im, Hyungsoon; Kilcoyne, Aoife; Fexon, Lioubov; Pivovarov, Misha; Weissleder, Ralph; Lee, Hakho; Castro, Cesar M.] Harvard Univ, Massachusetts Gen Hosp, Ctr Syst Biol, Sch Med, Boston, MA 02114 USA. [Pathania, Divya; Im, Hyungsoon; Kilcoyne, Aoife; Pivovarov, Misha; Weissleder, Ralph; Lee, Hakho] Harvard Univ, Massachusetts Gen Hosp, Dept Radiol, Sch Med, Boston, MA 02114 USA. [Sohani, Aliyah R.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Abramson, Jeremy S.] Massachusetts Gen Hosp, Ctr Lymphoma, Boston, MA 02114 USA. [Abramson, Jeremy S.; Randall, Thomas C.; Chabner, Bruce A.; Castro, Cesar M.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA. [Abramson, Jeremy S.; Chabner, Bruce A.; Castro, Cesar M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med, Boston, MA 02114 USA. [Randall, Thomas C.] Dana Farber Harvard Canc Ctr, Global Oncol Initiat, Boston, MA 02115 USA. [Randall, Thomas C.] Massachusetts Gen Hosp, Dept Obstet Gynecol & Reprod Biol, Boston, MA 02114 USA. [Weissleder, Ralph] Harvard Univ, Dept Syst Biol, Sch Med, Boston, MA 02115 USA. RP Weissleder, R; Lee, H; Castro, CM (reprint author), Massachusetts Gen Hosp, Ctr Syst Biol, 185 Cambridge St,CPZN 5206, Boston, MA 02114 USA. EM rweissleder@mgh.harvard.edu; hlee@mgh.harvard.edu; castro.cesar@mgh.harvard.edu FU US NIH Grants [R01-HL113156, R01-EB010011, R01-EB00462605A1, T32CA79443, K12CA087723-11A1, K99CA201248-01]; MGH Physician Scientist Development Award; Department of Defense Ovarian Cancer Research Program [W81XWH-14-1-0279]; Mac Erlaine Research Scholarship from the Academic Radiology Research Trust, St. Vincent's Radiology Group, Dublin, Ireland FX We especially thank the members of the MGH Interventional Radiology Division who assisted with sample collection as well as the clinical providers within the MGH Center for Lymphoma. This work was supported in part by US NIH Grants R01-HL113156 (to H.L.), R01-EB010011 (to R.W.), R01-EB00462605A1 (to R.W.), T32CA79443 (to R.W.), K12CA087723-11A1 (to C.M.C.), K99CA201248-01 (to. H.I.), MGH Physician Scientist Development Award (to C.M.C.) and Department of Defense Ovarian Cancer Research Program Award W81XWH-14-1-0279 (to H.L.). AK was supported by the Mac Erlaine Research Scholarship from the Academic Radiology Research Trust, St. Vincent's Radiology Group, Dublin, Ireland. NR 17 TC 0 Z9 0 U1 3 U2 3 PU IVYSPRING INT PUBL PI LAKE HAVEN PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA SN 1838-7640 J9 THERANOSTICS JI Theranostics PY 2016 VL 6 IS 10 BP 1603 EP 1610 DI 10.7150/thno.15534 PG 8 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA DP6HA UT WOS:000378596800011 PM 27446494 ER PT J AU Wiens, MO Kissoon, N Kumbakumba, E Singer, J Moschovis, PP Ansermino, JM Ndamira, A Kiwanuka, J Larson, CP AF Wiens, Matthew O. Kissoon, Niranjan Kumbakumba, Elias Singer, Joel Moschovis, Peter P. Ansermino, J. Mark Ndamira, Andrew Kiwanuka, Julius Larson, Charles P. TI Selecting candidate predictor variables for the modelling of post-discharge mortality from sepsis: a protocol development project SO AFRICAN HEALTH SCIENCES LA English DT Article DE Candidate predictor variables; pediatrics; prediction; post-discharge mortality; sepsis ID PROGNOSIS AB Background: Post-discharge mortality is a frequent but poorly recognized contributor to child mortality in resource limited countries. The identification of children at high risk for post-discharge mortality is a critically important first step in addressing this problem. Objectives: The objective of this project was to determine the variables most likely to be associated with post-discharge mortality which are to be included in a prediction modelling study. Methods: A two-round modified Delphi process was completed for the review of a priori selected variables and selection of new variables. Variables were evaluated on relevance according to (1) prediction (2) availability (3) cost and (4) time required for measurement. Participants included experts in a variety of relevant fields. Results: During the first round of the modified Delphi process, 23 experts evaluated 17 variables. Forty further variables were suggested and were reviewed during the second round by 12 experts. During the second round 16 additional variables were evaluated. Thirty unique variables were compiled for use in the prediction modelling study. Conclusion: A systematic approach was utilized to generate an optimal list of candidate predictor variables for the incorporation into a study on prediction of pediatric post-discharge mortality in a resource poor setting. C1 [Wiens, Matthew O.; Singer, Joel; Larson, Charles P.] Univ British Columbia, Sch Populat & Publ Hlth, Vancouver, BC, Canada. [Kissoon, Niranjan] Univ British Columbia, Dept Pediat, Vancouver, BC, Canada. [Kumbakumba, Elias; Ndamira, Andrew; Kiwanuka, Julius] Mbarara Univ Sci & Technol, Dept Pediat, Mbarara, Uganda. [Moschovis, Peter P.] Harvard Med Sch, Massachusetts Gen Hosp, Pediat Global Hlth, Boston, MA USA. [Ansermino, J. Mark] Univ British Columbia, Dept Anesthesiol, Vancouver, BC, Canada. RP Wiens, MO (reprint author), Univ British Columbia, Sch Populat & Publ Hlth, Vancouver, BC, Canada. EM mowiens@outlook.com OI Ansermino, J Mark/0000-0001-8427-2035 FU NHLBI NIH HHS [F32 HL124951] NR 9 TC 1 Z9 1 U1 1 U2 1 PU MAKERERE UNIV, FAC MED PI KAMPALA PA PO BOX 7072, KAMPALA, 00000, UGANDA SN 1680-6905 EI 1729-0503 J9 AFR HEALTH SCI JI Afr. Health Sci. PY 2016 VL 16 IS 1 BP 162 EP 169 DI 10.4314/ahs.v16i1.22 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA DP9WE UT WOS:000378847700022 PM 27358628 ER PT J AU Ring, D AF Ring, David TI The World Learns Together SO ARCHIVES OF BONE AND JOINT SURGERY-ABJS LA English DT Editorial Material C1 [Ring, David] Harvard Univ, Orthoped Surg, Boston, MA 02115 USA. RP Ring, D (reprint author), Massachusetts Gen Hosp, David Ring Hand & Upper Extrem Serv, 55 Fruit St, Boston, MA 02114 USA. EM dring31@gmail.com NR 0 TC 0 Z9 0 U1 0 U2 0 PU MASHHAD UNIV MED SCIENCES PI MASHHAD PA VICE-CHANCELLOR FOR RES CTR OFF IJBMS, DANESHGAH ST, PO BOX 9138813944 - 445, MASHHAD, 00000, IRAN SN 2345-4644 EI 2345-461X J9 ARCH BONE JT SURG-AB JI Arch. Bone Jt. Surg.-ABJS PD JAN PY 2016 VL 4 IS 1 BP 1 EP 1 PG 1 WC Orthopedics SC Orthopedics GA DP7LT UT WOS:000378681400001 PM 26894210 ER PT J AU Peters, RM Menendez, ME Mellema, JJ Ring, D Vranceanu, AM AF Peters, Rinne Marijn Menendez, Mariano Esteban Mellema, Jos Jasper Ring, David Vranceanu, Ana-Maria TI Sleep Disturbance and Upper-Extremity Disability SO ARCHIVES OF BONE AND JOINT SURGERY-ABJS LA English DT Article DE Disability; Pain interference; Sleep disturbance; Upper extremity ID HEALTH-STATUS; ITEM BANK; PAIN; OUTCOMES; ADOLESCENTS; DEPRESSION; ANXIETY; ADULTS AB Background: Although upper-extremity disability correlates with psychosocial aspects of illness the association with sleep disturbance in upper extremity disability is less certain. To evaluate whether sleep disturbance is associated with upper-extremity disability among patients with upper extremity illness, accounting for sociodemographic, condition-related, and psychosocial factors. Methods: A cohort of 111 new or follow-up patients presenting to an urban academic hospital-based hand surgeon completed a sociodemographic survey and measures of sleep disturbance (PROMIS Sleep Disturbance), disability (PROMIS Upper-Extremity Physical Function), ineffective coping strategies (PROMIS Pain Interference), and depression (PROMIS Depression). Bivariate and multivariable linear regression modeling were performed. Results: Sleep disturbance correlated with disability (r=-0.38; P<0.001) in bivariate analysis. Symptoms of depression (r=-0.44; P<0.001) and ineffective coping strategies (PROMIS Pain Interference: r=-0.71; P<0.001) also correlated with upper-extremity specific disability in bivariate analysis. Pain Interference was the only factor associated with disability in multivariable analysis. Conclusions: Sleep disturbance is not as strongly or directly associated with symptom intensity and magnitude of disability as ineffective coping strategies. Interventions to reduce pain interference (e.g. cognitive behavioral therapy) hold great potential to decrease musculoskeletal symptom intensity and magnitude of disability, and perhaps even sleep disturbance. C1 [Peters, Rinne Marijn; Menendez, Mariano Esteban; Mellema, Jos Jasper; Ring, David; Vranceanu, Ana-Maria] Yawkey Ctr, Dept Orthopaed, Boston, MA USA. [Peters, Rinne Marijn; Menendez, Mariano Esteban; Mellema, Jos Jasper; Ring, David] Massachusetts Gen Hosp, Dept Orthopaed Surg, Yawkey Ctr, Hand & Upper Extrem Serv, Boston, MA 02114 USA. [Vranceanu, Ana-Maria] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA. RP Ring, D (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Yawkey Ctr,Orthopaed Hand & Upper Extrem Serv, Suite 2100,55 Fruit St, Boston, MA 02114 USA.; Ring, D (reprint author), Massachusetts Gen Hosp, Dept Orthopaed Surg, Yawkey Ctr, Hand & Upper Extrem Serv, Boston, MA 02114 USA. EM Dring@mgh.harvard.edu NR 25 TC 1 Z9 1 U1 2 U2 2 PU MASHHAD UNIV MED SCIENCES PI MASHHAD PA VICE-CHANCELLOR FOR RES CTR OFF IJBMS, DANESHGAH ST, PO BOX 9138813944 - 445, MASHHAD, 00000, IRAN SN 2345-4644 EI 2345-461X J9 ARCH BONE JT SURG-AB JI Arch. Bone Jt. Surg.-ABJS PD JAN PY 2016 VL 4 IS 1 BP 35 EP 40 PG 6 WC Orthopedics SC Orthopedics GA DP7LT UT WOS:000378681400007 PM 26894216 ER PT J AU Beck, AK Baker, A Kelly, PJ Deane, FP Shakeshaft, A Hunt, D Forbes, E Kelly, JF AF Beck, Alison K. Baker, Amanda Kelly, Peter J. Deane, Frank P. Shakeshaft, Anthony Hunt, David Forbes, Erin Kelly, John F. TI Protocol for a systematic review of evaluation research for adults who have participated in the "SMART recovery' mutual support programme SO BMJ OPEN LA English DT Review DE Substance misuse < PSYCHIATRY; Adult psychiatry < PSYCHIATRY; STATISTICS & RESEARCH METHODS ID SUBSTANCE USE DISORDERS; ALCOHOL DEPENDENCE; INTERVENTIONS; ADDICTION; QUALITY; PEOPLE AB Introduction Self-Management and Recovery Training (SMART Recovery) offers an alternative to predominant 12-step approaches to mutual aid (eg, alcoholics anonymous). Although the principles (eg, self-efficacy) and therapeutic approaches (eg, motivational interviewing and cognitive behavioural therapy) of SMART Recovery are evidence based, further clarity regarding the direct evidence of its effectiveness as a mutual aid package is needed. Relative to methodologically rigorous reviews supporting the efficacy of 12-step approaches, to date, reviews of SMART Recovery have been descriptive. We aim to address this gap by providing a comprehensive overview of the evidence for SMART Recovery in adults with problematic alcohol, substance and/or behavioural addiction, including a commentary on outcomes assessed, potential mediators, feasibility (including economic outcomes) and a critical evaluation of the methods used. Methods and analysis Methods are informed by the Cochrane Guidelines for Systematic Reviews and the Preferred Reporting Items for Systematic Reviews and Meta-Analysis statement. 6 electronic peer-reviewed and 4 grey literature databases have been identified. Preliminary searches have been conducted for SMART Recovery literature (liberal inclusion criteria, not restricted to randomised controlled trials (RCTs), qualitative-only designs excluded). Eligible evaluation' articles will be assessed against standardised criteria and checked by an independent assessor. The searches will be re-run just before final analyses and further studies retrieved for inclusion. A narrative synthesis of the findings will be reported, structured around intervention type and content, population characteristics, and outcomes. Where possible, summary of findings' tables will be generated for each comparison. When data are available, we will calculate a risk ratio and its 95% CI (dichotomous outcomes) and/or effect size according to Cohen's formula (continuous outcomes) for the primary outcome of each trial. Ethics and dissemination No ethical issues are foreseen. Findings will be disseminated widely to clinicians and researchers via journal publication and conference presentation(s). Prospero registration number CRD42015025574. C1 [Beck, Alison K.; Baker, Amanda; Forbes, Erin] Univ Newcastle, Sch Med & Publ Hlth, Newcastle, NSW 2300, Australia. [Kelly, Peter J.; Deane, Frank P.] Univ Wollongong, Sch Psychol, Wollongong, NSW, Australia. [Shakeshaft, Anthony] Univ New S Wales, Dept NDARC, Sydney, NSW, Australia. [Hunt, David] SMART Recovery Australia, Sydney, NSW, Australia. [Kelly, John F.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Recovery Res Inst, Boston, MA USA. RP Beck, AK (reprint author), Univ Newcastle, Sch Med & Publ Hlth, Newcastle, NSW 2300, Australia. EM Alison.Beck@newcastle.edu.au OI Kelly, Peter/0000-0003-0500-1865 FU NHMRC Centre of Research Excellence for Mental Health and Substance Use FX Funding support for the conduct of this review has been provided by the NHMRC Centre of Research Excellence for Mental Health and Substance Use. NR 36 TC 1 Z9 1 U1 5 U2 7 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 2044-6055 J9 BMJ OPEN JI BMJ Open PY 2016 VL 6 IS 5 AR e009934 DI 10.1136/bmjopen-2015-009934 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA DP3SF UT WOS:000378414700018 PM 27217279 ER PT J AU Katsanos, K Geisler, BP Garner, AM Zayed, H Cleveland, T Pietzsch, JB AF Katsanos, Konstantinos Geisler, Benjamin P. Garner, Abigail M. Zayed, Hany Cleveland, Trevor Pietzsch, Jan B. TI Economic analysis of endovascular drug-eluting treatments for femoropopliteal artery disease in the UK SO BMJ OPEN LA English DT Article DE Peripheral arterial disease; Cost-effectiveness; angioplasty; stents; drug-coated balloons; drug-eluting stents ID SUPERFICIAL FEMORAL-ARTERY; NITINOL STENT IMPLANTATION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; COST-EFFECTIVENESS ANALYSIS; PACLITAXEL-COATED BALLOONS; RESILIENT RANDOMIZED-TRIAL; BARE METAL STENTS; POPLITEAL ARTERY; FOLLOW-UP; PILOT TRIAL AB Objectives To estimate the clinical and economic impact of drug-eluting endovascular treatment strategies for femoropopliteal artery disease compared with current standard of care. Design Systematic literature search to pool target lesion revascularisations (TLR). Model-based per-patient cost impact and quasi-cost-effectiveness projection over 24months based on pooled TLRs and current reimbursement. Setting The UK's National Health Service (NHS). Participants Patients presenting with symptomatic femoropopliteal disease eligible for endovascular treatment. Interventions Current National Institute for Health and Care Excellence (NICE) guideline-recommended treatment with percutaneous transluminal balloon angioplasty (PTA) and bailout bare metal stenting (BMS) versus primary BMS placement, or drug-coated balloon (DCB), or drug-eluting stent (DES) treatment. Primary and secondary outcome measures 24-month per-patient cost impact to NHS (primary outcome). Secondary outcomes: pooled 24-month TLR rates; numbers needed to treat (NNTs); cost per TLR avoided and estimated incremental cost-effectiveness ratio (ICER) in per quality-adjusted life year (QALY). Results N=28 studies were identified, reporting on 5167 femoropopliteal lesions. Over 24months, DCB, DES and BMS reduced TLRs of de novo lesions from 36.2% to 17.6%, 19.4% and 26.9%, respectively, at an increased cost of 43 pound, 44 pound and 112 pound. NNTs to avoid 1 TLR in 24months were 5.4, 6.0 and 10.8, resulting in cost per TLR avoided of 231 pound, 264 pound and 1204 pound. DCB was estimated to add 0.011 QALYs, DES 0.010 QALYs and BMS 0.005 QALYs, resulting in estimated ICERs of 3983 pound, 4534 pound and 20719 pound per QALY gained. A subset analysis revealed more favourable clinical and economic outcomes for a 3.5 mu g/mm(2) DCB with urea excipient, compared with the rest of DCBs. A modest reduction of 10% in DCB and DES prices made drug-eluting treatments dominant. Conclusions Widespread adoption of drug-eluting endovascular therapies for femoropopliteal disease would add meaningful clinical benefit at reasonable additional costs to the NHS. Based on currently available data, DCBs offer the highest clinical and economic value. C1 [Katsanos, Konstantinos; Zayed, Hany] Guys & St Thomas NHS Fdn Trust, London, England. [Geisler, Benjamin P.; Garner, Abigail M.; Pietzsch, Jan B.] Wing Tech Inc, Menlo Pk, CA USA. [Geisler, Benjamin P.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. [Cleveland, Trevor] Sheffield Teaching Hosp NHS Fdn Trust, Sheffield, S Yorkshire, England. RP Katsanos, K (reprint author), Guys & St Thomas NHS Fdn Trust, London, England. EM katsanos@med.upatras.gr OI Geisler, Benjamin/0000-0003-1704-6067 NR 50 TC 4 Z9 4 U1 2 U2 3 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 2044-6055 J9 BMJ OPEN JI BMJ Open PY 2016 VL 6 IS 5 AR e011245 DI 10.1136/bmjopen-2016-011245 PG 11 WC Medicine, General & Internal SC General & Internal Medicine GA DP3SF UT WOS:000378414700126 PM 27160845 ER PT J AU Nakanishi, T Shiga, T Homma, Y Koyama, Y Goto, T AF Nakanishi, Taizo Shiga, Takashi Homma, Yosuke Koyama, Yasuaki Goto, Tadahiro TI Comparison of the force applied on oral structures during intubation attempts by novice physicians between the Macintosh direct laryngoscope, Airway Scope and C-MAC PM: a high-fidelity simulator-based study SO BMJ OPEN LA English DT Article DE ACCIDENT & EMERGENCY MEDICINE; MEDICAL EDUCATION & TRAINING; ANAESTHETICS ID INTENSIVE-CARE-UNIT; VIDEO-LARYNGOSCOPY; TRACHEAL INTUBATION; MAXILLARY INCISORS; MANNEQUIN AB Objective We examined whether the use of Airway Scope (AWS) and C-MAC PM (C-MAC) decreased the force applied on oral structures during intubation attempts as compared with the force applied with the use of Macintosh direct laryngoscope (DL). Design Prospective cross-over study. Participants A total of 35 novice physicians participated. Interventions We used 6 simulation scenarios based on the difficulty of intubation and intubation devices. Outcome measures Our primary outcome measures were the maximum force applied on the maxillary incisors and tongue during intubation attempts, measured by a high-fidelity simulator. Results The maximum force applied on maxillary incisors was higher with the use of the C-MAC than with the DL and AWS in the normal airway scenario (DL, 26 Newton (N); AWS, 18N; C-MAC, 52N; p<0.01) and the difficult airway scenario (DL, 42N; AWS, 24N; C-MAC, 68N; p<0.01). In contrast, the maximum force applied on the tongue was higher with the use of the DL than with the AWS and C-MAC in both airway scenarios (DL, 16N; AWS, 1N; C-MAC, 7N; p<0.01 in the normal airway scenario; DL, 12N; AWS, 4N; C-MAC, 7N; p<0.01 in the difficult airway scenario). Conclusions The use of C-MAC, compared with the DL and AWS, was associated with the higher maximum force applied on maxillary incisors during intubation attempts. In contrast, the use of video laryngoscopes was associated with the lower force applied on the tongue in both airway scenarios, compared with the DL. Our study was a simulation-based study, and further research on living patients would be warranted. C1 [Nakanishi, Taizo] Fukui Prefectural Hosp, Dept Emergency Med, Fukui, Japan. [Shiga, Takashi; Homma, Yosuke] Noguchi Hideyo Mem Int Hosp, Tokyo Bay Urayasu Ichikawa Med Ctr, Dept Emergency Med, Urayasu, Japan. [Koyama, Yasuaki] Univ Tsukuba Hosp, Dept Emergency & Crit Care Med, Tsukuba, Ibaraki, Japan. [Goto, Tadahiro] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA. RP Nakanishi, T (reprint author), Fukui Prefectural Hosp, Dept Emergency Med, Fukui, Japan. EM taizo81@gmail.com NR 23 TC 0 Z9 0 U1 0 U2 0 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 2044-6055 J9 BMJ OPEN JI BMJ Open PY 2016 VL 6 IS 5 AR e011039 DI 10.1136/bmjopen-2016-011039 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA DP3SF UT WOS:000378414700105 PM 27217284 ER PT J AU Isaac, ST Tan, TC Polly, P AF Isaac, Stephanie T. Tan, Timothy C. Polly, Patsie TI Endoplasmic Reticulum Stress, Calcium Dysregulation and Altered Protein Translation: Intersection of Processes That Contribute to Cancer Cachexia Induced Skeletal Muscle Wasting SO CURRENT DRUG TARGETS LA English DT Article DE Skeletal muscle; cancer cachexia; endoplasmic reticulum; protein translation; calcium; cytokines ID TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; INCLUSION-BODY MYOSITIS; SERUM INTERLEUKIN-6 LEVELS; PANCREATIC-CANCER; MESSENGER-RNA; FACTOR-ALPHA; TRANSCRIPTION FACTOR; LUNG-CANCER; WEIGHT-LOSS AB Cancer cachexia is a debilitating paraneoplastic wasting syndrome characterized by skeletal muscle depletion and unintentional weight loss. It affects up to 50-80% of patients with cancer and directly accounts for one-quarter of cancer-related deaths due to cardio-respiratory failure. Muscle weakness, one of the hallmarks of this syndrome, has been postulated to be due to a combination of muscle breakdown, dysfunction and decrease in the ability to repair, with effective treatment strategies presently limited. Excessive inflammatory cytokine levels due to the host-tumor interaction, such as Interleukin (IL)-6 and Tumor Necrosis Factor (TNF)-alpha, are hypothesised to drive this pathological process but the specific mechanisms by which these cytokines produce skeletal muscle dysfunction in cancer cachexia remain undefined. Endoplasmic Reticulum ( ER) stress and the associated disruptions in calcium signaling have been implicated in cytokine-mediated disruptions in skeletal muscle and function. Disrupted ER stress-related processes such as the Unfolded Protein Response (UPR), calcium homeostasis and altered muscle protein synthesis have been reported in clinical and experimental cachexia and other inflammation-driven muscle diseases such as myositis, potentially suggesting a link between increased IL-6 and TNF-alpha and ER stress in skeletal muscle cells. As the concept of upregulated ER stress in skeletal muscle cells due to elevated cytokines is novel and potentially very relevant to our understanding of cancer cachexia, this review aims to examine the potential relationship between inflammatory cytokine mediated muscle breakdown and ER stress, in the context of cancer cachexia, and to discuss the molecular signaling pathways underpinning this pathology. C1 [Isaac, Stephanie T.; Tan, Timothy C.; Polly, Patsie] UNSW Australia, Fac Med, Sch Med Sci, Inflammat & Infect Res Ctr, Sydney, NSW 2052, Australia. [Isaac, Stephanie T.; Polly, Patsie] UNSW Australia, Fac Med, Sch Med Sci, Dept Pathol, Sydney, NSW 2052, Australia. [Tan, Timothy C.] Blacktown Clin Sch, 18 Blacktown Rd, Blacktown, NSW 2148, Australia. [Tan, Timothy C.] Blacktown Hosp, 18 Blacktown Rd, Blacktown, NSW 2148, Australia. [Tan, Timothy C.] Massachusetts Gen Hosp, Cardiac Ultrasound Lab, Dept Cardiol, Boston, MA 02114 USA. RP Polly, P (reprint author), UNSW Australia, Fac Med, Sch Med Sci, Rm 420 Wallace Wurth East Bldg, Sydney, NSW 2052, Australia. EM patsie.polly@unsw.edu.au NR 87 TC 1 Z9 1 U1 0 U2 0 PU BENTHAM SCIENCE PUBL LTD PI SHARJAH PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES SN 1389-4501 EI 1873-5592 J9 CURR DRUG TARGETS JI Curr. Drug Targets PY 2016 VL 17 IS 10 BP 1140 EP 1146 DI 10.2174/1389450116666150416115721 PG 7 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA DQ0UI UT WOS:000378916400005 PM 25882219 ER PT J AU Compagno, M Wang, Q Pighi, C Meng, FG Cheong, TC Yeap, LS Poggio, TA Langellotto, FA Voena, C Gostissa, M Alt, FW Chiarle, R AF Compagno, M. Wang, Q. Pighi, C. Meng, F. G. Cheong, T. -C. Yeap, L. -S. Poggio, T. A. Langellotto, F. A. Voena, C. Gostissa, M. Alt, F. W. Chiarle, R. TI PI3K delta Inhibitors Increase Genomic Instability by Upregulating AID Expression SO CYTOGENETIC AND GENOME RESEARCH LA English DT Meeting Abstract CT 21st International Chromosome Conference (ICC) CY JUL 10-13, 2016 CL Foz do Iguacu, BRAZIL C1 [Compagno, M.; Wang, Q.; Pighi, C.; Cheong, T. -C.; Langellotto, F. A.; Voena, C.; Chiarle, R.] Boston Childrens Hosp, Dept Pathol, Boston, MA USA. [Compagno, M.; Wang, Q.; Pighi, C.; Cheong, T. -C.; Langellotto, F. A.; Voena, C.; Chiarle, R.] Harvard Univ, Sch Med, Boston, MA USA. [Meng, F. G.; Yeap, L. -S.; Gostissa, M.; Alt, F. W.] Boston Childrens Hosp, Howard Hughes Med Inst, Program Cellular & Mol Med, Boston, MA USA. [Meng, F. G.; Yeap, L. -S.; Gostissa, M.; Alt, F. W.] Harvard Univ, Sch Med, Dept Genet, Boston, MA USA. [Poggio, T. A.; Voena, C.; Chiarle, R.] Univ Turin, Dept Mol Biotechnol & Hlth Sci, Turin, Italy. EM roberto.chiarle@childrens.harvard.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1424-8581 EI 1424-859X J9 CYTOGENET GENOME RES JI Cytogenet. Genome Res. PY 2016 VL 148 IS 2-3 MA V.2 BP 132 EP 132 PG 1 WC Cell Biology; Genetics & Heredity SC Cell Biology; Genetics & Heredity GA DP8WA UT WOS:000378777400116 ER PT J AU Xavier, RJ AF Xavier, Ramnik J. TI Microbiota as Therapeutic Targets SO DIGESTIVE DISEASES LA English DT Article DE Functional dysbiosis; Host immunity and IBD ID INFLAMMATORY-BOWEL-DISEASE; CROHNS-DISEASE; GUT MICROBIOTA; CLOSTRIDIUM-DIFFICILE; IMMUNE-SYSTEM; GENE ATG16L1; MUC2 MUCIN; T-CELLS; COMMENSAL; INTESTINE AB Background: Inflammatory bowel disease (IBD) represents a family of diseases including Crohn's disease and ulcerative colitis. IBD has garnered significant attention in recent years due to successes in 2 areas of basic science: complex human genetics and host-microbe interactions. Advances in understanding the genetics of IBD, mainly driven by genome-wide association studies, have identified more than 160 genetic loci that modulate the risk of disease. Notably, several of these genes have pointed to alterations in host-microbe interactions as being critical factors in pathogenesis. Investigations into the microbial communities of the gastrointestinal tract (or the 'gut microbiome') in IBD have yielded important insights into several aspects of interactions between microbiota and the host immune system, including how alterations to microbial community composition and function have important consequences for immune homeostasis. Key Messages: The anatomy of the gastrointestinal tract plays a role in defining not only intestinal function, but also the microbial ecosystem that lives within the gut. Careful investigations into the composition and function of these microbial communities have suggested that patients with IBD have an imbalance in their gut microbiota, termed dysbiosis. These studies, as well as studies using samples from healthy individuals, have begun to uncover mechanisms of crosstalk between particular microbes (and microbial products) and immunomodulatory pathways, alterations which may drive immune diseases such as IBD. Conclusions: Investigations into the role of the microbiome in IBD have provided important clues to potential pathogenic mechanisms. Harnessing this knowledge to develop therapeutics and identify biomarkers is currently a major translational goal, holding great promise for clinically meaningful progress. (C) 2016 S. Karger AG, Basel C1 [Xavier, Ramnik J.] Massachusetts Gen Hosp, Ctr Study Inflammatory Bowel Dis, Gastrointestinal Unit, Boston, MA 02114 USA. [Xavier, Ramnik J.] Massachusetts Gen Hosp, Ctr Computat & Integrat Biol, Boston, MA 02114 USA. [Xavier, Ramnik J.] Harvard Univ, Sch Med, Boston, MA USA. [Xavier, Ramnik J.] MIT, Broad Inst, 77 Massachusetts Ave, Cambridge, MA 02139 USA. [Xavier, Ramnik J.] MIT, Ctr Microbiome Informat & Therapeut, 77 Massachusetts Ave, Cambridge, MA 02139 USA. RP Xavier, RJ (reprint author), Massachusetts Gen Hosp, Sch Med, GastrointestinalI Unit, 55 Fruit St, Boston, MA 02114 USA. EM Xavier@molbio.mgh.harvard.edu FU NIDDK NIH HHS [P30 DK043351] NR 60 TC 2 Z9 2 U1 4 U2 6 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0257-2753 EI 1421-9875 J9 DIGEST DIS JI Dig. Dis. PY 2016 VL 34 IS 5 BP 558 EP 565 DI 10.1159/000445263 PG 8 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DP8VQ UT WOS:000378776400016 PM 27331403 ER PT J AU Manchikanti, L Hirsch, JA AF Manchikanti, Laxmaiah Hirsch, Joshua A. TI Evolution of the Epidural Treatment of Sciatica Provides Excellent Historic Review with Incomplete Modern Evidence SO EUROPEAN NEUROLOGY LA English DT Letter ID INJECTIONS C1 [Manchikanti, Laxmaiah] Univ Louisville, Dept Anesthesiol & Perioperat Med, Louisville, KY 40292 USA. [Manchikanti, Laxmaiah] Pain Management Ctr Paducah, Paducah, KY 42003 USA. [Hirsch, Joshua A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Neurointervent Spine Serv & Intervent Care,De, Boston, MA USA. RP Manchikanti, L (reprint author), Pain Management Ctr Paducah, Anesthesiol & Perioperat Med, 2831 Lone Oak Rd, Paducah, KY 42003 USA.; Manchikanti, L (reprint author), Pain Management Ctr Paducah, 2831 Lone Oak Rd, Paducah, KY 42003 USA. EM drlm@thepainmd.com NR 6 TC 1 Z9 1 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0014-3022 EI 1421-9913 J9 EUR NEUROL JI Eur. Neurol. PY 2016 VL 75 IS 5-6 BP 225 EP 226 DI 10.1159/000445885 PG 2 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA DP8ZX UT WOS:000378787600004 PM 27120099 ER PT J AU Brewer-Smyth, K Pohlig, RT Bucurescu, G AF Brewer-Smyth, Kathleen Pohlig, Ryan T. Bucurescu, Gabriel TI Female children with incarcerated adult family members at risk for lifelong neurological decline SO HEALTH CARE FOR WOMEN INTERNATIONAL LA English DT Article ID TRAUMATIC BRAIN-INJURY; PARENTAL INCARCERATION; CHILDHOOD ABUSE; MENTAL-ILLNESS; SEXUAL-ABUSE; YOUNG-ADULTS; HEALTH; CONSEQUENCES; IMPRISONMENT; EXPERIENCES AB A secondary analysis of data from adult female prison inmates in the mid-Atlantic United States defined relationships between having incarcerated adult family members during childhood and neurological outcomes. Of 135 inmates, 99 (60%) had one or more incarcerated adult family members during childhood. Regression analyses revealed that having incarcerated adult family members was related to greater frequency and severity of childhood abuse and higher incidence of neurological deficits in adulthood, especially related to traumatic brain injuries, compared to those without incarcerated adult family members. Along with being role models, adult family members impact the neurological health of children throughout their life-span. C1 [Brewer-Smyth, Kathleen] Univ Delaware, Sch Nursing, Coll Hlth Sci, McDowell Hall, Newark, DE 19716 USA. [Pohlig, Ryan T.] Univ Delaware, Coll Hlth Sci, Newark, DE 19716 USA. [Bucurescu, Gabriel] US Dept Vet Affairs, Philadelphia, PA USA. RP Brewer-Smyth, K (reprint author), Univ Delaware, Sch Nursing, Coll Hlth Sci, McDowell Hall, Newark, DE 19716 USA. EM kbsmyth@udel.edu FU National Institutes of Health [20RR016472-04, T32NR07036]; Sigma Theta Tau International Honor Society; Rehabilitation Nursing Foundation; Baxter Foundation; University of Delaware General University Research Fund; University of Delaware Research Foundation FX Data collection for this study was funded in part by the National Institutes of Health 20RR016472-04, T32NR07036, Sigma Theta Tau International Honor Society, Rehabilitation Nursing Foundation, The Baxter Foundation, University of Delaware General University Research Fund, and University of Delaware Research Foundation. NR 29 TC 0 Z9 0 U1 5 U2 5 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 0739-9332 EI 1096-4665 J9 HEALTH CARE WOMEN IN JI Health Care Women Int. PY 2016 VL 37 IS 7 BP 802 EP 813 DI 10.1080/07399332.2016.1140768 PG 12 WC Public, Environmental & Occupational Health; Women's Studies SC Public, Environmental & Occupational Health; Women's Studies GA DP7WO UT WOS:000378710100009 PM 26788781 ER PT J AU Robbins, GK Cohn, SE Harrison, LJ Smeaton, L Moran, L Rusin, D Dehlinger, M Flynn, T Lammert, S Wu, AW Safren, SA Reynolds, NR AF Robbins, Gregory K. Cohn, Susan E. Harrison, Linda J. Smeaton, Laura Moran, Laura Rusin, David Dehlinger, Marjorie Flynn, Theresa Lammert, Sara Wu, Albert W. Safren, Steven A. Reynolds, Nancy R. TI Characteristics associated with virologic failure in high-risk HIV-positive participants with prior failure: a post hoc analysis of ACTG 5251 SO HIV CLINICAL TRIALS LA English DT Article DE Adherence; Antiretroviral therapy; High risk populations; Virologic failure ID ANTIRETROVIRAL THERAPY; UNITED-STATES; PERCEPTION QUESTIONNAIRE; CLINICAL-TRIALS; ADHERENCE; CARE; TRANSMISSION; PREVENTION; SUPPORT; ILLNESS AB Patients with prior virologic failure (VF) are at an increased risk of subsequent failure, emergence of resistance, and death. This analysis identifies outcomes and correlates of VF in a high-risk population. Methods: A5251 was designed to evaluate an enhanced adherence counseling intervention delivered by nurses from a central call site on virologic suppression. Due to slow enrollment, the study was closed prematurely and revised study endpoints were evaluated (week 24 VF (HIV-1 RNA >= 200 copies/ml) and non-perfect adherence (<100% self-reported using both the ACTG adherence questionnaire and visual analog scale (VAS)). Results: Fifty-nine participants were enrolled, 43 (73%) black non-Hispanic and 23 (39%) women. Median prior antiretroviral regimen changes were three and the co-morbidity in this population was higher than typical for HIV clinical trials. At week 24 (n = 41), 24 (59%) failed to reach virologic suppression (HIV-1 RNA <200 copies/ml) and 25 (63%) reported non-perfect adherence. Higher depression (CES-D10) and adverse illness perceptions (IPQ-B) were associated with week 24 non-adherence. Early clinical assessments (week 12 HIV-RNA = 200 copies/mL and non-perfect adherence) as well as higher depression and adverse illness perceptions were associated with week 24 VF. Discussion: In this high-risk population, the proportion of participants with suboptimal adherence and VF was unacceptably high. Interventions to address this treatment gap are clearly needed. Depression and a higher illness perception score, failure to achieve virologic suppression by week 12, and less than perfect adherence could be used to target individuals for early interventions in treatment-experienced, high-risk individuals at high risk for VF. C1 [Robbins, Gregory K.; Flynn, Theresa; Lammert, Sara] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. [Cohn, Susan E.] Northwestern Univ, Feinberg Sch Med, Dept Med, Chicago, IL 60611 USA. [Harrison, Linda J.; Smeaton, Laura] Harvard TH Chan Sch Publ Hlth, Ctr Biostat AIDS Res, Boston, MA USA. [Moran, Laura] Social & Sci Syst Inc, Silver Spring, MD USA. [Rusin, David] Frontier Sci & Technol Res Fdn Inc, Amherst, NY USA. [Dehlinger, Marjorie] NIAID, NIH, Bethesda, MD 20892 USA. [Wu, Albert W.] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA. [Safren, Steven A.] Univ Miami, Dept Psychol, Coral Gables, FL 33124 USA. [Reynolds, Nancy R.] Yale Univ, Sch Nursing, New Haven, CT 06536 USA. RP Robbins, GK (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA. EM grobbins@partners.org FU AIDS Clinical Trial Group; National Institute of Nursing Research FX AIDS Clinical Trial Group and National Institute of Nursing Research. NR 28 TC 0 Z9 0 U1 0 U2 0 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND SN 1528-4336 EI 1945-5771 J9 HIV CLIN TRIALS JI HIV Clin. Trials PY 2016 VL 17 IS 4 BP 165 EP 172 DI 10.1080/15284336.2016.1189754 PG 8 WC Infectious Diseases; Pharmacology & Pharmacy SC Infectious Diseases; Pharmacology & Pharmacy GA DQ0PV UT WOS:000378903200005 PM 27347650 ER PT J AU Hoscheidt, SM Starks, EJ Oh, JM Zetterberg, H Blennow, K Krause, RA Gleason, CE Puglielli, L Atwood, CS Carlsson, CM Asthana, S Johnson, SC Bendlin, BB AF Hoscheidt, Siobhan M. Starks, Erika J. Oh, Jennifer M. Zetterberg, Henrik Blennow, Kaj Krause, Rachel A. Gleason, Carey E. Puglielli, Luigi Atwood, Craig S. Carlsson, Cynthia M. Asthana, Sanjay Johnson, Sterling C. Bendlin, Barbara B. TI Insulin Resistance is Associated with Increased Levels of Cerebrospinal Fluid Biomarkers of Alzheimer's Disease and Reduced Memory Function in At-Risk Healthy Middle-Aged Adults SO JOURNAL OF ALZHEIMERS DISEASE LA English DT Article DE APOE epsilon 4; CSF AD biomarkers; insulin resistance; memory function ID AMYLOID PRECURSOR PROTEIN; MILD COGNITIVE IMPAIRMENT; APOLIPOPROTEIN-E GENOTYPE; CENTRAL-NERVOUS-SYSTEM; LATE-ONSET ALZHEIMERS; GRAY-MATTER VOLUME; SYNAPTIC PLASTICITY; FAMILY-HISTORY; DIABETES-MELLITUS; DEGRADING ENZYME AB Background: Type 2 diabetes is associated with an increased risk for Alzheimer's disease (AD). Regulation of normal insulin function may be important in reducing the prevalence of dementia due to AD, particularly in individuals who harbor genetic risk for or have a parental family history of AD. The relationship between insulin resistance (IR) and AD pathology remains poorly understood, particularly in midlife prior to the onset of clinical metabolic disease or cognitive decline. Objective: We examined associations between IR as indexed by HOMA-IR, cerebrospinal fluid (CSF) biomarkers of AD pathology, and memory in middle-aged adults enriched for AD. We postulated that higher HOMA-IR and APOE epsilon 4 carriage would be associated with greater CSF AD pathology and poor memory performance. Methods: Cognitively asymptomatic middle-aged adults (N = 70, mean age = 57.7 years) from the Wisconsin Alzheimer's Disease Research Center with a parental family history of dementia due to AD underwent lumbar puncture, blood draw, and neuropsychological testing. CSF AD biomarkers including soluble amyloid-beta protein precursor beta (sA beta PP beta), amyloid-beta 42 (A beta(42)), and phosphorylated tau (P-tau(181)) were examined with respect to HOMA-IR and APOE epsilon 4 status. Delayed memory performance was examined with respect to HOMA-IR, CSF AD biomarkers, and APOE epsilon 4 status. Results: Higher HOMA-IR was associated with higher sA beta PP beta and A beta(42). APOE epsilon 4 carriers had significantly higher levels of sA beta PP beta, sA beta PP beta, and P-tau(181)/A beta(42) compared to noncarriers. The concurrent presence of higher HOMA-IR and CSF AD pathology predicted worse delayed memory performance. Conclusion: Overall, the findings suggest that IR and APOE epsilon 4 are contributing factors to the development of AD pathology in midlife, and provide support for targeting insulin function as a potentially modifiable risk factor for AD. C1 [Hoscheidt, Siobhan M.; Starks, Erika J.; Oh, Jennifer M.; Krause, Rachel A.; Gleason, Carey E.; Puglielli, Luigi; Atwood, Craig S.; Carlsson, Cynthia M.; Asthana, Sanjay; Johnson, Sterling C.; Bendlin, Barbara B.] Univ Wisconsin, Sch Med & Publ Hlth, Wisconsin Alzheimers Dis Res Ctr, Madison, WI USA. [Zetterberg, Henrik; Blennow, Kaj] Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Clin Neurochem Lab,Dept Psychiat & Neurochem, Gothenburg, Sweden. [Zetterberg, Henrik] UCL Inst Neurol, Dept Mol Neurosci, Queen Sq, London, England. [Gleason, Carey E.; Puglielli, Luigi; Atwood, Craig S.; Carlsson, Cynthia M.; Asthana, Sanjay; Johnson, Sterling C.] William S Middleton Mem Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin, Madison, WI USA. [Carlsson, Cynthia M.; Asthana, Sanjay; Johnson, Sterling C.; Bendlin, Barbara B.] Univ Wisconsin, Sch Med & Publ Hlth, Wisconsin Alzheimers Inst, Madison, WI USA. RP Bendlin, BB (reprint author), Univ Wisconsin, Ctr Clin Sci, J5-1M,600 Highland Ave, Madison, WI 53792 USA. EM bbb@medicine.wisc.edu FU NIH [P50 AG033514]; University of Wisconsin Institute for Clinical and Translational Research through National Center for Research Resources/National Institutes of Health Clinical and Translational Science Award [1UL1RR025011]; National Center for Research Resources; United States National Institutes of Health; Swedish Research Council; Swedish Brain Foundation; Torsten Soderberg's Foundation FX This research was supported by NIH grant P50 AG033514, University of Wisconsin Institute for Clinical and Translational Research, funded through a National Center for Research Resources/National Institutes of Health Clinical and Translational Science Award, 1UL1RR025011, a program of the National Center for Research Resources, United States National Institutes of Health, the Swedish Research Council, the Swedish Brain Foundation, and Torsten Soderberg's Foundation to the University of Gothenburg. We want to thank the MRI staff at the Wisconsin Institute for Medical Research, Chuck Illingworth, the staff at the Wisconsin ADRC, and, above all, our dedicated participants. NR 79 TC 1 Z9 1 U1 1 U2 2 PU IOS PRESS PI AMSTERDAM PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS SN 1387-2877 EI 1875-8908 J9 J ALZHEIMERS DIS JI J. Alzheimers Dis. PY 2016 VL 52 IS 4 BP 1373 EP 1383 DI 10.3233/JAD-160110 PG 11 WC Neurosciences SC Neurosciences & Neurology GA DP9BQ UT WOS:000378792100019 PM 27079723 ER PT J AU Ferguson, LR De Caterina, R Gorman, U Allayee, H Kohlmeier, M Prasad, C Choi, MS Curi, R de Luis, DA Gil, A Kang, JX Martin, RL Milagro, FI Nicoletti, CF Nonino, CB Ordovas, JM Parslow, VR Portillo, MP Santos, JL Serhan, CN Simopoulos, AP Velazquez-Arellano, A Zulet, MA Martinez, JA AF Ferguson, Lynnette R. De Caterina, Raffaele Gorman, Ulf Allayee, Hooman Kohlmeier, Martin Prasad, Chandan Choi, Myung Sook Curi, Rui Antonio de Luis, Daniel Gil, Angel Kang, Jing X. Martin, Ron L. Milagro, Fermin I. Nicoletti, Carolina Ferreira Nonino, Carla Barbosa Ordovas, Jose Maria Parslow, Virginia R. Portillo, Maria P. Santos, Jose Luis Serhan, Charles N. Simopoulos, Artemis P. Velazquez-Arellano, Antonio Zulet, Maria Angeles Martinez, J. Alfredo TI Guide and Position of the International Society of Nutrigenetics/Nutrigenomics on Personalised Nutrition: Part 1-Fields of Precision Nutrition SO JOURNAL OF NUTRIGENETICS AND NUTRIGENOMICS LA English DT Article DE Precision nutrition; Omics; Genetic tests; Nutrigenetics; Nutrigenomics; Health and disease ID LEUKOCYTE TELOMERE LENGTH; GUT MICROBIOTA; CARDIOVASCULAR-DISEASE; DNA METHYLATION; NUTRIGENOMICS RESEARCH; HUMAN PLASMA; MISSING HERITABILITY; MASS-SPECTROMETRY; SYSTEMS BIOLOGY; POSTGENOMIC ERA AB Diversity in the genetic profile between individuals and specific ethnic groups affects nutrient requirements, metabolism and response to nutritional and dietary interventions. Indeed, individuals respond differently to lifestyle interventions (diet, physical activity, smoking, etc.). The sequencing of the human genome and subsequent increased knowledge regarding human genetic variation is contributing to the emergence of personalized nutrition. These advances in genetic science are raising numerous questions regarding the mode that precision nutrition can contribute solutions to emerging problems in public health, by reducing the risk and prevalence of nutrition-related diseases. Current views on personalized nutrition encompass omics technologies (nutrigenomics, transcriptomics, epigenomics, foodomics, metabolomics, metagenomics, etc.), functional food development and challenges related to legal and ethical aspects, application in clinical practice, and population scope, in terms of guidelines and epidemiological factors. In this context, precision nutrition can be considered as occurring at three levels: (1) conventional nutrition based on general guidelines for population groups by age, gender and social determinants; (2) individualized nutrition that adds phenotypic information about the person's current nutritional status (e.g. anthropometry, biochemical and metabolic analysis, physical activity, among others), and (3) genotype-directed nutrition based on rare or common gene variation. Research and appropriate translation into medical practice and dietary recommendations must be based on a solid foundation of knowledge derived from studies on nutrigenetics and nutrigenomics. A scientific society, such as the International Society of Nutrigenetics/Nutrigenomics (ISNN), internationally devoted to the study of nutrigenetics/nutrigenomics, can indeed serve the commendable roles of (1) promoting science and favoring scientific communication and (2) permanently working as a 'clearing house' to prevent disqualifying logical jumps, correct or stop unwarranted claims, and prevent the creation of unwarranted expectations in patients and in the general public. In this statement, we are focusing on the scientific aspects of disciplines covering nutrigenetics and nutrigenomics issues. Genetic screening and the ethical, legal, social and economic aspects will be dealt with in subsequent statements of the Society. (C) 2016 S. Karger AG, Basel C1 [Ferguson, Lynnette R.; Parslow, Virginia R.] Univ Auckland, Discipline Nutr, Auckland 1, New Zealand. [Ferguson, Lynnette R.; Parslow, Virginia R.] Univ Auckland, Auckland Canc Soc, Res Ctr, FM & HS, Auckland 1, New Zealand. [Ferguson, Lynnette R.; Parslow, Virginia R.] Univ Auckland, Nutrigen New Zealand, Auckland 1, New Zealand. [De Caterina, Raffaele] Univ G DAnnunzio, Inst Cardiol, Chieti, Italy. [De Caterina, Raffaele] Ctr Excellence Aging, Chieti, Italy. [Gorman, Ulf] Lund Univ, Eth Unit, Ctr Theol & Religious Studies, Lund, Sweden. [Allayee, Hooman] USC Keck Sch Med, Inst Med Genet, Los Angeles, CA USA. [Allayee, Hooman] USC Keck Sch Med, Dept Prevent Med, Los Angeles, CA USA. [Kohlmeier, Martin] Univ N Carolina, Sch Med, Sch Publ Hlth, Dept Nutr, Chapel Hill, NC USA. [Prasad, Chandan] Texas Womans Univ, Dept Nutr & Food Sci, Denton, TX 76204 USA. [Prasad, Chandan] LSU Hlth Sci Ctr, Dept Med, New Orleans, LA USA. [Choi, Myung Sook] Kyungpook Natl Univ, Dept Food Sci & Nutr, Ctr Food & Nutrit Genom, Daegu, South Korea. [Curi, Rui] Univ Sao Paulo, Inst Biomed Sci, Dept Physiol & Biophys, Sao Paulo, Brazil. [Antonio de Luis, Daniel] Univ Valladolid, Ctr Invest Endocrinol & Nutr, Sch Med, Hosp Clin Univ, Valladolid, Spain. [Antonio de Luis, Daniel] Univ Valladolid, Hosp Clin Univ, Dept Endocrinol & Nutr, Valladolid, Spain. [Gil, Angel] Univ Granada, Dept Biochem & Mol Biol 2, Inst Nutr & Food Technol, Ctr Biomed Res, Granada, Spain. [Gil, Angel; Milagro, Fermin I.; Portillo, Maria P.; Zulet, Maria Angeles; Martinez, J. Alfredo] Inst Salud Carlos III, CIBERobn, Physiopathol Obes, Madrid, Spain. [Kang, Jing X.] Massachusetts Gen Hosp, Dept Med, Lab Lipid Med & Technol, Boston, MA 02114 USA. [Kang, Jing X.] Harvard Univ, Sch Med, Boston, MA USA. [Martin, Ron L.] Nutrigenet Unltd Inc, Fullerton, CA USA. [Milagro, Fermin I.; Zulet, Maria Angeles; Martinez, J. Alfredo] Univ Navarra, Dept Nutr Food Sci & Physiol, E-31080 Pamplona, Spain. [Milagro, Fermin I.; Zulet, Maria Angeles; Martinez, J. Alfredo] Univ Navarra, Ctr Nutr Res, E-31080 Pamplona, Spain. [Nicoletti, Carolina Ferreira; Nonino, Carla Barbosa] Univ Sao Paulo, Div Nutr, Dept Internal Med, Fac Med Ribeirao Preto, BR-14049 Ribeirao Preto, Brazil. [Ordovas, Jose Maria] Tufts Univ, Nutr & Genom Lab, Jean Mayer US, Dept Agr,Human Nutr Res Ctr Aging, Boston, MA 02111 USA. [Ordovas, Jose Maria] IMDEA Alimentac, Madrid, Spain. [Portillo, Maria P.] Univ Basque Country, Nutr & Obes Grp, Dept Nutr & Food Sci, Vitoria, Spain. [Santos, Jose Luis] Pontificia Univ Catolica Chile, Dept Nutr Diabet & Metab, Sch Med, Alameda 340, Santiago, Chile. [Serhan, Charles N.] Brigham & Womens Hosp, Harvard Inst Med, Ctr Expt Therapeut & Reperfus Injury, Dept Anesthesiol Perioperat & Pain Med, 75 Francis St, Boston, MA 02115 USA. [Serhan, Charles N.] Harvard Univ, Sch Med, Boston, MA USA. [Simopoulos, Artemis P.] Ctr Genet Nutr & Hlth, Washington, DC USA. [Velazquez-Arellano, Antonio] Univ Nacl Autonoma Mexico, Inst Invest Biomed, Dept Mol Genet & Biotechnol, Mexico City 04510, DF, Mexico. [Martinez, J. Alfredo] Navarra Inst Hlth Res IdiSNA, Pamplona, Spain. [Martinez, J. Alfredo] IUNS, Vienna, Austria. RP Martinez, JA (reprint author), Univ Navarra, Dept Nutr Food Sci & Physiol, Irunlarrea 1, ES-31008 Pamplona, Spain. EM jalfmtz@unav.es RI De Caterina, Raffaele/K-3857-2016; Gil, Angel/L-2275-2014; Nonino, Carla/D-4637-2012; OI De Caterina, Raffaele/0000-0003-1637-574X; Gil, Angel/0000-0001-7663-0939; Nonino, Carla/0000-0001-8559-0772; PORTILLO BAQUEDANO, MARIA PUY/0000-0003-2290-592X; Zulet, M. Angeles/0000-0002-3926-0892; Santos, Jose Luis/0000-0003-2895-0369 NR 133 TC 2 Z9 2 U1 19 U2 24 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1661-6499 EI 1661-6758 J9 J NUTRIGENET NUTRIGE JI J. Nutrigenet. Nutrigenomics PY 2016 VL 9 IS 1 BP 12 EP 27 DI 10.1159/000445350 PG 16 WC Genetics & Heredity; Nutrition & Dietetics SC Genetics & Heredity; Nutrition & Dietetics GA DP9DS UT WOS:000378797500002 PM 27169401 ER PT J AU Kohlmeier, M De Caterina, R Ferguson, LR Gorman, U Allayee, H Prasad, C Kang, JX Nicoletti, CF Martinez, JA AF Kohlmeier, Martin De Caterina, Raffaele Ferguson, Lynnette R. Gorman, Ulf Allayee, Hooman Prasad, Chandan Kang, Jing X. Nicoletti, Carolina Ferreira Alfredo Martinez, J. TI Guide and Position of the International Society of Nutrigenetics/Nutrigenomics on Personalized Nutrition: Part 2-Ethics, Challenges and Endeavors of Precision Nutrition SO JOURNAL OF NUTRIGENETICS AND NUTRIGENOMICS LA English DT Article DE Nutrigenetics; Nutrigenomics; Nutriomics; Genetic tests; Functional foods; Personalized nutrition; Omics; Public health ID WEIGHT-LOSS; GENETIC INFORMATION; DIETARY RECOMMENDATIONS; NUTRIGENOMICS RESEARCH; FUTURE PERSPECTIVES; RANDOMIZED-TRIAL; MOBILE DEVICES; DOWN-SYNDROME; NUTRIGENETICS; GENOMICS AB Nutrigenetics considers the influence of individual genetic variation on differences in response to dietary components, nutrient requirements and predisposition to disease. Nutrigenomics involves the study of interactions between the genome and diet, including how nutrients affect the transcription and translation process plus subsequent proteomic and metabolomic changes, and also differences in response to dietary factors based on the individual genetic makeup. Personalized characteristics such as age, gender, physical activity, physiological state and social status, and special conditions such as pregnancy and risk of disease can inform dietary advice that more closely meets individual needs. Precision nutrition has a promising future in treating the individual according to their phenotype and genetic characteristics, aimed at both the treatment and prevention of disease. However, many aspects are still in progress and remain as challenges for the future of nutrition. The integration of the human genotype and microbiome needs to be better understood. Further advances in data interpretation tools are also necessary, so that information obtained through newer tests and technologies can be properly transferred to consumers. Indeed, precision nutrition will integrate genetic data with phenotypical, social, cultural and personal preferences and lifestyles matters to provide a more individual nutrition, but considering public health perspectives, where ethical, legal and policy aspects need to be defined and implemented. (C) 2016 S. Karger AG, Basel C1 [Kohlmeier, Martin] Univ N Carolina, Sch Publ Hlth, Dept Nutr, Sch Med, Chapel Hill, NC 27599 USA. [De Caterina, Raffaele] Univ G DAnnunzio, Inst Cardiol, Chieti, Italy. [De Caterina, Raffaele] Ctr Excellence Aging, Chieti, Italy. [Ferguson, Lynnette R.] Univ Auckland, Discipline Nutr, Auckland 1, New Zealand. [Ferguson, Lynnette R.] Univ Auckland, Auckland Canc Soc, Res Ctr, FM & HS, Auckland 1, New Zealand. [Ferguson, Lynnette R.] Univ Auckland, Nutrigen New Zealand, Auckland 1, New Zealand. [Gorman, Ulf] Lund Univ, Eth Unit, Ctr Theol & Religious Studies, Lund, Sweden. [Allayee, Hooman] USC Keck Sch Med, Dept Prevent Med, Los Angeles, CA USA. [Prasad, Chandan] Texas Womans Univ, Dept Nutr & Food Sci, Denton, TX 76204 USA. [Kang, Jing X.] Massachusetts Gen Hosp, Lab Lipid Med & Technol, Dept Med, Boston, MA 02114 USA. [Kang, Jing X.] Harvard Univ, Sch Med, Boston, MA USA. [Nicoletti, Carolina Ferreira] Univ Sao Paulo, Dept Internal Med, Fac Med Ribeirao Preto, BR-14049 Ribeirao Preto, Brazil. [Alfredo Martinez, J.] Univ Navarra, Dept Nutr Food Sci & Physiol, Irunlarrea 1, ES-31008 Pamplona, Spain. [Alfredo Martinez, J.] Univ Navarra, Ctr Nutr Res, E-31080 Pamplona, Spain. [Alfredo Martinez, J.] Navarra Inst Hlth Res IdiSNA, Pamplona, Spain. [Alfredo Martinez, J.] Inst Salud Carlos III, CIBERobn, Physiopathol Obes, Madrid, Spain. RP Martinez, JA (reprint author), Univ Navarra, Dept Nutr Food Sci & Physiol, Irunlarrea 1, ES-31008 Pamplona, Spain. EM jalfmtz@unav.es RI De Caterina, Raffaele/K-3857-2016 OI De Caterina, Raffaele/0000-0003-1637-574X NR 150 TC 1 Z9 1 U1 10 U2 13 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1661-6499 EI 1661-6758 J9 J NUTRIGENET NUTRIGE JI J. Nutrigenet. Nutrigenomics PY 2016 VL 9 IS 1 BP 28 EP 46 DI 10.1159/000446347 PG 19 WC Genetics & Heredity; Nutrition & Dietetics SC Genetics & Heredity; Nutrition & Dietetics GA DP9DS UT WOS:000378797500003 PM 27286972 ER PT J AU Obaid, G Broekgaarden, M Bulin, AL Huang, HC Kuriakose, J Liu, J Hasan, T AF Obaid, Girgis Broekgaarden, Mans Bulin, Anne-Laure Huang, Huang-Chiao Kuriakose, Jerrin Liu, Joyce Hasan, Tayyaba TI Photonanomedicine: a convergence of photodynamic therapy and nanotechnology SO NANOSCALE LA English DT Review ID GROWTH-FACTOR RECEPTOR; NEAR-INFRARED PHOTOIMMUNOTHERAPY; MESOPOROUS SILICA NANOPARTICLES; FLUORESCENCE-GUIDED SURGERY; SQUAMOUS-CELL CARCINOMA; MOUSE-TUMOR MODEL; SINGLET OXYGEN LUMINESCENCE; LONG-CIRCULATING LIPOSOMES; OVARIAN-CANCER CELLS; OF-THE-ART AB As clinical nanomedicine has emerged over the past two decades, phototherapeutic advancements using nanotechnology have also evolved and impacted disease management. Because of unique features attributable to the light activation process of molecules, photonanomedicine (PNM) holds significant promise as a personalized, image-guided therapeutic approach for cancer and non-cancer pathologies. The convergence of advanced photochemical therapies such as photodynamic therapy (PDT) and imaging modalities with sophisticated nanotechnologies is enabling the ongoing evolution of fundamental PNM formulations, such as Visudyne (R), into progressive forward-looking platforms that integrate theranostics (therapeutics and diagnostics), molecular selectivity, the spatiotemporally controlled release of synergistic therapeutics, along with regulated, sustained drug dosing. Considering that the envisioned goal of these integrated platforms is proving to be realistic, this review will discuss how PNM has evolved over the years as a preclinical and clinical amalgamation of nanotechnology with PDT. The encouraging investigations that emphasize the potent synergy between photochemistry and nanotherapeutics, in addition to the growing realization of the value of these multi-faceted theranostic nanoplatforms, will assist in driving PNM formulations into mainstream oncological clinical practice as a necessary tool in the medical armamentarium. C1 [Obaid, Girgis; Broekgaarden, Mans; Bulin, Anne-Laure; Huang, Huang-Chiao; Kuriakose, Jerrin; Liu, Joyce; Hasan, Tayyaba] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. [Obaid, Girgis; Broekgaarden, Mans; Bulin, Anne-Laure; Huang, Huang-Chiao; Kuriakose, Jerrin; Liu, Joyce; Hasan, Tayyaba] Harvard Univ, Sch Med, Boston, MA 02114 USA. [Hasan, Tayyaba] Harvard Univ, Div Hlth Sci & Technol, Cambridge, MA 02139 USA. [Hasan, Tayyaba] MIT, Cambridge, MA 02139 USA. RP Hasan, T (reprint author), Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.; Hasan, T (reprint author), Harvard Univ, Sch Med, Boston, MA 02114 USA.; Hasan, T (reprint author), Harvard Univ, Div Hlth Sci & Technol, Cambridge, MA 02139 USA.; Hasan, T (reprint author), MIT, Cambridge, MA 02139 USA. EM thasan@mgh.harvard.edu FU National Institutes of Health [P01CA084203, R01CA156177, R01CA160998]; Bullock-Wellman Postdoctoral Fellowship [223794]; MGH-Tosteson-Funds for Medical Discovery (FMD) Fellowship [224889] FX We thank Dr Bryan Spring, Dr Srivalleesha Mallidi and Dr Akilan Palanisami for insightful discussions. The support of the National Institutes of Health Grants P01CA084203, R01CA156177, and R01CA160998 to T. H. is gratefully acknowledged. Financial support by the Bullock-Wellman Postdoctoral Fellowship # 223794 for G. O. and the MGH-Tosteson-Funds for Medical Discovery (FMD) Fellowship #224889 for H.-C. H. is also gratefully acknowledged. NR 266 TC 6 Z9 6 U1 32 U2 59 PU ROYAL SOC CHEMISTRY PI CAMBRIDGE PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND SN 2040-3364 EI 2040-3372 J9 NANOSCALE JI Nanoscale PY 2016 VL 8 IS 25 BP 12471 EP 12503 DI 10.1039/c5nr08691d PG 33 WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied SC Chemistry; Science & Technology - Other Topics; Materials Science; Physics GA DP8BE UT WOS:000378722100006 PM 27328309 ER PT S AU Zhang, EZ Hartinger, AE Vakoc, BJ AF Zhang, Ellen Z. Hartinger, Alzbeta E. Vakoc, Benjamin J. BE Jansen, ED TI A Monte Carlo simulator of PS-OCT local birefringence imaging (Conference Presentation) SO OPTICAL INTERACTIONS WITH TISSUE AND CELLS XXVII SE Proceedings of SPIE LA English DT Proceedings Paper CT Conference on Optical Interactions with Tissue and Cells XXVII CY FEB 14-17, 2016 CL San Francisco, CA SP SPIE C1 [Zhang, Ellen Z.; Hartinger, Alzbeta E.; Vakoc, Benjamin J.] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Zhang, EZ (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPIE-INT SOC OPTICAL ENGINEERING PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA SN 0277-786X BN 978-1-62841-940-5 J9 PROC SPIE PY 2016 VL 9706 AR 97060X DI 10.1117/12.2208352 PG 1 WC Engineering, Biomedical; Engineering, Electrical & Electronic; Optics; Physics, Applied SC Engineering; Optics; Physics GA BF0HH UT WOS:000378852400028 ER PT J AU Li, XY Xu, Z Bai, JP Yang, SY Zhao, SL Zhang, YJ Chen, XD Wang, YM AF Li, Xiuying Xu, Zhuo Bai, Jinping Yang, Shuyuan Zhao, Shuli Zhang, Yingjie Chen, Xiaodong Wang, Yimin TI Umbilical Cord Tissue-Derived Mesenchymal Stem Cells Induce T Lymphocyte Apoptosis and Cell Cycle Arrest by Expression of Indoleamine 2, 3-Dioxygenase SO STEM CELLS INTERNATIONAL LA English DT Article ID BONE-MARROW; IMMUNOSUPPRESSIVE PROPERTIES; DEPENDENT KINASES; STROMAL CELLS; IFN-GAMMA; DIFFERENTIATION; PROLIFERATION; INHIBITION; MOLECULES; PLACENTA AB It has been reported that human mesenchymal stem cells are able to inhibit T lymphocyte activation; however, the discrepancy among different sources of MSCs is not well documented. In this study, we have compared the MSCs from bone marrow (BM), adipose tissue (AT), placenta (PL), and umbilical cord (UC) to determine which one displayed the most efficient immunosuppressive effects on phytohemagglutinin-induced T cell proliferation. Among them we found that hUC-MSC has the strongest effects on inhibiting T cell proliferation and is chosen to do the further study. We observed that T lymphocyte spontaneously released abundant IFN-gamma And IFN-gamma secreted by T lymphocyte could induce the expression of indoleamine 2, 3-dioxygenase (IDO) in hUC-MSCs. IDO was previously reported to induce T lymphocyte apoptosis and cell cycle arrest in S phase. When cocultured with hUC-MSCs, T lymphocyte expression of caspase 3 was significantly increased, while Bcl2 and CDK4mRNA expression decreased dramatically. Addition of 1-methyl tryptophan (1-MT), an IDO inhibitor, restored T lymphocyte proliferation, reduced apoptosis, and induced resumption of the cell cycle. In addition, the changes in caspase 3, CDK4, and Bcl2 expression were reversed by 1-MT. These findings demonstrate that hUC-MSCs induce T lymphocyte apoptosis and cell cycle arrest by expressing abundant IDO and provide an explanation for some of the immunomodulatory effects of MSCs. C1 [Li, Xiuying; Bai, Jinping; Wang, Yimin] Jilin Univ, China Japan Union Hosp, Ctr Sci Res, 126 Xiantai St, Changchun 130033, Jilin, Peoples R China. [Xu, Zhuo] Jilin Univ, China Japan Union Hosp, Rehabil Dept, 126 Xiantai St, Changchun 130033, Jilin, Peoples R China. [Yang, Shuyuan; Zhao, Shuli] Shulanshi Peoples Hosp, Shulan 132600, Jilin, Peoples R China. [Zhang, Yingjie] Eugenom Inc, 11107 Roselle St, San Diego, CA 92121 USA. [Chen, Xiaodong] South Texas Vet Hlth Care Syst, Audie L Murphy Div, Res Serv, San Antonio, TX 78229 USA. [Chen, Xiaodong] Univ Texas Hlth Sci Ctr San Antonio, Dept Comprehens Dent, San Antonio, TX 78229 USA. RP Wang, YM (reprint author), Jilin Univ, China Japan Union Hosp, Ctr Sci Res, 126 Xiantai St, Changchun 130033, Jilin, Peoples R China. EM yiminwang@hotmail.com NR 38 TC 1 Z9 1 U1 5 U2 6 PU HINDAWI PUBLISHING CORP PI NEW YORK PA 315 MADISON AVE 3RD FLR, STE 3070, NEW YORK, NY 10017 USA SN 1687-966X EI 1687-9678 J9 STEM CELLS INT JI Stem Cells Int. PY 2016 AR 7495135 DI 10.1155/2016/7495135 PG 11 WC Cell & Tissue Engineering SC Cell Biology GA DQ2XC UT WOS:000379065900001 ER PT J AU Wang, L Mori, W Cheng, R Yui, JJ Hatori, A Ma, LL Zhang, YD Rotstein, BH Fujinaga, M Shimoda, Y Yamasaki, T Xie, L Nagai, Y Minamimoto, T Higuchi, M Vasdev, N Zhang, MR Liang, SH AF Wang, Lu Mori, Wakana Cheng, Ran Yui, Joji Hatori, Akiko Ma, Longle Zhang, Yiding Rotstein, Benjamin H. Fujinaga, Masayuki Shimoda, Yoko Yamasaki, Tomoteru Xie, Lin Nagai, Yuji Minamimoto, Takafumi Higuchi, Makoto Vasdev, Neil Zhang, Ming-Rong Liang, Steven H. TI Synthesis and Preclinical Evaluation of Sulfonamido-based [C-11-Carbonyl]-Carbamates and Ureas for Imaging Monoacylglycerol Lipase SO THERANOSTICS LA English DT Article DE positron emission tomography; monoacylglycerol lipase; MAGL; carbon-11; nonhuman primate; SAR127303 ID ACID AMIDE HYDROLASE; BLOOD-BRAIN-BARRIER; ENDOCANNABINOID SYSTEM; MONOGLYCERIDE LIPASE; ALZHEIMERS-DISEASE; NERVOUS-SYSTEM; INHIBITORS; PET; METABOLISM; LIGANDS AB Monoacylglycerol lipase (MAGL) is a 33 kDa member of the serine hydrolase superfamily that preferentially degrades 2-arachidonoylglycerol (2-AG) to arachidonic acid in the endocannabinoid system. Inhibition of MAGL is not only of interest for probing the cannabinoid pathway but also as a therapeutic and diagnostic target for neuroinflammation. Limited attempts have been made to image MAGL in vivo and a suitable PET ligand for this target has yet to be identified and is urgently sought to guide small molecule drug development in this pathway. Herein we synthesized and evaluated the physiochemical properties of an array of eleven sulfonamido-based carbamates and ureas with a series of terminal aryl moieties, linkers and leaving groups. The most potent compounds were a novel MAGL inhibitor, N-((1-(1H-1,2,4-triazole-1-carbonyl) piperidin-4-yl) methyl)-4-chlorobenzenesulfonamide (TZPU; IC50 = 35.9 nM), and the known inhibitor 1,1,1,3,3,3-hexafluoropropan-2-yl 4-(((4-chlorophenyl) sulfonamido) methyl) piperidine-1-carboxylate (SAR127303; IC50 = 39.3 nM), which were also shown to be selective for MAGL over fatty acid amide hydrolase (FAAH), and cannabinoid receptors (CB1 & CB2). Both of these compounds were radiolabeled with carbon-11 via [C-11] COCl2, followed by comprehensive ex vivo biodistribution and in vivo PET imaging studies in normal rats to determine their brain permeability, specificity, clearance and metabolism. Whereas TZPU did not show adequate specificity to warrant further evaluation, [C-11] SAR127303 was advanced for preliminary PET neuroimaging studies in nonhuman primate. The tracer showed good brain permeability (ca. 1 SUV) and heterogeneous regional brain distribution which is consistent with the distribution of MAGL. C1 [Wang, Lu; Cheng, Ran; Ma, Longle; Rotstein, Benjamin H.; Vasdev, Neil; Liang, Steven H.] Harvard Univ, Div Nucl Med & Mol Imaging, Gordon Ctr Med Imaging, Massachusetts Gen Hosp,Med Sch, Boston, MA 02114 USA. [Wang, Lu; Cheng, Ran; Ma, Longle; Rotstein, Benjamin H.; Vasdev, Neil; Liang, Steven H.] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02114 USA. [Mori, Wakana; Yui, Joji; Hatori, Akiko; Zhang, Yiding; Fujinaga, Masayuki; Shimoda, Yoko; Yamasaki, Tomoteru; Xie, Lin; Nagai, Yuji; Minamimoto, Takafumi; Higuchi, Makoto; Zhang, Ming-Rong] Natl Inst Radiol Sci, Mol Imaging Ctr, Chiba 2638555, Japan. [Cheng, Ran] Tianjin Univ, Sch Pharmaceut Sci & Technol, Tianjin 300072, Peoples R China. RP Liang, SH (reprint author), Harvard Univ, Div Nucl Med & Mol Imaging, Gordon Ctr Med Imaging, Massachusetts Gen Hosp,Med Sch, Boston, MA 02114 USA.; Liang, SH (reprint author), Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02114 USA.; Zhang, MR (reprint author), Natl Inst Radiol Sci, Mol Imaging Ctr, Chiba 2638555, Japan. EM zhang@nirs.go.jp; liang.steven@mgh.harvard.edu RI Minamimoto, Takafumi/D-6610-2012 OI Minamimoto, Takafumi/0000-0003-4305-0174 FU China Scholarship Council Fellowship [201506250036]; NIH career development award from the National Institute on Drug Abuse (NIDA) [1K01DA038000] FX We would like to thank the staff at the radiochemistry program, Gordon Center for Medical Imaging, Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital, MA, USA and National Institute of Radiological Sciences, Chiba, Japan for their support with cyclotron operation, radioisotope production, radiosynthesis and animal experiments. We thank the National Institute of Mental Health's Psychoactive Drug Screening Program (NIMH PDSP) for the compound screening. The NIMH PDSP is directed by Bryan L. Roth MD, PhD at the University of North Carolina at Chapel Hill and Project Officer Jamie Driscoll at NIMH, Bethesda MD, USA. We also thank Drs. Thomas J. Brady and Lee Collier for helpful discussion. R.C. is supported by China Scholarship Council Fellowship (201506250036). S.H.L is a recipient of NIH career development award from the National Institute on Drug Abuse (NIDA 1K01DA038000). NR 44 TC 0 Z9 0 U1 2 U2 6 PU IVYSPRING INT PUBL PI LAKE HAVEN PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA SN 1838-7640 J9 THERANOSTICS JI Theranostics PY 2016 VL 6 IS 8 BP 1145 EP 1159 DI 10.7150/thno.15257 PG 15 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA DP5IL UT WOS:000378529400007 PM 27279908 ER PT S AU Andreozzi, JM Zhang, RX Glaser, AK Gladstone, DJ Jarvis, LA Pogue, BW AF Andreozzi, Jacqueline M. Zhang, Rongxiao Glaser, Adam K. Gladstone, David J. Jarvis, Lesley A. Pogue, Brian W. BE Wax, A Backman, V TI Cherenkov imaging during volumetric modulated arc therapy for real-time radiation beam tracking and treatment response monitoring SO BIOPHYSICS, BIOLOGY, AND BIOPHOTONICS: THE CROSSROADS SE Proceedings of SPIE LA English DT Proceedings Paper CT Conference on Biophysics, Biology, and Biophotonics - The Crossroads CY FEB 13-14, 2016 CL San Francisco, CA SP SPIE DE Cherenkov; Cerenkov; VMAT; radiotherapy; imaging; beam tracking; real-time ID RADIOTHERAPY; TOMOGRAPHY; DOSIMETRY; EMISSION AB External beam radiotherapy utilizes high energy radiation to target cancer with dynamic, patient-specific treatment plans. The otherwise invisible radiation beam can be observed via the optical Cherenkov photons emitted from interaction between the high energy beam and tissue. Using a specialized camera-system, the Cherenkov emission can thus be used to track the radiation beam on the surface of the patient in real-time, even for complex cases such as volumetric modulated arc therapy (VMAT). Two patients undergoing VMAT of the head and neck were imaged and analyzed, and the viability of the system to provide clinical feedback was established. C1 [Andreozzi, Jacqueline M.; Pogue, Brian W.] Thayer Sch Engn Dartmouth, 14 Engn Dr, Hanover, NH 03755 USA. [Zhang, Rongxiao] Massachusetts Gen Hosp, Radiat Oncol Dept, 125 Nashua St, Boston, MA 02114 USA. [Glaser, Adam K.] Univ Washington, Mech Engn, Stevens Way,Box 352600, Seattle, WA 98195 USA. [Gladstone, David J.; Jarvis, Lesley A.] Dartmouth Hitchcock Med Ctr, Norris Cotton Canc Ctr, 1 Med Ctr Dr, Lebanon, NH 03766 USA. RP Andreozzi, JM (reprint author), Thayer Sch Engn Dartmouth, 14 Engn Dr, Hanover, NH 03755 USA. NR 15 TC 0 Z9 0 U1 0 U2 0 PU SPIE-INT SOC OPTICAL ENGINEERING PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA SN 0277-786X BN 978-1-62841-953-5 J9 PROC SPIE PY 2016 VL 9719 AR 971905 DI 10.1117/12.2212844 PG 7 WC Biology; Biophysics; Optics SC Life Sciences & Biomedicine - Other Topics; Biophysics; Optics GA BE9YR UT WOS:000378351400002 ER PT S AU Blatter, C Meijer, EFJ Nam, AS Jones, D Padera, TP Vakoc, BJ AF Blatter, Cedric Meijer, Eelco F. J. Nam, Ahhyun S. Jones, Dennis Padera, Timothy P. Vakoc, Benjamin J. BE Wax, A Backman, V TI Label-free in-vivo measurement of lymph flow velocity using Doppler optical coherence tomography (Conference Presentation) SO BIOPHYSICS, BIOLOGY, AND BIOPHOTONICS: THE CROSSROADS SE Proceedings of SPIE LA English DT Proceedings Paper CT Conference on Biophysics, Biology, and Biophotonics - The Crossroads CY FEB 13-14, 2016 CL San Francisco, CA SP SPIE C1 [Blatter, Cedric; Nam, Ahhyun S.] Wellman Ctr Photomed, Boston, MA 02114 USA. [Meijer, Eelco F. J.; Jones, Dennis; Padera, Timothy P.; Vakoc, Benjamin J.] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Blatter, C (reprint author), Wellman Ctr Photomed, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPIE-INT SOC OPTICAL ENGINEERING PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA SN 0277-786X BN 978-1-62841-953-5 J9 PROC SPIE PY 2016 VL 9719 AR 97190O DI 10.1117/12.2213223 PG 1 WC Biology; Biophysics; Optics SC Life Sciences & Biomedicine - Other Topics; Biophysics; Optics GA BE9YR UT WOS:000378351400019 ER PT J AU Chaudhari, AJ Ferrero, A Godinez, F Yang, K Shelton, DK Hunter, JC Naguwa, SM Boone, JM Raychaudhuri, SP Badawi, RD AF Chaudhari, Abhijit J. Ferrero, Andrea Godinez, Felipe Yang, Kai Shelton, David K. Hunter, John C. Naguwa, Stanley M. Boone, John M. Raychaudhuri, Siba P. Badawi, Ramsey D. TI High-resolution F-18-FDG PET/CT for assessing disease activity in rheumatoid and psoriatic arthritis: findings of a prospective pilot study SO BRITISH JOURNAL OF RADIOLOGY LA English DT Article ID POSITRON-EMISSION-TOMOGRAPHY; CLASSIFICATION CRITERIA; COMPUTED-TOMOGRAPHY; AMERICAN-COLLEGE; BONE EROSIONS; JOINT; SCANNER; BREAST; WRIST; QUANTIFICATION AB Objective: Rheumatoid arthritis (RA) and psoriatic arthritis (PsA) commonly affect the small joints of the wrist and hand. We evaluated the performance of a new, high resolution extremity positron emission tomography (PET)/CT scanner for characterizing and quantifying pathologies associated with the two arthritides in the wrist and hand joints. Methods: Patients with RA or PsA underwent fluorine-18 fludeoxyglucose (F-18-FDG) PET/CT wrist and hand imaging, respectively, on the high-resolution scanner, Calibrated CT images and co-registered PET images were reconstructed. PET/CT was derived for the radiocarpal and pisiform-triquetral compartments, joints with erosive changes, sites of synovitis or tenosynovitis and the nail bed and were correlated with clinical and MRI findings, Results: Significantly elevated F-18-FDG uptake was measured for the radiocarpal and pisiform-triquetral compartments and at sites of bone erosion, synovitis, pannus and oedema, compared with unaffected joints (p < 0.05) in patients with RA, consistent with their clinical findings. In patients with PsA, significantly elevated F-18-FDG uptake was measured for joints with synovitis compared with unaffected joints (p < 0,05), with patterns of F-18-FDG uptake along the tendons, at the enthesis and in the nail bed, consistent with tenosynovitis, enthesitis and nail dystrophy, respectively. Conclusion: High-resolution F-18-FDG PET/CT imaging of the wrist and hand is feasible in an RA or PsA patient cohort and is capable of providing quantifiable measures of disease activity (synovitis, enthesitis, oedema and bone destruction). Advances in knowledge: High-resolution PET/CT imaging shows promise as a tool for understanding the pathogenesis of the arthritic process and for noninvasive, objective assessment of RA or PsA severity and therapy selection. C1 [Chaudhari, Abhijit J.; Ferrero, Andrea; Godinez, Felipe; Yang, Kai; Shelton, David K.; Hunter, John C.; Boone, John M.; Badawi, Ramsey D.] Univ Calif Davis, Dept Radiol, Sacramento, CA 95817 USA. [Ferrero, Andrea] Mayo Clin, Dept Radiol, Rochester, MN USA. [Yang, Kai] Massachusetts Gen Hosp, Dept Radiol, Boston, MA USA. [Naguwa, Stanley M.; Raychaudhuri, Siba P.] Univ Calif Davis, Dept Internal Med, Sacramento, CA 95817 USA. [Raychaudhuri, Siba P.] Sacramento Vet Affairs Med Ctr, Rancho Cordova, CA USA. RP Chaudhari, AJ (reprint author), Univ Calif Davis, Dept Radiol, Sacramento, CA 95817 USA. EM ajchaudhari@ucdavis.edu FU National Institutes of Health [2K12 HD051958, R03 EB015099, R01 CA129561, R01 EB002138, UL1 TR000002] FX This study was funded by the National Institutes of Health grants 2K12 HD051958 and R03 EB015099 to AJC, R01 CA129561 to RDB, R01 EB002138 to JMB and UL1 TR000002 pilot award to RDB and AJC. The views expressed in this article are the authors' own and do not necessarily represent the views of the National Institutes of Health or the US Government. NR 45 TC 1 Z9 1 U1 1 U2 1 PU BRITISH INST RADIOLOGY PI LONDON PA 36 PORTLAND PLACE, LONDON W1N 4AT, ENGLAND SN 0007-1285 EI 1748-880X J9 BRIT J RADIOL JI Br. J. Radiol. PY 2016 VL 89 IS 1063 AR 20160138 DI 10.1259/bjr.20160138 PG 10 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA DO9HP UT WOS:000378096400018 PM 27109738 ER PT J AU Weinstein, GM Arkun, K Kryzanski, J Lanfranchi, M Gupta, GK Bedi, H AF Weinstein, Gene M. Arkun, Knarik Kryzanski, James Lanfranchi, Michael Gupta, Gaurav K. Bedi, Harprit TI Spinal Intradural, Extramedullary Ependymoma with Astrocytoma Component: A Case Report and Review of the Literature SO CASE REPORTS IN PATHOLOGY LA English DT Review ID ANAPLASTIC EPENDYMOMA; TUMORS; DIFFERENTIATION; ORIGIN AB Ependymomas are common spinal lesions, with the vast majority arising in an intramedullary location. Several cases have been described in the literature of ependymomas in an intradural, extramedullary location. The authors present a case of a 56-year-old female who presented with several weeks of lower back pain and weakness. MRI revealed an intradural, extramedullary enhancing mass at L1-L2. The mass was successfully resected surgically. Pathologic evaluation revealed a low grade glioma with components of both ependymoma and pilocytic astrocytoma with MUTYH G382D mutation. Extramedullary ependymomas are very rare tumors. To the authors' knowledge, this is the first case of ependymoma/astrocytoma collision tumors described in an extramedullary location. C1 [Weinstein, Gene M.; Bedi, Harprit] Tufts Med Ctr, Dept Radiol, Boston, MA USA. [Arkun, Knarik; Gupta, Gaurav K.] Tufts Med Ctr, Dept Pathol & Lab Med, Boston, MA USA. [Kryzanski, James] Tufts Med Ctr, Dept Neurosurg, Boston, MA USA. [Lanfranchi, Michael] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. RP Weinstein, GM (reprint author), Tufts Med Ctr, Dept Radiol, Boston, MA USA. EM gene.weinstein@gmail.com NR 24 TC 0 Z9 0 U1 0 U2 0 PU HINDAWI PUBLISHING CORP PI NEW YORK PA 315 MADISON AVE 3RD FLR, STE 3070, NEW YORK, NY 10017 USA SN 2090-6781 EI 2090-679X J9 CASE REP PATHOL JI Case Rep. Pathol. PY 2016 AR 3534791 DI 10.1155/2016/3534791 PG 5 WC Pathology SC Pathology GA DP1SR UT WOS:000378270200001 ER PT J AU Hanson, AJ Banks, WA Saucedo, HH Craft, S AF Hanson, Angela J. Banks, William A. Saucedo, Hector Hernandez Craft, Suzanne TI Apolipoprotein E Genotype and Sex Influence Glucose Tolerance in Older Adults: A Cross-Sectional Study SO DEMENTIA AND GERIATRIC COGNITIVE DISORDERS EXTRA LA English DT Article DE Apolipoprotein epsilon 4 allele; Glucose intolerance; Alzheimer's disease; Oral glucose tolerance test ID MODERATE ALZHEIMERS-DISEASE; INSULIN-RESISTANCE; E POLYMORPHISM; APOE GENOTYPE; INTRANASAL INSULIN; RISK; METABOLISM; POPULATION; BRAIN; ASSOCIATION AB Background: Glucose intolerance and apolipoprotein epsilon 4 allele (epsilon 4+) are risk factors for Alzheimer's disease (AD). Insulin sensitizers show promise for treating AD, but are less effective in E4+ individuals. Little is known about how the APOE genotype influences glucose metabolism. Methods: Cross-sectional analysis of 319 older adults who underwent oral glucose tolerance tests; a subset had insulin, amyloid beta (A beta(42)), and Mini Mental Status Examination. Glucose and insulin patterns with respect to cognitive diagnosis, E4 status, and sex were examined with analysis of covariance and Pearson correlation. Results: People with cognitive impairment had higher fasting insulin levels. E4 status did not affect fasting glucose values, whereas men had higher fasting glucose levels than women. E4+ men had the lowest and E4+ women had the highest glucose levels, compared to E4-groups; insulin did not differ by sex or E4 group. E4 status and sex moderated correlations between metabolic measures and AD risk factors including age and A beta. Conclusions: Insulin resistance was associated with cognitive impairment, and sex, E4 status, and glucose values are interrelated in older adults at risk of AD. Understanding glucose metabolism for different APOE and sex groups may help elucidate differences in therapeutic responses. (C) 2016 The Author(s) Published by S. Karger AG, Basel C1 [Hanson, Angela J.; Banks, William A.] Univ Washington, Sch Med, Dept Med, 325 9th Ave,POB 359755, Seattle, WA 98104 USA. [Hanson, Angela J.; Banks, William A.] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA. [Saucedo, Hector Hernandez; Craft, Suzanne] Wake Forest Univ, Bowman Gray Sch Med, Dept Internal Med, Sticht Ctr Aging, Winston Salem, NC 27103 USA. RP Hanson, AJ (reprint author), Univ Washington, Med Ctr, Dept Med, 325 9th Ave,POB 359755, Seattle, WA 98104 USA. EM hansonaj@uw.edu FU NIA NIH HHS [R01 AG046619, T32 AG000258] NR 38 TC 1 Z9 1 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 1664-5464 J9 DEMENT GER COGN D EX JI Dement. Geriatr. Cogn. Disord. Extra PY 2016 VL 6 IS 1 BP 78 EP 89 DI 10.1159/000444079 PG 12 WC Clinical Neurology SC Neurosciences & Neurology GA DP3VC UT WOS:000378422800008 PM 27065114 ER PT S AU Tehrani, KF Pendleton, EG Lin, CP Mortensen, LJ AF Tehrani, Kayvan F. Pendleton, Emily G. Lin, Charles P. Mortensen, Luke J. BE Farkas, DL Nicolau, DV Leif, RC TI Deep tissue single cell MSC ablation using a fiber laser source to evaluate therapeutic potential in osteogenesis imperfecta SO IMAGING, MANIPULATION, AND ANALYSIS OF BIOMOLECULES, CELLS, AND TISSUES IX SE Proceedings of SPIE LA English DT Proceedings Paper CT Conference on Imaging, Manipulation, and Analysis of Biomolecules, Cells, and Tissues IX CY FEB 16-17, 2016 CL San Francisco, CA SP SPIE DE Ablation of tissue; Fluorescence microscopy; Nonlinear optics; Nonlinear microscopy ID MESENCHYMAL CELLS; STEM-CELL; BONE; CHILDREN; REGENERATION; IMMUNE AB Osteogenesis imperfecta (OI) is a currently uncurable disease where a mutation in collagen type I yields brittle bones. One potential therapy is transplantation of mesenchymal stem cells (MSCs), but controlling and enhancing transplanted cell survival has proven challenging. Therefore, we use a 2-photon imaging system to study individual transplanted cells in the living bone marrow. We ablated cells deep in the bone marrow and observed minimal collateral damage to surrounding tissue. Future work will evaluate the local impact of transplanted MSCs on bone deposition in vivo. C1 [Tehrani, Kayvan F.; Pendleton, Emily G.; Mortensen, Luke J.] Univ Georgia, Regenerat Biosci Ctr, Rhodes Ctr ADS, Athens, GA 30602 USA. [Lin, Charles P.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Adv Microscopy Program,Ctr Syst Biol, Boston, MA USA. [Lin, Charles P.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed, Boston, MA USA. [Mortensen, Luke J.] Univ Georgia, Coll Engn, Athens, GA 30602 USA. RP Mortensen, LJ (reprint author), Univ Georgia, Regenerat Biosci Ctr, Rhodes Ctr ADS, Athens, GA 30602 USA.; Mortensen, LJ (reprint author), Univ Georgia, Coll Engn, Athens, GA 30602 USA. EM luke.mortensen@uga.edu OI Mortensen, Luke/0000-0002-4331-4099 NR 19 TC 1 Z9 1 U1 2 U2 2 PU SPIE-INT SOC OPTICAL ENGINEERING PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA SN 0277-786X BN 978-1-62841-945-0 J9 PROC SPIE PY 2016 VL 9711 AR 97110D DI 10.1117/12.2213292 PG 8 WC Optics; Radiology, Nuclear Medicine & Medical Imaging SC Optics; Radiology, Nuclear Medicine & Medical Imaging GA BE9WA UT WOS:000378222000004 ER PT J AU Liu, WH Ren, LN Wang, T Navarro-Alvarez, N Tang, LJ AF Liu, Wei-hui Ren, Li-na Wang, Tao Navarro-Alvarez, Nalu Tang, Li-jun TI The Involving Roles of Intrahepatic and Extrahepatic Stem/Progenitor Cells (SPCs) to Liver Regeneration SO INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES LA English DT Review DE liver stem/progenitor cells (LSPCs); sinusoidal endothelial progenitor cells (SEPCs); mesenchymal stem cells (MSCs); hematopoietic stem cells (HSCs); liver regeneration ID HEPATIC PROGENITOR CELLS; MESENCHYMAL STEM-CELLS; SINUSOIDAL ENDOTHELIAL-CELLS; BONE-MARROW; RAT-LIVER; ADULT LIVER; STELLATE CELLS; MURINE MODEL; MOUSE-LIVER; OVAL CELLS AB Liver regeneration is usually attributed to mature hepatocytes, which possess a remarkable potential to proliferate under mild to moderate injury. However, when the liver is severely damaged or hepatocyte proliferation is greatly inhibited, liver stem/progenitor cells (LSPCs) will contribute to the liver regeneration process. LSPCs in the developing liver have been extensively characterized, however, their contributing role to liver regeneration has not been completely understood. In addition to the restoration of the liver parenchymal tissue by hepatocytes or/and LSPCs, or in some cases bone marrow (BM) derived cells, such as hematopoietic stem cells (HSCs) and mesenchymal stem cells (MSCs), the wound healing after injury in terms of angiopoiesis by liver sinusoidal endothelial cells (LSECs) or/and sinusoidal endothelial progenitor cells (SEPCs) is another important aspect taking place during regeneration. To conclude, liver regeneration can be mainly divided into three distinct restoring levels according to the cause and severity of injury: hepatocyte dominant regeneration, LSPCs mediated regeneration, extrahepatic stem cells participative regeneration. In this review, we focus on the recent findings of liver regeneration, especially on those related to stem/progenitor cells (SPCs)-mediated regeneration and their potential clinical applications and challenges. C1 [Liu, Wei-hui; Ren, Li-na; Wang, Tao; Tang, Li-jun] Chengdu Mil Gen Hosp, Gen Surg Ctr, Chengdu 610083, Sichuan Provinc, Peoples R China. [Navarro-Alvarez, Nalu] Harvard Univ, Sch Med, Dept Surg, Massachusetts Gen Hosp, Boston, MA 02115 USA. RP Liu, WH (reprint author), Chengdu Mil Gen Hosp, PLA, Gen Surg Ctr, Chengdu 610083, Sichuan Provinc, Peoples R China. EM audiliu12@163.com NR 85 TC 2 Z9 2 U1 0 U2 1 PU IVYSPRING INT PUBL PI LAKE HAVEN PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA SN 1449-2288 J9 INT J BIOL SCI JI Int. J. Biol. Sci. PY 2016 VL 12 IS 8 BP 954 EP 963 DI 10.7150/ijbs.15715 PG 10 WC Biochemistry & Molecular Biology; Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics GA DP1SQ UT WOS:000378270100005 PM 27489499 ER PT J AU Parekh, A Nguyen, PL West, LJ Duarte, C Graham, PL Larock, DR Yeung, V Hurwitz, MD AF Parekh, Arti Nguyen, Paul L. West, Laura J. Duarte, Catherine Graham, Powell L. Larock, Dennis R. Yeung, Vincent Hurwitz, Mark D. TI Feasibility of brachytherapy as monotherapy for high-volume, low-risk prostate cancer SO JOURNAL OF CANCER RESEARCH AND THERAPEUTICS LA English DT Article DE Brachytherapy; percent positive cores; prognostic factors; prostate; prostate-specific antigen ID EXTERNAL-BEAM RADIATION; PERMANENT INTERSTITIAL BRACHYTHERAPY; POSITIVE BIOPSY CORES; LOW-DOSE-RATE; PERINEURAL INVASION; ANDROGEN DEPRIVATION; CLINICAL UTILITY; THERAPY; PERCENTAGE; RADIOTHERAPY AB Background: We sought to determine whether patients with high-volume, low-risk prostate cancer are suitable candidates for ultrasound-guided brachytherapy, monotherapy alone, without supplemental external beam radiation. Materials and Methods: The study cohort comprised 200 consecutive patients who received ultrasound-guided monotherapy from November 02, 1998 to March 26, 2010. Real-time intraoperative treatment planning was performed for all patients. 145 Gy with I-125 was prescribed to the prostate with no margin. The primary endpoint was time to prostate-specific antigen (PSA) failure using the phoenix definition. Cox multivariable regression analysis was used to determine the factors significantly associated with time to PSA failure. Results: Median follow-up was 59 months (range 1.2-146.8 months). The median PSA was 5.0 ng/ml. For the overall cohort, both 5- and 8-year PSA failure-free survival was 92.3% (95% confidence interval [95% CI]: 86.5-95.7%). Low-risk patients per the NCCN criteria had 5- and 8-year PSA failure-free survival of 93.6%. On cox multivariable analysis, only baseline PSA (adjusted hazard ratio: 1.29 [95% CI: 1.02-1.65], P = 0.036) was associated with outcome. Among patients with <33% cores positive, 33-<50% cores positive, and >= 50% cores positive, the 5-year PSA failure-free survival was 92.3% (95% CI: 85.1-96.1%), 91.0% (95% CI: 68.5-97.6%), and 93.3% (95% CI: 61.2-99.0%), respectively. Conclusions: Our analysis indicates that patients with a high number of cores positive for cancer can be adequately treated with modern brachytherapy as monotherapy and be spared the additional morbidity and cost of supplemental external beam radiation or androgen deprivation therapy. C1 [Parekh, Arti] Johns Hopkins Univ Hosp, Dept Radiat Oncol, Baltimore, MD 21287 USA. [Nguyen, Paul L.; West, Laura J.; Duarte, Catherine; Graham, Powell L.] Harvard Univ, Sch Med, Dept Radiat Oncol, Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA. [Larock, Dennis R.] St Annes Hosp, Dept Urol, Fall River, MA USA. [Yeung, Vincent; Hurwitz, Mark D.] Thomas Jefferson Univ, Sidney Kimmel Med Coll, Dept Radiat Oncol, Philadelphia, PA 19107 USA. RP Hurwitz, MD (reprint author), Bodine Ctr, Suite G-301,111 South 11th St, Philadelphia, PA 19107 USA. EM mark.hurwitz@jefferson.edu NR 27 TC 0 Z9 0 U1 2 U2 2 PU MEDKNOW PUBLICATIONS & MEDIA PVT LTD PI MUMBAI PA B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA SN 0973-1482 EI 1998-4138 J9 J CANCER RES THER JI J. Canc. Res. Ther. PD JAN-MAR PY 2016 VL 12 IS 1 BP 406 EP 410 DI 10.4103/0973-1482.180083 PG 5 WC Oncology SC Oncology GA DP0JM UT WOS:000378176100071 PM 27072271 ER PT J AU Fogelberg, DJ Hughes, AJ Vitiello, MV Hoffman, JM Amtmann, D AF Fogelberg, Donald J. Hughes, Abbey J. Vitiello, Michael V. Hoffman, Jeanne M. Amtmann, Dagmar TI Comparison of Sleep Problems in Individuals with Spinal Cord Injury and Multiple Sclerosis SO JOURNAL OF CLINICAL SLEEP MEDICINE LA English DT Article DE multiple sclerosis; self-reported health outcomes; sleep; spinal cord injury ID RESTLESS LEGS SYNDROME; DISABILITY STATUS SCALE; QUALITY-OF-LIFE; FATIGUE; PREVALENCE; INSOMNIA; DISTURBANCES; DYSFUNCTION; POPULATION; SYMPTOMS AB Study Objectives: Sleep problems are common in spinal cord injury (SCI) and multiple sclerosis (MS). However, the degree to which sleep problems differ between these distinct clinical populations has not been evaluated. In this study, we examined self-reported sleep problems in individuals with SCI and those with MS, and compared these clinical groups on the Medical Outcomes Study Sleep Scale (MOS-SS). Methods: Participants were 1,677 individuals (SCI = 581; MS = 1,096) enrolled in longitudinal study of self-reported health outcomes in SCI and MS. Univariate and multivariate analysis of covariance examined group differences on global sleep problems and domain-specific subscales of the MOS-SS. Results: Individuals with SCI reported an average of 30 fewer min of sleep per night (Sleep Quantity subscale) and significantly greater difficulty initiating and maintaining sleep (Sleep Disturbance subscale) compared to individuals with MS. However, groups did not differ on global sleep problems (Sleep Problems Index 9). Conclusions: Although global sleep problems are more common in SCI and MS than in the general population, these groups exhibit differing sleep problem profiles, and thus may require unique treatment approaches to address the specific domains of sleep affected. For individuals with SCI, an additional focus on increasing sleep quantity and reducing sleep disruptions may be warranted. C1 [Fogelberg, Donald J.; Hughes, Abbey J.; Hoffman, Jeanne M.; Amtmann, Dagmar] Univ Washington, Dept Rehabil Med, Box 356490, Seattle, WA 98195 USA. [Hughes, Abbey J.] Vet Affairs Puget Sound Hlth Care Syst, Seattle Div, Multiple Sclerosis Ctr Excellence West, Seattle, WA USA. [Vitiello, Michael V.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. RP Fogelberg, DJ (reprint author), Univ Washington, Dept Rehabil Med, Box 356490, Seattle, WA 98195 USA. EM fogelberg@uw.edu FU Department of Education [NIDRR H133B031129, H133B080025]; National Institutes of Health [NIAMS 5U01AR052171, NICHD K01HD076183]; National Multiple Sclerosis Society [MB 0026] FX This was not an industry supported study. The contents of this article were developed under grants from the Department of Education (NIDRR H133B031129 & H133B080025) and the National Institutes of Health (NIAMS 5U01AR052171 and NICHD K01HD076183). The contents of this paper do not represent the view of the National Institutes of Health or the Department of Education. In addition, the work reported in this manuscript was supported by a mentor-based fellowship grant from the National Multiple Sclerosis Society (MB 0026). The authors have indicated no financial conflicts of interest. The research reported in this manuscript was completed at the University of Washington. NR 43 TC 0 Z9 0 U1 2 U2 2 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 1550-9389 EI 1550-9397 J9 J CLIN SLEEP MED JI J. Clin. Sleep Med. PY 2016 VL 12 IS 5 BP 695 EP 701 DI 10.5664/jcsm.5798 PG 7 WC Clinical Neurology SC Neurosciences & Neurology GA DP2QD UT WOS:000378333300012 PM 26857058 ER PT J AU Aurora, RN Bista, SR Casey, KR Chowdhuri, S Kristo, DA Mallea, JM Ramar, K Rowley, JA Zak, RS Heald, JL AF Aurora, R. Nisha Bista, Sabin R. Casey, Kenneth R. Chowdhuri, Susmita Kristo, David A. Mallea, Jorge M. Ramar, Kannan Rowley, James A. Zak, Rochelle S. Heald, Jonathan L. TI Updated Adaptive Servo-Ventilation Recommendations for the 2012 AASM Guideline: "The Treatment of Central Sleep Apnea Syndromes in Adults: Practice Parameters with an Evidence-Based Literature Review and Meta-Analyses" SO JOURNAL OF CLINICAL SLEEP MEDICINE LA English DT Article DE central sleep apnea; adaptive servo-ventilation; clinical practice guideline ID CHRONIC HEART-FAILURE; CHEYNE-STOKES RESPIRATION; POSITIVE AIRWAY PRESSURE; RANDOMIZED CONTROLLED-TRIAL; SYMPATHETIC-NERVE ACTIVITY; IMPROVES CARDIAC-FUNCTION; AUTO-SERVOVENTILATION; PROGNOSIS; THERAPY AB An update of the 2012 systematic review and meta-analyses were performed and a modified-GRADE approach was used to update the recommendation for the use of adaptive servo-ventilation (ASV) for the treatment of central sleep apnea syndrome (CSAS) related to congestive heart failure (CHF). Meta-analyses demonstrated an improvement in LVEF and a normalization of AHI in all patients. Analyses also demonstrated an increased risk of cardiac mortality in patients with an LVEF of <= 45% and moderate or severe CSA predominant sleep-disordered breathing. These data support a Standard level recommendation against the use of ASV to treat CHF-associated CSAS in patients with an LVEF of <= 45% and moderate or severe CSAS, and an Option level recommendation for the use of ASV in the treatment CHF-associated CSAS in patients with an LVEF > 45% or mild CHF-related CSAS. The application of these recommendations is limited to the target patient populations; the ultimate judgment regarding propriety of any specific care must be made by the clinician. C1 [Aurora, R. Nisha] Johns Hopkins Univ, Sch Med, Baltimore, MD USA. [Bista, Sabin R.] Univ Nebraska Med Ctr, Omaha, NE USA. [Casey, Kenneth R.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. [Chowdhuri, Susmita] John D Dingell VA Med Ctr, Detroit, MI USA. [Chowdhuri, Susmita] Wayne State Univ, Detroit, MI USA. [Kristo, David A.] Univ Pittsburgh, Pittsburgh, PA USA. [Mallea, Jorge M.] Mayo Clin Florida, Transplant Ctr, Jacksonville, FL USA. [Ramar, Kannan] Mayo Clin, Rochester, MN USA. [Rowley, James A.] Wayne State Univ, Sch Med, Dept Med, Detroit, MI 48201 USA. [Zak, Rochelle S.] Univ Calif San Francisco, Sleep Disorders Ctr, San Francisco, CA 94143 USA. [Heald, Jonathan L.] Amer Acad Sleep Med, Darien, IL USA. RP Aurora, RN (reprint author), Johns Hopkins Sleep Disorders Ctr, Johns Hopkins Sch Med, Baltimore, MD USA. EM research@aasmnet.org NR 33 TC 6 Z9 6 U1 3 U2 3 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 1550-9389 EI 1550-9397 J9 J CLIN SLEEP MED JI J. Clin. Sleep Med. PY 2016 VL 12 IS 5 BP 757 EP 761 DI 10.5664/jcsm.5812 PG 5 WC Clinical Neurology SC Neurosciences & Neurology GA DP2QD UT WOS:000378333300019 PM 27092695 ER PT J AU Parent, V Birtwell, KB Lambright, N DuBard, M AF Parent, Veronique Birtwell, Kirstin B. Lambright, Nathan DuBard, Melanie TI Combining CBT and Behavior-Analytic Approaches to Target Severe Emotion Dysregulation in Verbal Youth With ASD and ID SO JOURNAL OF MENTAL HEALTH RESEARCH IN INTELLECTUAL DISABILITIES LA English DT Article DE ABA; adolescents; aggressive behavior; ASD; CBT; emotion dysregulation; generalization; ID; intervention; mental health; youth ID AUTISM SPECTRUM DISORDERS; BASE-LINE DESIGNS; UNITED-STATES; CHILDREN; DISABILITIES; THERAPY; ANXIETY AB This article presents an individual intervention combining cognitive-behavioral and behavior-analytic approaches to target severe emotion dysregulation in verbal youth with autism spectrum disorder (ASD) concurrent with intellectual disability (ID). The article focuses on two specific individuals who received the treatment within a therapeutic school setting. Single-subject methodology utilizing a nonconcurrent multiple-baseline design across behaviors and participants was used to evaluate the intervention. The two participants presented with severe behavioral challenges, including physical aggression and verbal threats to harm others. Results suggest positive outcomes, including a reduction in the frequency and intensity of severe aggressive behavior and an increase in the use of coping skills, self-advocacy, and social participation. The planning and implementation of specific skills-generalization strategies was one innovative element of the intervention that proved to be pivotal to its successful application. Assessment and treatment techniques for different intervention phases are detailed along with two case examples. Intervention challenges, treatment outcomes, and future directions for clinical research are discussed. C1 [Parent, Veronique] Judge Baker Childrens Ctr, Boston, MA USA. [Birtwell, Kirstin B.] Massachusetts Gen Hosp, Lurie Ctr Autism, Lexington, MA USA. [Birtwell, Kirstin B.] Harvard Univ, Sch Med, Boston, MA USA. [Lambright, Nathan] May Inst, Randolph, MA USA. [DuBard, Melanie] Bradley Sch, Providence, RI USA. RP Parent, V (reprint author), 53 Parker Hill Ave, Boston, MA 02120 USA. EM vparent@jbcc.harvard.edu NR 29 TC 0 Z9 0 U1 7 U2 8 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 1931-5864 EI 1931-5872 J9 J MENT HEALTH RES IN JI J. Ment. Health Res. Intellect. Disabil. PY 2016 VL 9 IS 1-2 BP 60 EP 82 DI 10.1080/19315864.2016.1166301 PG 23 WC Education, Special; Psychiatry; Rehabilitation SC Education & Educational Research; Psychiatry; Rehabilitation GA DO9VQ UT WOS:000378136500005 ER PT S AU Fu, MJ Woo, J Liang, ZP Sutton, BP AF Fu, Maojing Woo, Jonghye Liang, Zhi-Pei Sutton, Bradley P. BE Gimi, B Krol, A TI Spatiotemporal-atlas-based Dynamic Speech Imaging SO MEDICAL IMAGING 2016-BIOMEDICAL APPLICATIONS IN MOLECULAR, STRUCTURAL, AND FUNCTIONAL IMAGING SE Proceedings of SPIE LA English DT Proceedings Paper CT SPIE Biomedical Applications in Molecular, Structural and Functional Imaging Conference CY MAR 01-03, 2016 CL San Diego, CA SP SPIE, Modus Med Devices Inc, Bruker, Poco Graphite, imXPAD DE speech imaging; dynamic MRI; partial separability; spatiotemporal atlas; sparsity constraint ID MRI; RECONSTRUCTION; REGISTRATION; ACQUISITION; IMPATIENT AB Dynamic magnetic resonance imaging (DS-MRI) has been recognized as a promising method for visualizing articulatory motion of speech in scientific research and clinical applications. However, characterization of the gestural and acoustical properties of the vocal tract remains a challenging task for DS-MRI because it requires: 1) reconstructing high-quality spatiotemporal images by incorporating stronger prior knowledge; and 2) quantitatively interpreting the reconstructed images that contain great motion variability. This work presents a novel imaging method that simultaneously meets both requirements by integrating a spatiotemporal atlas into a Partial Separability (PS) model-based imaging framework. Through the use of an atlas-driven sparsity constraint, this method is capable of capturing high-quality articulatory dynamics at an imaging speed of 102 frames per second and a spatial resolution of 2.2 x 2.2 mm(2). Moreover, the proposed method enables quantitative characterization of variability of speech motion, compared to the generic motion pattern across all subjects, through the spatial residual components. C1 [Fu, Maojing; Liang, Zhi-Pei] Univ Illinois, Dept Elect & Comp Engn, Urbana, IL 61801 USA. [Fu, Maojing; Liang, Zhi-Pei; Sutton, Bradley P.] Univ Illinois, Beckman Inst Adv Sci & Technol, Urbana, IL 61801 USA. [Woo, Jonghye] Massachusetts Gen Hosp, Gordon Ctr Med Imaging, Boston, MA 02114 USA. [Sutton, Bradley P.] Univ Illinois, Dept Bioengn, Urbana, IL 61801 USA. RP Fu, MJ (reprint author), Univ Illinois, Dept Elect & Comp Engn, Urbana, IL 61801 USA.; Fu, MJ (reprint author), Univ Illinois, Beckman Inst Adv Sci & Technol, Urbana, IL 61801 USA. EM mfu2@illinois.edu RI Sutton, Bradley/A-4801-2008 OI Sutton, Bradley/0000-0002-8443-0408 NR 37 TC 0 Z9 0 U1 1 U2 1 PU SPIE-INT SOC OPTICAL ENGINEERING PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA SN 0277-786X BN 978-1-5106-0023-2 J9 PROC SPIE PY 2016 VL 9788 AR 978804 DI 10.1117/12.2216528 PG 9 WC Optics; Radiology, Nuclear Medicine & Medical Imaging SC Optics; Radiology, Nuclear Medicine & Medical Imaging GA BE9WB UT WOS:000378223800004 ER PT S AU Helmer, KG Chou, MC Preciado, RI Gimi, B Rollins, NK Song, A Turner, J Mori, S AF Helmer, K. G. Chou, M-C. Preciado, R. I. Gimi, B. Rollins, N. K. Song, A. Turner, J. Mori, S. BE Gimi, B Krol, A TI Multi-site study of diffusion metric variability: effects of site, vendor, field strength, and echo time on regions-of-interest and histogram-bin analyses SO MEDICAL IMAGING 2016-BIOMEDICAL APPLICATIONS IN MOLECULAR, STRUCTURAL, AND FUNCTIONAL IMAGING SE Proceedings of SPIE LA English DT Proceedings Paper CT SPIE Biomedical Applications in Molecular, Structural and Functional Imaging Conference CY MAR 01-03, 2016 CL San Diego, CA SP SPIE, Modus Med Devices Inc, Bruker, Poco Graphite, imXPAD DE MRI; diffusion; multi-site study; calibration ID PRINCIPAL EIGENVECTOR MEASUREMENTS; FRACTIONAL ANISOTROPY; MEAN DIFFUSIVITY; BRAIN; REPRODUCIBILITY; 1.5T; VALUES; MRI AB It is now common for magnetic-resonance-imaging (MRI) based multi-site trials to include diffusion-weighted imaging (DWI) as part of the protocol. It is also common for these sites to possess MR scanners of different manufacturers, different software and hardware, and different software licenses. These differences mean that scanners may not be able to acquire data with the same number of gradient amplitude values and number of available gradient directions. Variability can also occur in achievable b-values and minimum echo times. The challenge of a multi-site study then, is to create a common protocol by understanding and then minimizing the effects of scanner variability and identifying reliable and accurate diffusion metrics. This study describes the effect of site, scanner vendor, field strength, and TE on two diffusion metrics: the first moment of the diffusion tensor field (mean diffusivity, MD), and the fractional anisotropy (FA) using two common analyses (region-of-interest and mean-bin value of whole brain histograms). The goal of the study was to identify sources of variability in diffusion-sensitized imaging and their influence on commonly reported metrics. The results demonstrate that the site, vendor, field strength, and echo time all contribute to variability in FA and MD, though to different extent. We conclude that characterization of the variability of DTI metrics due to site, vendor, field strength, and echo time is a worthwhile step in the construction of multi-center trials. C1 [Helmer, K. G.; Preciado, R. I.] Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA. [Helmer, K. G.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA USA. [Helmer, K. G.] Harvard Univ, Sch Med, Boston, MA USA. [Chou, M-C.] Kaohsiung Med Univ, Dept Med Imaging & Radiol Sci, Kaohsiung, Taiwan. [Gimi, B.] Geisel Sch Med Dartmouth, Hanover, NH USA. [Rollins, N. K.] Univ Texas SW Med Ctr Dallas, Radiol, Dallas, TX 75390 USA. [Song, A.] Duke Univ, Sch Med, Brain Imaging & Anal Ctr, Durham, NC USA. [Turner, J.] MIND Res Network, Albuquerque, NM USA. [Mori, S.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA. RP Helmer, KG (reprint author), Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA.; Helmer, KG (reprint author), Massachusetts Gen Hosp, Dept Radiol, Boston, MA USA.; Helmer, KG (reprint author), Harvard Univ, Sch Med, Boston, MA USA. EM helmer@nmr.mgh.harvard.edu NR 14 TC 0 Z9 0 U1 2 U2 2 PU SPIE-INT SOC OPTICAL ENGINEERING PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA SN 0277-786X BN 978-1-5106-0023-2 J9 PROC SPIE PY 2016 VL 9788 AR 97882U DI 10.1117/12.2217445 PG 10 WC Optics; Radiology, Nuclear Medicine & Medical Imaging SC Optics; Radiology, Nuclear Medicine & Medical Imaging GA BE9WB UT WOS:000378223800095 ER PT S AU Helmer, KG Chou, MC Preciado, RI Gimi, B Rollins, NK Song, A Turner, J Mori, S AF Helmer, K. G. Chou, M-C. Preciado, R. I. Gimi, B. Rollins, N. K. Song, A. Turner, J. Mori, S. BE Gimi, B Krol, A TI Multi-site Study of Diffusion Metric Variability: Characterizing the Effects of Site, Vendor, Field Strength, and Echo Time using the Histogram Distance SO MEDICAL IMAGING 2016-BIOMEDICAL APPLICATIONS IN MOLECULAR, STRUCTURAL, AND FUNCTIONAL IMAGING SE Proceedings of SPIE LA English DT Proceedings Paper CT SPIE Biomedical Applications in Molecular, Structural and Functional Imaging Conference CY MAR 01-03, 2016 CL San Diego, CA SP SPIE, Modus Med Devices Inc, Bruker, Poco Graphite, imXPAD DE MRI; diffusion; multi-site study; calibration; histogram distance AB MRI-based multi-site trials now routinely include some form of diffusion-weighted imaging (DWI) in their protocol. These studies can include data originating from scanners built by different vendors, each with their own set of unique protocol restrictions, including restrictions on the number of available gradient directions, whether an externally generated list of gradient directions can be used, and restrictions on the echo time (TE). One challenge of multi-site studies is to create a common imaging protocol that will result in a reliable and accurate set of diffusion metrics. The present study describes the effect of site, scanner vendor, field strength, and TE on two common metrics: the first moment of the diffusion tensor field (mean diffusivity, MD), and the fractional anisotropy (FA). We have shown in earlier work that ROI metrics and the mean of MD and FA histograms are not sufficiently sensitive for use in site characterization. Here we use the distance between whole brain histograms of FA and MD to investigate within- and between-site effects. We concluded that the variability of DTI metrics due to site, vendor, field strength, and echo time could influence the results in multi-center trials and that histogram distance is sensitive metrics for each of these variables. C1 [Helmer, K. G.; Preciado, R. I.] Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA. [Helmer, K. G.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA. [Helmer, K. G.] Harvard Univ, Sch Med, Boston, MA 02115 USA. [Chou, M-C.] Kaohsiung Med Univ, Dept Med Imaging & Radiol Sci, Kaohsiung, Taiwan. [Gimi, B.] Geisel Sch Med Dartmouth, Hanover, NH USA. [Rollins, N. K.] Univ Texas SW Med Ctr Dallas, Radiol, Dallas, TX 75390 USA. [Song, A.] Duke Univ, Sch Med, Brain Imaging & Anal Ctr, Durham, NC USA. [Turner, J.] MIND Res Network, Albuquerque, NM USA. [Mori, S.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA. RP Helmer, KG (reprint author), Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA.; Helmer, KG (reprint author), Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.; Helmer, KG (reprint author), Harvard Univ, Sch Med, Boston, MA 02115 USA. EM helmer@nmr.mgh.harvard.edu NR 14 TC 0 Z9 0 U1 1 U2 1 PU SPIE-INT SOC OPTICAL ENGINEERING PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA SN 0277-786X BN 978-1-5106-0023-2 J9 PROC SPIE PY 2016 VL 9788 AR 97881G DI 10.1117/12.2217449 PG 11 WC Optics; Radiology, Nuclear Medicine & Medical Imaging SC Optics; Radiology, Nuclear Medicine & Medical Imaging GA BE9WB UT WOS:000378223800047 ER PT S AU Ghani, MU Wu, D Wong, MD Ren, LQ Zheng, B Yang, K Wu, XZ Liu, H AF Ghani, Muhammad. U. Wu, Di Wong, Molly D. Ren, Liqiang Zheng, Bin Yang, Kai Wu, Xizeng Liu, Hong BE Kontos, D Flohr, TG Lo, JY TI Quantitative Comparison of Spatial Resolution in Step-and-Shoot and Continuous Motion Digital Breast Tomosynthesis SO MEDICAL IMAGING 2016: PHYSICS OF MEDICAL IMAGING SE Proceedings of SPIE LA English DT Proceedings Paper CT Conference on Medical Imaging - Physics of Medical Imaging CY FEB 28-MAR 02, 2016 CL San Diego, CA SP SPIE, Modus Med Devices Inc, Bruker, Poco Graphite, ImXPAD, Carestream Hlth Inc, GE Healthcare DE Digital Breast Tomosynthesis; step-and-shoot; continuous motion; spatial resolution ID MAMMOGRAPHY; MTF AB This study compares the spatial resolution in step-and-shoot and continuous motion acquisition modes of digital tomosynthesis using a bench-top prototype designed for breast phantoms imaging. The prototype employs a flat panel detector with a 50 mu m pixel pitch, a micro focus x-ray tube and a motorized stage. A sharp metal edge with a thickness of 0.2 mm was used to measure the modulation transfer function (MTF). The edge was rotated from -7.5 degrees to +7.5 degrees with 1.5 degrees increments to acquire 11 angular projections using 40 kVp, 500 mu A with 5.55 s per projection. In continuous motion mode, the motorized stage moved the test object for the whole exposure time at a speed of 0.377 mm/s. The impact of acquisition speed in continuous DBT was also investigated, and a high speed of 0.753 mm/s was used. In step-and-shoot mode, the cutoff frequencies (10% MTF) in projection view (0 degrees) and reconstructed DBT slices were 5.55 lp/mm and 4.95 lp/mm. Spatial resolution dropped in the continuous motion mode of the DBT due to the blur caused by the rotation of the stage and the cutoff frequencies reduced to 3.6 lp/mm and 3.18 lp/mm in the projection view (0 degrees) and reconstructed DBT slices. At high rotational speed in continuous motion mode, the cutoff frequencies in the DBT slices dropped by 17 % to 2.65 lp/mm. Rotational speed of the rotation stage and spatial resolution are interconnected. Hence, reducing the motion blur in the continuous acquisition mode is important to maintain high spatial resolution for diagnostic purposes. C1 [Ghani, Muhammad. U.; Wu, Di; Wong, Molly D.; Ren, Liqiang; Zheng, Bin; Liu, Hong] Univ Oklahoma, Ctr Biomed Engn, Norman, OK 73019 USA. [Ghani, Muhammad. U.; Wu, Di; Wong, Molly D.; Ren, Liqiang; Zheng, Bin; Liu, Hong] Univ Oklahoma, Sch Elect & Comp Engn, Norman, OK 73019 USA. [Yang, Kai] Massachusetts Gen Hosp, Dept Radiol, 55 Fruit St, Boston, MA 02114 USA. [Wu, Xizeng] Univ Alabama Birmingham, Dept Radiol, 619 19th St S 331, Birmingham, AL 35249 USA. RP Liu, H (reprint author), Univ Oklahoma, Ctr Biomed Engn, Norman, OK 73019 USA.; Liu, H (reprint author), Univ Oklahoma, Sch Elect & Comp Engn, Norman, OK 73019 USA. EM liu@ou.edu NR 13 TC 0 Z9 0 U1 0 U2 0 PU SPIE-INT SOC OPTICAL ENGINEERING PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA SN 0277-786X BN 978-1-5106-0018-8 J9 PROC SPIE PY 2016 VL 9783 AR 97836D DI 10.1117/12.2216102 PG 6 WC Optics; Physics, Multidisciplinary; Radiology, Nuclear Medicine & Medical Imaging SC Optics; Physics; Radiology, Nuclear Medicine & Medical Imaging GA BE9YS UT WOS:000378352900215 ER PT S AU Wang, H Yin, ZY Jin, YN Wu, MY Yao, YY Tao, K Kalra, MK De Man, B AF Wang, Hui Yin, Zhye Jin, Yannan Wu, Mingye Yao, Yangyang Tao, Kun Kalra, Mannudeep K. De Man, Bruno BE Kontos, D Flohr, TG Lo, JY TI CT Dose Minimization using Personalized Protocol Optimization and Aggressive Bowtie SO MEDICAL IMAGING 2016: PHYSICS OF MEDICAL IMAGING SE Proceedings of SPIE LA English DT Proceedings Paper CT Conference on Medical Imaging - Physics of Medical Imaging CY FEB 28-MAR 02, 2016 CL San Diego, CA SP SPIE, Modus Med Devices Inc, Bruker, Poco Graphite, ImXPAD, Carestream Hlth Inc, GE Healthcare DE Computed Tomography; mA modulation; dose reduction; aggressive bowtie ID RECONSTRUCTION AB In this study, we propose to use patient-specific x-ray fluence control to reduce the radiation dose to sensitive organs while still achieving the desired image quality (IQ) in the region of interest (ROI). The mA modulation profile is optimized view by view, based on the sensitive organs and the ROI, which are obtained from an ultra-low-dose volumetric CT scout scan Pt We use a clinical chest CT scan to demonstrate the feasibility of the proposed concept: the breast region is selected as the sensitive organ region while the cardiac region is selected as IQ ROI. Two groups of simulations are performed based on the clinical CT dataset. (1) a constant mA scan adjusted based on the patient attenuation (120 kVp, 300 mA), which serves as baseline; (2) an optimized scan with aggressive bowtie and ROI centering combined with patient-specific mA modulation. The results shows that the combination of the aggressive bowtie and the optimized mA modulation can result in 40% dose reduction in the breast region, while the IQ in the cardiac region is maintained More generally, this paper demonstrates the general concept of using a 3D scout scan for optimal scan planning. C1 [Wang, Hui; Wu, Mingye; Yao, Yangyang; Tao, Kun] GE Global Res, CT & Xray Lab, Shanghai, Peoples R China. [Yin, Zhye; Jin, Yannan; De Man, Bruno] GE Global Res, Image Reconstruct Lab, Moscow 123098, Russia. [Kalra, Mannudeep K.] Massachusetts Gen Hosp, Thorac & Cardiac Imaging, Boston, MA 02114 USA. RP De Man, B (reprint author), GE Global Res, Image Reconstruct Lab, Moscow 123098, Russia. EM deman@ge.com NR 10 TC 0 Z9 0 U1 0 U2 0 PU SPIE-INT SOC OPTICAL ENGINEERING PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA SN 0277-786X BN 978-1-5106-0018-8 J9 PROC SPIE PY 2016 VL 9783 AR 978338 DI 10.1117/12.2216570 PG 6 WC Optics; Physics, Multidisciplinary; Radiology, Nuclear Medicine & Medical Imaging SC Optics; Physics; Radiology, Nuclear Medicine & Medical Imaging GA BE9YS UT WOS:000378352900110 ER PT S AU Wu, D Ghani, MU Wong, MD Li, YH Yang, K Chen, WR Zheng, B Liu, H AF Wu, Di Ghani, Muhammad U. Wong, Molly D. Li, Yuhua Yang, Kai Chen, Wei R. Zheng, Bin Liu, Hong BE Kontos, D Flohr, TG Lo, JY TI Quantitative Imaging of the Microbubble Concentrations by Using an In-line Phase Contrast Tomosynthesis Prototype: A Preliminary Phantom Study SO MEDICAL IMAGING 2016: PHYSICS OF MEDICAL IMAGING SE Proceedings of SPIE LA English DT Proceedings Paper CT Conference on Medical Imaging - Physics of Medical Imaging CY FEB 28-MAR 02, 2016 CL San Diego, CA SP SPIE, Modus Med Devices Inc, Bruker, Poco Graphite, ImXPAD, Carestream Hlth Inc, GE Healthcare DE High-energy in-line phase contrast tomosynthesis; Microbubble; CNR; Quantitative imaging; Radiation dose ID RAY; AGENTS AB The purpose of this study is to demonstrate the feasibility of using a high-energy in-line phase contrast tomosynthesis system to quantitatively imaging microbubbles in a tissue simulating phantom under a limited radiation dose. The imaging system used in the investigation was a bench top in-line phase contrast tomosynthesis prototype operated under 120 kVp tube voltage and 0.5 mA tube current. A prime beam filter made of 2.3 mm Cu, 0.8 mm Pb and 1.0 mm Al was employed to obtain as large as possible portion of x-ray photon energy higher than 60 keV. The tissue simulating phantom was built by three acrylic slabs and a wax slab to mimic a 40 mm thick compressed breast. There were two tiny-sized structures with average 1 mm depth engraved on the two different layers. The microbubble suspensions with different concentrations were injected into those tiny structures. The in line phase contrast angular projections acquired were used to reconstruct the in-plane slices of the tiny structures on different layers. The CNRs vs microbubble concentrations were investigated. As the result, the microbubble suspensions were clearly visible, showing higher CNR when compared with the areas with no microbubble. Furthermore, a monotonously increasing relation between CNRs and microbubble concentrations was observed after calculating the area CNR of the phase contrast tomosynthesis slices. C1 [Wu, Di; Ghani, Muhammad U.; Wong, Molly D.; Li, Yuhua; Zheng, Bin; Liu, Hong] Univ Oklahoma, Ctr Bioengn, Norman, OK 73019 USA. [Wu, Di; Ghani, Muhammad U.; Wong, Molly D.; Li, Yuhua; Zheng, Bin; Liu, Hong] Univ Oklahoma, Sch Elect & Comp Engn, Norman, OK 73019 USA. [Yang, Kai] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Chen, Wei R.] Univ Cent Oklahoma, Dept Engn & Phys, Edmond, OK USA. RP Wu, D (reprint author), Univ Oklahoma, Ctr Bioengn, Norman, OK 73019 USA.; Wu, D (reprint author), Univ Oklahoma, Sch Elect & Comp Engn, Norman, OK 73019 USA. NR 19 TC 0 Z9 0 U1 0 U2 0 PU SPIE-INT SOC OPTICAL ENGINEERING PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA SN 0277-786X BN 978-1-5106-0018-8 J9 PROC SPIE PY 2016 VL 9783 AR 97835L DI 10.1117/12.2216661 PG 7 WC Optics; Physics, Multidisciplinary; Radiology, Nuclear Medicine & Medical Imaging SC Optics; Physics; Radiology, Nuclear Medicine & Medical Imaging GA BE9YS UT WOS:000378352900189 ER PT J AU Rayburn, WF Tracy, EE AF Rayburn, William F. Tracy, Erin E. TI Changes in the Practice of Obstetrics and Gynecology SO OBSTETRICAL & GYNECOLOGICAL SURVEY LA English DT Review ID UNITED-STATES; NURSE-PRACTITIONERS; CLINICAL-PRACTICE; AMERICAN-COLLEGE; SURGICAL VOLUME; CLEARER VISION.; CARE; PHYSICIANS; TRENDS; FUTURE AB A projected shortage of obstetrician-gynecologists (OB-GYNs) is a result of both the increasing US population and the relatively static number of residency graduates. In addition, generational changes have contributed to increasing subspecialization, more desiring part-time employment, and earlier retirement. This article reviews data regarding changes in the practice of obstetrics and gynecology. Residency education is focusing more on a core curriculum in general obstetrics and gynecology, while subspecialty fellowship training has grown in popularity. There are no recent data to describe whether OB-GYNs are working fewer hours, yet more are employed in larger practices at mostly metropolitan locations. A team-based care model that incorporates nonphysician clinicians and digital conversion of clinical data has been encouraged to increase accessibility, improve comprehensiveness, commit to more continuity of care, and reduce redundancy. Compared with other medical specialists, OB-GYNs retire slightly earlier, especially females who will represent the field more. The specialty is moving toward a more comprehensive women's health care practice model that is more patient-centered, efficient, cost controlling, team-based, and adaptable to the needs of a diverse population. Implications from these changes for our practices and improving patient care are currently unclear and await more reported experience. Target Audience: Obstetricians, gynecologists, and family physicians. Learning Objectives: After completing this activity, the learner will be better able to describe what changes will impact the future OB-GYN workforce; discuss what changes in practice will be most likely experienced by OB-GYNs; identify various means of addressing the increasing demand for women's health care; describe aims of a framework to guide women's health care. C1 [Rayburn, William F.] Univ New Mexico, Sch Med, Dept Obstet & Gynecol, MSC 10 5580,1 Univ New Mexico Dr, Albuquerque, NM 87131 USA. [Tracy, Erin E.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Vincent Dept Obstet & Gynecol, Boston, MA USA. RP Rayburn, WF (reprint author), Univ New Mexico, Sch Med, Dept Obstet & Gynecol, MSC 10 5580,1 Univ New Mexico Dr, Albuquerque, NM 87131 USA. EM wrayburn@salud.unm.edu NR 53 TC 1 Z9 1 U1 4 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0029-7828 EI 1533-9866 J9 OBSTET GYNECOL SURV JI Obstet. Gynecol. Surv. PD JAN PY 2016 VL 71 IS 1 BP 43 EP 50 PG 8 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA DP0JD UT WOS:000378175200020 PM 26819135 ER PT S AU Brachtel, EF Johnson, NB Huck, AE Rice-Stitt, TL Vangel, MG Smith, BL Tearney, GJ Kang, D AF Brachtel, Elena F. Johnson, Nicole B. Huck, Amelia E. Rice-Stitt, Travis L. Vangel, Mark G. Smith, Barbara L. Tearney, Guillermo J. Kang, DongKyun BE Alfano, RR Demos, SG TI Spectrally encoded confocal microscopy (SECM) for rapid assessment of breast excision specimens (Conference Presentation) SO OPTICAL BIOPSY XIV: TOWARD REAL-TIME SPECTROSCOPIC IMAGING AND DIAGNOSIS SE Proceedings of SPIE LA English DT Proceedings Paper CT Conference on Optical Biopsy XIV - Toward Real-Time Spectroscopic Imaging and Diagnosis CY FEB 15-17, 2016 CL San Francisco, CA SP SPIE C1 [Brachtel, Elena F.; Huck, Amelia E.; Rice-Stitt, Travis L.; Vangel, Mark G.; Smith, Barbara L.; Tearney, Guillermo J.; Kang, DongKyun] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Johnson, Nicole B.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA. RP Brachtel, EF (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPIE-INT SOC OPTICAL ENGINEERING PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA SN 0277-786X BN 978-1-62841-937-5 J9 PROC SPIE PY 2016 VL 9703 AR 97030C DI 10.1117/12.2209699 PG 1 WC Optics; Radiology, Nuclear Medicine & Medical Imaging SC Optics; Radiology, Nuclear Medicine & Medical Imaging GA BE9UY UT WOS:000378218400011 ER PT S AU Adams, DC Hariri, LP Miller, AJ Villiger, M Holz, J Szabari, MV Bouma, BE Luster, AD Medoff, BD Suter, MJ AF Adams, David C. Hariri, Lida P. Miller, Alyssa J. Villiger, Martin Holz, Jasmin Szabari, Margit V. Bouma, Brett E. Luster, Andrew D. Medoff, Benjamin D. Suter, Melissa J. BE Izatt, JA Fujimoto, JG Tuchin, VV TI Studying airway smooth muscle in vivo with PS-OCT SO OPTICAL COHERENCE TOMOGRAPHY AND COHERENCE DOMAIN OPTICAL METHODS IN BIOMEDICINE XX SE Proceedings of SPIE LA English DT Proceedings Paper CT Conference on Optical Coherence Tomography and Coherence Domain Optical Methods in Biomedicine XX CY FEB 15-17, 2016 CL San Francisco, CA SP SPIE C1 [Adams, David C.; Hariri, Lida P.; Miller, Alyssa J.; Villiger, Martin; Holz, Jasmin; Szabari, Margit V.; Luster, Andrew D.; Medoff, Benjamin D.; Suter, Melissa J.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Bouma, Brett E.] Wellman Ctr Photomed, Boston, MA USA. RP Adams, DC (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU SPIE-INT SOC OPTICAL ENGINEERING PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA SN 0277-786X BN 978-1-62841-931-3 J9 PROC SPIE PY 2016 VL 9697 AR 96971H DI 10.1117/12.2214772 PG 1 WC Optics; Radiology, Nuclear Medicine & Medical Imaging SC Optics; Radiology, Nuclear Medicine & Medical Imaging GA BE9SD UT WOS:000378122900041 ER PT S AU Alex, A Li, AR Men, J Jerwick, J Tanzi, RE Zhou, C Zhang, Z Zeng, XX AF Alex, Aneesh Li, Airong Men, Jing Jerwick, Jason Tanzi, Rudolph E. Zhou, Chao Zhang, Zhan Zeng, Xianxu BE Izatt, JA Fujimoto, JG Tuchin, VV TI An integrated optical coherence microscopy imaging and optical stimulation system for optogenetic pacing in Drosophila melanogaster SO OPTICAL COHERENCE TOMOGRAPHY AND COHERENCE DOMAIN OPTICAL METHODS IN BIOMEDICINE XX SE Proceedings of SPIE LA English DT Proceedings Paper CT Conference on Optical Coherence Tomography and Coherence Domain Optical Methods in Biomedicine XX CY FEB 15-17, 2016 CL San Francisco, CA SP SPIE C1 [Alex, Aneesh; Men, Jing; Jerwick, Jason; Zhou, Chao; Zeng, Xianxu] Lehigh Univ, Bethlehem, PA 18015 USA. [Li, Airong; Tanzi, Rudolph E.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Zhang, Zhan] Zhengzhou Univ, Affiliated Hosp 3, Zhengzhou, Peoples R China. RP Alex, A (reprint author), Lehigh Univ, Bethlehem, PA 18015 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPIE-INT SOC OPTICAL ENGINEERING PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA SN 0277-786X BN 978-1-62841-931-3 J9 PROC SPIE PY 2016 VL 9697 AR 96971A DI 10.1117/12.2214671 PG 1 WC Optics; Radiology, Nuclear Medicine & Medical Imaging SC Optics; Radiology, Nuclear Medicine & Medical Imaging GA BE9SD UT WOS:000378122900037 ER PT S AU Curatolo, A Villiger, M Lorenser, D Wijesinghe, P Fritz, A Kennedy, BF Sampson, DD AF Curatolo, Andrea Villiger, Martin Lorenser, Dirk Wijesinghe, Philip Fritz, Alexander Kennedy, Brendan F. Sampson, David D. BE Izatt, JA Fujimoto, JG Tuchin, VV TI Ultrahigh resolution optical coherence elastography using a Bessel beam for extended depth of field SO OPTICAL COHERENCE TOMOGRAPHY AND COHERENCE DOMAIN OPTICAL METHODS IN BIOMEDICINE XX SE Proceedings of SPIE LA English DT Proceedings Paper CT Conference on Optical Coherence Tomography and Coherence Domain Optical Methods in Biomedicine XX CY FEB 15-17, 2016 CL San Francisco, CA SP SPIE DE Optical coherence tomography; Laser beam shaping; Image enhancement; Tissue characterization ID TOMOGRAPHY; MICROSCOPY AB Visualizing stiffness within the local tissue environment at the cellular and sub-cellular level promises to provide insight into the genesis and progression of disease. In this paper, we propose ultrahigh-resolution optical coherence elastography, and demonstrate three-dimensional imaging of local axial strain of tissues undergoing compressive loading. The technique employs a dual-arm extended focus optical coherence microscope to measure tissue displacement under compression. The system uses a broad bandwidth supercontinuum source for ultrahigh axial resolution, Bessel beam illumination and Gaussian beam detection, maintaining sub-2 mu m transverse resolution over nearly 100 mu m depth of field, and spectral-domain detection allowing high displacement sensitivity. The system produces strain elastograms with a record resolution (x,y,z) of 2x2x15 mu m. We benchmark the advances in terms of resolution and strain sensitivity by imaging a suitable inclusion phantom. We also demonstrate this performance on freshly excised mouse aorta and reveal the mechanical heterogeneity of vascular smooth muscle cells and elastin sheets, otherwise unresolved in a typical, lower resolution optical coherence elastography system. C1 [Curatolo, Andrea; Lorenser, Dirk; Wijesinghe, Philip; Fritz, Alexander; Kennedy, Brendan F.; Sampson, David D.] Univ Western Australia, Opt Biomed Engn Lab, 35 Stirling Highway, Crawley, WA 6009, Australia. [Villiger, Martin] Harvard Univ, Sch Med, Wellman Ctr Photomed, 40 Blossom St, Boston, MA 02114 USA. [Villiger, Martin] Massachusetts Gen Hosp, 40 Blossom St, Boston, MA 02114 USA. [Sampson, David D.] Univ Western Australia, Ctr Microscopy Characterisat & Anal, 35 Stirling Highway, Crawley, WA 6009, Australia. RP Curatolo, A (reprint author), Univ Western Australia, Opt Biomed Engn Lab, 35 Stirling Highway, Crawley, WA 6009, Australia. NR 23 TC 0 Z9 0 U1 1 U2 1 PU SPIE-INT SOC OPTICAL ENGINEERING PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA SN 0277-786X BN 978-1-62841-931-3 J9 PROC SPIE PY 2016 VL 9697 AR 96971Q DI 10.1117/12.2214684 PG 8 WC Optics; Radiology, Nuclear Medicine & Medical Imaging SC Optics; Radiology, Nuclear Medicine & Medical Imaging GA BE9SD UT WOS:000378122900048 ER PT S AU Hariri, LP Adams, DC Colby, TV Tager, AM Suter, MJ AF Hariri, Lida P. Adams, David C. Colby, Thomas V. Tager, Andrew M. Suter, Melissa J. BE Izatt, JA Fujimoto, JG Tuchin, VV TI Assessing idiopathic pulmonary fibrosis (IPF) with bronchoscopic OCT SO OPTICAL COHERENCE TOMOGRAPHY AND COHERENCE DOMAIN OPTICAL METHODS IN BIOMEDICINE XX SE Proceedings of SPIE LA English DT Proceedings Paper CT Conference on Optical Coherence Tomography and Coherence Domain Optical Methods in Biomedicine XX CY FEB 15-17, 2016 CL San Francisco, CA SP SPIE C1 [Hariri, Lida P.; Adams, David C.; Tager, Andrew M.; Suter, Melissa J.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Colby, Thomas V.] Mayo Clin Arizona, Phoenix, AZ USA. RP Hariri, LP (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPIE-INT SOC OPTICAL ENGINEERING PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA SN 0277-786X BN 978-1-62841-931-3 J9 PROC SPIE PY 2016 VL 9697 AR 969710 DI 10.1117/12.2214666 PG 1 WC Optics; Radiology, Nuclear Medicine & Medical Imaging SC Optics; Radiology, Nuclear Medicine & Medical Imaging GA BE9SD UT WOS:000378122900032 ER PT S AU Siddiqui, M Tozburun, S Vakoc, BJ AF Siddiqui, Meena Tozburun, Serhat Vakoc, Benjamin J. BE Izatt, JA Fujimoto, JG Tuchin, VV TI Simultaneous high-speed and long-range imaging with optically subsampled OCT (Conference Presentation) SO OPTICAL COHERENCE TOMOGRAPHY AND COHERENCE DOMAIN OPTICAL METHODS IN BIOMEDICINE XX SE Proceedings of SPIE LA English DT Proceedings Paper CT Conference on Optical Coherence Tomography and Coherence Domain Optical Methods in Biomedicine XX CY FEB 15-17, 2016 CL San Francisco, CA SP SPIE C1 [Siddiqui, Meena] MIT, 77 Massachusetts Ave, Cambridge, MA 02139 USA. [Tozburun, Serhat] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. [Vakoc, Benjamin J.] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Siddiqui, M (reprint author), MIT, 77 Massachusetts Ave, Cambridge, MA 02139 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPIE-INT SOC OPTICAL ENGINEERING PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA SN 0277-786X BN 978-1-62841-931-3 J9 PROC SPIE PY 2016 VL 9697 AR 96970N DI 10.1117/12.2214686 PG 1 WC Optics; Radiology, Nuclear Medicine & Medical Imaging SC Optics; Radiology, Nuclear Medicine & Medical Imaging GA BE9SD UT WOS:000378122900021 ER PT S AU Tozburun, S Blatter, C Siddiqui, M Nam, AS Vakoc, BJ AF Tozburun, Serhat Blatter, Cedric Siddiqui, Meena Nam, Ahhyun S. Vakoc, Benjamin J. BE Izatt, JA Fujimoto, JG Tuchin, VV TI Angiographic imaging using an 18.9 MHz swept-wavelength laser that is phase-locked to the data acquisition clock and resonant scanners (Conference Presentation) SO OPTICAL COHERENCE TOMOGRAPHY AND COHERENCE DOMAIN OPTICAL METHODS IN BIOMEDICINE XX SE Proceedings of SPIE LA English DT Proceedings Paper CT Conference on Optical Coherence Tomography and Coherence Domain Optical Methods in Biomedicine XX CY FEB 15-17, 2016 CL San Francisco, CA SP SPIE C1 [Tozburun, Serhat; Blatter, Cedric; Vakoc, Benjamin J.] Wellman Ctr Photomed, Boston, MA 02114 USA. [Siddiqui, Meena] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. [Nam, Ahhyun S.] MIT, Cambridge, MA 02139 USA. RP Tozburun, S (reprint author), Wellman Ctr Photomed, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU SPIE-INT SOC OPTICAL ENGINEERING PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA SN 0277-786X BN 978-1-62841-931-3 J9 PROC SPIE PY 2016 VL 9697 AR 969708 DI 10.1117/12.2214775 PG 1 WC Optics; Radiology, Nuclear Medicine & Medical Imaging SC Optics; Radiology, Nuclear Medicine & Medical Imaging GA BE9SD UT WOS:000378122900008 ER PT S AU Villiger, M Lorenser, D McLaughlin, RA Quirk, BC Kirk, RW Bouma, BE Sampson, DD AF Villiger, Martin Lorenser, Dirk McLaughlin, Robert A. Quirk, Bryden C. Kirk, Rodney W. Bouma, Brett E. Sampson, David D. BE Izatt, JA Fujimoto, JG Tuchin, VV TI Needle-based polarization-sensitive OCT of breast tumor SO OPTICAL COHERENCE TOMOGRAPHY AND COHERENCE DOMAIN OPTICAL METHODS IN BIOMEDICINE XX SE Proceedings of SPIE LA English DT Proceedings Paper CT Conference on Optical Coherence Tomography and Coherence Domain Optical Methods in Biomedicine XX CY FEB 15-17, 2016 CL San Francisco, CA SP SPIE C1 [Villiger, Martin; Bouma, Brett E.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. [Lorenser, Dirk; McLaughlin, Robert A.; Quirk, Bryden C.; Kirk, Rodney W.; Sampson, David D.] Univ Western Australia, Nedlands, WA 6009, Australia. RP Villiger, M (reprint author), Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU SPIE-INT SOC OPTICAL ENGINEERING PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA SN 0277-786X BN 978-1-62841-931-3 J9 PROC SPIE PY 2016 VL 9697 AR 96971E DI 10.1117/12.2214773 PG 1 WC Optics; Radiology, Nuclear Medicine & Medical Imaging SC Optics; Radiology, Nuclear Medicine & Medical Imaging GA BE9SD UT WOS:000378122900040 ER PT S AU Wartak, A Haindl, R Trasischker, W Baumann, B Pircher, M Hitzenberger, CK AF Wartak, Andreas Haindl, Richard Trasischker, Wolfgang Baumann, Bernhard Pircher, Michael Hitzenberger, Christoph K. BE Izatt, JA Fujimoto, JG Tuchin, VV TI Depth encoded three-beam swept source Doppler optical coherence tomography SO OPTICAL COHERENCE TOMOGRAPHY AND COHERENCE DOMAIN OPTICAL METHODS IN BIOMEDICINE XX SE Proceedings of SPIE LA English DT Proceedings Paper CT Conference on Optical Coherence Tomography and Coherence Domain Optical Methods in Biomedicine XX CY FEB 15-17, 2016 CL San Francisco, CA SP SPIE DE optical coherence tomography; Doppler; swept source; multi-channel; joint aperture ID BLOOD-FLOW MEASUREMENT; RESOLUTION AB A novel approach for investigation of human retinal and choroidal blood flow by the means of multi-channel swept source Doppler optical coherence tomography (SS-D-OCT) system is being developed. We present preliminary in vitro measurement results for quantification of the 3D velocity vector of scatterers in a flow phantom. The absolute flow velocity of moving scatterers can be obtained without prior knowledge of flow orientation. In contrast to previous spectral domain (SD-) D-OCT investigations, that already proved the three-channel D-OCT approach to be suitable for in vivo retinal blood flow evaluation, this current work aims for a similar functional approach by means of a differing technique. To the best of our knowledge, this is the first three-channel D-OCT setup featuring a wavelength tunable laser source. Furthermore, we present a modification of our setup allowing a reduction of the former three active illumination channels to one active illumination channel and two passive channels, which only probe the illuminated sample. This joint aperture (JA) approach provides the advantage of not having to divide beam power among three beams to meet corresponding laser safety limits. The in vitro measurement results regarding the flow phantom show good agreement between theoretically calculated and experimentally obtained flow velocity values. C1 [Wartak, Andreas; Haindl, Richard; Trasischker, Wolfgang; Baumann, Bernhard; Pircher, Michael; Hitzenberger, Christoph K.] Med Univ Vienna, Ctr Med Phys & Biomed Engn, Vienna, Austria. [Trasischker, Wolfgang] Harvard Univ, Sch Med, Boston, MA USA. [Trasischker, Wolfgang] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. RP Wartak, A (reprint author), Med Univ Vienna, Ctr Med Phys & Biomed Engn, Vienna, Austria. EM andreas.wartak@meduniwien.ac.at OI Baumann, Bernhard/0000-0001-6419-1932 NR 16 TC 0 Z9 0 U1 0 U2 0 PU SPIE-INT SOC OPTICAL ENGINEERING PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA SN 0277-786X BN 978-1-62841-931-3 J9 PROC SPIE PY 2016 VL 9697 AR 96970K DI 10.1117/12.2214471 PG 7 WC Optics; Radiology, Nuclear Medicine & Medical Imaging SC Optics; Radiology, Nuclear Medicine & Medical Imaging GA BE9SD UT WOS:000378122900019 ER PT S AU Anand, S Thomas, E Hasan, T Maytin, EV AF Anand, Sanjay Thomas, Erik Hasan, Tayyaba Maytin, Edward V. BE Kessel, DH Hasan, T TI Vitamin D for combination photodynamic therapy of skin cancer in individuals with vitamin D deficiency: Insights from a preclinical study in a mouse model of squamous cell carcinoma SO OPTICAL METHODS FOR TUMOR TREATMENT AND DETECTION: MECHANISMS AND TECHNIQUES IN PHOTODYNAMIC THERAPY XXV SE Proceedings of SPIE LA English DT Proceedings Paper CT Conference on Optical Methods for Tumor Treatment and Detection - Mechanisms and Techniques in Photodynamic Therapy XXV CY FEB 13-14, 2016 CL San Francisco, CA SP SPIE ID PROTOPORPHYRIN-IX PRODUCTION; AMINOLEVULINIC ACID; MURINE MODEL; TUMORS; DEATH AB Combination photodynamic therapy (cPDT) in which vitamin D (VD) is given prior to aminolevulinate, a precursor (pro-drug) for protoporphyrin IX (PpIX), is an approach developed in our laboratory. We previously showed that 1 alpha, 25-dihydroxyvitamin D3 (calcitriol), given prior to PDT, enhances accumulation of PpIX and improves cell death post-PDT in a mouse skin cancer model. However, since calcitriol poses a risk for hypercalcemia, we replaced systemic calcitriol with oral cholecalciferol (D3), administered as a high (tenfold, "10K") diet over a ten-day period. Here, we ask whether VD deficiency might alter the response to cPDT. Nude mice were fed a VD-deficient diet for at least 4 weeks ("deficient"); controls were fed a normal 1,000 IU/kg diet ("1K"). Human A431 cells were implanted subcutaneously and mice were switched to the 10K diet or continued on their baseline diets (controls). In other experiments, mice received a human equivalent dose of 50,000 IU D3 by oral gavage, to simulate administration of a single, high-dose VD pill. At various times, tumors were harvested and serum was collected to measure levels of VD metabolic intermediates. A significant increase in PpIX levels and in the expression of differentiation and proliferation markers in tumor tissue was observed after VD supplementation of both the deficient and 1K mice. Further results describing mechanistic details of PpIX enhancement through alteration of heme-and VD-metabolic enzyme levels will be presented. Based on these results, a clinical study using oral vitamin D prior to PDT for human skin cancer should be performed. C1 [Anand, Sanjay; Thomas, Erik; Maytin, Edward V.] Cleveland Clin, Dept Biomed Engn, Cleveland, OH 44106 USA. [Anand, Sanjay; Maytin, Edward V.] Cleveland Clin, Dept Dermatol, Cleveland, OH 44106 USA. [Hasan, Tayyaba; Maytin, Edward V.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed, Boston, MA USA. RP Anand, S (reprint author), Cleveland Clin, Dept Biomed Engn, Cleveland, OH 44106 USA.; Anand, S (reprint author), Cleveland Clin, Dept Dermatol, Cleveland, OH 44106 USA. NR 23 TC 0 Z9 0 U1 0 U2 0 PU SPIE-INT SOC OPTICAL ENGINEERING PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA SN 0277-786X BN 978-1-62841-928-3 J9 PROC SPIE PY 2016 VL 9694 AR 96940K DI 10.1117/12.2214463 PG 7 WC Engineering, Biomedical; Optics; Radiology, Nuclear Medicine & Medical Imaging SC Engineering; Optics; Radiology, Nuclear Medicine & Medical Imaging GA BE9SE UT WOS:000378123900018 ER PT S AU Anbil, SR Rizvi, I Khan, AP Celli, JP Maytin, EV Hasan, T AF Anbil, Sriram R. Rizvi, Imran Khan, Amjad P. Celli, Jonathan P. Maytin, Edward V. Hasan, Tayyaba BE Kessel, DH Hasan, T TI Adapting biomodulatory strategies for treatment in new contexts: pancreatic and oral cancers (Conference Presentation) SO OPTICAL METHODS FOR TUMOR TREATMENT AND DETECTION: MECHANISMS AND TECHNIQUES IN PHOTODYNAMIC THERAPY XXV SE Proceedings of SPIE LA English DT Proceedings Paper CT Conference on Optical Methods for Tumor Treatment and Detection - Mechanisms and Techniques in Photodynamic Therapy XXV CY FEB 13-14, 2016 CL San Francisco, CA SP SPIE C1 [Anbil, Sriram R.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. [Rizvi, Imran] Brigham & Womens Hosp, Boston, MA 02115 USA. [Khan, Amjad P.; Hasan, Tayyaba] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Celli, Jonathan P.] Univ Massachusetts Boston, Boston, MA USA. [Maytin, Edward V.] Cleveland Clin, Lerner Res Inst, Cleveland, OH USA. RP Anbil, SR (reprint author), Harvard Univ, Sch Med, Cambridge, MA 02138 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPIE-INT SOC OPTICAL ENGINEERING PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA SN 0277-786X BN 978-1-62841-928-3 J9 PROC SPIE PY 2016 VL 9694 AR 96940M DI 10.1117/12.2213922 PG 1 WC Engineering, Biomedical; Optics; Radiology, Nuclear Medicine & Medical Imaging SC Engineering; Optics; Radiology, Nuclear Medicine & Medical Imaging GA BE9SE UT WOS:000378123900020 ER PT S AU de Andrade, CT Nogueira, MS Kanick, SC Marra, K Gunn, J Andreozzi, J Samkoe, KS Kurachi, C Pogue, BW AF de Andrade, Cintia Teles Nogueira, Marcelo Saito Kanick, Stephen Chad Marra, Kayla Gunn, Jason Andreozzi, Jacqueline Samkoe, Kimberley S. Kurachi, Cristina Pogue, Brian W. BE Kessel, DH Hasan, T TI Optical spectroscopy of radiotherapy and photodynamic therapy responses in normal rat skin shows vascular breakdown products SO OPTICAL METHODS FOR TUMOR TREATMENT AND DETECTION: MECHANISMS AND TECHNIQUES IN PHOTODYNAMIC THERAPY XXV SE Proceedings of SPIE LA English DT Proceedings Paper CT Conference on Optical Methods for Tumor Treatment and Detection - Mechanisms and Techniques in Photodynamic Therapy XXV CY FEB 13-14, 2016 CL San Francisco, CA SP SPIE DE photodynamic therapy; radiotherapy; optical spectroscopy; vascular breakdown products ID RADIATION AB Photodynamic therapy (PDT) and radiotherapy are non-systemic cancer treatment options with different mechanisms of damage. So combining these techniques has been shown to have some synergy, and can mitigate their limitations such as low PDT light penetration or radiotherapy side effects. The present study monitored the induced tissue changes after PDT, radiotherapy, and a combination protocol in normal rat skin, using an optical spectroscopy system to track the observed biophysical changes. The Wistar rats were treated with one of the protocols: PDT followed by radiotherapy, PDT, radiotherapy and radiotherapy followed by PDT. Reflectance spectra were collected in order to observe the effects of these combined therapies, especially targeting vascular response. From the reflectance, information about oxygen saturation, met-hemoglobin and bilirubin concentration, blood volume fraction (BVF) and vessel radius were extracted from model fitting of the spectra. The rats were monitored for 24 hours after treatment. Results showed that there was no significant variation in the vessel size or BVF after the treatments. However, the PDT caused a significant increase in the met-hemoglobin and bilirubin concentrations, indicating an important blood breakdown. These results may provide an important clue on how the damage establishment takes place, helping to understand the effect of the combination of those techniques in order to verify the existence of a known synergistic effect. C1 [de Andrade, Cintia Teles; Nogueira, Marcelo Saito; Kurachi, Cristina] Univ Sao Paulo, Sao Carlos Inst Phys, BR-13590090 Sao Carlos, SP, Brazil. [de Andrade, Cintia Teles] Minist Educ Brazil, CAPES Fdn, BR-70040020 Brasilia, DF, Brazil. [de Andrade, Cintia Teles; Kanick, Stephen Chad; Marra, Kayla; Gunn, Jason; Samkoe, Kimberley S.; Pogue, Brian W.] Dartmouth Coll, Geisel Sch Med, Dept Surg, 1 Med Ctr Dr, Lebanon, NH 03756 USA. [Andreozzi, Jacqueline; Samkoe, Kimberley S.; Pogue, Brian W.] Dartmouth Coll, Thayer Sch Engn, Hanover, NH 03755 USA. [Pogue, Brian W.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. RP de Andrade, CT (reprint author), Univ Sao Paulo, Sao Carlos Inst Phys, BR-13590090 Sao Carlos, SP, Brazil.; de Andrade, CT (reprint author), Minist Educ Brazil, CAPES Fdn, BR-70040020 Brasilia, DF, Brazil.; de Andrade, CT (reprint author), Dartmouth Coll, Geisel Sch Med, Dept Surg, 1 Med Ctr Dr, Lebanon, NH 03756 USA. RI Sao Carlos Institute of Physics, IFSC/USP/M-2664-2016; USP, CePOF/J-3608-2015 NR 11 TC 0 Z9 0 U1 1 U2 1 PU SPIE-INT SOC OPTICAL ENGINEERING PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA SN 0277-786X BN 978-1-62841-928-3 J9 PROC SPIE PY 2016 VL 9694 AR 969410 DI 10.1117/12.2210988 PG 5 WC Engineering, Biomedical; Optics; Radiology, Nuclear Medicine & Medical Imaging SC Engineering; Optics; Radiology, Nuclear Medicine & Medical Imaging GA BE9SE UT WOS:000378123900033 ER PT S AU Huang, HC Mallidi, S Liu, J Chiang, CT Mai, ZM Goldschmidt, R Rizvi, I Ebrahim-Zadeh, N Hasan, T AF Huang, Huang-Chiao Mallidi, Srivalleesha Liu, Joyce Chiang, Chun-Te Mai, Zhiming Goldschmidt, Ruth Rizvi, Imran Ebrahim-Zadeh, Neema Hasan, Tayyaba BE Kessel, DH Hasan, T TI Mechanistic exploration of a bi-directional PDT-based combination in pancreatic cancer SO OPTICAL METHODS FOR TUMOR TREATMENT AND DETECTION: MECHANISMS AND TECHNIQUES IN PHOTODYNAMIC THERAPY XXV SE Proceedings of SPIE LA English DT Proceedings Paper CT Conference on Optical Methods for Tumor Treatment and Detection - Mechanisms and Techniques in Photodynamic Therapy XXV CY FEB 13-14, 2016 CL San Francisco, CA SP SPIE C1 [Huang, Huang-Chiao; Mallidi, Srivalleesha; Liu, Joyce; Chiang, Chun-Te; Mai, Zhiming; Goldschmidt, Ruth; Rizvi, Imran; Ebrahim-Zadeh, Neema; Hasan, Tayyaba] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Huang, HC (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 3 U2 3 PU SPIE-INT SOC OPTICAL ENGINEERING PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA SN 0277-786X BN 978-1-62841-928-3 J9 PROC SPIE PY 2016 VL 9694 AR 96940W DI 10.1117/12.2217925 PG 1 WC Engineering, Biomedical; Optics; Radiology, Nuclear Medicine & Medical Imaging SC Engineering; Optics; Radiology, Nuclear Medicine & Medical Imaging GA BE9SE UT WOS:000378123900029 ER PT S AU Liu, H Rudd, G Daly, L Hempstead, J Liu, YR Khan, AP Mallidi, S Thomas, R Rizvi, I Arnason, S Cuckov, F Hasan, T Celli, JP AF Liu, Hui Rudd, Grant Daly, Liam Hempstead, Joshua Liu, Yiran Khan, Amjad Pervez Mallidi, Srivalleesha Thomas, Richard Rizvi, Imran Arnason, Stephen Cuckov, Filip Hasan, Tayyaba Celli, Jonathan P. BE Kessel, DH Hasan, T TI Development of low-cost devices for image-guided photodynamic therapy treatment of oral cancer in global health settings SO OPTICAL METHODS FOR TUMOR TREATMENT AND DETECTION: MECHANISMS AND TECHNIQUES IN PHOTODYNAMIC THERAPY XXV SE Proceedings of SPIE LA English DT Proceedings Paper CT Conference on Optical Methods for Tumor Treatment and Detection - Mechanisms and Techniques in Photodynamic Therapy XXV CY FEB 13-14, 2016 CL San Francisco, CA SP SPIE DE Photodynamic therapy; Oral Cancer; LED; Low-cost; Battery-powered ID TOPICAL 5-AMINOLEVULINIC ACID; LIGHT-EMITTING DIODE; LEUKOPLAKIA; CAVITY AB Photodynamic therapy (PDT) is a light-based modality that shows promise for adaptation and implementation as a cancer treatment technology in resource-limited settings. In this context PDT is particularly well suited for treatment of pre-cancer and early stage malignancy of the oral cavity, that present a major global health challenge, but for which light delivery can be achieved without major infrastructure requirements. In recent reports we demonstrated that a prototype low-cost battery-powered 635nm LED light source for ALA-PpIX PDT achieves tumoricidal efficacy in vitro and vivo, comparable to a commercial turn-key laser source. Here, building on these reports, we describe the further development of a prototype PDT device to enable intraoral light delivery, designed for ALA-PDT treatment of precancerous and cancerous lesions of the oral cavity. We evaluate light delivery via fiber bundles and customized 3D printed light applicators for flexible delivery to lesions of varying size and position within the oral cavity. We also briefly address performance requirements (output power, stability, and light delivery) and present validation of the device for ALA-PDT treatment in monolayer squamous carcinoma cell cultures. C1 [Liu, Hui; Hempstead, Joshua; Liu, Yiran; Thomas, Richard; Arnason, Stephen; Celli, Jonathan P.] Univ Massachusetts, Dept Phys, Boston, MA 02125 USA. [Rudd, Grant; Daly, Liam; Cuckov, Filip] Univ Massachusetts, Dept Engn, Boston, MA 02125 USA. [Khan, Amjad Pervez; Mallidi, Srivalleesha; Rizvi, Imran; Hasan, Tayyaba] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. RP Liu, H (reprint author), Univ Massachusetts, Dept Phys, Boston, MA 02125 USA. NR 15 TC 0 Z9 0 U1 0 U2 0 PU SPIE-INT SOC OPTICAL ENGINEERING PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA SN 0277-786X BN 978-1-62841-928-3 J9 PROC SPIE PY 2016 VL 9694 AR 96940C DI 10.1117/12.2212918 PG 6 WC Engineering, Biomedical; Optics; Radiology, Nuclear Medicine & Medical Imaging SC Engineering; Optics; Radiology, Nuclear Medicine & Medical Imaging GA BE9SE UT WOS:000378123900011 ER PT S AU Obaid, G Wang, YC Kuriakose, J Broekgaarden, M Alkhateeb, A Bulin, AL Hui, J Tsourkas, A Hasan, T AF Obaid, Girgis Wang, Yucheng Kuriakose, Jerrin Broekgaarden, Mans Alkhateeb, Ahmed Bulin, Anne-Laure Hui, James Tsourkas, Andrew Hasan, Tayyaba BE Kessel, DH Hasan, T TI Site-specific antibody-liposome conjugation through copper-free click chemistry: a molecular biology approach for targeted photodynamic therapy SO OPTICAL METHODS FOR TUMOR TREATMENT AND DETECTION: MECHANISMS AND TECHNIQUES IN PHOTODYNAMIC THERAPY XXV SE Proceedings of SPIE LA English DT Proceedings Paper CT Conference on Optical Methods for Tumor Treatment and Detection - Mechanisms and Techniques in Photodynamic Therapy XXV CY FEB 13-14, 2016 CL San Francisco, CA SP SPIE C1 [Obaid, Girgis; Wang, Yucheng; Kuriakose, Jerrin; Bulin, Anne-Laure; Hasan, Tayyaba] Wellman Ctr Photomed, Boston, MA 02114 USA. [Broekgaarden, Mans; Alkhateeb, Ahmed] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Wellman Ctr Photomed, Cambridge, MA 02138 USA. [Hui, James; Tsourkas, Andrew] Univ Penn, Philadelphia, PA 19104 USA. RP Obaid, G (reprint author), Wellman Ctr Photomed, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPIE-INT SOC OPTICAL ENGINEERING PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA SN 0277-786X BN 978-1-62841-928-3 J9 PROC SPIE PY 2016 VL 9694 AR 96940U DI 10.1117/12.2214253 PG 1 WC Engineering, Biomedical; Optics; Radiology, Nuclear Medicine & Medical Imaging SC Engineering; Optics; Radiology, Nuclear Medicine & Medical Imaging GA BE9SE UT WOS:000378123900027 ER PT S AU Rizvi, I Briars, EA Bulin, AL Anbil, SR Vecchio, D Alkhateeb, A Hanna, WR Celli, JP Hasan, T AF Rizvi, Imran Briars, Emma A. Bulin, Anne-Laure Anbil, Sriram R. Vecchio, Daniela Alkhateeb, Ahmed Hanna, William R. Celli, Jonathan P. Hasan, Tayyaba BE Kessel, DH Hasan, T TI Designing PDT-based combinations to overcome chemoresistance in heterocellular 3D tumor models (Conference Presentation) SO OPTICAL METHODS FOR TUMOR TREATMENT AND DETECTION: MECHANISMS AND TECHNIQUES IN PHOTODYNAMIC THERAPY XXV SE Proceedings of SPIE LA English DT Proceedings Paper CT Conference on Optical Methods for Tumor Treatment and Detection - Mechanisms and Techniques in Photodynamic Therapy XXV CY FEB 13-14, 2016 CL San Francisco, CA SP SPIE C1 [Rizvi, Imran] Brigham & Womens Hosp, Boston, MA 02115 USA. [Briars, Emma A.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Bulin, Anne-Laure; Anbil, Sriram R.; Vecchio, Daniela; Alkhateeb, Ahmed; Hasan, Tayyaba] Wellman Ctr Photomed, Boston, MA USA. [Hanna, William R.; Celli, Jonathan P.] Univ Massachusetts, Amherst, MA 01003 USA. RP Rizvi, I (reprint author), Brigham & Womens Hosp, Boston, MA 02115 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPIE-INT SOC OPTICAL ENGINEERING PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA SN 0277-786X BN 978-1-62841-928-3 J9 PROC SPIE PY 2016 VL 9694 AR 969404 DI 10.1117/12.2213436 PG 1 WC Engineering, Biomedical; Optics; Radiology, Nuclear Medicine & Medical Imaging SC Engineering; Optics; Radiology, Nuclear Medicine & Medical Imaging GA BE9SE UT WOS:000378123900003 ER PT S AU Spring, BQ Sears, RB Zheng, LZ Mai, ZM Watanabe, R Sherwood, ME Schoenfeld, DA Pogue, BW Pereira, SP Villa, E Hasan, T AF Spring, Bryan Q. Sears, R. Bryan Zheng, Lei Z. Mai, Zhiming Watanabe, Reika Sherwood, Margaret E. Schoenfeld, David A. Pogue, Brian W. Pereira, Stephen P. Villa, Elizabeth Hasan, Tayyaba BE Kessel, DH Hasan, T TI Photodynamic therapy with simultaneous suppression of multiple treatment escape pathways (Conference Presentation) SO OPTICAL METHODS FOR TUMOR TREATMENT AND DETECTION: MECHANISMS AND TECHNIQUES IN PHOTODYNAMIC THERAPY XXV SE Proceedings of SPIE LA English DT Proceedings Paper CT Conference on Optical Methods for Tumor Treatment and Detection - Mechanisms and Techniques in Photodynamic Therapy XXV CY FEB 13-14, 2016 CL San Francisco, CA SP SPIE C1 [Spring, Bryan Q.; Sears, R. Bryan; Zheng, Lei Z.; Mai, Zhiming; Sherwood, Margaret E.; Schoenfeld, David A.; Hasan, Tayyaba] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Watanabe, Reika; Villa, Elizabeth] Univ Calif San Diego, La Jolla, CA 92093 USA. [Pogue, Brian W.] Thayer Sch Engn Dartmouth, Hanover, NH USA. [Pereira, Stephen P.] UCL, London WC1E 6BT, England. RP Spring, BQ (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU SPIE-INT SOC OPTICAL ENGINEERING PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA SN 0277-786X BN 978-1-62841-928-3 J9 PROC SPIE PY 2016 VL 9694 AR 969409 DI 10.1117/12.2213828 PG 1 WC Engineering, Biomedical; Optics; Radiology, Nuclear Medicine & Medical Imaging SC Engineering; Optics; Radiology, Nuclear Medicine & Medical Imaging GA BE9SE UT WOS:000378123900008 ER PT J AU Ahmed, R Rifat, AA Yetisen, AK Salem, MS Yun, SH Butt, H AF Ahmed, Rajib Rifat, Ahmmed A. Yetisen, Ali K. Salem, Michel Saab Yun, Seok-Hyun Butt, Haider TI Optical microring resonator based corrosion sensing SO RSC ADVANCES LA English DT Article ID WAVE-GUIDE; RING-RESONATOR; STEEL; DEVICES AB A refractive index (RI) based corrosion sensor that could measure the oxidation of iron metal to iron-oxide was numerically investigated with a finite element method. The sensor is based on an optical microring resonator with periodically arranged iron nanodisks (NDs) in a ring waveguide (WG). The microring resonator showed a linear resonance frequency shift as iron was oxidized due to RI variation and back scattered light, as compared to conditions with no ND ring. The resonance wavelength shift depended on the number of NDs and the spacing between the NDs. Free spectral range and sensor sensitivity were 40 nm and 517 nm RIU-1 with 10 NDs with 50 nm spacing. Optimization of the sensor parameters allowed a two-fold improvement in sensitivity and achieved a quality factor of 188. The sensitivity and Q-factor showed a linear relationship with increasing ND numbers and spacing. The microring resonator based optical corrosion sensor will find applications in real-time, label-free corrosion quantification. C1 [Ahmed, Rajib; Salem, Michel Saab; Butt, Haider] Univ Birmingham, Sch Engn, Nanotechnol Lab, Birmingham B15 2TT, W Midlands, England. [Rifat, Ahmmed A.] Univ Malaya, Dept Elect Engn, Integrated Lightwave Res Grp, Fac Engn, Kuala Lumpur 50603, Malaysia. [Yetisen, Ali K.; Yun, Seok-Hyun] Harvard Univ, Sch Med, 65 Landsdowne St, Cambridge, MA 02139 USA. [Yetisen, Ali K.; Yun, Seok-Hyun] Massachusetts Gen Hosp, Wellman Ctr Photomed, 65 Landsdowne St, Cambridge, MA 02139 USA. [Yetisen, Ali K.; Yun, Seok-Hyun] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA. RP Butt, H (reprint author), Univ Birmingham, Sch Engn, Nanotechnol Lab, Birmingham B15 2TT, W Midlands, England. EM h.butt@bham.ac.uk RI engineering, @UM-2016/I-9329-2016; OI Butt, Haider/0000-0003-2434-9525 NR 37 TC 11 Z9 11 U1 4 U2 5 PU ROYAL SOC CHEMISTRY PI CAMBRIDGE PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND SN 2046-2069 J9 RSC ADV JI RSC Adv. PY 2016 VL 6 IS 61 BP 56127 EP 56133 DI 10.1039/c6ra11538a PG 7 WC Chemistry, Multidisciplinary SC Chemistry GA DP1UR UT WOS:000378275400055 ER PT S AU Humar, M Yun, SH AF Humar, Matjaz Yun, Seok-Hyun BE Bui, TX Sprague, RH TI Microlasers Inside Live Cells SO 2016 49TH HAWAII INTERNATIONAL CONFERENCE ON SYSTEM SCIENCES (HICSS) SE Proceedings of the Annual Hawaii International Conference on System Sciences LA English DT Proceedings Paper CT 49th Hawaii International Conference on System Sciences (HICSS) CY JAN 05-08, 2016 CL Koloa, HI SP Pacific Res Inst Informat Syst & Management, Univ Hawaii, Shidler Coll Business, Dept IT Management, IBM, Provalis Res, Int Soc Serv Innovat, Teradata, Univ Network ID OPTICAL MICROCAVITIES; LABEL-FREE; SINGLE AB Here we show, for the first time to our knowledge, stand-alone cell lasers with both gain medium and cavity inside cells. Cells have natural tendency to engulf micro beads made of polystyrene or glass, and we use these microspheres to generate whispering-galley-mode (WGM) lasing inside cytoplasm. The gain was provided by fluorescent dye molecules embedded in the microspheres or in the cytosol. Upon optical pumping, the output emission from the cells show characteristic WGM resonance. By analyzing the wavelengths of the oscillation modes we can determine the bead size with a precision of 50 pm. Using the mode diameter as a unique identifier, one may distinguish more than thousands of cells. Furthermore, we demonstrate real-time sensing of the intracellular refractive index changes. C1 [Humar, Matjaz; Yun, Seok-Hyun] Harvard Univ, Sch Med, Dept Dermatol, Wellman Ctr Photomed, 65 Landsdowne St UP-5, Cambridge, MA 02139 USA. [Humar, Matjaz; Yun, Seok-Hyun] Massachusetts Gen Hosp, Cambridge, MA 02139 USA. [Humar, Matjaz] Jozef Stefan Inst, Condensed Matter Dept, Ljubljana 1000, Bangladesh. RP Humar, M (reprint author), Harvard Univ, Sch Med, Dept Dermatol, Wellman Ctr Photomed, 65 Landsdowne St UP-5, Cambridge, MA 02139 USA. EM mhumar@mgh.harvard.edu RI Humar, Matjaz/I-8862-2012 OI Humar, Matjaz/0000-0003-3338-6723 NR 12 TC 0 Z9 0 U1 1 U2 2 PU IEEE COMPUTER SOC PI LOS ALAMITOS PA 10662 LOS VAQUEROS CIRCLE, PO BOX 3014, LOS ALAMITOS, CA 90720-1264 USA SN 1060-3425 BN 978-0-7695-5670-3 J9 P ANN HICSS PY 2016 PG 2 WC Computer Science, Information Systems; Computer Science, Theory & Methods; Engineering, Electrical & Electronic SC Computer Science; Engineering GA BE9EW UT WOS:000377358203069 ER PT J AU Bohr, S Pallua, N AF Bohr, S. Pallua, N. TI Early Functional Treatment and Modern Cast Making for Indications in Hand Surgery SO ADVANCES IN ORTHOPEDICS LA English DT Review ID FRACTURES AB Cast treatment can serve both as a nonsurgical treatment option and as a means for providing postoperative protection. However, with the duration of immobilization intervals, the benefits of cast treatment, especially in hand surgery, are at risk of being outweighed by undesired drawbacks such as joint stiffening and contracture formation. In order to minimize potential complications commonly associated with cast treatment, efforts to further improve cast making must attempt to reconcile two conflicting objectives: (1) to achieve stability and rigidity at the site of injury (e.g., fracture retention) and (2) to allow free range of joint movement as early as possible. In addition, in order to assure patient compliance, modern cast treatments should aim to improve wearing-comfort of the cast. This paper describes modern cast designs for four common types hand injuries, with sample cases highlighting the clinical outcome of each treatment. C1 [Bohr, S.; Pallua, N.] Rhein Westfal TH Aachen, Univ Clin, Burn Ctr, Dept Plast & Hand Surg, Pauwelsstr 30,9th Floor,B2 R11, D-52074 Aachen, Germany. [Bohr, S.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Engn Med Surg Serv, Boston, MA 02114 USA. [Bohr, S.] Shriners Hosp Children, Boston, MA 02114 USA. [Bohr, S.] Univ Clin, Dept Trauma Surg Plast & Reconstruct Surg, Gottingen, Germany. RP Bohr, S (reprint author), Rhein Westfal TH Aachen, Univ Clin, Burn Ctr, Dept Plast & Hand Surg, Pauwelsstr 30,9th Floor,B2 R11, D-52074 Aachen, Germany.; Bohr, S (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Engn Med Surg Serv, Boston, MA 02114 USA.; Bohr, S (reprint author), Shriners Hosp Children, Boston, MA 02114 USA.; Bohr, S (reprint author), Univ Clin, Dept Trauma Surg Plast & Reconstruct Surg, Gottingen, Germany. EM sbohr@ukaachen.de NR 24 TC 0 Z9 0 U1 1 U2 1 PU HINDAWI PUBLISHING CORP PI NEW YORK PA 315 MADISON AVE 3RD FLR, STE 3070, NEW YORK, NY 10017 USA SN 2090-3464 EI 2090-3472 J9 ADV ORTHOP JI Adv. Orthop. PY 2016 AR 5726979 DI 10.1155/2016/5726979 PG 7 WC Orthopedics SC Orthopedics GA DO8XU UT WOS:000378069600001 ER PT J AU Rhee, EP Clish, CB Wenger, J Roy, J Elmariah, S Pierce, KA Bullock, K Anderson, AH Gerszten, RE Feldman, HI AF Rhee, Eugene P. Clish, Clary B. Wenger, Julia Roy, Jason Elmariah, Sammy Pierce, Kerry A. Bullock, Kevin Anderson, Amanda H. Gerszten, Robert E. Feldman, Harold I. TI Metabolomics of Chronic Kidney Disease Progression: A Case-Control Analysis in the Chronic Renal Insufficiency Cohort Study SO AMERICAN JOURNAL OF NEPHROLOGY LA English DT Article DE Bionnarkers; Chronic kidney disease; Chronic kidney disease progression; Metabolism; Metabolomics ID URIC-ACID; GENERAL-POPULATION; WIDE ASSOCIATION; INCIDENT CKD; AMINO-ACIDS; RISK; COMMUNITY; 1,25-DIHYDROXYVITAMIN-D; DYSFUNCTION; METABOLISM AB Background: Whereas several longitudinal metabolomics studies have been conducted in individuals with normal estimated glonnerular filtration rate (eGFR) at baseline, disease progression among individuals with established chronic kidney disease (CKD) has not been rigorously examined. Methods: We performed a nested case -control study of rapid CKD progression in the Chronic Renal Insufficiency Cohort Study, profiling baseline plasma from 200 individuals each with eGFR slope <-3 nnl/nnin/1.73 m(2)/year (cases) or between -1 and +1 ml/nnin/1.73 m(2)/year (controls), matched on baseline eGFR and proteinuria. To directly assess how the kidney modulates circulating metabolites, we profiled plasma from the aorta and renal vein of 25 hospital-based individuals. Results: At baseline, cases and controls had a mean eGFR of 41.7 13.3 and 45.0 14.5 ml/nnin/1.73 m(2), respectively. Ten plasma metabolites were nominally associated with CKD progression in logistic regression models adjusted for age, sex, race/ethnicity, hypertension, systolic and diastolic blood pressure, diabetes, eGFR and proteinuria; no metabolite achieved the Bonferroni-adjusted significance threshold (p < 0.0003). In a cross-sectional analysis, all 6 of the metabolites that were higher in cases than controls were significantly associated with eGFR at baseline. By contrast, threonine, nnethionine and arginine were lower in cases than in controls and had no association with baseline eGFR. Furthermore, in the hospital -based cohort that underwent renal arteriovenous sampling, these 3 metabolites were net released from the kidney. Combining these metabolites into a panel of markers further strengthened their association with CKD progression. Conclusion: Our results motivate interest in arginine, nnethionine and threonine as potential indicators of renal metabolic function and markers of renal prognosis. (C) 2016 S. Karger AG, Basel C1 [Rhee, Eugene P.; Clish, Clary B.; Pierce, Kerry A.; Bullock, Kevin] Broad Inst, Metabolite Profiling, Cambridge, MA USA. [Wenger, Julia] Univ N Carolina, Kidney Ctr, Chapel Hill, NC USA. [Rhee, Eugene P.] Massachusetts Gen Hosp, Renal Unit, Thier Bldg,50 Blossom St,Thier 1051, Boston, MA 02114 USA. [Rhee, Eugene P.] Massachusetts Gen Hosp, Endocrine Unit, Thier Bldg,50 Blossom St,Thier 1051, Boston, MA 02114 USA. [Elmariah, Sammy] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA. [Gerszten, Robert E.] Beth Israel Deaconess Med Ctr, Div Cardiovasc Med, Boston, MA 02215 USA. [Anderson, Amanda H.; Feldman, Harold I.] Univ Penn, Perelman Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. [Feldman, Harold I.] Univ Penn, Perelman Sch Med, Renal Elect & Hypertens Div, Dept Med, Philadelphia, PA 19104 USA. RP Rhee, EP (reprint author), Massachusetts Gen Hosp, Renal Unit, Thier Bldg,50 Blossom St,Thier 1051, Boston, MA 02114 USA.; Rhee, EP (reprint author), Massachusetts Gen Hosp, Endocrine Unit, Thier Bldg,50 Blossom St,Thier 1051, Boston, MA 02114 USA. EM eprhee@partners.org FU NIH [U01DK060990, K08-DK-090142]; Extramural Grant Program of Satellite Healthcare FX This study was supported by NIH grants U01DK060990, K08-DK-090142 and the Extramural Grant Program of Satellite Healthcare, a not-for-profit renal care provider. NR 32 TC 2 Z9 2 U1 5 U2 9 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0250-8095 EI 1421-9670 J9 AM J NEPHROL JI Am. J. Nephrol. PY 2016 VL 43 IS 5 BP 366 EP 374 DI 10.1159/000446484 PG 9 WC Urology & Nephrology SC Urology & Nephrology GA DO7UX UT WOS:000377989600008 PM 27172772 ER PT J AU Saulite, I Roider, E Darlenksi, R Jalili, A Guenova, E AF Saulite, Ieva Roider, Elisabeth Darlenksi, Razvigor Jalili, Ahmad Guenova, Emmanuella TI Cutaneous Oncology: From Research to Diagnosis and Management SO BIOMED RESEARCH INTERNATIONAL LA English DT Editorial Material C1 [Saulite, Ieva] Riga Stradins Univ, Dept Infectol & Dermatol, Riga, Latvia. [Roider, Elisabeth] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Dermatol,Cutaneous Biol Res Ctr, Charlestown, MA USA. [Darlenksi, Razvigor] Tokuda Hosp Sofia, Dept Dermatol & Venereol, Sofia, Bulgaria. [Darlenksi, Razvigor] Trakia Univ, Sect Dermatol & Venereol, Stara Zagora, Bulgaria. [Jalili, Ahmad] Med Univ Vienna, Dept Dermatol, DIAID, Vienna, Austria. [Guenova, Emmanuella] Univ Zurich, Univ Zurich Hosp, Dept Dermatol, Gloriastr 31, CH-8091 Zurich, Switzerland. RP Guenova, E (reprint author), Univ Zurich, Univ Zurich Hosp, Dept Dermatol, Gloriastr 31, CH-8091 Zurich, Switzerland. EM emmanuella.guenova@gmail.com NR 0 TC 0 Z9 0 U1 1 U2 1 PU HINDAWI PUBLISHING CORP PI NEW YORK PA 315 MADISON AVE 3RD FLR, STE 3070, NEW YORK, NY 10017 USA SN 2314-6133 EI 2314-6141 J9 BIOMED RES INT JI Biomed Res. Int. PY 2016 AR 7819428 DI 10.1155/2016/7819428 PG 2 WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental SC Biotechnology & Applied Microbiology; Research & Experimental Medicine GA DO7TX UT WOS:000377987000001 ER PT J AU Kim, PG Suh, J Adelman, MW Oduro, K Williams, E Brunner, AM Kuter, DJ AF Kim, Peter Geon Suh, Joome Adelman, Max W. Oduro, Kwadwo Williams, Erik Brunner, Andrew M. Kuter, David J. TI Pure White Cell Aplasia and Necrotizing Myositis SO CASE REPORTS IN HEMATOLOGY LA English DT Article ID INTRAVENOUS IMMUNOGLOBULIN; MYASTHENIA-GRAVIS; AGRANULOCYTOSIS; THYMOMA; ANTIBODIES; PATIENT; AUTOANTIBODIES; AZITHROMYCIN; INHIBITION; REMISSION AB Pure white cell aplasia (PWCA) is a rare hematologic disorder characterized by the absence of neutrophil lineages in the bone marrow with intact megakaryopoiesis and erythropoiesis. PWCA has been associated with autoimmune, drug-induced, and viral exposures. Here, we report a case of a 74-year-old female who presented with severe proximal weakness without pain and was found to have PWCA with nonspecific inflammatory necrotizingmyositis and acute liver injury on biopsies. These findings were associated with a recent course of azithromycin and her daily use of a statin. Myositis improved on prednisone but PWCA persisted. With intravenous immunoglobulin and granulocyte-colony stimulating factor therapies, her symptoms and neutrophil counts improved and were sustained for months. C1 [Kim, Peter Geon; Suh, Joome; Adelman, Max W.; Brunner, Andrew M.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. [Oduro, Kwadwo; Williams, Erik] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA. [Brunner, Andrew M.; Kuter, David J.] Massachusetts Gen Hosp, Dept Hematol Oncol, Boston, MA 02114 USA. RP Kim, PG (reprint author), Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. EM gkim0@partners.org NR 33 TC 0 Z9 0 U1 0 U2 0 PU HINDAWI PUBLISHING CORP PI NEW YORK PA 315 MADISON AVE 3RD FLR, STE 3070, NEW YORK, NY 10017 USA SN 2090-6560 EI 2090-6579 J9 CASE REP HEMATOL JI Case Rep. Hematol. PY 2016 AR 4161679 DI 10.1155/2016/4161679 PG 5 WC Hematology SC Hematology GA DO9AF UT WOS:000378076000001 ER PT J AU Nigwekar, SU Kang, A Zoungas, S Cass, A Gallagher, MP Kulshrestha, S Navaneethan, SD Perkovic, V Strippoli, GFM Jardine, MJ AF Nigwekar, Sagar U. Kang, Amy Zoungas, Sophia Cass, Alan Gallagher, Martin P. Kulshrestha, Satyarth Navaneethan, Sankar D. Perkovic, Vlado Strippoli, Giovanni F. M. Jardine, Meg J. TI Interventions for lowering plasma homocysteine levels in dialysis patients SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS LA English DT Review ID STAGE RENAL-DISEASE; CHRONIC KIDNEY-DISEASE; RANDOMIZED CONTROLLED-TRIAL; FOLIC-ACID SUPPLEMENTATION; CHRONIC-HEMODIALYSIS PATIENTS; N-3 FATTY-ACIDS; INTRAVENOUS N-ACETYLCYSTEINE; PLACEBO-CONTROLLED TRIAL; INTIMA-MEDIA THICKNESS; DECREASES CARDIOVASCULAR EVENTS AB Background People with end-stage kidney disease (ESKD) have high rates of cardiovascular events. Randomised controlled trials (RCTs) of homocysteine-lowering therapies have not shown reductions in cardiovascular event rates in the general population. However, people with kidney disease have higher levels of homocysteine and may have different mechanisms of cardiovascular disease. We performed a systematic review of the effect of homocysteine-lowering therapies in people with ESKD. Objectives To evaluate the benefits and harms of established homocysteine lowering therapy (folic acid, vitamin B-6, vitamin B-12) on all-cause mortality and cardiovascular event rates in patients with ESKD. Search methods We searched Cochrane Kidney and Transplant's Specialised Register to 25 January 2016 through contact with the Information Specialist using search terms relevant to this review. Selection criteria Studies conducted in people with ESKD that reported at least 100 patient-years of follow-up and assessed the effect of therapies that are known to have homocysteine-lowering properties were included. Data collection and analysis Two authors independently extracted data using a standardised form. The primary outcome was cardiovascular mortality. Secondary outcomes included all-cause mortality, incident cardiovascular disease (fatal and nonfatal myocardial infarction and coronary revascularisation), cerebrovascular disease (stroke and cerebrovascular revascularisation), peripheral vascular disease (lower limb amputation), venous thromboembolic disease (deep vein thrombosis and pulmonary embolism), thrombosis of dialysis access, and adverse events. The effects of homocysteine-lowering therapies on outcomes were assessed with meta-analyses using random-effects models. Prespecified subgroup and sensitivity analyses were conducted. Main results We included six studies that reported data on 2452 participants with ESKD. Interventions investigated were folic acid with or without other vitamins (vitamin B-6, vitamin B-12). Participants' mean age was 48 to 65 years, and proportions of male participants ranged from 50% to 98%. Homocysteine-lowering therapy probably leads to little or no effect on cardiovascular mortality (4 studies, 1186 participants: RR 0.93, 95% CI 0.70 to 1.22). There was no evidence of heterogeneity among the included studies (I-2 = 0%). Homocysteine-lowering therapy had little or no effect on all-cause mortality or any other of this review's secondary outcomes. All prespecified subgroup and sensitivity analyses demonstrated little or no difference. Reported adverse events were mild and there was no increase in the incidence of adverse events from homocysteine-lowering therapies (3 studies, 1248 participants: RR 1.12, 95% CI 0.51 to 2.47; I-2 = 0%). Overall, studies were assessed as being at low risk of bias and there was no evidence of publication bias. Authors' conclusions Homocysteine-lowering therapies were not found to reduce mortality (cardiovascular and all-cause) or cardiovascular events among people with ESKD. C1 [Nigwekar, Sagar U.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Nephrol,Scholars Clin Sci Program, Boston, MA USA. [Kang, Amy] Univ Sydney, Sydney Med Sch, Sydney, NSW 2006, Australia. [Kang, Amy; Cass, Alan; Gallagher, Martin P.; Perkovic, Vlado; Jardine, Meg J.] Univ Sydney, George Inst Global Hlth, Renal & Metab Div, Camperdown, NSW, Australia. [Zoungas, Sophia] Monash Univ, Sch Publ Hlth & Prevent Med, Monash Ctr Hlth Res & Implementat, Diabet & Vasc Res Program, Clayton, Vic, Australia. [Cass, Alan] Menzies Sch Hlth Res, Casuarina, Australia. [Kulshrestha, Satyarth] Univ Iowa, Carver Coll Med, Dept Nephrol, Iowa City, IA USA. [Navaneethan, Sankar D.] Baylor Coll Med, Houston, TX 77030 USA. [Strippoli, Giovanni F. M.] Childrens Hosp Westmead, Ctr Kidney Res, Cochrane Kidney & Transplant, Westmead, NSW, Australia. [Strippoli, Giovanni F. M.] Univ Bari, Dept Emergency & Organ Transplantat, Bari, Italy. [Strippoli, Giovanni F. M.] Diaverum, Med Sci Off, Lund, Sweden. [Strippoli, Giovanni F. M.] Diaverum Acad, Bari, Italy. [Strippoli, Giovanni F. M.] Univ Sydney, Sydney Sch Publ Hlth, Sydney, NSW 2006, Australia. [Jardine, Meg J.] Concord Repatriat Gen Hosp, Dept Renal Med, Concord, Australia. RP Nigwekar, SU (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Nephrol,Scholars Clin Sci Program, Boston, MA USA. EM sagarnigs@gmail.com FU Clinical Scientist in Nephrology award from the American Kidney Fund, USA FX External sources; Clinical Scientist in Nephrology award from the American Kidney Fund, USA. NR 257 TC 1 Z9 1 U1 2 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1469-493X EI 1361-6137 J9 COCHRANE DB SYST REV JI Cochrane Database Syst Rev. PY 2016 IS 5 AR CD004683 DI 10.1002/14651858.CD004683.pub4 PG 57 WC Medicine, General & Internal SC General & Internal Medicine GA DO7KQ UT WOS:000377961800028 PM 27243372 ER PT J AU Singh, JA Hossain, A Ghogomu, ET Kotb, A Christensen, R Mudano, AS Maxwell, LJ Shah, NP Tugwell, P Wells, GA AF Singh, Jasvinder A. Hossain, Alomgir Ghogomu, Elizabeth Tanjong Kotb, Ahmed Christensen, Robin Mudano, Amy S. Maxwell, Lara J. Shah, Nipam P. Tugwell, Peter Wells, George A. TI Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS LA English DT Review ID PLACEBO-CONTROLLED TRIAL; ANTITUMOR NECROSIS FACTOR; RANDOMIZED-CONTROLLED-TRIAL; QUALITY-OF-LIFE; INTERLEUKIN-1 RECEPTOR ANTAGONIST; ALPHA MONOCLONAL-ANTIBODY; RECEIVING CONCOMITANT METHOTREXATE; CONVENTIONAL COMBINATION TREATMENT; COSTIMULATION MODULATOR ABATACEPT; ADALIMUMAB PLUS METHOTREXATE AB Background This is an update of the 2009 Cochrane overview and network meta-analysis (NMA) of biologics for rheumatoid arthritis (RA). Objectives To assess the benefits and harms of nine biologics (abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, rituximab, tocilizumab) and small molecule tofacitinib, versus comparator(MTX, DMARD, placebo (PL), or a combination) in adults with rheumatoid arthritis who have failed to respond tomethotrexate (MTX) or other disease-modifying anti-rheumatic drugs (DMARDs), i.e., MTX/DMARD incomplete responders (MTX/DMARD-IR). Methods We searched for randomized controlled trials (RCTs) in the Cochrane Central Register of Controlled Trials (CENTRAL) (via The Cochrane Library Issue 6, June 2015), MEDLINE (via OVID 1946 to June 2015), and EMBASE (via OVID 1947 to June 2015). Data extraction, risk of bias and GRADE assessments were done in duplicate. We calculated both direct estimates using standard meta-analysis and used Bayesian mixed treatment comparisons approach for NMA estimates to calculate odds ratios (OR) and 95% credible intervals (CrI). We converted OR to risk ratios (RR) which are reported in the abstract for the ease of interpretation. Main results This update included 73 new RCTs for a total of 90 RCTs; 79 RCTs with 32,874 participants provided usable data. Few trials were at high risk of bias for blinding of assessors/participants (13% to 21%), selective reporting (4%) or major baseline imbalance (8%); a large number had unclear risk of bias for random sequence generation (68%) or allocation concealment (74%). Based on direct evidence of moderate quality (downgraded for inconsistency), biologic+MTX/DMARD was associated with a statistically significant and clinically meaningful improvement in ACR50 versus comparator (RR 2.71 (95% confidence interval (CI) 2.36 to 3.10); absolute benefit 24% more patients (95% CI 19% to 29%), number needed to treat for an additional beneficial outcome (NNTB) = 5 (4 to 6). NMA estimates for ACR50 in tumor necrosis factor (TNF) biologic+MTX/DMARD (RR 3.23 (95% credible interval (Crl) 2.75 to 3.79), non-TNF biologic+MTX/DMARD (RR 2.99; 95% Crl 2.36 to 3.74), and anakinra + MTX/DMARD (RR 2.37 (95% Crl 1.00 to 4.70) were similar to the direct estimates. Based on direct evidence of moderate quality (downgraded for inconsistency), biologic+MTX/DMARD was associated with a clinically and statistically important improvement in function measured by the Health Assessment Questionnaire (0 to 3 scale, higher = worse function) with a mean difference (MD) based on direct evidence of -0.25 (95% CI -0.28 to -0.22); absolute benefit of -8.3% (95% CI -9.3% to -7.3%), NNTB = 3 (95% CI 2 to 4). NMA estimates for TNF biologic+MTX/DMARD (absolute benefit, -10.3% (95% Crl -14% to -6.7%) and non-TNF biologic+MTX/DMARD (absolute benefit, -7.3% (95% Crl -13.6% to -0.67%) were similar to respective direct estimates. Based on direct evidence of moderate quality (downgraded for inconsistency), biologic+MTX/DMARD was associated with clinically and statistically significantly greater proportion of participants achieving remission in RA (defined by disease activity score DAS < 1.6 or DAS28 < 2.6) versus comparator (RR 2.81 (95% CI, 2.23 to 3.53); absolute benefit 18% more patients (95% CI 12% to 25%), NNTB = 6 (4 to 9)). NMA estimates for TNF biologic+MTX/DMARD (absolute improvement 17% (95% Crl 11% to 23%)) and non-TNF biologic+MTX/DMARD (absolute improvement 19% (95% Crl 12% to 28%) were similar to respective direct estimates. Based on direct evidence of moderate quality (downgraded for inconsistency), radiographic progression (scale 0 to 448) was statistically significantly reduced in those on biologics+MTX/DMARDs versus comparator, MD -2.61 (95% CI -4.08 to -1.14). The absolute reduction was small, -0.58% (95% CI -0.91% to -0.25%) and we are unsure of the clinical relevance of this reduction. NMA estimates of TNF biologic+MTX/DMARD (absolute reduction -0.67% (95% Crl -1.4% to -0.12%) and non-TNF biologic+MTX/DMARD (absolute reduction, -0.68% (95% Crl -2.36% to 0.92%)) were similar to respective direct estimates. Based on direct evidence of moderate quality (downgraded for imprecision), results for withdrawals due to adverse events were inconclusive, with wide confidence intervals encompassing the null effect and evidence of an important increase in withdrawals, RR 1.11 (95% CI 0.96 to 1.30). The NMA estimates of TNF biologic+MTX/DMARD (RR 1.24 (95% Crl 0.99 to 1.57)) and non-TNF biologic+MTX/DMARD (RR 1.20 (95% Crl 0.87 to 1.67)) were similarly inconclusive and downgraded to low for both imprecision and indirectness. Based on direct evidence of high quality, biologic+MTX/DMARD was associated with clinically significantly increased risk (statistically borderline significant) of serious adverse events on biologic+MTX/DMARD (Peto OR [can be interpreted as RR due to low event rate] 1.12 (95% CI 0.99 to 1.27); absolute risk 1% (0% to 2%), As well, the NMA estimate for TNF biologic+MTX/DMARD (Peto OR 1.20 (95% Crl 1.01 to 1.43)) showed moderate quality evidence of an increase in the risk of serious adverse events. The other two NMA estimates were downgraded to low quality due to imprecision and indirectness and had wide confidence intervals resulting in uncertainty around the estimates: non-TNF biologics+MTX/DMARD: 1.07 (95% Crl 0.89 to 1.29) and anakinra: RR 1.06 (95% Crl 0.65 to 1.75). Based on direct evidence of low quality (downgraded for serious imprecision), results were inconclusive for cancer (Peto OR 1.07 (95% CI 0.68 to 1.68) for all biologic+MTX/DMARD combinations. The NMA estimates of TNF biologic+MTX/DMARD (Peto OR 1.21 (95% Crl 0.63 to 2.38) and non-TNF biologic+MTX/DMARD (Peto OR 0.99 (95% Crl 0.58 to 1.78)) were similarly inconclusive and downgraded to low quality for both imprecision and indirectness. Main results text shows the results for tofacitinib and differences between medications. Authors' conclusions Based primarily on RCTs of 6 months' to 12 months' duration, there is moderate quality evidence that the use of biologic+MTX/DMARD in people with rheumatoid arthritis who have failed to respond to MTX or other DMARDs results in clinically important improvement in function and higher ACR50 and remission rates, and increased risk of serious adverse events than the comparator (MTX/DMARD/PL; high quality evidence). Radiographic progression is slowed but its clinical relevance is uncertain. Results were inconclusive for whether biologics + MTX/DMARDs are associated with an increased risk of cancer or withdrawals due to adverse events. C1 [Singh, Jasvinder A.] Birmingham VA Med Ctr, Dept Med, Fac Off Tower 805B,510 20th St South, Birmingham, AL 35294 USA. [Hossain, Alomgir; Kotb, Ahmed] Univ Ottawa Heart Inst, Cardiovasc Res Methods Ctr, Ottawa, ON, Canada. [Ghogomu, Elizabeth Tanjong] Univ Ottawa, Bruyere Res Inst, Ottawa, ON, Canada. [Christensen, Robin] Copenhagen Univ Hosp, Parker Inst, Musculoskeletal Stat Unit, Copenhagen, Denmark. [Mudano, Amy S.] Univ Alabama Birmingham, Dept Med Rheumatol, Birmingham, AL USA. [Maxwell, Lara J.] Ottawa Hosp, OHRI, CPCR, Gen Campus, Ottawa, ON, Canada. [Shah, Nipam P.] Univ Alabama Birmingham, Dept Clin Immunol & Rheumatol, Birmingham, AL USA. [Tugwell, Peter] Univ Ottawa, Dept Med, Fac Med, Ottawa, ON, Canada. [Wells, George A.] Univ Ottawa, Dept Epidemiol & Community Med, Ottawa, ON, Canada. RP Singh, JA (reprint author), Birmingham VA Med Ctr, Dept Med, Fac Off Tower 805B,510 20th St South, Birmingham, AL 35294 USA. EM jasvinder.md@gmail.com OI Tugwell, Peter/0000-0001-5062-0556 NR 257 TC 5 Z9 5 U1 2 U2 8 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1469-493X EI 1361-6137 J9 COCHRANE DB SYST REV JI Cochrane Database Syst Rev. PY 2016 IS 5 AR CD012183 DI 10.1002/14651858.CD012183 PG 75 WC Medicine, General & Internal SC General & Internal Medicine GA DO7KQ UT WOS:000377961800124 PM 27175934 ER PT J AU Papoian, V Biller, BMK Webb, SM Campbell, KK Hodin, RA Phitayakorn, R AF Papoian, Vardan Biller, Beverly M. K. Webb, Susan M. Campbell, Karen K. Hodin, Richard A. Phitayakorn, Roy TI PATIENTS' PERCEPTION ON CLINICAL OUTCOME AND QUALITY OF LIFE AFTER A DIAGNOSIS OF CUSHING SYNDROME SO ENDOCRINE PRACTICE LA English DT Article ID LAPAROSCOPIC BILATERAL ADRENALECTOMY; CHANGE SYMPTOM RESOLUTION; LONG-TERM; PITUITARY-ADENOMAS; DISEASE; COMORBIDITIES; QUESTIONNAIRE; EPIDEMIOLOGY; METAANALYSIS; IMPAIRMENTS AB Objective: Excess cortisol production (Cushing syndrome, CS) is a chronic disease affecting many organ systems and impacting quality of life (QoL). This study analyzed factors associated with self-reported QoL, including aspects related to the diagnosis and treatment modalities of CS. Methods: In collaboration with the Cushing's Support and Research Foundation (CSRF), surveys using a validated QoL instrument were sent to CSRF members. Data were analyzed for associations between QoL and demographic, treatment, and disease factors. Results: A total of 269 patients completed the survey. Respondents were 89.9% female, and the mean age was 48 years (SD 12, range 16-76). Respondents visited a median of 4 physicians (range 1-40) prior to the diagnosis of CS, with a median of 5 years (mean 7, SD 5, range 1-30) to obtain a diagnosis, showing a statistically significant negative correlation (P < .001). In one-quarter of cases, someone other than a physician suggested the diagnosis. Multiple regression analysis demonstrated that remission status, time to diagnosis, radiation therapy, and hypopituitarism were significant predictors of QoL. There was no association between QoL and patient's sex, age, replacement steroid use, having follow-up with an endocrinologist, or surgical approach. Conclusion: This is one of the largest QoL studies of CS patients and provides information for treatment and education goals. It is notable that early diagnosis and treatment was the major predictor of better QoL after achieving remission from disease, highlighting the need for awareness about the disorder. Patients in remission had better QoL, emphasizing the importance of disease control. C1 [Papoian, Vardan] MedStar Washington Hosp Ctr, Dept Surg, Washington, DC USA. [Biller, Beverly M. K.] Massachusetts Gen Hosp, Dept Med, Neuroendocrine Unit, Boston, MA 02114 USA. [Webb, Susan M.] IIB St Pau, Hosp St Pau, Endocrinol Med Dept, Madrid, Spain. [Webb, Susan M.] ISCIII, CIBERER, Unidad 747, Madrid, Spain. [Webb, Susan M.] Univ Autonoma Barcelona, E-08193 Barcelona, Spain. [Campbell, Karen K.] Cushings Support & Res Fdn, Plymouth, MA USA. [Hodin, Richard A.; Phitayakorn, Roy] Massachusetts Gen Hosp, Dept Surg, Endocrine Surg Unit, Boston, MA 02114 USA. RP Papoian, V (reprint author), 110 Irving St NW, Washington, DC 20010 USA. EM vpapoian@gmail.com OI Phitayakorn, Roy/0000-0002-8327-1484 FU Cortendo; Novartis FX Dr. Beverly Biller is a PI of Research Grants to Massachusetts General Hospital from Cortendo and Novartis. Also occasionally receives consulting honoraria from Cortendo, HRA Pharmaceuticals, Ipsen and Novartis and the other authors have no multiplicity of interest to disclose. NR 32 TC 1 Z9 1 U1 0 U2 1 PU AMER ASSOC CLINICAL ENDOCRINOLOGISTS PI JACKSONVILLE PA 245 RIVERSIDE AVENUE, STE 200, JACKSONVILLE, FL 32202 USA SN 1530-891X EI 1934-2403 J9 ENDOCR PRACT JI Endocr. Pract. PD JAN PY 2016 VL 22 IS 1 BP 51 EP 67 DI 10.4158/EP15855.OR PG 17 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA DO7MU UT WOS:000377967500010 PM 26437213 ER PT J AU Pazaitou-Panayiotou, K Panagiotou, G Polyzos, SA Mantzoros, CS AF Pazaitou-Panayiotou, Kalliopi Panagiotou, Grigorios Polyzos, Stergios A. Mantzoros, Christos S. TI SERUM ADIPONECTIN AND INSULIN-LIKE GROWTH FACTOR 1 IN PREDOMINANTLY FEMALE PATIENTS WITH THYROID CANCER: ASSOCIATION WITH THE HISTOLOGIC CHARACTERISTICS OF THE TUMOR SO ENDOCRINE PRACTICE LA English DT Article ID IGF BINDING PROTEIN-3; FACTOR-I; PLASMA ADIPONECTIN; COLORECTAL-CANCER; BREAST-CANCER; RISK; CARCINOMA; EXPRESSION; RECEPTORS; OBESITY AB Objective: Insulin-like growth factor (IGF)-1 and adiponectin have been proposed to contribute to the pathogenesis of different malignancies. However, data regarding their association with histologic characteristics of thyroid cancer are scarce. The main aims of the present study were the comparative evaluation of IGF-1, IGF-binding protein 3 (BP3), and adiponectin serum levels between different histologic types of thyroid cancer, as well as within specific histologic characteristics of the tumors. Methods: A total of 179 thyroid cancer patients (126 [70.4%] women) were recruited. A total of 129 (72.1%) had papillary thyroid carcinoma (including variants), 26 had follicular thyroid carcinoma (14.5%), and 24 had medullary thyroid carcinoma (13.4%). Parameters from history, physical examination, and thyroid histology were selected. Serum adiponectin, IGF-1, and IGF-BP3 were measured in fasting morning samples. Results: IGF-1, IGF-BP3, and adiponectin levels were similar among different histologic types of thyroid carcinoma, with a trend towards higher IGF-1 and IGF-BP3 levels in patients with intrathyroid invasion, compared to those without. In addition, ratios of IGF-1 to adiponectin (P = .012) and IGF-1 to (adiponectin x IGF-BP3) (P = .003), as well as type 2 diabetes (P = .001), were positively associated with tumor size. Conclusion: Although IGF-1, IGF-BP3, and adiponectin were not separately different between groups or within specific histologic lesions, when they were combined to produce IGF-1 to adiponectin and IGF-1 to (adiponectin x IGF-BP3) ratios, they were independently associated with tumor size. Future prospective studies are needed to evaluate whether these ratios could serve as prognostic markers of thyroid tumor aggressiveness. C1 [Pazaitou-Panayiotou, Kalliopi] Theagenio Canc Hosp, Div Endocrinol Endocrine Oncol, 2 Simeonidi Str, Thessaloniki 54007, Greece. [Panagiotou, Grigorios; Polyzos, Stergios A.; Mantzoros, Christos S.] Harvard Univ, Beth Israel Deaconess Med Ctr, Div Endocrinol Diabet & Metab, Sch Med, Boston, MA 02215 USA. [Mantzoros, Christos S.] Harvard Univ, Endocrinol Sect, VA Boston Healthcare Syst, Sch Med, Boston, MA 02215 USA. RP Pazaitou-Panayiotou, K (reprint author), Theagenio Canc Hosp, Div Endocrinol Endocrine Oncol, 2 Simeonidi Str, Thessaloniki 54007, Greece. EM kpazaitoupanayiotou@gmail.com OI Panagiotou, Grigorios/0000-0003-0690-1478 NR 35 TC 0 Z9 0 U1 1 U2 1 PU AMER ASSOC CLINICAL ENDOCRINOLOGISTS PI JACKSONVILLE PA 245 RIVERSIDE AVENUE, STE 200, JACKSONVILLE, FL 32202 USA SN 1530-891X EI 1934-2403 J9 ENDOCR PRACT JI Endocr. Pract. PD JAN PY 2016 VL 22 IS 1 BP 68 EP 75 DI 10.4158/EP15814.OR PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA DO7MU UT WOS:000377967500011 PM 26484409 ER PT J AU Ananthakrishnan, AN Cagan, A Cai, TX Gainer, VS Shaw, SY Savova, G Churchill, S Karlson, EW Murphy, SN Liao, KP Kohane, I AF Ananthakrishnan, Ashwin N. Cagan, Andrew Cai, Tianxi Gainer, Vivian S. Shaw, Stanley Y. Savova, Guergana Churchill, Susanne Karlson, Elizabeth W. Murphy, Shawn N. Liao, Katherine P. Kohane, Isaac TI Identification of Nonresponse to Treatment Using Narrative Data in an Electronic Health Record Inflammatory Bowel Disease Cohort SO INFLAMMATORY BOWEL DISEASES LA English DT Article DE Crohn's disease; ulcerative colitis; treatment response; biologic; infliximab ID MEDICAL-RECORDS; CROHNS-DISEASE; RHEUMATOID-ARTHRITIS; ULCERATIVE-COLITIS; NOTE QUALITY; RECONCILIATION; HOSPITALS; DISCOVERY; GENOMICS; FATIGUE AB Background: Electronic health records, increasingly a part of healthcare, provide a wealth of untapped narrative free text data that have the potential to accurately inform clinical outcomes. Methods: From a validated cohort of patients with Crohn's disease or ulcerative colitis, we identified patients with >= 1 coded or narrative mention of monoclonal antibodies to tumor necrosis factor alpha. Chart review by ascertained true use of therapy, time of initiation, and cessation of treatment, and also clinical response stratified as nonresponse, partial, or complete response at 1 year. Internal consistency was assessed in an independent validation cohort. Results: A total of 3087 patients had a mention of an antibodies to tumor necrosis factor alpha. Actual therapy initiation was within 60 days of the first coded mention in 74% of patients. In the derivation cohort, 18% of antibodies to tumor necrosis factor alpha starts were classified as nonresponse at 1 year, 21% as partial, and 56% as complete response. On multivariate analysis, the number of narrative mentions of diarrhea (odds ratio 1.08; 95% confidence interval, 1.02-1.14) and fatigue (odds ratio 1.16; 95% confidence interval, 1.02-1.32) was independently associated with nonresponse at 1 year (area under the curve 0.82). A likelihood of nonresponse score comprising a weighted sum of both demonstrated a good dose-response relationship across nonresponders (2.18), partial (1.20), and complete (0.50) responders (P < 0.0001) and correlated well with need for surgery or hospitalizations. Conclusions: Narrative data in an electronic health record offer considerable potential to define temporally evolving disease outcomes such as nonresponse to treatment. C1 [Ananthakrishnan, Ashwin N.] Massachusetts Gen Hosp, Div Gastroenterol, Boston, MA 02114 USA. [Ananthakrishnan, Ashwin N.; Shaw, Stanley Y.; Karlson, Elizabeth W.; Murphy, Shawn N.; Liao, Katherine P.; Kohane, Isaac] Harvard Univ, Sch Med, Boston, MA USA. [Ananthakrishnan, Ashwin N.; Shaw, Stanley Y.; Murphy, Shawn N.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA. [Cagan, Andrew; Gainer, Vivian S.] Partners HealthCare, Res IS & Comp, Charlestown, MA USA. [Cai, Tianxi] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. [Shaw, Stanley Y.] Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA. [Savova, Guergana] Boston Childrens Hosp, Childrens Hosp Informat Program, Boston, MA USA. [Churchill, Susanne; Murphy, Shawn N.; Kohane, Isaac] Brigham & Womens Hosp, Natl Ctr Biomed Comp I2b2, 75 Francis St, Boston, MA 02115 USA. [Karlson, Elizabeth W.; Liao, Katherine P.] Brigham & Womens Hosp, Div Rheumatol Allergy & Immunol, 75 Francis St, Boston, MA 02115 USA. [Murphy, Shawn N.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA. [Kohane, Isaac] Childrens Hosp Boston, Boston, MA USA. RP Ananthakrishnan, AN (reprint author), Massachusetts Gen Hosp, Crohns & Colitis Ctr, 165 Cambridge St,9th Floor, Boston, MA 02114 USA. EM aananthakrishnan@mgh.harvard.edu FU NIH [U54-LM008748, K08 AR060257, K24 AR052403, P60 AR047782, R01 AR049880]; US National Institutes of Health [K23 DK097142]; Amgen; Harold and Duval Bowen Fund; Cubist FX Supported by NIH U54-LM008748. A. N. Ananthakrishnan is supported by funding from the US National Institutes of Health ( K23 DK097142) and Amgen. K. P. Liao is supported by NIH K08 AR060257 and the Harold and Duval Bowen Fund. E. W. Karlson is supported by grants from the NIH ( K24 AR052403, P60 AR047782, R01 AR049880).; A. N. Ananthakrishnan and S. Churchill received funding from Amgen; A. N. Ananthakrishnan has received research support from Cubist and has served on the scientific advisory boards for Cubist and Abbvie. The remaining authors have no conflict of interest to disclose. NR 32 TC 2 Z9 2 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1078-0998 EI 1536-4844 J9 INFLAMM BOWEL DIS JI Inflamm. Bowel Dis. PD JAN PY 2016 VL 22 IS 1 BP 151 EP 158 DI 10.1097/MIB.0000000000000580 PG 8 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DO3ZR UT WOS:000377721800021 PM 26332313 ER PT J AU Sonnenberg, A Genta, RM AF Sonnenberg, Amnon Genta, Robert M. TI Inverse Association Between Helicobacter pylori Gastritis and Microscopic Colitis SO INFLAMMATORY BOWEL DISEASES LA English DT Article DE demographic characteristics; environmental epidemiology; socioeconomic risk factors; ZIP codes ID INFLAMMATORY-BOWEL-DISEASE; ESOPHAGEAL EOSINOPHILIA; PATHOLOGY DATABASE; NEGATIVE GASTRITIS; INFECTION; RISK; PREVALENCE; POLYPS; COLON AB Background: Inflammatory bowel disease is known to be inversely associated with Helicobacter pylori infection of the upper gastrointestinal tract. We hypothesized that a similar inverse association also applied to microscopic colitis. Methods: The associations between microscopic colitis and presence of H. pylori-positive chronic active gastritis (CAG), H. pylori-negative CAG, intestinal metaplasia, or gastric atrophy were expressed as odds ratios with their 95% confidence intervals. Multivariate logistic regression analyses were used to adjust these associations for sex, age, percentage residents per ZIP code with white, black, Hispanic, or Asian ethnicity, percentage with college education, average housing values, annual income, and population size of individual ZIP codes. Results: H. pylori-positive CAG was less common among patients with than without microscopic colitis (odds ratio = 0.61; 95% confidence interval, 0.52-0.70). Intestinal metaplasia also occurred less frequently among patients with than without microscopic colitis (0.75, 0.65-0.86). These inverse associations remained unaffected by adjustments for parameters of ethnicity and socioeconomic status. In contradistinction with H. pylori-positive CAG, H. pylori-negative CAG was more common in patients with than without microscopic colitis (1.54, 1.17-1.97). Conclusions: H. pylori infection and microscopic colitis are inversely associated. This observation is consistent with similar inverse associations found between H. pylori and inflammatory bowel disease. These relationships may provide clues about the yet unknown etiology of microscopic colitis. C1 [Sonnenberg, Amnon; Genta, Robert M.] Miraca Life Sci, Irving, TX USA. [Sonnenberg, Amnon] Oregon Hlth & Sci Univ, Div Gastroenterol, Portland, OR 97201 USA. [Genta, Robert M.] Univ Texas SW Med Ctr Dallas, Dept Pathol, Dallas, TX 75390 USA. RP Sonnenberg, A (reprint author), Portland VA Med Ctr, P3 GI, Portland, OR 97239 USA. EM sonnenbe@ohsu.edu NR 22 TC 3 Z9 3 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1078-0998 EI 1536-4844 J9 INFLAMM BOWEL DIS JI Inflamm. Bowel Dis. PD JAN PY 2016 VL 22 IS 1 BP 182 EP 186 DI 10.1097/MIB.0000000000000595 PG 5 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA DO3ZR UT WOS:000377721800025 PM 26383914 ER PT J AU Luckianow, GM Smith, D Bullen, D Kaplan, LJ AF Luckianow, Gina M. Smith, David Bullen, David Kaplan, Lewis J. TI Understanding percutaneous and subcutaneous central venous access devices SO JAAPA-JOURNAL OF THE AMERICAN ACADEMY OF PHYSICIAN ASSISTANTS LA English DT Review DE central venous access devices; catheters; percutaneous; thrombosis; peripherally inserted central catheters; hemodialysis ID CATHETER-RELATED INFECTIONS; PREVENTION; GUIDELINES; ADULTS AB Central venous access devices (CVADs) are commonly used in the inpatient and outpatient settings. Physician assistants must understand CVADs' indications, intended uses, functional lifespans, complications, and indications for removal. This article describes common CVADs used for administering medications, nutrition, and chemotherapy, and for hemodialysis and venous access for laboratory sampling. C1 [Luckianow, Gina M.] Yale New Haven Med Ctr, 20 York St, New Haven, CT 06504 USA. [Smith, David; Bullen, David] Philadelphia VA Med Ctr, Surg ICU, Philadelphia, PA USA. [Kaplan, Lewis J.] Philadelphia VA Med Ctr, Surg, Philadelphia, PA USA. [Kaplan, Lewis J.] Univ Penn, Perelman Sch Med, Surg, Philadelphia, PA 19104 USA. RP Luckianow, GM (reprint author), Yale New Haven Med Ctr, 20 York St, New Haven, CT 06504 USA. NR 13 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1547-1896 EI 0893-7400 J9 JAAPA-J AM ACAD PHYS JI JAAPA-J. Am. Acad. Physician Assist. PD JAN PY 2016 VL 29 IS 1 BP 33 EP 36 DI 10.1097/01.JAA.0000472630.68218.42 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA DO3PC UT WOS:000377692500011 PM 26704651 ER PT J AU Beshai, J Smedley, K Beshai, T AF Beshai, James Smedley, Kerrie Beshai, Teresa TI The relationship between NEO personality factors and Hoge's Intrinsic Religious Motivation SO JOURNAL OF BELIEFS & VALUES-STUDIES IN RELIGION & EDUCATION LA English DT Article DE Psychology of religion; religious orientation; personality ID OPENNESS AB Personality traits have shown variable relationships to measures of religious motivation. For example, Costa and McCrae (1985) and McCrae and Costa (1999) suggested that individuals who are high in agreeableness and conscientious gravitate toward religion once they 'meet' with religion as a cultural identity Openness to experience involves varied expressions including sensitivity to aesthetics, and egalitarian values (e.g. McCrae and Costa, 1996). As such, it has been shown to be negatively correlated with measures of religious fundamentalism, and positively correlated with intrinsic religious motivation. However, other reviews have found only small correlations between personality and religious motivation. Our study was designed to test the relationships among the Big 5 personality factors with Hoge's Intrinsic Religious Motivation in an undergraduate sample. Results showed that only openness to experience and intrinsic religious motivation were significantly correlated, providing further support for the idea that religious motivation and personality factors may require further research elaboration. C1 [Beshai, James] US Dept Vet Affairs, Lebanon, PA USA. [Smedley, Kerrie] Lebanon Valley Coll, Dept Psychol, Annville, PA USA. RP Beshai, J (reprint author), US Dept Vet Affairs, Lebanon, PA USA. EM Jimmy.Beshai@gmail.com NR 9 TC 0 Z9 0 U1 2 U2 2 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 1361-7672 EI 1469-9362 J9 J BELIEFS VALUES JI J. Beliefs Values-Stud. Relig. Educ. PY 2016 VL 37 IS 1 BP 114 EP 117 DI 10.1080/13617672.2016.1142124 PG 4 WC Education & Educational Research; Religion SC Education & Educational Research; Religion GA DO7TE UT WOS:000377985100010 ER PT J AU Soble, JR Marceaux, JC Galindo, J Sordahl, JA Highsmith, JM O'Rourke, JJF Gonzalez, DA Critchfield, EA Mccoy, KJM AF Soble, Jason R. Marceaux, Janice C. Galindo, Juliette Sordahl, Jeffrey A. Highsmith, Jonathan M. O'Rourke, Justin J. F. Gonzalez, David Andres Critchfield, Edan A. McCoy, Karin J. M. TI The effect of perceptual reasoning abilities on confrontation naming performance: An examination of three naming tests SO JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY LA English DT Article DE Boston Naming Test; Visual Naming Test; Neuropsychological Assessment Battery; language; perceptual reasoning abilities; mediation ID MEMORY-MALINGERING TOMM; ALZHEIMERS-DISEASE; ASSOCIATION; FAMILIARITY; ACCURACY; TRIAL-1; MODELS; NORMS AB Introduction: Confrontation naming tests are a common neuropsychological method of assessing language and a critical diagnostic tool in identifying certain neurodegenerative diseases; however, there is limited literature examining the visual-perceptual demands of these tasks. This study investigated the effect of perceptual reasoning abilities on three confrontation naming tests, the Boston Naming Test (BNT), Neuropsychological Assessment Battery (NAB) Naming Test, and Visual Naming Test (VNT) to elucidate the diverse cognitive functions underlying these tasks to assist with test selection procedures and increase diagnostic accuracy. Method: A mixed clinical sample of 121 veterans were administered the BNT, NAB, VNT, and Wechsler Adult Intelligence Scale-4th Edition (WAIS-IV) Verbal Comprehension Index (VCI) and Perceptual Reasoning Index (PRI) as part of a comprehensive neuropsychological evaluation. Results: Multiple regression indicated that PRI accounted for 23%, 13%, and 15% of the variance in BNT, VNT, and NAB scores, respectively, but dropped out as a significant predictor once VCI was added. Follow-up bootstrap mediation analyses revealed that PRI had a significant indirect effect on naming performance after controlling education, primary language, and severity of cognitive impairment, as well as the mediating effect of general verbal abilities for the BNT (B = 0.13; 95% confidence interval, CI [.07,.20]), VNT (B = 0.01; 95% CI [.002,.03]), and NAB (B = 0.03; 95% CI [.01,.06]). Conclusions: Findings revealed a complex relationship between perceptual reasoning abilities and confrontation naming that is mediated by general verbal abilities. However, when verbal abilities were statistically controlled, perceptual reasoning abilities were found to have a significant indirect effect on performance across all three confrontation naming measures with the largest effect noted with the BNT relative to the VNT and NAB Naming Test. C1 [Soble, Jason R.; Marceaux, Janice C.; Galindo, Juliette; Sordahl, Jeffrey A.; Highsmith, Jonathan M.; O'Rourke, Justin J. F.; Gonzalez, David Andres; Critchfield, Edan A.; McCoy, Karin J. M.] South Texas Vet Hlth Care Syst, Psychol Serv, San Antonio, TX USA. [Galindo, Juliette] Univ Alabama Birmingham, Dept Psychol, Birmingham, AL 35294 USA. [Sordahl, Jeffrey A.] Boise VA Med Ctr, Neuropsychol Serv, Boise, ID USA. [Galindo, Juliette] Univ Oklahoma, Hlth Sci Ctr, Dept Psychiat & Behav Sci, Oklahoma City, OK 73190 USA. RP Soble, JR (reprint author), South Texas Vet Healthcare Syst Psychol Serv 116B, 7400 Merton Minter, San Antonio, TX 78229 USA. EM Jason.Soble@va.gov NR 34 TC 1 Z9 1 U1 1 U2 3 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 1380-3395 EI 1744-411X J9 J CLIN EXP NEUROPSYC JI J. Clin. Exp. Neuropsychol. PY 2016 VL 38 IS 3 BP 284 EP 292 DI 10.1080/13803395.2015.1107030 PG 9 WC Psychology, Clinical; Clinical Neurology; Psychology SC Psychology; Neurosciences & Neurology GA DO7TQ UT WOS:000377986300003 PM 26644041 ER PT J AU Waldron, PR Belitskaya-Levy, I Chary, A Won, J Winters, M Monto, A Ryan, J Lazzeroni, LC Holodniy, M AF Waldron, Paul Ravi Belitskaya-Levy, Ilana Chary, Aarthi Won, Johann Winters, Mark Monto, Alexander Ryan, James Lazzeroni, Laura C. Holodniy, Mark TI Genetic Variation in the IL-6 and HLA-DQB1 Genes Is Associated with Spontaneous Clearance of Hepatitis C Virus Infection SO JOURNAL OF IMMUNOLOGY RESEARCH LA English DT Article ID WHOLE-GENOME ASSOCIATION; COINFECTED PATIENTS; INTERLEUKIN-6; INTERFERON; IL28B; POLYMORPHISMS; PREDICTORS; CYTOKINES; RIBAVIRIN; THERAPY AB Background. Millions of people are infected with hepatitis C virus (HCV) worldwide and 30% spontaneously clear the infection. Reasons for HCV clearance without antiviral treatment are not well understood. Methods. Blood was collected for DNA analysis from patients with chronic HCV infection or evidence of spontaneous clearance. To overcome anticipated limitations of small sample size, primary analyses consisted of a candidate gene analysis of 12 preselected genes based on known association with host immunologic response to HCV infection. To further reduce the impact of multiple testing on power, a single likelihood ratio test was conducted for each gene using all associated SNPs assayed on the Illumina Quad 610/660W chip. Step-down permutation methods were used to adjust for multiple testing in all analyses. Results. Ninety-five and 62 patients with HCV chronic infection or spontaneous clearance, respectively, were included for analysis. HLA-DQB1 (p = 1.76 * 10(-5)) and IL-6 (p = 0.0007) genes were significantly associated with spontaneous HCV clearance. IL-28B was not significantly associated with spontaneous clearance (p = 0.17). Conclusion. Our whole-gene analytic strategy identified a previously unreported association of IL-6 with spontaneous clearance of HCV infection. We also confirmed the finding that HLA-DQB1 is associated with spontaneous resolution of HCV infection. C1 [Waldron, Paul Ravi; Chary, Aarthi; Winters, Mark; Holodniy, Mark] VA Palo Alto Hlth Care Syst, Palo Alto, CA 94304 USA. [Waldron, Paul Ravi; Chary, Aarthi; Winters, Mark; Holodniy, Mark] Stanford Univ, Div Infect Dis & Geog Med, Stanford, CA 94305 USA. [Belitskaya-Levy, Ilana; Won, Johann; Lazzeroni, Laura C.] VA Palo Alto Hlth Care Syst, Cooperat Studies Program Coordinating Ctr, Palo Alto, CA 94304 USA. [Monto, Alexander; Ryan, James] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Monto, Alexander; Ryan, James] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Lazzeroni, Laura C.] Stanford Univ, Dept Psychiat, Stanford, CA 94305 USA. RP Waldron, PR (reprint author), VA Palo Alto Hlth Care Syst, Palo Alto, CA 94304 USA.; Waldron, PR (reprint author), Stanford Univ, Div Infect Dis & Geog Med, Stanford, CA 94305 USA. EM pwaldron@stanford.edu FU Clinical Science Research & Development Service of the Department of Veterans Affairs (A Cooperative Studies Program-Wide DNA Bank, CSP) [478]; NIH [T32 AI007502] FX This work was supported by research funding to Mark Holodniy and the Cooperative Studies Program Coordinating Center, Palo Alto, from the Clinical Science Research & Development Service of the Department of Veterans Affairs (A Cooperative Studies Program-Wide DNA Bank, CSP #478). Additional support was provided by NIH Training Grant T32 AI007502 (Upinder Singh PI). NR 37 TC 0 Z9 0 U1 1 U2 2 PU HINDAWI PUBLISHING CORP PI NEW YORK PA 315 MADISON AVE 3RD FLR, STE 3070, NEW YORK, NY 10017 USA SN 2314-8861 EI 2314-7156 J9 J IMMUNOL RES JI J Immunol. Res. PY 2016 AR 6530436 DI 10.1155/2016/6530436 PG 9 WC Immunology SC Immunology GA DO6DV UT WOS:000377874400001 ER PT J AU Lo, WCY Villiger, M Golberg, A Broelsch, GF Khan, S Lian, CG Austen, WG Yarmush, M Bouma, BE AF Lo, William C. Y. Villiger, Martin Golberg, Alexander Broelsch, G. Felix Khan, Saiqa Lian, Christine G. Austen, William G., Jr. Yarmush, Martin Bouma, Brett E. TI Longitudinal, 3D Imaging of Collagen Remodeling in Murine Hypertrophic Scars In Vivo Using Polarization-Sensitive Optical Frequency Domain Imaging SO JOURNAL OF INVESTIGATIVE DERMATOLOGY LA English DT Article ID COHERENCE TOMOGRAPHY; TREATMENT STRATEGIES; KELOIDS; TISSUE; EXPRESSION; APOPTOSIS; SECTIONS; LASER AB Hypertrophic scars (HTS), frequently seen after traumatic injuries and surgery, remain a major clinical challenge because of the limited success of existing therapies. A significant obstacle to understanding HTS etiology is the lack of tools to monitor scar remodeling longitudinally and noninvasively. We present an in vivo, label-free technique using polarization-sensitive optical frequency domain imaging for the 3D, longitudinal assessment of collagen remodeling in murine HTS. In this study, HTS was induced with a mechanical tension device for 4-10 days on incisional wounds and imaged up to 1 month after device removal; an excisional HTS model was also imaged at 6 months after injury to investigate deeper and more mature scars. We showed that local retardation and degree of polarization provide a robust signature for HTS. Compared with normal skin with heterogeneous local retardation and low degree of polarization, HTS was characterized by an initially low local retardation, which increased as collagen fibers remodeled, and a persistently high degree of polarization. This study demonstrates that polarization-sensitive optical frequency domain imaging offers a powerful tool to gain significant biological insights into HTS remodeling by enabling longitudinal assessment of collagen in vivo, which is critical to elucidating HTS etiology and developing more effective HTS therapies. C1 [Lo, William C. Y.; Villiger, Martin; Bouma, Brett E.] Massachusetts Gen Hosp, Wellman Ctr Photomed, 50 Blossom St, Boston, MA 02114 USA. [Lo, William C. Y.; Villiger, Martin; Bouma, Brett E.] Massachusetts Gen Hosp, Dept Dermatol, 50 Blossom St, Boston, MA 02114 USA. [Lo, William C. Y.; Villiger, Martin; Bouma, Brett E.] Harvard Univ, Sch Med, 50 Blossom St, Boston, MA 02114 USA. [Lo, William C. Y.; Bouma, Brett E.] Harvard Massachusetts Inst Technol, Div Hlth Sci & Technol, Cambridge, MA USA. [Golberg, Alexander; Yarmush, Martin] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Engn Med,Dept Surg, Boston, MA USA. [Golberg, Alexander; Yarmush, Martin] Shriners Burns Hosp, Boston, MA USA. [Golberg, Alexander] Tel Aviv Univ, Porter Sch Environm Studies, IL-69978 Tel Aviv, Israel. [Broelsch, G. Felix; Khan, Saiqa; Austen, William G., Jr.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Plast & Reconstruct Surg, Boston, MA USA. [Lian, Christine G.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Program Dermatopathol,Dept Pathol, Boston, MA 02115 USA. [Yarmush, Martin] Rutgers State Univ, Dept Biomed Engn, Piscataway, NJ USA. RP Lo, WCY (reprint author), Massachusetts Gen Hosp, Wellman Ctr Photomed, 50 Blossom St, Boston, MA 02114 USA.; Lo, WCY (reprint author), Massachusetts Gen Hosp, Dept Dermatol, 50 Blossom St, Boston, MA 02114 USA.; Lo, WCY (reprint author), Harvard Univ, Sch Med, 50 Blossom St, Boston, MA 02114 USA. EM Lo.William@mgh.harvard.edu OI Lo, William Chun Yip/0000-0002-6562-088X FU National Institutes of Health [P41 EB015903]; Shriners Foundation [85120-BOS]; Canadian Institutes of Health Research (CIHR) Doctoral Foreign Study Award; Swiss National Science Foundation FX Research reported in this publication was funded in part by the National Institutes of Health P41 EB015903 grant and by the Shriners Foundation grant no. 85120-BOS. WCYL was supported by the Canadian Institutes of Health Research (CIHR) Doctoral Foreign Study Award and MV was supported by the Swiss National Science Foundation. NR 29 TC 7 Z9 7 U1 2 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-202X EI 1523-1747 J9 J INVEST DERMATOL JI J. Invest. Dermatol. PD JAN PY 2016 VL 136 IS 1 BP 84 EP 92 DI 10.1038/JID.2015.399 PG 9 WC Dermatology SC Dermatology GA DO7HJ UT WOS:000377952900018 PM 26763427 ER PT J AU Dekel, S Hankin, IT Pratt, JA Hackler, DR Lanman, ON AF Dekel, Sharon Hankin, Ian T. Pratt, Jacob A. Hackler, Dusty R. Lanman, Olivia N. TI Posttraumatic Growth in Trauma Recollections of 9/11 Survivors: A Narrative Approach SO JOURNAL OF LOSS & TRAUMA LA English DT Article DE Content analysis; gender; narrative; posttraumatic growth; posttraumatic stress disorder; trauma memory ID STRESS-DISORDER; GENDER-DIFFERENCES; EXPOSURE; EVENTS; MEMORY; PTSD; SELF AB The relationship between posttraumatic growth (PTG) and adaptation is unclear. This study is the first to examine PTG in trauma narratives of survivors of the World Trade Center (WTC) attacks. Participants recalled their experiences 7 and 18 months post 9/11, and content analysis was conducted to detect PTG. Posttraumatic stress was also measured. PTG was commonly reported. Relating to others and positivity were frequent in the PTSD and non-PTSD group, although less frequent over time in the PTSD. Greater appreciation for life was reported by the non-PTSD group but relatively absent in the PTSD group. Women but not men reported relating to others across time. It appears that there are distinct profiles of growth implicated in distress and adaptation. C1 [Dekel, Sharon; Hankin, Ian T.; Pratt, Jacob A.; Lanman, Olivia N.] Massachusetts Gen Hosp, Dept Psychiat, Charlestown, MA USA. [Dekel, Sharon] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA. [Hackler, Dusty R.] Columbia Univ, Teachers Coll, Dept Org Psychol, New York, NY 10027 USA. RP Dekel, S (reprint author), Massachusetts Gen Hosp East, PTSD Res Lab, 120 Second Ave, Charlestown, MA 02129 USA. EM sdekel@mgh.harvard.edu FU Brain & Behavior Research Foundation; National Science Foundation [BCS-0202772, BCS-0337643] FX This work was supported in part by the Brain & Behavior Research Foundation (Young Investigator Grant offered to Sharon Dekel) and by the National Science Foundation (BCS-0202772, BCS-0337643). NR 31 TC 0 Z9 0 U1 2 U2 2 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 1532-5024 EI 1532-5032 J9 J LOSS TRAUMA JI J. Loss Trauma PY 2016 VL 21 IS 4 BP 315 EP 324 DI 10.1080/15325024.2015.1108791 PG 10 WC Psychology, Social SC Psychology GA DO8PY UT WOS:000378046900007 ER PT J AU Kuperberg, GR AF Kuperberg, Gina R. TI Separate streams or probabilistic inference? What the N400 can tell us about the comprehension of events SO LANGUAGE COGNITION AND NEUROSCIENCE LA English DT Editorial Material DE Bayesian; ERP; generative; prediction; thematic role ID SYNTACTIC AMBIGUITY RESOLUTION; ONLINE SENTENCE COMPREHENSION; INTERACTIVE ACTIVATION MODEL; LANGUAGE COMPREHENSION; BRAIN POTENTIALS; THEMATIC RELATIONSHIPS; SEMANTIC RELATEDNESS; LETTER PERCEPTION; WORD-RECOGNITION; LEVEL CONTEXT AB Since the early 2000s, several event-related potential studies have challenged the assumption that we always use syntactic contextual information to influence semantic processing of incoming words, as reflected by the N400 component. One approach for explaining these findings is to posit distinct semantic and syntactic processing mechanisms, each with distinct time courses. While this approach can explain specific datasets, it cannot account for the wider body of findings. I propose an alternative explanation: a dynamic generative framework in which our goal is to infer the underlying event that best explains the set of inputs encountered at any given time. Within this framework, combinations of semantic and syntactic cues with varying reliabilities are used as evidence to weight probabilistic hypotheses about this event. I further argue that the computational principles of this framework can be extended to understand how we infer situation models during discourse comprehension, and intended messages during spoken communication. C1 [Kuperberg, Gina R.] Tufts Univ, Dept Psychol, Medford, MA 02155 USA. [Kuperberg, Gina R.] Tufts Univ, Ctr Cognit Studies, Medford, MA 02155 USA. [Kuperberg, Gina R.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02115 USA. [Kuperberg, Gina R.] Athinoula A Martinos Ctr Biomed Imaging, Boston, MA USA. RP Kuperberg, GR (reprint author), Tufts Univ, Dept Psychol, Medford, MA 02155 USA.; Kuperberg, GR (reprint author), Tufts Univ, Ctr Cognit Studies, Medford, MA 02155 USA.; Kuperberg, GR (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02115 USA.; Kuperberg, GR (reprint author), Athinoula A Martinos Ctr Biomed Imaging, Boston, MA USA. EM kuperber@nmr.mgh.harvard.edu FU NICHD [R01 HD082527] FX This work was funded by NICHD [R01 HD082527]. NR 137 TC 2 Z9 2 U1 4 U2 6 PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND SN 2327-3798 EI 2327-3801 J9 LANG COGN NEUROSCI JI Lang. Cogn. Neurosci. PY 2016 VL 31 IS 5 BP 602 EP 616 DI 10.1080/23273798.2015.1130233 PG 15 WC Audiology & Speech-Language Pathology; Behavioral Sciences; Linguistics; Psychology, Experimental SC Audiology & Speech-Language Pathology; Behavioral Sciences; Linguistics; Psychology GA DO4TP UT WOS:000377777300003 PM 27570786 ER PT S AU Razavi, P Dobrev, I Ravicz, ME Cheng, JT Furlong, C Rosowski, JJ AF Razavi, Payam Dobrev, Ivo Ravicz, Michael E. Cheng, Jeffery Tao Furlong, Cosme Rosowski, John J. BE Tekalur, SA Zavattieri, P Korach, CS TI Transient Response of the Eardrum Excited by Localized Mechanical Forces SO MECHANICS OF BIOLOGICAL SYSTEMS AND MATER IALS, VOL 6 SE Conference Proceedings of the Society for Experimental Mechanics Series LA English DT Proceedings Paper CT Annual Conference and Exposition of the Society-for-Experimental-Mechanics on Experimental and Applied Mechanics CY JUN 08-11, 2015 CL Costa Mesa, CA SP Soc Expt Mech DE Digital high-speed holography; Mechanical excitation; Otology; Transient response; Tympanic membrane ID TYMPANIC-MEMBRANE; SURFACE; MOTION AB The Tympanic Membrane (TM, eardrum) is the interface between the middle and outer ear and helps transform the variations in sound pressure in the ear canal into vibrations of the ossicles. However, the transient acoustic response of TM due to the complexity of wave interference, hinders the understanding of the motions. Therefore, to reduce this effect, local (<1 mm(2) area) mechanical excitation rather than entire-surface acoustic loading is proposed. To focus on the initial stages of the evolution of motion, we have developed a high-speed digital holographic system based on local phase correlation method, enabling the acquisition of full-field displacements of the TM up to 10 mu s temporal and 150 k points spatial resolution. A piezoelectric plunger equipped with a feedback load sensor excites the TM by a 50 mu s click and the mechanical contact is guaranteed during the experiment by > 100 mu m indentation of TM surface towards the camera. The results include characterization of wave travelling speed versus input force and localized mechanical properties, such as damping ratio, modal frequencies, and time constants. We expect that the results will lead to an improved understanding of the TM's localized material properties and modeling of the eardrum behavior. C1 [Razavi, Payam; Dobrev, Ivo; Furlong, Cosme] Ctr Holog Studies & Laser Micromech CHSLT, Worcester, MA 01609 USA. [Razavi, Payam; Furlong, Cosme] Worcester Polytech Inst, Dept Mech Engn, Worcester, MA 01609 USA. [Dobrev, Ivo] Univ Zurich Hosp, CH-8091 Zurich, Switzerland. [Ravicz, Michael E.; Cheng, Jeffery Tao; Furlong, Cosme; Rosowski, John J.] Massachusetts Eye & Ear Infirm, Eaton Peabody Lab, Boston, MA 02114 USA. [Ravicz, Michael E.; Cheng, Jeffery Tao; Furlong, Cosme; Rosowski, John J.] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA. RP Razavi, P (reprint author), Ctr Holog Studies & Laser Micromech CHSLT, Worcester, MA 01609 USA.; Razavi, P (reprint author), Worcester Polytech Inst, Dept Mech Engn, Worcester, MA 01609 USA. EM prazavi@wpi.edu NR 13 TC 2 Z9 2 U1 1 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES SN 2191-5644 BN 978-3-319-21455-9; 978-3-319-21454-2 J9 C PROC SOC EXP MECH PY 2016 BP 31 EP 37 DI 10.1007/978-3-319-21455-9_4 PG 7 WC Engineering, Biomedical; Engineering, Mechanical; Materials Science, Multidisciplinary SC Engineering; Materials Science GA BE9KU UT WOS:000377718500004 ER PT S AU Khaleghi, M Furlong, C Cheng, JT Rosowski, JJ AF Khaleghi, Morteza Furlong, Cosme Cheng, Jeffrey Tao Rosowski, John J. BE Tekalur, SA Zavattieri, P Korach, CS TI Characterization of Acoustically-Induced Forces of the Human Eardrum SO MECHANICS OF BIOLOGICAL SYSTEMS AND MATER IALS, VOL 6 SE Conference Proceedings of the Society for Experimental Mechanics Series LA English DT Proceedings Paper CT Annual Conference and Exposition of the Society-for-Experimental-Mechanics on Experimental and Applied Mechanics CY JUN 08-11, 2015 CL Costa Mesa, CA SP Soc Expt Mech DE Digital holographic interferometry; Human eardrum; Micro-scale force measurements; Sound-induced motions ID HUMAN TYMPANIC MEMBRANE; MOTION AB Human eardrum or Tympanic Membrane (TM) is a thin structure located at the boundary between outer and middle ears. Shape, deformations, and thickness of the mammalian TMs have been studied by several groups; however, sound-induced forces of the TM, and the question of "how large the forces produced by acoustic waves are along the manubrium at the input to the middle-ear ossicular system?" have not been fully answered. In this paper, sound-induced forces in the human TM are measured at different tonal frequencies and at several points on its surface. A calibrated force sensor with a resolution of 0.5 mu N is used with a 3D nano-positioner, enabling accurate placing of the sensor at points of interests on the TM surface. A closed-loop control system is designed and implemented in order to realize constant preload of the sensor at all the measuring points. Concomitant to the force measurements, time-averaged and three-dimensional stroboscopic holographic interferometry are used to compare the modal shape of the sound-induced motion of the TM before and after the presence of the force sensor. The preliminary results show that the maximum sound-induced forces at the umbo occurs at frequencies between 1.5 and 2.3 kHz, whereas the maximum forces for locations on the surface of the TM occurs at around 5-6 kHz. C1 [Khaleghi, Morteza; Furlong, Cosme] Worcester Polytech Inst, Dept Mech Engn, Ctr Holog Studies & Laser MicromechaTron CHSLT, Worcester, MA 01609 USA. [Furlong, Cosme; Cheng, Jeffrey Tao; Rosowski, John J.] Massachusetts Eye & Ear Infirm, Eaton Peabody Lab, Boston, MA 02114 USA. [Furlong, Cosme; Cheng, Jeffrey Tao; Rosowski, John J.] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02114 USA. RP Khaleghi, M (reprint author), Worcester Polytech Inst, Dept Mech Engn, Ctr Holog Studies & Laser MicromechaTron CHSLT, Worcester, MA 01609 USA. EM khaleghi29@gmail.com NR 11 TC 1 Z9 1 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING STREET, NEW YORK, NY 10013, UNITED STATES SN 2191-5644 BN 978-3-319-21455-9; 978-3-319-21454-2 J9 C PROC SOC EXP MECH PY 2016 BP 147 EP 154 DI 10.1007/978-3-319-21455-9_18 PG 8 WC Engineering, Biomedical; Engineering, Mechanical; Materials Science, Multidisciplinary SC Engineering; Materials Science GA BE9KU UT WOS:000377718500018 ER PT S AU Beaudette, K Lo, W Villiger, M Shishkov, M Godbout, N Bouma, BE Boudoux, C AF Beaudette, Kathy Lo, William Villiger, Martin Shishkov, Milen Godbout, Nicolas Bouma, Brett E. Boudoux, Caroline BE Azar, FS Intes, X TI Towards in vivo laser coagulation and concurrent optical coherence tomography through double-clad fiber devices SO MULTIMODAL BIOMEDICAL IMAGING XI SE Proceedings of SPIE LA English DT Proceedings Paper CT Conference on Multimodal Biomedical Imaging XI CY FEB 13, 2016 CL San Francisco, CA SP SPIE DE Optical coherence tomography; laser coagulation; double-clad fiber; coupler; catheter; clinical imaging; multimodal imaging ID TISSUE COAGULATION AB There is a strong clinical need for an optical coherence tomography (OCT) system capable of delivering concurrent coagulation light enabling image-guided dynamic laser marking for targeted collection of biopsies, as opposed to a random sampling, to reduce false-negative findings. Here, we present a system based on double-clad fiber (DCF) capable of delivering pulsed laser light through the inner cladding while performing OCT through the core. A previously clinically validated commercial OCT system (NVisionVLE, Ninepoint Medical) was adapted to enable in vivo esophageal image-guided dynamic laser marking An optimized DCF coupler was implemented into the system to couple both modalities into the DCF. A DCF-based rotary joint was used to couple light to the spinning DCF-based catheter for helical scanning DCF-based OCT catheters, providing a beam waist diameter of 62 mu m at a working distance of 9.3mm, for use with a 17-mm diameter balloon sheath, were used for ex vivo imaging of a swine esophagus. Imaging results using the DCF-based clinical system show an image quality comparable with a conventional system with minimal crosstalk-induced artifacts. To further optimize DCF catheter optical design in order to achieve single-pulse marking, a Zemax model of the DCF output and its validation are presented. C1 [Beaudette, Kathy; Godbout, Nicolas; Boudoux, Caroline] Polytech Montreal, Dept Engn Phys, Stn Ctr Ville, POB 6079, Montreal, PQ H3C 3A7, Canada. [Beaudette, Kathy; Lo, William; Villiger, Martin; Shishkov, Milen; Bouma, Brett E.] Harvard Univ, Sch Med, Wellman Ctr Photomed, Boston, MA 02114 USA. [Beaudette, Kathy; Lo, William; Villiger, Martin; Shishkov, Milen; Bouma, Brett E.] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Boudoux, C (reprint author), Polytech Montreal, Dept Engn Phys, Stn Ctr Ville, POB 6079, Montreal, PQ H3C 3A7, Canada. EM caroline.boudoux@polymtl.ca RI Godbout, Nicolas/A-6397-2012 OI Godbout, Nicolas/0000-0001-9494-1175 NR 6 TC 0 Z9 0 U1 1 U2 1 PU SPIE-INT SOC OPTICAL ENGINEERING PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA SN 0277-786X BN 978-1-62841-935-1 J9 PROC SPIE PY 2016 VL 9701 AR 97010B DI 10.1117/12.2209382 PG 6 WC Microscopy; Optics; Radiology, Nuclear Medicine & Medical Imaging SC Microscopy; Optics; Radiology, Nuclear Medicine & Medical Imaging GA BE9SA UT WOS:000378118500004 ER PT S AU Kwong, TC Nouizi, F Lin, YT Zhu, Y Sampathkumaran, U Gulsen, G AF Kwong, Tiffany C. Nouizi, Farouk Lin, Yuting Zhu, Yue Sampathkumaran, Uma Gulsen, Gultekin BE Azar, FS Intes, X TI Thermal Outlining using Focused Ultrasound (TOFU) with Reversible Temperature Sensitive Fluorescent Probes SO MULTIMODAL BIOMEDICAL IMAGING XI SE Proceedings of SPIE LA English DT Proceedings Paper CT Conference on Multimodal Biomedical Imaging XI CY FEB 13, 2016 CL San Francisco, CA SP SPIE DE Fluorescence Tomography; Optical Imaging; In Vivo Imaging; Fluorescent probes; Focused Ultrasound; Multimodality Imaging; Indocyanine Green (ICG) ID DIFFUSE OPTICAL TOMOGRAPHY; DEPTH LOCALIZATION; RESOLUTION; AGENTS AB Optical imaging has long been hindered by the high absorption and scattering of light in biological tissue. This makes it difficult to probe beyond a few millimeters beneath the surface without sacrificing image resolution and quantitative accuracy. Strong scattering and the inherent nature of the inverse problem makes fluorescence diffuse optical tomography (FT) extremely challenging. To this end, multi-modality techniques that combine anatomical imaging with the functional optical information have been used to improve the resolution and accuracy of FT. Previously, we have reported on the feasibility of a new imaging method, "Thermal Outlining using Focused Ultrasound" (TOFU), which combines the sensitivity of FT with the resolution of focused ultrasound using temperature reversible fluorescent probes. In this method, the position of the temperature reversible fluorescent probes is localized by an increase in fluorescent signal when the hot spot of the focused ultrasound beam is scanned over the medium. This a priori information is then utilized to guide and constrain conventional reconstruction algorithm to recover the position and concentration of the probes more accurately. The small size of the focal spot (similar to 1.4 mm) up to a depth of 6 cm, allows imaging the distribution of these temperature sensitive agents with not only high spatial resolution but also high quantitative accuracy in deep tissue. In this work, the performance of the system will be evaluated using simulation and phantoms to investigate the dependence that size of the fluorescent distribution has on the TOFU system performance. C1 [Kwong, Tiffany C.; Nouizi, Farouk; Lin, Yuting; Gulsen, Gultekin] Univ Calif Irvine, Ctr Funct Oncoimaging Radiol Sci, Irvine, CA 92697 USA. [Lin, Yuting] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA. [Lin, Yuting] Harvard Univ, Sch Med, Boston, MA USA. [Zhu, Yue; Sampathkumaran, Uma] InnoSense LLC, Torrance, CA 90505 USA. RP Kwong, TC (reprint author), Univ Calif Irvine, Ctr Funct Oncoimaging Radiol Sci, Irvine, CA 92697 USA. NR 25 TC 0 Z9 0 U1 0 U2 0 PU SPIE-INT SOC OPTICAL ENGINEERING PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA SN 0277-786X BN 978-1-62841-935-1 J9 PROC SPIE PY 2016 VL 9701 AR 97010L DI 10.1117/12.2213799 PG 7 WC Microscopy; Optics; Radiology, Nuclear Medicine & Medical Imaging SC Microscopy; Optics; Radiology, Nuclear Medicine & Medical Imaging GA BE9SA UT WOS:000378118500009 ER PT J AU Linnstaedt, SD Bortsov, AV Soward, AC Swor, R Peak, DA Jones, J Rathlev, N Lee, DC Domeier, R Hendry, PL McLean, SA AF Linnstaedt, Sarah D. Bortsov, Andrey V. Soward, April C. Swor, Robert Peak, David A. Jones, Jeffrey Rathlev, Niels Lee, David C. Domeier, Robert Hendry, Phyllis L. McLean, Samuel A. TI CRHBP polymorphisms predict chronic pain development following motor vehicle collision SO PAIN LA English DT Article DE Genetic variant; CRHBP; HPA axis; Musculoskeletal pain; Stress-induced hyperalgesia; Motor vehicle collision ID WHIPLASH-ASSOCIATED DISORDERS; HPA AXIS GENES; GLUCOCORTICOID-RECEPTOR; EMERGENCY-DEPARTMENT; MUSCULOSKELETAL PAIN; IMMUNOPHILIN FKBP51; SUICIDAL-BEHAVIOR; BINDING-PROTEIN; CHILDHOOD ABUSE; STRESS AB Musculoskeletal pain (MSP) is a common sequela of traumatic stress exposure. While biological factors contributing to chronic MSP after motor vehicle collision (MVC) have traditionally focused on tissue injury, increasing evidence suggests that neuro/stress/immune processes mediated by stress system activation may play a more dominant role. In a previous study, we found that genetic variants in the hypothalamic-pituitary-adrenal (HPA) axis-related gene FKBP5 influence vulnerability to persistent MSP 6 weeks after MVC. In the present cohort study (n5855), we evaluated whether genetic variants in several other important HPA axis-related genes, including the glucocorticoid receptor (NR3C1), corticotropin-releasing hormone receptor R1 (CRHR1), and corticotropin-releasing hormone-binding protein (CRHBP), influence risk of chronic MSP over time after MVC. Genetic polymorphism rs7718461 in the CRHBP gene showed significant association (P = 0.0012) with overall pain severity during the year after MVC in regression models controlling for multiple comparisons. Two additional CRHBP alleles in high linkage disequilibrium with rs7718461 also showed trend-level significance. In secondary analyses, a significant interaction between this CRHBP locus (minor allele frequency = 0.33) and time was observed (P = 0.015), with increasing effect observed over time following trauma. A significant CRHBP x FKBP5 interaction was also observed, with substantially increased MSP after MVC in those with a risk allele in both genes compared with either gene alone. The results of this study indicate that genetic variants in 2 different HPA axis genes predict chronic MSP severity following MVC and support the hypothesis that the HPA axis is involved in chronic post-MVC MSP pathogenesis. C1 [Linnstaedt, Sarah D.; Bortsov, Andrey V.; Soward, April C.; McLean, Samuel A.] Univ N Carolina, TRYUMPH Res Program, Chapel Hill, NC USA. [Linnstaedt, Sarah D.; Bortsov, Andrey V.; Soward, April C.; McLean, Samuel A.] Univ N Carolina, Anesthesiol, Chapel Hill, NC USA. [Swor, Robert] William Beaumont Hosp, Emergency Med, Royal Oak, MI 48072 USA. [Peak, David A.] Massachusetts Gen Hosp, Emergency Med, Boston, MA 02114 USA. [Jones, Jeffrey] Spectrum Hlth Syst, Emergency Med, Grand Rapids, MI USA. [Rathlev, Niels] Baystate Med Ctr, Emergency Med, Springfield, MA USA. [Lee, David C.] N Shore Univ Hosp, Emergency Med, Manhasset, NY USA. [Domeier, Robert] St Joseph Mercy Hlth Syst, Emergency Med, Ypsilanti, MI USA. [Hendry, Phyllis L.] Univ Florida, Coll Med, Emergency Med, Jacksonville, FL USA. [McLean, Samuel A.] Univ N Carolina, Emergency Med, Chapel Hill, NC USA. RP McLean, SA (reprint author), Univ N Carolina, Sch Med, Emergency Med, Wing C CB 7010, Chapel Hill, NC 27599 USA. EM smclean@aims.unc.edu FU National Institute of Arthritis and Musculoskeletal and Skin diseases [R01AR056328] FX The project described was supported by Award Number R01AR056328 from the National Institute of Arthritis and Musculoskeletal and Skin diseases. NR 59 TC 3 Z9 3 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0304-3959 EI 1872-6623 J9 PAIN JI Pain PD JAN PY 2016 VL 157 IS 1 BP 273 EP 279 DI 10.1097/j.pain.0000000000000374 PG 7 WC Anesthesiology; Clinical Neurology; Neurosciences SC Anesthesiology; Neurosciences & Neurology GA DN5KD UT WOS:000377104800028 PM 26447706 ER PT J AU Bohnert, KM Sripada, RK Mach, J McCarthy, JF AF Bohnert, Kipling M. Sripada, Rebecca K. Mach, Jennifer McCarthy, John F. TI Same-Day Integrated Mental Health Care and PTSD Diagnosis and Treatment Among VHA Primary Care Patients With Positive PTSD Screens SO PSYCHIATRIC SERVICES LA English DT Article ID POSTTRAUMATIC-STRESS-DISORDER; COLLABORATIVE CARE; RANDOMIZED-TRIAL; MEDICAL HOME; DEPRESSION; VETERANS; SERVICES; INITIATION; OUTCOMES; ACCESS AB Objective: The study examined whether same-day integrated mental health services are associated with increased diagnosis and treatment initiation among primary care patients with positive posttraumatic stress disorder (PTSD) screens. Methods: Data were from a national sample of Veterans Health Administration (VHA) primary care patients with a positive PTSD screen (N=21,427). Patients were assessed for PTSD diagnosis and treatment initiation on the screening day and <= 7 days, <= 12 weeks, <= 6 months, and <= 1 year after screening positive. The service setting on screening day was categorized as primary care only, same-day primary care-mental health integration (PC-MHI), or same-day specialty mental health care. Multivariable generalized estimating equations logistic regression was used to estimate associations between category of screening day services and diagnosis and treatment initiation, with adjustment for demographic characteristics, prior psychiatric diagnoses, prior VHA service utilization, and PTSD screen score. Results: Of the 21,427 patients with positive PTSD screens, 10,809 (50.4%) received a diagnosis within one year of screening positive. Same-day PC-MHI services were associated with greater odds of PTSD diagnosis, both on the same day as (odds ratio [OR]= 2.23) and one year (OR=1.67) after screening positive compared with primary care-only services (p<.001). Among those who received a diagnosis on the same day as their positive screen, same-day PC-MHI services were associated with increased odds of initiating PTSD treatment (OR=3.39) within 12 weeks of diagnosis, compared with primary care only (p<.001). Conclusions: Same-day integrated mental health services may help facilitate PTSD diagnosis and treatment initiation after a positive screen. C1 [Bohnert, Kipling M.; Sripada, Rebecca K.] US Dept Vet Affairs, Ctr Clin Management Res, Ann Arbor, MI 48105 USA. [Bohnert, Kipling M.; Sripada, Rebecca K.; Mach, Jennifer; McCarthy, John F.] US Dept Vet Affairs, SMITREC, Ann Arbor, MI 48105 USA. [Bohnert, Kipling M.; Sripada, Rebecca K.; McCarthy, John F.] Univ Michigan, Sch Med, Dept Psychiat, Ann Arbor, MI 48109 USA. RP Bohnert, KM (reprint author), US Dept Vet Affairs, Ctr Clin Management Res, Ann Arbor, MI 48105 USA.; Bohnert, KM (reprint author), US Dept Vet Affairs, SMITREC, Ann Arbor, MI 48105 USA.; Bohnert, KM (reprint author), Univ Michigan, Sch Med, Dept Psychiat, Ann Arbor, MI 48109 USA. EM kiplingb@med.umich.edu OI Sripada, Rebecca/0000-0002-2844-3458 FU VA Health Services Research & Development Career Development Award [CDA 11-245]; SMITREC Advanced Fellowship Program in Mental Illness Research and Treatment from the VA Office of Academic Affiliations FX Study analyses were conducted as part of the VA National Primary Care-Mental Health Integration Evaluation (Dr. Mach and Dr. McCarthy). Dr. Bohnert is supported by a VA Health Services Research & Development Career Development Award (CDA 11-245). Dr. Sripada is supported by the SMITREC Advanced Fellowship Program in Mental Illness Research and Treatment from the VA Office of Academic Affiliations. NR 28 TC 1 Z9 1 U1 1 U2 2 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 EI 1557-9700 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD JAN PY 2016 VL 67 IS 1 BP 94 EP 100 DI 10.1176/appi.ps.201500035 PG 7 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA DO4SX UT WOS:000377775000016 PM 26423103 ER PT J AU Kotb, S Detappe, A Lux, F Appaix, F Barbier, EL Tran, VL Plissonneau, M Gehan, H Lefranc, F Rodriguez-Lafrasse, C Verry, C Berbeco, R Tillement, O Sancey, L AF Kotb, Shady Detappe, Alexandre Lux, Francois Appaix, Florence Barbier, Emmanuel L. Vu-Long Tran Plissonneau, Marie Gehan, Helene Lefranc, Florence Rodriguez-Lafrasse, Claire Verry, Camille Berbeco, Ross Tillement, Olivier Sancey, Lucie TI Gadolinium-Based Nanoparticles and Radiation Therapy for Multiple Brain Melanoma Metastases: Proof of Concept before Phase I Trial SO THERANOSTICS LA English DT Article DE AGuIX; radiosensitizer; radiation therapy; brain metastases; nanoparticles; imaged-guided therapy; personalized medicine ID SQUAMOUS-CELL CARCINOMA; AGUIX NANOPARTICLES; GOLD NANOPARTICLES; TARGETED THERAPIES; RANDOMIZED-TRIAL; MRI; PARAMETERS; ENHANCE; TUMORS; RADIOTHERAPY AB Nanoparticles containing high-Z elements are known to boost the efficacy of radiation therapy. Gadolinium (Gd) is particularly attractive because this element is also a positive contrast agent for MRI, which allows for the simultaneous use of imaging to guide the irradiation and to delineate the tumor. In this study, we used the Gd-based nanoparticles, AGuIX (R). After intravenous injection into animals bearing B16F10 tumors, some nanoparticles remained inside the tumor cells for more than 24 hours, indicating that a single administration of nanoparticles might be sufficient for several irradiations. Combining AGuIX (R) with radiation therapy increases tumor cell death, and improves the life spans of animals bearing multiple brain melanoma metastases. These results provide preclinical proof-of-concept for a phase I clinical trial. C1 [Kotb, Shady; Detappe, Alexandre; Lux, Francois; Vu-Long Tran; Plissonneau, Marie; Gehan, Helene; Tillement, Olivier; Sancey, Lucie] Univ Lyon 1, CNRS, Inst Lumiere Mat, UMR5306, F-69622 Villeurbanne, France. [Detappe, Alexandre; Berbeco, Ross] Brigham & Womens Hosp, Dept Radiat Oncol, Dana Farber Canc Inst, 75 Francis St, Boston, MA 02115 USA. [Detappe, Alexandre; Berbeco, Ross] Harvard Univ, Sch Med, Boston, MA USA. [Detappe, Alexandre; Plissonneau, Marie; Gehan, Helene] Nano H, F-38070 St Quentin Fallavier, France. [Appaix, Florence; Barbier, Emmanuel L.] INSERM, U836, GIN, F-38706 Grenoble, France. [Barbier, Emmanuel L.] Univ Grenoble Alpes, Grenoble, France. [Lefranc, Florence] Univ Libre Bruxelles, Hop Erasme, Serv Neurochirurg, 808 Route Lennik, B-1070 Brussels, Belgium. [Rodriguez-Lafrasse, Claire] Univ Lyon 1, Fac Med Lyon Sud, EMR3738, Lab Radiobiol Cellulaire & Mol, Oullins, France. [Verry, Camille] Grenoble Univ Hosp, Dept Radiotherapy, F-38043 Grenoble, France. RP Sancey, L (reprint author), Univ Lyon 1, UMR CNRS 5306, Equipe FENNEC, Inst Lumiere Mat, Batiment Jules Raulin,2,Rue V Grignard, F-69622 Villeurbanne, France. EM lucie.sancey@univ-lyon1.fr RI Barbier, Emmanuel/E-6302-2011; OI Barbier, Emmanuel/0000-0002-4952-1240; Detappe, Alexandre/0000-0001-9364-1621 FU LABEX PRIMES of Lyon 1 University within the program "Investissements d'Avenir" [ANR-11-LABX-0063, ANR-11-IDEX-0063]; Lyon Science Transfert; French program 'Investissement d'Avenir' run by the French National Research Agency, grant 'Infrastructure d'avenir en Biologie Sante' [ANR-11-INBS-0006] FX The authors gratefully acknowledge the LABEX PRIMES (ANR-11-LABX-0063) of Lyon 1 University within the program "Investissements d'Avenir" (ANR-11-IDEX-0063), which was operated by the French National Research Agency (ANR) within the ANR Multimage ANR-12-RPIB-0010, as well as the Lyon Science Transfert, for financial support. TPLSM imaging was performed at the Two-Photon Microscopy Platform (GIS-IBiSA ISdV), Photonic Imaging Center, Grenoble Institute of Neuroscience. The MRI facility IRMaGe is partly funded by the French program 'Investissement d'Avenir' run by the French National Research Agency, grant 'Infrastructure d'avenir en Biologie Sante' - ANR-11-INBS-0006. We also wholeheartedly acknowledge the CT mu of Villeurbanne (A. Rivoire and C. Boule), the animal facility of Lyon Sud (P. Manas) and of Optimal - Grenoble (J. Vollaire and V. Josserand), C. Cadet and the EMR3837 team for fruitful discussions and technical help, and F. Rossetti and M. Bonnel for AGuIX (R) synthesis. NR 46 TC 6 Z9 6 U1 2 U2 15 PU IVYSPRING INT PUBL PI LAKE HAVEN PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA SN 1838-7640 J9 THERANOSTICS JI Theranostics PY 2016 VL 6 IS 3 BP 418 EP 427 DI 10.7150/thno.14018 PG 10 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA DO5AY UT WOS:000377797200010 PM 26909115 ER PT J AU Cunningham, KF Beeson, GC Beeson, CC McDermott, PJ AF Cunningham, Kathryn F. Beeson, Gyda C. Beeson, Craig C. McDermott, Paul J. TI Increased expression of estrogen-related receptor beta during adaptation of adult cardiomyocytes to sustained hypoxia SO AMERICAN JOURNAL OF CARDIOVASCULAR DISEASE LA English DT Article DE Cardiomyocyte; hypoxia; estrogen-related receptor; estrogen-related receptor beta; peroxisome proliferator-activated receptor gamma coactivator-1 ID ELECTRICALLY STIMULATED CONTRACTION; PROMOTES CARDIAC MITOCHONDRIAL; ACID-BINDING PROTEIN; ERR-ALPHA; GENE-EXPRESSION; TRANSCRIPTIONAL NETWORK; PGC-1 COACTIVATORS; FELINE CARDIOCYTES; GAMMA; HEART AB Estrogen-related Receptors (ERR) are members of the steroid hormone receptor superfamily of transcription factors that regulate expression of genes required for energy metabolism including mitochondrial biogenesis, fatty acid oxidation and oxidative phosphorylation. While ERR alpha and EPP gamma isoforms are known to share a wide array of target genes in the adult myocardium, the function of ERR beta has not been characterized in cardiomyocytes. The purpose of this study was to determine the role of ERR beta in regulating energy metabolism in adult cardiomyocytes in primary culture. Adult feline cardiomyocytes were electrically stimulated to contract in either hypoxia (0.5% O-2) or normoxia (21% O-2). As compared to baseline values measured in normoxia, ERR beta mRNA levels increased significantly after 8 hours of hypoxia and remained elevated over 24 h. Conversely, ERR beta mRNA decreased to normoxic levels after 4 hours of reoxygenation. Hypoxia increased expression of the alpha and beta isoforms of Peroxisome Proliferator-Activated Receptor. Coactivator-1 (PGC-1) mRNA by 6-fold and 3-fold, respectively. Knockdown of ERR beta expression via adenoviral-mediated delivery of ERR beta shRNA blocked hypoxia-induced increases in PGC-1 beta mRNA, but not PGC-1 alpha mRNA. Loss of ERR beta had no effect on mtDNA content as measured after 24 h of hypoxia. To determine whether loss of ERR beta affected mitochondrial function, oxygen consumption rates (OCR) were measured in contracting versus quiescent cardiomyocytes in normoxia. OCR was significantly lower in contracting cardiomyocytes expressing ERR beta shRNA than scrambled shRNA controls. Maximal OCR also was reduced by ERR beta knockdown. In conclusion: 1) hypoxia increases in ERR beta mRNA expression in contracting cardiomyocytes; 2) ERR beta is required for induction of the PGC-1 beta isoform in response to hypoxia; 3) ERR beta expression is required to sustain OCR in normoxic conditions. C1 [Cunningham, Kathryn F.; McDermott, Paul J.] Med Univ S Carolina, Dept Med, Gazes Cardiac Res Inst, Charleston, SC 29425 USA. [Beeson, Gyda C.; Beeson, Craig C.] Med Univ S Carolina, Dept Drug Discovery & Biomed Sci, Charleston, SC 29425 USA. [McDermott, Paul J.] Ralph H Johnson Dept Vet Affairs Med Ctr, Charleston, SC USA. RP McDermott, PJ (reprint author), Med Univ S Carolina, Gazes Cardiac Res Inst, 301 Strom Thurmond Bldg,114 Doughty St,MSC 773, Charleston, SC 29425 USA. EM mcdermp@musc.edu FU NHLBI NIH HHS [T32 HL007260] NR 41 TC 0 Z9 0 U1 0 U2 0 PU E-CENTURY PUBLISHING CORP PI MADISON PA 40 WHITE OAKS LN, MADISON, WI 53711 USA SN 2160-200X J9 AM J CARDIOVASC DIS JI Am. J. Cardiovasc. Dis. PY 2016 VL 6 IS 2 BP 46 EP 54 PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA DO3JQ UT WOS:000377678300004 PM 27335690 ER PT J AU Kim, B Breton, S AF Kim, Bongki Breton, Sylvie TI The MAPK/ERK-Signaling Pathway Regulates the Expression and Distribution of Tight Junction Proteins in the Mouse Proximal Epididymis SO BIOLOGY OF REPRODUCTION LA English DT Article DE epididymis; epithelial cell biology; male reproductive tract ID EPITHELIAL BARRIER FUNCTION; RAT EPIDIDYMIS; MEMBRANE-PROTEIN; TRANSGENIC MICE; BASAL-CELLS; KINASE ERK; OCCLUDIN; DISRUPTION; INTERACTS; ZO-1 AB The initial segment (IS) in rodents is functionally and structurally distinct from other epididymal segments and plays an important role in sperm maturation. The MAPK/ERK1/2 pathway is maintained active in the IS by testicular luminal factors and plays crucial roles in the maintenance and differentiation of the IS epithelium. Tight junctions (TJs) are constituents of the blood-epididymis barrier, which mediates the paracellular transport of ions, solutes, and water and controls epithelial cell differentiation, thereby contributing to the establishment of a unique luminal environment. We examine here the role of the MAPK/ERK1/2 pathway in the regulation of TJ proteins in the IS. Inhibition of mitogen activated protein kinase kinase (MAPKK or MEK1/2) with PD325901, followed by reduction of ERK1/2 phosphorylation (pERK), decreased zonula occludens (ZO)-2 expression and increased ZO-3 expression in TJs but had no effect on ZO-1 expression. In control mice, in addition to being located in TJs, claudin (Cldn)-1, Cldn-3, and Cldn-4 were detected in the basolateral membrane of epithelial cells, with enriched expression of Cldn-1 and Cldn-4 in basal cells. PD325901 reduced the expression of Cldn-1 and Cldn-4 at all locations without affecting Cldn-3. Occludin was undetectable in the IS of control mice, but PD325901 triggered its expression in TJs. No effect was observed for any of the proteins examined in the other epididymal regions. Our results indicate the participation of the MAPK/ERK1/2 pathway in the regulation of cell-cell events that control the formation and maintenance of the blood-epididymis barrier. C1 Massachusetts Gen Hosp, Ctr Syst Biol, Program Membrane Biol, Boston, MA 02114 USA. Massachusetts Gen Hosp, Dept Med, Div Nephrol, Boston, MA 02114 USA. Harvard Univ, Sch Med, Boston, MA USA. RP Breton, S (reprint author), Massachusetts Gen Hosp, Program Membrane Biol, Div Nephrol, Simches Res Ctr, 185 Cambridge St,Suite 8-204, Boston, MA 02114 USA. EM breton.sylvie@mgh.harvard.edu FU National Institutes of Health [RO1HD040793, RO1DK097124]; Microscopy Core facility of the Massachusetts General Hospital (MGH) Program in Membrane Biology from the Boston Area Diabetes and Endocrinology Research Center [DK57521]; Center for the Study of Inflammatory Bowel Disease [DK43351]; Charles and Ann Sanders Research Scholar Award at MGH FX This work was supported by National Institutes of Health grants RO1HD040793 and RO1DK097124 (to S.B.). The Microscopy Core facility of the Massachusetts General Hospital (MGH) Program in Membrane Biology receives support from the Boston Area Diabetes and Endocrinology Research Center (DK57521) and the Center for the Study of Inflammatory Bowel Disease (DK43351). S.B. is a recipient of the Charles and Ann Sanders Research Scholar Award at MGH. NR 53 TC 2 Z9 2 U1 1 U2 41 PU SOC STUDY REPRODUCTION PI MADISON PA 1691 MONROE ST,SUITE # 3, MADISON, WI 53711-2021 USA SN 0006-3363 EI 1529-7268 J9 BIOL REPROD JI Biol. Reprod. PD JAN 1 PY 2016 VL 94 IS 1 AR 22 DI 10.1095/biolreprod.115.134965 PG 12 WC Reproductive Biology SC Reproductive Biology GA DO0CF UT WOS:000377446300009 PM 26658708 ER PT S AU Haindl, R Trasischker, W Wartak, A Baumann, B Pircher, M Hitzenberger, CK AF Haindl, Richard Trasischker, Wolfgang Wartak, Andreas Baumann, Bernhard Pircher, Michael Hitzenberger, Christoph K. BE Manns, F Soderberg, PG Ho, A TI Total retinal blood flow and reproducibility evaluation by three beam optical Doppler tomography SO OPHTHALMIC TECHNOLOGIES XXVI SE Proceedings of SPIE LA English DT Proceedings Paper CT 26th Conference on Ophthalmic Technologies CY FEB 13-14, 2016 CL Moscone Ctr, San Francisco, CA SP SPIE HO Moscone Ctr DE Medical optics and biotechnology; Retina; Blood flow; Optical coherence tomography; Doppler; Functional monitoring and imaging; Imaging systems; Multi beam ID COHERENCE TOMOGRAPHY AB We present a three beam optical Doppler tomography (ODT) technique suitable for 3-D velocity and flow measurements to evaluate total retinal blood circulation from and to the optic nerve head (ONH). The system consists of three independent ODT channels. Superluminescent diodes with a central wavelength of 840 nm and a spectral bandwidth of 50 nm were used. The sources are coupled to collimators resting in a specially designed mount to ensure a well-defined beam geometry, necessary for the full reconstruction of the three dimensional velocity vector. The reconstruction works without prior knowledge on the vessel geometry, which is normally required for ODT systems with less than three beams. The beams share a common bulk optics Michelson interferometer, while the detection comprises three identical spectrometers with a line scan rate of 50 kHz. 20 eyes of healthy volunteers were imaged with the 3 beam ODT, employing a circular scan pattern around the ONH. The mean total blood flow was calculated for arteries (47.1 +/- 2.4 mu l/min (mean +/- SD)) and veins (47.1 +/- 2.7 mu l/min (mu)l /min) independently. The two results showed no significant difference (paired t-test, p > 0.96), rendering both equally reliable for total flow measurements. Furthermore the reproducibility of the method was evaluated for the total flow and flow, velocities within each individual vessel of 6 eyes. The average variation for total flow measurements is sufficiently low to detect deviations of similar to 6% indicating high precision of the proposed method. C1 [Haindl, Richard; Trasischker, Wolfgang; Wartak, Andreas; Baumann, Bernhard; Pircher, Michael; Hitzenberger, Christoph K.] Med Univ Vienna, Ctr Med Phys & Biomed Engn, Vienna, Austria. [Trasischker, Wolfgang] Harvard Univ, Sch Med, Boston, MA USA. [Trasischker, Wolfgang] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA. RP Haindl, R (reprint author), Med Univ Vienna, Ctr Med Phys & Biomed Engn, Vienna, Austria. EM richard.haindl@meduniwien.ac.at OI Baumann, Bernhard/0000-0001-6419-1932 NR 9 TC 0 Z9 0 U1 0 U2 0 PU SPIE-INT SOC OPTICAL ENGINEERING PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA SN 0277-786X BN 978-1-62841-927-6 J9 PROC SPIE PY 2016 VL 9693 AR 969302 DI 10.1117/12.2210910 PG 5 WC Ophthalmology; Optics SC Ophthalmology; Optics GA BE9FL UT WOS:000377398700002 ER PT J AU Gallagher, RM AF Gallagher, Rollin M. TI Pain Medicine and Oxford University Press: Building a Scholarly Pain Community Together SO PAIN MEDICINE LA English DT Editorial Material C1 [Gallagher, Rollin M.] Univ Penn, Philadelphia VA Med Ctr, Pain Med, Philadelphia, PA 19104 USA. RP Gallagher, RM (reprint author), Univ Penn, Philadelphia VA Med Ctr, Pain Med, Philadelphia, PA 19104 USA. EM rgallagher@mail.med.upenn.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1526-2375 EI 1526-4637 J9 PAIN MED JI Pain Med. PD JAN PY 2016 VL 17 IS 1 BP 1 EP 2 DI 10.1093/pm/pnv049 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA DI8DD UT WOS:000373730500001 PM 26768182 ER PT J AU DiNapoli, EA Craine, M Dougherty, P Gentili, A Kochersberger, G Morone, NE Murphy, JL Rodakowski, J Rodriguez, E Thielke, S Weiner, DK AF DiNapoli, Elizabeth A. Craine, Michael Dougherty, Paul Gentili, Angela Kochersberger, Gary Morone, Natalia E. Murphy, Jennifer L. Rodakowski, Juleen Rodriguez, Eric Thielke, Stephen Weiner, Debra K. TI Deconstructing Chronic Low Back Pain in the Older Adult - Step by Step Evidence and Expert-Based Recommendations for Evaluation and Treatment. Part V: Maladaptive Coping SO PAIN MEDICINE LA English DT Review DE Aged; Assessment; Maladaptive Coping; Chronic Pain; Elderly; Low Back Pain; Primary Care; Chronic Low Back Pain ID FEAR-AVOIDANCE BELIEFS; BEHAVIORAL TREATMENT; PERSISTENT PAIN; DISABILITY; DEPRESSION; STRATEGIES; IMPACT; EXPERIENCE; MANAGEMENT; DEMENTIA AB Objective. As part of a series of articles designed to deconstruct chronic low back pain (CLBP) in older adults, this article focuses on maladaptive copinga significant contributor of psychological distress, increased pain, and heightened disability in older adults with CLBP. Methods. A modified Delphi technique was used to develop a maladaptive coping algorithm and table providing the rationale for the various components of the algorithm. A seven-member content expert panel and a nine-member primary care panel were involved in the iterative development of the materials. While the algorithm was developed keeping in mind resources available within the Veterans Health Administration (VHA) facilities, panelists were not exclusive to the VHA, and therefore, materials can be applied in both VHA and civilian settings. The illustrative clinical case was taken from one of the contributors' clinical practice. Results. We present a treatment algorithm and supporting table to be used by providers treating older adults who have CLBP and engage in maladaptive coping strategies. A case of an older adult with CLBP and maladaptive coping is provided to illustrate the approach to management. Conclusions. To promote early engagement in skill-focused treatments, providers can routinely evaluate pain coping strategies in older adults with CLBP using a treatment algorithm. C1 [DiNapoli, Elizabeth A.] VA Pittsburgh Healthcare Syst, Mental Illness Res Educ & Clin Ctr, Pittsburgh, PA USA. [Morone, Natalia E.; Weiner, Debra K.] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. [Craine, Michael] VA Eastern Colorado Healthcare Syst, Denver, CO USA. [Craine, Michael] Univ Colorado, Sch Med, Dept Phys Med & Rehabil, Denver, CO 80202 USA. [Dougherty, Paul; Kochersberger, Gary] Canandaigua VA Med Ctr, Canandaigua, NY USA. [Dougherty, Paul] New York Chiropract Coll, Seneca Falls, NY USA. [Gentili, Angela] Hunter Holmes McGuire VA Med Ctr, Richmond, VA USA. [Gentili, Angela] Virginia Commonwealth Univ Hlth Syst, Richmond, VA USA. [DiNapoli, Elizabeth A.; Kochersberger, Gary] Univ Rochester, Div Geriatr, Rochester, NY USA. [Weiner, Debra K.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA. [Morone, Natalia E.] Univ Pittsburgh, Sch Med, Div Gen Internal Med, Ctr Res Hlth Care, Pittsburgh, PA USA. [Morone, Natalia E.; Weiner, Debra K.] Univ Pittsburgh, Sch Med, Clin & Translat Sci Inst, Pittsburgh, PA USA. [Murphy, Jennifer L.] James A Haley Vet Hosp, Tampa, FL USA. [Murphy, Jennifer L.] Univ S Florida, Tampa, FL USA. [Rodakowski, Juleen] Univ Pittsburgh, Dept Occupat Therapy, Pittsburgh, PA USA. [Rodriguez, Eric; Weiner, Debra K.] Univ Pittsburgh, Sch Med, Dept Med, Div Geriatr Med, Pittsburgh, PA 15213 USA. [Thielke, Stephen] Puget Sound VA Med Ctr, Geriatr Res Educ & Clin Ctr, Seattle, WA USA. [Thielke, Stephen] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Weiner, Debra K.] Univ Pittsburgh, Sch Med, Dept Anesthesiol, Pittsburgh, PA 15261 USA. [Weiner, Debra K.] VA Pittsburgh Healthcare Syst, Univ Dr,Bldg 30,00GR, Pittsburgh, PA 15240 USA. RP Weiner, DK (reprint author), Univ Pittsburgh, Sch Med, Dept Anesthesiol, Pittsburgh, PA 15261 USA.; Weiner, DK (reprint author), VA Pittsburgh Healthcare Syst, Univ Dr,Bldg 30,00GR, Pittsburgh, PA 15240 USA. EM debra.weiner@va.gov OI Rodakowski, Juleen/0000-0002-6397-8124 FU Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Rehabilitation Research and Development Service FX This material is based on work supported by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Rehabilitation Research and Development Service. NR 43 TC 0 Z9 0 U1 1 U2 2 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1526-2375 EI 1526-4637 J9 PAIN MED JI Pain Med. PD JAN PY 2016 VL 17 IS 1 BP 64 EP 73 DI 10.1093/pm/pnv055 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA DI8DD UT WOS:000373730500011 PM 26768183 ER PT J AU Manchikanti, L Boswell, MV Kaye, AD Hirsch, JA AF Manchikanti, Laxmaiah Boswell, Mark V. Kaye, Alan David Hirsch, Joshua A. TI Cervical Transforaminal with Low-Dose Local Anesthetic Is Not a Safeguard for Neurological Complications SO PAIN MEDICINE LA English DT Letter ID EPIDURAL STEROID INJECTIONS C1 [Manchikanti, Laxmaiah] Univ Louisville, Anesthesiol & Perioperat Med, Louisville, KY USA. [Manchikanti, Laxmaiah] Pain Management Ctr Paducah, Paducah, KY USA. [Boswell, Mark V.] Univ Louisville, Dept Anesthesiol & Perioperat Med, Louisville, KY USA. [Kaye, Alan David] LSU Hlth Sci Ctr, Dept Anesthesia, New Orleans, LA USA. [Hirsch, Joshua A.] Massachusetts Gen Hosp, Neurointervent Spine Serv, Intervent Care, Boston, MA 02114 USA. [Hirsch, Joshua A.] Harvard Univ, Sch Med, Radiol, Boston, MA USA. RP Manchikanti, L (reprint author), Univ Louisville, Anesthesiol & Perioperat Med, Louisville, KY USA.; Manchikanti, L (reprint author), Pain Management Ctr Paducah, Paducah, KY USA. NR 10 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1526-2375 EI 1526-4637 J9 PAIN MED JI Pain Med. PD JAN PY 2016 VL 17 IS 1 BP 191 EP 192 DI 10.1111/pme.12922 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA DI8DD UT WOS:000373730500023 PM 26408526 ER PT S AU Andreozzi, JM Zhang, RX Glaser, AK Gladstone, DJ Jarvis, LA Pogue, BW AF Andreozzi, Jacqueline M. Zhang, Rongxiao Glaser, Adam K. Gladstone, David J. Jarvis, Lesley A. Pogue, Brian W. BE Choi, B Kollias, N Zeng, H Kang, HW Wong, BJF Ilgner, JF Tearney, GJ Gregory, KW Marcu, L Skala, MC Campagnola, PJ Mandelis, A TI Using a reflectance-based correction on Cherenkov images to strengthen correlation with radiation surface dose in an anthropomorphic breast phantom SO PHOTONIC THERAPEUTICS AND DIAGNOSTICS XII SE Proceedings of SPIE LA English DT Proceedings Paper CT Conference on Photonic Therapeutics and Diagnostics XII CY FEB 13-14, 2016 CL San Francisco, CA SP SPIE DE Cherenkov; Cerenkov; surface dose; radiotherapy; imaging; in vivo dosimetry; real-time ID DOSIMETRY; BEAM AB Cherenkov imaging during radiotherapy is a method by which an optical analog for the high-energy radiation beam can be observed directly on the surface of the patient. While simple geometries and volumes demonstrate a strong correlation between Cherenkov emission intensity and surface dose, in vivo data collected from 14 whole-breast patients has not exhibited the same correlation. The purpose of this anthropomorphic phantom study was to investigate a new method for improving the in vivo correlation based on a pixel-by-pixel correction from a reference reflectance image. The pixel intensities in Cherenkov images of a phantom were correlated with the surface dose measured from thermoluminescent dosimeters (TLDs) placed on the phantom's surface. Because the phantom had homogeneous optical properties, results show a no appreciable change in correlation between Cherenkov intensity and surface dose when using the correction method on images of an anthropomorphic solid silicone phantom, nor a change in the dose fall-off at the edges of the phantom. The method may improve correlation with in vivo data. C1 [Andreozzi, Jacqueline M.; Pogue, Brian W.] Thayer Sch Engn Dartmouth, 14 Engn Dr, Hanover, NH 03755 USA. [Zhang, Rongxiao] Massachusetts Gen Hosp, Radiat Oncol Dept, 125 Nashua St, Boston, MA 02114 USA. [Glaser, Adam K.] Univ Washington, Mech Engn, Stevens Way,Box 352600, Seattle, WA 98195 USA. [Gladstone, David J.; Jarvis, Lesley A.] Dartmouth Hitchcock Med Ctr, Norris Cotton Canc Ctr, 1 Med Ctr Dr, Lebanon, NH 03766 USA. RP Andreozzi, JM (reprint author), Thayer Sch Engn Dartmouth, 14 Engn Dr, Hanover, NH 03755 USA. OI Glaser, Adam/0000-0003-3558-8994 NR 8 TC 0 Z9 0 U1 0 U2 0 PU SPIE-INT SOC OPTICAL ENGINEERING PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA SN 0277-786X BN 978-1-62841-924-5 J9 PROC SPIE PY 2016 VL 9689 AR 968941 DI 10.1117/12.2212648 PG 6 WC Microscopy; Optics SC Microscopy; Optics GA BE9FK UT WOS:000377396200106 ER PT S AU Fard, AM Gardecki, JA Ughi, GJ Hyun, C Tearney, GJ AF Fard, Ali M. Gardecki, Joseph A. Ughi, Giovanni J. Hyun, Chulho Tearney, Guillermo J. BE Choi, B Kollias, N Zeng, H Kang, HW Wong, BJF Ilgner, JF Tearney, GJ Gregory, KW Marcu, L Skala, MC Campagnola, PJ Mandelis, A TI Compensation of spectral artifacts in dual-modality intravascular optical coherence tomography and near-infrared spectroscopy SO PHOTONIC THERAPEUTICS AND DIAGNOSTICS XII SE Proceedings of SPIE LA English DT Proceedings Paper CT Conference on Photonic Therapeutics and Diagnostics XII CY FEB 13-14, 2016 CL San Francisco, CA SP SPIE C1 [Fard, Ali M.; Gardecki, Joseph A.; Ughi, Giovanni J.; Tearney, Guillermo J.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. [Hyun, Chulho] Massachusetts Gen Hosp, Boston, MA 02114 USA. RP Fard, AM (reprint author), Harvard Univ, Sch Med, Cambridge, MA 02138 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPIE-INT SOC OPTICAL ENGINEERING PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA SN 0277-786X BN 978-1-62841-924-5 J9 PROC SPIE PY 2016 VL 9689 AR 96892Z DI 10.1117/12.2219948 PG 1 WC Microscopy; Optics SC Microscopy; Optics GA BE9FK UT WOS:000377396200080 ER PT S AU Hosoda, M Wang, J Tshikudi, DM Nadkarni, SK AF Hosoda, Masaki Wang, Jing Tshikudi, Diane M. Nadkarni, Seemantini K. BE Choi, B Kollias, N Zeng, H Kang, HW Wong, BJF Ilgner, JF Tearney, GJ Gregory, KW Marcu, L Skala, MC Campagnola, PJ Mandelis, A TI Intravascular laser speckle imaging for the mechanical analysis of coronary plaques SO PHOTONIC THERAPEUTICS AND DIAGNOSTICS XII SE Proceedings of SPIE LA English DT Proceedings Paper CT Conference on Photonic Therapeutics and Diagnostics XII CY FEB 13-14, 2016 CL San Francisco, CA SP SPIE C1 [Hosoda, Masaki; Tshikudi, Diane M.] Massachusetts Gen Hosp, Boston, MA 02114 USA. [Wang, Jing; Nadkarni, Seemantini K.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. RP Hosoda, M (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU SPIE-INT SOC OPTICAL ENGINEERING PI BELLINGHAM PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98227-0010 USA SN 0277-786X BN 978-1-62841-924-5 J9 PROC SPIE PY 2016 VL 9689 AR 96893K DI 10.1117/12.2218152 PG 1 WC Microscopy; Optics SC Microscopy; Optics GA BE9FK UT WOS:000377396200097 ER EF